Allogeneic	O	O
marrow	O	O
transplantation	O	O
in	O	O
patients	O	O
with	O	O
chronic	Condition	O
myeloid	Condition	O
leukemia	Condition	O
in	O	O
the	O	O
chronic	Condition	O
phase	Condition	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
two	O	O
irradiation	O	O
regimens	O	O
.	O	O

A	O	O
randomized	O	O
trial	O	O
was	O	O
performed	O	O
to	O	O
compare	O	O
two	O	O
regimens	O	O
of	O	O
total	O	O
body	O	O
irradiation	O	O
in	O	O
patients	O	O
with	O	O
chronic	Condition	O
myeloid	Condition	O
leukemia	Condition	O
treated	O	O
by	O	O
allogeneic	Condition	O
marrow	Condition	O
transplantation	Condition	O
while	O	O
in	O	O
the	O	O
chronic	Condition	O
phase	Condition	O
.	O	O

All	O	O
patients	O	O
received	O	O
cyclophosphamide	O	O
120	O	O
mg/kg	O	O
followed	O	O
by	O	O
total	O	O
body	O	O
irradiation	O	O
and	O	O
marrow	O	O
from	O	O
HLA-identical	O	O
siblings	O	O
.	O	O

Cyclosporine	O	O
and	O	O
methotrexate	O	O
were	O	O
used	O	O
for	O	O
prophylaxis	O	O
against	O	O
acute	O	O
graft-versus-host	O	O
disease	O	O
.	O	O

Fifty-seven	SampleSize	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
2.0	O	O
Gy	O	O
fractions	O	O
of	O	O
irradiation	O	O
daily	O	O
for	O	O
6	O	O
days	O	O
and	O	O
59	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
2.25	O	O
Gy	O	O
fractions	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

The	O	O
probabilities	O	O
of	O	O
relapse	O	O
at	O	O
4	O	O
years	O	O
were	O	O
0.25	O	O
for	O	O
the	O	O
12.0	O	O
Gy	O	O
group	O	O
and	O	O
0.00	O	O
for	O	O
the	O	O
15.75	O	O
Gy	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.008	O	O
)	O	O
.	O	O

The	O	O
actuarial	O	O
probabilities	O	O
of	O	O
survival	O	O
and	O	O
relapse-free	O	O
survival	O	O
at	O	O
4	O	O
years	O	O
were	O	O
0.60	O	O
and	O	O
0.58	O	O
among	O	O
the	O	O
patients	O	O
who	O	O
received	O	O
12.0	O	O
Gy	O	O
compared	O	O
with	O	O
0.66	O	O
and	O	O
0.66	O	O
for	O	O
those	O	O
who	O	O
received	O	O
15.75	O	O
Gy	O	O
.	O	O

The	O	O
4-year	O	O
probabilities	O	O
of	O	O
transplant-related	O	O
mortality	O	O
were	O	O
0.24	O	O
and	O	O
0.34	O	O
respectively	O	O
(	O	O
P	O	O
=	O	O
.13	O	O
)	O	O
while	O	O
the	O	O
probability	O	O
of	O	O
moderate	O	O
to	O	O
severe	O	O
acute	O	O
graft-versus-host	O	O
disease	O	O
was	O	O
0.33	O	O
for	O	O
the	O	O
12.0	O	O
Gy	O	O
group	O	O
and	O	O
0.44	O	O
for	O	O
the	O	O
15.75	O	O
Gy	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.15	O	O
)	O	O
.	O	O

The	O	O
lower	O	O
relapse	O	O
probability	O	O
in	O	O
the	O	O
patients	O	O
receiving	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
total	O	O
body	O	O
irradiation	O	O
did	O	O
not	O	O
result	O	O
in	O	O
improved	O	O
survival	O	O
because	O	O
mortality	O	O
from	O	O
causes	O	O
other	O	O
than	O	O
relapse	O	O
was	O	O
increased	O	O
.	O	O

Acute	O	O
effects	O	O
of	O	O
decaffeinated	O	O
coffee	O	O
and	O	O
the	O	O
major	O	O
coffee	O	O
components	O	O
chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
on	O	O
glucose	Condition	O
tolerance	Condition	O
.	O	O

OBJECTIVE	O	O
Coffee	O	O
consumption	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
lower	O	O
risk	O	O
of	O	O
type	Condition	O
2	Condition	O
diabetes	Condition	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
acute	O	O
effects	O	O
of	O	O
decaffeinated	O	O
coffee	O	O
and	O	O
the	O	O
major	O	O
coffee	O	O
components	O	O
chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
on	O	O
glucose	O	O
tolerance	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
We	O	O
conducted	O	O
a	O	O
randomized	O	O
crossover	O	O
trial	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
12	O	O
g	O	O
decaffeinated	O	O
coffee	O	O
,	O	O
1	O	O
g	O	O
chlorogenic	O	O
acid	O	O
,	O	O
500	O	O
mg	O	O
trigonelline	O	O
,	O	O
and	O	O
placebo	O	O
(	O	O
1	O	O
g	O	O
mannitol	O	O
)	O	O
on	O	O
glucose	O	O
and	O	O
insulin	O	O
concentrations	O	O
during	O	O
a	O	O
2-h	O	O
oral	O	O
glucose	O	O
tolerance	O	O
test	O	O
(	O	O
OGTT	O	O
)	O	O
in	O	O
15	SampleSize	O
overweight	Condition	O
men	Sex	O
.	O	O

RESULTS	O	O
Chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
ingestion	O	O
significantly	O	O
reduced	O	O
glucose	O	O
(	O	O
-0.7	O	O
mmol/l	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
,	O	O
and	O	O
-0.5	O	O
mmol/l	O	O
,	O	O
P	O	O
=	O	O
0.024	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
insulin	O	O
(	O	O
-73	O	O
pmol/l	O	O
,	O	O
P	O	O
=	O	O
0.038	O	O
,	O	O
and	O	O
-117	O	O
pmol/l	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
)	O	O
concentrations	O	O
15	O	O
min	O	O
following	O	O
an	O	O
OGTT	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

None	O	O
of	O	O
the	O	O
treatments	O	O
affected	O	O
insulin	O	O
or	O	O
glucose	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
values	O	O
during	O	O
the	O	O
OGTT	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

CONCLUSIONS	O	O
Chlorogenic	O	O
acid	O	O
and	O	O
trigonelline	O	O
reduced	O	O
early	O	O
glucose	O	O
and	O	O
insulin	O	O
responses	O	O
during	O	O
an	O	O
OGTT	O	O
.	O	O

Behavioral	O	O
effects	O	O
of	O	O
Org	O	O
2766	O	O
,	O	O
a	O	O
synthetic	O	O
analog	O	O
of	O	O
the	O	O
adrenocorticotrophic	O	O
hormone	O	O
(	O	O
4-9	O	O
)	O	O
,	O	O
in	O	O
14	SampleSize	O
outpatient	O	O
autistic	Condition	O
children	Age	O
.	O	O

Fourteen	SampleSize	O
children	Age	O
(	O	O
12	SampleSize	O
infantile	Condition	O
autism	Condition	O
full	O	O
syndrome	O	O
present	O	O
,	O	O
2	SampleSize	O
atypical	Condition	O
pervasive	Condition	O
developmental	Condition	O
disorder	Condition	O
)	O	O
between	O	O
5	Age	Age
and	Age	Age
13	Age	Age
years	O	O
of	O	O
age	O	O
participated	O	O
in	O	O
a	O	O
double-blind	O	O
placebo-controlled	O	O
cross-over	O	O
trial	O	O
.	O	O

Each	O	O
child	O	O
received	O	O
20	O	O
mg	O	O
Org	O	O
2766	O	O
(	O	O
synthetic	O	O
analog	O	O
of	O	O
ACTH	O	O
4-9	O	O
)	O	O
/day	O	O
during	O	O
4	O	O
weeks	O	O
,	O	O
or	O	O
placebo	O	O
in	O	O
a	O	O
randomly	O	O
assigned	O	O
sequence	O	O
.	O	O

Drug	O	O
effects	O	O
were	O	O
monitored	O	O
by	O	O
ethological	O	O
playroom	O	O
observation	O	O
and	O	O
by	O	O
Aberrant	O	O
Behavior	O	O
Checklist	O	O
ratings	O	O
by	O	O
parents	O	O
and	O	O
teachers	O	O
.	O	O

Data	O	O
of	O	O
the	O	O
playroom	O	O
observation	O	O
pointed	O	O
to	O	O
an	O	O
activating	O	O
influence	O	O
of	O	O
Org	O	O
2766	O	O
,	O	O
as	O	O
revealed	O	O
by	O	O
a	O	O
significant	O	O
decrease	O	O
of	O	O
stereotypic	O	O
behavior	O	O
and	O	O
significant	O	O
increases	O	O
in	O	O
change	O	O
toys	O	O
,	O	O
locomote	O	O
,	O	O
and	O	O
talk	O	O
.	O	O

Checklist	O	O
ratings	O	O
did	O	O
not	O	O
show	O	O
significant	O	O
changes	O	O
.	O	O

The	O	O
clinical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

Long	O	O
pediatric	O	O
colonoscope	O	O
versus	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
for	O	O
colonoscopy	O	O
.	O	O

BACKGROUND	O	O
Controversy	O	O
exists	O	O
on	O	O
how	O	O
the	O	O
length	O	O
and	O	O
diameter	O	O
of	O	O
colonoscopes	O	O
affect	O	O
the	O	O
quality	O	O
of	O	O
colonoscopy	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
a	O	O
long	O	O
pediatric	O	O
colonoscope	O	O
with	O	O
an	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
with	O	O
regards	O	O
to	O	O
completion	O	O
rate	O	O
and	O	O
cecal	O	O
intubation	O	O
time	O	O
.	O	O

Whether	O	O
either	O	O
scope	O	O
may	O	O
be	O	O
more	O	O
efficient	O	O
in	O	O
any	O	O
subgroups	O	O
was	O	O
also	O	O
investigated	O	O
.	O	O

METHODS	O	O
Asymptomatic	Condition	O
patients	O	O
admitted	O	O
to	O	O
the	O	O
physical	O	O
check-up	O	O
department	O	O
of	O	O
Buddhist	O	O
Dalin	O	O
Tzu	O	O
Chi	O	O
General	O	O
Hospital	O	O
were	O	O
included	O	O
.	O	O

A	O	O
single	O	O
endoscopist	O	O
performed	O	O
all	O	O
of	O	O
the	O	O
colonoscopic	O	O
examinations	O	O
under	O	O
sedation	O	O
.	O	O

Consecutive	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
undergo	O	O
colonoscopy	O	O
with	O	O
either	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
(	O	O
CF-240I	O	O
)	O	O
or	O	O
long	O	O
pediatric	O	O
colonoscope	O	O
(	O	O
PCF-240L	O	O
)	O	O
.	O	O

The	O	O
success	O	O
rate	O	O
and	O	O
time	O	O
required	O	O
to	O	O
reach	O	O
cecum	O	O
were	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
Between	O	O
April	O	O
2005	O	O
and	O	O
February	O	O
2006	O	O
,	O	O
a	O	O
total	O	O
of	O	O
918	SampleSize	SampleSize
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Incomplete	O	O
colonoscopy	O	O
occurred	O	O
in	O	O
21	O	O
(	O	O
2.3	O	O
%	O	O
)	O	O
cases	O	O
(	O	O
14	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
and	O	O
seven	O	O
in	O	O
the	O	O
PCF-240L	O	O
group	O	O
,	O	O
P	O	O
>	O	O
0.1	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
cecal	O	O
mean	O	O
insertion	O	O
time	O	O
was	O	O
6.00	O	O
+/-	O	O
3.66	O	O
min	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
CF-240I	O	O
and	O	O
PCF	O	O
240L	O	O
groups	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
cecal	O	O
intubation	O	O
rate	O	O
(	O	O
96.9	O	O
%	O	O
vs	O	O
98.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.18	O	O
)	O	O
,	O	O
the	O	O
need	O	O
for	O	O
abdominal	O	O
pressure	O	O
(	O	O
71.7	O	O
%	O	O
vs	O	O
73.4	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.55	O	O
)	O	O
and	O	O
change	O	O
of	O	O
position	O	O
(	O	O
13.5	O	O
%	O	O
vs	O	O
11.5	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.37	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
cecal	O	O
intubation	O	O
time	O	O
was	O	O
shorter	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
(	O	O
5.75	O	O
+/-	O	O
3.18	O	O
vs	O	O
6.26	O	O
+/-	O	O
3.30	O	O
min	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

Subgroup	O	O
analysis	O	O
by	O	O
sex	O	O
,	O	O
age	O	O
,	O	O
and	O	O
body	O	O
mass	O	O
index	O	O
showed	O	O
comparable	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
except	O	O
that	O	O
the	O	O
cecal	O	O
intubation	O	O
times	O	O
were	O	O
significantly	O	O
shorter	O	O
in	O	O
the	O	O
CF-240I	O	O
group	O	O
when	O	O
only	O	O
men	O	O
(	O	O
4.78	O	O
+/-	O	O
2.57	O	O
vs	O	O
5.50	O	O
+/-	O	O
2.93	O	O
min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
or	O	O
those	O	O
younger	O	O
than	O	O
50	O	O
years	O	O
(	O	O
5.50	O	O
+/-	O	O
2.90	O	O
vs	O	O
6.25	O	O
+/-	O	O
3.68	O	O
min	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
were	O	O
considered	O	O
.	O	O

CONCLUSION	O	O
Cecal	O	O
intubation	O	O
time	O	O
is	O	O
shorter	O	O
in	O	O
patients	O	O
examined	O	O
with	O	O
an	O	O
intermediate	O	O
length	O	O
adult	O	O
colonoscope	O	O
,	O	O
mainly	O	O
in	O	O
the	O	O
subgroups	O	O
of	O	O
men	O	Sex
and	O	O
those	O	O
younger	O	O
than	O	O
50	O	O
years	O	O
of	O	O
age	O	O
.	O	O

Randomized	O	O
controlled	O	O
trial	O	O
to	O	O
compare	O	O
the	O	O
early	O	O
and	O	O
mid-term	O	O
results	O	O
of	O	O
stapled	O	O
versus	O	O
open	O	O
hemorrhoidectomy	Condition	O
.	O	O

BACKGROUND	O	O
The	O	O
new	O	O
technique	O	O
of	O	O
circular	O	O
stapler	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
hemorrhoids	Condition	O
has	O	O
shown	O	O
early	O	O
promise	O	O
in	O	O
terms	O	O
of	O	O
minimal	O	O
or	O	O
no	O	O
postoperative	O	O
pain	O	O
,	O	O
early	O	O
discharge	O	O
from	O	O
hospital	O	O
,	O	O
and	O	O
quick	O	O
return	O	O
to	O	O
work	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
stapled	O	O
technique	O	O
with	O	O
the	O	O
well-accepted	O	O
conventional	O	O
Milligan	O	O
Morgan	O	O
hemorrhoidectomy	O	O
.	O	O

METHODS	O	O
After	O	O
fulfilling	O	O
the	O	O
selection	O	O
criteria	O	O
,	O	O
84	SampleSize	O
patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
the	O	O
stapled	O	O
(	O	O
n	O	O
=	O	O
42	SampleSize	O
)	O	O
or	O	O
open	O	O
group	O	O
(	O	O
n	O	O
=	O	O
42	SampleSize	O
)	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
operated	O	O
on	O	O
under	O	Condition
spinal	O	Condition
anesthesia	O	Condition
.	O	O

The	O	O
2	O	O
techniques	O	O
were	O	O
evaluated	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
operative	O	O
time	O	O
,	O	O
pain	O	O
scores	O	O
,	O	O
complications	O	O
,	O	O
day	O	O
of	O	O
discharge	O	O
,	O	O
return	O	O
to	O	O
work	O	O
,	O	O
and	O	O
level	O	O
of	O	O
satisfaction	O	O
.	O	O

RESULTS	O	O
The	O	O
mean	O	O
age	O	O
of	O	O
patients	O	O
was	O	O
46.02	Age	O
years	O	O
(	O	O
SD	O	O
,	O	O
12.33	O	O
)	O	O
in	O	O
the	O	O
stapled	O	O
group	O	O
and	O	O
48.64	Age	O
years	O	O
(	O	O
14.57	O	O
)	O	O
in	O	O
the	O	O
open	O	O
group	O	O
.	O	O

Grade	Condition	O
III	Condition	O
or	Condition	O
IV	Condition	O
hemorrhoids	Condition	O
were	O	O
more	O	O
common	O	O
in	O	O
men	O	O
(	O	O
ie	O	O
,	O	O
80.9	O	O
%	O	O
and	O	O
85.7	O	O
%	O	O
in	O	O
the	O	O
stapled	O	O
and	O	O
open	O	O
group	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
operative	O	O
time	O	O
was	O	O
shorter	O	O
in	O	O
the	O	O
stapled	O	O
group	O	O
24.28	O	O
minutes	O	O
(	O	O
4.25	O	O
)	O	O
versus	O	O
45.21	O	O
minutes	O	O
(	O	O
5.36	O	O
)	O	O
in	O	O
the	O	O
Milligan-Morgan	O	O
group	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
blood	O	O
loss	O	O
,	O	O
pain	O	O
scores	O	O
and	O	O
requirement	O	O
of	O	O
analgesics	O	O
was	O	O
significantly	O	O
less	O	O
in	O	O
the	O	O
stapled	O	O
group	O	O
.	O	O

Mean	O	O
hospital	O	O
stay	O	O
was	O	O
1.24	O	O
days	O	O
(	O	O
0.62	O	O
)	O	O
and	O	O
2.76	O	O
days	O	O
(	O	O
1.01	O	O
)	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
in	O	O
the	O	O
stapled	O	O
and	O	O
open	O	O
group	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
patients	O	O
in	O	O
the	O	O
stapled	O	O
group	O	O
returned	O	O
to	O	O
work	O	O
or	O	O
routine	O	O
activities	O	O
earlier	O	O
(	O	O
ie	O	O
,	O	O
within	O	O
8.12	O	O
days	O	O
[	O	O
2.48	O	O
]	O	O
)	O	O
as	O	O
compared	O	O
with	O	O
17.62	O	O
(	O	O
5.59	O	O
)	O	O
in	O	O
the	O	O
open	O	O
group	O	O
.	O	O

Only	O	O
88.1	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
satisfied	O	O
by	O	O
the	O	O
open	O	O
method	O	O
compared	O	O
with	O	O
97.6	O	O
%	O	O
after	O	O
the	O	O
stapled	O	O
technique	O	O
.	O	O

The	O	O
median	O	O
follow-up	O	O
period	O	O
was	O	O
11	O	O
months	O	O
with	O	O
a	O	O
maximum	O	O
follow-up	O	O
of	O	O
19	O	O
months	O	O
(	O	O
range	O	O
2-19	O	O
months	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Stapled	O	O
hemorrhoidectomy	O	O
is	O	O
a	O	O
safe	O	O
and	O	O
effective	O	O
day-care	O	O
procedure	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
grade	Condition	O
III	Condition	O
and	Condition	O
grade	Condition	O
IV	Condition	O
hemorrhoids	Condition	O
.	O	O

It	O	O
ensures	O	O
lesser	O	O
postoperative	O	O
pain	O	O
,	O	O
early	O	O
discharge	O	O
,	O	O
less	O	O
time	O	O
off	O	O
work	O	O
,	O	O
complications	O	O
similar	O	O
to	O	O
the	O	O
open	O	O
technique	O	O
,	O	O
and	O	O
in	O	O
the	O	O
end	O	O
a	O	O
more	O	O
satisfied	O	O
patient	O	O
with	O	O
no	O	O
perianal	O	O
wound	O	O
.	O	O

However	O	O
,	O	O
more	O	O
such	O	O
randomized	O	O
trials	O	O
are	O	O
essential	O	O
to	O	O
deny	O	O
any	O	O
long-term	O	O
complication	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
therapeutic	O	O
effects	O	O
of	O	O
a	O	O
hippotherapy	O	O
simulator	O	O
in	O	O
children	Age	O
with	O	O
cerebral	Condition	O
palsy	Condition	O
:	O	O
a	O	O
stratified	O	O
single-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
investigate	O	O
whether	O	O
hippotherapy	O	O
(	O	O
when	O	O
applied	O	O
by	O	O
a	O	O
simulator	O	O
)	O	O
improves	O	O
postural	O	O
control	O	O
and	O	O
balance	O	O
in	O	O
children	Age	O
with	O	O
cerebral	Condition	O
palsy	Condition	O
.	O	O

DESIGN	O	O
Stratified	O	O
single-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
with	O	O
an	O	O
independent	O	O
assessor	O	O
.	O	O

Stratification	O	O
was	O	O
made	O	O
by	O	O
gross	O	O
motor	O	O
function	O	O
classification	O	O
system	O	O
levels	O	O
,	O	O
and	O	O
allocation	O	O
was	O	O
concealed	O	O
.	O	O

SUBJECTS	O	O
Children	Age	O
between	O	O
4	Age	O
and	Age	O
18	Age	O
years	O	O
old	O	O
with	O	O
cerebral	Condition	O
palsy	Condition	O
.	O	O

INTERVENTIONS	O	O
Participants	O	O
were	O	O
randomized	O	O
to	O	O
an	O	O
intervention	O	O
(	O	O
simulator	O	O
ON	O	O
)	O	O
or	O	O
control	O	O
(	O	O
simulator	O	O
OFF	O	O
)	O	O
group	O	O
after	O	O
getting	O	O
informed	O	O
consent	O	O
.	O	O

Treatment	O	O
was	O	O
provided	O	O
once	O	O
a	O	O
week	O	O
(	O	O
15	O	O
minutes	O	O
)	O	O
for	O	O
10	O	O
weeks	O	O
.	O	O

MAIN	O	O
MEASURES	O	O
Gross	O	O
Motor	O	O
Function	O	O
Measure	O	O
(	O	O
dimension	O	O
B	O	O
for	O	O
balance	O	O
and	O	O
the	O	O
Total	O	O
Score	O	O
)	O	O
and	O	O
Sitting	O	O
Assessment	O	O
Scale	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
baseline	O	O
(	O	O
prior	O	O
to	O	O
randomization	O	O
)	O	O
,	O	O
end	O	O
of	O	O
intervention	O	O
and	O	O
12	O	O
weeks	O	O
after	O	O
completing	O	O
the	O	O
intervention	O	O
.	O	O

RESULTS	O	O
Thirty-eight	SampleSize	O
children	Age	O
participated	O	O
.	O	O

The	O	O
groups	O	O
were	O	O
balanced	O	O
at	O	O
baseline	O	O
.	O	O

Sitting	O	O
balance	O	O
(	O	O
measured	O	O
by	O	O
dimension	O	O
B	O	O
of	O	O
the	O	O
Gross	O	O
Motor	O	O
Function	O	O
Measure	O	O
)	O	O
improved	O	O
significantly	O	O
in	O	O
the	O	O
treatment	O	O
group	O	O
(	O	O
effect	O	O
size	O	O
=	O	O
0.36	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.01-0.71	O	O
)	O	O
and	O	O
the	O	O
effect	O	O
size	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
severely	O	O
disabled	O	O
group	O	O
(	O	O
effect	O	O
size	O	O
=	O	O
0.80	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.13-1.47	O	O
)	O	O
.	O	O

The	O	O
improvements	O	O
in	O	O
sitting	O	O
balance	O	O
were	O	O
not	O	O
maintained	O	O
over	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

Changes	O	O
in	O	O
the	O	O
total	O	O
score	O	O
of	O	O
the	O	O
Gross	O	O
Motor	O	O
Function	O	O
Measure	O	O
and	O	O
the	O	O
Sitting	O	O
Assessment	O	O
Scale	O	O
were	O	O
not	O	O
significant	O	O
.	O	O

CONCLUSION	O	O
Hippotherapy	O	O
with	O	O
a	O	O
simulator	O	O
can	O	O
improve	O	O
sitting	O	O
balance	O	O
in	O	O
cerebral	Condition	O
palsy	Condition	O
children	Age	O
who	O	O
have	O	O
higher	O	O
levels	O	O
of	O	O
disability	O	O
.	O	O

However	O	O
,	O	O
this	O	O
did	O	O
not	O	O
lead	O	O
to	O	O
a	O	O
change	O	O
in	O	O
the	O	O
overall	O	O
function	O	O
of	O	O
these	O	O
children	O	O
(	O	O
Gross	O	O
Motor	O	O
Function	O	O
Classification	O	O
System	O	O
level	O	O
V	O	O
)	O	O
.	O	O

Impact	O	O
of	O	O
a	O	O
single	O	O
intravenous	O	O
administration	O	O
of	O	O
nicorandil	O	O
before	O	O
reperfusion	O	O
in	O	O
patients	O	O
with	O	O
ST-segment-elevation	Condition	O
myocardial	Condition	O
infarction	Condition	O
.	O	O

BACKGROUND	O	O
Intravenous	O	O
nicorandil	O	O
,	O	O
a	O	O
hybrid	O	O
compound	O	O
of	O	O
ATP-sensitive	O	O
potassium	O	O
channel	O	O
opener	O	O
and	O	O
nitric	O	O
oxide	O	O
donor	O	O
,	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
ameliorate	O	O
early	O	O
functional	O	O
and	O	O
clinical	O	O
problems	O	O
in	O	O
patients	O	O
with	O	O
acute	O	Condition
myocardial	O	Condition
infarction	O	Condition
.	O	O

However	O	O
,	O	O
its	O	O
effects	O	O
on	O	O
the	O	O
late	O	O
phase	O	O
remain	O	O
unclear	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
This	O	O
follow-up	O	O
study	O	O
to	O	O
5	O	O
years	O	O
of	O	O
a	O	O
randomized	O	O
,	O	O
double-blinded	O	O
trial	O	O
was	O	O
conducted	O	O
among	O	O
368	SampleSize	SampleSize
patients	O	O
with	O	O
first	O	O
ST-segment-elevation	O	O
myocardial	O	O
infarction	O	O
undergoing	O	O
percutaneous	Condition	O
coronary	Condition	O
intervention	Condition	O
(	O	O
PCI	Condition	O
)	O	O
.	O	O

They	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
12	O	O
mg	O	O
of	O	O
nicorandil	O	O
or	O	O
a	O	O
placebo	O	O
intravenously	O	O
just	O	O
before	O	O
reperfusion	O	O
.	O	O

We	O	O
analyzed	O	O
incidence	O	O
of	O	O
cardiovascular	O	O
death	O	O
or	O	O
rehospitalization	O	O
for	O	O
congestive	O	O
heart	O	O
failure	O	O
after	O	O
PCI	O	O
as	O	O
well	O	O
as	O	O
various	O	O
aspects	O	O
of	O	O
epicardial	O	O
flow	O	O
and	O	O
microvascular	O	O
function	O	O
.	O	O

Mean	O	O
follow-up	O	O
was	O	O
2.4	O	O
years	O	O
(	O	O
SD	O	O
,	O	O
1.4	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
12	O	O
(	O	O
6.5	O	O
%	O	O
)	O	O
patients	O	O
receiving	O	O
nicorandil	O	O
and	O	O
30	O	O
(	O	O
16.4	O	O
%	O	O
)	O	O
receiving	O	O
placebo	O	O
had	O	O
cardiovascular	O	O
death	O	O
or	O	O
hospital	O	O
admission	O	O
for	O	O
congestive	O	O
heart	O	O
failure	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
0.39	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.20	O	O
to	O	O
0.76	O	O
;	O	O
P=0.0058	O	O
)	O	O
.	O	O

Postprocedural	O	O
TIMI	O	O
3	O	O
flow	O	O
was	O	O
obtained	O	O
in	O	O
89.7	O	O
%	O	O
of	O	O
the	O	O
nicorandil	O	O
group	O	O
and	O	O
in	O	O
81.4	O	O
%	O	O
of	O	O
the	O	O
placebo	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
1.99	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.09	O	O
to	O	O
3.65	O	O
;	O	O
P=0.025	O	O
)	O	O
.	O	O

Corrected	O	O
TIMI	O	O
frame	O	O
count	O	O
was	O	O
furthermore	O	O
lower	O	O
in	O	O
the	O	O
nicorandil	O	O
group	O	O
(	O	O
21.0+/-9.1	O	O
versus	O	O
25.1+/-14.1	O	O
;	O	O
P=0.0009	O	O
)	O	O
.	O	O

ST-segment	O	O
resolution	O	O
>	O	O
50	O	O
%	O	O
was	O	O
observed	O	O
in	O	O
79.5	O	O
%	O	O
and	O	O
61.2	O	O
%	O	O
of	O	O
the	O	O
nicorandil	O	O
and	O	O
placebo	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
2.45	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.54	O	O
to	O	O
3.90	O	O
;	O	O
P=0.0002	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
addition	O	O
of	O	O
intravenous	O	O
nicorandil	O	O
to	O	O
PCI	O	O
leads	O	O
to	O	O
beneficial	O	O
clinical	O	O
outcomes	O	O
and	O	O
prevents	O	O
cardiovascular	O	O
events	O	O
of	O	O
long	O	O
duration	O	O
and	O	O
death	O	O
in	O	O
patients	O	O
with	O	O
ST-segment-elevation	O	O
myocardial	O	O
infarction	O	O
.	O	O

Treatment	O	O
with	O	O
metformin	O	O
of	O	O
non-diabetic	Condition	O
men	Sex	O
with	O	O
hypertension	Condition	Condition
,	O	O
hypertriglyceridaemia	Condition	O
and	O	O
central	Condition	O
fat	Condition	O
distribution	Condition	O
:	O	O
the	O	O
BIGPRO	O	O
1.2	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
In	O	O
the	O	O
BIGPRO	O	O
1	O	O
trial	O	O
,	O	O
one	O	O
year	O	O
of	O	O
treatment	O	O
with	O	O
metformin	O	O
in	O	O
non-diabetic	Condition	Condition
obese	Condition	Condition
subjects	O	O
with	O	O
a	O	O
central	Condition	O
fat	Condition	O
distribution	Condition	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
fasting	O	O
plasma	O	O
triglyceride	O	O
concentration	O	O
or	O	O
on	O	O
blood	O	O
pressure	O	O
despite	O	O
a	O	O
decrease	O	O
in	O	O
weight	O	O
,	O	O
fasting	O	O
plasma	O	O
insulin	O	O
and	O	O
glucose	O	O
concentrations	O	O
.	O	O

To	O	O
re-evaluate	O	O
the	O	O
effect	O	O
of	O	O
metformin	O	O
on	O	O
fasting	O	O
triglyceride	O	O
concentration	O	O
and	O	O
on	O	O
blood	O	O
pressure	O	O
,	O	O
the	O	O
BIGPRO	O	O
1.2	O	O
trial	O	O
included	O	O
non-diabetic	Condition	O
men	Sex	O
(	O	O
n=168	SampleSize	O
)	O	O
with	O	O
a	O	O
fasting	O	O
plasma	O	O
triglyceride	O	O
concentration	O	O
>	Condition	O
or	Condition	O
=1.7	Condition	O
and	Condition	O
<	Condition	O
or	Condition	O
=6.5	Condition	O
mmol/l	Condition	O
,	O	O
high	Condition	O
blood	Condition	O
pressure	Condition	O
(	O	O
systolic	O	O
>	O	O
or	O	O
=140	O	O
and	O	O
<	O	O
or	O	O
=180	O	O
and/or	O	O
diastolic	O	O
>	O	O
or	O	O
=90	O	O
and	O	O
<	O	O
or	O	O
=105	O	O
mmHg	O	O
,	O	O
or	O	O
treatment	O	O
for	O	O
hypertension	Condition	O
)	O	O
and	O	O
a	O	O
waist-to-hip	Condition	O
ratio	Condition	O
>	Condition	O
or	Condition	O
=0.95	Condition	O
.	Condition	O

METHODS	O	O
A	O	O
randomised	O	O
double-blind	O	O
trial	O	O
comparing	O	O
metformin	O	O
treatment	O	O
(	O	O
850	O	O
mg	O	O
bid	O	O
)	O	O
with	O	O
placebo	O	O
.	O	O

RESULTS	O	O
Metformin	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
either	O	O
on	O	O
blood	O	O
pressure	O	O
or	O	O
plasma	O	O
triglyceride	O	O
concentration	O	O
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
fasting	O	O
plasma	O	O
insulin	O	O
(	O	O
p	O	O
<	O	O
0.04	O	O
)	O	O
,	O	O
total	O	O
cholesterol	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
and	O	O
Apo	O	O
B	O	O
(	O	O
p	O	O
<	O	O
0.008	O	O
)	O	O
concentrations	O	O
decreased	O	O
more	O	O
in	O	O
the	O	O
metformin	O	O
group	O	O
in	O	O
the	O	O
BIGPRO	O	O
1	O	O
.	O	O

2	O	O
trial	O	O
,	O	O
confirming	O	O
most	O	O
of	O	O
the	O	O
previous	O	O
results	O	O
of	O	O
the	O	O
BIGPRO	O	O
1	O	O
trial	O	O
.	O	O

Tissue	O	O
plasminogen	O	O
activator	O	O
antigen	O	O
concentration	O	O
decreased	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
only	O	O
in	O	O
the	O	O
metformin	O	O
group	O	O
,	O	O
but	O	O
this	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0.12	O	O
)	O	O
;	O	O
further	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
change	O	O
in	O	O
plasminogen	O	O
activator	O	O
inhibitor	O	O
1	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
consistency	O	O
of	O	O
the	O	O
two	O	O
BIGPRO	O	O
trials	O	O
supports	O	O
the	O	O
conclusion	O	O
that	O	O
metformin	O	O
affects	O	O
several	O	O
cardiovascular	O	O
risk	O	O
factors	O	O
favourably	O	O
in	O	O
non-diabetic	Condition	O
subjects	O	O
with	O	O
a	O	O
central	Condition	O
fat	Condition	O
distribution	Condition	O
.	O	O

Observer	O	O
variation	O	O
in	O	O
the	O	O
assessment	O	O
of	O	O
outcome	O	O
in	O	O
traumatic	O	Condition
brain	O	Condition
injury	O	Condition
:	O	Condition
experience	O	O
from	O	O
a	O	O
multicenter	O	O
,	O	O
international	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
Accurate	O	O
and	O	O
consistent	O	O
outcome	O	O
assessment	O	O
is	O	O
essential	O	O
to	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
explore	O	O
observer	O	O
variation	O	O
in	O	O
the	O	O
assessment	O	O
of	O	O
outcome	O	O
in	O	O
a	O	O
recently	O	O
completed	O	O
trial	O	O
of	O	O
dexanabinol	O	O
in	O	O
head	Condition	O
injury	Condition	O
and	O	O
to	O	O
consider	O	O
steps	O	O
to	O	O
reduce	O	O
such	O	O
variation	O	O
.	O	O

METHODS	O	O
Eight	SampleSize	SampleSize
hundred	SampleSize	Condition
sixty-one	SampleSize	Condition
patients	O	Condition
with	O	Condition
severe	Condition	Condition
traumatic	Condition	Condition
brain	Condition	Condition
injury	Condition	Condition
who	O	Condition
were	O	Condition
admitted	O	Condition
to	O	Condition
86	O	Condition
centers	O	Condition
were	O	O
included	O	O
in	O	O
a	O	O
multicenter	O	O
,	O	O
placebo-controlled	O	O
,	O	O
Phase	O	O
III	O	O
trial	O	O
.	O	O

Outcome	O	O
was	O	O
assessed	O	O
at	O	O
3	O	O
and	O	O
6	O	O
months	O	O
postinjury	O	O
using	O	O
the	O	O
extended	O	O
Glasgow	O	O
Outcome	O	O
Scale	O	O
;	O	O
standardized	O	O
assessment	O	O
was	O	O
facilitated	O	O
by	O	O
the	O	O
use	O	O
of	O	O
a	O	O
structured	O	O
interview	O	O
.	O	O

Before	O	O
initiation	O	O
of	O	O
trial	O	O
centers	O	O
,	O	O
outcome	O	O
ratings	O	O
were	O	O
obtained	O	O
for	O	O
sample	O	O
cases	O	O
to	O	O
establish	O	O
initial	O	O
levels	O	O
of	O	O
agreement	O	O
.	O	O

Training	O	O
sessions	O	O
in	O	O
outcome	O	O
assessment	O	O
were	O	O
held	O	O
,	O	O
and	O	O
problems	O	O
in	O	O
assigning	O	O
outcome	O	O
were	O	O
investigated	O	O
.	O	O

During	O	O
the	O	O
trial	O	O
,	O	O
a	O	O
process	O	O
of	O	O
central	O	O
review	O	O
was	O	O
established	O	O
to	O	O
monitor	O	O
performance	O	O
.	O	O

Interobserver	O	O
variation	O	O
was	O	O
analyzed	O	O
using	O	O
the	O	O
kappa	O	O
statistic	O	O
.	O	O

RESULTS	O	O
Substantial	O	O
observer	O	O
variation	O	O
was	O	O
found	O	O
in	O	O
the	O	O
rating	O	O
of	O	O
sample	O	O
cases	O	O
(	O	O
weighted	O	O
kappa	O	O
,	O	O
0.72	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.68-0.75	O	O
)	O	O
and	O	O
in	O	O
assigning	O	O
outcome	O	O
based	O	O
on	O	O
completed	O	O
structured	O	O
interviews	O	O
(	O	O
weighted	O	O
kappa	O	O
,	O	O
0.61	O	O
;	O	O
confidence	O	O
interval	O	O
,	O	O
0.57-0.64	O	O
)	O	O
.	O	O

In	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
a	O	O
relatively	O	O
large	O	O
number	O	O
of	O	O
discrepancies	O	O
(	O	O
29-37	O	O
%	O	O
)	O	O
were	O	O
identified	O	O
on	O	O
central	O	O
review	O	O
.	O	O

This	O	O
number	O	O
declined	O	O
as	O	O
the	O	O
trial	O	O
progressed	O	O
and	O	O
coincided	O	O
with	O	O
investigator	O	O
training	O	O
and	O	O
feedback	O	O
from	O	O
central	O	O
review	O	O
.	O	O

Centers	O	O
with	O	O
higher	O	O
enrollment	O	O
rates	O	O
showed	O	O
better	O	O
performance	O	O
.	O	O

CONCLUSION	O	O
Observer	O	O
variation	O	O
in	O	O
outcome	O	O
assessment	O	O
is	O	O
a	O	O
significant	O	O
problem	O	O
for	O	O
head	O	O
injury	O	O
trials	O	O
.	O	O

Consistency	O	O
can	O	O
be	O	O
improved	O	O
by	O	O
standardizing	O	O
procedures	O	O
,	O	O
training	O	O
assessors	O	O
,	O	O
and	O	O
monitoring	O	O
the	O	O
quality	O	O
of	O	O
assessments	O	O
and	O	O
providing	O	O
feedback	O	O
to	O	O
interviewers	O	O
.	O	O

Is	O	O
a	O	O
calculated	O	O
total	O	O
hip	O	O
BMD	O	O
of	O	O
clinical	O	O
use	O	O
?	O	O
The	O	O
diagnosis	O	O
of	O	O
osteoporosis	O	O
is	O	O
based	O	O
on	O	O
bone	O	O
mass	O	O
measurement	O	O
.	O	O

To	O	O
avoid	O	O
the	O	O
errors	O	O
associated	O	O
with	O	O
the	O	O
measurement	O	O
of	O	O
spinal	O	O
bone	O	O
density	O	O
the	O	O
total	O	O
hip	O	O
has	O	O
been	O	O
accepted	O	O
as	O	O
the	O	O
standard	O	O
measurement	O	O
site	O	O
.	O	O

This	O	O
information	O	O
is	O	O
not	O	O
available	O	O
for	O	O
many	O	O
early	O	O
measurements	O	O
.	O	O

We	O	O
have	O	O
assessed	O	O
whether	O	O
it	O	O
is	O	O
possible	O	O
to	O	O
derive	O	O
clinically	O	O
useful	O	O
information	O	O
about	O	O
total	O	O
hip	O	O
bone	O	O
mineral	O	O
density	O	O
(	O	O
BMD	O	O
)	O	O
from	O	O
measurements	O	O
at	O	O
other	O	O
hip	O	O
sites	O	O
.	O	O

The	O	O
bone	O	O
mass	O	O
measurements	O	O
of	O	O
46	SampleSize	O
patients	O	O
participating	O	O
in	O	O
a	O	O
current	O	O
trial	O	O
of	O	O
therapy	O	O
for	O	O
osteoporosis	Condition	O
were	O	O
reviewed	O	O
.	O	O

The	O	O
total	O	O
hip	O	O
BMD	O	O
as	O	O
directly	O	O
measured	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
obtained	O	O
from	O	O
the	O	O
formula	O	O
:	O	O
Total	O	O
hip	O	O
BMD	O	O
=	O	O
0.48	O	O
x	O	O
Neck	O	O
BMD	O	O
+	O	O
0.62	O	O
x	O	O
Trochanteric	O	O
BMD	O	O
+	O	O
0.03	O	O
.	O	O

In	O	O
30	SampleSize	O
patients	O	O
with	O	O
follow-up	O	O
data	O	O
the	O	O
rate	O	O
of	O	O
change	O	O
in	O	O
hip	O	O
BMD	O	O
over	O	O
a	O	O
year	O	O
was	O	O
also	O	O
determined	O	O
by	O	O
both	O	O
methods	O	O
.	O	O

In	O	O
the	O	O
pretreatment	O	O
state	O	O
there	O	O
was	O	O
good	O	O
agreement	O	O
between	O	O
the	O	O
two	O	O
measures	O	O
(	O	O
r2	O	O
=	O	O
0.96	O	O
,	O	O
SEE	O	O
0.012	O	O
g/cm2	O	O
)	O	O
.	O	O

If	O	O
the	O	O
formula	O	O
was	O	O
used	O	O
to	O	O
compute	O	O
a	O	O
change	O	O
in	O	O
total	O	O
hip	O	O
BMD	O	O
,	O	O
the	O	O
agreement	O	O
between	O	O
both	O	O
methods	O	O
remained	O	O
good	O	O
.	O	O

However	O	O
,	O	O
the	O	O
standard	O	O
error	O	O
of	O	O
the	O	O
estimate	O	O
of	O	O
the	O	O
change	O	O
represented	O	O
59	O	O
%	O	O
of	O	O
the	O	O
observed	O	O
change	O	O
.	O	O

This	O	O
indicates	O	O
that	O	O
the	O	O
error	O	O
associated	O	O
with	O	O
this	O	O
estimate	O	O
is	O	O
too	O	O
great	O	O
to	O	O
allow	O	O
clinically	O	O
meaningful	O	O
conclusions	O	O
to	O	O
be	O	O
drawn	O	O
from	O	O
calculated	O	O
total	O	O
hip	O	O
BMD	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
,	O	O
whilst	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
obtain	O	O
reasonable	O	O
point	O	O
estimates	O	O
of	O	O
total	O	O
hip	O	O
BMD	O	O
from	O	O
other	O	O
measures	O	O
in	O	O
the	O	O
hip	O	O
,	O	O
these	O	O
estimates	O	O
are	O	O
too	O	O
imprecise	O	O
to	O	O
allow	O	O
conclusions	O	O
about	O	O
change	O	O
in	O	O
BMD	O	O
to	O	O
be	O	O
made	O	O
.	O	O

Treatment	O	O
of	O	O
stable	Condition	O
angina	Condition	O
of	Condition	O
effort	Condition	O
with	O	O
verapamil	O	O
:	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
randomized	O	O
crossover	O	O
study	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
verapamil	O	O
were	O	O
assessed	O	O
in	O	O
26	SampleSize	SampleSize
patients	O	O
with	O	O
stable	Condition	O
exertional	Condition	O
angina	Condition	O
pectoris	Condition	O
in	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
randomized	O	O
crossover	O	O
protocol	O	O
using	O	O
serial	O	O
treadmill	O	O
tests	O	O
.	O	O

Verapamil	O	O
,	O	O
480	O	O
mg/day	O	O
,	O	O
reduced	O	O
anginal	O	O
frequency	O	O
from	O	O
5.6	O	O
+/-	O	O
7.3	O	O
to	O	O
2.2	O	O
+/-	O	O
3.9	O	O
attacks	O	O
per	O	O
week	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
nitroglycerin	O	O
consumption	O	O
from	O	O
3.4	O	O
+/-	O	O
4.9	O	O
to	O	O
1.2	O	O
+/-	O	O
2.5	O	O
tablets	O	O
per	O	O
week	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

Treadmill	O	O
time	O	O
increased	O	O
from	O	O
6.4	O	O
+/-	O	O
2.1	O	O
minutes	O	O
during	O	O
the	O	O
placebo	O	O
phase	O	O
to	O	O
7.5	O	O
+/-	O	O
1.8	O	O
minutes	O	O
during	O	O
the	O	O
verapamil	O	O
phase	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Verapamil	O	O
's	O	O
beneficial	O	O
effect	O	O
appeared	O	O
to	O	O
be	O	O
related	O	O
,	O	O
in	O	O
part	O	O
,	O	O
to	O	O
a	O	O
10	O	O
%	O	O
reduction	O	O
of	O	O
the	O	O
rate-pressure	O	O
product	O	O
at	O	O
rest	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
and	O	O
a	O	O
12	O	O
%	O	O
reduction	O	O
during	O	O
submaximal	O	O
exercise	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Verapamil	O	O
also	O	O
caused	O	O
less	O	O
marked	O	O
ST-segment	O	O
depressions	O	O
at	O	O
peak	O	O
exercise	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
at	O	O
a	O	O
similar	O	O
rate-pressure	O	O
product	O	O
,	O	O
suggesting	O	O
a	O	O
favorable	O	O
redistribution	O	O
of	O	O
coronary	O	O
blood	O	O
flow	O	O
to	O	O
the	O	O
ischemic	O	O
zone	O	O
.	O	O

Side	O	O
effects	O	O
from	O	O
verapamil	O	O
were	O	O
minimal	O	O
,	O	O
consisting	O	O
mainly	O	O
of	O	O
constipation	O	O
(	O	O
six	O	O
patients	O	O
)	O	O
.	O	O

Verapamil	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
safe	O	O
and	O	O
effective	O	O
drug	O	O
for	O	O
treating	O	O
angina	Condition	O
of	O	O
effort	O	O
.	O	O

Sunbathing	O	O
and	O	O
sunbed	O	O
use	O	O
related	O	O
to	O	O
self-image	O	O
in	O	O
a	O	O
randomized	O	O
sample	O	O
of	O	O
Swedish	O	O
adolescents	Age	Age
.	O	O

In	O	O
1996	O	O
a	O	O
randomized	O	O
sample	O	O
of	O	O
4,020	SampleSize	Age
Swedish	O	Age
adolescents	Age	Age
from	O	O
three	O	O
birth	O	O
cohorts	O	O
were	O	O
sent	O	O
a	O	O
questionnaire	O	O
consisting	O	O
of	O	O
50	O	SampleSize
items	O	O
concerning	O	O
habitual	O	O
sun-related	O	O
behaviours	O	O
and	O	O
attitudes	O	O
,	O	O
knowledge	O	O
about	O	O
melanoma	O	O
,	O	O
risk	O	O
perception	O	O
and	O	O
self-image	O	O
.	O	O

A	O	O
total	O	O
of	O	O
2,615	SampleSize	O
questionnaires	O	O
were	O	O
returned	O	O
.	O	O

Girls	Sex	O
sunbathed	O	O
and	O	O
used	O	O
sunbeds	O	O
more	O	O
than	O	O
boys	Sex	O
at	O	O
all	O	O
ages	O	O
.	O	O

Sunbathing	O	O
and	O	O
sunbed	O	O
use	O	O
increased	O	O
with	O	O
age	O	O
.	O	O

Boys	O	O
who	O	O
were	O	O
most	O	O
satisfied	O	O
and	O	O
girls	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
sunbathed	O	O
most	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
used	O	O
sunbeds	O	O
most	O	O
frequently	O	O
.	O	O

Girls	O	O
reported	O	O
a	O	O
higher	O	O
perceived	O	O
susceptibility	O	O
to	O	O
melanoma	O	O
than	O	O
did	O	O
boys	O	O
.	O	O

The	O	O
perception	O	O
of	O	O
susceptibility	O	O
increased	O	O
with	O	O
age	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
least	O	O
satisfied	O	O
with	O	O
themselves	O	O
reported	O	O
feeling	O	O
most	O	O
susceptible	O	O
.	O	O

The	O	O
overall	O	O
main	O	O
reason	O	O
for	O	O
sunbathing	O	O
was	O	O
appearance	O	O
,	O	O
both	O	O
for	O	O
own	O	O
sunbathing	O	O
,	O	O
and	O	O
to	O	O
an	O	O
even	O	O
higher	O	O
degree	O	O
,	O	O
as	O	O
a	O	O
supposed	O	O
reason	O	O
for	O	O
other	O	O
adolescents	O	O
'	O	O
behaviour	O	O
,	O	O
and	O	O
was	O	O
reported	O	O
most	O	O
frequently	O	O
by	O	O
girls	O	O
and	O	O
the	O	O
older	O	O
age	O	O
groups	O	O
.	O	O

The	O	O
second	O	O
most	O	O
'important	O	O
'	O	O
reason	O	O
for	O	O
sunbathing	O	O
was	O	O
'feeling	O	O
warm	O	O
and	O	O
comfortable	O	O
'	O	O
.	O	O

Preventive	O	O
programmes	O	O
aimed	O	O
at	O	O
a	O	O
change	O	O
of	O	O
sun	O	O
related	O	O
behaviours	O	O
among	O	O
Swedish	O	O
adolescents	O	O
have	O	O
to	O	O
be	O	O
tailored	O	O
to	O	O
the	O	O
climate	O	O
and	O	O
cultural	O	O
conditions	O	O
and	O	O
must	O	O
take	O	O
into	O	O
account	O	O
that	O	O
having	O	O
a	O	O
tan	O	O
,	O	O
and	O	O
the	O	O
warmth	O	O
of	O	O
the	O	O
sun	O	O
,	O	O
are	O	O
highly	O	O
valued	O	O
by	O	O
most	O	O
adolescents	O	O
.	O	O

Niacin	O	O
revisited	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
of	O	O
wax-matrix	O	O
sustained-release	O	O
niacin	O	O
in	O	O
hypercholesterolemia	Condition	O
.	O	O

Two	SampleSize	SampleSize
hundred	SampleSize	SampleSize
one	SampleSize	SampleSize
male	Sex	O
and	Sex	O
female	Sex	O
subjects	O	O
,	O	O
aged	O	O
20	Age	Age
to	Age	Age
70	Age	Age
years	O	O
,	O	O
with	O	O
elevated	Condition	O
low-density	Condition	O
lipoprotein	Condition	O
cholesterol	O	O
values	O	O
(	O	O
in	O	O
the	O	O
75th	Condition	O
to	Condition	O
95th	Condition	O
percentiles	Condition	O
)	O	O
,	O	O
participated	O	O
in	O	O
a	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
double-blind	O	O
study	O	O
using	O	O
a	O	O
new	O	O
form	O	O
of	O	O
niacin	O	O
(	O	O
Enduracin	O	O
)	O	O
,	O	O
which	O	O
employs	O	O
a	O	O
wax-matrix	O	O
vehicle	O	O
for	O	O
sustained	O	O
release	O	O
.	O	O

Four	O	O
niacin	O	O
treatment	O	O
groups	O	O
(	O	O
daily	O	O
doses	O	O
of	O	O
2000	O	O
,	O	O
1500	O	O
,	O	O
1250	O	O
,	O	O
and	O	O
1000	O	O
mg	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
placebo-	O	O
and	O	O
diet-treated	O	O
controls	O	O
to	O	O
determine	O	O
side-effect	O	O
profile	O	O
and	O	O
optimal	O	O
range	O	O
of	O	O
efficacy	O	O
.	O	O

The	O	O
groups	O	O
given	O	O
2000	O	O
and	O	O
1500	O	O
mg	O	O
demonstrated	O	O
significant	O	O
reductions	O	O
in	O	O
values	O	O
of	O	O
low-density	O	O
lipoprotein	O	O
cholesterol	O	O
(	O	O
-26	O	O
%	O	O
and	O	O
-19.3	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
total	O	O
cholesterol	O	O
(	O	O
-18.4	O	O
%	O	O
and	O	O
-13.3	O	O
%	O	O
)	O	O
,	O	O
and	O	O
total	O	O
cholesterol-high-density	O	O
lipoprotein	O	O
cholesterol	O	O
ratio	O	O
(	O	O
-20.4	O	O
%	O	O
and	O	O
-19.4	O	O
%	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
diet-	O	O
and	O	O
placebo-treated	O	O
controls	O	O
.	O	O

Smaller	O	O
improvements	O	O
were	O	O
seen	O	O
in	O	O
high-density	O	O
lipoprotein	O	O
cholesterol	O	O
and	O	O
triglyceride	O	O
levels	O	O
.	O	O

Blood	O	O
chemistry	O	O
monitoring	O	O
indicated	O	O
that	O	O
reduction	O	O
in	O	O
low-density	O	O
lipoprotein	O	O
cholesterol	O	O
level	O	O
strongly	O	O
correlated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
baseline	O	O
levels	O	O
of	O	O
some	O	O
enzymes	O	O
for	O	O
niacin-treated	O	O
subjects	O	O
.	O	O

The	O	O
improved	O	O
side-effect	O	O
profile	O	O
of	O	O
the	O	O
wax-matrix	O	O
form	O	O
of	O	O
niacin	O	O
was	O	O
particularly	O	O
notable	O	O
.	O	O

The	O	O
dropout	O	O
rate	O	O
due	O	O
to	O	O
side	O	O
effects	O	O
was	O	O
only	O	O
3.4	O	O
%	O	O
and	O	O
was	O	O
coupled	O	O
with	O	O
good	O	O
medication	O	O
compliance	O	O
.	O	O

Pre-bent	O	O
instruments	O	O
used	O	O
in	O	O
single-port	O	O
laparoscopic	O	O
surgery	O	O
versus	O	O
conventional	O	O
laparoscopic	O	O
surgery	O	O
:	O	O
comparative	O	O
study	O	O
of	O	O
performance	O	O
in	O	O
a	O	O
dry	O	O
lab	O	O
.	O	O

BACKGROUND	O	O
Different	O	O
types	O	O
of	O	O
single-incision	O	O
laparoscopic	O	O
surgery	O	O
(	O	O
SILS	O	O
)	O	O
have	O	O
become	O	O
increasingly	O	O
popular	O	O
.	O	O

Although	O	O
SILS	O	O
is	O	O
technically	O	O
even	O	O
more	O	O
challenging	O	O
than	O	O
conventional	O	O
laparoscopy	O	O
,	O	O
published	O	O
data	O	O
of	O	O
first	O	O
clinical	O	O
series	O	O
seem	O	O
to	O	O
demonstrate	O	O
the	O	O
feasibility	O	O
of	O	O
these	O	O
approaches	O	O
.	O	O

Various	O	O
attempts	O	O
have	O	O
been	O	O
made	O	O
to	O	O
overcome	O	O
restrictions	O	O
due	O	O
to	O	O
loss	O	O
of	O	O
triangulation	O	O
in	O	O
SILS	O	O
by	O	O
specially	O	O
designed	O	O
SILS-specific	O	O
instruments	O	O
.	O	O

This	O	O
study	O	O
involving	O	O
novices	O	O
in	O	O
a	O	O
dry	O	O
lab	O	O
compared	O	O
task	O	O
performances	O	O
between	O	O
conventional	O	O
laparoscopic	O	O
surgery	O	O
(	O	O
CLS	O	O
)	O	O
and	O	O
single-port	O	O
laparoscopic	O	O
surgery	O	O
(	O	O
SPLS	O	O
)	O	O
using	O	O
newly	O	O
designed	O	O
pre-bent	O	O
instruments	O	O
.	O	O

METHODS	O	O
In	O	O
this	O	O
study	O	O
,	O	O
90	SampleSize	O
medical	Condition	O
students	O	O
without	O	O
previous	O	O
experience	O	O
in	O	O
laparoscopic	O	O
techniques	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
undergo	O	O
one	O	O
of	O	O
three	O	O
procedures	O	O
:	O	O
CLS	O	O
,	O	O
SPLS	O	O
using	O	O
two	O	O
pre-bent	O	O
instruments	O	O
(	O	O
SPLS-pp	O	O
)	O	O
,	O	O
or	O	O
SPLS	O	O
using	O	O
one	O	O
pre-bent	O	O
and	O	O
one	O	O
straight	O	O
laparoscopic	O	O
instrument	O	O
(	O	O
SPLS-ps	O	O
)	O	O
.	O	O

In	O	O
the	O	O
dry	O	O
lab	O	O
,	O	O
the	O	O
participants	O	O
performed	O	O
four	O	O
typical	O	O
laparoscopic	O	O
tasks	O	O
of	O	O
increasing	O	O
difficulty	O	O
.	O	O

Evaluation	O	O
included	O	O
performance	O	O
times	O	O
or	O	O
number	O	O
of	O	O
completed	O	O
tasks	O	O
within	O	O
a	O	O
given	O	O
time	O	O
frame	O	O
.	O	O

All	O	O
performances	O	O
were	O	O
videotaped	O	O
and	O	O
evaluated	O	O
for	O	O
unsuccessful	O	O
attempts	O	O
and	O	O
unwanted	O	O
interactions	O	O
of	O	O
instruments	O	O
.	O	O

Using	O	O
subjective	O	O
questionnaires	O	O
,	O	O
the	O	O
participants	O	O
rated	O	O
difficulties	O	O
with	O	O
two-dimensional	O	O
vision	O	O
and	O	O
coordination	O	O
of	O	O
instruments	O	O
.	O	O

RESULTS	O	O
Task	O	O
performances	O	O
were	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
CLS	O	O
group	O	O
than	O	O
in	O	O
either	O	O
SPLS	O	O
group	O	O
.	O	O

The	O	O
SPLS-ps	O	O
group	O	O
showed	O	O
a	O	O
tendency	O	O
toward	O	O
better	O	O
performances	O	O
than	O	O
the	O	O
SPLS-pp	O	O
group	O	O
,	O	O
but	O	O
the	O	O
difference	O	O
was	O	O
not	O	O
significant	O	O
.	O	O

Video	O	O
sequences	O	O
and	O	O
participants`	O	O
questionnaires	O	O
showed	O	O
instrument	O	O
interaction	O	O
as	O	O
the	O	O
major	O	O
problem	O	O
in	O	O
the	O	O
single-incision	O	O
surgery	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
SILS	O	O
is	O	O
feasible	O	O
,	O	O
as	O	O
shown	O	O
in	O	O
clinical	O	O
series	O	O
published	O	O
by	O	O
laparoscopically	O	O
experienced	O	O
experts	O	O
,	O	O
SILS	O	O
techniques	O	O
are	O	O
demanding	O	O
due	O	O
to	O	O
restrictions	O	O
that	O	O
come	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
triangulation	O	O
.	O	O

These	O	O
can	O	O
be	O	O
compensated	O	O
only	O	O
partially	O	O
by	O	O
currently	O	O
available	O	O
SILS-designed	O	O
instruments	O	O
.	O	O

The	O	O
future	O	O
of	O	O
SILS	O	O
depends	O	O
on	O	O
further	O	O
improvements	O	O
in	O	O
the	O	O
available	O	O
equipment	O	O
or	O	O
the	O	O
development	O	O
of	O	O
new	O	O
approaches	O	O
such	O	O
as	O	O
needlescopically	O	O
assisted	O	O
or	O	O
robotically	O	O
assisted	O	O
procedures	O	O
.	O	O

Lactobacillus	O	O
plantarum	O	O
CECT7315	O	O
and	O	O
CECT7316	O	O
stimulate	O	O
immunoglobulin	O	O
production	O	O
after	O	O
influenza	Condition	O
vaccination	Condition	O
in	O	O
elderly	Age	O
.	O	O

OBJECTIVE	O	O
The	O	O
effectiveness	O	O
of	O	O
influenza	O	O
vaccination	O	O
in	O	O
preventing	O	O
illness	O	O
is	O	O
lower	O	O
in	O	O
the	O	O
elderly	O	O
;	O	O
this	O	O
is	O	O
why	O	O
the	O	O
ability	O	O
of	O	O
Lactobacillus	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
to	O	O
stimulate	O	O
the	O	O
response	O	O
to	O	O
influenza	Condition	O
vaccination	Condition	O
in	O	O
elderly	Age	O
was	O	O
evaluated	O	O
.	O	O

RESEARCH	O	O
METHODS	O	O
AND	O	O
PROCEDURES	O	O
A	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
human	O	O
trial	O	O
including	O	O
60	SampleSize	O
institutionalized	O	O
volunteers	O	O
aged	O	O
65-85	Age	O
years	O	O
was	O	O
performed	O	O
.	O	O

All	O	O
the	O	O
volunteers	O	O
were	O	O
vaccinated	O	O
with	O	O
a	O	O
trivalent	O	O
influenza	O	O
vaccine	O	O
(	O	O
A/Wisconsin/67/2005	O	O
NYMC	O	O
X-161B	O	O
(	O	O
H3N2	O	O
)	O	O
,	O	O
A/Solomon	O	O
Islands/3/2006	O	O
(	O	O
H1N1	O	O
)	O	O
and	O	O
B/Malaysia/2506/2004	O	O
)	O	O
for	O	O
the	O	O
Spanish	O	O
vaccine	O	O
campaign	O	O
2006/2007	O	O
.	O	O

The	O	O
consumption	O	O
of	O	O
the	O	O
probiotic	O	O
began	O	O
between	O	O
three	O	O
and	O	O
four	O	O
months	O	O
after	O	O
the	O	O
vaccination	O	O
.	O	O

Volunteers	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
three	O	O
following	O	O
groups	O	O
:	O	O
group	O	O
A	O	O
(	O	O
receiving	O	O
5*10	O	O
(	O	O
9	O	O
)	O	O
cfu/day	O	O
of	O	O
L.	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
in	O	O
20	O	O
g	O	O
powdered	O	O
skim	O	O
milk	O	O
)	O	O
,	O	O
group	O	O
B	O	O
(	O	O
receiving	O	O
5*10	O	O
(	O	O
8	O	O
)	O	O
cfu/day	O	O
of	O	O
L.	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
in	O	O
20	O	O
g	O	O
powdered	O	O
skim	O	O
milk	O	O
)	O	O
and	O	O
group	O	O
C	O	O
or	O	O
placebo	O	O
(	O	O
20	O	O
g	O	O
powered	O	O
skim	O	O
milk	O	O
)	O	O
.	O	O

The	O	O
participants	O	O
consumed	O	O
the	O	O
probiotic	O	O
during	O	O
3	O	O
months	O	O
.	O	O

RESULTS	O	O
The	O	O
consumption	O	O
of	O	O
L.	O	O
plantarum	O	O
CECT	O	O
7315/7316	O	O
during	O	O
3	O	O
months	O	O
after	O	O
influenza	O	O
vaccination	O	O
increased	O	O
the	O	O
levels	O	O
of	O	O
influenza-specific	O	O
IgA	O	O
and	O	O
IgG	O	O
antibodies	O	O
.	O	O

Moreover	O	O
,	O	O
a	O	O
trend	O	O
towards	O	O
an	O	O
increase	O	O
in	O	O
influenza-specific	O	O
IgM	O	O
antibodies	O	O
was	O	O
also	O	O
observed	O	O
.	O	O

CONCLUSION	O	O
L.	O	O
plantarum	O	O
CECT7315/7316	O	O
has	O	O
an	O	O
immunostimulating	O	O
effect	O	O
and	O	O
could	O	O
be	O	O
used	O	O
to	O	O
improve	O	O
the	O	O
response	O	O
to	O	O
influenza	O	O
vaccination	O	O
in	O	O
elderly	O	O
.	O	O

Arthroscopic	O	O
rotator	O	O
cuff	O	O
repair	O	O
with	O	O
and	O	O
without	O	O
acromioplasty	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
full-thickness	Condition	O
rotator	Condition	O
cuff	Condition	O
tears	Condition	O
:	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
The	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
prospective	O	O
randomized	O	O
controlled	O	O
trial	O	O
was	O	O
to	O	O
compare	O	O
functional	O	O
and	O	O
quality-of-life	O	O
indices	O	O
and	O	O
rates	O	O
of	O	O
revision	O	O
surgery	O	O
in	O	O
arthroscopic	O	O
rotator	O	O
cuff	O	O
repair	O	O
with	O	O
and	O	O
without	O	O
acromioplasty	O	O
.	O	O

METHODS	O	O
Eighty-six	SampleSize	SampleSize
patients	O	O
consented	O	O
and	O	O
were	O	O
randomly	O	O
assigned	O	O
intraoperatively	O	O
to	O	O
one	O	O
of	O	O
two	O	O
study	O	O
groups	O	O
,	O	O
and	O	O
sixty-eight	SampleSize	O
of	O	O
them	O	O
completed	O	O
the	O	O
study	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
the	O	O
Western	O	O
Ontario	O	O
Rotator	O	O
Cuff	O	O
(	O	O
WORC	O	O
)	O	O
index	O	O
.	O	O

Secondary	O	O
outcome	O	O
measures	O	O
included	O	O
the	O	O
American	O	O
Shoulder	O	O
and	O	O
Elbow	O	O
Surgeons	O	O
(	O	O
ASES	O	O
)	O	O
shoulder	O	O
assessment	O	O
form	O	O
and	O	O
a	O	O
count	O	O
of	O	O
revisions	O	O
required	O	O
in	O	O
each	O	O
group	O	O
.	O	O

Outcome	O	O
measures	O	O
were	O	O
completed	O	O
preoperatively	O	O
and	O	O
at	O	O
three	O	O
,	O	O
six	O	O
,	O	O
twelve	O	O
,	O	O
eighteen	O	O
,	O	O
and	O	O
twenty-four	O	O
months	O	O
after	O	O
surgery	O	O
.	O	O

RESULTS	O	O
WORC	O	O
and	O	O
ASES	O	O
scores	O	O
improved	O	O
significantly	O	O
in	O	O
each	O	O
group	O	O
over	O	O
time	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
WORC	O	O
or	O	O
ASES	O	O
scores	O	O
between	O	O
the	O	O
groups	O	O
that	O	O
had	O	O
arthroscopic	O	O
cuff	O	O
repair	O	O
with	O	O
or	O	O
without	O	O
acromioplasty	O	O
at	O	O
any	O	O
time	O	O
point	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
scores	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
acromion	O	O
type	O	O
,	O	O
nor	O	O
were	O	O
any	O	O
interaction	O	O
effects	O	O
identified	O	O
between	O	O
group	O	O
and	O	O
acromion	O	O
type	O	O
.	O	O

Four	O	O
participants	O	O
(	O	O
9	O	O
%	O	O
)	O	O
in	O	O
the	O	O
group	O	O
that	O	O
had	O	O
arthroscopic	O	O
cuff	O	O
repair	O	O
alone	O	O
,	O	O
one	O	O
with	O	O
a	O	O
Type-2	O	O
and	O	O
three	O	O
with	O	O
a	O	O
Type-3	O	O
acromion	O	O
,	O	O
required	O	O
additional	O	O
surgery	O	O
by	O	O
the	O	O
twenty-four-month	O	O
time	O	O
point	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
required	O	O
additional	O	O
surgery	O	O
was	O	O
greater	O	O
(	O	O
p	O	O
=	O	O
0.05	O	O
)	O	O
in	O	O
the	O	O
group	O	O
that	O	O
had	O	O
arthroscopic	O	O
cuff	O	O
repair	O	O
alone	O	O
than	O	O
in	O	O
the	O	O
group	O	O
that	O	O
had	O	O
arthroscopic	O	O
cuff	O	O
repair	O	O
and	O	O
acromioplasty	O	O
.	O	O

CONCLUSIONS	O	O
Our	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
previous	O	O
research	O	O
reports	O	O
in	O	O
which	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
functional	O	O
and	O	O
quality-of-life	O	O
indices	O	O
for	O	O
patients	O	O
who	O	O
had	O	O
rotator	O	O
cuff	O	O
repair	O	O
with	O	O
or	O	O
without	O	O
acromioplasty	O	O
.	O	O

The	O	O
higher	O	O
reoperation	O	O
rate	O	O
was	O	O
found	O	O
in	O	O
the	O	O
group	O	O
without	O	O
acromioplasty	O	O
.	O	O

Further	O	O
study	O	O
that	O	O
includes	O	O
follow-up	O	O
imaging	O	O
and	O	O
patient-reported	O	O
outcomes	O	O
over	O	O
a	O	O
greater	O	O
follow-up	O	O
period	O	O
is	O	O
needed	O	O
.	O	O

Family	O	O
education	O	O
for	O	O
people	O	O
with	O	O
schizophrenia	Condition	O
in	O	O
Beijing	O	O
,	O	O
China	O	O
:	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Much	O	O
of	O	O
China	O	O
lacks	O	O
well-developed	O	O
services	O	O
for	O	O
people	O	O
with	O	O
schizophrenia	O	O
and	O	O
their	O	O
families	O	O
,	O	O
and	O	O
most	O	O
of	O	O
the	O	O
existing	O	O
services	O	O
focus	O	O
on	O	O
hospitals	O	O
.	O	O

There	O	O
is	O	O
a	O	O
need	O	O
for	O	O
culturally	O	O
sensitive	O	O
family	O	O
treatments	O	O
offered	O	O
by	O	O
nurses	O	O
.	O	O

AIMS	O	O
To	O	O
conduct	O	O
a	O	O
longitudinal	O	O
experimental	O	O
study	O	O
examining	O	O
the	O	O
effect	O	O
of	O	O
patient	O	O
and	O	O
family	O	O
education	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
Chinese	O	O
people	O	O
with	O	O
schizophrenia	O	O
.	O	O

METHOD	O	O
A	O	O
randomised	O	O
controlled	O	O
trial	O	O
was	O	O
conducted	O	O
in	O	O
a	O	O
large	O	O
hospital	O	O
with	O	O
a	O	O
was	O	O
conducted	O	O
in	O	O
a	O	O
large	O	O
hospital	O	O
with	O	O
a	O	O
sample	O	O
of	O	O
101	SampleSize	SampleSize
patients	O	O
with	O	O
schizophrenia	O	O
and	O	O
their	O	O
families	O	O
.	O	O

Data	O	O
were	O	O
collected	O	O
at	O	O
admission	O	O
and	O	O
at	O	O
discharge	O	O
,	O	O
and	O	O
then	O	O
at	O	O
3	O	O
and	O	O
9	O	O
months	O	O
after	O	O
discharge	O	O
.	O	O

The	O	O
intervention	O	O
group	O	O
received	O	O
family	O	O
education	O	O
,	O	O
and	O	O
data	O	O
on	O	O
their	O	O
knowledge	O	O
about	O	O
schizophrenia	O	O
,	O	O
symptoms	O	O
,	O	O
functioning	O	O
,	O	O
psychosocial	O	O
behaviour	O	O
,	O	O
relapse	O	O
and	O	O
medication	O	O
adherence	O	O
were	O	O
collected	O	O
and	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
knowledge	O	O
about	O	O
schizophrenia	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
and	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
symptom	O	O
scores	O	O
and	O	O
functioning	O	O
at	O	O
9	O	O
months	O	O
after	O	O
discharge	O	O
.	O	O

Patients	O	O
who	O	O
were	O	O
nonadherent	O	O
to	O	O
medication	O	O
regimens	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
relapse	O	O
.	O	O

CONCLUSIONS	O	O
Family	O	O
education	O	O
on	O	O
schizophrenia	O	O
by	O	O
nurses	O	O
in	O	O
China	O	O
was	O	O
effective	O	O
in	O	O
improving	O	O
knowledge	O	O
and	O	O
promoting	O	O
improvement	O	O
in	O	O
patients	O	O
'	O	O
symptoms	O	O
.	O	O

Longitudinal	O	O
follow-up	O	O
of	O	O
children	Age	O
with	O	O
autism	Condition	O
receiving	O	O
targeted	O	O
interventions	O	O
on	O	O
joint	O	O
attention	O	O
and	O	O
play	O	O
.	O	O

OBJECTIVE	O	O
This	O	O
study	O	O
examines	O	O
the	O	O
cognitive	O	O
and	O	O
language	O	O
outcomes	O	O
of	O	O
children	O	O
with	O	O
an	O	O
autism	Condition	O
spectrum	Condition	O
disorder	Condition	O
(	O	O
ASD	Condition	O
)	O	O
over	O	O
a	O	O
5-year	O	O
period	O	O
after	O	O
receiving	O	O
targeted	O	O
early	O	O
interventions	O	O
that	O	O
focused	O	O
on	O	O
joint	O	O
attention	O	O
and	O	O
play	O	O
skills	O	O
.	O	O

METHOD	O	O
Forty	SampleSize	SampleSize
children	O	O
from	O	O
the	O	O
original	O	O
study	O	O
(	O	O
n	O	O
=	O	O
58	SampleSize	O
)	O	O
had	O	O
complete	O	O
data	O	O
at	O	O
the	O	O
5-year	O	O
follow-up	O	O
.	O	O

RESULTS	O	O
In	O	O
all	O	O
,	O	O
80	O	O
%	O	O
of	O	O
children	O	O
had	O	O
achieved	O	O
functional	O	O
use	O	O
of	O	O
spoken	O	O
language	O	O
with	O	O
baseline	O	O
play	O	O
level	O	O
predicting	O	O
spoken	O	O
language	O	O
at	O	O
the	O	O
5-year	O	O
follow-up	O	O
.	O	O

Of	O	O
children	O	O
who	O	O
were	O	O
using	O	O
spoken	O	O
language	O	O
at	O	O
age	O	O
8	O	O
years	O	O
,	O	O
several	O	O
baseline	O	O
behaviors	O	O
predicted	O	O
their	O	O
later	O	O
ability	O	O
,	O	O
including	O	O
earlier	O	O
age	O	O
of	O	O
entry	O	O
into	O	O
the	O	O
study	O	O
,	O	O
initiating	O	O
joint	O	O
attention	O	O
skill	O	O
,	O	O
play	O	O
level	O	O
,	O	O
and	O	O
assignment	O	O
to	O	O
either	O	O
the	O	O
joint	O	O
attention	O	O
or	O	O
symbolic	O	O
play	O	O
intervention	O	O
group	O	O
.	O	O

Only	O	O
baseline	O	O
play	O	O
diversity	O	O
predicted	O	O
cognitive	O	O
scores	O	O
at	O	O
age	O	O
8	O	O
years	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
is	O	O
one	O	O
of	O	O
the	O	O
only	O	O
long-term	O	O
follow-up	O	O
studies	O	O
of	O	O
children	Age	O
who	O	O
participated	O	O
in	O	O
preschool	O	O
early	O	O
interventions	O	O
aimed	O	O
at	O	O
targeting	O	O
core	Condition	O
developmental	Condition	O
difficulties	Condition	O
.	O	O

The	O	O
study	O	O
findings	O	O
suggest	O	O
that	O	O
focusing	O	O
on	O	O
joint	O	O
attention	O	O
and	O	O
play	O	O
skills	O	O
in	O	O
comprehensive	O	O
treatment	O	O
models	O	O
is	O	O
important	O	O
for	O	O
long-term	O	O
spoken	O	O
language	O	O
outcomes	O	O
.	O	O

Attenuation	O	O
of	O	O
hemodynamic	O	O
responses	O	O
to	O	O
laryngoscopy	O	O
and	O	O
tracheal	O	O
intubation	O	O
during	O	O
rapid	O	O
sequence	O	O
induction	O	O
:	O	O
remifentanil	O	O
vs.	O	O
lidocaine	O	O
with	O	O
esmolol	O	O
.	O	O

AIM	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
the	O	O
effectiveness	O	O
of	O	O
remifentanil	O	O
vs.	O	O
a	O	O
lidocaine-esmolol	O	O
combination	O	O
in	O	O
blunting	O	O
the	O	O
hemodynamic	O	O
response	O	O
to	O	O
laryngoscopy	O	O
and	O	O
intubation	O	O
during	O	O
rapid	O	O
sequence	O	O
induction	O	O
using	O	O
thiopental	O	O
and	O	O
rocuronium	O	O
in	O	O
normotensive	Condition	O
patients	O	O
.	O	O

METHODS	O	O
Sixty-six	SampleSize	SampleSize
patients	O	O
with	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
(	Condition	O
ASA	Condition	O
)	Condition	O
physical	Condition	O
status	Condition	O
class	Condition	Condition
I	Condition	Condition
who	O	Condition
required	O	Condition
tracheal	Condition	Condition
intubation	Condition	Condition
for	O	O
elective	O	O
surgery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
groups	O	O
.	O	O

Group	O	O
R	O	O
received	O	O
0.9	O	O
%	O	O
saline	O	O
10	O	O
ml	O	O
and	O	O
remifentanil	O	O
1	O	O
microg/kg	O	O
.	O	O

Group	O	O
LE	O	O
received	O	O
lidocaine	O	O
1.5	O	O
mg/kg	O	O
and	O	O
esmolol	O	O
1.0	O	O
mg/kg	O	O
.	O	O

Anesthesia	O	O
was	O	O
induced	O	O
with	O	O
thiopental	O	O
sodium	O	O
5	O	O
mg/kg	O	O
,	O	O
followed	O	O
by	O	O
rocuronium	O	O
1.0	O	O
mg/kg	O	O
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
were	O	O
recorded	O	O
at	O	O
baseline	O	O
,	O	O
after	O	O
induction	O	O
,	O	O
immediately	O	O
after	O	O
intubation	O	O
and	O	O
every	O	O
minute	O	O
for	O	O
five	O	O
minutes	O	O
after	O	O
intubation	O	O
.	O	O

RESULTS	O	O
Changes	O	O
in	O	O
mean	O	O
arterial	O	O
pressure	O	O
over	O	O
time	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
significantly	O	O
different	O	O
(	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
maximum	O	O
pressor	O	O
response	O	O
was	O	O
observed	O	O
immediately	O	O
after	O	O
intubation	O	O
,	O	O
at	O	O
which	O	O
time	O	O
the	O	O
mean	O	O
arterial	O	O
pressure	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
group	O	O
LE	O	O
(	O	O
29.7	O	O
%	O	O
)	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
:	O	O
116.1	O	O
,	O	O
121.9	O	O
)	O	O
was	O	O
higher	O	O
than	O	O
that	O	O
in	O	O
group	O	O
R	O	O
(	O	O
4.4	O	O
%	O	O
)	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
92.9	O	O
,	O	O
98.5	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Two	O	O
patients	O	O
in	O	O
group	O	O
R	O	O
and	O	O
15	O	O
patients	O	O
in	O	O
group	O	O
LE	O	O
developed	O	O
hypertension	O	O
(	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
:	O	O
0.064	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
heart	O	O
rate	O	O
over	O	O
time	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
(	O	O
P=0.465	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
show	O	O
that	O	O
remifentanil	O	O
1	O	O
mg/kg	O	O
is	O	O
more	O	O
effective	O	O
than	O	O
the	O	O
combination	O	O
of	O	O
lidocaine	O	O
1.5	O	O
mg/kg	O	O
and	O	O
esmolol	O	O
1	O	O
mg/kg	O	O
for	O	O
attenuating	O	O
the	O	O
hemodynamic	O	O
responses	O	O
to	O	O
rapid	O	O
sequence	O	O
intubation	O	O
.	O	O

Effects	O	O
of	O	O
tonabersat	O	O
on	O	O
migraine	Condition	O
with	Condition	O
aura	Condition	O
:	O	O
a	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Migraine	O	O
with	O	O
aura	O	O
is	O	O
thought	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
cortical	O	O
spreading	O	O
depression	O	O
(	O	O
CSD	O	O
)	O	O
.	O	O

Tonabersat	O	O
inhibits	O	O
CSD	O	O
,	O	O
and	O	O
we	O	O
therefore	O	O
investigated	O	O
whether	O	O
tonabersat	O	O
has	O	O
a	O	O
preventive	O	O
effect	O	O
in	O	O
migraine	O	O
with	O	O
aura	O	O
.	O	O

METHODS	O	O
In	O	O
this	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
trial	O	O
,	O	O
40	O	O
mg	O	O
tonabersat	O	O
once	O	O
daily	O	O
was	O	O
compared	O	O
with	O	O
matched	O	O
placebo	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
at	O	O
least	O	O
one	Condition	O
aura	Condition	O
attack	Condition	O
per	Condition	O
month	Condition	O
during	O	O
the	O	O
past	O	O
3	O	O
months	O	O
.	O	O

Randomisation	O	O
was	O	O
by	O	O
computer-generated	O	O
list	O	O
.	O	O

Patients	O	O
kept	O	O
a	O	O
detailed	O	O
diary	O	O
to	O	O
enable	O	O
objective	O	O
diagnosis	O	O
of	O	O
each	O	O
attack	O	O
as	O	O
migraine	O	O
with	O	O
aura	O	O
,	O	O
migraine	O	O
without	O	O
aura	O	O
,	O	O
or	O	O
other	O	O
type	O	O
of	O	O
headache	O	O
.	O	O

Primary	O	O
endpoints	O	O
were	O	O
a	O	O
reduction	O	O
in	O	O
aura	O	O
attacks	O	O
with	O	O
or	O	O
without	O	O
headache	O	O
and	O	O
a	O	O
reduction	O	O
in	O	O
migraine	O	O
headache	O	O
days	O	O
with	O	O
or	O	O
without	O	O
an	O	O
aura	O	O
.	O	O

Analysis	O	O
was	O	O
per	O	O
protocol	O	O
.	O	O

This	O	O
trial	O	O
is	O	O
registered	O	O
,	O	O
number	O	O
NCT00332007	O	O
.	O	O

FINDINGS	O	O
39	SampleSize	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
,	O	O
of	O	O
whom	O	O
31	SampleSize	SampleSize
were	O	O
included	O	O
in	O	O
the	O	O
statistical	O	O
analysis	O	O
of	O	O
efficacy	O	O
.	O	O

Median	O	O
(	O	O
IQR	O	O
)	O	O
attacks	O	O
of	O	O
aura	O	O
were	O	O
reduced	O	O
from	O	O
3.2	O	O
(	O	O
1.0-5.0	O	O
)	O	O
per	O	O
12	O	O
weeks	O	O
on	O	O
placebo	O	O
to	O	O
1.0	O	O
(	O	O
0-3.0	O	O
)	O	O
on	O	O
tonabersat	O	O
(	O	O
p=0.01	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
other	O	O
primary	O	O
outcome	O	O
measure	O	O
,	O	O
median	O	O
migraine	O	O
headache	O	O
days	O	O
with	O	O
or	O	O
without	O	O
aura	O	O
,	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
placebo	O	O
and	O	O
tonabersat	O	O
groups	O	O
(	O	O
3.0	O	O
days	O	O
in	O	O
each	O	O
group	O	O
;	O	O
p=0.09	O	O
)	O	O
.	O	O

Tonabersat	O	O
was	O	O
well	O	O
tolerated	O	O
but	O	O
overall	O	O
had	O	O
more	O	O
side-effects	O	O
than	O	O
placebo	O	O
.	O	O

INTERPRETATION	O	O
Tonabersat	O	O
showed	O	O
a	O	O
preventive	O	O
effect	O	O
on	O	O
attacks	O	O
of	O	O
migraine	O	O
aura	O	O
but	O	O
no	O	O
efficacy	O	O
on	O	O
non-aura	O	O
attacks	O	O
,	O	O
in	O	O
keeping	O	O
with	O	O
its	O	O
known	O	O
inhibitory	O	O
effect	O	O
on	O	O
CSD	O	O
.	O	O

The	O	O
results	O	O
support	O	O
the	O	O
theory	O	O
that	O	O
auras	O	O
are	O	O
caused	O	O
by	O	O
CSD	O	O
and	O	O
that	O	O
this	O	O
phenomenon	O	O
is	O	O
not	O	O
involved	O	O
in	O	O
attacks	O	O
without	O	O
aura	O	O
.	O	O

FUNDING	O	O
Minster	O	O
Pharmaceuticals	O	O
;	O	O
Lundbeck	O	O
Foundation	O	O
.	O	O

Ilioinguinal-iliohypogastric	O	O
nerve	O	O
block	O	O
within	O	O
travenous	O	O
dexketoprofen	O	O
improves	O	O
postoperative	O	O
analgesia	O	O
in	O	O
abdominal	Condition	O
hysterectomies	Condition	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVE	O	O
In	O	O
this	O	O
study	O	O
,	O	O
our	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
intravenous	O	O
dexketoprofen	O	O
trometamol	O	O
with	O	O
ilioinguinal	O	O
and	O	O
iliohypogastric	O	O
nerve	O	O
block	O	O
on	O	O
analgesic	O	O
quality	O	O
and	O	O
morphine	O	O
consumption	O	O
after	O	O
total	Condition	O
abdominal	Condition	O
hysterectomy	Condition	O
operations	O	O
.	O	O

METHODS	O	O
We	O	O
conducted	O	O
this	O	O
randomized	O	O
controlled	O	O
clinical	O	O
study	O	O
on	O	O
61	SampleSize	O
patients	O	O
.	O	O

The	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
the	O	O
operation	O	O
room	O	O
,	O	O
post-anesthesia	O	O
care	O	O
unit	O	O
,	O	O
and	O	O
inpatient	O	O
clinic	O	O
.	O	O

We	O	O
randomly	O	O
grouped	O	O
the	O	O
61	O	O
patients	O	O
into	O	O
control	O	O
group	O	O
(	O	O
group	O	O
C	O	O
)	O	O
,	O	O
block	O	O
group	O	O
(	O	O
group	O	O
B	O	O
)	O	O
and	O	O
dexketoprofen-block	O	O
group	O	O
(	O	O
group	O	O
DB	O	O
)	O	O
.	O	O

Before	O	O
the	O	O
skin	O	O
incision	O	O
performed	O	O
after	O	O
anesthesia	O	O
induction	O	O
,	O	O
we	O	O
performed	O	O
ilioinguinal	O	O
iliohypogastric	O	O
block	O	O
(	O	O
group	O	O
C	O	O
given	O	O
saline	O	O
and	O	O
group	O	O
P	O	O
and	O	O
DB	O	O
given	O	O
levobupivacaine	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
group	O	O
C	O	O
and	O	O
B	O	O
,	O	O
group	O	O
DB	O	O
was	O	O
given	O	O
dexketoprofen	O	O
.	O	O

We	O	O
administered	O	O
morphine	O	O
analgesia	O	O
to	O	O
all	O	O
patients	O	O
by	O	O
patient-controlled	O	O
analgesia	O	O
(	O	O
PCA	O	O
)	O	O
during	O	O
the	O	O
postoperative	O	O
24	O	O
hours	O	O
.	O	O

We	O	O
recorded	O	O
Visual	O	O
Analogue	O	O
Scale	O	O
(	O	O
VAS	O	O
)	O	O
,	O	O
satisfaction	O	O
scores	O	O
,	O	O
morphine	O	O
consumption	O	O
and	O	O
side	O	O
effects	O	O
during	O	O
postoperative	O	O
24	O	O
hours	O	O
.	O	O

RESULTS	O	O
We	O	O
found	O	O
the	O	O
DB	O	O
group?s	O	O
VAS	O	O
scores	O	O
to	O	O
be	O	O
lower	O	O
than	O	O
the	O	O
control	O	O
group	O	O
and	O	O
block	O	O
group?s	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
values	O	O
at	O	O
postoperative	O	O
1st	O	O
,	O	O
2nd	O	O
,	O	O
6th	O	O
and	O	O
12th	O	O
hours	O	O
.	O	O

VAS	O	O
scores	O	O
of	O	O
group	O	O
C	O	O
were	O	O
higher	O	O
than	O	O
of	O	O
group	O	O
B	O	O
at	O	O
postoperative	O	O
fi	O	O
rst	O	O
2	O	O
hours	O	O
.	O	O

Time	O	O
to	O	O
fi	O	O
rst	O	O
PCA	O	O
demand	O	O
was	O	O
longer	O	O
,	O	O
morphine	O	O
consumption	O	O
values	O	O
were	O	O
lower	O	O
and	O	O
satisfaction	O	O
scores	O	O
were	O	O
higher	O	O
in	O	O
group	O	O
DB	O	O
than	O	O
in	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Ilioinguinal-iliohypogastric	O	O
nerve	O	O
block	O	O
with	O	O
IV	O	O
dexketoprofen	O	O
increases	O	O
patient	O	O
satisfaction	O	O
by	O	O
decreasing	O	O
opioid	O	O
consumption	O	O
,	O	O
increasing	O	O
patient	O	O
satisfaction	O	O
,	O	O
which	O	O
suggests	O	O
that	O	O
dexketoprofen	O	O
trometamol	O	O
is	O	O
an	O	O
effective	O	O
non-steroidal	O	O
anti-inflammatory	O	O
analgesic	O	O
in	O	O
postoperative	O	O
analgesia	O	O
.	O	O

In	O	O
school-aged	Age	O
children	Age	O
a	O	O
combination	O	O
of	O	O
galacto-oligosaccharides	O	O
and	O	O
Lactobacillus	O	O
GG	O	O
increases	O	O
bifidobacteria	O	O
more	O	O
than	O	O
Lactobacillus	O	O
GG	O	O
on	O	O
its	O	O
own	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
a	O	O
combination	O	O
of	O	O
Lactobacillus	O	O
GG	O	O
(	O	O
LGG	O	O
)	O	O
and	O	O
galacto-oligosaccharides	O	O
(	O	O
GOS	O	O
)	O	O
with	O	O
LGG	O	O
on	O	O
its	O	O
own	O	O
,	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
the	O	O
intestinal	O	O
microbiota	O	O
in	O	O
school-aged	O	O
children	O	O
.	O	O

The	O	O
randomized	O	O
,	O	O
double-blinded	O	O
,	O	O
crossover	O	O
study	O	O
comprised	O	O
30	SampleSize	O
healthy	Condition	O
children	O	O
.	O	O

There	O	O
were	O	O
two	O	O
3-week	O	O
study	O	O
periods	O	O
with	O	O
a	O	O
4-week	O	O
wash-out	O	O
period	O	O
in	O	O
between	O	O
.	O	O

The	O	O
children	O	O
ingested	O	O
daily	O	O
65	O	O
ml	O	O
of	O	O
milk-based	O	O
fruit	O	O
juice	O	O
containing	O	O
either	O	O
LGG	O	O
alone	O	O
(	O	O
6.5	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
CFU	O	O
)	O	O
or	O	O
LGG	O	O
plus	O	O
2	O	O
g	O	O
of	O	O
GOS	O	O
.	O	O

Symptom	O	O
diaries	O	O
were	O	O
filled	O	O
during	O	O
the	O	O
study	O	O
periods	O	O
.	O	O

Fecal	O	O
samples	O	O
were	O	O
collected	O	O
at	O	O
the	O	O
beginning	O	O
and	O	O
end	O	O
of	O	O
both	O	O
study	O	O
periods	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
both	O	O
study	O	O
periods	O	O
,	O	O
the	O	O
amount	O	O
of	O	O
bifidobacteria	O	O
was	O	O
significantly	O	O
greater	O	O
after	O	O
the	O	O
ingestion	O	O
of	O	O
LGG	O	O
+	O	O
GOS	O	O
compared	O	O
with	O	O
LGG	O	O
alone	O	O
(	O	O
geometric	O	O
mean	O	O
9.33	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
vs.	O	O
4.28	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
CFU/g	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
seen	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
lactobacilli	O	O
or	O	O
LGG	O	O
,	O	O
nor	O	O
did	O	O
gastrointestinal	O	O
symptoms	O	O
,	O	O
defecation	O	O
frequency	O	O
,	O	O
consistency	O	O
of	O	O
stools	O	O
or	O	O
ease	O	O
of	O	O
defecation	O	O
differ	O	O
between	O	O
the	O	O
two	O	O
study	O	O
periods	O	O
.	O	O

Ingestion	O	O
of	O	O
LGG	O	O
combined	O	O
with	O	O
2	O	O
g	O	O
of	O	O
GOS	O	O
increased	O	O
the	O	O
bifidobacteria	O	O
more	O	O
than	O	O
LGG	O	O
on	O	O
its	O	O
own	O	O
and	O	O
thus	O	O
GOS	O	O
clearly	O	O
has	O	O
a	O	O
prebiotic	O	O
effect	O	O
in	O	O
children	Age	O
.	O	O

The	O	O
children	O	O
tolerated	O	O
well	O	O
a	O	O
daily	O	O
intake	O	O
of	O	O
2	O	O
g	O	O
of	O	O
GOS	O	O
.	O	O

Effect	O	O
of	O	O
a	O	O
multi-faceted	O	O
intervention	O	O
on	O	O
gingival	O	O
health	O	O
among	O	O
adults	Age	Age
with	O	O
systemic	Condition	Condition
sclerosis	Condition	Condition
.	O	O

OBJECTIVES	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
adaptive	O	O
oral	O	O
hygiene	O	O
devices	O	O
and	O	O
orofacial	O	O
exercise	O	O
to	O	O
improve	O	O
gingival	O	O
health	O	O
among	O	O
adults	Age	O
with	O	O
systemic	Condition	Condition
sclerosis	Condition	Condition
(	O	Condition
SSc	Condition	Condition
)	O	Condition
.	O	O

METHODS	O	O
Forty-eight	SampleSize	SampleSize
patients	O	O
with	O	O
SSc	Condition	O
were	O	O
assigned	O	O
randomly	O	O
to	O	O
the	O	O
multifaceted	O	O
oral	O	O
health	O	O
intervention	O	O
or	O	O
usual	O	O
dental	O	O
care	O	O
control	O	O
group	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
received	O	O
a	O	O
rechargeable	O	O
,	O	O
powered	O	O
Oral-B?	O	O
oscillating-rotating-pulsating	O	O
toothbrush	O	O
and	O	O
a	O	O
Reach?	O	O
Access?	O	O
Flosser	O	O
that	O	O
has	O	O
a	O	O
toothbrush-like	O	O
handle	O	O
.	O	O

For	O	O
those	O	O
with	O	O
an	O	O
oral	O	O
aperture	O	O
of	O	O
less	O	O
than	O	O
40	O	O
mm	O	O
,	O	O
orofacial	O	O
exercises	O	O
were	O	O
taught	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
each	O	O
given	O	O
a	O	O
manual	O	O
toothbrush	O	O
and	O	O
dental	O	O
floss	O	O
.	O	O

Participants	O	O
in	O	O
both	O	O
groups	O	O
received	O	O
instructions	O	O
and	O	O
demonstration	O	O
on	O	O
the	O	O
use	O	O
of	O	O
the	O	O
devices	O	O
,	O	O
and	O	O
were	O	O
requested	O	O
to	O	O
perform	O	O
the	O	O
respective	O	O
intervention	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
6	O	O
months	O	O
.	O	O

Evaluations	O	O
were	O	O
at	O	O
baseline	O	O
,	O	O
3-	O	O
,	O	O
and	O	O
6-months	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
gingival	O	O
index	O	O
(	O	O
GI	O	O
)	O	O
,	O	O
an	O	O
indicator	O	O
of	O	O
gingival	O	O
inflammation	O	O
.	O	O

RESULTS	O	O
Both	O	O
groups	O	O
showed	O	O
significant	O	O
reduction	O	O
in	O	O
GI	O	O
scores	O	O
at	O	O
6	O	O
months	O	O
(	O	O
ps	O	O
<	O	O
0.005	O	O
)	O	O
.	O	O

Reduction	O	O
in	O	O
GI	O	O
scores	O	O
of	O	O
the	O	O
intervention	O	O
group	O	O
at	O	O
6	O	O
months	O	O
was	O	O
20.8	O	O
%	O	O
which	O	O
is	O	O
considered	O	O
to	O	O
be	O	O
clinically	O	O
significant	O	O
.	O	O

Compared	O	O
to	O	O
the	O	O
control	O	O
group	O	O
,	O	O
the	O	O
intervention	O	O
group	O	O
showed	O	O
a	O	O
significant	O	O
and	O	O
larger	O	O
reduction	O	O
in	O	O
GI	O	O
score	O	O
by	O	O
8	O	O
%	O	O
at	O	O
6	O	O
months	O	O
(	O	O
p=0.0007	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Results	O	O
support	O	O
the	O	O
use	O	O
of	O	O
adaptive	O	O
devices	O	O
and	O	O
orofacial	O	O
exercise	O	O
to	O	O
improve	O	O
gingival	O	O
health	O	O
in	O	O
adults	O	O
with	O	O
SSc	O	O
when	O	O
compared	O	O
to	O	O
use	O	O
of	O	O
manual	O	O
toothbrushing	O	O
and	O	O
finger-held	O	O
flossing	O	O
.	O	O

Recommending	O	O
and	O	O
educating	O	O
patients	O	O
with	O	O
SSc	O	O
to	O	O
use	O	O
adaptive	O	O
devices	O	O
to	O	O
clean	O	O
the	O	O
tooth	O	O
surfaces	O	O
looks	O	O
promising	O	O
for	O	O
long-term	O	O
oral	O	Condition
health	O	Condition
improvement	O	Condition
.	O	O

Diode	O	O
laser	O	O
photocoagulation	O	O
for	O	O
threshold	O	O
retinopathy	Condition	O
of	Condition	O
prematurity	Condition	O
.	O	O

A	O	O
randomized	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Although	O	O
peripheral	O	O
cryotherapy	O	O
decreases	O	O
the	O	O
incidence	O	O
of	O	O
unfavorable	O	O
anatomic	O	O
outcomes	O	O
in	O	O
threshold	O	Condition
retinopathy	Condition	Condition
of	Condition	Condition
prematurity	Condition	Condition
(	O	O
ROP	Condition	O
)	O	O
,	O	O
apnea	O	O
,	O	O
bradycardia	O	O
,	O	O
and	O	O
lid	O	O
edema	O	O
can	O	O
occur	O	O
.	O	O

Argon	O	O
laser	O	O
indirect	O	O
ophthalmoscope	O	O
photocoagulation	O	O
has	O	O
been	O	O
used	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
cryotherapy	O	O
,	O	O
with	O	O
fewer	O	O
adverse	O	O
effects	O	O
.	O	O

Retinal	O	O
lesions	O	O
placed	O	O
with	O	O
diode	O	O
lasers	O	O
are	O	O
deeper	O	O
than	O	O
similar	O	O
argon	O	O
laser	O	O
lesions	O	O
,	O	O
and	O	O
it	O	O
is	O	O
not	O	O
known	O	O
whether	O	O
this	O	O
difference	O	O
could	O	O
influence	O	O
the	O	O
response	O	O
to	O	O
ablative	O	O
therapy	O	O
.	O	O

METHODS	O	O
Patients	O	O
were	O	O
enrolled	O	O
under	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
protocol	O	O
.	O	O

One	O	O
eye	O	O
of	O	O
each	O	O
patient	O	O
with	O	O
symmetric	O	O
,	O	O
threshold	O	O
ROP	O	O
was	O	O
treated	O	O
with	O	O
an	O	O
814/815	O	O
nm	O	O
diode	O	O
laser	O	O
,	O	O
while	O	O
the	O	O
other	O	O
eye	O	O
was	O	O
treated	O	O
with	O	O
cryotherapy	O	O
.	O	O

Patients	O	O
with	O	O
asymmetric	O	O
diseases	O	O
also	O	O
were	O	O
randomized	O	O
for	O	O
treatment	O	O
in	O	O
the	O	O
threshold	O	O
eye	O	O
.	O	O

RESULTS	O	O
Nineteen	SampleSize	O
infants	O	O
(	O	O
33	SampleSize	O
eyes	O	O
)	O	O
were	O	O
treated	O	O
,	O	O
ranging	O	O
from	O	O
485	O	O
to	O	O
863	O	O
g	O	O
birth	O	O
weight	O	O
(	O	O
23	O	O
to	O	O
27	O	O
weeks	O	O
gestational	O	O
age	O	O
)	O	O
;	O	O
18	SampleSize	O
patients	O	O
(	O	O
32	SampleSize	O
eyes	O	O
)	O	O
were	O	O
followed	O	O
for	O	O
3	O	O
months	O	O
or	O	O
longer	O	O
.	O	O

Four	SampleSize	O
patients	O	O
(	O	O
8	SampleSize	O
eyes	O	O
)	O	O
had	O	O
bilateral	O	Condition
zone	O	Condition
1	O	Condition
disease	O	Condition
.	O	O

Postconceptional	O	O
age	O	O
was	O	O
36	Age	O
to	Age	O
45	Age	O
weeks	O	O
at	O	O
the	O	O
time	O	O
of	O	O
treatment	O	O
.	O	O

The	O	O
diode	O	O
laser	O	O
treatment	O	O
was	O	O
better	O	O
tolerated	O	O
than	O	O
cryotherapy	O	O
,	O	O
and	O	O
the	O	O
treatment	O	O
apparatus	O	O
was	O	O
more	O	O
easily	O	O
transported	O	O
.	O	O

Apneic	O	O
episodes	O	O
requiring	O	O
intubation	O	O
resulted	O	O
from	O	O
two	O	O
cryotherapy	O	O
sessions	O	O
but	O	O
no	O	O
diode	O	O
laser	O	O
sessions	O	O
.	O	O

Five	O	O
cryotherapy-treated	O	O
eyes	O	O
required	O	O
retreatment	O	O
because	O	O
of	O	O
persistent	O	O
disease	O	O
with	O	O
adjacent	O	O
skip	O	O
areas	O	O
.	O	O

In	O	O
the	O	O
group	O	O
followed	O	O
for	O	O
3	O	O
to	O	O
15	O	O
months	O	O
,	O	O
1	O	O
cryotherapy-treated	O	O
eye	O	O
and	O	O
1	O	O
diode	O	O
laser-treated	O	O
eye	O	O
progressed	O	O
to	O	O
stage	O	O
5	O	O
retinal	O	O
detachment	O	O
.	O	O

CONCLUSION	O	O
Compared	O	O
with	O	O
cryotherapy	O	O
,	O	O
the	O	O
diode	O	O
laser	O	O
was	O	O
more	O	O
convenient	O	O
,	O	O
technically	O	O
easier	O	O
to	O	O
administer	O	O
,	O	O
and	O	O
better	O	O
tolerated	O	O
by	O	O
the	O	O
patient	O	O
.	O	O

Although	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
was	O	O
too	O	O
small	O	O
for	O	O
meaningful	O	O
statistical	O	O
analysis	O	O
of	O	O
outcome	O	O
,	O	O
diode	O	O
laser	O	O
peripheral	O	O
retinal	O	O
ablation	O	O
appeared	O	O
to	O	O
be	O	O
as	O	O
effective	O	O
as	O	O
cryotherapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
threshold	O	O
ROP	O	O
.	O	O

Randomized	O	O
trial	O	O
of	O	O
tailored	O	O
skin	Condition	O
cancer	Condition	O
prevention	O	O
for	O	O
children	Age	Age
:	O	O
the	O	O
Project	O	O
SCAPE	O	O
family	O	O
study	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
a	O	O
tailored	O	O
intervention	O	O
to	O	O
promote	O	O
sun	O	O
protection	O	O
in	O	O
parents	Age	O
and	O	O
their	O	O
children	O	O
,	O	O
hypothesizing	O	O
that	O	O
the	O	O
tailored	O	O
intervention	O	O
would	O	O
lead	O	O
to	O	O
improved	O	O
skin	O	O
cancer	O	O
prevention	O	O
behaviors	O	O
compared	O	O
to	O	O
generic	O	O
materials	O	O
.	O	O

Families	O	O
were	O	O
recruited	O	O
through	O	O
schools	O	O
and	O	O
community	O	O
centers	O	O
and	O	O
were	O	O
included	O	O
if	O	O
there	O	O
was	O	O
1	O	O
child	O	O
in	O	O
Grades	O	O
1-3	O	O
at	O	O
moderate	O	O
to	O	O
high	O	O
risk	O	O
for	O	O
skin	O	O
cancer	O	O
.	O	O

Participants	O	O
were	O	O
randomized	O	O
into	O	O
one	O	O
of	O	O
two	O	O
intervention	O	O
groups	O	O
:	O	O
a	O	O
tailored	O	O
intervention	O	O
,	O	O
in	O	O
which	O	O
they	O	O
received	O	O
personalized	O	O
skin	O	O
cancer	O	O
education	O	O
through	O	O
the	O	O
mail	O	O
;	O	O
or	O	O
a	O	O
control	O	O
group	O	O
who	O	O
received	O	O
generic	O	O
skin	O	O
cancer	O	O
information	O	O
materials	O	O
.	O	O

Before	O	O
and	O	O
after	O	O
intervention	O	O
,	O	O
parents	O	O
completed	O	O
questionnaires	O	O
about	O	O
their	O	O
and	O	O
their	O	O
children	O	O
's	O	O
skin	O	O
cancer	O	O
risk	O	O
and	O	O
prevention	O	O
knowledge	O	O
and	O	O
behaviors	O	O
.	O	O

Parents	O	O
also	O	O
completed	O	O
4-day	O	O
sun	O	O
exposure	O	O
and	O	O
protection	O	O
diaries	O	O
for	O	O
their	O	O
child	O	O
and	O	O
themselves	O	O
.	O	O

Tailored	O	O
group	O	O
participants	O	O
demonstrated	O	O
significantly	O	O
greater	O	O
positive	O	O
changes	O	O
in	O	O
prevention	O	O
behavior	O	O
after	O	O
the	O	O
intervention	O	O
,	O	O
including	O	O
children	O	O
's	O	O
use	O	O
of	O	O
sunscreen	O	O
,	O	O
shirts	O	O
,	O	O
and	O	O
hats	O	O
,	O	O
and	O	O
parents	O	O
'	O	O
use	O	O
of	O	O
shade	O	O
,	O	O
and	O	O
skin	O	O
examinations	O	O
.	O	O

Effect	O	O
sizes	O	O
were	O	O
small	O	O
and	O	O
perceived	O	O
benefits	O	O
and	O	O
social	O	O
norms	O	O
mediated	O	O
intervention	O	O
effects	O	O
.	O	O

Findings	O	O
from	O	O
this	O	O
study	O	O
support	O	O
the	O	O
efficacy	O	O
of	O	O
focusing	O	O
tailored	O	O
communications	O	O
to	O	O
families	O	O
in	O	O
order	O	O
to	O	O
change	O	O
skin	O	O
cancer	O	O
prevention	O	O
practices	O	O
in	O	O
young	Age	O
children	O	O
.	O	O

Validity	O	O
and	O	O
reliability	O	O
assessment	O	O
of	O	O
the	O	O
Siriraj	O	O
Asthma	Condition	O
Control	O	O
Questionnaire	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
present	O	O
study	O	O
assessed	O	O
the	O	O
validity	O	O
and	O	O
reliability	O	O
of	O	O
the	O	O
Siriraj	O	O
Asthma	O	O
Control	O	O
Questionnaire	O	O
in	O	O
Asthma	O	O
Clinic	O	O
,	O	O
Siriraj	O	O
Hospital	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHOD	O	O
The	O	O
data	O	O
of	O	O
the	O	O
questionnaire	O	O
responses	O	O
and	O	O
spirometric	O	O
results	O	O
from	O	O
20	SampleSize	O
randomized	O	O
asthmatic	Condition	O
patients	O	O
in	O	O
the	O	O
clinic	O	O
including	O	O
the	O	O
record	O	O
of	O	O
3	O	O
visits	O	O
for	O	O
each	O	O
subject	O	O
.	O	O

The	O	O
validation	O	O
was	O	O
performed	O	O
by	O	O
Kruskal-Wallis	O	O
test	O	O
comparing	O	O
the	O	O
scores	O	O
with	O	O
the	O	O
level	O	O
of	O	O
asthma	O	O
control	O	O
determined	O	O
by	O	O
physicians	O	O
according	O	O
to	O	O
GINA	O	O
guideline	O	O
.	O	O

Internal	O	O
consistency	O	O
reliability	O	O
was	O	O
analyzed	O	O
by	O	O
Cronbach	O	O
's	O	O
alpha	O	O
.	O	O

RESULTS	O	O
Sixty	O	O
questionnaires	O	O
from	O	O
20	O	O
patients	O	O
with	O	O
age	O	O
29-73	Age	O
years	O	O
were	O	O
analyzed	O	O
.	O	O

There	O	O
were	O	O
40	O	O
controlled	O	O
,	O	O
7	O	O
partly	O	O
controlled	O	O
and	O	O
13	O	O
uncontrolled	O	O
visits	O	O
.	O	O

The	O	O
scores	O	O
from	O	O
5-items	O	O
questionnaires	O	O
and	O	O
6-items	O	O
clinical	O	O
score	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
the	O	O
physician-diagnosed	O	O
groups	O	O
(	O	O
i.e.	O	O
,	O	O
controlled	O	O
,	O	O
partly	O	O
controlled	O	O
and	O	O
uncontrolled	O	O
groups	O	O
)	O	O
.	O	O

Median	O	O
scores	O	O
(	O	O
min	O	O
,	O	O
max	O	O
)	O	O
were	O	O
0	O	O
(	O	O
0	O	O
,	O	O
5	O	O
)	O	O
,	O	O
2	O	O
(	O	O
0	O	O
,	O	O
6	O	O
)	O	O
,	O	O
4	O	O
(	O	O
0	O	O
,	O	O
12	O	O
)	O	O
respectively	O	O
,	O	O
(	O	O
5-items	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
2	O	O
(	O	O
0	O	O
,	O	O
7	O	O
)	O	O
,	O	O
3	O	O
(	O	O
1	O	O
,	O	O
7	O	O
)	O	O
,	O	O
6	O	O
(	O	O
2,15	O	O
)	O	O
respectively	O	O
,	O	O
(	O	O
6-items	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Internal	O	O
consistency	O	O
reliability	O	O
of	O	O
both	O	O
5-items	O	O
questionnaire	O	O
and	O	O
6-items	O	O
clinical	O	O
score	O	O
were	O	O
within	O	O
the	O	O
acceptable	O	O
range	O	O
(	O	O
0.829	O	O
and	O	O
0.708	O	O
respectively	O	O
)	O	O
.	O	O

5-items	O	O
questionnaire	O	O
is	O	O
more	O	O
associated	O	O
with	O	O
the	O	O
physician	O	O
diagnosed	O	O
group	O	O
and	O	O
more	O	O
consistent	O	O
than	O	O
6-items	O	O
clinical	O	O
score	O	O
.	O	O

Further	O	O
analysis	O	O
revealed	O	O
cutoff	O	O
point	O	O
at	O	O
2.5	O	O
to	O	O
separate	O	O
uncontrolled	O	O
from	O	O
controlled	O	O
or	O	O
partly	O	O
controlled	O	O
patient	O	O
with	O	O
sensitivity	O	O
76.9	O	O
%	O	O
and	O	O
specificity	O	O
89.4	O	O
%	O	O
and	O	O
cutoff	O	O
point	O	O
at	O	O
1.5	O	O
to	O	O
separate	O	O
uncontrolled	O	O
or	O	O
partly	O	O
controlled	O	O
from	O	O
controlled	O	O
patient	O	O
with	O	O
sensitivity	O	O
70.0	O	O
%	O	O
and	O	O
specificity	O	O
85.0	O	O
%	O	O
.	O	O

CONCLUSION	O	O
The	O	O
validity	O	O
and	O	O
reliability	O	O
of	O	O
Siriraj	O	O
Asthma	O	O
Control	O	O
Questionnaire	O	O
is	O	O
acceptable	O	O
and	O	O
might	O	O
be	O	O
used	O	O
in	O	O
the	O	O
clinical	O	O
practice	O	O
and	O	O
research	O	O
in	O	O
Thai	O	O
asthmatic	Condition	O
patients	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
amino	O	O
acid	O	O
and	O	O
ketoacid	O	O
on	O	O
protein	O	O
metabolism	O	O
in	O	O
humans	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
insulin	O	O
,	O	O
amino	O	O
acid	O	O
(	O	O
AA	O	O
)	O	O
,	O	O
and	O	O
branched-chain	O	O
ketoacid	O	O
(	O	O
KA	O	O
)	O	O
availability	O	O
on	O	O
leucine	O	O
kinetics	O	O
in	O	O
eight	SampleSize	O
healthy	Condition	O
volunteers	O	O
(	O	O
age	O	O
=	O	O
22	Age	O
+/-	Age	O
2	Age	O
y	O	O
,	O	O
body	O	O
mass	O	O
index	O	O
=	O	O
24	Condition	O
+/-	Condition	O
1	Condition	O
kg	Condition	O
)	O	O
by	O	O
using	O	O
the	O	O
euglycemic	O	O
insulin	O	O
clamp	O	O
and	O	O
[	O	O
1-14C	O	O
]	O	O
leucine	O	O
turnover	O	O
techniques	O	O
.	O	O

Four	O	O
experimental	O	O
conditions	O	O
were	O	O
studied	O	O
:	O	O
study	O	O
I	O	O
,	O	O
hyperinsulinemia	O	O
;	O	O
study	O	O
II	O	O
,	O	O
hyperinsulinemia	O	O
with	O	O
maintenance	O	O
of	O	O
basal	O	O
plasma	O	O
AA	O	O
and	O	O
branched-chain	O	O
KA	O	O
concentrations	O	O
;	O	O
study	O	O
III	O	O
,	O	O
hyperinsulinemia	O	O
with	O	O
hyperaminoacidemia	O	O
and	O	O
basal	O	O
plasma	O	O
branched-chain	O	O
KA	O	O
concentrations	O	O
;	O	O
and	O	O
study	O	O
IV	O	O
,	O	O
hyperinsulinemia	O	O
plus	O	O
basal	O	O
plasma	O	O
AA	O	O
concentrations	O	O
and	O	O
elevated	O	O
branched-chain	O	O
KA	O	O
levels	O	O
.	O	O

Basal	O	O
endogenous	O	O
leucine	O	O
flux	O	O
(	O	O
ELF	O	O
)	O	O
averaged	O	O
1.20	O	O
+/-	O	O
0.05	O	O
(	O	O
mumol.kg-1.min-1	O	O
,	O	O
mean	O	O
+/-	O	O
SE	O	O
)	O	O
;	O	O
basal	O	O
leucine	O	O
oxidation	O	O
(	O	O
LOX	O	O
)	O	O
was	O	O
0.25	O	O
+/-	O	O
0.01	O	O
;	O	O
and	O	O
basal	O	O
non-oxidative	O	O
leucine	O	O
disposal	O	O
(	O	O
NOLD	O	O
)	O	O
was	O	O
0.95	O	O
+/-	O	O
0.04	O	O
.	O	O

ELF	O	O
significantly	O	O
decreased	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.77	O	O
+/-	O	O
0.06	O	O
mumol.kg-1.min-1	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
.	O	O

When	O	O
plasma	O	O
AA	O	O
and	O	O
branched-chain	O	O
KA	O	O
were	O	O
either	O	O
maintained	O	O
at	O	O
their	O	O
basal	O	O
levels	O	O
(	O	O
study	O	O
II	O	O
)	O	O
or	O	O
increased	O	O
above	O	O
baseline	O	O
values	O	O
(	O	O
studies	O	O
III	O	O
and	O	O
IV	O	O
)	O	O
,	O	O
ELF	O	O
declined	O	O
further	O	O
(	O	O
0.64	O	O
+/-	O	O
0.05	O	O
,	O	O
0.66	O	O
+/-	O	O
0.02	O	O
,	O	O
and	O	O
0.66	O	O
+/-	O	O
0.03	O	O
mumol.kg-1.min-1	O	O
,	O	O
respectively	O	O
;	O	O
all	O	O
Ps	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
and	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
study	O	O
I	O	O
)	O	O
.	O	O

LOX	O	O
declined	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.12	O	O
+/-	O	O
0.02	O	O
mumol.kg-1.min-1	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
but	O	O
increased	O	O
significantly	O	O
in	O	O
studies	O	O
II	O	O
,	O	O
III	O	O
,	O	O
and	O	O
IV	O	O
(	O	O
0.31	O	O
+/-	O	O
0.04	O	O
,	O	O
0.37	O	O
+/-	O	O
0.03	O	O
,	O	O
and	O	O
0.40	O	O
+/-	O	O
0.03	O	O
mumol.kg-1.min-1	O	O
,	O	O
respectively	O	O
,	O	O
all	O	O
Ps	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
,	O	O
P	O	O
<	O	O
0.05	O	O
study	O	O
IV	O	O
versus	O	O
study	O	O
II	O	O
,	O	O
and	O	O
P	O	O
<	O	O
0.05	O	O
study	O	O
III	O	O
versus	O	O
study	O	O
II	O	O
)	O	O
.	O	O

NOLD	O	O
declined	O	O
in	O	O
study	O	O
I	O	O
(	O	O
0.65	O	O
+/-	O	O
0.05	O	O
mumol/kg.min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
,	O	O
whereas	O	O
neither	O	O
the	O	O
maintenance	O	O
of	O	O
basal	O	O
plasma	O	O
AA/branched-chain	O	O
KA	O	O
levels	O	O
(	O	O
study	O	O
II	O	O
;	O	O
0.89	O	O
+/-	O	O
0.2	O	O
mumol.kg-1.min-1	O	O
)	O	O
nor	O	O
the	O	O
elevation	O	O
of	O	O
plasma	O	O
branched-chain	O	O
KA	O	O
concentration	O	O
(	O	O
study	O	O
IV	O	O
;	O	O
0.96	O	O
+/-	O	O
0.1	O	O
mumol.kg-1.min-1	O	O
)	O	O
increased	O	O
NOLD	O	O
above	O	O
baseline	O	O
level	O	O
.	O	O

A	O	O
stimulation	O	O
of	O	O
NOLD	O	O
was	O	O
observed	O	O
only	O	O
when	O	O
plasma	O	O
AA	O	O
levels	O	O
were	O	O
increased	O	O
(	O	O
study	O	O
III	O	O
;	O	O
1.23	O	O
+/-	O	O
0.03	O	O
mumol/kg.min	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
versus	O	O
basal	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
present	O	O
data	O	O
do	O	O
not	O	O
support	O	O
the	O	O
concept	O	O
of	O	O
a	O	O
direct	O	O
anabolic	O	O
action	O	O
of	O	O
ketoanalogs	O	O
but	O	O
do	O	O
provide	O	O
additional	O	O
evidence	O	O
for	O	O
the	O	O
pivotal	O	O
role	O	O
of	O	O
AA	O	O
availability	O	O
in	O	O
the	O	O
stimulation	O	O
of	O	O
whole-body	O	O
protein	O	O
synthesis	O	O
.	O	O

Enhanced	O	O
small	O	O
group	O	O
instruction	O	O
using	O	O
choral	O	O
responding	O	O
and	O	O
student	O	O
interaction	O	O
for	O	O
children	O	Age
with	O	O
autism	Condition	O
and	O	O
developmental	Condition	O
disabilities	Condition	O
.	O	O

The	O	O
use	O	O
of	O	O
effective	O	O
instructional	O	O
strategies	O	O
in	O	O
small	O	O
groups	O	O
was	O	O
investigated	O	O
to	O	O
determine	O	O
learning	O	O
effects	O	O
for	O	O
24	SampleSize	O
elementary	Age	O
age	Age	O
students	O	O
with	O	O
autism	Condition	O
and	O	O
developmental	Condition	O
disabilities	Condition	O
.	O	O

Effective	O	O
strategies	O	O
included	O	O
(	O	O
a	O	O
)	O	O
the	O	O
use	O	O
of	O	O
choral	O	O
responding	O	O
;	O	O
(	O	O
b	O	O
)	O	O
the	O	O
use	O	O
of	O	O
student-to-student	O	O
responding	O	O
;	O	O
(	O	O
c	O	O
)	O	O
the	O	O
rotation	O	O
of	O	O
materials	O	O
every	O	O
5	O	O
minutes	O	O
during	O	O
the	O	O
30-minute	O	O
group	O	O
while	O	O
teaching	O	O
2	O	O
to	O	O
3	O	O
concepts	O	O
;	O	O
and	O	O
(	O	O
d	O	O
)	O	O
the	O	O
use	O	O
of	O	O
random	O	O
,	O	O
unpredictable	O	O
trials	O	O
for	O	O
student	O	O
responding	O	O
.	O	O

Thirty-minute	O	O
language	O	O
groups	O	O
were	O	O
targeted	O	O
to	O	O
teach	O	O
receptive	O	O
and	O	O
expressive	O	O
skills	O	O
using	O	O
pictures	O	O
and	O	O
common	O	O
objects	O	O
across	O	O
five	O	O
categories	O	O
(	O	O
e.g.	O	O
,	O	O
household	O	O
items	O	O
,	O	O
foods	O	O
)	O	O
.	O	O

Results	O	O
showed	O	O
increased	O	O
opportunities	O	O
to	O	O
respond	O	O
,	O	O
increased	O	O
levels	O	O
of	O	O
responding	O	O
and	O	O
academic	O	O
engagement	O	O
,	O	O
higher	O	O
gains	O	O
on	O	O
weekly	O	O
criterion-referenced	O	O
pre-	O	O
and	O	O
posttests	O	O
,	O	O
and	O	O
decreased	O	O
passive	O	O
and	O	O
inappropriate	O	O
student	O	O
behavior	O	O
during	O	O
interventions	O	O
.	O	O

The	O	O
evaluation	O	O
of	O	O
pulmonary	O	O
hypertension	O	O
using	O	O
right	O	O
ventricular	O	O
myocardial	O	O
isovolumic	O	O
relaxation	O	O
time	O	O
.	O	O

Right	O	O
ventricular	O	O
(	O	O
RV	O	O
)	O	O
blood	O	O
pool-derived	O	O
isovolumic	O	O
relaxation	O	O
time	O	O
(	O	O
IVRT	O	O
)	O	O
correlates	O	O
well	O	O
with	O	O
systolic	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
PAP	O	O
)	O	O
.	O	O

However	O	O
,	O	O
because	O	O
of	O	O
complex	O	O
parameter	O	O
derivation	O	O
,	O	O
the	O	O
method	O	O
is	O	O
rarely	O	O
used	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
validate	O	O
the	O	O
measurement	O	O
of	O	O
myocardial	O	O
velocity	O	O
imaging-derived	O	O
RV	O	O
IVRT	O	O
(	O	O
IVRT	O	O
'	O	O
)	O	O
against	O	O
invasively	O	O
measured	O	O
PAP	O	O
.	O	O

Transthoracic	O	O
echocardiography	O	O
with	O	O
myocardial	O	O
velocity	O	O
imaging	O	O
and	O	O
right	O	Condition
heart	O	Condition
catheterization	O	Condition
were	O	O
performed	O	O
in	O	O
33	SampleSize	O
patients	O	O
with	O	O
pulmonary	Condition	O
hypertension	Condition	O
.	O	O

Blood	O	O
pool	O	O
IVRT	O	O
and	O	O
myocardial	O	O
IVRTs	O	O
for	O	O
the	O	O
tricuspid	O	O
valve	O	O
annulus	O	O
ring	O	O
,	O	O
basal	O	O
and	O	O
apical	O	O
RV	O	O
free	O	O
wall	O	O
segments	O	O
were	O	O
measured	O	O
and	O	O
compared	O	O
with	O	O
data	O	O
from	O	O
33	SampleSize	O
age-	O	O
and	O	O
sex-matched	O	O
control	O	O
subjects	O	O
.	O	O

Measured	O	O
IVRTs	O	O
were	O	O
significantly	O	O
longer	O	O
in	O	O
patients	O	O
with	O	O
pulmonary	O	O
hypertension	O	O
than	O	O
in	O	O
control	O	O
subjects	O	O
.	O	O

The	O	O
strongest	O	O
correlation	O	O
(	O	O
R	O	O
=	O	O
0.74	O	O
,	O	O
P	O	O
<	O	O
.0001	O	O
)	O	O
was	O	O
found	O	O
between	O	O
systolic	O	O
PAP	O	O
and	O	O
the	O	O
heart	O	O
rate-corrected	O	O
IVRT	O	O
'	O	O
derived	O	O
from	O	O
the	O	O
basal	O	O
RV	O	O
free	O	O
wall	O	O
segment	O	O
.	O	O

The	O	O
basal	O	O
segment	O	O
IVRT	O	O
'	O	O
corrected	O	O
for	O	O
heart	O	O
rate	O	O
correlates	O	O
well	O	O
with	O	O
the	O	O
invasive	O	O
PAP	O	O
measurement	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
can	O	O
be	O	O
used	O	O
to	O	O
predict	O	O
systolic	O	O
PAP	O	O
.	O	O

It	O	O
can	O	O
even	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
tricuspid	O	O
regurgitation-derived	O	O
PAP	O	O
systolic	O	O
when	O	O
tricuspid	O	O
regurgitation	O	O
is	O	O
nonrecordable	O	O
.	O	O

A	O	O
proposed	O	O
method	O	O
to	O	O
derive	O	O
systolic	O	O
PAP	O	O
should	O	O
be	O	O
used	O	O
while	O	O
screening	O	O
the	O	O
patients	O	O
at	O	O
risk	O	O
for	O	O
pulmonary	O	O
hypertension	O	O
,	O	O
monitoring	O	O
the	O	O
disease	O	O
progression	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
treatment	O	O
.	O	O

Atrial	O	O
natriuretic	O	O
factor	O	O
inhibits	O	O
metoclopramide	O	O
stimulated	O	O
aldosterone	O	O
release	O	O
in	O	O
man	Sex	O
.	O	O

1	O	O
.	O	O

Atrial	O	O
natriuretic	O	O
factor	O	O
(	O	O
ANF	O	O
)	O	O
has	O	O
an	O	O
inhibitory	O	O
effect	O	O
on	O	O
angiotensin	O	O
II	O	O
and	O	O
ACTH	O	O
stimulated	O	O
aldosterone	O	O
secretion	O	O
in	O	O
man	O	O
.	O	O

The	O	O
selectivity	O	O
of	O	O
this	O	O
aldosterone	O	O
suppressing	O	O
effect	O	O
of	O	O
ANF	O	O
is	O	O
unclear	O	O
in	O	O
man	O	Sex
.	O	O

The	O	O
present	O	O
study	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
ANF	O	O
on	O	O
the	O	O
increase	O	O
in	O	O
plasma	O	O
aldosterone	O	O
due	O	O
to	O	O
metoclopramide	O	O
in	O	O
man	Sex	Sex
.	O	O

2	O	O
.	O	O

Eight	SampleSize	SampleSize
normal	Condition	O
male	Sex	O
volunteers	O	O
were	O	O
studied	O	O
on	O	O
three	O	O
occasions	O	O
.	O	O

Metoclopramide	O	O
(	O	O
10	O	O
mg	O	O
slow	O	O
i.v	O	O
.	O	O

)	O	O
was	O	O
given	O	O
on	O	O
all	O	O
study	O	O
days	O	O
and	O	O
each	O	O
volunteer	O	O
was	O	O
randomised	O	O
to	O	O
receive	O	O
45	O	O
min	O	O
infusion	O	O
of	O	O
either	O	O
5	O	O
%	O	O
D-glucose	O	O
(	O	O
placebo	O	O
)	O	O
or	O	O
ANF	O	O
(	O	O
99-126	O	O
)	O	O
3	O	O
or	O	O
15	O	O
pmol	O	O
kg-1	O	O
min-1	O	O
.	O	O

3	O	O
.	O	O

Metoclopramide	O	O
increased	O	O
plasma	O	O
aldosterone	O	O
to	O	O
approximately	O	O
170	O	O
%	O	O
of	O	O
baseline	O	O
levels	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

Concomitant	O	O
infusion	O	O
of	O	O
ANF	O	O
3	O	O
pmol	O	O
kg-1	O	O
min-1	O	O
and	O	O
15	O	O
pmol	O	O
kg-1	O	O
min-1	O	O
significantly	O	O
attenuated	O	O
this	O	O
rise	O	O
in	O	O
plasma	O	O
aldosterone	O	O
to	O	O
approximately	O	O
130	O	O
%	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
and	O	O
110	O	O
%	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
of	O	O
baseline	O	O
values	O	O
respectively	O	O
.	O	O

4	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
,	O	O
in	O	O
the	O	O
light	O	O
of	O	O
previous	O	O
findings	O	O
,	O	O
that	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
ANF	O	O
represents	O	O
a	O	O
non-selective	O	O
action	O	O
of	O	O
ANF	O	O
on	O	O
aldosterone	O	O
release	O	O
.	O	O

Effectiveness	O	O
and	O	O
safety	O	O
of	O	O
the	O	O
Levitan	O	O
FPS	O	O
Scope?	O	O
for	O	O
tracheal	O	O
intubation	O	O
under	O	O
general	O	O
anesthesia	O	O
with	O	O
a	O	O
simulated	O	O
difficult	O	O
airway	O	O
.	O	O

PURPOSE	O	O
Studies	O	O
show	O	O
that	O	O
the	O	O
Levitan	O	O
FPS	O	O
(	O	O
first	O	O
pass	O	O
success	O	O
)	O	O
Scope?	O	O
(	O	O
LFS	O	O
)	O	O
is	O	O
analogous	O	O
to	O	O
a	O	O
bougie	O	O
in	O	O
simulated	O	O
difficult	O	O
airways	O	O
with	O	O
comparable	O	O
tracheal	O	O
intubation	O	O
success	O	O
rates	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
tracheal	O	O
intubation	O	O
with	O	O
the	O	O
LFS	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
the	O	O
Macintosh	O	O
laryngoscope	O	O
utilizing	O	O
manual	O	O
in-line	O	O
stabilization	O	O
(	O	O
MILS	O	O
)	O	O
to	O	O
simulate	O	O
difficult	O	O
airways	O	O
.	O	O

METHODS	O	O
Ninety-four	O	SampleSize
subjects	O	O
successfully	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Manual	O	O
in-line	O	O
stabilization	O	O
of	O	O
the	O	O
cervical	O	O
spine	O	O
was	O	O
applied	O	O
and	O	O
the	O	O
initial	O	O
laryngoscopy	O	O
was	O	O
performed	O	O
using	O	O
either	O	O
the	O	O
Macintosh	O	O
or	O	O
the	O	O
LFS	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Macintosh	O	O
.	O	O

Following	O	O
the	O	O
initial	O	O
grading	O	O
,	O	O
a	O	O
second	O	O
laryngoscopy	O	O
was	O	O
repeated	O	O
using	O	O
the	O	O
second	O	O
randomized	O	O
technique	O	O
.	O	O

Cormack-Lehane	O	O
grades	O	O
,	O	O
percentage	O	O
of	O	O
glottic	O	O
opening	O	O
(	O	O
POGO	O	O
)	O	O
scores	O	O
,	O	O
time	O	O
to	O	O
intubate	O	O
,	O	O
number	O	O
of	O	O
intubation	O	O
attempts	O	O
,	O	O
and	O	O
the	O	O
use	O	O
of	O	O
alternate	O	O
techniques	O	O
were	O	O
recorded	O	O
.	O	O

The	O	O
anesthesiologist	O	O
rated	O	O
the	O	O
subjective	O	O
difficulty	O	O
in	O	O
using	O	O
each	O	O
technique	O	O
with	O	O
a	O	O
numeric	O	O
rating	O	O
scale	O	O
and	O	O
a	O	O
visual	O	O
rating	O	O
scale	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
primary	O	O
outcome	O	O
good	O	O
laryngoscopic	O	O
views	O	O
(	O	O
Cormack-Lehane	O	O
grade	O	O
1	O	O
and	O	O
2	O	O
)	O	O
compared	O	O
with	O	O
poor	O	O
laryngoscopic	O	O
views	O	O
(	O	O
Cormack-Lehane	O	O
grade	O	O
3	O	O
and	O	O
4	O	O
)	O	O
between	O	O
the	O	O
LFS	O	O
and	O	O
the	O	O
Macintosh	O	O
.	O	O

There	O	O
were	O	O
higher	O	O
POGO	O	O
scores	O	O
with	O	O
the	O	O
LFS	O	O
compared	O	O
with	O	O
the	O	O
Macintosh	O	O
(	O	O
80	O	O
%	O	O
vs	O	O
20	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
,	O	O
but	O	O
this	O	O
did	O	O
not	O	O
translate	O	O
to	O	O
easier	O	O
intubations	O	O
,	O	O
as	O	O
documented	O	O
by	O	O
the	O	O
need	O	O
for	O	O
an	O	O
alternate	O	O
intubation	O	O
technique	O	O
or	O	O
time	O	O
to	O	O
intubate	O	O
(	O	O
<	O	O
30	O	O
and	O	O
<	O	O
60	O	O
sec	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
mucosal	O	O
trauma	O	O
,	O	O
sore	O	O
throat	O	O
,	O	O
and	O	O
hemodynamic	O	O
responses	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
techniques	O	O
.	O	O

CONCLUSION	O	O
The	O	O
LFS	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Macintosh	O	O
laryngoscope	O	O
does	O	O
not	O	O
improve	O	O
the	O	O
efficacy	O	O
or	O	O
safety	O	O
of	O	O
tracheal	O	O
intubation	O	O
in	O	O
a	O	O
simulated	O	O
difficult	O	O
airway	O	O
.	O	O

Effect	O	O
of	O	O
motivational	O	O
music	O	O
on	O	O
lactate	O	O
levels	O	O
during	O	O
recovery	O	O
from	O	O
intense	O	O
exercise	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
music	O	O
played	O	O
during	O	O
an	O	O
exercise	O	O
task	O	O
on	O	O
athletic	O	O
performance	O	O
have	O	O
been	O	O
previously	O	O
studied	O	O
.	O	O

Yet	O	O
,	O	O
these	O	O
results	O	O
are	O	O
not	O	O
applicable	O	O
for	O	O
competitive	O	O
athletes	O	O
,	O	O
who	O	O
can	O	O
use	O	O
music	O	O
only	O	O
during	O	O
warm-up	O	O
or	O	O
recovery	O	O
from	O	O
exercise	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
motivational	O	O
music	O	O
(	O	O
music	O	O
that	O	O
stimulates	O	O
or	O	O
inspires	O	O
physical	O	O
activity	O	O
)	O	O
during	O	O
recovery	O	O
from	O	O
intense	O	O
exercise	O	O
,	O	O
on	O	O
activity	O	O
pattern	O	O
,	O	O
rate	O	O
of	O	O
perceived	O	O
exertion	O	O
(	O	O
RPE	O	O
)	O	O
,	O	O
and	O	O
blood	O	O
lactate	O	O
concentration	O	O
.	O	O

Twenty	O	O
young	O	O
,	O	O
active	O	O
men	O	O
(	O	O
mean	O	O
age	O	O
26.2	O	O
?	O	O
2.1	O	O
years	O	O
)	O	O
performed	O	O
a	O	O
6-minute	O	O
run	O	O
at	O	O
peak	O	O
oxygen	O	O
consumption	O	O
speed	O	O
(	O	O
predetermined	O	O
from	O	O
the	O	O
VO	O	O
(	O	O
2	O	O
)	O	O
max	O	O
test	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
RPE	O	O
,	O	O
number	O	O
of	O	O
steps	O	O
(	O	O
determined	O	O
by	O	O
step	O	O
counter	O	O
)	O	O
,	O	O
and	O	O
blood	O	O
lactate	O	O
concentrations	O	O
were	O	O
determined	O	O
at	O	O
3	O	O
,	O	O
6	O	O
,	O	O
9	O	O
,	O	O
12	O	O
,	O	O
and	O	O
15	O	O
minutes	O	O
during	O	O
the	O	O
recovery	O	O
from	O	O
the	O	O
exercise	O	O
,	O	O
with	O	O
and	O	O
without	O	O
motivational	O	O
music	O	O
(	O	O
2	O	O
separate	O	O
sessions	O	O
,	O	O
at	O	O
random	O	O
order	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
mean	O	O
HR	O	O
during	O	O
the	O	O
recovery	O	O
with	O	O
and	O	O
without	O	O
music	O	O
.	O	O

Listening	O	O
to	O	O
motivational	O	O
music	O	O
during	O	O
the	O	O
recovery	O	O
was	O	O
associated	O	O
with	O	O
increased	O	O
voluntary	O	O
activity	O	O
of	O	O
the	O	O
participants	O	O
,	O	O
determined	O	O
by	O	O
increased	O	O
number	O	O
of	O	O
steps	O	O
(	O	O
499.4	O	O
?	O	O
220.1	O	O
vs.	O	O
413.2	O	O
?	O	O
150.6	O	O
steps	O	O
,	O	O
with	O	O
and	O	O
without	O	O
music	O	O
,	O	O
respectively	O	O
;	O	O
p	O	O
?	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
increased	O	O
number	O	O
of	O	O
steps	O	O
during	O	O
the	O	O
recovery	O	O
was	O	O
accompanied	O	O
by	O	O
a	O	O
significantly	O	O
greater	O	O
decrease	O	O
in	O	O
blood	O	O
lactate	O	O
concentration	O	O
percentage	O	O
(	O	O
28.1	O	O
?	O	O
12.2	O	O
vs.	O	O
22.8	O	O
?	O	O
10.9	O	O
%	O	O
,	O	O
with	O	O
and	O	O
without	O	O
music	O	O
,	O	O
respectively	O	O
,	O	O
p	O	O
?	O	O
0.05	O	O
)	O	O
.	O	O

This	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
greater	O	O
decrease	O	O
in	O	O
RPE	O	O
(	O	O
77.7	O	O
?	O	O
14.4	O	O
vs.	O	O
73.1	O	O
?	O	O
14.7	O	O
%	O	O
with	O	O
and	O	O
without	O	O
music	O	O
,	O	O
respectively	O	O
;	O	O
p	O	O
?	O	O
0.05	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
listening	O	O
to	O	O
motivational	O	O
music	O	O
during	O	O
nonstructured	O	O
recovery	O	O
from	O	O
intense	O	O
exercise	O	O
leads	O	O
to	O	O
increased	O	O
activity	O	O
,	O	O
faster	O	O
lactate	O	O
clearance	O	O
,	O	O
and	O	O
reduced	O	O
RPE	O	O
and	O	O
therefore	O	O
may	O	O
be	O	O
used	O	O
by	O	O
athletes	O	O
in	O	O
their	O	O
effort	O	O
to	O	O
enhance	O	O
recovery	O	O
.	O	O

Immunogenicity	O	O
and	O	O
safety	O	O
of	O	O
a	O	O
plasma-derived	O	O
heat-inactivated	O	O
hepatitis	O	O
B	O	O
vaccine	O	O
(	O	O
CLB	O	O
)	O	O
.	O	O

Studies	O	O
in	O	O
volunteers	O	O
at	O	O
a	O	O
low	Condition	O
risk	Condition	O
of	O	O
infection	O	O
with	O	O
hepatitis	Condition	O
B	Condition	O
virus	Condition	O
.	O	O

The	O	O
safety	O	O
and	O	O
immunogenicity	O	O
of	O	O
a	O	O
plasma-derived	O	O
heat-inactivated	O	O
hepatitis	O	O
B	O	O
vaccine	O	O
(	O	O
CLB	O	O
)	O	O
were	O	O
evaluated	O	O
in	O	O
471	SampleSize	SampleSize
healthy	Condition	O
human	O	O
volunteers	O	O
,	O	O
who	O	O
,	O	O
both	O	O
in	O	O
their	O	O
occupations	O	O
and	O	O
in	O	O
their	O	O
private	O	O
lives	O	O
,	O	O
had	O	O
been	O	O
at	O	O
minimal	Condition	O
risk	Condition	O
of	O	O
being	O	O
infected	O	O
with	O	O
hepatitis	Condition	O
B	Condition	O
virus	Condition	O
.	O	O

The	O	O
first	O	O
202	O	SampleSize
individuals	O	O
received	O	O
three	O	O
3-micrograms	O	O
doses	O	O
of	O	O
heat-inactivated	O	O
hepatitis	O	O
B	O	O
surface	O	O
antigen	O	O
(	O	O
HBsAg	O	O
)	O	O
at	O	O
one-month	O	O
intervals	O	O
(	O	O
trial	O	O
A	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
42	O	O
%	O	O
one	O	O
month	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
,	O	O
84	O	O
%	O	O
after	O	O
two	O	O
months	O	O
,	O	O
and	O	O
93	O	O
%	O	O
after	O	O
five	O	O
months	O	O
had	O	O
become	O	O
anti-HBs	O	O
(	O	O
antibody	O	O
to	O	O
hepatitis	O	O
B	O	O
surface	O	O
antigen	O	O
)	O	O
positive	O	O
.	O	O

In	O	O
a	O	O
second	O	O
randomized	O	O
study	O	O
(	O	O
trial	O	O
B	O	O
)	O	O
,	O	O
the	O	O
immunogenicity	O	O
of	O	O
five	O	O
different	O	O
dosages	O	O
of	O	O
the	O	O
vaccine	O	O
was	O	O
compared	O	O
in	O	O
269	O	O
volunteers	O	O
.	O	O

When	O	O
the	O	O
dose	O	O
of	O	O
HBsAg	O	O
was	O	O
diminished	O	O
from	O	O
3	O	O
micrograms	O	O
to	O	O
1.5	O	O
,	O	O
0.6	O	O
,	O	O
and	O	O
0.25	O	O
microgram	O	O
,	O	O
no	O	O
decrease	O	O
of	O	O
the	O	O
anti-HBs	O	O
response	O	O
was	O	O
observed	O	O
.	O	O

However	O	O
,	O	O
when	O	O
the	O	O
dose	O	O
was	O	O
diminished	O	O
to	O	O
0.1	O	O
microgram	O	O
of	O	O
HBsAg	O	O
,	O	O
the	O	O
anti-HBs	O	O
response	O	O
dropped	O	O
significantly	O	O
to	O	O
63	O	O
%	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
the	O	O
recipients	O	O
of	O	O
all	O	O
five	O	O
vaccine	O	O
dosages	O	O
,	O	O
no	O	O
influence	O	O
of	O	O
sex	O	O
and	O	O
age	O	O
was	O	O
found	O	O
on	O	O
the	O	O
anti-HBs	O	O
conversion	O	O
rates	O	O
.	O	O

During	O	O
the	O	O
eight-month	O	O
observation	O	O
period	O	O
,	O	O
none	O	O
of	O	O
the	O	O
vaccinees	O	O
became	O	O
HBsAg	O	O
and/or	O	O
anti-HBc	O	O
(	O	O
antibody	O	O
to	O	O
hepatitis	O	O
B	O	O
core	O	O
antigen	O	O
)	O	O
positive	O	O
,	O	O
and	O	O
none	O	O
developed	O	O
antibodies	O	O
associated	O	O
with	O	O
autoimmune	O	O
liver	O	O
disease	O	O
.	O	O

No	O	O
serious	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

Comparison	O	O
of	O	O
intravenous	O	O
and	O	O
intra-arterial	O	O
urokinase	O	O
thrombolysis	O	O
for	O	O
acute	Condition	O
ischaemic	Condition	O
stroke	Condition	O
.	O	O

Intravenous	O	O
fibrinolysis	O	O
(	O	O
IVF	O	O
)	O	O
with	O	O
rt-PA	O	O
(	O	O
alteplase	O	O
)	O	O
provides	O	O
significant	O	O
benefits	O	O
in	O	O
acute	O	O
ischaemic	O	O
stroke	O	O
when	O	O
it	O	O
is	O	O
given	O	O
within	O	O
the	O	O
first	O	O
three	O	O
hours	O	O
following	O	O
stroke	O	O
onset	O	O
.	O	O

Intra-arterial	O	O
fibrinolysis	O	O
(	O	O
IAF	O	O
)	O	O
with	O	O
pro-urokinase	O	O
in	O	O
PROACT	O	O
II	O	O
study	O	O
provides	O	O
quite	O	O
the	O	O
same	O	O
benefit	O	O
in	O	O
the	O	O
first	O	O
6	O	O
hours	O	O
.	O	O

IVF	O	O
and	O	O
IAF	O	O
have	O	O
never	O	O
been	O	O
compared	O	O
.	O	O

To	O	O
compare	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
IVF	O	O
and	O	O
IAF	O	O
with	O	O
urokinase	O	O
given	O	O
within	O	O
the	O	O
first	O	O
6	O	O
hours	O	O
of	O	O
acute	Condition	O
ischaemic	Condition	O
stroke	Condition	O
.	O	O

Patients	O	O
fulfilling	O	O
the	O	O
selection	O	O
criteria	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
urokinase	O	O
900,000	O	O
units	O	O
via	O	O
intravenous	O	O
or	O	O
intra-arterial	O	O
routes	O	O
.	O	O

This	O	O
randomised	O	O
monocentre	O	O
study	O	O
was	O	O
done	O	O
between	O	O
December	O	O
1995	O	O
and	O	O
August	O	O
1997	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
a	O	O
modified	O	O
Rankin	O	O
score	O	O
of	O	O
2	O	O
or	O	O
less	O	O
.	O	O

Secondary	O	O
outcomes	O	O
included	O	O
mortality	O	O
,	O	O
frequency	O	O
of	O	O
symptomatic	O	O
intracranial	O	O
haemorrhage	O	O
(	O	O
SIH	O	O
)	O	O
,	O	O
neurological	O	O
and	O	O
functional	O	O
scores	O	O
.	O	O

Fourteen	SampleSize	O
patients	O	O
were	O	O
given	O	O
IVF	O	O
and	O	O
13	SampleSize	O
IAF	O	O
.	O	O

The	O	O
study	O	O
was	O	O
terminated	O	O
by	O	O
the	O	O
National	O	O
Health	O	O
Authorities	O	O
when	O	O
27	SampleSize	O
patients	O	O
had	O	O
been	O	O
included	O	O
because	O	O
of	O	O
the	O	O
mortality	O	O
rate	O	O
.	O	O

Seven	O	O
patients	O	O
(	O	O
26	O	O
%	O	O
)	O	O
died	O	O
,	O	O
4	O	O
in	O	O
the	O	O
IV	O	O
group	O	O
(	O	O
oedematous	O	O
infarct	O	O
in	O	O
3	O	O
and	O	O
recurrence	O	O
in	O	O
1	O	O
)	O	O
,	O	O
3	O	O
in	O	O
the	O	O
IA	O	O
group	O	O
(	O	O
SIH	O	O
in	O	O
2	O	O
,	O	O
and	O	O
oedematous	O	O
infarct	O	O
in	O	O
1	O	O
)	O	O
.	O	O

Patients	O	O
given	O	O
IVF	O	O
were	O	O
treated	O	O
significantly	O	O
earlier	O	O
(	O	O
4:16	O	O
h	O	O
vs	O	O
5:24	O	O
h	O	O
;	O	O
p=.007	O	O
)	O	O
.	O	O

Although	O	O
IA	O	O
patients	O	O
showed	O	O
greater	O	O
and	O	O
earlier	O	O
improvement	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
primary	O	O
and	O	O
secondary	O	O
outcomes	O	O
.	O	O

Because	O	O
of	O	O
premature	O	O
termination	O	O
,	O	O
the	O	O
trial	O	O
was	O	O
too	O	O
small	O	O
to	O	O
provide	O	O
any	O	O
reliable	O	O
and	O	O
conclusive	O	O
results	O	O
.	O	O

Intra-arterial	O	O
fibrinolysis	O	O
began	O	O
significantly	O	O
later	O	O
than	O	O
IV	O	O
fibrinolysis	O	O
but	O	O
it	O	O
gave	O	O
non-significantly	O	O
better	O	O
results	O	O
in	O	O
this	O	O
prematurely	O	O
terminated	O	O
study	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
adherence	O	O
to	O	O
a	O	O
low-fat	O	O
dietary	O	O
pattern	O	O
in	O	O
the	O	O
Women	O	O
's	O	O
Health	O	O
Initiative	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
examine	O	O
whether	O	O
the	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
adherance	O	O
to	O	O
a	O	O
low-fat	O	O
(	O	O
20	O	O
%	O	O
energy	O	O
)	O	O
dietary	O	O
pattern	O	O
are	O	O
mediated	O	O
by	O	O
participation	O	O
in	O	O
an	O	O
intervention	O	O
program	O	O
(	O	O
attending	O	O
sessions	O	O
and	O	O
self-monitoring	O	O
)	O	O
.	O	O

DESIGN	O	O
The	O	O
Baron	O	O
and	O	O
Kenny	O	O
mediator	O	O
model	O	O
,	O	O
a	O	O
series	O	O
of	O	O
4	O	O
regression	O	O
analyses	O	O
,	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
whether	O	O
:	O	O
a	O	O
)	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
predicted	O	O
program	O	O
participation	O	O
,	O	O
b	O	O
)	O	O
program	O	O
participation	O	O
predicted	O	O
dietary	O	O
adherence	O	O
,	O	O
c	O	O
)	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
factors	O	O
predicted	O	O
dietary	O	O
adherence	O	O
,	O	O
and	O	O
,	O	O
ultimately	O	O
d	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
on	O	O
dietary	O	O
adherence	O	O
were	O	O
mediated	O	O
by	O	O
program	O	O
participation	O	O
.	O	O

SUBJECTS/SETTING	O	O
Data	O	O
from	O	O
13,277	SampleSize	O
postmenopausal	Condition	O
women	Sex	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
low-fat	O	O
intervention	O	O
arm	O	O
of	O	O
the	O	O
Women	O	O
's	O	O
Health	O	O
Initiative	O	O
Dietary	O	O
Modification	O	O
Trial	O	O
.	O	O

INTERVENTION	O	O
The	O	O
nutrition	O	O
goals	O	O
for	O	O
women	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
low-fat	O	O
intervention	O	O
were	O	O
to	O	O
reduce	O	O
total	O	O
fat	O	O
intake	O	O
to	O	O
20	O	O
%	O	O
or	O	O
less	O	O
of	O	O
energy	O	O
from	O	O
fat	O	O
and	O	O
to	O	O
consume	O	O
5	O	O
or	O	O
more	O	O
fruit/vegetable	O	O
servings	O	O
daily	O	O
and	O	O
6	O	O
or	O	O
more	O	O
grain	O	O
servings	O	O
daily	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Year	O	O
1	O	O
program	O	O
participation	O	O
(	O	O
degree	O	O
of	O	O
attending	O	O
group	O	O
sessions	O	O
and	O	O
submitting	O	O
fat	O	O
scores	O	O
)	O	O
and	O	O
adherence	O	O
to	O	O
the	O	O
low-fat	O	O
dietary	O	O
pattern	O	O
(	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
)	O	O
as	O	O
predicted	O	O
by	O	O
baseline	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
(	O	O
eight	O	O
SF-36	O	O
Health	O	O
Survey	O	O
subscales	O	O
)	O	O
.	O	O

RESULTS	O	O
Participating	O	O
in	O	O
the	O	O
dietary	O	O
intervention	O	O
program	O	O
reduced	O	O
(	O	O
mediated	O	O
)	O	O
the	O	O
negative	O	O
effect	O	O
of	O	O
poorer	O	O
mental	O	O
health	O	O
on	O	O
dietary	O	O
adherence	O	O
by	O	O
15	O	O
%	O	O
.	O	O

Additional	O	O
findings	O	O
included	O	O
that	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
physical	O	O
functioning	O	O
increased	O	O
session	O	O
attendance	O	O
by	O	O
0.4	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
and	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
mental	O	O
health	O	O
predicted	O	O
a	O	O
decrease	O	O
in	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
of	O	O
0.3	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Program	O	O
participation	O	O
had	O	O
a	O	O
marked	O	O
effect	O	O
on	O	O
dietary	O	O
adherence	O	O
:	O	O
a	O	O
10	O	O
%	O	O
increase	O	O
in	O	O
session	O	O
attendance	O	O
predicted	O	O
a	O	O
1.2	O	O
%	O	O
decrease	O	O
in	O	O
percent	O	O
energy	O	O
from	O	O
fat	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

APPLICATIONS/CONCLUSIONS	O	O
Understanding	O	O
and	O	O
using	O	O
instruments	O	O
to	O	O
assess	O	O
the	O	O
physical	O	O
and	O	O
emotional	O	O
status	O	O
of	O	O
a	O	O
target	O	O
population	O	O
will	O	O
help	O	O
dietetic	O	O
professionals	O	O
promote	O	O
healthful	O	O
dietary	O	O
change	O	O
and	O	O
maintenance	O	O
.	O	O

In-hospital	O	O
costs	O	O
of	O	O
self-expanding	O	O
nitinol	O	O
stent	O	O
implantation	O	O
versus	O	O
balloon	O	O
angioplasty	O	O
in	O	O
the	O	O
femoropopliteal	O	O
artery	O	O
(	O	O
the	O	O
VascuCoil	O	O
Trial	O	O
)	O	O
.	O	O

PURPOSE	O	O
Although	O	O
several	O	O
prospective	O	O
studies	O	O
have	O	O
examined	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
stent	O	O
placement	O	O
for	O	O
femoropopliteal	Condition	O
arterial	Condition	O
disease	Condition	O
,	O	O
the	O	O
current	O	O
cost	O	O
of	O	O
these	O	O
procedures	O	O
is	O	O
unknown	O	O
.	O	O

To	O	O
estimate	O	O
and	O	O
compare	O	O
hospital	O	O
costs	O	O
associated	O	O
with	O	O
conventional	O	O
balloon	O	O
angioplasty	O	O
(	O	O
percutaneous	O	O
transluminal	O	O
angioplasty	O	O
[	O	O
PTA	O	O
]	O	O
)	O	O
and	O	O
stent	O	O
placement	O	O
for	O	O
patients	O	O
with	O	O
symptomatic	O	O
peripheral	O	O
arterial	O	O
disease	O	O
,	O	O
the	O	O
authors	O	O
performed	O	O
a	O	O
prospective	O	O
economic	O	O
evaluation	O	O
in	O	O
conjunction	O	O
with	O	O
the	O	O
Intracoil	O	O
Femoropopliteal	O	O
Stent	O	O
Trial	O	O
(	O	O
VascuCoil	O	O
)	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Between	O	O
May	O	O
1997	O	O
and	O	O
December	O	O
1999	O	O
,	O	O
266	SampleSize	O
patients	O	O
with	O	O
stenotic	Condition	O
or	Condition	O
occluded	Condition	O
superficial	Condition	O
femoral	Condition	O
or	Condition	O
popliteal	Condition	O
arteries	Condition	O
were	O	O
prospectively	O	O
randomized	O	O
to	O	O
treatment	O	O
with	O	O
the	O	O
IntraCoil	O	O
stent	O	O
or	O	O
PTA	O	O
.	O	O

Detailed	O	O
resource	O	O
use	O	O
and	O	O
cost	O	O
data	O	O
for	O	O
each	O	O
patient	O	O
's	O	O
initial	O	O
revascularization	O	O
procedure	O	O
and	O	O
ensuing	O	O
hospitalization	O	O
were	O	O
collected	O	O
and	O	O
analyzed	O	O
on	O	O
an	O	O
intention-to-treat	O	O
basis	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
conventional	O	O
balloon	O	O
angioplasty	O	O
,	O	O
stent	O	O
placement	O	O
did	O	O
not	O	O
improve	O	O
clinical	O	O
outcomes	O	O
but	O	O
increased	O	O
procedure	O	O
duration	O	O
,	O	O
equipment	O	O
costs	O	O
,	O	O
and	O	O
physician	O	O
services	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
initial	O	O
hospital	O	O
costs	O	O
were	O	O
approximately	O	O
3,500	O	O
dollars	O	O
higher	O	O
for	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
IntraCoil	O	O
stent	O	O
,	O	O
compared	O	O
with	O	O
PTA	O	O
(	O	O
8,435	O	O
dollars	O	O
vs	O	O
4,980	O	O
dollars	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
As	O	O
performed	O	O
in	O	O
the	O	O
VascuCoil	O	O
trial	O	O
,	O	O
primary	O	O
stent	O	O
placement	O	O
for	O	O
femoropopliteal	O	O
disease	O	O
did	O	O
not	O	O
improve	O	O
clinical	O	O
outcomes	O	O
but	O	O
increased	O	O
initial	O	O
treatment	O	O
costs	O	O
by	O	O
more	O	O
than	O	O
3,000	O	O
dollars	O	O
.	O	O

Because	O	O
there	O	O
were	O	O
no	O	O
substantial	O	O
differences	O	O
in	O	O
subsequent	O	O
clinical	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
treatments	O	O
,	O	O
it	O	O
is	O	O
unlikely	O	O
that	O	O
these	O	O
increased	O	O
initial	O	O
costs	O	O
would	O	O
be	O	O
offset	O	O
by	O	O
savings	O	O
in	O	O
follow-up	O	O
costs	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
a	O	O
strategy	O	O
of	O	O
routine	O	O
stent	O	O
implantation	O	O
for	O	O
patients	O	O
undergoing	O	O
femoropopliteal	Condition	O
PTA	Condition	O
is	O	O
not	O	O
optimal	O	O
on	O	O
economic	O	O
grounds	O	O
and	O	O
that	O	O
PTA	O	O
with	O	O
provisional	O	O
stent	O	O
implantation	O	O
is	O	O
preferred	O	O
.	O	O

Using	O	O
baby	O	O
books	O	O
to	O	O
increase	O	O
new	Condition	O
mothers	Condition	O
'	O	O
safety	O	O
practices	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
whether	O	O
educational	O	O
baby	O	O
books	O	O
are	O	O
an	O	O
effective	O	O
method	O	O
for	O	O
increasing	O	O
low-income	O	O
,	O	O
first-time	O	O
mothers	O	O
'	O	O
safety	O	O
practices	O	O
during	O	O
their	O	O
child	O	O
's	O	O
first	O	O
18	O	O
months	O	O
.	O	O

METHODS	O	O
Primiparous	Condition	O
women	Sex	O
(	O	O
n	O	O
=	O	O
167	SampleSize	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
1	O	O
of	O	O
3	O	O
groups	O	O
:	O	O
an	O	O
educational	O	O
book	O	O
group	O	O
,	O	O
a	O	O
noneducational	O	O
book	O	O
group	O	O
,	O	O
or	O	O
a	O	O
no-book	O	O
group	O	O
.	O	O

Home	O	O
visits	O	O
and	O	O
interviews	O	O
measured	O	O
safety	O	O
practices	O	O
when	O	O
women	O	O
were	O	O
in	O	O
their	O	O
third	O	O
trimester	O	O
of	O	O
pregnancy	O	O
(	O	O
baseline	O	O
)	O	O
and	O	O
when	O	O
their	O	O
children	O	O
were	O	O
2	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
9	O	O
,	O	O
12	O	O
,	O	O
and	O	O
18	O	O
months	O	O
of	O	O
age	O	O
.	O	O

RESULTS	O	O
Women	O	O
in	O	O
the	O	O
educational	O	O
book	O	O
group	O	O
had	O	O
fewer	O	O
risks	O	O
in	O	O
their	O	O
homes	O	O
and	O	O
exercised	O	O
more	O	O
safety	O	O
practices	O	O
than	O	O
the	O	O
no-book	O	O
group	O	O
(	O	O
-	O	O
20	O	O
%	O	O
risk	O	O
reduction	O	O
;	O	O
effect	O	O
size	O	O
=	O	O
-.30	O	O
)	O	O
.	O	O

When	O	O
the	O	O
safety	O	O
practices	O	O
involved	O	O
little	O	O
time	O	O
or	O	O
expense	O	O
(	O	O
eg	O	O
,	O	O
putting	O	O
away	O	O
sharp	O	O
objects	O	O
)	O	O
,	O	O
the	O	O
educational	O	O
book	O	O
group	O	O
was	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
engage	O	O
in	O	O
these	O	O
behaviors	O	O
than	O	O
the	O	O
no-book	O	O
group	O	O
(	O	O
40	O	O
%	O	O
higher	O	O
practices	O	O
;	O	O
effect	O	O
size	O	O
=	O	O
0.19	O	O
)	O	O
or	O	O
noneducational	O	O
book	O	O
group	O	O
(	O	O
27	O	O
%	O	O
higher	O	O
practices	O	O
;	O	O
effect	O	O
size	O	O
=	O	O
0.13	O	O
)	O	O
.	O	O

However	O	O
,	O	O
no	O	O
differences	O	O
were	O	O
found	O	O
between	O	O
groups	O	O
for	O	O
behaviors	O	O
that	O	O
required	O	O
high	O	O
effort	O	O
in	O	O
time	O	O
,	O	O
money	O	O
,	O	O
or	O	O
hassle	O	O
(	O	O
eg	O	O
,	O	O
installing	O	O
latches	O	O
on	O	O
cabinets	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Educational	O	O
baby	O	O
books	O	O
appear	O	O
to	O	O
be	O	O
an	O	O
easy	O	O
and	O	O
low-cost	O	O
way	O	O
to	O	O
increase	O	O
the	O	O
safety	O	O
practices	O	O
of	O	O
new	O	O
mothers	O	O
,	O	O
especially	O	O
if	O	O
the	O	O
practices	O	O
involve	O	O
little	O	O
to	O	O
no	O	O
time	O	O
,	O	O
money	O	O
,	O	O
or	O	O
hassle	O	O
.	O	O

Propofol	O	O
sedation	O	O
with	O	O
bispectral	O	O
index	O	O
monitoring	O	O
is	O	O
useful	O	O
for	O	O
endoscopic	O	O
submucosal	O	O
dissection	O	O
:	O	O
a	O	O
randomized	O	O
prospective	O	O
phase	O	O
II	O	O
clinical	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
STUDY	O	O
AIMS	O	O
Endoscopic	O	O
submucosal	O	O
dissection	O	O
(	O	O
ESD	O	O
)	O	O
has	O	O
become	O	O
a	O	O
standard	O	O
treatment	O	O
.	O	O

However	O	O
,	O	O
the	O	O
treatment	O	O
time	O	O
tends	O	O
to	O	O
be	O	O
relatively	O	O
long	O	O
and	O	O
insufflation	O	O
and	O	O
manipulation	O	O
of	O	O
the	O	O
endoscope	O	O
can	O	O
increase	O	O
pain	O	O
and	O	O
discomfort	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
find	O	O
an	O	O
optimal	O	O
method	O	O
for	O	O
sedation	O	O
during	O	O
ESD	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Patients	O	O
scheduled	O	O
to	O	O
undergo	O	O
ESD	O	O
for	O	O
early	Condition	O
gastric	Condition	O
cancer	Condition	O
or	Condition	O
adenoma	Condition	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
sedation	O	O
with	O	O
midazolam	O	O
or	O	O
propofol	O	O
,	O	O
and	O	O
consciousness	O	O
level	O	O
was	O	O
evaluated	O	O
by	O	O
bispectral	O	O
index	O	O
(	O	O
BIS	O	O
)	O	O
monitoring	O	O
.	O	O

Primary	O	O
end	O	O
points	O	O
of	O	O
effectiveness	O	O
(	O	O
three	O	O
parameters	O	O
)	O	O
and	O	O
secondary	O	O
end	O	O
points	O	O
of	O	O
safety	O	O
during	O	O
ESD	O	O
and	O	O
after	O	O
return	O	O
to	O	O
the	O	O
ward	O	O
were	O	O
compared	O	O
between	O	O
the	O	O
groups	O	O
.	O	O

Study	O	O
registration	O	O
was	O	O
in	O	O
the	O	O
UMIN	O	O
Clinical	O	O
Trial	O	O
Registry	O	O
(	O	O
UMIN	O	O
000001497	O	O
)	O	O
,	O	O
and	O	O
the	O	O
institutional	O	O
trial	O	O
number	O	O
was	O	O
KDOG	O	O
0801	O	O
.	O	O

RESULTS	O	O
From	O	O
June	O	O
2008	O	O
through	O	O
June	O	O
2009	O	O
,	O	O
we	O	O
enrolled	O	O
178	SampleSize	O
patients	O	O
(	O	O
90	O	O
midazolam	O	O
,	O	O
88	O	O
propofol	O	O
)	O	O
.	O	O

Regarding	O	O
safety	O	O
after	O	O
ESD	O	O
,	O	O
recovery	O	O
was	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
propofol	O	O
group	O	O
immediately	O	O
after	O	O
and	O	O
at	O	O
1	O	O
hour	O	O
and	O	O
2	O	O
hours	O	O
after	O	O
return	O	O
to	O	O
the	O	O
ward	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
required	O	O
a	O	O
continuous	O	O
supply	O	O
of	O	O
oxygen	O	O
2	O	O
hours	O	O
after	O	O
returning	O	O
to	O	O
the	O	O
ward	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
propofol	O	O
group	O	O
(	O	O
midazolam	O	O
18	O	O
;	O	O
propofol	O	O
6	O	O
;	O	O
P	O	O
=	O	O
0.010	O	O
)	O	O
.	O	O

Though	O	O
propofol	O	O
seemed	O	O
to	O	O
be	O	O
better	O	O
for	O	O
effectiveness	O	O
and	O	O
safety	O	O
,	O	O
there	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
for	O	O
all	O	O
three	O	O
primary	O	O
end	O	O
points	O	O
and	O	O
the	O	O
safety	O	O
parameters	O	O
(	O	O
hypotension	O	O
,	O	O
hypoxia	O	O
,	O	O
bradycardia	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Propofol	O	O
with	O	O
BIS	O	O
monitoring	O	O
improved	O	O
recovery	O	O
of	O	O
patients	O	O
after	O	O
ESD	O	O
,	O	O
though	O	O
this	O	O
study	O	O
was	O	O
underpowered	O	O
to	O	O
prove	O	O
the	O	O
effectiveness	O	O
and	O	O
safety	O	O
of	O	O
propofol	O	O
.	O	O

Somatostatin	O	O
and	O	O
ranitidine	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
non-variceal	Condition	O
upper	Condition	O
gastrointestinal	Condition	O
bleeding	Condition	O
:	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
controlled	O	O
study	O	O
.	O	O

BACKGROUND/AIMS	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
of	O	O
somatostatin	O	O
vs.	O	O
ranitidine	O	O
in	O	O
controlling	O	O
acute	Condition	O
non-variceal	Condition	O
gastrointestinal	Condition	O
bleeding	Condition	O
.	O	O

METHODOLOGY	O	O
A	O	O
total	O	O
of	O	O
48	SampleSize	SampleSize
patients	O	O
with	O	O
acute	Condition	O
upper	Condition	O
gastrointestinal	Condition	O
bleeding	Condition	O
due	O	O
to	O	O
duodenal	Condition	O
or	Condition	O
gastric	Condition	Condition
ulcer	Condition	Condition
were	O	O
divided	O	O
into	O	O
2	O	O
groups	O	O
.	O	O

Group	O	O
I	O	O
consisted	O	O
of	O	O
15	SampleSize	O
patients	O	O
with	O	O
Forrest	O	O
IB	O	O
and	O	O
Group	O	O
II	O	O
consisted	O	O
of	O	O
30	SampleSize	SampleSize
patients	O	O
with	O	O
Forrest	O	O
II	O	O
.	O	O

Two	O	O
regimens	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
all	O	O
patients	O	O
within	O	O
half	O	O
an	O	O
hour	O	O
after	O	O
the	O	O
endoscopic	O	O
procedure	O	O
:	O	O
1	O	O
)	O	O
somatostatin-UCB	O	O
250	O	O
mcg	O	O
i.v	O	O
.	O	O

bolus	O	O
followed	O	O
by	O	O
continuous	O	O
i.v	O	O
.	O	O

infusion	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
6	O	O
mg/d	O	O
for	O	O
72	O	O
h	O	O
,	O	O
or	O	O
2	O	O
)	O	O
ranitidine	O	O
300	O	O
mg/d	O	O
by	O	O
continuous	O	O
i.v	O	O
.	O	O

infusion	O	O
for	O	O
72	O	O
h.	O	O
RESULTS	O	O
In	O	O
Group	O	O
I	O	O
,	O	O
although	O	O
mean	O	O
blood	O	O
transfusion	O	O
requirements	O	O
(	O	O
no	O	O
.	O	O

of	O	O
units	O	O
)	O	O
were	O	O
lower	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
somatostatin	O	O
than	O	O
in	O	O
those	O	O
treated	O	O
with	O	O
ranitidine	O	O
,	O	O
this	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
(	O	O
mean	O	O
+/-	O	O
SD	O	O
:	O	O
2.56	O	O
+/-	O	O
3.05	O	O
vs.	O	O
5.17	O	O
+/-	O	O
4.96	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
;	O	O
the	O	O
time	O	O
of	O	O
bleeding	O	O
stop	O	O
was	O	O
shorter	O	O
in	O	O
the	O	O
somatostatin	O	O
group	O	O
than	O	O
in	O	O
the	O	O
ranitidine	O	O
group	O	O
(	O	O
mean	O	O
+/-	O	O
SD	O	O
:	O	O
3.24	O	O
+/-	O	O
2.45	O	O
vs.	O	O
11.25	O	O
+/-	O	O
11.63	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
=	O	O
0.0383	O	O
)	O	O
.	O	O

The	O	O
rebleeding	O	O
and	O	O
the	O	O
mortality	O	O
rates	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
treatment	O	O
groups	O	O
in	O	O
both	O	O
Group	O	O
I	O	O
and	O	O
Group	O	O
II	O	O
.	O	O

CONCLUSIONS	O	O
Somatostatin	O	O
is	O	O
more	O	O
effective	O	O
than	O	O
ranitidine	O	O
in	O	O
controlling	O	O
acute	O	O
non-variceal	O	O
gastrointestinal	O	O
bleeding	O	O
in	O	O
patients	O	O
with	O	O
Forrest	O	O
IB	O	O
bleeding	O	O
activity	O	O
.	O	O

Somatostatin	O	O
has	O	O
no	O	O
additional	O	O
benefit	O	O
in	O	O
those	O	O
with	O	O
Forrest	O	O
II	O	O
bleeding	O	O
activity	O	O
.	O	O

Multiple	O	O
courses	O	O
of	O	O
rituximab	O	O
produce	O	O
sustained	O	O
clinical	O	O
and	O	O
radiographic	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
patients	O	O
with	O	O
rheumatoid	Condition	O
arthritis	Condition	O
and	O	O
an	O	O
inadequate	O	O
response	O	O
to	O	O
1	O	O
or	O	O
more	O	O
tumor	O	O
necrosis	O	O
factor	O	O
inhibitors	O	O
:	O	O
5-year	O	O
data	O	O
from	O	O
the	O	O
REFLEX	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
This	O	O
5-year	O	O
observational	O	O
posthoc	O	O
analysis	O	O
of	O	O
the	O	O
REFLEX	O	O
study	O	O
and	O	O
its	O	O
open-label	O	O
extension	O	O
assessed	O	O
clinical	O	O
efficacy	O	O
,	O	O
radiographic	O	O
response	O	O
,	O	O
and	O	O
safety	O	O
of	O	O
rituximab	O	O
(	O	O
RTX	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
(	O	O
RA	Condition	O
)	O	O
who	O	O
had	O	O
an	O	O
inadequate	O	O
response	O	O
to	O	O
tumor	O	O
necrosis	O	O
factor	O	O
(	O	O
TNF	O	O
)	O	O
inhibitors	O	O
.	O	O

METHODS	O	O
Patients	O	O
in	O	O
REFLEX	O	O
were	O	O
originally	O	O
randomized	O	O
to	O	O
placebo	O	O
(	O	O
PBO	O	O
)	O	O
+	O	O
methotrexate	O	O
(	O	O
MTX	O	O
;	O	O
PBO-randomized	O	O
)	O	O
or	O	O
RTX	O	O
+	O	O
MTX	O	O
(	O	O
RTX-randomized	O	O
)	O	O
.	O	O

PBO-randomized	O	O
patients	O	O
were	O	O
rescued	O	O
with	O	O
RTX	O	O
as	O	O
appropriate	O	O
.	O	O

Patients	O	O
responding	O	O
to	O	O
initial	O	O
RTX	O	O
treatment	O	O
could	O	O
receive	O	O
further	O	O
RTX	O	O
courses	O	O
.	O	O

For	O	O
clinical	O	O
efficacy	O	O
and	O	O
safety	O	O
analyses	O	O
,	O	O
PBO-randomized	O	O
patients	O	O
were	O	O
re-baselined	O	O
prior	O	O
to	O	O
first	O	O
RTX	O	O
treatment	O	O
and	O	O
the	O	O
data	O	O
were	O	O
pooled	O	O
with	O	O
RTX-randomized	O	O
patient	O	O
data	O	O
.	O	O

Efficacy	O	O
outcomes	O	O
24	O	O
weeks	O	O
after	O	O
each	O	O
course	O	O
were	O	O
calculated	O	O
relative	O	O
to	O	O
first	O	O
RTX	O	O
pretreatment	O	O
baseline	O	O
.	O	O

Radiographic	O	O
outcomes	O	O
were	O	O
assessed	O	O
relative	O	O
to	O	O
randomization	O	O
baseline	O	O
for	O	O
both	O	O
PBO-randomized	O	O
and	O	O
RTX-randomized	O	O
groups	O	O
.	O	O

RESULTS	O	O
A	O	O
total	O	O
of	O	O
480	O	O
patients	O	O
received	O	O
?	O	O
1	O	O
RTX	O	O
course	O	O
.	O	O

At	O	O
24	O	O
weeks	O	O
,	O	O
American	O	O
College	O	O
of	O	O
Rheumatology	O	O
20/50/70	O	O
responses	O	O
were	O	O
62.0	O	O
%	O	O
,	O	O
30.8	O	O
%	O	O
,	O	O
and	O	O
13.0	O	O
%	O	O
,	O	O
respectively	O	O
at	O	O
course	O	O
1	O	O
(	O	O
n	O	O
=	O	O
400	O	O
)	O	O
and	O	O
70.3	O	O
%	O	O
,	O	O
41.8	O	O
%	O	O
,	O	O
and	O	O
22.0	O	O
%	O	O
at	O	O
course	O	O
5	O	O
(	O	O
n	O	O
=	O	O
91	O	O
)	O	O
.	O	O

European	O	O
League	O	O
Against	O	O
Rheumatism	O	O
good/moderate	O	O
responses	O	O
were	O	O
77.2	O	O
%	O	O
and	O	O
84.4	O	O
%	O	O
at	O	O
courses	O	O
1	O	O
(	O	O
n	O	O
=	O	O
390	O	O
)	O	O
and	O	O
5	O	O
(	O	O
n	O	O
=	O	O
90	O	O
)	O	O
.	O	O

Rates	O	O
of	O	O
adverse	O	O
events	O	O
(	O	O
AE	O	O
)	O	O
,	O	O
serious	O	O
AE	O	O
,	O	O
and	O	O
infections	O	O
generally	O	O
remained	O	O
stable	O	O
.	O	O

Rate	O	O
of	O	O
progressive	O	O
joint	O	O
damage	O	O
(	O	O
PJD	O	O
;	O	O
change	O	O
in	O	O
mean	O	O
Total	O	O
Sharp	O	O
Score	O	O
)	O	O
decreased	O	O
over	O	O
time	O	O
in	O	O
both	O	O
PBO-randomized	O	O
(	O	O
n	O	O
=	O	O
79	O	O
)	O	O
and	O	O
RTX-randomized	O	O
(	O	O
n	O	O
=	O	O
105	O	O
)	O	O
groups	O	O
.	O	O

Mean	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
PJD	O	O
over	O	O
5	O	O
years	O	O
was	O	O
greater	O	O
in	O	O
PBO-randomized	O	O
versus	O	O
RTX-randomized	O	O
patients	O	O
(	O	O
5.51	O	O
vs	O	O
3.21	O	O
)	O	O
.	O	O

CONCLUSION	O	O
RTX	O	O
re-treatment	O	O
over	O	O
5	O	O
years	O	O
is	O	O
associated	O	O
with	O	O
maintained	O	O
or	O	O
improved	O	O
efficacy	O	O
,	O	O
continued	O	O
inhibition	O	O
of	O	O
PJD	O	O
,	O	O
and	O	O
a	O	O
safety	O	O
profile	O	O
consistent	O	O
with	O	O
that	O	O
previously	O	O
reported	O	O
.	O	O

A	O	O
delay	O	O
in	O	O
initiating	O	O
RTX	O	O
treatment	O	O
may	O	O
result	O	O
in	O	O
increased	O	O
PJD	O	O
.	O	O

Warfarin	O	O
for	O	O
atrial	Condition	O
fibrillation	Condition	O
.	O	O

The	O	O
patient	O	O
's	O	O
perspective	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
the	O	O
minimal	O	O
clinically	O	O
important	O	O
difference	O	O
(	O	O
MCID	O	O
)	O	O
of	O	O
warfarin	O	O
therapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
nonvalvular	Condition	O
atrial	Condition	O
fibrillation	Condition	O
from	O	O
the	O	O
perspective	O	O
of	O	O
patients	O	O
using	O	O
2	O	O
different	O	O
elicitation	O	O
methods	O	O
.	O	O

DESIGN	O	O
All	O	O
patients	O	O
completed	O	O
2	O	O
face-to-face	O	O
interviews	O	O
,	O	O
which	O	O
were	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

For	O	O
each	O	O
interview	O	O
,	O	O
they	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
1	O	O
of	O	O
2	O	O
elicitation	O	O
methods	O	O
:	O	O
ping-ponging	O	O
or	O	O
starting	O	O
at	O	O
the	O	O
known	O	O
efficacy	O	O
.	O	O

SETTING	O	O
The	O	O
practices	O	O
of	O	O
2	O	O
university-affiliated	O	O
family	O	O
medicine	O	O
centers	O	O
(	O	O
8	O	O
physicians	O	O
each	O	O
)	O	O
,	O	O
14	O	SampleSize
community-based	O	O
family	O	O
physicians	O	O
,	O	O
and	O	O
2	O	O
cardiologists	O	O
.	O	O

PATIENTS	O	O
Sixty-four	SampleSize	SampleSize
patients	O	O
with	O	O
nonvalvular	Condition	O
atrial	Condition	O
fibrillation	Condition	O
who	O	O
were	O	O
initiated	O	O
with	O	O
warfarin	O	O
therapy	O	O
at	O	O
least	O	O
3	O	O
months	O	O
before	O	O
the	O	O
study	O	O
.	O	O

INTERVENTION	O	O
During	O	O
each	O	O
interview	O	O
,	O	O
the	O	O
patients	O	O
'	O	O
MCIDs	O	O
were	O	O
determined	O	O
by	O	O
using	O	O
(	O	O
1	O	O
)	O	O
a	O	O
pictorial	O	O
flip	O	O
chart	O	O
to	O	O
describe	O	O
atrial	O	O
fibrillation	O	O
;	O	O
the	O	O
consequences	O	O
of	O	O
a	O	O
minor	O	O
stroke	O	O
,	O	O
a	O	O
major	O	O
stroke	O	O
,	O	O
and	O	O
a	O	O
major	O	O
bleeding	O	O
episode	O	O
;	O	O
the	O	O
chance	O	O
of	O	O
stroke	O	O
if	O	O
not	O	O
taking	O	O
warfarin	O	O
;	O	O
the	O	O
chance	O	O
of	O	O
a	O	O
major	O	O
bleeding	O	O
episode	O	O
if	O	O
taking	O	O
warfarin	O	O
;	O	O
examples	O	O
of	O	O
the	O	O
inconvenience	O	O
,	O	O
minor	O	O
side	O	O
effects	O	O
,	O	O
and	O	O
costs	O	O
of	O	O
warfarin	O	O
therapy	O	O
;	O	O
and	O	O
then	O	O
(	O	O
2	O	O
)	O	O
1	O	O
of	O	O
the	O	O
2	O	O
elicitation	O	O
methods	O	O
to	O	O
determine	O	O
their	O	O
MCIDs	O	O
(	O	O
the	O	O
smallest	O	O
reduction	O	O
in	O	O
stroke	O	O
risk	O	O
at	O	O
which	O	O
the	O	O
patients	O	O
were	O	O
willing	O	O
to	O	O
take	O	O
warfarin	O	O
)	O	O
.	O	O

Patients	O	O
'	O	O
knowledge	O	O
of	O	O
their	O	O
stroke	O	O
risk	O	O
,	O	O
acceptability	O	O
of	O	O
the	O	O
interview	O	O
process	O	O
,	O	O
and	O	O
factors	O	O
determining	O	O
their	O	O
preferences	O	O
were	O	O
also	O	O
assessed	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
Given	O	O
a	O	O
baseline	O	O
risk	O	O
of	O	O
having	O	O
a	O	O
stroke	O	O
in	O	O
the	O	O
next	O	O
2	O	O
years	O	O
,	O	O
if	O	O
not	O	O
taking	O	O
warfarin	O	O
,	O	O
of	O	O
10	O	O
of	O	O
100	O	O
,	O	O
the	O	O
mean	O	O
MCID	O	O
was	O	O
2.01	O	O
of	O	O
100	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.60-2.42	O	O
)	O	O
.	O	O

Fifty-two	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
would	O	O
take	O	O
warfarin	O	O
for	O	O
an	O	O
absolute	O	O
decrease	O	O
in	O	O
stroke	O	O
risk	O	O
of	O	O
1	O	O
%	O	O
over	O	O
2	O	O
years	O	O
.	O	O

Before	O	O
eliciting	O	O
their	O	O
MCIDs	O	O
,	O	O
patients	O	O
showed	O	O
poor	O	O
knowledge	O	O
of	O	O
their	O	O
stroke	O	O
risk	O	O
,	O	O
which	O	O
improved	O	O
afterward	O	O
.	O	O

The	O	O
interview	O	O
process	O	O
was	O	O
well	O	O
accepted	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

The	O	O
MCID	O	O
using	O	O
the	O	O
ping-ponging	O	O
elicitation	O	O
method	O	O
was	O	O
1.015	O	O
of	O	O
100	O	O
smaller	O	O
compared	O	O
with	O	O
use	O	O
of	O	O
the	O	O
starting	O	O
at	O	O
the	O	O
known	O	O
efficacy	O	O
method	O	O
(	O	O
P	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
We	O	O
were	O	O
able	O	O
to	O	O
determine	O	O
the	O	O
MCID	O	O
of	O	O
warfarin	O	O
therapy	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
stroke	O	O
from	O	O
the	O	O
perspective	O	O
of	O	O
patients	O	O
with	O	O
nonvalvular	Condition	O
atrial	Condition	O
fibrillation	Condition	O
.	O	O

Their	O	O
MCIDs	O	O
were	O	O
much	O	O
smaller	O	O
than	O	O
those	O	O
that	O	O
have	O	O
been	O	O
implied	O	O
by	O	O
some	O	O
experts	O	O
and	O	O
clinicians	O	O
.	O	O

The	O	O
interview	O	O
process	O	O
,	O	O
using	O	O
the	O	O
flip	O	O
chart	O	O
approach	O	O
,	O	O
appeared	O	O
to	O	O
improve	O	O
the	O	O
patients	O	O
'	O	O
knowledge	O	O
of	O	O
their	O	O
disease	O	O
and	O	O
its	O	O
consequences	O	O
and	O	O
treatment	O	O
.	O	O

The	O	O
method	O	O
used	O	O
to	O	O
elicit	O	O
the	O	O
patients	O	O
'	O	O
MCIDs	O	O
can	O	O
have	O	O
a	O	O
clinically	O	O
important	O	O
effect	O	O
on	O	O
patient	O	O
responses	O	O
.	O	O

The	O	O
method	O	O
used	O	O
in	O	O
our	O	O
study	O	O
can	O	O
be	O	O
generalized	O	O
to	O	O
other	O	O
conditions	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
could	O	O
be	O	O
helpful	O	O
in	O	O
3	O	O
ways	O	O
:	O	O
(	O	O
1	O	O
)	O	O
from	O	O
a	O	O
clinical	O	O
decision-making	O	O
perspective	O	O
,	O	O
it	O	O
could	O	O
facilitate	O	O
patient-physician	O	O
communication	O	O
;	O	O
(	O	O
2	O	O
)	O	O
it	O	O
could	O	O
clarify	O	O
the	O	O
patient	O	O
perspective	O	O
when	O	O
interpreting	O	O
the	O	O
results	O	O
of	O	O
previously	O	O
completed	O	O
trials	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
it	O	O
could	O	O
be	O	O
used	O	O
to	O	O
derive	O	O
more	O	O
clinically	O	O
relevant	O	O
sample	O	O
sizes	O	O
for	O	O
randomized	O	O
treatment	O	O
trials	O	O
.	O	O

Codeine/acetaminophen	O	O
and	O	O
hydrocodone/acetaminophen	O	O
combination	O	O
tablets	O	O
for	O	O
the	O	O
management	O	O
of	O	O
chronic	Condition	Condition
cancer	Condition	Condition
pain	Condition	Condition
in	O	O
adults	Age	Age
:	O	O
a	O	O
23-day	O	O
,	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
randomized	O	O
,	O	O
parallel-group	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Analgesics	O	O
are	O	O
an	O	O
essential	O	O
component	O	O
of	O	O
the	O	O
treatment	O	O
of	O	O
cancer-associated	O	O
pain	O	O
.	O	O

Pharmacologic	O	O
treatment	O	O
is	O	O
usually	O	O
begun	O	O
with	O	O
nonopioid	O	O
analgesics	O	O
,	O	O
most	O	O
frequently	O	O
acetaminophen	O	O
.	O	O

If	O	O
pain	O	O
relief	O	O
is	O	O
not	O	O
achieved	O	O
,	O	O
the	O	O
so-called	O	O
weak	O	O
opioids	O	O
,	O	O
such	O	O
as	O	O
codeine	O	O
and	O	O
hydrocodone	O	O
,	O	O
may	O	O
be	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
acetaminophen	O	O
.	O	O

Adverse	O	O
effects	O	O
(	O	O
AEs	O	O
)	O	O
of	O	O
the	O	O
opioids	O	O
include	O	O
constipation	O	O
,	O	O
somnolence	O	O
,	O	O
nausea	O	O
,	O	O
and	O	O
vomiting	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
results	O	O
of	O	O
a	O	O
literature	O	O
search	O	O
,	O	O
data	O	O
comparing	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
opioids	O	O
are	O	O
lacking	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
analgesic	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
codeine	O	O
phosphate	O	O
versus	O	O
hydrocodone	O	O
bitartrate	O	O
in	O	O
combination	O	O
with	O	O
acetaminophen	O	O
in	O	O
the	O	O
relief	O	O
of	O	O
cancer-related	O	O
pain	O	O
.	O	O

METHODS	O	O
This	O	O
23-day	O	O
,	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
randomized	O	O
,	O	O
parallel-group	O	O
study	O	O
was	O	O
conducted	O	O
at	O	O
3	O	O
Colombian	O	O
centers	O	O
:	O	O
University	O	O
Libre	O	O
,	O	O
Social	O	O
Security	O	O
Institute	O	O
,	O	O
and	O	O
General	O	O
Hospital	O	O
of	O	O
Medell?n	O	O
,	O	O
Cali	O	O
,	O	O
Colombia	O	O
.	O	O

Outpatients	O	O
with	O	O
cancer	O	O
were	O	O
eligible	O	O
for	O	O
the	O	O
study	O	O
if	O	O
they	O	O
were	O	O
aged	O	O
>	O	O
-18	O	O
years	O	O
and	O	O
had	O	O
chronic	O	O
(	O	O
duration	O	O
,	O	O
>	O	O
/=	O	O
3	O	O
months	O	O
)	O	O
moderate	O	O
to	O	O
severe	O	O
cancer-related	O	O
pain	O	O
(	O	O
score	O	O
on	O	O
10-cm	O	O
visual	O	O
analog	O	O
scale	O	O
[	O	O
VAS	O	O
]	O	O
,	O	O
>	O	O
3	O	O
cm	O	O
[	O	O
moderate	O	O
]	O	O
;	O	O
score	O	O
on	O	O
a	O	O
4-point	O	O
verbal	O	O
pain-intensity	O	O
scale	O	O
,	O	O
>	O	O
1	O	O
[	O	O
moderate	O	O
]	O	O
)	O	O
.	O	O

Eligible	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
1	O	O
tablet	O	O
of	O	O
codeine/acetaminophen	O	O
(	O	O
C/A	O	O
)	O	O
30/500	O	O
mg	O	O
or	O	O
hydrocodone/acetaminophen	O	O
(	O	O
H/A	O	O
)	O	O
5/500	O	O
mg	O	O
PO	O	O
q4h	O	O
(	O	O
total	O	O
daily	O	O
doses	O	O
,	O	O
150/2500	O	O
and	O	O
25/2500	O	O
mg	O	O
,	O	O
respectively	O	O
)	O	O
for	O	O
23	O	O
days	O	O
.	O	O

In	O	O
both	O	O
groups	O	O
,	O	O
if	O	O
pain	O	O
intensity	O	O
was	O	O
rated	O	O
as	O	O
>	O	O
3	O	O
on	O	O
the	O	O
VAS	O	O
at	O	O
week	O	O
1	O	O
or	O	O
2	O	O
,	O	O
the	O	O
dosage	O	O
was	O	O
doubled	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
who	O	O
achieved	O	O
pain	O	O
relief	O	O
(	O	O
defined	O	O
as	O	O
a	O	O
score	O	O
of	O	O
>	O	O
1	O	O
on	O	O
a	O	O
5-point	O	O
verbal	O	O
rating	O	O
scale	O	O
[	O	O
VRS	O	O
]	O	O
(	O	O
0	O	O
=	O	O
none	O	O
;	O	O
1	O	O
=	O	O
a	O	O
little	O	O
;	O	O
2	O	O
=	O	O
some	O	O
;	O	O
3	O	O
=	O	O
a	O	O
lot	O	O
;	O	O
and	O	O
4	O	O
=	O	O
complete	O	O
)	O	O
on	O	O
study	O	O
days	O	O
1	O	O
and	O	O
2	O	O
and	O	O
weeks	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
.	O	O

The	O	O
secondary	O	O
end	O	O
point	O	O
was	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
in	O	O
whom	O	O
pain	O	O
was	O	O
decreased	O	O
(	O	O
VAS	O	O
score	O	O
,	O	O
<	O	O
-	O	O
3	O	O
cm	O	O
)	O	O
.	O	O

AEs	O	O
were	O	O
self-reported	O	O
on	O	O
a	O	O
4-point	O	O
VRS	O	O
(	O	O
0	O	O
=	O	O
absent	O	O
;	O	O
1	O	O
=	O	O
mild	O	O
;	O	O
2	O	O
=	O	O
moderate	O	O
;	O	O
and	O	O
3	O	O
=	O	O
severe	O	O
)	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
121	O	O
patients	O	O
who	O	O
participated	O	O
,	O	O
59	O	O
received	O	O
C/A	O	O
and	O	O
62	O	O
received	O	O
H/A	O	O
.	O	O

Of	O	O
the	O	O
total	O	O
number	O	O
of	O	O
cases	O	O
,	O	O
59	O	O
%	O	O
were	O	O
aged	O	O
60	O	Age
to	O	Age
89	O	Age
years	O	O
,	O	O
and	O	O
55	O	O
%	O	O
were	O	O
men	O	Sex
.	O	O

At	O	O
baseline	O	O
,	O	O
88	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
described	O	O
their	O	O
pain	O	O
intensity	O	O
as	O	O
moderate	O	O
;	O	O
12	O	O
%	O	O
,	O	O
severe	O	O
.	O	O

Of	O	O
the	O	O
patients	O	O
who	O	O
received	O	O
C/A	O	O
,	O	O
58	O	O
%	O	O
responded	O	O
to	O	O
the	O	O
initial	O	O
dosage	O	O
of	O	O
150/2500	O	O
mg/d	O	O
,	O	O
and	O	O
8	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
responded	O	O
to	O	O
the	O	O
double	O	O
dosage	O	O
;	O	O
34	O	O
%	O	O
did	O	O
not	O	O
experience	O	O
pain	O	O
relief	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
H/A	O	O
,	O	O
pain	O	O
was	O	O
reported	O	O
as	O	O
absent	O	O
or	O	O
mild	O	O
in	O	O
56	O	O
%	O	O
of	O	O
patients	O	O
at	O	O
the	O	O
starting	O	O
dosage	O	O
of	O	O
25/2500	O	O
mg/d	O	O
;	O	O
an	O	O
additional	O	O
15	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
responded	O	O
to	O	O
the	O	O
double	O	O
dosage	O	O
;	O	O
the	O	O
remaining	O	O
29	O	O
%	O	O
of	O	O
patients	O	O
did	O	O
not	O	O
experience	O	O
any	O	O
pain	O	O
relief	O	O
.	O	O

None	O	O
of	O	O
the	O	O
between-group	O	O
differences	O	O
in	O	O
response	O	O
rates	O	O
were	O	O
significant	O	O
.	O	O

The	O	O
most	O	O
common	O	O
AEs	O	O
in	O	O
the	O	O
C/A	O	O
and	O	O
H/A	O	O
groups	O	O
were	O	O
constipation	O	O
(	O	O
36	O	O
%	O	O
and	O	O
29	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
dizziness	O	O
(	O	O
24	O	O
%	O	O
and	O	O
19	O	O
%	O	O
)	O	O
,	O	O
vomiting	O	O
(	O	O
24	O	O
%	O	O
and	O	O
16	O	O
%	O	O
)	O	O
,	O	O
and	O	O
dry	O	O
mouth	O	O
(	O	O
15	O	O
%	O	O
and	O	O
18	O	O
%	O	O
)	O	O
,	O	O
with	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
In	O	O
this	O	O
study	O	O
,	O	O
efficacy	O	O
and	O	O
tolerability	O	O
were	O	O
comparable	O	O
between	O	O
C/A	O	O
and	O	O
H/A	O	O
over	O	O
23	O	O
days	O	O
of	O	O
treatment	O	O
in	O	O
these	O	O
patients	O	O
with	O	O
moderate	O	O
or	O	O
severe	O	O
,	O	O
chronic	O	O
,	O	O
cancer-related	O	O
pain	O	O
.	O	O

Predictors	O	O
of	O	O
postdischarge	O	O
outcomes	O	O
from	O	O
information	O	O
acquired	O	O
shortly	O	O
after	O	O
admission	O	O
for	O	O
acute	Condition	Condition
heart	Condition	Condition
failure	Condition	Condition
:	O	O
a	O	O
report	O	O
from	O	O
the	O	O
Placebo-Controlled	O	O
Randomized	O	O
Study	O	O
of	O	O
the	O	O
Selective	O	O
A1	O	O
Adenosine	O	O
Receptor	O	O
Antagonist	O	O
Rolofylline	O	O
for	O	O
Patients	O	O
Hospitalized	O	O
With	O	O
Acute	Condition	O
Decompensated	Condition	O
Heart	Condition	O
Failure	Condition	O
and	O	O
Volume	Condition	O
Overload	Condition	O
to	O	O
Assess	O	O
Treatment	O	O
Effect	O	O
on	O	O
Congestion	O	O
and	O	O
Renal	O	O
Function	O	O
(	O	O
PROTECT	O	O
)	O	O
Study	O	O
.	O	O

BACKGROUND	O	O
Acute	Condition	O
heart	Condition	O
failure	Condition	O
is	O	O
a	O	O
common	O	O
reason	O	O
for	O	O
admission	O	O
,	O	O
and	O	O
outcome	O	O
is	O	O
often	O	O
poor	O	O
.	O	O

Improved	O	O
prognostic	O	O
risk	O	O
stratification	O	O
may	O	O
assist	O	O
in	O	O
the	O	O
design	O	O
of	O	O
future	O	O
trials	O	O
and	O	O
in	O	O
patient	O	O
management	O	O
.	O	O

Using	O	O
data	O	O
from	O	O
a	O	O
large	O	O
randomized	O	O
trial	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
prognostic	O	O
value	O	O
of	O	O
clinical	O	O
variables	O	O
,	O	O
measured	O	O
at	O	O
hospital	O	O
admission	O	O
for	O	O
acute	O	Condition
heart	O	Condition
failure	O	Condition
,	O	O
to	O	O
determine	O	O
whether	O	O
a	O	O
few	O	O
selected	O	O
variables	O	O
were	O	O
inferior	O	O
to	O	O
an	O	O
extended	O	O
data	O	O
set	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
The	O	O
prognostic	O	O
model	O	O
included	O	O
37	O	O
clinical	O	O
characteristics	O	O
collected	O	O
at	O	O
baseline	O	O
in	O	O
PROTECT	O	O
,	O	O
a	O	O
study	O	O
comparing	O	O
rolofylline	O	O
and	O	O
placebo	O	O
in	O	O
2033	SampleSize	O
patients	O	O
admitted	O	O
with	O	O
acute	Condition	Condition
heart	Condition	Condition
failure	Condition	Condition
.	O	O

Prespecified	O	O
outcomes	O	O
at	O	O
30	O	O
days	O	O
were	O	O
death	O	O
or	O	O
rehospitalization	O	O
for	O	O
any	O	O
reason	O	O
;	O	O
death	O	O
or	O	O
rehospitalization	O	O
for	O	O
cardiovascular	O	O
or	O	O
renal	O	O
reasons	O	O
;	O	O
and	O	O
,	O	O
at	O	O
both	O	O
30	O	O
and	O	O
180	O	O
days	O	O
,	O	O
all-cause	O	O
mortality	O	O
.	O	O

No	O	O
variable	O	O
had	O	O
a	O	O
c-index	O	O
>	O	O
0.70	O	O
,	O	O
and	O	O
few	O	O
had	O	O
values	O	O
>	O	O
0.60	O	O
;	O	O
c-indices	O	O
were	O	O
lower	O	O
for	O	O
composite	O	O
outcomes	O	O
than	O	O
for	O	O
mortality	O	O
.	O	O

Blood	O	O
urea	O	O
was	O	O
generally	O	O
the	O	O
strongest	O	O
single	O	O
predictor	O	O
.	O	O

Eighteen	O	O
variables	O	O
contributed	O	O
independent	O	O
prognostic	O	O
information	O	O
,	O	O
but	O	O
a	O	O
reduced	O	O
model	O	O
using	O	O
only	O	O
8	O	O
items	O	O
(	O	O
age	O	O
,	O	O
previous	O	O
heart	O	O
failure	O	O
hospitalization	O	O
,	O	O
peripheral	O	O
edema	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
,	O	O
serum	O	O
sodium	O	O
,	O	O
urea	O	O
,	O	O
creatinine	O	O
,	O	O
and	O	O
albumin	O	O
)	O	O
performed	O	O
similarly	O	O
.	O	O

For	O	O
prediction	O	O
of	O	O
all-cause	O	O
mortality	O	O
at	O	O
180	O	O
days	O	O
,	O	O
the	O	O
model	O	O
c-index	O	O
using	O	O
all	O	O
variables	O	O
was	O	O
0.72	O	O
and	O	O
for	O	O
the	O	O
simplified	O	O
model	O	O
,	O	O
also	O	O
0.72	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
few	O	O
simple	O	O
clinical	O	O
variables	O	O
measured	O	O
on	O	O
admission	O	O
in	O	O
patients	O	O
with	O	O
acute	Condition	Condition
heart	Condition	Condition
failure	Condition	Condition
predict	O	O
a	O	O
variety	O	O
of	O	O
adverse	O	O
outcomes	O	O
with	O	O
accuracy	O	O
similar	O	O
to	O	O
more	O	O
complex	O	O
models	O	O
.	O	O

However	O	O
,	O	O
predictive	O	O
models	O	O
were	O	O
of	O	O
only	O	O
moderate	O	O
accuracy	O	O
,	O	O
especially	O	O
for	O	O
outcomes	O	O
that	O	O
included	O	O
nonfatal	O	O
events	O	O
.	O	O

Better	O	O
methods	O	O
of	O	O
risk	O	O
stratification	O	O
are	O	O
required	O	O
.	O	O

CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
URL	O	O
:	O	O
http	O	O
:	O	O
//www.clinicaltrials.gov	O	O
.	O	O

Unique	O	O
identifiers	O	O
:	O	O
NCT00328692	O	O
and	O	O
NCT00354458	O	O
.	O	O

Shorter	O	O
treatment	O	O
for	O	O
vaginal	Condition	O
candidosis	Condition	O
:	O	O
comparison	O	O
between	O	O
single-dose	O	O
oral	O	O
fluconazole	O	O
and	O	O
three-day	O	O
treatment	O	O
with	O	O
local	O	O
miconazole	O	O
.	O	O

Fluconazole	O	O
is	O	O
an	O	O
effective	O	O
,	O	O
simple	O	O
and	O	O
safe	O	O
,	O	O
although	O	O
slightly	O	O
expensive	O	O
,	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
vaginal	Condition	O
candidosis	Condition	O
.	O	O

Single-dose	O	O
fluconazole	O	O
(	O	O
150	O	O
mg	O	O
)	O	O
administered	O	O
orally	O	O
in	O	O
capsule	O	O
form	O	O
was	O	O
compared	O	O
with	O	O
three-day	O	O
local	O	O
treatment	O	O
with	O	O
miconazole	O	O
pessaries	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
vaginal	Condition	O
candidosis	Condition	O
in	O	O
a	O	O
randomized	O	O
study	O	O
in	O	O
Finland	O	O
.	O	O

Cure	O	O
rates	O	O
were	O	O
good	O	O
(	O	O
>	O	O
80	O	O
%	O	O
)	O	O
in	O	O
randomized	O	O
patient	O	O
groups	O	O
assessed	O	O
both	O	O
clinically	O	O
and	O	O
by	O	O
the	O	O
results	O	O
of	O	O
yeast	O	O
cultures	O	O
.	O	O

Oral	O	O
administration	O	O
was	O	O
preferred	O	O
to	O	O
local	O	O
therapy	O	O
by	O	O
patients	O	O
in	O	O
both	O	O
the	O	O
miconazole	O	O
and	O	O
fluconazole	O	O
groups	O	O
.	O	O

For	O	O
the	O	O
time	O	O
being	O	O
,	O	O
fluconazole	O	O
is	O	O
not	O	O
recommended	O	O
for	O	O
use	O	O
during	O	O
pregnancy	O	O
or	O	O
lactation	O	O
.	O	O

Effects	O	O
of	O	O
alfuzosin	O	O
10	O	O
mg	O	O
once	O	O
daily	O	O
on	O	O
sexual	O	O
function	O	O
in	O	O
men	Sex	O
treated	O	O
for	O	O
symptomatic	Condition	O
benign	Condition	O
prostatic	Condition	O
hyperplasia	Condition	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
effects	O	O
of	O	O
extended-release	O	O
alfuzosin	O	O
HCl	O	O
10	O	O
mg	O	O
once	O	O
daily	O	O
(	O	O
q.d	O	O
.	O	O

)	O	O
on	O	O
sexual	O	O
function	O	O
in	O	O
men	O	O
with	O	O
lower	Condition	Condition
urinary	Condition	Condition
tract	Condition	Condition
symptoms	Condition	Condition
associated	O	O
with	O	O
benign	Condition	O
prostatic	Condition	O
hyperplasia	Condition	O
(	O	O
BPH	Condition	O
)	O	O
.	O	O

In	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
of	O	O
men	O	O
aged	O	O
>	Age	O
or	Age	O
=	Age	O
50	Age	O
years	O	O
,	O	O
after	O	O
a	O	O
28-day	O	O
placebo	O	O
run-in	O	O
period	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
alfuzosin	O	O
10	O	O
mg	O	O
q.d	O	O
.	O	O

or	O	O
matching	O	O
placebo	O	O
for	O	O
28	O	O
days	O	O
.	O	O

The	O	O
mean	O	O
change	O	O
from	O	O
baseline	O	O
(	O	O
day	O	O
1	O	O
)	O	O
in	O	O
sexual	O	O
function	O	O
on	O	O
day	O	O
29	O	O
was	O	O
assessed	O	O
using	O	O
the	O	O
Danish	O	O
Prostate	O	O
Symptom	O	O
Score	O	O
Sex	O	O
(	O	O
DAN-PSSsex	O	O
)	O	O
questionnaire	O	O
.	O	O

A	O	O
total	O	O
of	O	O
372	SampleSize	SampleSize
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
alfuzosin	O	O
(	O	O
n=186	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
n=186	O	O
)	O	O
,	O	O
with	O	O
355	SampleSize	O
completing	O	O
the	O	O
study	O	O
.	O	O

At	O	O
baseline	O	O
,	O	O
64	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
reported	O	O
erectile	Condition	O
dysfunction	Condition	O
(	O	O
ED	Condition	O
)	O	O
and	O	O
63	O	O
%	O	O
reported	O	O
ejaculatory	Condition	O
dysfunction	Condition	O
(	O	O
EjD	Condition	O
)	O	O
.	O	O

For	O	O
the	O	O
320	O	SampleSize
patients	O	O
who	O	O
completed	O	O
the	O	O
DAN-PSSsex	O	O
,	O	O
alfuzosin	O	O
treatment	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
mean	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
erectile	O	O
function	O	O
on	O	O
day	O	O
29	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
P=0.02	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
groups	O	O
in	O	O
the	O	O
mean	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
ejaculatory	O	O
function	O	O
on	O	O
day	O	O
29	O	O
.	O	O

For	O	O
patients	O	O
with	O	O
ED	O	O
at	O	O
baseline	O	O
,	O	O
a	O	O
marginal	O	O
improvement	O	O
in	O	O
erectile	O	O
function	O	O
was	O	O
demonstrated	O	O
with	O	O
alfuzosin	O	O
treatment	O	O
(	O	O
P=0.09	O	O
vs	O	O
placebo	O	O
)	O	O
.	O	O

For	O	O
patients	O	O
with	O	O
EjD	O	O
at	O	O
baseline	O	O
,	O	O
the	O	O
mean	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
ejaculatory	O	O
function	O	O
with	O	O
alfuzosin	O	O
was	O	O
comparable	O	O
to	O	O
that	O	O
with	O	O
placebo	O	O
.	O	O

Dizziness	O	O
was	O	O
the	O	O
most	O	O
common	O	O
adverse	O	O
event	O	O
with	O	O
alfuzosin	O	O
treatment	O	O
(	O	O
5	O	O
vs	O	O
0	O	O
%	O	O
with	O	O
placebo	O	O
)	O	O
,	O	O
with	O	O
other	O	O
adverse	O	O
events	O	O
reported	O	O
with	O	O
comparable	O	O
frequency	O	O
in	O	O
both	O	O
treatment	O	O
groups	O	O
.	O	O

After	O	O
1	O	O
month	O	O
of	O	O
treatment	O	O
,	O	O
alfuzosin	O	O
10	O	O
mg	O	O
q.d	O	O
.	O	O

significantly	O	O
improved	O	O
erectile	O	O
function	O	O
in	O	O
men	O	O
with	O	O
lower	O	Condition
urinary	O	Condition
tract	O	Condition
symptoms/	O	Condition
benign	O	Condition
prostatic	O	Condition
hypertrophy	O	Condition
and	O	O
had	O	O
no	O	O
adverse	O	O
effect	O	O
on	O	O
ejaculatory	O	O
function	O	O
.	O	O

Cytokine	O	O
levels	O	O
and	O	O
systemic	O	O
toxicity	O	O
in	O	O
patients	O	Condition
undergoing	O	Condition
isolated	Condition	Condition
limb	Condition	Condition
perfusion	Condition	Condition
with	O	O
high-dose	O	O
tumor	O	O
necrosis	O	O
factor	O	O
,	O	O
interferon	O	O
gamma	O	O
,	O	O
and	O	O
melphalan	O	O
.	O	O

PURPOSE	O	O
Isolated	O	O
limb	O	O
perfusion	O	O
(	O	O
ILP	O	O
)	O	O
with	O	O
tumor	O	O
necrosis	O	O
factor	O	O
(	O	O
TNF	O	O
)	O	O
,	O	O
interferon	O	O
gamma	O	O
,	O	O
and	O	O
melphalan	O	O
(	O	O
M	O	O
)	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
result	O	O
in	O	O
high	O	O
response	O	O
rates	O	O
for	O	O
extremity	O	O
melanoma	O	O
and	O	O
sarcoma	O	O
.	O	O

We	O	O
have	O	O
evaluated	O	O
the	O	O
relationship	O	O
of	O	O
systemic	O	O
TNF	O	O
exposure	O	O
to	O	O
induction	O	O
of	O	O
several	O	O
secondary	O	O
mediators	O	O
and	O	O
incidence	O	O
of	O	O
systemic	O	O
toxicity	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Nineteen	SampleSize	SampleSize
patients	O	O
with	O	O
extremity	Condition	Condition
melanoma	Condition	Condition
(	O	O
n	O	O
=	O	O
16	SampleSize	O
)	O	O
or	O	O
sarcoma	Condition	O
(	O	O
n	O	O
=	O	O
3	SampleSize	O
)	O	O
,	O	O
underwent	O	O
90-minute	O	O
ILP	O	O
with	O	O
TNF-alpha	O	O
,	O	O
interferon	O	O
gamma	O	O
(	O	O
0.2	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
M	O	O
(	O	O
10	O	O
to	O	O
13	O	O
mg/L	O	O
of	O	O
limb	O	O
volume	O	O
)	O	O
(	O	O
TNF/IFN/M	O	O
)	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
,	O	O
or	O	O
M	O	O
alone	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
.	O	O

Continuous	O	O
intraoperative	O	O
monitoring	O	O
(	O	O
CIM	O	O
)	O	O
for	O	O
systemic	O	O
leak	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
was	O	O
performed	O	O
using	O	O
radioactive	O	O
iodine-131	O	O
albumin	O	O
.	O	O

Cytokine	O	O
levels	O	O
in	O	O
the	O	O
perfusate	O	O
and	O	O
systemic	O	O
circulation	O	O
during	O	O
and	O	O
after	O	O
ILP	O	O
were	O	O
measured	O	O
by	O	O
enzyme-linked	O	O
immunosorbent	O	O
assay	O	O
.	O	O

RESULTS	O	O
Systemic	O	O
leaks	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
occurred	O	O
in	O	O
six	O	O
patients	O	O
who	O	O
received	O	O
TNF/IFN/M	O	O
and	O	O
in	O	O
four	O	O
who	O	O
received	O	O
M	O	O
alone	O	O
.	O	O

Hypotension	O	O
that	O	O
required	O	O
vasopressor	O	O
support	O	O
occurred	O	O
in	O	O
six	O	O
of	O	O
six	O	O
patients	O	O
with	O	O
evidence	O	O
of	O	O
a	O	O
leak	O	O
(	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
)	O	O
and	O	O
zero	O	O
of	O	O
six	O	O
patients	O	O
without	O	O
a	O	O
leak	O	O
(	O	O
<	O	O
1	O	O
%	O	O
)	O	O
.	O	O

These	O	O
six	O	O
patients	O	O
had	O	O
significantly	O	O
higher	O	O
peak	O	O
systemic	O	O
TNF	O	O
levels	O	O
during	O	O
and	O	O
after	O	O
perfusion	O	O
than	O	O
patients	O	O
without	O	O
a	O	O
leak	O	O
(	O	O
2.8	O	O
and	O	O
8.2	O	O
ng/mL	O	O
v	O	O
0.7	O	O
and	O	O
2.0	O	O
ng/mL	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
who	O	O
received	O	O
TNF/IFN/M	O	O
had	O	O
significantly	O	O
greater	O	O
increases	O	O
in	O	O
systemic	O	O
interleukin-6	O	O
(	O	O
IL-6	O	O
)	O	O
levels	O	O
than	O	O
in	O	O
patients	O	O
with	O	O
M	O	O
alone	O	O
(	O	O
12,395	O	O
+/-	O	O
10,374	O	O
pg/mL	O	O
v	O	O
79.4	O	O
+/-	O	O
7.2	O	O
pg/mL	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Intracellular	O	O
adhesion	O	O
molecule	O	O
(	O	O
ICAM	O	O
)	O	O
,	O	O
IL-8	O	O
,	O	O
and	O	O
TNF-R	O	O
levels	O	O
were	O	O
also	O	O
increased	O	O
after	O	O
ILP	O	O
with	O	O
TNF/IFN/M	O	O
.	O	O

CONCLUSION	O	O
ILP	O	O
with	O	O
TNF/IFN/M	O	O
can	O	O
be	O	O
safely	O	O
performed	O	O
,	O	O
as	O	O
I131	O	O
albumin	O	O
provides	O	O
a	O	O
sensitive	O	O
measure	O	O
of	O	O
systemic	O	O
leakage	O	O
from	O	O
the	O	O
perfusion	O	O
circuit	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
measured	O	O
leak	O	O
of	O	O
>	O	O
or	O	O
=	O	O
1	O	O
%	O	O
develop	O	O
mild	O	O
and	O	O
transient	O	O
postoperative	O	O
hypotension	O	O
with	O	O
significantly	O	O
higher	O	O
systemic	O	O
TNF	O	O
levels	O	O
and	O	O
lower	O	O
perfusate	O	O
TNF	O	O
levels	O	O
than	O	O
in	O	O
patients	O	O
without	O	O
leaks	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
body	O	O
positioning	O	O
upon	O	O
maximal	O	O
oxygenation	O	O
of	O	O
patients	O	O
with	O	O
unilateral	Condition	O
lung	Condition	O
pathology	Condition	O
.	O	O

A	O	O
quasi-experimental	O	O
,	O	O
repeated-measures	O	O
cross-over	O	O
design	O	O
study	O	O
on	O	O
the	O	O
effect	O	O
of	O	O
body	O	O
position	O	O
on	O	O
oxygenation	O	O
(	O	O
SaO2	O	O
)	O	O
blood	O	O
pressure	O	O
,	O	O
respiration	O	O
and	O	O
pulse	O	O
in	O	O
patients	O	O
with	O	O
unilateral	Condition	O
lung	Condition	O
pathology	Condition	O
was	O	O
conducted	O	O
.	O	O

Previous	O	O
research	O	O
strongly	O	O
suggests	O	O
that	O	O
positioning	O	O
with	O	O
the	O	O
healthy	O	O
(	O	O
unaffected	O	O
)	O	O
lung	O	O
in	O	O
the	O	O
dependent	O	O
lateral	O	O
(	O	O
down	O	O
)	O	O
position	O	O
is	O	O
related	O	O
to	O	O
improved	O	O
oxygenation	O	O
,	O	O
but	O	O
knowledge	O	O
about	O	O
whether	O	O
this	O	O
effect	O	O
is	O	O
maintained	O	O
over	O	O
time	O	O
is	O	O
lacking	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
:	O	O
(	O	O
1	O	O
)	O	O
Is	O	O
positioning	O	O
with	O	O
the	O	O
unaffected	O	O
lung	O	O
in	O	O
the	O	O
dependent	O	O
lateral	O	O
position	O	O
related	O	O
to	O	O
increased	O	O
arterial	O	O
blood	O	O
saturation	O	O
levels	O	O
and	O	O
decreased	O	O
blood	O	O
pressure	O	O
,	O	O
pulse	O	O
and	O	O
respiration	O	O
?	O	O
(	O	O
2	O	O
)	O	O
What	O	O
is	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
dependent	O	O
variables	O	O
--	O	O
oxygenation	O	O
saturation	O	O
levels	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
pulse	O	O
and	O	O
respiration	O	O
--	O	O
and	O	O
the	O	O
independent	O	O
variables	O	O
--	O	O
body	O	O
position	O	O
and	O	O
time	O	O
in	O	O
the	O	O
position	O	O
?	O	O
Thirty-nine	SampleSize	O
patients	O	O
with	O	O
unilateral	Condition	O
lung	Condition	O
pathology	Condition	O
were	O	O
positioned	O	O
on	O	O
their	O	O
sides	O	O
with	O	O
the	O	O
unaffected	O	O
lung	O	O
down	O	O
,	O	O
on	O	O
their	O	O
sides	O	O
with	O	O
the	O	O
affected	O	O
lung	O	O
down	O	O
,	O	O
and	O	O
also	O	O
in	O	O
semi-Fowler	O	O
's	O	O
position	O	O
.	O	O

Arterial	O	O
(	O	O
SaO2	O	O
)	O	O
blood	O	O
saturation	O	O
and	O	O
vital	O	O
signs	O	O
were	O	O
measured	O	O
at	O	O
baseline	O	O
0	O	O
,	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
.	O	O

There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
relationship	O	O
between	O	O
oxygenation	O	O
level	O	O
or	O	O
systolic	O	O
blood	O	O
pressure	O	O
.	O	O

Diastolic	O	O
blood	O	O
pressure	O	O
,	O	O
respiration	O	O
and	O	O
pulse	O	O
did	O	O
vary	O	O
significantly	O	O
with	O	O
position	O	O
.	O	O

Treatment	O	O
of	O	O
adults	Age	O
with	O	O
acute	Condition	Condition
lymphoblastic	Condition	Condition
leukemia	Condition	Condition
:	O	O
do	O	O
the	O	O
specifics	O	O
of	O	O
the	O	O
regimen	O	O
matter	O	O
?	O	O
:	O	O
Results	O	O
from	O	O
a	O	O
prospective	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Induction	O	O
therapy	O	O
for	O	O
adults	Age	Age
with	O	O
acute	Condition	Condition
lymphoblastic	Condition	Condition
leukemia	Condition	Condition
(	O	O
ALL	Condition	O
)	O	O
is	O	O
similar	O	O
across	O	O
essentially	O	O
all	O	O
regimens	O	O
,	O	O
comprised	O	O
of	O	O
vincristine	O	O
,	O	O
corticosteroids	O	O
,	O	O
and	O	O
anthracyclines	O	O
intensified	O	O
with	O	O
cyclophosphamide	O	O
,	O	O
asparaginase	O	O
,	O	O
or	O	O
both	O	O
.	O	O

Given	O	O
the	O	O
lack	O	O
of	O	O
randomized	O	O
data	O	O
,	O	O
to	O	O
date	O	O
,	O	O
no	O	O
regimen	O	O
has	O	O
emerged	O	O
as	O	O
standard	O	O
.	O	O

The	O	O
authors	O	O
previously	O	O
evaluated	O	O
cytarabine	O	O
3	O	O
g/m	O	O
(	O	O
2	O	O
)	O	O
daily	O	O
for	O	O
5	O	O
days	O	O
with	O	O
mitoxantrone	O	O
80	O	O
mg/m	O	O
(	O	O
2	O	O
)	O	O
(	O	O
the	O	O
ALL-2	O	O
regimen	O	O
)	O	O
as	O	O
a	O	O
novel	O	O
induction	O	O
regimen	O	O
.	O	O

Compared	O	O
with	O	O
historic	O	O
controls	O	O
,	O	O
the	O	O
ALL-2	O	O
regimen	O	O
was	O	O
superior	O	O
in	O	O
terms	O	O
of	O	O
incidence	O	O
of	O	O
complete	O	O
remission	O	O
,	O	O
failure	O	O
with	O	O
resistant	O	O
disease	O	O
,	O	O
and	O	O
activity	O	O
in	O	O
patients	O	O
with	O	O
Philadelphia	Condition	O
chromosome	Condition	O
(	Condition	O
Ph	Condition	O
)	Condition	O
-positive	Condition	O
ALL	O	O
.	O	O

METHODS	O	O
The	O	O
authors	O	O
conducted	O	O
a	O	O
multicenter	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
trial	O	O
of	O	O
the	O	O
ALL-2	O	O
regimen	O	O
compared	O	O
with	O	O
a	O	O
standard	O	O
4-drug	O	O
induction	O	O
(	O	O
the	O	O
L-20	O	O
regimen	O	O
)	O	O
.	O	O

Patients	O	O
also	O	O
received	O	O
consolidation	O	O
,	O	O
maintenance	O	O
therapy	O	O
,	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
prophylaxis	O	O
.	O	O

The	O	O
trial	O	O
accrued	O	O
patients	O	O
from	O	O
August	O	O
1996	O	O
to	O	O
October	O	O
2004	O	O
.	O	O

RESULTS	O	O
The	O	O
median	O	O
follow-up	O	O
for	O	O
survivors	O	O
was	O	O
7	O	O
years	O	O
,	O	O
and	O	O
the	O	O
median	O	O
patient	O	O
age	O	O
was	O	O
43	Age	O
years	O	O
.	O	O

Responses	O	O
were	O	O
evaluated	O	O
in	O	O
164	SampleSize	SampleSize
patients	O	O
.	O	O

The	O	O
treatment	O	O
arms	O	O
were	O	O
balanced	O	O
in	O	O
terms	O	O
of	O	O
pretreatment	O	O
characteristics	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
complete	O	O
remission	O	O
for	O	O
the	O	O
ALL-2	O	O
regimen	O	O
versus	O	O
the	O	O
L-20	O	O
regimen	O	O
was	O	O
83	O	O
%	O	O
versus	O	O
71	O	O
%	O	O
(	O	O
P	O	O
=	O	O
.06	O	O
)	O	O
.	O	O

More	O	O
patients	O	O
on	O	O
the	O	O
L-20	O	O
arm	O	O
failed	O	O
with	O	O
resistant	O	O
disease	O	O
(	O	O
21	O	O
%	O	O
vs	O	O
8	O	O
%	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
.	O	O

Induction	O	O
deaths	O	O
were	O	O
comparable	O	O
at	O	O
9	O	O
%	O	O
(	O	O
ALL-2	O	O
)	O	O
versus	O	O
7	O	O
%	O	O
(	O	O
L-20	O	O
)	O	O
.	O	O

The	O	O
median	O	O
survival	O	O
was	O	O
similar	O	O
;	O	O
and	O	O
,	O	O
at	O	O
5	O	O
years	O	O
,	O	O
the	O	O
survival	O	O
rate	O	O
was	O	O
33	O	O
%	O	O
alive	O	O
on	O	O
the	O	O
ALL-2	O	O
arm	O	O
versus	O	O
27	O	O
%	O	O
on	O	O
the	O	O
L-20	O	O
.	O	O

CONCLUSIONS	O	O
Despite	O	O
superior	O	O
results	O	O
of	O	O
induction	O	O
therapy	O	O
with	O	O
the	O	O
ALL-2	O	O
regimen	O	O
,	O	O
this	O	O
treatment	O	O
did	O	O
not	O	O
improve	O	O
long-term	O	O
outcomes	O	O
.	O	O

When	O	O
coupled	O	O
to	O	O
the	O	O
reported	O	O
experience	O	O
of	O	O
other	O	O
studies	O	O
in	O	O
adults	O	O
with	O	O
ALL	O	O
,	O	O
the	O	O
results	O	O
of	O	O
this	O	O
randomized	O	O
trial	O	O
raise	O	O
the	O	O
possibility	O	O
that	O	O
ultimate	O	O
outcomes	O	O
in	O	O
adult	O	O
ALL	O	O
may	O	O
be	O	O
independent	O	O
of	O	O
the	O	O
specific	O	O
regimen	O	O
chosen	O	O
.	O	O

Cancer	O	O
2013	O	O
.	O	O

?	O	O
2012	O	O
American	O	O
Cancer	O	O
Society	O	O
.	O	O

Take	O	O
a	O	O
walk	O	O
in	O	O
the	O	O
park	O	O
?	O	O
A	O	O
cross-over	O	O
pilot	O	O
trial	O	O
comparing	O	O
brisk	O	O
walking	O	O
in	O	O
two	O	O
different	O	O
environments	O	O
:	O	O
park	O	O
and	O	O
urban	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
objective	O	O
of	O	O
the	O	O
present	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
whether	O	O
differences	O	O
exist	O	O
between	O	O
a	O	O
30	O	O
minute	O	O
brisk	O	O
walk	O	O
taken	O	O
in	O	O
two	O	O
different	O	O
environments	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
which	O	O
environment	O	O
best	O	O
facilitates	O	O
current	O	O
physical	O	O
activity	O	O
guidelines	O	O
:	O	O
park	O	O
or	O	O
urban	O	O
.	O	O

METHODS	O	O
In	O	O
this	O	O
randomised	O	O
cross-over	O	O
pilot	O	O
study	O	O
,	O	O
participants	O	O
performed	O	O
a	O	O
self-timed	O	O
30	O	O
minute	O	O
brisk	Condition	O
walk	Condition	O
in	O	O
two	O	O
different	O	O
environments	O	O
,	O	O
park	O	O
and	O	O
urban	O	O
,	O	O
in	O	O
Glasgow	O	O
,	O	O
Scotland	O	O
(	O	O
October	O	O
2009	O	O
to	O	O
January	O	O
2010	O	O
)	O	O
.	O	O

Cadence	O	O
,	O	O
recorded	O	O
using	O	O
the	O	O
activPAL?	O	O
activity	O	O
monitor	O	O
,	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
intensity	O	O
.	O	O

Outcome	O	O
measures	O	O
were	O	O
:	O	O
mean	O	O
cadence	O	O
;	O	O
moderate-to-vigorous	O	O
physical	O	O
activity	O	O
time	O	O
accumulated	O	O
in	O	O
bouts	O	O
lasting	O	O
?	O	O
10	O	O
min	O	O
;	O	O
number	O	O
of	O	O
walking	O	O
breaks	O	O
;	O	O
and	O	O
duration	O	O
.	O	O

RESULTS	O	O
A	O	O
convenience	O	O
sample	O	O
of	O	O
40	O	O
healthy	O	O
adults	O	O
was	O	O
recruited	O	O
:	O	O
16	O	O
males	O	O
,	O	O
24	O	SampleSize
females	O	O
,	O	O
mean	O	O
age	O	O
22.9	O	O
(	O	O
5.5	O	O
)	O	O
years	O	O
.	O	O

The	O	O
mean	O	O
cadence	O	O
for	O	O
the	O	O
whole	O	O
walk	O	O
was	O	O
higher	O	O
in	O	O
the	O	O
park	O	O
:	O	O
119.3	O	O
(	O	O
8.3	O	O
)	O	O
vs.	O	O
110.9	O	O
(	O	O
8.9	O	O
)	O	O
steps/min	O	O
.	O	O

Participants	O	O
accumulated	O	O
more	O	O
moderate-to-vigorous	O	O
physical	O	O
activity	O	O
in	O	O
?	O	O
10	O	O
minute	O	O
bouts	O	O
during	O	O
park	O	O
walks	O	O
:	O	O
25.5	O	O
(	O	O
9.6	O	O
)	O	O
[	O	O
median	O	O
(	O	O
interquartile	O	O
range	O	O
)	O	O
]	O	O
vs.	O	O
14.0	O	O
(	O	O
20.3	O	O
)	O	O
min	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
self-timed	O	O
duration	O	O
between	O	O
locations	O	O
.	O	O

CONCLUSION	O	O
Participants	O	O
accumulated	O	O
more	O	O
moderate-to-vigorous	O	O
physical	O	O
activity	O	O
in	O	O
bouts	O	O
?	O	O
10	O	O
min	O	O
in	O	O
duration	O	O
on	O	O
park	O	O
walks	O	O
due	O	O
to	O	O
the	O	O
lack	O	O
of	O	O
interruptions	O	O
in	O	O
walking	O	O
.	O	O

Hence	O	O
the	O	O
park	O	O
environment	O	O
better	O	O
facilitated	O	O
the	O	O
achievement	O	O
of	O	O
current	O	O
physical	O	O
activity	O	O
guidelines	O	O
.	O	O

Further	O	O
research	O	O
involving	O	O
a	O	O
larger	O	O
,	O	O
more	O	O
heterogeneous	O	O
sample	O	O
is	O	O
recommended	O	O
.	O	O

Rationale	O	O
and	O	O
design	O	O
of	O	O
RE-LY	O	O
:	O	O
randomized	O	O
evaluation	O	O
of	O	O
long-term	O	O
anticoagulant	O	O
therapy	O	O
,	O	O
warfarin	O	O
,	O	O
compared	O	O
with	O	O
dabigatran	O	O
.	O	O

Vitamin	O	O
K	O	O
antagonists	O	O
(	O	O
VKAs	O	O
)	O	O
are	O	O
effective	O	O
for	O	O
stroke	O	O
prevention	O	O
in	O	O
patients	O	O
with	O	O
atrial	Condition	O
fibrillation	Condition	O
(	O	O
AF	Condition	O
)	O	O
but	O	O
are	O	O
difficult	O	O
to	O	O
use	O	O
.	O	O

Dabigatran	O	O
etexilate	O	O
is	O	O
a	O	O
prodrug	O	O
that	O	O
is	O	O
rapidly	O	O
converted	O	O
to	O	O
the	O	O
active	O	O
direct	O	O
thrombin	O	O
inhibitor	O	O
dabigatran	O	O
.	O	O

It	O	O
is	O	O
administered	O	O
in	O	O
a	O	O
fixed	O	O
dose	O	O
without	O	O
laboratory	O	O
monitoring	O	O
and	O	O
is	O	O
being	O	O
compared	O	O
with	O	O
warfarin	O	O
(	O	O
international	O	O
normalized	O	O
ratio	O	O
2-3	O	O
)	O	O
in	O	O
the	O	O
RE-LY	O	O
trial	O	O
.	O	O

Two	O	O
doses	O	O
of	O	O
dabigatran	O	O
(	O	O
110	O	O
and	O	O
150	O	O
mg	O	O
BID	O	O
)	O	O
are	O	O
being	O	O
evaluated	O	O
.	O	O

RE-LY	O	O
is	O	O
a	O	O
phase	O	O
3	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
open-label	O	O
multinational	O	O
(	O	O
44	O	O
countries	O	O
)	O	O
trial	O	O
of	O	O
patients	O	O
with	O	O
nonvalvular	Condition	O
AF	Condition	O
and	O	O
at	O	O
least	O	O
1	O	O
risk	O	O
factor	O	O
for	O	O
stroke	O	O
.	O	O

Recruitment	O	O
concluded	O	O
with	O	O
a	O	O
total	O	O
of	O	O
18,113	SampleSize	O
patients	O	O
.	O	O

Patients	O	O
who	O	O
were	O	O
VKA-naive	O	O
and	O	O
experienced	O	O
are	O	O
included	O	O
in	O	O
balanced	O	O
proportions	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
is	O	O
stroke	O	O
(	O	O
including	O	O
hemorrhagic	O	O
)	O	O
or	O	O
systemic	O	O
embolism	O	O
.	O	O

Safety	O	O
outcomes	O	O
are	O	O
bleeding	O	O
,	O	O
liver	O	O
function	O	O
abnormalities	O	O
,	O	O
and	O	O
other	O	O
adverse	O	O
events	O	O
.	O	O

Adjudication	O	O
of	O	O
end	O	O
points	O	O
is	O	O
blinded	O	O
to	O	O
drug	O	O
assignment	O	O
.	O	O

The	O	O
trial	O	O
is	O	O
expected	O	O
to	O	O
accrue	O	O
a	O	O
minimum	O	O
of	O	O
450	O	O
events	O	O
with	O	O
a	O	O
minimum	O	O
1-year	O	O
of	O	O
follow-up	O	O
.	O	O

RE-LY	O	O
is	O	O
the	O	O
largest	O	O
AF	O	O
stroke	O	O
prevention	O	O
trial	O	O
yet	O	O
undertaken	O	O
.	O	O

It	O	O
is	O	O
unique	O	O
because	O	O
it	O	O
includes	O	O
equal	O	O
numbers	O	O
of	O	O
VKA-experienced	O	O
and	O	O
naive	O	O
patients	O	O
and	O	O
evaluates	O	O
2	O	O
different	O	O
dosages	O	O
of	O	O
dabigatran	O	O
,	O	O
which	O	O
may	O	O
allow	O	O
tailoring	O	O
of	O	O
dosing	O	O
to	O	O
individual	O	O
patient	O	O
needs	O	O
.	O	O

The	O	O
worldwide	O	O
site	O	O
distribution	O	O
and	O	O
broad	O	O
range	O	O
of	O	O
stroke	O	O
risk	O	O
further	O	O
increase	O	O
the	O	O
general	O	O
applicability	O	O
of	O	O
the	O	O
trial	O	O
.	O	O

Results	O	O
are	O	O
expected	O	O
in	O	O
2009	O	O
.	O	O

Prophylactic	O	O
vs	O	O
therapeutic	O	O
blood	O	O
patch	O	O
for	O	O
obstetric	Condition	O
patients	O	O
with	O	O
accidental	Condition	O
dural	Condition	O
puncture	Condition	O
--	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

Epidural	O	O
blood	O	O
patch	O	O
is	O	O
a	O	O
standard	O	O
treatment	O	O
for	O	O
obstetric	Condition	O
patients	O	O
experiencing	O	O
a	O	O
severe	Condition	O
post-dural	Condition	O
puncture	Condition	O
headache	Condition	O
.	O	O

Patients	O	O
who	O	O
sustained	O	O
an	O	O
accidental	Condition	O
dural	Condition	O
puncture	Condition	O
during	O	O
establishment	O	O
of	O	O
epidural	Condition	O
analgesia	Condition	O
during	O	O
labour	Condition	O
or	O	O
at	O	O
caesarean	Condition	O
delivery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
a	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
or	O	O
conservative	O	O
treatment	O	O
with	O	O
a	O	O
therapeutic	O	O
epidural	O	O
blood	O	O
patch	O	O
if	O	O
required	O	O
.	O	O

Eleven	SampleSize	O
of	O	O
60	SampleSize	O
(	O	O
18.3	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
group	O	O
developed	O	O
a	O	O
post-dural	O	O
puncture	O	O
headache	O	O
compared	O	O
with	O	O
39	SampleSize	O
of	O	O
49	SampleSize	O
(	O	O
79.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
therapeutic	O	O
epidural	O	O
blood	O	O
patch	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

A	O	O
blood	O	O
patch	O	O
was	O	O
performed	O	O
in	O	O
36	O	O
(	O	O
73.4	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
therapeutic	O	O
group	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
needed	O	O
a	O	O
second	O	O
blood	O	O
patch	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
:	O	O
6	O	O
(	O	O
10.0	O	O
%	O	O
)	O	O
for	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
and	O	O
4	O	O
(	O	O
11.1	O	O
%	O	O
)	O	O
for	O	O
therapeutic	O	O
epidural	O	O
blood	O	O
patch	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
prophylactic	O	O
epidural	O	O
blood	O	O
patch	O	O
is	O	O
an	O	O
effective	O	O
method	O	O
to	O	O
reduce	O	O
the	O	O
development	O	O
of	O	O
post-dural	O	O
puncture	O	O
headache	O	O
in	O	O
obstetric	Condition	O
patients	O	O
.	O	O

Clinically	O	O
relevant	O	O
improvement	O	O
of	O	O
recurrence-free	O	O
survival	O	O
with	O	O
5-aminolevulinic	O	O
acid	O	O
induced	O	O
fluorescence	O	O
diagnosis	O	O
in	O	O
patients	O	O
with	O	O
superficial	Condition	O
bladder	Condition	O
tumors	Condition	O
.	O	O

PURPOSES	O	O
Fluorescence	O	O
diagnosis	O	O
induced	O	O
by	O	O
5-aminolevulinic	O	O
acid	O	O
enables	O	O
more	O	O
thorough	O	O
transurethral	O	O
resection	O	O
of	O	O
superficial	Condition	O
bladder	Condition	O
carcinoma	Condition	O
compared	O	O
with	O	O
conventional	O	O
white	O	O
light	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
prospective	O	O
,	O	O
single	O	O
institution	O	O
,	O	O
randomized	O	O
trial	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
and	O	O
long-term	O	O
tumor	O	O
recurrence	O	O
can	O	O
be	O	O
decreased	O	O
by	O	O
fluorescence	O	O
diagnosis	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
A	O	O
total	O	O
of	O	O
301	SampleSize	O
patients	O	O
underwent	O	O
transurethral	Condition	O
resection	Condition	O
of	O	O
bladder	Condition	O
tumors	Condition	O
with	O	O
white	O	O
light	O	O
or	O	O
fluorescence	O	O
diagnosis	O	O
.	O	O

Transurethral	O	O
resection	O	O
was	O	O
repeated	O	O
5	O	O
to	O	O
6	O	O
weeks	O	O
later	O	O
to	O	O
evaluate	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
.	O	O

To	O	O
determine	O	O
recurrence-free	O	O
survival	O	O
patient	O	O
followup	O	O
was	O	O
performed	O	O
every	O	O
3	O	O
months	O	O
by	O	O
white	O	O
light	O	O
cystoscopy	O	O
and	O	O
urine	O	O
cytology	O	O
.	O	O

Recurrence-free	O	O
survival	O	O
was	O	O
analyzed	O	O
via	O	O
Kaplan-Meier	O	O
methods	O	O
and	O	O
multivariable	O	O
Cox	O	O
regression	O	O
analysis	O	O
.	O	O

RESULTS	O	O
A	O	O
total	O	O
of	O	O
191	SampleSize	SampleSize
patients	O	O
with	O	O
superficial	Condition	O
bladder	Condition	O
carcinoma	Condition	O
were	O	O
available	O	O
for	O	O
efficacy	O	O
analysis	O	O
.	O	O

The	O	O
residual	O	O
tumor	O	O
rate	O	O
was	O	O
25.2	O	O
%	O	O
in	O	O
the	O	O
white	O	O
light	O	O
arm	O	O
versus	O	O
4.5	O	O
%	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
arm	O	O
(	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Median	O	O
followup	O	O
in	O	O
the	O	O
white	O	O
light	O	O
arm	O	O
in	O	O
103	O	O
cases	O	O
was	O	O
21.2	O	O
months	O	O
(	O	O
range	O	O
4	O	O
to	O	O
40	O	O
)	O	O
compared	O	O
with	O	O
20.5	O	O
(	O	O
range	O	O
3	O	O
to	O	O
40	O	O
)	O	O
in	O	O
the	O	O
88	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
arm	O	O
.	O	O

Recurrence-free	O	O
survival	O	O
in	O	O
the	O	O
fluorescence	O	O
diagnosis	O	O
group	O	O
was	O	O
89.6	O	O
%	O	O
after	O	O
12	O	O
and	O	O
24	O	O
months	O	O
compared	O	O
with	O	O
73.8	O	O
%	O	O
and	O	O
65.9	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
white	O	O
light	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
.	O	O

This	O	O
superiority	O	O
proved	O	O
to	O	O
be	O	O
independent	O	O
of	O	O
risk	O	O
group	O	O
.	O	O

The	O	O
adjusted	O	O
hazard	O	O
ratio	O	O
of	O	O
fluorescence	O	O
diagnosis	O	O
versus	O	O
white	O	O
light	O	O
transurethral	O	O
resection	O	O
was	O	O
0.33	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.16	O	O
to	O	O
0.67	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Fluorescence	O	O
diagnosis	O	O
is	O	O
significantly	O	O
superior	O	O
to	O	O
conventional	O	O
white	O	O
light	O	O
transurethral	O	O
resection	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
residual	O	O
tumor	O	O
rate	O	O
and	O	O
recurrence-free	O	O
survival	O	O
.	O	O

The	O	O
differences	O	O
in	O	O
recurrence-free	O	O
survival	O	O
imply	O	O
that	O	O
fluorescence	O	O
diagnosis	O	O
is	O	O
a	O	O
clinically	O	O
relevant	O	O
procedure	O	O
for	O	O
decreasing	O	O
the	O	O
number	O	O
of	O	O
tumor	O	O
recurrences	O	O
.	O	O

Comparison	O	O
of	O	O
antihypertensives	O	O
after	O	O
coronary	O	O
artery	O	O
surgery	O	O
.	O	O

Hypertension	O	O
following	O	O
coronary	Condition	O
artery	Condition	O
bypass	Condition	O
grafting	Condition	O
is	O	O
a	O	O
common	O	O
problem	O	O
that	O	O
may	O	O
result	O	O
in	O	O
postoperative	O	O
myocardial	O	O
infraction	O	O
or	O	O
bleeding	O	O
,	O	O
Hemodynamic	O	O
effects	O	O
were	O	O
compared	O	O
in	O	O
45	SampleSize	SampleSize
hypertensive	Condition	Condition
coronary	Condition	Condition
bypass	Condition	Condition
patients	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
diltiazem	O	O
,	O	O
nitroglycerin	O	O
,	O	O
or	O	O
sodium	O	O
nitroprusside	O	O
.	O	O

Diltiazem	O	O
was	O	O
administered	O	O
as	O	O
an	O	O
intravenous	O	O
bolus	O	O
of	O	O
0.3	O	O
mg.kg-1	O	O
within	O	O
5	O	O
min	O	O
,	O	O
followed	O	O
by	O	O
infusion	O	O
of	O	O
0.1-0.8	O	O
mg.kg-1.h-1	O	O
in	O	O
group	O	O
1	O	O
.	O	O

Nitroglycerin	O	O
was	O	O
infused	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
1-3	O	O
microg.kg.h-1	O	O
in	O	O
group	O	O
2	O	O
,	O	O
and	O	O
sodium	O	O
nitroprusside	O	O
was	O	O
given	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
1-3	O	O
microg.kg-1.min-1	O	O
in	O	O
group	O	O
3	O	O
.	O	O

Hemodynamic	O	O
measurements	O	O
were	O	O
carried	O	O
out	O	O
before	O	O
infusion	O	O
(	O	O
T1	O	O
)	O	O
and	O	O
at	O	O
30	O	O
min	O	O
(	O	O
T2	O	O
)	O	O
,	O	O
2	O	O
h	O	O
(	O	O
T3	O	O
)	O	O
,	O	O
and	O	O
12	O	O
h	O	O
(	O	O
T4	O	O
)	O	O
after	O	O
initiation	O	O
of	O	O
treatment	O	O
in	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
decreased	O	O
significantly	O	O
in	O	O
all	O	O
groups	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
among	O	O
groups	O	O
at	O	O
T1	O	O
and	O	O
T2	O	O
.	O	O

At	O	O
T3	O	O
,	O	O
heart	O	O
rate	O	O
in	O	O
group	O	O
2	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
group	O	O
1	O	O
.	O	O

At	O	O
T3	O	O
and	O	O
T4	O	O
,	O	O
the	O	O
double	O	O
product	O	O
was	O	O
highest	O	O
in	O	O
group	O	O
3	O	O
(	O	O
group	O	O
1	O	O
vs.	O	O
3	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
hemodynamic	O	O
effects	O	O
of	O	O
the	O	O
3	O	O
drugs	O	O
are	O	O
similar	O	O
within	O	O
the	O	O
first	O	O
30	O	O
min	O	O
.	O	O

However	O	O
,	O	O
after	O	O
30	O	O
min	O	O
,	O	O
diltiazem	O	O
affords	O	O
better	O	O
myocardial	O	O
performance	O	O
and	O	O
more	O	O
effective	O	O
control	O	O
of	O	O
hypertension	O	O
.	O	O

Cyclosporin	O	O
versus	O	O
cyclophosphamide	O	O
for	O	O
patients	O	O
with	O	O
steroid-dependent	Condition	O
and	O	O
frequently	Condition	O
relapsing	Condition	O
idiopathic	Condition	O
nephrotic	Condition	O
syndrome	Condition	O
:	O	O
a	O	O
multicentre	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	O	O
(	O	O
maintenance	O	O
of	O	O
remission	O	O
)	O	O
,	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
cyclosporin	O	O
(	O	O
CsA	O	O
)	O	O
with	O	O
those	O	O
of	O	O
cyclophosphamide	O	O
in	O	O
patients	O	O
with	O	O
steroid-dependent	Condition	O
or	O	O
frequently	Condition	O
relapsing	Condition	O
nephrotic	Condition	O
syndrome	Condition	O
(	O	O
NS	Condition	O
)	O	O
.	O	O

DESIGN	O	O
Open	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
multicentre	O	O
,	O	O
controlled	O	O
study	O	O
for	O	O
parallel	O	O
groups	O	O
,	O	O
stratified	O	O
for	O	O
adults	Age	Age
and	O	O
children	Age	O
.	O	O

The	O	O
setting	O	O
was	O	O
in	O	O
nephrological	O	O
departments	O	O
in	O	O
Italy	O	O
.	O	O

SUBJECTS	O	O
AND	O	O
INTERVENTIONS	O	O
Seventy-three	SampleSize	SampleSize
patients	O	O
with	O	O
steroid-sensitive	Condition	O
idiopathic	Condition	O
NS	Condition	O
admitted	O	O
to	O	O
the	O	O
study	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
cyclophosphamide	O	O
(	O	O
2.5	O	O
mg/kg/day	O	O
)	O	O
for	O	O
8	O	O
weeks	O	O
or	O	O
CsA	O	O
(	O	O
5	O	O
mg/kg/day	O	O
in	O	O
adults	O	O
,	O	O
6	O	O
mg/kg/day	O	O
in	O	O
children	O	O
)	O	O
for	O	O
9	O	O
months	O	O
,	O	O
tapered	O	O
off	O	O
by	O	O
25	O	O
%	O	O
every	O	O
month	O	O
until	O	O
complete	O	O
discontinuation	O	O
at	O	O
month	O	O
12	O	O
.	O	O

Seven	O	O
patients	O	O
lost	O	O
to	O	O
follow	O	O
up	O	O
were	O	O
not	O	O
considered	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

The	O	O
remaining	O	O
66	O	O
patients	O	O
were	O	O
followed	O	O
up	O	O
for	O	O
3-24	O	O
months	O	O
after	O	O
randomization	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Relapse-free	O	O
survival	O	O
;	O	O
number	O	O
of	O	O
N.S	O	O
.	O	O

relapses/patient/year	O	O
;	O	O
cumulative	O	O
dose	O	O
of	O	O
prednisone/patient	O	O
;	O	O
laboratory	O	O
investigations	O	O
(	O	O
kidney	O	O
and	O	O
liver	O	O
functions	O	O
,	O	O
haematological	O	O
parameters	O	O
)	O	O
;	O	O
incidence	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

RESULTS	O	O
At	O	O
month	O	O
9	O	O
,	O	O
26	O	O
of	O	O
35	O	O
CsA-treated	O	O
patients	O	O
were	O	O
still	O	O
in	O	O
complete	O	O
remission	O	O
and	O	O
a	O	O
further	O	O
five	O	O
patients	O	O
were	O	O
in	O	O
partial	O	O
remission	O	O
;	O	O
18	O	O
of	O	O
28	O	O
cyclophosphamide-treated	O	O
patients	O	O
were	O	O
in	O	O
complete	O	O
remission	O	O
,	O	O
and	O	O
one	O	O
in	O	O
partial	O	O
remission	O	O
(	O	O
P	O	O
=	O	O
NS	O	O
)	O	O
.	O	O

No	O	O
difference	O	O
between	O	O
adults	O	O
and	O	O
children	O	O
was	O	O
seen	O	O
with	O	O
either	O	O
treatment	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
relapse	O	O
was	O	O
similar	O	O
between	O	O
frequent	O	O
relapsers	O	O
(	O	O
19	O	O
of	O	O
22	O	O
)	O	O
and	O	O
steroid-dependent	O	O
patients	O	O
(	O	O
8	O	O
of	O	O
14	O	O
)	O	O
given	O	O
CsA	O	O
,	O	O
and	O	O
those	O	O
given	O	O
cyclophosphamide	O	O
(	O	O
5	O	O
of	O	O
15	O	O
and	O	O
6	O	O
of	O	O
15	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
number	O	O
of	O	O
relapses	O	O
per	O	O
year	O	O
and	O	O
the	O	O
mean	O	O
dose	O	O
of	O	O
prednisone	O	O
per	O	O
year	O	O
were	O	O
significantly	O	O
less	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
in	O	O
both	O	O
groups	O	O
for	O	O
the	O	O
experimental	O	O
year	O	O
than	O	O
for	O	O
the	O	O
year	O	O
before	O	O
randomization	O	O
.	O	O

At	O	O
2	O	O
years	O	O
,	O	O
25	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
given	O	O
CsA	O	O
(	O	O
50	O	O
%	O	O
adults	O	O
and	O	O
20	O	O
%	O	O
children	O	O
)	O	O
and	O	O
63	O	O
%	O	O
of	O	O
those	O	O
given	O	O
cyclophosphamide	O	O
(	O	O
40	O	O
%	O	O
adults	O	O
and	O	O
68	O	O
%	O	O
children	O	O
)	O	O
had	O	O
not	O	O
had	O	O
any	O	O
relapse	O	O
of	O	O
NS	O	O
.	O	O

Tolerance	O	O
to	O	O
the	O	O
two	O	O
drugs	O	O
was	O	O
generally	O	O
good	O	O
.	O	O

The	O	O
CsA-related	O	O
side-effects	O	O
were	O	O
mild	O	O
and	O	O
disappeared	O	O
after	O	O
drug	O	O
discontinuation	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
both	O	O
treatments	O	O
are	O	O
effective	O	O
and	O	O
well	O	O
tolerated	O	O
;	O	O
more	O	O
patients	O	O
given	O	O
cyclophosphamide	O	O
had	O	O
stable	O	O
remissions	O	O
.	O	O

Learning	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
:	O	O
does	O	O
comparing	O	O
with	O	O
inequality	O	O
symbols	O	O
help	O	O
?	O	O
This	O	O
study	O	O
investigated	O	O
whether	O	O
instruction	O	O
that	O	O
involves	O	O
comparing	O	O
the	O	O
equal	O	O
sign	O	O
with	O	O
other	O	O
relational	O	O
symbols	O	O
is	O	O
more	O	O
effective	O	O
at	O	O
imparting	O	O
a	O	O
relational	O	O
interpretation	O	O
of	O	O
the	O	O
equal	O	O
sign	O	O
than	O	O
instruction	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
alone	O	O
.	O	O

Third-	Age	O
and	Age	O
fourth-grade	Age	O
students	Age	O
in	O	O
a	O	O
comparing	O	O
symbols	O	O
group	O	O
learned	O	O
about	O	O
the	O	O
greater	O	O
than	O	O
,	O	O
less	O	O
than	O	O
,	O	O
and	O	O
equal	O	O
signs	O	O
and	O	O
had	O	O
the	O	O
opportunity	O	O
to	O	O
compare	O	O
the	O	O
inequality	O	O
symbols	O	O
with	O	O
the	O	O
equal	O	O
sign	O	O
.	O	O

Students	O	O
in	O	O
an	O	O
equal	O	O
sign	O	O
group	O	O
learned	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
only	O	O
.	O	O

A	O	O
third	O	O
group	O	O
of	O	O
students	O	O
served	O	O
as	O	O
a	O	O
control	O	O
group	O	O
.	O	O

Three	O	O
aspects	O	O
of	O	O
students	O	O
'	O	O
knowledge	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
lesson	O	O
:	O	O
(	O	O
a	O	O
)	O	O
conceptual	O	O
understanding	O	O
of	O	O
the	O	O
equal	O	O
sign	O	O
,	O	O
(	O	O
b	O	O
)	O	O
equation	O	O
encoding	O	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
problem	O	O
solving	O	O
.	O	O

Students	O	O
in	O	O
the	O	O
comparing	O	O
symbols	O	O
group	O	O
showed	O	O
greater	O	O
gains	O	O
in	O	O
conceptual	O	O
understanding	O	O
from	O	O
pretest	O	O
to	O	O
posttest	O	O
than	O	O
students	O	O
in	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
,	O	O
and	O	O
students	O	O
in	O	O
the	O	O
comparing	O	O
symbols	O	O
group	O	O
also	O	O
scored	O	O
higher	O	O
on	O	O
a	O	O
posttest	O	O
that	O	O
assessed	O	O
knowledge	O	O
about	O	O
inequality	O	O
symbols	O	O
and	O	O
inequality	O	O
problem	O	O
solving	O	O
.	O	O

Thus	O	O
,	O	O
they	O	O
learned	O	O
about	O	O
three	O	O
symbols	O	O
in	O	O
the	O	O
same	O	O
amount	O	O
of	O	O
time	O	O
as	O	O
other	O	O
students	O	O
learned	O	O
about	O	O
the	O	O
equal	O	O
sign	O	O
alone	O	O
or	O	O
not	O	O
at	O	O
all	O	O
.	O	O

Therefore	O	O
,	O	O
an	O	O
instructional	O	O
approach	O	O
involving	O	O
comparison	O	O
can	O	O
be	O	O
an	O	O
effective	O	O
tool	O	O
for	O	O
learning	O	O
about	O	O
concepts	O	O
in	O	O
mathematics	O	O
.	O	O

Iron	O	O
in	O	O
relation	O	O
to	O	O
gastric	Condition	O
cancer	Condition	O
in	O	O
the	O	O
Alpha-tocopherol	O	O
,	O	O
Beta-carotene	O	O
Cancer	O	O
Prevention	O	O
Study	O	O
.	O	O

BACKGROUND	O	O
Iron	O	O
is	O	O
an	O	O
essential	O	O
micronutrient	O	O
that	O	O
can	O	O
have	O	O
carcinogenic	O	O
effects	O	O
when	O	O
at	O	O
high	O	O
or	O	O
low	O	O
concentrations	O	O
.	O	O

Previous	O	O
studies	O	O
of	O	O
iron	O	O
in	O	O
relation	O	O
to	O	O
gastric	O	O
cancer	O	O
have	O	O
not	O	O
assessed	O	O
subtype-specific	O	O
relationships	O	O
.	O	O

We	O	O
used	O	O
the	O	O
prospective	O	O
Alpha-Tocopherol	O	O
,	O	O
Beta-Carotene	O	O
(	O	O
ATBC	O	O
)	O	O
Cancer	O	O
Prevention	O	O
Study	O	O
to	O	O
assess	O	O
whether	O	O
iron	O	O
metrics	O	O
were	O	O
associated	O	O
with	O	O
gastric	Condition	O
cardia	Condition	O
cancer	Condition	O
(	O	O
GCC	Condition	O
)	O	O
and	O	O
gastric	Condition	O
noncardia	Condition	O
cancer	Condition	O
(	O	O
GNCC	Condition	O
)	O	O
.	O	O

METHODS	O	O
We	O	O
selected	O	O
341	SampleSize	O
incident	O	O
gastric	O	O
cancer	O	O
cases	O	O
(	O	O
86	O	O
cardia	O	O
,	O	O
172	O	O
noncardia	O	O
,	O	O
and	O	O
83	O	O
nonspecified	O	O
)	O	O
,	O	O
accrued	O	O
during	O	O
22	O	O
years	O	O
of	O	O
follow-up	O	O
,	O	O
and	O	O
341	SampleSize	O
individually	O	O
matched	O	O
controls	O	O
.	O	O

We	O	O
measured	O	O
prediagnostic	O	O
serum	O	O
iron	O	O
,	O	O
ferritin	O	O
,	O	O
unsaturated	O	O
iron	O	O
binding	O	O
capacity	O	O
,	O	O
and	O	O
C-reactive	O	O
protein	O	O
.	O	O

Total	O	O
iron-binding	O	O
capacity	O	O
(	O	O
TIBC	O	O
)	O	O
and	O	O
transferrin	O	O
saturation	O	O
were	O	O
estimated	O	O
from	O	O
these	O	O
metrics	O	O
.	O	O

Dietary	O	O
iron	O	O
exposures	O	O
were	O	O
estimated	O	O
from	O	O
a	O	O
food	O	O
frequency	O	O
questionnaire	O	O
.	O	O

Multivariable	O	O
logistic	O	O
regression	O	O
was	O	O
used	O	O
for	O	O
analysis	O	O
.	O	O

RESULTS	O	O
Serum	O	O
iron	O	O
metrics	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
GCC	O	O
,	O	O
except	O	O
for	O	O
a	O	O
potential	O	O
n	O	O
-shaped	O	O
relationship	O	O
with	O	O
TIBC	O	O
(	O	O
global	O	O
P	O	O
=	O	O
0.038	O	O
)	O	O
.	O	O

GNCC	O	O
was	O	O
inversely	O	O
associated	O	O
with	O	O
serum	O	O
ferritin	O	O
(	O	O
global	O	O
P	O	O
=	O	O
0.024	O	O
)	O	O
,	O	O
serum	O	O
iron	O	O
(	O	O
global	O	O
P	O	O
=	O	O
0.060	O	O
)	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
transferrin	O	O
saturation	O	O
.	O	O

TIBC	O	O
appeared	O	O
to	O	O
share	O	O
a	O	O
u	O	O
-shaped	O	O
relationship	O	O
with	O	O
GNCC	O	O
(	O	O
global	O	O
P	O	O
=	O	O
0.033	O	O
)	O	O
.	O	O

Dietary	O	O
iron	O	O
exposures	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
either	O	O
subsite	O	O
.	O	O

Adjustment	O	O
for	O	O
Helicobacter	O	O
pylori	O	O
and	O	O
gastric	O	O
atrophy	O	O
had	O	O
little	O	O
effect	O	O
on	O	O
observed	O	O
associations	O	O
.	O	O

CONCLUSIONS	O	O
We	O	O
found	O	O
little	O	O
evidence	O	O
for	O	O
the	O	O
involvement	O	O
of	O	O
iron	O	O
exposure	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
GCC	O	O
.	O	O

GNCC	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
iron	O	O
profile	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
iron	O	O
deficiency	O	O
.	O	O

IMPACT	O	O
Our	O	O
findings	O	O
indicate	O	O
that	O	O
inverse	O	O
associations	O	O
between	O	O
iron	O	O
metrics	O	O
and	O	O
gastric	O	O
cancer	O	O
are	O	O
driven	O	O
by	O	O
associations	O	O
with	O	O
GNCC	O	O
.	O	O

Further	O	O
elucidation	O	O
of	O	O
potential	O	O
mechanisms	O	O
is	O	O
warranted	O	O
.	O	O

Outcomes	O	O
in	O	O
a	O	O
nursing	O	O
home	O	O
transition	O	O
case-management	O	O
program	O	O
targeting	O	O
new	O	O
admissions	O	O
.	O	O

PURPOSE	O	O
The	O	O
Providing	O	O
Assistance	O	O
to	O	O
Caregivers	O	O
in	O	O
Transition	O	O
(	O	O
PACT	O	O
)	O	O
program	O	O
offers	O	O
nursing	O	O
home	O	O
discharge	O	O
planning	O	O
and	O	O
case	O	O
management	O	O
for	O	O
individuals	O	O
in	O	O
the	O	O
transitional	O	O
period	O	O
following	O	O
a	O	O
return	O	O
to	O	O
the	O	O
community	O	O
.	O	O

The	O	O
PACT	O	O
program	O	O
targeted	O	O
individuals	O	O
newly	O	O
admitted	O	O
to	O	O
nursing	Condition	O
homes	Condition	O
and	O	O
worked	O	O
with	O	O
a	O	O
family	O	O
caregiver	O	O
to	O	O
develop	O	O
and	O	O
implement	O	O
a	O	O
nursing	O	O
home	O	O
discharge	O	O
plan	O	O
.	O	O

DESIGN	O	O
AND	O	O
METHOD	O	O
Reported	O	O
are	O	O
the	O	O
results	O	O
of	O	O
a	O	O
randomized	O	O
control	O	O
design	O	O
evaluating	O	O
the	O	O
program	O	O
's	O	O
effectiveness	O	O
.	O	O

Those	O	O
individuals	O	O
randomly	O	O
assigned	O	O
to	O	O
the	O	O
intervention	O	O
group	O	O
(	O	O
n	O	O
=	O	O
33	SampleSize	O
)	O	O
received	O	O
PACT	O	O
case	O	O
management	O	O
in	O	O
addition	O	O
to	O	O
their	O	O
usual	O	O
medical	O	O
and	O	O
nursing	O	O
home	O	O
care	O	O
.	O	O

The	O	O
individuals	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
29	SampleSize	O
)	O	O
continued	O	O
their	O	O
usual	O	O
care	O	O
.	O	O

RESULT	O	O
There	O	O
were	O	O
no	O	O
statistical	O	O
differences	O	O
in	O	O
the	O	O
discharge	O	O
rate	O	O
(	O	O
84	O	O
%	O	O
treatment	O	O
vs	O	O
76	O	O
%	O	O
controls	O	O
)	O	O
or	O	O
in	O	O
the	O	O
median	O	O
length	O	O
of	O	O
stay	O	O
(	O	O
42	O	O
days	O	O
vs	O	O
55	O	O
days	O	O
)	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
of	O	O
individuals	O	O
.	O	O

IMPLICATIONS	O	O
Replications	O	O
or	O	O
extensions	O	O
of	O	O
a	O	O
PACT-type	O	O
intervention	O	O
might	O	O
consider	O	O
a	O	O
broader	O	O
mix	O	O
of	O	O
nursing	O	O
homes	O	O
,	O	O
working	O	O
directly	O	O
with	O	O
the	O	O
nursing	O	O
home	O	O
's	O	O
admission	O	O
Minimum	O	O
Data	O	O
Set	O	O
coordinator	O	O
in	O	O
patient	O	O
selection	O	O
,	O	O
or	O	O
working	O	O
with	O	O
Medicare	O	O
or	O	O
Medicaid	O	O
HMO	O	O
plans	O	O
.	O	O

Fine	O	O
needle	O	O
aspiration	O	O
coupled	O	O
with	O	O
real-time	O	O
PCR	O	O
:	O	O
a	O	O
painless	O	O
methodology	O	O
to	O	O
study	O	O
adaptive	O	O
functional	O	O
changes	O	O
in	O	O
skeletal	O	O
muscle	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
AIM	O	O
In	O	O
this	O	O
study	O	O
we	O	O
developed	O	O
a	O	O
new	O	O
methodology	O	O
for	O	O
obtaining	O	O
human	O	O
skeletal	O	O
muscle	O	O
samples	O	O
to	O	O
evaluate	O	O
gene	O	O
expression	O	O
.	O	O

This	O	O
approach	O	O
is	O	O
based	O	O
on	O	O
a	O	O
fine	O	O
needle	O	O
aspiration	O	O
technique	O	O
,	O	O
which	O	O
allows	O	O
us	O	O
to	O	O
extract	O	O
a	O	O
small	O	O
tissue	O	O
sample	O	O
in	O	O
a	O	O
significantly	O	O
less	O	O
invasive	O	O
manner	O	O
than	O	O
with	O	O
classic	O	O
biopsy	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Multiplex	O	O
tandem	O	O
RT-PCR	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
mRNA	O	O
levels	O	O
of	O	O
genes	O	O
involved	O	O
in	O	O
ATP	O	O
production	O	O
and	O	O
mitochondrial	O	O
biogenesis	O	O
in	O	O
muscle	O	O
tissue	O	O
.	O	O

Samples	O	O
of	O	O
vastus	O	O
lateralis	O	O
muscle	O	O
were	O	O
obtained	O	O
from	O	O
21	SampleSize	O
healthy	Condition	O
subjects	Condition	O
with	O	O
different	O	O
fitness	Condition	O
levels	Condition	O
.	O	O

The	O	O
principal	O	O
findings	O	O
in	O	O
our	O	O
study	O	O
show	O	O
a	O	O
strong	O	O
correlation	O	O
between	O	O
PGC-1alpha	O	O
and	O	O
COX5B	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
between	O	O
PGC-1alpha	O	O
and	O	O
MT-CO2	O	O
(	O	O
p=0.017	O	O
)	O	O
expression	O	O
.	O	O

Furthermore	O	O
,	O	O
a	O	O
significant	O	O
positive	O	O
correlation	O	O
between	O	O
mtDNA	O	O
content	O	O
and	O	O
the	O	O
percentage	O	O
of	O	O
MHCI	O	O
present	O	O
in	O	O
the	O	O
aspired	O	O
samples	O	O
were	O	O
found	O	O
(	O	O
p=0.028	O	O
)	O	O
.	O	O

These	O	O
data	O	O
are	O	O
in	O	O
agreement	O	O
with	O	O
current	O	O
knowledge	O	O
on	O	O
skeletal	O	O
muscle	O	O
physiology	O	O
and	O	O
show	O	O
the	O	O
reliability	O	O
of	O	O
the	O	O
proposed	O	O
method	O	O
.	O	O

CONCLUSION	O	O
This	O	O
painless	O	O
methodology	O	O
can	O	O
be	O	O
used	O	O
to	O	O
investigate	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
human	O	O
muscle	O	O
RNA	O	O
and	O	O
DNA	O	O
adaptations	O	O
in	O	O
response	O	O
to	O	O
either	O	O
physiological	O	O
and/or	O	O
pharmacological	O	O
stimuli	O	O
.	O	O

This	O	O
method	O	O
has	O	O
major	O	O
clinical	O	O
relevance	O	O
,	O	O
such	O	O
as	O	O
its	O	O
application	O	O
in	O	O
clarifying	O	O
the	O	O
mechanisms	O	O
underling	O	O
metabolic	O	O
and	O	O
systemic	O	O
disorders	O	O
.	O	O

Transcutaneous	O	O
electrical	O	O
nerve	O	O
stimulation	O	O
following	O	O
appendicectomy	Condition	O
:	O	O
the	O	O
placebo	O	O
effect	O	O
.	O	O

A	O	O
controlled	O	O
trial	O	O
was	O	O
undertaken	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
of	O	O
transcutaneous	O	O
electrical	O	O
nerve	O	O
stimulation	O	O
(	O	O
TENS	O	O
)	O	O
with	O	O
standard	O	O
intramuscular	O	O
opiate	O	O
analgesia	O	O
in	O	O
the	O	O
management	O	O
of	O	O
postoperative	O	O
pain	O	O
following	O	O
appendicectomy	Condition	O
.	O	O

Consecutive	O	O
patients	O	O
undergoing	O	O
emergency	O	O
appendicectomy	Condition	O
were	O	O
randomised	O	O
into	O	O
control	O	O
,	O	O
sham	O	O
TENS	O	O
and	O	O
active	O	O
TENS	O	O
groups	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
pain	O	O
severity	O	O
and	O	O
analgesic	O	O
intake	O	O
in	O	O
both	O	O
active	O	O
and	O	O
sham	O	O
TENS	O	O
groups	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

No	O	O
difference	O	O
was	O	O
demonstrated	O	O
in	O	O
pain	O	O
severity	O	O
between	O	O
active	O	O
and	O	O
sham	O	O
TENS	O	O
groups	O	O
but	O	O
the	O	O
active	O	O
TENS	O	O
group	O	O
required	O	O
slightly	O	O
less	O	O
analgesia	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
major	O	O
benefit	O	O
of	O	O
TENS	O	O
in	O	O
the	O	O
postappendicectomy	Condition	O
patient	O	O
is	O	O
due	O	O
to	O	O
its	O	O
'placebo	O	O
effect	O	O
'	O	O
and	O	O
its	O	O
use	O	O
in	O	O
this	O	O
situation	O	O
can	O	O
not	O	O
be	O	O
recommended	O	O
.	O	O

Can	O	O
a	O	O
home-visit	O	O
invitation	O	O
increase	O	O
Pap	O	O
smear	O	O
screening	O	O
in	O	O
Samliem	O	O
,	O	O
Khon	O	O
Kaen	O	O
,	O	O
Thailand	O	O
?	O	O
Our	O	O
objective	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
efficiency	O	O
of	O	O
a	O	O
home-visit	O	O
invitation	O	O
aimed	O	O
to	O	O
increase	O	O
uptake	O	O
of	O	O
cervical	Condition	O
cancer	Condition	O
screening	Condition	O
in	O	O
women	Sex	O
between	O	O
35	Age	Age
and	Age	Age
60	Age	Age
years	O	Age
of	O	O
age	O	O
.	O	O

From	O	O
May	O	O
,	O	O
2006	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
quasi-randomized	O	O
trial	O	O
to	O	O
determine	O	O
if	O	O
an	O	O
in-home	O	O
education	O	O
and	O	O
invitation	O	O
intervention	O	O
would	O	O
increase	O	O
uptake	O	O
of	O	O
cervical	O	O
cancer	O	O
screening	O	O
.	O	O

We	O	O
randomly	O	O
recruited	O	O
304	SampleSize	SampleSize
women	O	Sex
from	O	O
the	O	O
Samliem	O	O
inner-city	O	O
community	O	O
,	O	O
Khon	O	O
Kaen	O	O
,	O	O
Northeast	O	O
Thailand	O	O
,	O	O
and	O	O
assigned	O	O
participants	O	O
to	O	O
either	O	O
the	O	O
intervention	O	O
or	O	O
control	O	O
zone	O	O
.	O	O

Baseline	O	O
screening	O	O
coverage	O	O
interviews	O	O
were	O	O
then	O	O
performed	O	O
:	O	O
58	O	O
of	O	O
158	SampleSize	SampleSize
women	O	Sex
in	O	O
the	O	O
intervention	O	O
zone	O	O
and	O	O
46	O	O
of	O	O
146	SampleSize	O
in	O	O
the	O	O
control	O	O
zone	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
because	O	O
of	O	O
having	O	O
had	O	O
a	O	O
Pap	O	O
smear	O	O
within	O	O
5	O	O
years	O	O
,	O	O
but	O	O
these	O	O
were	O	O
included	O	O
in	O	O
the	O	O
final	O	O
analysis	O	O
.	O	O

First	O	O
,	O	O
100	O	SampleSize
women	O	Sex
in	O	O
the	O	O
intervention	O	O
group	O	O
were	O	O
visited	O	O
in	O	O
their	O	O
homes	O	O
by	O	O
one	O	O
of	O	O
the	O	O
researchers	O	O
,	O	O
who	O	O
provided	O	O
culturally-sensitive	O	O
health	O	O
education	O	O
that	O	O
emphasized	O	O
the	O	O
need	O	O
for	O	O
screening	O	O
.	O	O

Four	O	O
months	O	O
later	O	O
,	O	O
post-intervention	O	O
,	O	O
screening-coverage	O	O
interviews	O	O
were	O	O
again	O	O
performed	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
in	O	O
combination	O	O
with	O	O
the	O	O
same	O	O
health	O	O
education	O	O
for	O	O
100	O	SampleSize
women	O	Sex
in	O	O
the	O	O
control	O	O
group	O	O
for	O	O
a	O	O
comparison	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
baseline	O	O
Pap	O	O
smear	O	O
screening-coverage	O	O
rate	O	O
in	O	O
the	O	O
intervention	O	O
vs.	O	O
control	O	O
zones	O	O
(	O	O
36.7	O	O
vs.	O	O
31.5	O	O
%	O	O
,	O	O
p=0.339	O	O
)	O	O
.	O	O

One	O	O
hundred	O	O
women	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
completed	O	O
the	O	O
intervention	O	O
interviews	O	O
and	O	O
after	O	O
four	O	O
months	O	O
,	O	O
100	O	SampleSize
women	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
and	O	O
100	O	SampleSize
in	O	O
the	O	O
control	O	O
group	O	O
also	O	O
completed	O	O
the	O	O
post-intervention	O	O
interviews	O	O
.	O	O

The	O	O
increased	O	O
screening-coverage	O	O
rate	O	O
in	O	O
the	O	O
intervention	O	O
zone	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
the	O	O
control	O	O
zone	O	O
(	O	O
43.6	O	O
vs.	O	O
34.9	O	O
%	O	O
,	O	O
p=0.119	O	O
)	O	O
;	O	O
however	O	O
,	O	O
there	O	O
was	O	O
a	O	O
borderline	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
intervention	O	O
zone	O	O
compared	O	O
with	O	O
baseline	O	O
(	O	O
36.7	O	O
to	O	O
43.6	O	O
%	O	O
,	O	O
p=0.070	O	O
)	O	O
.	O	O

Therefore	O	O
,	O	O
home	O	O
visit	O	O
education	O	O
and	O	O
invitation	O	O
intervention	O	O
produced	O	O
only	O	O
a	O	O
nominal	O	O
effect	O	O
on	O	O
increasing	O	O
Pap	O	O
smear	O	O
coverage	O	O
within	O	O
a	O	O
4-month	O	O
study	O	O
period	O	O
.	O	O

Glibenclamide	O	O
vs	O	O
gliclazide	O	O
in	O	O
reducing	O	O
oxidative	O	O
stress	O	O
in	O	O
patients	O	O
of	O	O
noninsulin	Condition	O
dependent	Condition	O
diabetes	Condition	O
mellitus	Condition	O
--	O	O
a	O	O
double	O	O
blind	O	O
randomized	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
Parameters	O	O
of	O	O
oxidative	O	O
stress	O	O
were	O	O
quantitated	O	O
in	O	O
50	SampleSize	SampleSize
patients	O	O
with	O	O
type	Condition	O
2	Condition	O
diabetes	Condition	O
mellitus	Condition	O
in	Condition	O
uncontrolled	Condition	O
state	Condition	O
and	O	O
after	O	O
control	O	O
using	O	O
oral	O	O
glibenclamide	O	O
or	O	O
gliclazide	O	O
.	O	O

The	O	O
estimates	O	O
were	O	O
further	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
irrespective	O	O
of	O	O
drug	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
difference	O	O
,	O	O
if	O	O
any	O	O
.	O	O

METHODS	O	O
The	O	O
study	O	O
was	O	O
a	O	O
double	O	O
blind	O	O
,	O	O
uncontrolled	O	O
,	O	O
noncrossover	O	O
and	O	O
randomized	O	O
trial	O	O
.	O	O

Fifty	SampleSize	O
patients	O	O
of	O	O
uncontrolled	Condition	O
type	Condition	O
2	Condition	O
diabetes	Condition	O
were	O	O
divided	O	O
in	O	O
to	O	O
two	O	O
groups	O	O
.	O	O

Group	O	O
I	O	O
(	O	O
25	O	O
patients	O	O
)	O	O
received	O	O
capsule	O	O
A	O	O
(	O	O
glibenclamide	O	O
)	O	O
while	O	O
Group	O	O
II	O	O
(	O	O
25	O	SampleSize
patients	O	O
)	O	O
received	O	O
capsule	O	O
B	O	O
(	O	O
gliclazide	O	O
)	O	O
.	O	O

The	O	O
parameters	O	O
studied	O	O
were	O	O
Superoxide	O	O
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
,	O	O
malonyl-dialdehyde	O	O
(	O	O
MDA	O	O
)	O	O
and	O	O
reduced	O	O
glutathione	O	O
(	O	O
GSH	O	O
)	O	O
.	O	O

They	O	O
were	O	O
done	O	O
at	O	O
(	O	O
a	O	O
)	O	O
uncontrolled	O	O
stage	O	O
(	O	O
FBS	O	O
--	O	O
165	O	O
+/-	O	O
16.7	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
240	O	O
+/-	O	O
30.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
10.5	O	O
+/-	O	O
0.9	O	O
%	O	O
in	O	O
group	O	O
I	O	O
and	O	O
FBS	O	O
--	O	O
150	O	O
+/-	O	O
15.8	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
246	O	O
+/-	O	O
29.1	O	O
mg/dl	O	O
HbA1	O	O
10.6	O	O
+/-	O	O
0.8	O	O
%	O	O
in	O	O
group	O	O
II	O	O
)	O	O
and	O	O
during	O	O
controlled	O	O
stage	O	O
at	O	O
12	O	O
weeks	O	O
(	O	O
FBS	O	O
--	O	O
120	O	O
+/-	O	O
18.5	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
180	O	O
+/-	O	O
19.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
8.4	O	O
+/-	O	O
0.29	O	O
%	O	O
in	O	O
group	O	O
I	O	O
and	O	O
FBS	O	O
--	O	O
118	O	O
+/-	O	O
17.6	O	O
mg/dl	O	O
,	O	O
PP	O	O
--	O	O
176	O	O
+/-	O	O
20.1	O	O
mg/dl	O	O
and	O	O
HbA1	O	O
--	O	O
8.5	O	O
+/-	O	O
0.39	O	O
%	O	O
in	O	O
group	O	O
II	O	O
patients	O	O
)	O	O
.	O	O

RESULTS	O	O
The	O	O
significantly	O	O
raised	O	O
levels	O	O
of	O	O
MDA	O	O
and	O	O
SOD	O	O
,	O	O
and	O	O
decreased	O	O
levels	O	O
of	O	O
reduced	O	O
glutathione	O	O
(	O	O
GSH	O	O
)	O	O
during	O	O
uncontrolled	O	O
stage	O	O
of	O	O
diabetes	O	O
indicated	O	O
free	O	O
radical	O	O
stress	O	O
induced	O	O
lipid	O	O
peroxidation	O	O
.	O	O

The	O	O
significant	O	O
fall	O	O
of	O	O
MDA	O	O
and	O	O
SOD	O	O
and	O	O
increased	O	O
levels	O	O
of	O	O
GSH	O	O
in	O	O
blood	O	O
in	O	O
both	O	O
groups	O	O
after	O	O
control	O	O
revealed	O	O
beneficial	O	O
effects	O	O
of	O	O
glycemic	O	O
control	O	O
on	O	O
oxidative	O	O
stress	O	O
.	O	O

The	O	O
levels	O	O
were	O	O
not	O	O
normalized	O	O
and	O	O
stayed	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
controls	O	O
.	O	O

On	O	O
intergroup	O	O
comparison	O	O
;	O	O
the	O	O
control	O	O
of	O	O
diabetes	O	O
with	O	O
gliclazide	O	O
(	O	O
group	O	O
II	O	O
)	O	O
showed	O	O
improvement	O	O
in	O	O
oxidative	O	O
stress	O	O
(	O	O
MDA	O	O
,	O	O
GSH	O	O
)	O	O
better	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
than	O	O
glibenclamide	O	O
(	O	O
group	O	O
I	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Oxidative	O	O
stress	O	O
in	O	O
uncontrolled	O	O
diabetes	O	O
is	O	O
decreased	O	O
with	O	O
glycemic	O	O
control	O	O
.	O	O

The	O	O
control	O	O
of	O	O
diabetes	O	O
with	O	O
gliclazide	O	O
reduced	O	O
oxidative	O	O
stress	O	O
more	O	O
than	O	O
glibenclamide	O	O
,	O	O
indicating	O	O
higher	O	O
antioxidant	O	O
properties	O	O
of	O	O
gliclazide	O	O
.	O	O

Normalization	O	O
of	O	O
oxidative	O	O
stress	O	O
was	O	O
not	O	O
achieved	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
required	O	O
to	O	O
see	O	O
long-term	O	O
effect	O	O
of	O	O
drug	O	O
therapy	O	O
in	O	O
combating	O	O
oxidative	O	O
stress	O	O
after	O	O
achieving	O	O
acceptable	O	O
control	O	O
of	O	O
diabetes	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
a	O	O
parent-implemented	O	O
imitation	O	O
intervention	O	O
on	O	O
spontaneous	O	O
imitation	O	O
skills	O	O
in	O	O
young	Age	Age
children	Age	Age
with	O	O
autism	Condition	O
.	O	O

Children	O	O
with	O	O
autism	O	O
exhibit	O	O
significant	O	O
deficits	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
spontaneously	O	O
imitate	O	O
the	O	O
play	O	O
actions	O	O
and	O	O
descriptive	O	O
gestures	O	O
of	O	O
others	O	O
.	O	O

Reciprocal	O	O
imitation	O	O
training	O	O
(	O	O
RIT	O	O
)	O	O
is	O	O
a	O	O
naturalistic	O	O
imitation	O	O
intervention	O	O
designed	O	O
to	O	O
teach	O	O
spontaneous	O	O
imitation	O	O
skills	O	O
during	O	O
play	O	O
.	O	O

This	O	O
study	O	O
assessed	O	O
the	O	O
effectiveness	O	O
of	O	O
parent-implemented	O	O
RIT	O	O
using	O	O
a	O	O
multiple-baseline	O	O
design	O	O
across	O	O
three	SampleSize	O
young	O	O
children	O	O
with	O	O
autism	O	O
and	O	O
their	O	O
mothers	O	O
.	O	O

After	O	O
an	O	O
initial	O	O
baseline	O	O
,	O	O
mothers	O	O
were	O	O
taught	O	O
to	O	O
implement	O	O
RIT	O	O
techniques	O	O
with	O	O
their	O	O
child	O	O
twice	O	O
a	O	O
week	O	O
for	O	O
10	O	O
weeks	O	O
in	O	O
a	O	O
clinic	O	O
setting	O	O
.	O	O

Two	O	O
mothers	O	O
were	O	O
taught	O	O
to	O	O
use	O	O
RIT	O	O
to	O	O
teach	O	O
object	O	O
imitation	O	O
.	O	O

The	O	O
third	O	O
mother	O	O
was	O	O
taught	O	O
to	O	O
use	O	O
RIT	O	O
to	O	O
target	O	O
both	O	O
object	O	O
and	O	O
gesture	O	O
imitation	O	O
in	O	O
a	O	O
multiple-baseline	O	O
design	O	O
across	O	O
behaviors	O	O
.	O	O

Generalization	O	O
was	O	O
assessed	O	O
in	O	O
the	O	O
families	O	O
'	O	O
homes	O	O
at	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
and	O	O
a	O	O
1-month	O	O
follow-up	O	O
.	O	O

Parents	O	O
learned	O	O
to	O	O
use	O	O
the	O	O
intervention	O	O
strategies	O	O
and	O	O
their	O	O
children	O	Age
exhibited	O	O
increases	O	O
in	O	O
spontaneous	O	O
imitation	O	O
.	O	O

These	O	O
findings	O	O
replicate	O	O
the	O	O
results	O	O
from	O	O
previous	O	O
studies	O	O
,	O	O
indicating	O	O
that	O	O
RIT	O	O
is	O	O
effective	O	O
for	O	O
teaching	O	O
imitation	O	O
skills	O	O
to	O	O
young	O	O
children	O	O
with	O	O
autism	O	O
in	O	O
a	O	O
naturalistic	O	O
setting	O	O
and	O	O
extend	O	O
the	O	O
findings	O	O
to	O	O
parents	O	O
.	O	O

White	O	O
coat	O	O
effect	O	O
detected	O	O
using	O	O
self-monitoring	O	O
of	O	O
blood	O	O
pressure	O	O
at	O	O
home	O	O
:	O	O
comparison	O	O
with	O	O
ambulatory	O	O
blood	O	O
pressure	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
home	O	O
blood	O	O
pressure	O	O
(	O	O
HBP	O	O
)	O	O
is	O	O
a	O	O
reliable	O	O
alternative	O	O
to	O	O
ambulatory	O	O
blood	O	O
pressure	O	O
(	O	O
ABP	O	O
)	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
the	O	O
white	O	O
coat	O	O
effect	O	O
(	O	O
WCE	O	O
)	O	O
.	O	O

Hypertensive	Condition	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
measure	O	O
HBP	O	O
for	O	O
2	O	O
weeks	O	O
or	O	O
ABP	O	O
for	O	O
24	O	O
h.	O	O
The	O	O
alternative	O	O
measurement	O	O
was	O	O
then	O	O
performed	O	O
.	O	O

Clinic	O	O
blood	O	O
pressure	O	O
(	O	O
CBP	O	O
)	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
beginning	O	O
and	O	O
end	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Subjects	O	O
with	O	O
a	O	O
difference	O	O
of	O	O
>	O	O
or	O	O
=	O	O
20	O	O
mm	O	O
Hg	O	O
systolic	O	O
or	O	O
>	O	O
or	O	O
=	O	O
10	O	O
mm	O	O
Hg	O	O
diastolic	O	O
BP	O	O
between	O	O
CBP	O	O
and	O	O
awake	O	O
ABP	O	O
or	O	O
CBP	O	O
and	O	O
HBP	O	O
,	O	O
were	O	O
classified	O	O
as	O	O
clinic	O	O
reactors	O	O
.	O	O

A	O	O
total	O	O
of	O	O
189	SampleSize	SampleSize
patients	O	O
completed	O	O
the	O	O
study	O	O
(	O	O
79	SampleSize	O
on	O	O
stable	O	O
antihypertensive	O	O
treatment	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
magnitude	O	O
of	O	O
WCE	O	O
assessed	O	O
using	O	O
the	O	O
ABP	O	O
or	O	O
the	O	O
HBP	O	O
method	O	O
(	O	O
mean	O	O
discrepancy	O	O
,	O	O
systolic	O	O
BP	O	O
:	O	O
-1.5	O	O
+/-	O	O
11.7	O	O
mm	O	O
Hg	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
-3.2	O	O
,	O	O
0.2	O	O
;	O	O
diastolic	O	O
BP	O	O
:	O	O
0.9	O	O
+/-	O	O
7.0	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
-0.1	O	O
,	O	O
1.9	O	O
)	O	O
.	O	O

A	O	O
strong	O	O
association	O	O
existed	O	O
between	O	O
WCE	O	O
calculated	O	O
using	O	O
the	O	O
HBP	O	O
or	O	O
the	O	O
ABP	O	O
method	O	O
(	O	O
r	O	O
=	O	O
0.64/0.59	O	O
systolic/diastolic	O	O
,	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
patients	O	O
classified	O	O
as	O	O
clinic	O	O
reactors	O	O
was	O	O
identical	O	O
using	O	O
the	O	O
HBP	O	O
or	O	O
the	O	O
ABP	O	O
method	O	O
(	O	O
25.9	O	O
%	O	O
)	O	O
.	O	O

Agreement	O	O
between	O	O
methods	O	O
in	O	O
the	O	O
classification	O	O
of	O	O
clinic	O	O
reactors	O	O
was	O	O
found	O	O
in	O	O
147	O	O
patients	O	O
(	O	O
78	O	O
%	O	O
)	O	O
.	O	O

The	O	O
sensitivity	O	O
and	O	O
specificity	O	O
of	O	O
the	O	O
HBP	O	O
method	O	O
to	O	O
classify	O	O
correctly	O	O
clinic	O	O
reactors	O	O
(	O	O
ABP	O	O
method	O	O
used	O	O
as	O	O
the	O	O
standard	O	O
)	O	O
were	O	O
57	O	O
%	O	O
and	O	O
85	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
its	O	O
positive	O	O
and	O	O
negative	O	O
predictive	O	O
value	O	O
were	O	O
57	O	O
%	O	O
and	O	O
85	O	O
%	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
HBP	O	O
is	O	O
not	O	O
appropriate	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
ABP	O	O
diagnostic	O	O
testing	O	O
in	O	O
the	O	O
detection	O	O
of	O	O
WCE	O	O
.	O	O

Nevertheless	O	O
,	O	O
HBP	O	O
appears	O	O
useful	O	O
as	O	O
a	O	O
screening	O	O
test	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
this	O	O
phenomenon	O	O
.	O	O

Parent-mediated	O	O
communication-focused	O	O
treatment	O	O
in	O	O
children	Age	O
with	O	O
autism	Condition	O
(	O	O
PACT	O	O
)	O	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Results	O	O
of	O	O
small	O	O
trials	O	O
suggest	O	O
that	O	O
early	O	O
interventions	O	O
for	O	O
social	O	O
communication	O	O
are	O	O
effective	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
autism	O	O
in	O	O
children	O	O
.	O	O

We	O	O
therefore	O	O
investigated	O	O
the	O	O
efficacy	O	O
of	O	O
such	O	O
an	O	O
intervention	O	O
in	O	O
a	O	O
larger	O	O
trial	O	O
.	O	O

METHODS	O	O
Children	O	O
with	O	O
core	Condition	O
autism	Condition	O
(	O	O
aged	O	Age
2	Age	Age
years	Age	Age
to	Age	Age
4	Age	Age
years	Age	Age
and	Age	O
11	Age	O
months	Age	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
in	O	O
a	O	O
one-to-one	O	O
ratio	O	O
to	O	O
a	O	O
parent-mediated	O	O
communication-focused	O	O
(	O	O
Preschool	O	O
Autism	O	O
Communication	O	O
Trial	O	O
[	O	O
PACT	O	O
]	O	O
)	O	O
intervention	O	O
or	O	O
treatment	O	O
as	O	O
usual	O	O
at	O	O
three	O	O
specialist	O	O
centres	O	O
in	O	O
the	O	O
UK	O	O
.	O	O

Those	O	O
assigned	O	O
to	O	O
PACT	O	O
were	O	O
also	O	O
given	O	O
treatment	O	O
as	O	O
usual	O	O
.	O	O

Randomisation	O	O
was	O	O
by	O	O
use	O	O
of	O	O
minimisation	O	O
of	O	O
probability	O	O
in	O	O
the	O	O
marginal	O	O
distribution	O	O
of	O	O
treatment	O	O
centre	O	O
,	O	O
age	O	O
(	O	O
<	O	O
/=42	O	O
months	O	O
or	O	O
>	O	O
42	O	O
months	O	O
)	O	O
,	O	O
and	O	O
autism	O	O
severity	O	O
(	O	O
Autism	O	O
Diagnostic	O	O
Observation	O	O
Schedule-Generic	O	O
[	O	O
ADOS-G	O	O
]	O	O
algorithm	O	O
score	O	O
12-17	O	O
or	O	O
18-24	O	O
)	O	O
.	O	O

Primary	O	O
outcome	O	O
was	O	O
severity	O	O
of	O	O
autism	O	O
symptoms	O	O
(	O	O
a	O	O
total	O	O
score	O	O
of	O	O
social	O	O
communication	O	O
algorithm	O	O
items	O	O
from	O	O
ADOS-G	O	O
,	O	O
higher	O	O
score	O	O
indicating	O	O
greater	O	O
severity	O	O
)	O	O
at	O	O
13	O	O
months	O	O
.	O	O

Complementary	O	O
secondary	O	O
outcomes	O	O
were	O	O
measures	O	O
of	O	O
parent-child	O	O
interaction	O	O
,	O	O
child	O	O
language	O	O
,	O	O
and	O	O
adaptive	O	O
functioning	O	O
in	O	O
school	O	O
.	O	O

Analysis	O	O
was	O	O
by	O	O
intention	O	O
to	O	O
treat	O	O
.	O	O

This	O	O
study	O	O
is	O	O
registered	O	O
as	O	O
an	O	O
International	O	O
Standard	O	O
Randomised	O	O
Controlled	O	O
Trial	O	O
,	O	O
number	O	O
ISRCTN58133827	O	O
.	O	O

RESULTS	O	O
152	SampleSize	SampleSize
children	O	Age
were	O	O
recruited	O	O
.	O	O

77	SampleSize	SampleSize
were	O	O
assigned	O	O
to	O	O
PACT	O	O
(	O	O
London	O	O
[	O	O
n=26	O	O
]	O	O
,	O	O
Manchester	O	O
[	O	O
n=26	O	O
]	O	O
,	O	O
and	O	O
Newcastle	O	O
[	O	O
n=25	O	O
]	O	O
)	O	O
;	O	O
and	O	O
75	SampleSize	O
to	O	O
treatment	O	O
as	O	O
usual	O	O
(	O	O
London	O	O
[	O	O
n=26	O	O
]	O	O
,	O	O
Manchester	O	O
[	O	O
n=26	O	O
]	O	O
,	O	O
and	O	O
Newcastle	O	O
[	O	O
n=23	O	O
]	O	O
)	O	O
.	O	O

At	O	O
the	O	O
13-month	O	O
endpoint	O	O
,	O	O
the	O	O
severity	O	O
of	O	O
symptoms	O	O
was	O	O
reduced	O	O
by	O	O
3.9	O	O
points	O	O
(	O	O
SD	O	O
4.7	O	O
)	O	O
on	O	O
the	O	O
ADOS-G	O	O
algorithm	O	O
in	O	O
the	O	O
group	O	O
assigned	O	O
to	O	O
PACT	O	O
,	O	O
and	O	O
2.9	O	O
(	O	O
3.9	O	O
)	O	O
in	O	O
the	O	O
group	O	O
assigned	O	O
to	O	O
treatment	O	O
as	O	O
usual	O	O
,	O	O
representing	O	O
a	O	O
between-group	O	O
effect	O	O
size	O	O
of	O	O
-0.24	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
-0.59	O	O
to	O	O
0.11	O	O
)	O	O
,	O	O
after	O	O
adjustment	O	O
for	O	O
centre	O	O
,	O	O
sex	O	O
,	O	O
socioeconomic	O	O
status	O	O
,	O	O
age	O	O
,	O	O
and	O	O
verbal	O	O
and	O	O
non-verbal	O	O
abilities	O	O
.	O	O

Treatment	O	O
effect	O	O
was	O	O
positive	O	O
for	O	O
parental	O	O
synchronous	O	O
response	O	O
to	O	O
child	O	O
(	O	O
1.22	O	O
,	O	O
0.85	O	O
to	O	O
1.59	O	O
)	O	O
,	O	O
child	O	O
initiations	O	O
with	O	O
parent	O	O
(	O	O
0.41	O	O
,	O	O
0.08	O	O
to	O	O
0.74	O	O
)	O	O
,	O	O
and	O	O
for	O	O
parent-child	O	O
shared	O	O
attention	O	O
(	O	O
0.33	O	O
,	O	O
-0.02	O	O
to	O	O
0.68	O	O
)	O	O
.	O	O

Effects	O	O
on	O	O
directly	O	O
assessed	O	O
language	O	O
and	O	O
adaptive	O	O
functioning	O	O
in	O	O
school	O	O
were	O	O
small	O	O
.	O	O

INTERPRETATION	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
our	O	O
findings	O	O
,	O	O
we	O	O
can	O	O
not	O	O
recommend	O	O
the	O	O
addition	O	O
of	O	O
the	O	O
PACT	O	O
intervention	O	O
to	O	O
treatment	O	O
as	O	O
usual	O	O
for	O	O
the	O	O
reduction	O	O
of	O	O
autism	O	O
symptoms	O	O
;	O	O
however	O	O
,	O	O
a	O	O
clear	O	O
benefit	O	O
was	O	O
noted	O	O
for	O	O
parent-child	O	O
dyadic	O	O
social	O	O
communication	O	O
.	O	O

FUNDING	O	O
UK	O	O
Medical	O	O
Research	O	O
Council	O	O
,	O	O
and	O	O
UK	O	O
Department	O	O
for	O	O
Children	O	O
,	O	O
Schools	O	O
and	O	O
Families	O	O
.	O	O

Olanzapine	O	O
versus	O	O
haloperidol	O	O
in	O	O
children	Age	O
with	O	O
autistic	Condition	Condition
disorder	Condition	Condition
:	O	O
an	O	O
open	O	O
pilot	O	O
study	O	O
.	O	O

OBJECTIVES	O	O
Conventional	O	O
neuroleptics	O	O
ameliorate	O	O
symptoms	O	O
in	O	O
children	Age	O
with	O	O
autistic	Condition	Condition
disorder	Condition	Condition
;	O	O
however	O	O
,	O	O
they	O	O
are	O	O
known	O	O
to	O	O
cause	O	O
dyskinesias	O	O
.	O	O

Atypical	O	O
neuroleptics	O	O
,	O	O
including	O	O
olanzapine	O	O
,	O	O
may	O	O
have	O	O
less	O	O
risk	O	O
for	O	O
dyskinesia	O	O
,	O	O
but	O	O
their	O	O
efficacy	O	O
in	O	O
autistic	O	O
disorder	O	O
is	O	O
not	O	O
established	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
safety	O	O
and	O	O
effectiveness	O	O
of	O	O
open-label	O	O
olanzapine	O	O
as	O	O
a	O	O
treatment	O	O
for	O	O
children	Age	O
with	O	O
autistic	Condition	O
disorder	Condition	O
by	O	O
using	O	O
haloperidol	O	O
as	O	O
a	O	O
standard	O	O
comparator	O	O
treatment	O	O
.	O	O

METHOD	O	O
In	O	O
a	O	O
parallel	O	O
groups	O	O
design	O	O
,	O	O
12	SampleSize	SampleSize
children	Age	Age
with	O	O
DSM-IV	Condition	O
autistic	Condition	O
disorder	Condition	O
(	O	O
mean	O	O
age	O	O
7.8+/-2.1	Age	O
years	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
6	O	O
weeks	O	O
of	O	O
open	O	O
treatment	O	O
with	O	O
olanzapine	O	O
or	O	O
haloperidol	O	O
.	O	O

Mean	O	O
final	O	O
dosages	O	O
were	O	O
7.9+/-2.5	O	O
mg/day	O	O
for	O	O
olanzapine	O	O
and	O	O
1.4+/-0.7	O	O
mg/day	O	O
for	O	O
haloperidol	O	O
.	O	O

Outcome	O	O
measures	O	O
included	O	O
the	O	O
Clinical	O	O
Global	O	O
Impressions	O	O
(	O	O
CGI	O	O
)	O	O
and	O	O
the	O	O
Children	O	O
's	O	O
Psychiatric	O	O
Rating	O	O
Scale	O	O
(	O	O
CPRS	O	O
)	O	O
.	O	O

RESULTS	O	O
Both	O	O
groups	O	O
had	O	O
symptom	O	O
reduction	O	O
.	O	O

Five	O	O
of	O	O
six	O	O
in	O	O
the	O	O
olanzapine	O	O
group	O	O
and	O	O
three	O	O
of	O	O
six	O	O
in	O	O
the	O	O
haloperidol	O	O
group	O	O
were	O	O
rated	O	O
as	O	O
responders	O	O
according	O	O
to	O	O
the	O	O
CGI	O	O
Improvement	O	O
item	O	O
.	O	O

Subjects	O	O
showed	O	O
improvement	O	O
on	O	O
the	O	O
CPRS	O	O
Autism	O	O
Factor	O	O
(	O	O
F1,9	O	O
=	O	O
24.4	O	O
,	O	O
p	O	O
=	O	O
.0008	O	O
)	O	O
.	O	O

Side	O	O
effects	O	O
included	O	O
drowsiness	O	O
and	O	O
weight	O	O
gain	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
findings	O	O
suggest	O	O
that	O	O
olanzapine	O	O
is	O	O
a	O	O
promising	O	O
treatment	O	O
for	O	O
children	Age	O
with	O	O
autistic	Condition	Condition
disorder	Condition	Condition
.	O	O

Further	O	O
placebo-controlled	O	O
and	O	O
long-term	O	O
studies	O	O
of	O	O
olanzapine	O	O
in	O	O
autistic	O	O
disorder	O	O
are	O	O
required	O	O
.	O	O

Mechanisms	O	O
underlying	O	O
the	O	O
lack	O	O
of	O	O
effect	O	O
of	O	O
implantable	O	O
cardioverter-defibrillator	O	O
therapy	O	O
on	O	O
mortality	O	O
in	O	O
high-risk	O	O
patients	O	O
with	O	O
recent	O	O
myocardial	Condition	O
infarction	Condition	O
:	O	O
insights	O	O
from	O	O
the	O	O
Defibrillation	O	O
in	O	O
Acute	O	O
Myocardial	O	O
Infarction	O	O
Trial	O	O
(	O	O
DINAMIT	O	O
)	O	O
.	O	O

BACKGROUND	O	O
although	O	O
implantable	O	O
cardioverter-defibrillators	O	O
(	O	O
ICDs	O	O
)	O	O
lower	O	O
mortality	O	O
in	O	O
stable	O	O
patients	O	O
with	O	O
low	Condition	Condition
ejection	Condition	Condition
fraction	Condition	Condition
late	O	Condition
after	O	Condition
myocardial	O	Condition
infarction	O	Condition
,	O	O
randomized	O	O
trials	O	O
of	O	O
ICD	O	O
versus	O	O
control	O	O
subjects	O	O
implanted	O	O
early	O	O
after	O	O
myocardial	O	Condition
infarction	O	Condition
do	O	O
not	O	O
show	O	O
mortality	O	O
benefit	O	O
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
investigate	O	O
possible	O	O
mechanisms	O	O
underlying	O	O
the	O	O
lack	O	O
of	O	O
mortality	O	O
benefit	O	O
in	O	O
the	O	O
Defibrillation	O	O
in	O	O
Acute	O	O
Myocardial	O	O
Infarction	O	O
Trial	O	O
(	O	O
DINAMIT	O	O
)	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
this	O	O
is	O	O
a	O	O
secondary	O	O
analysis	O	O
of	O	O
the	O	O
prospective	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

Outpatients	O	O
with	O	O
recent	O	O
(	O	O
6	O	O
to	O	O
40	O	O
days	O	O
)	O	O
acute	Condition	O
myocardial	Condition	O
infarction	Condition	O
,	O	O
left	Condition	O
ventricular	Condition	O
dysfunction	Condition	O
(	Condition	O
ejection	Condition	O
fraction	Condition	O
<	Condition	O
35	Condition	O
%	Condition	O
)	O	O
,	O	O
and	O	O
low	Condition	O
heart	Condition	O
rate	Condition	O
variability	Condition	O
were	O	O
randomized	O	O
to	O	O
ICD	O	O
(	O	O
n=311	O	O
)	O	O
or	O	O
to	O	O
standard	O	O
medical	O	O
therapy	O	O
(	O	O
n=342	O	O
)	O	O
.	O	O

In	O	O
a	O	O
competing-risks	O	O
analysis	O	O
,	O	O
those	O	O
factors	O	O
that	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
arrhythmic	O	O
death	O	O
also	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
nonarrhythmic	O	O
deaths	O	O
.	O	O

After	O	O
adjustment	O	O
for	O	O
these	O	O
factors	O	O
,	O	O
receiving	O	O
an	O	O
ICD	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
decreased	O	O
risk	O	O
of	O	O
arrhythmic	O	O
death	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
0.33	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0.15	O	O
to	O	O
0.71	O	O
)	O	O
but	O	O
an	O	O
increase	O	O
in	O	O
nonarrhythmic	O	O
death	O	O
(	O	O
hazard	O	O
ratio	O	O
,	O	O
1.70	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.00	O	O
to	O	O
2.80	O	O
)	O	O
.	O	O

In	O	O
an	O	O
adjusted	O	O
time-dependent	O	O
analysis	O	O
,	O	O
patients	O	O
receiving	O	Condition
an	O	Condition
ICD	O	Condition
and	O	Condition
having	O	Condition
appropriate	O	Condition
ICD	O	Condition
therapy	O	Condition
had	O	O
a	O	O
15.1	O	O
%	O	O
yearly	O	O
hazard	O	O
of	O	O
mortality	O	O
compared	O	O
with	O	O
5.2	O	O
%	O	O
in	O	O
ICD	Condition	O
patients	O	O
with	O	O
no	O	O
appropriate	O	O
therapy	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
sudden	O	O
death	O	O
in	O	O
ICD	Condition	O
patients	O	O
was	O	O
completely	O	O
offset	O	O
by	O	O
increased	O	O
nonarrhythmic	O	O
deaths	O	O
,	O	O
which	O	O
were	O	O
greatest	O	O
in	O	O
patients	O	Condition
receiving	O	Condition
ICD	O	Condition
shock	O	Condition
therapy	O	Condition
(	O	O
hazard	O	O
ratio	O	O
,	O	O
6.0	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
2.8	O	O
to	O	O
12.7	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
in	O	O
patients	O	O
receiving	O	O
ICDs	Condition	O
early	O	O
after	O	O
myocardial	Condition	O
infarction	Condition	O
,	O	O
those	O	O
factors	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
arrhythmia	O	O
requiring	O	O
ICD	O	O
therapy	O	O
are	O	O
also	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
nonsudden	O	O
death	O	O
,	O	O
negating	O	O
the	O	O
benefit	O	O
of	O	O
ICDs	O	O
in	O	O
this	O	O
setting	O	O
.	O	O

Double-blind	O	O
randomized	O	O
evaluation	O	O
of	O	O
intercostal	O	O
nerve	O	O
blocks	O	O
as	O	O
an	O	O
adjuvant	O	O
to	O	O
subarachnoid	O	O
administered	O	O
morphine	O	O
for	O	O
post-thoracotomy	Condition	O
analgesia	Condition	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Thoracotomy	O	O
is	O	O
associated	O	O
with	O	O
pain	O	O
and	O	O
compromised	O	O
pulmonary	O	O
function	O	O
.	O	O

Intercostal	O	O
nerve	O	O
blocks	O	O
(	O	O
INB	O	O
)	O	O
and	O	O
subarachnoid	O	O
morphine	O	O
(	O	O
SM	O	O
)	O	O
act	O	O
on	O	O
different	O	O
portions	O	O
of	O	O
the	O	O
pain	O	O
pathway	O	O
.	O	O

Each	O	O
is	O	O
effective	O	O
for	O	O
post-thoracotomy	O	O
pain	O	O
relief	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
these	O	O
two	O	O
modalities	O	O
in	O	O
relieving	O	O
post-thoracotomy	O	O
pain	O	O
and	O	O
improving	O	O
postoperative	O	O
pulmonary	O	O
function	O	O
has	O	O
not	O	O
been	O	O
investigated	O	O
.	O	O

METHODS	O	O
In	O	O
a	O	O
double-blind	O	O
study	O	O
,	O	O
20	SampleSize	SampleSize
patients	O	O
undergoing	O	O
lateral	Condition	Condition
thoracotomy	Condition	Condition
for	O	Condition
lung	Condition	Condition
resection	Condition	Condition
were	O	O
randomized	O	O
to	O	O
receive	O	O
0.5	O	O
mg	O	O
SM	O	O
preoperatively	O	O
and	O	O
INB	O	O
with	O	O
bupivacaine	O	O
(	O	O
INB+	O	O
)	O	O
prior	O	O
to	O	O
wound	O	O
closure	O	O
or	O	O
0.5	O	O
mg	O	O
SM	O	O
with	O	O
INB	O	O
using	O	O
saline	O	O
(	O	O
INB-	O	O
)	O	O
.	O	O

Visual	O	O
analog	O	O
scale	O	O
pain	O	O
scores	O	O
at	O	O
rest	O	O
,	O	O
with	O	O
cough	O	O
,	O	O
and	O	O
with	O	O
movement	O	O
of	O	O
the	O	O
ipsilateral	O	O
arm	O	O
,	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
second	O	O
(	O	O
FEV1	O	O
)	O	O
,	O	O
and	O	O
forced	O	O
vital	O	O
capacity	O	O
(	O	O
FVC	O	O
)	O	O
were	O	O
measured	O	O
at	O	O
4	O	O
,	O	O
24	O	O
,	O	O
48	O	O
,	O	O
and	O	O
72	O	O
hours	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

Opioid	O	O
use	O	O
was	O	O
measured	O	O
during	O	O
the	O	O
initial	O	O
24	O	O
hours	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

RESULTS	O	O
At	O	O
4	O	O
hours	O	O
,	O	O
the	O	O
INB+	O	O
group	O	O
demonstrated	O	O
better	O	O
FEV1	O	O
(	O	O
56.6	O	O
%	O	O
vs.	O	O
40.4	O	O
%	O	O
of	O	O
baseline	O	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
FVC	O	O
values	O	O
(	O	O
54.6	O	O
%	O	O
vs.	O	O
39.6	O	O
%	O	O
of	O	O
baseline	O	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
less	O	O
resting	O	O
and	O	O
cough	O	O
pain	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

However	O	O
,	O	O
FEV1	O	O
continued	O	O
to	O	O
decline	O	O
in	O	O
the	O	O
INB+	O	O
group	O	O
at	O	O
24	O	O
hours	O	O
to	O	O
lower	O	O
than	O	O
the	O	O
INB-	O	O
group	O	O
although	O	O
pain	O	O
scores	O	O
were	O	O
similar	O	O
beyond	O	O
4	O	O
hours	O	O
.	O	O

Opioid	O	O
usage	O	O
during	O	O
the	O	O
first	O	O
24	O	O
hours	O	O
was	O	O
similar	O	O
(	O	O
INB-	O	O
,	O	O
16.7	O	O
mg	O	O
vs.	O	O
INB+	O	O
,	O	O
13.2	O	O
mg	O	O
,	O	O
P	O	O
=	O	O
.7	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
postoperative	O	O
INB	O	O
provided	O	O
modest	O	O
improvements	O	O
in	O	O
pain	O	O
and	O	O
pulmonary	O	O
function	O	O
when	O	O
used	O	O
as	O	O
an	O	O
adjuvant	O	O
to	O	O
0.5	O	O
mg	O	O
SM	O	O
for	O	O
post-thoracotomy	O	O
analgesia	O	O
,	O	O
the	O	O
benefits	O	O
were	O	O
transient	O	O
.	O	O

The	O	O
authors	O	O
do	O	O
not	O	O
recommend	O	O
adding	O	O
INB	O	O
for	O	O
patients	O	O
undergoing	O	O
lateral	O	Condition
thoracotomy	O	Condition
who	O	O
receive	O	O
0.5	O	O
mg	O	O
SM	O	O
.	O	O

Efficacy	O	O
of	O	O
physiotherapy	O	O
management	O	O
of	O	O
knee	Condition	O
joint	Condition	O
osteoarthritis	Condition	O
:	O	O
a	O	O
randomised	O	O
,	O	O
double	O	O
blind	O	O
,	O	O
placebo	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
whether	O	O
a	O	O
multimodal	O	O
physiotherapy	O	O
programme	O	O
including	O	O
taping	O	O
,	O	O
exercises	O	O
,	O	O
and	O	O
massage	O	O
is	O	O
effective	O	O
for	O	O
knee	Condition	O
osteoarthritis	Condition	O
,	O	O
and	O	O
if	O	O
benefits	O	O
can	O	O
be	O	O
maintained	O	O
with	O	O
self	O	O
management	O	O
.	O	O

METHODS	O	O
Randomised	O	O
,	O	O
double	O	O
blind	O	O
,	O	O
placebo	O	O
controlled	O	O
trial	O	O
;	O	O
140	SampleSize	O
community	O	O
volunteers	O	O
with	O	O
knee	Condition	O
osteoarthritis	Condition	O
participated	O	O
and	O	O
119	SampleSize	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Physiotherapy	O	O
and	O	O
placebo	O	O
interventions	O	O
were	O	O
applied	O	O
by	O	O
10	O	O
physiotherapists	O	O
in	O	O
private	O	O
practices	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

Physiotherapy	O	O
included	O	O
exercise	O	O
,	O	O
massage	O	O
,	O	O
taping	O	O
,	O	O
and	O	O
mobilisation	O	O
,	O	O
followed	O	O
by	O	O
12	O	O
weeks	O	O
of	O	O
self	O	O
management	O	O
.	O	O

Placebo	O	O
was	O	O
sham	O	O
ultrasound	O	O
and	O	O
light	O	O
application	O	O
of	O	O
a	O	O
non-therapeutic	O	O
gel	O	O
,	O	O
followed	O	O
by	O	O
no	O	O
treatment	O	O
.	O	O

Primary	O	O
outcomes	O	O
were	O	O
pain	O	O
measured	O	O
by	O	O
visual	O	O
analogue	O	O
scale	O	O
and	O	O
patient	O	O
global	O	O
change	O	O
.	O	O

Secondary	O	O
measures	O	O
included	O	O
WOMAC	O	O
,	O	O
knee	O	O
pain	O	O
scale	O	O
,	O	O
SF-36	O	O
,	O	O
assessment	O	O
of	O	O
quality	O	O
of	O	O
life	O	O
index	O	O
,	O	O
quadriceps	O	O
strength	O	O
,	O	O
and	O	O
balance	O	O
test	O	O
.	O	O

RESULTS	O	O
Using	O	O
an	O	O
intention	O	O
to	O	O
treat	O	O
analysis	O	O
,	O	O
physiotherapy	O	O
and	O	O
placebo	O	O
groups	O	O
showed	O	O
similar	O	O
pain	O	O
reductions	O	O
at	O	O
12	O	O
weeks	O	O
:	O	O
-2.2	O	O
cm	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
-2.6	O	O
to	O	O
-1.7	O	O
)	O	O
and	O	O
-2.0	O	O
cm	O	O
(	O	O
-2.5	O	O
to	O	O
-1.5	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

At	O	O
24	O	O
weeks	O	O
,	O	O
pain	O	O
remained	O	O
reduced	O	O
from	O	O
baseline	O	O
in	O	O
both	O	O
groups	O	O
:	O	O
-2.1	O	O
(	O	O
-2.6	O	O
to	O	O
-1.6	O	O
)	O	O
and	O	O
-1.6	O	O
(	O	O
-2.2	O	O
to	O	O
-1.0	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Global	O	O
improvement	O	O
was	O	O
reported	O	O
by	O	O
70	O	O
%	O	O
of	O	O
physiotherapy	O	O
participants	O	O
(	O	O
51/73	O	O
)	O	O
at	O	O
12	O	O
weeks	O	O
and	O	O
by	O	O
59	O	O
%	O	O
(	O	O
43/73	O	O
)	O	O
at	O	O
24	O	O
weeks	O	O
.	O	O

Similarly	O	O
,	O	O
global	O	O
improvement	O	O
was	O	O
reported	O	O
by	O	O
72	O	O
%	O	O
of	O	O
placebo	O	O
participants	O	O
(	O	O
48/67	O	O
)	O	O
at	O	O
12	O	O
weeks	O	O
and	O	O
by	O	O
49	O	O
%	O	O
(	O	O
33/67	O	O
)	O	O
at	O	O
24	O	O
weeks	O	O
(	O	O
all	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
physiotherapy	O	O
programme	O	O
tested	O	O
in	O	O
this	O	O
trial	O	O
was	O	O
no	O	O
more	O	O
effective	O	O
than	O	O
regular	O	O
contact	O	O
with	O	O
a	O	O
therapist	O	O
at	O	O
reducing	O	O
pain	O	O
and	O	O
disability	O	O
.	O	O

Ten-year	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
and	O	O
prognosis	O	O
after	O	O
infarction	O	O
.	O	O

Department	O	O
of	O	O
Veterans	O	O
Affairs	O	O
Cooperative	O	O
Study	O	O
of	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Surgery	O	O
.	O	O

BACKGROUND	O	O
The	O	O
10-year	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
(	O	O
fatal	O	O
and	O	O
nonfatal	O	O
)	O	O
and	O	O
the	O	O
prognosis	O	O
after	O	O
infarction	O	O
were	O	O
evaluated	O	O
in	O	O
686	SampleSize	SampleSize
patients	O	O
with	O	O
stable	Condition	Condition
angina	Condition	Condition
who	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
medical	O	O
or	O	O
surgical	O	O
treatment	O	O
in	O	O
the	O	O
Veterans	O	O
Administration	O	O
Cooperative	O	O
Study	O	O
of	O	O
Coronary	O	O
Artery	O	O
Bypass	O	O
Surgery	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Myocardial	O	O
infarction	O	O
was	O	O
defined	O	O
by	O	O
either	O	O
new	O	O
Q	O	O
wave	O	O
findings	O	O
or	O	O
clinical	O	O
symptoms	O	O
compatible	O	O
with	O	O
myocardial	Condition	O
infarction	Condition	O
accompanied	O	O
by	O	O
serum	O	O
enzyme	O	O
elevations	O	O
with	O	O
or	O	O
without	O	O
electrocardiographic	O	O
findings	O	O
.	O	O

Treatment	O	O
comparisons	O	O
were	O	O
made	O	O
according	O	O
to	O	O
original	O	O
treatment	O	O
assignment	O	O
;	O	O
35	O	O
%	O	O
of	O	O
the	O	O
medical	O	O
cohort	O	O
had	O	O
bypass	O	O
surgery	O	O
during	O	O
the	O	O
10-year	O	O
follow-up	O	O
period	O	O
.	O	O

The	O	O
overall	O	O
cumulative	O	O
infarction	O	O
rate	O	O
was	O	O
somewhat	O	O
higher	O	O
in	O	O
patients	O	O
assigned	O	O
to	O	O
surgery	O	O
(	O	O
36	O	O
%	O	O
)	O	O
than	O	O
in	O	O
medical	O	O
patients	O	O
(	O	O
31	O	O
%	O	O
)	O	O
(	O	O
p	O	O
=	O	O
0.13	O	O
)	O	O
due	O	O
to	O	O
perioperative	O	O
infarctions	O	O
(	O	O
13	O	O
%	O	O
)	O	O
and	O	O
an	O	O
accelerated	O	O
infarction	O	O
rate	O	O
after	O	O
the	O	O
fifth	O	O
year	O	O
of	O	O
follow-up	O	O
(	O	O
average	O	O
,	O	O
2.4	O	O
%	O	O
/yr	O	O
in	O	O
the	O	O
surgical	O	O
group	O	O
versus	O	O
1.4	O	O
%	O	O
/yr	O	O
in	O	O
the	O	O
medical	O	O
group	O	O
)	O	O
.	O	O

The	O	O
10-year	O	O
cumulative	O	O
incidence	O	O
of	O	O
death	O	O
or	O	O
myocardial	O	O
infarction	O	O
was	O	O
also	O	O
higher	O	O
in	O	O
surgical	O	O
(	O	O
54	O	O
%	O	O
)	O	O
than	O	O
in	O	O
medical	O	O
(	O	O
49	O	O
%	O	O
)	O	O
patients	O	O
(	O	O
p	O	O
=	O	O
0.20	O	O
)	O	O
.	O	O

According	O	O
to	O	O
the	O	O
Cox	O	O
model	O	O
,	O	O
the	O	O
estimated	O	O
risk	O	O
of	O	O
death	O	O
after	O	O
infarction	O	O
was	O	O
59	O	O
%	O	O
lower	O	O
in	O	O
surgical	O	O
than	O	O
in	O	O
medical	O	O
patients	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
postinfarction	O	O
mortality	O	O
with	O	O
surgery	O	O
was	O	O
most	O	O
striking	O	O
in	O	O
the	O	O
first	O	O
month	O	O
after	O	O
the	O	O
event	O	O
:	O	O
99	O	O
%	O	O
in	O	O
the	O	O
first	O	O
month	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
and	O	O
49	O	O
%	O	O
subsequently	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
estimated	O	O
risk	O	O
of	O	O
death	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
infarction	O	O
was	O	O
nearly	O	O
identical	O	O
regardless	O	O
of	O	O
treatment	O	O
(	O	O
p	O	O
=	O	O
0.75	O	O
)	O	O
.	O	O

Exclusion	O	O
of	O	O
perioperative	O	O
infarctions	O	O
did	O	O
not	O	O
alter	O	O
the	O	O
findings	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
surgery	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
myocardial	O	O
infarction	O	O
overall	O	O
,	O	O
it	O	O
does	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
mortality	O	O
after	O	O
infarction	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
first	O	O
30	O	O
days	O	O
after	O	O
the	O	O
event	O	O
(	O	O
fatal	O	O
infarctions	O	O
)	O	O
.	O	O

Enhancing	O	O
attitudes	O	O
and	O	O
intentions	O	O
in	O	O
prospective	Condition	O
blood	Condition	O
donors	Condition	O
:	O	O
evaluation	O	O
of	O	O
a	O	O
new	O	O
donor	O	O
recruitment	O	O
brochure	O	O
.	O	O

BACKGROUND	O	O
Although	O	O
little	O	O
empiric	O	O
evidence	O	O
has	O	O
been	O	O
published	O	O
concerning	O	O
the	O	O
efficacy	O	O
of	O	O
blood	O	O
donor	O	O
recruitment	O	O
materials	O	O
,	O	O
research	O	O
suggests	O	O
that	O	O
simple	O	O
attempts	O	O
to	O	O
enhance	O	O
knowledge	O	O
may	O	O
not	O	O
be	O	O
sufficient	O	O
to	O	O
motivate	O	O
donation	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
recent	O	O
donor	O	O
motivation	O	O
studies	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
anxiety	O	O
,	O	O
attitudes	O	O
,	O	O
and	O	O
perceived	O	O
ability	O	O
to	O	O
cope	O	O
with	O	O
donation	O	O
(	O	O
i.e.	O	O
,	O	O
self-efficacy	O	O
)	O	O
as	O	O
crucial	O	O
determinants	O	O
of	O	O
donation	O	O
intention	O	O
.	O	O

Therefore	O	O
,	O	O
recruitment	O	O
materials	O	O
that	O	O
specifically	O	O
address	O	O
these	O	O
constructs	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
outperform	O	O
traditional	O	O
educational	O	O
brochures	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
Participants	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
read	O	O
one	O	O
of	O	O
three	O	O
brochures	O	O
:	O	O
1	O	O
)	O	O
a	O	O
new	O	O
brochure	O	O
addressing	O	O
common	O	O
donor	O	O
concerns	O	O
and	O	O
suggesting	O	O
specific	O	O
coping	O	O
strategies	O	O
,	O	O
2	O	O
)	O	O
a	O	O
standard	O	O
blood	O	O
center	O	O
brochure	O	O
,	O	O
or	O	O
3	O	O
)	O	O
a	O	O
control	O	O
brochure	O	O
on	O	O
healthy	O	O
eating	O	O
and	O	O
exercise	O	O
.	O	O

Standardized	O	O
questionnaires	O	O
were	O	O
completed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
brochures	O	O
to	O	O
assess	O	O
change	O	O
in	O	O
blood	O	O
donation	O	O
anxiety	O	O
,	O	O
attitude	O	O
,	O	O
self-efficacy	O	O
,	O	O
and	O	O
intention	O	O
.	O	O

RESULTS	O	O
Although	O	O
no	O	O
significant	O	O
changes	O	O
were	O	O
noted	O	O
for	O	O
the	O	O
control	O	O
brochure	O	O
,	O	O
after	O	O
reading	O	O
the	O	O
new	O	O
brochure	O	O
participants	O	O
reported	O	O
significant	O	O
improvements	O	O
in	O	O
attitude	O	O
,	O	O
anxiety	O	O
,	O	O
self-efficacy	O	O
,	O	O
and	O	O
donation	O	O
intention	O	O
.	O	O

The	O	O
standard	O	O
donation	O	O
brochure	O	O
had	O	O
an	O	O
intermediate	O	O
effect	O	O
.	O	O

CONCLUSION	O	O
Efforts	O	O
to	O	O
address	O	O
common	O	O
donor	O	O
fears	O	O
and	O	O
to	O	O
provide	O	O
useful	O	O
coping	O	O
suggestions	O	O
may	O	O
improve	O	O
the	O	O
effectiveness	O	O
of	O	O
blood	O	O
donation	O	O
recruitment	O	O
materials	O	O
.	O	O

Psychoeducational	O	O
group	O	O
intervention	O	O
for	O	O
wives	Sex	O
of	O	O
men	Sex	O
with	O	O
prostate	Condition	O
cancer	Condition	O
.	O	O

OBJECTIVE	O	O
The	O	O
effects	O	O
of	O	O
a	O	O
6-week	O	O
psychoeducational	O	O
group	O	O
intervention	O	O
on	O	O
the	O	O
distress	O	O
,	O	O
coping	O	O
,	O	O
personal	O	O
growth	O	O
,	O	O
and	O	O
marital	O	O
communication	O	O
of	O	O
wives	Sex	O
of	O	O
men	Sex	O
diagnosed	O	O
with	O	O
prostate	Condition	Condition
cancer	Condition	Condition
were	O	O
evaluated	O	O
using	O	O
a	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

METHODS	O	O
Sixty	SampleSize	O
wives	Sex	O
completed	O	O
measures	O	O
prior	O	O
to	O	O
random	O	O
assignment	O	O
to	O	O
either	O	O
the	O	O
psychoeducational	O	O
group	O	O
intervention	O	O
or	O	O
a	O	O
no-treatment	O	O
control	O	O
group	O	O
,	O	O
and	O	O
1	O	O
month	O	O
after	O	O
completion	O	O
of	O	O
the	O	O
group	O	O
.	O	O

RESULTS	O	O
No	O	O
differences	O	O
with	O	O
regard	O	O
to	O	O
wives	O	O
'	O	O
general	O	O
distress	O	O
or	O	O
cancer-specific	O	O
distress	O	O
were	O	O
noted	O	O
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
participants	O	O
receiving	O	O
the	O	O
intervention	O	O
perceived	O	O
that	O	O
having	O	O
a	O	O
spouse	O	O
with	O	O
prostate	O	Condition
cancer	O	Condition
had	O	Condition
made	O	Condition
positive	O	Condition
contributions	O	Condition
to	O	O
their	O	O
lives	O	O
,	O	O
reported	O	O
gains	O	O
in	O	O
the	O	O
use	O	O
of	O	O
positive	O	O
reappraisal	O	O
coping	O	O
and	O	O
reductions	O	O
in	O	O
denial	O	O
coping	O	O
.	O	O

CONCLUSION	O	O
Although	O	O
the	O	O
psychoeducational	O	O
intervention	O	O
did	O	O
not	O	O
result	O	O
in	O	O
changes	O	O
in	O	O
psychological	O	O
distress	O	O
,	O	O
improvements	O	O
in	O	O
adaptive	O	O
coping	O	O
and	O	O
indicators	O	O
of	O	O
psychological	O	O
growth	O	O
were	O	O
found	O	O
.	O	O

The	O	O
utility	O	O
of	O	O
group	O	O
interventions	O	O
for	O	O
spouses	Sex	O
of	O	O
men	Sex	O
with	O	O
prostate	Condition	O
cancer	Condition	O
is	O	O
discussed	O	O
.	O	O

QT/QTc	O	O
study	O	O
conducted	O	O
in	O	O
Japanese	O	O
adult	Age	O
healthy	Condition	O
subjects	O	O
:	O	O
a	O	O
novel	O	O
xanthine	O	O
oxidase	O	O
inhibitor	O	O
topiroxostat	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
QT	O	O
prolongation	O	O
.	O	O

A	O	O
QT/QTc	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
compliance	O	O
with	O	O
ICH	O	O
E14	O	O
guideline	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
xanthine	O	O
oxidase	O	O
inhibitor	O	O
topiroxostat	O	O
in	O	O
Japanese	O	O
healthy	Condition	O
subjects	Condition	O
.	O	O

Forty-eight	SampleSize	SampleSize
Japanese	O	Condition
healthy	Condition	Condition
subjects	Condition	O
(	O	O
males	Sex	O
24	SampleSize	O
;	O	O
females	Sex	O
24	SampleSize	O
)	O	O
received	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
topiroxostat	O	O
(	O	O
60	O	O
or	O	O
180	O	O
mg	O	O
)	O	O
,	O	O
moxifloxacin	O	O
(	O	O
400	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
in	O	O
a	O	O
single-center	O	O
,	O	O
double-blind	O	O
,	O	O
four-period	O	O
crossover	O	O
design	O	O
.	O	O

Fridericia	O	O
's	O	O
formula	O	O
(	O	O
QTcF	O	O
=	O	O
QT/RR	O	O
(	O	O
0.33	O	O
)	O	O
)	O	O
was	O	O
used	O	O
as	O	O
a	O	O
primary	O	O
method	O	O
for	O	O
QT-interval	O	O
correction	O	O
.	O	O

The	O	O
mean	O	O
QTcF	O	O
was	O	O
prolonged	O	O
by	O	O
moxifloxacin	O	O
,	O	O
of	O	O
which	O	O
largest	O	O
time-matched	O	O
difference	O	O
from	O	O
placebo	O	O
administration	O	O
was	O	O
13.6	O	O
milliseconds	O	O
with	O	O
90	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
of	O	O
11.2	O	O
and	O	O
15.9	O	O
milliseconds	O	O
at	O	O
4	O	O
hours	O	O
post-dose	O	O
.	O	O

The	O	O
mean	O	O
QTcF	O	O
was	O	O
hardly	O	O
affected	O	O
by	O	O
either	O	O
dose	O	O
of	O	O
topiroxostat	O	O
,	O	O
of	O	O
which	O	O
largest	O	O
time-matched	O	O
difference	O	O
from	O	O
placebo	O	O
administration	O	O
was	O	O
2.9	O	O
milliseconds	O	O
with	O	O
90	O	O
%	O	O
CI	O	O
of	O	O
0.6	O	O
and	O	O
5.3	O	O
milliseconds	O	O
at	O	O
4	O	O
hours	O	O
post-dose	O	O
for	O	O
60	O	O
mg	O	O
,	O	O
and	O	O
2.3	O	O
milliseconds	O	O
with	O	O
90	O	O
%	O	O
CI	O	O
of	O	O
0	O	O
and	O	O
4.7	O	O
milliseconds	O	O
at	O	O
1	O	O
hour	O	O
post-dose	O	O
for	O	O
180	O	O
mg	O	O
.	O	O

The	O	O
results	O	O
were	O	O
essentially	O	O
the	O	O
same	O	O
in	O	O
the	O	O
sex	O	O
subgroup	O	O
analysis	O	O
.	O	O

Moxifloxacin	O	O
can	O	O
be	O	O
used	O	O
as	O	O
a	O	O
positive	O	O
control	O	O
for	O	O
QT/QTc	O	O
studies	O	O
in	O	O
Japanese	O	O
subjects	O	O
;	O	O
and	O	O
topiroxostat	O	O
may	O	O
not	O	O
cause	O	O
QT-interval	O	O
prolongation	O	O
in	O	O
males	O	O
as	O	O
well	O	O
as	O	O
females	O	O
.	O	O

[	O	O
Usage	O	O
of	O	O
titanoreine	O	O
after	O	O
procedure	Condition	O
for	Condition	O
prolapse	Condition	O
and	Condition	O
hemorrhoids	Condition	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
titanoreine	O	O
on	O	O
early	O	O
postoperative	O	O
symptoms	O	O
after	O	O
procedure	O	O
for	O	O
prolapse	O	O
and	O	O
hemorrhoids	O	O
(	O	O
PPH	O	O
)	O	O
.	O	O

METHODS	O	O
From	O	O
November	O	O
2002	O	O
to	O	O
July	O	O
2003	O	O
,	O	O
80	SampleSize	O
patients	O	O
who	O	O
received	O	O
PPH	O	O
were	O	O
randomly	O	O
divided	O	O
in	O	O
to	O	O
titanoreine	O	O
group	O	O
(	O	O
n=42	O	O
)	O	O
and	O	O
control	O	O
group	O	O
without	O	O
titanoreine	O	O
(	O	O
n=38	O	O
)	O	O
.	O	O

Symptom	O	O
relief	O	O
was	O	O
recorded	O	O
24	O	O
hours	O	O
,	O	O
6	O	O
days	O	O
and	O	O
12	O	O
days	O	O
after	O	O
PPH	O	O
,	O	O
urine	O	O
retention	O	O
24h	O	O
after	O	O
PPH	O	O
,	O	O
first	O	O
stool	O	O
time	O	O
,	O	O
wound	O	O
healing	O	O
time	O	O
,	O	O
mean	O	O
hospital	O	O
stay	O	O
were	O	O
also	O	O
recorded	O	O
.	O	O

RESULTS	O	O
The	O	O
score	O	O
of	O	O
symptom	O	O
was	O	O
lower	O	O
in	O	O
titanoreine	O	O
group	O	O
(	O	O
4.4	O	O
)	O	O
than	O	O
that	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
6.1	O	O
)	O	O
24	O	O
hours	O	O
after	O	O
PPH	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
but	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
symptom	O	O
grade	O	O
was	O	O
found	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
6	O	O
days	O	O
and	O	O
12	O	O
days	O	O
after	O	O
PPH	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

Decrements	O	O
of	O	O
symptom	O	O
grade	O	O
were	O	O
lower	O	O
in	O	O
titanoreine	O	O
group	O	O
than	O	O
those	O	O
of	O	O
control	O	O
group	O	O
at	O	O
any	O	O
point	O	O
after	O	O
PPH	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
urine	O	O
retention	O	O
rate	O	O
and	O	O
mean	O	O
hospital	O	O
stay	O	O
between	O	O
two	O	O
groups	O	O
(	O	O
P	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Titanoreine	O	O
can	O	O
effectively	O	O
relieve	O	O
the	O	O
early	O	O
postoperative	O	O
symptoms	O	O
after	O	O
PPH	O	O
.	O	O

Evaluation	O	O
of	O	O
reducing	O	O
postoperative	O	O
hip	O	O
precautions	O	O
in	O	O
total	Condition	Condition
hip	Condition	Condition
replacement	Condition	Condition
:	O	O
a	O	O
randomized	O	O
prospective	O	O
study	O	O
.	O	O

Currently	O	O
,	O	O
many	O	O
rehabilitation	O	O
protocols	O	O
for	O	O
total	O	O
hip	O	O
replacements	O	O
(	O	O
THRs	O	O
)	O	O
include	O	O
activity	O	O
restrictions	O	O
to	O	O
prevent	O	O
postoperative	O	O
dislocation	O	O
.	O	O

There	O	O
is	O	O
increasing	O	O
demand	O	O
for	O	O
more	O	O
efficient	O	O
and	O	O
safe	O	O
rehabilitation	O	O
protocols	O	O
.	O	O

This	O	O
randomized	O	O
prospective	O	O
study	O	O
evaluates	O	O
the	O	O
need	O	O
for	O	O
hip	O	O
restrictions	O	O
following	O	O
a	O	O
modified	O	O
anterolateral	O	O
procedure	O	O
.	O	O

From	O	O
2004	O	O
to	O	O
2008	O	O
,	O	O
81	SampleSize	SampleSize
patients	O	O
seeking	O	O
elective	O	Condition
THRs	O	Condition
were	O	O
randomly	O	O
assigned	O	O
into	O	O
a	O	O
standard	O	O
rehabilitation	O	O
group	O	O
or	O	O
an	O	O
early	O	O
rehabilitation	O	O
group	O	O
.	O	O

The	O	O
standard	O	O
group	O	O
included	O	O
restrictions	O	O
to	O	O
avoid	O	O
hip	O	O
flexion	O	O
>	O	O
90	O	O
degrees	O	O
and	O	O
avoidance	O	O
of	O	O
riding	O	O
in	O	O
a	O	O
car	O	O
for	O	O
the	O	O
first	O	O
postoperative	O	O
month	O	O
.	O	O

The	O	O
early	O	O
group	O	O
had	O	O
no	O	O
flexion	O	O
or	O	O
car	O	O
riding	O	O
restrictions	O	O
.	O	O

Forty-three	SampleSize	SampleSize
patients	O	O
were	O	O
in	O	O
the	O	O
standard	O	O
group	O	O
and	O	O
38	SampleSize	O
patients	O	O
were	O	O
in	O	O
the	O	O
early	O	O
group	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
demographic	O	O
differences	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

All	O	O
patients	O	O
completed	O	O
the	O	O
Short	O	O
Form	O	O
12-question	O	O
Health	O	O
Survey	O	O
and	O	O
Harris	O	O
Hip	O	O
Score	O	O
preoperatively	O	O
and	O	O
at	O	O
4	O	O
weeks	O	O
,	O	O
1	O	O
month	O	O
,	O	O
3	O	O
months	O	O
,	O	O
and	O	O
1	O	O
year	O	O
postoperatively	O	O
.	O	O

The	O	O
time-points	O	O
at	O	O
which	O	O
the	O	O
patient	O	O
first	O	O
drove	O	O
and	O	O
ambulated	O	O
with	O	O
a	O	O
cane	O	O
,	O	O
without	O	O
a	O	O
cane	O	O
,	O	O
and	O	O
without	O	O
a	O	O
limp	O	O
were	O	O
also	O	O
collected	O	O
.	O	O

No	O	O
incidents	O	O
of	O	O
dislocation	O	O
occurred	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
early	O	O
group	O	O
were	O	O
faster	O	O
to	O	O
ambulate	O	O
with	O	O
only	O	O
a	O	O
cane	O	O
(	O	O
P=.03	O	O
)	O	O
,	O	O
without	O	O
a	O	O
cane	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
and	O	O
without	O	O
a	O	O
limp	O	O
(	O	O
P=.003	O	O
)	O	O
.	O	O

They	O	O
also	O	O
drove	O	O
earlier	O	O
(	O	O
P=.02	O	O
)	O	O
.	O	O

Pace	O	O
of	O	O
recovery	O	O
was	O	O
the	O	O
only	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

The	O	O
early	O	O
rehabilitation	O	O
protocol	O	O
increases	O	O
the	O	O
pace	O	O
of	O	O
recovery	O	O
compared	O	O
to	O	O
a	O	O
pathway	O	O
with	O	O
hip	O	O
precautions	O	O
without	O	O
increasing	O	O
complications	O	O
.	O	O

Short-	O	O
and	O	O
long-term	O	O
effects	O	O
of	O	O
tactile	O	O
massage	O	O
on	O	O
salivary	O	O
cortisol	O	O
concentrations	O	O
in	O	O
Parkinson	Condition	O
's	Condition	O
disease	Condition	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
pilot	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Parkinson	O	O
's	O	O
disease	O	O
(	O	O
PD	O	O
)	O	O
is	O	O
a	O	O
chronic	O	O
neurodegenerative	O	O
disorder	O	O
with	O	O
limited	O	O
knowledge	O	O
about	O	O
the	O	O
normal	O	O
function	O	O
and	O	O
effects	O	O
of	O	O
non-pharmacological	O	O
therapies	O	O
on	O	O
the	O	O
hypothalamic-pituitary-adrenal	O	O
(	O	O
HPA	O	O
)	O	O
axis	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
analyse	O	O
the	O	O
basal	O	O
diurnal	O	O
and	O	O
total	O	O
secretion	O	O
of	O	O
salivary	O	O
cortisol	O	O
in	O	O
short-	O	O
and	O	O
long-term	O	O
aspects	O	O
of	O	O
tactile	O	O
massage	O	O
(	O	O
TM	O	O
)	O	O
.	O	O

METHODS	O	O
DESIGN	O	O
Prospective	O	O
,	O	O
Controlled	O	O
and	O	O
Randomised	O	O
Multicentre	O	O
Trial	O	O
.	O	O

SETTING	O	O
AND	O	O
INTERVENTIONS	O	O
Forty-five	SampleSize	O
women	Sex	O
and	Sex	O
men	Sex	O
,	O	O
aged	O	O
50-79	Age	Age
years	O	Age
,	O	O
were	O	O
recruited	O	O
.	O	O

Twenty-nine	SampleSize	O
of	O	O
them	O	O
were	O	O
blindly	O	O
randomised	O	O
to	O	O
tactile	O	O
massage	O	O
(	O	O
TM	O	O
)	O	O
and	O	O
16	SampleSize	O
of	O	O
them	O	O
to	O	O
the	O	O
control	O	O
group	O	O
,	O	O
rest	O	O
to	O	O
music	O	O
(	O	O
RTM	O	O
)	O	O
.	O	O

Ten	O	O
interventions	O	O
were	O	O
given	O	O
during	O	O
8	O	O
weeks	O	O
followed	O	O
by	O	O
a	O	O
26	O	O
weeks	O	O
of	O	O
follow	O	O
up	O	O
.	O	O

Salivary	O	O
cortisol	O	O
was	O	O
collected	O	O
at	O	O
8	O	O
am	O	O
,	O	O
1	O	O
pm	O	O
,	O	O
8	O	O
pm	O	O
,	O	O
and	O	O
8	O	O
am	O	O
the	O	O
next	O	O
day	O	O
,	O	O
on	O	O
five	O	O
occasions	O	O
.	O	O

With	O	O
the	O	O
first	O	O
and	O	O
eighth	O	O
interventions	O	O
,	O	O
it	O	O
was	O	O
collected	O	O
immediately	O	O
before	O	O
and	O	O
after	O	O
intervention	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
The	O	O
primary	O	O
aim	O	O
was	O	O
to	O	O
assess	O	O
and	O	O
compare	O	O
cortisol	O	O
concentrations	O	O
before	O	O
and	O	O
immediately	O	O
after	O	O
intervention	O	O
and	O	O
also	O	O
during	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

The	O	O
secondary	O	O
aim	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
impact	O	O
of	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
body	O	O
mass	O	O
index	O	O
(	O	O
BMI	O	O
)	O	O
,	O	O
duration	O	O
and	O	O
severity	O	O
of	O	O
PD	O	O
,	O	O
effects	O	O
of	O	O
interventional	O	O
time-point	O	O
of	O	O
the	O	O
day	O	O
,	O	O
and	O	O
levodopa	O	O
doses	O	O
on	O	O
cortisol	O	O
concentration	O	O
.	O	O

RESULTS	O	O
The	O	O
median	O	O
cortisol	O	O
concentrations	O	O
for	O	O
all	O	O
participants	O	O
were	O	O
16.0	O	O
,	O	O
5.8	O	O
,	O	O
2.8	O	O
,	O	O
and	O	O
14.0	O	O
nmol/L	O	O
at	O	O
baseline	O	O
,	O	O
later	O	O
reproduced	O	O
four	O	O
times	O	O
without	O	O
significant	O	O
differences	O	O
.	O	O

Cortisol	O	O
concentrations	O	O
decreased	O	O
significantly	O	O
after	O	O
TM	O	O
intervention	O	O
but	O	O
no	O	O
change	O	O
in	O	O
diurnal	O	O
salivary	O	O
cortisol	O	O
pattern	O	O
was	O	O
found	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
reduced	O	O
salivary	O	O
cortisol	O	O
concentrations	O	O
immediately	O	O
after	O	O
the	O	O
interventions	O	O
are	O	O
in	O	O
agreement	O	O
with	O	O
previous	O	O
studies	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
TM	O	O
and	O	O
control	O	O
groups	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
correlations	O	O
between	O	O
cortisol	O	O
concentrations	O	O
and	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
BMI	O	O
,	O	O
time-point	O	O
for	O	O
intervention	O	O
,	O	O
time	O	O
interval	O	O
between	O	O
anti-parkinson	O	O
pharmacy	O	O
intake	O	O
and	O	O
sampling	O	O
,	O	O
levodopa	O	O
doses	O	O
,	O	O
duration	O	O
,	O	O
or	O	O
severity	O	O
of	O	O
PD	O	O
.	O	O

CONCLUSIONS	O	O
Diurnal	O	O
salivary	O	O
cortisol	O	O
rhythm	O	O
was	O	O
normal	O	O
.	O	O

Salivary	O	O
cortisol	O	O
concentrations	O	O
were	O	O
significantly	O	O
reduced	O	O
after	O	O
the	O	O
TM	O	O
intervention	O	O
and	O	O
after	O	O
RTM	O	O
,	O	O
but	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
and	O	O
no	O	O
sustained	O	O
long-term	O	O
effect	O	O
.	O	O

No	O	O
associations	O	O
were	O	O
seen	O	O
between	O	O
salivary	O	O
cortisol	O	O
concentration	O	O
and	O	O
clinical	O	O
and/or	O	O
pharmacological	O	O
characteristics	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrial.gov	O	O
,	O	O
NCT01734876	O	O
and	O	O
FoU	O	O
Sweden	O	O
108881	O	O
.	O	O

Efficacy	O	O
of	O	O
amantadine	O	O
on	O	O
quality	O	O
of	O	O
life	O	O
in	O	O
patients	O	O
with	O	O
chronic	Condition	O
hepatitis	Condition	O
C	Condition	O
treated	O	O
with	O	O
interferon-alpha	O	O
and	O	O
ribavirin	O	O
:	O	O
results	O	O
from	O	O
a	O	O
randomized	O	O
,	O	O
placebo-controlled	O	O
,	O	O
double-blind	O	O
trial	O	O
.	O	O

AIM	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
amantadine	O	O
reduces	O	O
deterioration	O	O
of	O	O
quality	O	O
of	O	O
life	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
C	O	O
during	O	O
and	O	O
after	O	O
treatment	O	O
with	O	O
interferon-alpha	O	O
(	O	O
IFN-alpha	O	O
)	O	O
and	O	O
ribavirin	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
In	O	O
this	O	O
randomized	O	O
,	O	O
prospective	O	O
,	O	O
placebo-controlled	O	O
,	O	O
multicenter	O	O
trial	O	O
,	O	O
previously	O	O
untreated	O	O
patients	O	O
with	O	O
chronic	Condition	O
hepatitis	Condition	O
C	Condition	O
were	O	O
treated	O	O
with	O	O
IFN-alpha	O	O
plus	O	O
ribavirin	O	O
[	O	O
17	O	O
]	O	O
and	O	O
randomized	O	O
for	O	O
treatment	O	O
with	O	O
amantadine	O	O
(	O	O
200	O	O
mg/day	O	O
,	O	O
orally	O	O
,	O	O
n=136	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
n=131	O	O
)	O	O
.	O	O

Quality	O	O
of	O	O
life	O	O
was	O	O
assessed	O	O
with	O	O
the	O	O
'Profile	O	O
of	O	O
Mood	O	O
States	O	O
'	O	O
scale	O	O
and	O	O
the	O	O
'Everyday	O	O
Life	O	O
'	O	O
questionnaire	O	O
at	O	O
baseline	O	O
,	O	O
treatment	O	O
week	O	O
(	O	O
TW	O	O
)	O	O
8	O	O
,	O	O
TW24	O	O
,	O	O
TW48	O	O
,	O	O
and	O	O
at	O	O
follow-up	O	O
.	O	O

RESULTS	O	O
Early	O	O
during	O	O
treatment	O	O
at	O	O
TW8	O	O
,	O	O
quality	O	O
of	O	O
life	O	O
was	O	O
not	O	O
different	O	O
between	O	O
patients	O	O
in	O	O
the	O	O
control	O	O
and	O	O
the	O	O
amantadine	O	O
group	O	O
.	O	O

At	O	O
TW24	O	O
,	O	O
the	O	O
control	O	O
group	O	O
but	O	O
not	O	O
the	O	O
amantadine	O	O
group	O	O
,	O	O
however	O	O
,	O	O
showed	O	O
significant	O	O
deterioration	O	O
of	O	O
the	O	O
modalities	O	O
depression	O	O
,	O	O
fatigue	O	O
,	O	O
and	O	O
vigor	O	O
compared	O	O
with	O	O
baseline	O	O
.	O	O

Especially	O	O
,	O	O
nonresponders	O	O
in	O	O
the	O	O
amantadine	O	O
group	O	O
showed	O	O
significantly	O	O
lower	O	O
deterioration	O	O
of	O	O
depression	O	O
,	O	O
anger	O	O
,	O	O
mind	O	O
function	O	O
,	O	O
everyday	O	O
life	O	O
,	O	O
and	O	O
zest	O	O
for	O	O
life	O	O
than	O	O
those	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

After	O	O
treatment	O	O
,	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
amantadine	O	O
disappeared	O	O
.	O	O

CONCLUSION	O	O
The	O	O
addition	O	O
of	O	O
amantadine	O	O
to	O	O
IFN-alpha	O	O
plus	O	O
ribavirin	O	O
combination	O	O
therapy	O	O
may	O	O
reduce	O	O
deterioration	O	O
of	O	O
depression	O	O
,	O	O
fatigue	O	O
,	O	O
and	O	O
vigor	O	O
during	O	O
treatment	O	O
but	O	O
does	O	O
not	O	O
affect	O	O
quality	O	O
of	O	O
life	O	O
after	O	O
treatment	O	O
.	O	O

Short-term	O	O
studies	O	O
on	O	O
the	O	O
use	O	O
of	O	O
glycerol	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
continuous	Condition	O
ambulatory	Condition	O
peritoneal	Condition	O
dialysis	Condition	O
(	O	O
CAPD	Condition	O
)	O	O
.	O	O

The	O	O
use	O	O
of	O	O
glycerol	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
two	O	O
different	O	O
concentrations	O	O
(	O	O
92	O	O
mmol/l	O	O
and	O	O
272	O	O
mmol/l	O	O
)	O	O
in	O	O
peritoneal	O	O
dialysis	O	O
fluid	O	O
was	O	O
investigated	O	O
over	O	O
3	O	O
days	O	O
in	O	O
six	SampleSize	O
patients	O	O
on	O	O
continuous	Condition	O
ambulatory	Condition	O
peritoneal	Condition	O
dialysis	Condition	O
and	O	O
compared	O	O
with	O	O
two	O	O
concentrations	O	O
of	O	O
glucose	O	O
(	O	O
76	O	O
mmol/l	O	O
and	O	O
215	O	O
mmol/l	O	O
)	O	O
in	O	O
the	O	O
same	O	O
patients	O	O
.	O	O

The	O	O
calorific	O	O
value	O	O
of	O	O
the	O	O
absorbed	O	O
osmotic	O	O
agent	O	O
was	O	O
lower	O	O
,	O	O
by	O	O
19	O	O
%	O	O
with	O	O
isotonic	O	O
and	O	O
22	O	O
%	O	O
with	O	O
hypertonic	O	O
solutions	O	O
,	O	O
when	O	O
glycerol	O	O
was	O	O
used	O	O
in	O	O
place	O	O
of	O	O
glucose	O	O
.	O	O

However	O	O
,	O	O
glycerol	O	O
provided	O	O
significantly	O	O
lower	O	O
total	O	O
ultrafiltration	O	O
than	O	O
glucose	O	O
at	O	O
each	O	O
concentration	O	O
,	O	O
despite	O	O
a	O	O
higher	O	O
initial	O	O
osmotic	O	O
pressure	O	O
of	O	O
the	O	O
glycerol-based	O	O
solutions	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
higher	O	O
concentration	O	O
of	O	O
glycerol	O	O
required	O	O
to	O	O
provide	O	O
equal	O	O
ultrafiltration	O	O
may	O	O
offset	O	O
any	O	O
calorific	O	O
advantage	O	O
.	O	O

Equilibration	O	O
of	O	O
creatinine	O	O
and	O	O
urea	O	O
was	O	O
slower	O	O
and	O	O
creatinine	O	O
clearance	O	O
lower	O	O
with	O	O
glycerol	O	O
.	O	O

Solutions	O	O
containing	O	O
glycerol	O	O
were	O	O
initially	O	O
less	O	O
acid	O	O
(	O	O
pH	O	O
6.5	O	O
)	O	O
than	O	O
those	O	O
containing	O	O
glucose	O	O
(	O	O
pH	O	O
5.1	O	O
)	O	O
.	O	O

Blood	O	O
glycerol	O	O
levels	O	O
,	O	O
which	O	O
were	O	O
in	O	O
the	O	O
physiological	O	O
range	O	O
with	O	O
glucose	O	O
as	O	O
the	O	O
osmotic	O	O
agent	O	O
,	O	O
reached	O	O
a	O	O
peak	O	O
80-fold	O	O
greater	O	O
at	O	O
4.3	O	O
+/-	O	O
0.8	O	O
mmol/l	O	O
during	O	O
dialysis	O	O
with	O	O
fluid	O	O
containing	O	O
glycerol	O	O
at	O	O
272	O	O
mmol/l	O	O
and	O	O
eightfold	O	O
higher	O	O
at	O	O
0.42	O	O
+/-	O	O
0.09	O	O
mmol/l	O	O
with	O	O
glycerol	O	O
at	O	O
92	O	O
mmol/l	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
haemolysis	O	O
or	O	O
other	O	O
toxic	O	O
effect	O	O
despite	O	O
these	O	O
levels	O	O
.	O	O

The	O	O
rise	O	O
in	O	O
blood	O	O
glucose	O	O
and	O	O
insulin	O	O
noted	O	O
during	O	O
the	O	O
use	O	O
of	O	O
glucose-based	O	O
solutions	O	O
was	O	O
not	O	O
found	O	O
with	O	O
glycerol	O	O
.	O	O

Circulating	O	O
levels	O	O
of	O	O
lactate	O	O
,	O	O
pyruvate	O	O
,	O	O
alanine	O	O
,	O	O
non-esterified	O	O
fatty	O	O
acids	O	O
and	O	O
the	O	O
ketone	O	O
bodies	O	O
were	O	O
similar	O	O
with	O	O
the	O	O
two	O	O
agents	O	O
.	O	O

Although	O	O
these	O	O
short-term	O	O
studies	O	O
have	O	O
shown	O	O
no	O	O
conclusive	O	O
advantage	O	O
of	O	O
glycerol	O	O
over	O	O
glucose	O	O
,	O	O
long-term	O	O
effects	O	O
of	O	O
glycerol	O	O
,	O	O
particularly	O	O
on	O	O
circulating	O	O
lipid	O	O
levels	O	O
,	O	O
will	O	O
determine	O	O
its	O	O
future	O	O
role	O	O
as	O	O
an	O	O
osmotic	O	O
agent	O	O
in	O	O
continuous	O	O
ambulatory	Condition	O
peritoneal	Condition	O
dialysis	Condition	O
.	O	O

Comparative	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
twice	O	O
daily	O	O
fluticasone	O	O
propionate	O	O
powder	O	O
versus	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
moderate	Condition	O
asthma	Condition	O
.	O	O

BACKGROUND	O	O
Fluticasone	O	O
propionate	O	O
,	O	O
an	O	O
inhaled	O	O
corticosteroid	O	O
with	O	O
negligible	O	O
systemic	O	O
bioavailability	O	O
via	O	O
the	O	O
oral	O	O
route	O	O
,	O	O
is	O	O
efficacious	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
asthma	Condition	O
when	O	O
administered	O	O
via	O	O
metered-dose	O	O
inhaler	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
inhaled	O	O
fluticasone	O	O
propionate	O	O
powder	O	O
in	O	O
patients	O	O
with	O	O
moderate	Condition	O
asthma	Condition	O
previously	O	O
treated	O	O
with	O	O
an	O	O
inhaled	O	O
corticosteroid	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
parallel-group	O	O
,	O	O
multicenter	O	O
study	O	O
of	O	O
342	SampleSize	O
adolescent	Age	O
and	O	O
adult	Age	O
patients	O	O
with	O	O
moderate	Condition	Condition
asthma	Condition	Condition
[	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
second	O	O
(	O	O
FEV1	O	O
)	O	O
between	O	O
50	O	O
%	O	O
and	O	O
80	O	O
%	O	O
of	O	O
predicted	O	O
]	O	O
treated	O	O
previously	O	O
by	O	O
beclomethasone	O	O
dipropionate	O	O
or	O	O
triamcinolone	O	O
acetonide	O	O
.	O	O

Patients	O	O
received	O	O
fluticasone	O	O
propionate	O	O
powder	O	O
50	O	O
micrograms	O	O
,	O	O
100	O	O
micrograms	O	O
,	O	O
250	O	O
micrograms	O	O
,	O	O
or	O	O
placebo	O	O
via	O	O
a	O	O
breath-actuated	O	O
inhalation	O	O
device	O	O
,	O	O
the	O	O
Diskhaler	O	O
,	O	O
twice	O	O
daily	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

RESULTS	O	O
Patients	O	O
in	O	O
the	O	O
fluticasone	O	O
propionate	O	O
groups	O	O
experienced	O	O
a	O	O
mean	O	O
increase	O	O
from	O	O
baseline	O	O
to	O	O
endpoint	O	O
in	O	O
FEV1	O	O
ranging	O	O
from	O	O
0.43	O	O
L	O	O
to	O	O
0.47	O	O
L.	O	O
Patients	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
experienced	O	O
a	O	O
mean	O	O
decrease	O	O
from	O	O
baseline	O	O
of	O	O
0.22	O	O
L	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
probability	O	O
of	O	O
patients	O	O
remaining	O	O
in	O	O
the	O	O
study	O	O
over	O	O
time	O	O
without	O	O
developing	O	O
signs	O	O
of	O	O
exacerbating	O	O
asthma	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
fluticasone	O	O
propionate	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.001	O	O
)	O	O
.	O	O

Asthma	O	O
symptom	O	O
scores	O	O
,	O	O
supplemental	O	O
rescue	O	O
albuterol	O	O
use	O	O
,	O	O
and	O	O
number	O	O
of	O	O
nighttime	O	O
awakenings	O	O
due	O	O
to	O	O
asthma	O	O
requiring	O	O
treatment	O	O
also	O	O
improved	O	O
significantly	O	O
with	O	O
all	O	O
fluticasone	O	O
propionate	O	O
treatment	O	O
regimens	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
at	O	O
endpoint	O	O
among	O	O
the	O	O
three	O	O
fluticasone	O	O
propionate	O	O
groups	O	O
.	O	O

No	O	O
serious	O	O
drug-related	O	O
adverse	O	O
events	O	O
occurred	O	O
.	O	O

CONCLUSIONS	O	O
Fluticasone	O	O
propionate	O	O
powder	O	O
(	O	O
50	O	O
,	O	O
100	O	O
,	O	O
and	O	O
250	O	O
micrograms	O	O
)	O	O
was	O	O
well-tolerated	O	O
and	O	O
significantly	O	O
improved	O	O
lung	O	O
function	O	O
in	O	O
patients	O	O
with	O	O
moderate	Condition	Condition
asthma	Condition	Condition
.	O	O

Randomized	O	O
comparison	O	O
of	O	O
interferon	O	O
alpha	O	O
and	O	O
hydroxyurea	O	O
with	O	O
hydroxyurea	O	O
monotherapy	O	O
in	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
CML-study	O	O
II	O	O
)	O	O
:	O	O
prolongation	O	O
of	O	O
survival	O	O
by	O	O
the	O	O
combination	O	O
of	O	O
interferon	O	O
alpha	O	O
and	O	O
hydroxyurea	O	O
.	O	O

The	O	O
optimum	O	O
treatment	O	O
conditions	O	O
of	O	O
interferon	O	O
(	O	O
IFN	O	O
)	O	O
alpha	O	O
therapy	O	O
in	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
are	O	O
still	O	O
controversial	O	O
.	O	O

To	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
hydroxyurea	O	O
(	O	O
HU	O	O
)	O	O
for	O	O
the	O	O
outcome	O	O
of	O	O
IFN	O	O
therapy	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
randomized	O	O
trial	O	O
to	O	O
compare	O	O
the	O	O
combination	O	O
of	O	O
IFN	O	O
and	O	O
HU	O	O
vs	O	O
HU	O	O
monotherapy	O	O
(	O	O
CML-study	O	O
II	O	O
)	O	O
.	O	O

From	O	O
February	O	O
1991	O	O
to	O	O
December	O	O
1994	O	O
,	O	O
376	SampleSize	SampleSize
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
CML	Condition	O
in	O	O
chronic	Condition	Condition
phase	Condition	Condition
were	O	O
randomized	O	O
.	O	O

In	O	O
all	O	O
,	O	O
340	SampleSize	SampleSize
patients	O	O
were	O	O
Ph/BCR-ABL	Condition	O
positive	O	O
and	O	O
evaluable	O	O
.	O	O

Randomization	O	O
was	O	O
unbalanced	O	O
1:2	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
combination	O	O
therapy	O	O
,	O	O
since	O	O
study	O	O
conditions	O	O
were	O	O
identical	O	O
to	O	O
the	O	O
previous	O	O
CML-study	O	O
I	O	O
and	O	O
it	O	O
had	O	O
been	O	O
planned	O	O
in	O	O
advance	O	O
to	O	O
add	O	O
the	O	O
HU	O	O
patients	O	O
of	O	O
study	O	O
I	O	O
(	O	O
n=194	O	O
)	O	O
to	O	O
the	O	O
HU	O	O
control	O	O
group	O	O
.	O	O

Therefore	O	O
,	O	O
a	O	O
total	O	O
of	O	O
534	SampleSize	SampleSize
patients	O	O
were	O	O
evaluable	O	O
(	O	O
226	SampleSize	SampleSize
patients	O	O
with	O	O
IFN/HU	O	O
and	O	O
308	SampleSize	SampleSize
patients	O	O
with	O	O
HU	O	O
)	O	O
.	O	O

Analyses	O	O
were	O	O
according	O	O
to	O	O
intention-to-treat	O	O
.	O	O

Median	O	O
observation	O	O
time	O	O
of	O	O
nontransplanted	O	O
living	O	O
patients	O	O
was	O	O
7.6	O	O
years	O	O
(	O	O
7.9	O	O
years	O	O
for	O	O
IFN/HU	O	O
and	O	O
7.3	O	O
years	O	O
for	O	O
HU	O	O
)	O	O
.	O	O

The	O	O
risk	O	O
profile	O	O
(	O	O
new	O	O
CML	O	O
score	O	O
)	O	O
was	O	O
available	O	O
for	O	O
532	O	O
patients	O	O
:	O	O
200	O	O
patients	O	O
(	O	O
38	O	O
%	O	O
)	O	O
were	O	O
low	O	O
,	O	O
239	O	O
patients	O	O
(	O	O
45	O	O
%	O	O
)	O	O
intermediate	O	O
,	O	O
and	O	O
93	O	O
patients	O	O
(	O	O
17	O	O
%	O	O
)	O	O
high	O	O
risk	O	O
.	O	O

Complete	O	O
hematologic	O	O
response	O	O
rates	O	O
were	O	O
higher	O	O
in	O	O
IFN/HU-treated	O	O
patients	O	O
(	O	O
59	O	O
vs	O	O
32	O	O
%	O	O
)	O	O
.	O	O

Of	O	O
169	O	SampleSize
evaluable	O	O
IFN/HU-treated	O	O
patients	O	O
(	O	O
75	O	O
%	O	O
)	O	O
,	O	O
104	O	O
patients	O	O
(	O	O
62	O	O
%	O	O
)	O	O
achieved	O	O
a	O	O
cytogenetic	O	O
response	O	O
that	O	O
was	O	O
complete	O	O
in	O	O
12	O	O
%	O	O
(	O	O
n=21	O	O
)	O	O
,	O	O
major	O	O
in	O	O
14	O	O
%	O	O
(	O	O
n=24	O	O
)	O	O
,	O	O
and	O	O
at	O	O
least	O	O
minimal	O	O
in	O	O
35	O	O
%	O	O
(	O	O
n=59	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
534	SampleSize	O
patients	O	O
,	O	O
105	O	O
(	O	O
20	O	O
%	O	O
)	O	O
underwent	O	O
allogeneic	O	O
stem	O	O
cell	O	O
transplantation	O	O
in	O	O
first	O	O
chronic	O	O
phase	O	O
.	O	O

In	O	O
the	O	O
low-risk	O	O
group	O	O
,	O	O
65	O	O
of	O	O
200	O	O
patients	O	O
were	O	O
transplanted	O	O
(	O	O
33	O	O
%	O	O
)	O	O
,	O	O
30	O	O
(	O	O
13	O	O
%	O	O
)	O	O
in	O	O
the	O	O
intermediate-risk	O	O
group	O	O
,	O	O
and	O	O
nine	O	O
(	O	O
10	O	O
%	O	O
)	O	O
in	O	O
the	O	O
high-risk	O	O
group	O	O
.	O	O

Duration	O	O
of	O	O
chronic	O	O
phase	O	O
was	O	O
55	O	O
months	O	O
for	O	O
IFN/HU	O	O
and	O	O
41	O	O
months	O	O
for	O	O
HU	O	O
(	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Median	O	O
survival	O	O
was	O	O
64	O	O
months	O	O
for	O	O
IFN/HU	O	O
and	O	O
53	O	O
months	O	O
for	O	O
HU-treated	O	O
patients	O	O
(	O	O
P=0.0063	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
IFN	O	O
in	O	O
combination	O	O
with	O	O
HU	O	O
achieves	O	O
a	O	O
significant	O	O
long-term	O	O
survival	O	O
advantage	O	O
over	O	O
HU	O	O
monotherapy	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
data	O	O
of	O	O
CML-study	O	O
I	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
IFN/HU	O	O
is	O	O
also	O	O
superior	O	O
to	O	O
IFN	O	O
alone	O	O
.	O	O

HU	O	O
should	O	O
be	O	O
combined	O	O
with	O	O
IFN	O	O
in	O	O
IFN-based	O	O
therapies	O	O
and	O	O
for	O	O
comparisons	O	O
with	O	O
new	O	O
therapies	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
breast	O	O
size	O	O
on	O	O
late	O	O
radiation	O	O
effects	O	O
and	O	O
association	O	O
with	O	O
radiotherapy	O	O
dose	O	O
inhomogeneity	O	O
.	O	O

A	O	O
prospective	O	O
assessment	O	O
of	O	O
late	O	O
changes	O	O
in	O	O
breast	O	O
appearance	O	O
in	O	O
559	SampleSize	O
patients	O	O
after	O	O
tumour	Condition	O
excision	Condition	O
and	O	O
radiotherapy	Condition	O
for	O	O
early	Condition	O
breast	Condition	O
cancer	Condition	O
noted	O	O
a	O	O
strong	O	O
association	O	O
with	O	O
breast	O	O
size	O	O
.	O	O

Only	O	O
3/48	O	O
(	O	O
6	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
small	O	O
breasts	O	O
developed	O	O
moderate	O	O
or	O	O
severe	O	O
late	O	O
changes	O	O
compared	O	O
with	O	O
94/423	O	O
(	O	O
22	O	O
%	O	O
)	O	O
with	O	O
medium	O	O
sized	O	O
breasts	O	O
and	O	O
34/88	O	O
(	O	O
39	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
large	O	O
breasts	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

One	O	O
possibility	O	O
is	O	O
that	O	O
greater	O	O
radiation	O	O
changes	O	O
are	O	O
related	O	O
to	O	O
greater	O	O
dose	O	O
inhomogeneity	O	O
in	O	O
women	O	O
with	O	O
large	O	O
breasts	O	O
.	O	O

To	O	O
explore	O	O
this	O	O
hypothesis	O	O
,	O	O
radiation	O	O
dose	O	O
distributions	O	O
were	O	O
assessed	O	O
in	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
37	O	O
women	O	O
in	O	O
whom	O	O
three-level	O	O
transverse	O	O
computer	O	O
tomographic	O	O
images	O	O
of	O	O
the	O	O
breast	O	O
in	O	O
the	O	O
treatment	O	O
position	O	O
were	O	O
available	O	O
.	O	O

A	O	O
significant	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
breast	O	O
size	O	O
and	O	O
dose	O	O
inhomogeneity	O	O
which	O	O
may	O	O
account	O	O
for	O	O
the	O	O
marked	O	O
changes	O	O
in	O	O
breast	O	O
appearance	O	O
reported	O	O
in	O	O
women	O	O
with	O	O
large	O	O
breasts	O	O
.	O	O

Intra-articular	O	O
hyaluronic	O	O
acid	O	O
compared	O	O
to	O	O
exercise	O	O
therapy	O	O
in	O	O
osteoarthritis	Condition	O
of	O	O
the	O	O
ankle	Condition	O
.	O	O

A	O	O
prospective	O	O
randomized	O	O
trial	O	O
with	O	O
long-term	O	O
follow-up	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
has	O	O
been	O	O
to	O	O
determine	O	O
whether	O	O
hyaluronic	O	O
acid	O	O
(	O	O
HA	O	O
)	O	O
or	O	O
exercise	O	O
therapy	O	O
can	O	O
improve	O	O
functional	O	O
parameters	O	O
in	O	O
patients	O	O
with	O	O
osteoarthritis	O	O
(	O	O
OA	Condition	O
)	O	O
of	O	O
the	O	O
ankle	O	O
.	O	O

METHODS	O	O
In	O	O
a	O	O
prospective	O	O
clinical	O	O
trial	O	O
,	O	O
43	O	O
ankles	O	O
(	O	O
30	SampleSize	O
patients	O	O
)	O	O
with	O	O
radiographic	O	O
Kellgren	O	O
Lawrence	O	O
grade	O	O
III	O	O
OA	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
three	O	O
intra-articular	O	O
HA	O	O
injections	O	O
,	O	O
with	O	O
one-week	O	O
interval	O	O
of	O	O
or	O	O
exercise	O	O
therapy	O	O
for	O	O
six	O	O
weeks	O	O
.	O	O

Patients	O	O
were	O	O
evaluated	O	O
by	O	O
the	O	O
American	O	O
Orthopaedic	O	O
Foot	O	O
and	O	O
Ankle	O	O
Society	O	O
(	O	O
AOFAS	O	O
)	O	O
Ankle-Hindfoot	O	O
Scale	O	O
and	O	O
followed-up	O	O
after	O	O
12	O	O
months	O	O
.	O	O

RESULTS	O	O
Total	O	O
AOFAS	O	O
Ankle-Hindfoot	O	O
score	O	O
of	O	O
OA	O	O
patients	O	O
has	O	O
improved	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
varying	O	O
from	O	O
61.6+/-16.8	O	O
to	O	O
90.1+/-9.7	O	O
with	O	O
HA	O	O
treatment	O	O
and	O	O
from	O	O
72.1+/-16.6	O	O
to	O	O
87.5+/-17.5	O	O
using	O	O
exercise	O	O
therapy	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
trial	O	O
(	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
This	O	O
prospective	O	O
randomized	O	O
trial	O	O
confirmed	O	O
that	O	O
,	O	O
both	O	O
HA	O	O
injections	O	O
and	O	O
exercise	O	O
therapy	O	O
provide	O	O
functional	O	O
improvement	O	O
.	O	O

However	O	O
,	O	O
larger	O	O
trials	O	O
with	O	O
longer	O	O
follow-up	O	O
are	O	O
necessary	O	O
for	O	O
more	O	O
definite	O	O
conclusions	O	O
.	O	O

Is	O	O
chronic	O	O
sildenafil	O	O
therapy	O	O
safe	O	O
and	O	O
clinically	O	O
beneficial	O	O
in	O	O
patients	O	O
with	O	O
systolic	Condition	Condition
heart	Condition	Condition
failure	Condition	Condition
?	O	O
Sildenafil	O	O
is	O	O
a	O	O
selective	O	O
phosphodiesterase-5	O	O
inhibitor	O	O
and	O	O
causes	O	O
vasodilatation	O	O
,	O	O
particularly	O	O
in	O	O
pulmonary	O	O
circulation	O	O
.	O	O

Since	O	O
left	Condition	O
heart	Condition	O
failure	Condition	O
may	O	O
be	O	O
associated	O	O
with	O	O
pulmonary	O	O
hypertension	O	O
out	O	O
of	O	O
proportion	O	O
to	O	O
left	O	O
heart	O	O
disease	O	O
,	O	O
sildenafil	O	O
may	O	O
have	O	O
beneficial	O	O
effect	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

The	O	O
present	O	O
investigation	O	O
was	O	O
designed	O	O
as	O	O
a	O	O
12-week	O	O
,	O	O
single-center	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
evaluating	O	O
the	O	O
effects	O	O
of	O	O
sildenafil	O	O
on	O	O
mean	O	O
blood	O	O
pressure	O	O
(	O	O
primary	O	O
endpoint	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
left	Condition	Condition
systolic	Condition	Condition
heart	Condition	Condition
failure	Condition	Condition
.	O	O

Secondary	O	O
endpoints	O	O
included	O	O
exercise	O	O
capacity	O	O
assessed	O	O
by	O	O
6-minute	O	O
walk	O	O
test	O	O
.	O	O

A	O	O
total	O	O
of	O	O
106	SampleSize	O
patients	O	O
were	O	O
randomized	O	O
1:1	O	O
to	O	O
sildenafil	O	O
(	O	O
n=53	SampleSize	O
)	O	O
or	O	O
placebo	O	O
(	O	O
n=53	SampleSize	O
)	O	O
.	O	O

Patients	O	O
received	O	O
sildenafil	O	O
25	O	O
mg	O	O
twice	O	O
a	O	O
day	O	O
or	O	O
matching	O	O
placebo	O	O
for	O	O
the	O	O
first	O	O
2	O	O
weeks	O	O
and	O	O
50	O	O
mg	O	O
3	O	O
times	O	O
a	O	O
week	O	O
for	O	O
the	O	O
remainder	O	O
of	O	O
the	O	O
trial	O	O
.	O	O

The	O	O
placebo-corrected	O	O
effect	O	O
on	O	O
mean	O	O
blood	O	O
pressure	O	O
was	O	O
1.16	O	O
mm	O	O
Hg	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
-1.6	O	O
to	O	O
5.1	O	O
,	O	O
P	O	O
>	O	O
.05	O	O
)	O	O
,	O	O
demonstrating	O	O
that	O	O
sildenafil	O	O
did	O	O
not	O	O
decrease	O	O
mean	O	O
blood	O	O
pressure	O	O
.	O	O

Compared	O	O
with	O	O
placebo	O	O
,	O	O
sildenafil	O	O
increased	O	O
the	O	O
6-minute	O	O
walk	O	O
test	O	O
by	O	O
a	O	O
nonsignificant	O	O
treatment	O	O
effect	O	O
of	O	O
14	O	O
m	O	O
(	O	O
P=.67	O	O
)	O	O
.	O	O

Adverse	O	O
effects	O	O
occurred	O	O
in	O	O
a	O	O
comparable	O	O
proportion	O	O
of	O	O
patients	O	O
taking	O	O
sildenafil	O	O
and	O	O
placebo	O	O
,	O	O
and	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
needed	O	O
to	O	O
discontinue	O	O
therapy	O	O
.	O	O

Sildenafil	O	O
is	O	O
well	O	O
tolerated	O	O
in	O	O
left	O	O
heart	O	O
failure	O	O
patients	O	O
and	O	O
does	O	O
not	O	O
decrease	O	O
blood	O	O
pressure	O	O
.	O	O

It	O	O
can	O	O
be	O	O
safely	O	O
added	O	O
to	O	O
standard	O	O
heart	O	O
failure	O	O
therapy	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
release	O	O
of	O	O
digoxin	O	O
from	O	O
four	O	O
different	O	O
soft	O	O
gelatin	O	O
capsule	O	O
formulations	O	O
.	O	O

A	O	O
blinded	O	O
,	O	O
four-treatment	O	O
crossover	O	O
study	O	O
in	O	O
16	SampleSize	O
normal	O	O
adult	Age	O
male	Sex	O
volunteers	O	O
compared	O	O
plasma	O	O
concentrations	O	O
and	O	O
urinary	O	O
excretion	O	O
of	O	O
digoxin	O	O
,	O	O
measured	O	O
by	O	O
radioimmunoassay	O	O
,	O	O
after	O	O
oral	O	O
administration	O	O
of	O	O
soft	O	O
gelatin	O	O
capsule	O	O
formulations	O	O
of	O	O
digoxin	O	O
.	O	O

Four	O	O
0.4-mg	O	O
formulations	O	O
with	O	O
different	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
and	O	O
dissolution	O	O
rates	O	O
were	O	O
administered	O	O
,	O	O
with	O	O
2-week	O	O
intervals	O	O
between	O	O
treatments	O	O
.	O	O

The	O	O
two	O	O
capsules	O	O
with	O	O
lowest	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
(	O	O
2.9	O	O
and	O	O
16	O	O
min	O	O
)	O	O
gave	O	O
comparable	O	O
in	O	O
vivo	O	O
results	O	O
.	O	O

The	O	O
other	O	O
two	O	O
capsules	O	O
,	O	O
with	O	O
in	O	O
vitro	O	O
burst	O	O
times	O	O
of	O	O
62	O	O
and	O	O
229	O	O
min	O	O
,	O	O
produced	O	O
significant	O	O
delays	O	O
in	O	O
digoxin	O	O
absorption	O	O
.	O	O

In	O	O
vitro-in	O	O
vivo	O	O
correlations	O	O
were	O	O
obtained	O	O
by	O	O
comparing	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
burst	O	O
time	O	O
with	O	O
time	O	O
to	O	O
peak	O	O
plasma	O	O
level	O	O
and	O	O
the	O	O
time	O	O
to	O	O
the	O	O
first	O	O
measurable	O	O
plasma	O	O
level	O	O
(	O	O
>	O	O
or	O	O
=	O	O
0	O	O
.	O	O

05	O	O
ng/ml	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
mean	O	O
time	O	O
to	O	O
peak	O	O
plasma	O	O
level	O	O
correlated	O	O
with	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
time	O	O
required	O	O
to	O	O
release	O	O
either	O	O
50	O	O
%	O	O
or	O	O
85	O	O
%	O	O
of	O	O
the	O	O
digoxin	O	O
in	O	O
vitro	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
digoxin	O	O
absorbed	O	O
from	O	O
each	O	O
capsule	O	O
as	O	O
determined	O	O
by	O	O
urinary	O	O
excretion	O	O
or	O	O
AUC0-infinity	O	O
.	O	O

Effect	O	O
of	O	O
aliskiren	O	O
on	O	O
proteinuria	O	O
in	O	O
non-diabetic	Condition	Condition
chronic	Condition	Condition
kidney	Condition	Condition
disease	Condition	Condition
:	O	O
a	O	O
double-blind	O	O
,	O	O
crossover	O	O
,	O	O
randomised	O	O
,	O	O
controlled	O	O
trial	O	O
.	O	O

AIM	O	O
To	O	O
evaluate	O	O
the	O	O
proteinuria-lowering	O	O
effect	O	O
of	O	O
a	O	O
renin	O	O
inhibitor	O	O
(	O	O
aliskiren	O	O
)	O	O
,	O	O
compared	O	O
to	O	O
placebo	O	O
and	O	O
to	O	O
an	O	O
angiotensin-converting	O	O
enzyme	O	O
inhibitor	O	O
(	O	O
perindopril	O	O
)	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
non-diabetic	O	Condition
chronic	O	Condition
kidney	O	Condition
disease	O	Condition
.	O	O

METHODS	O	O
A	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
crossover	O	O
trial	O	O
was	O	O
performed	O	O
in	O	O
14	O	SampleSize
patients	O	O
with	O	O
nondiabetic	O	O
chronic	O	O
kidney	O	O
disease	O	O
with	O	O
24-h	O	O
mean	O	O
proteinuria	O	O
of	O	O
2.01	O	O
g	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.36?2.66	O	O
)	O	O
and	O	O
estimated	O	O
creatinine	O	O
clearance	O	O
of	O	O
93?6.8	O	O
ml/min	O	O
.	O	O

The	O	O
study	O	O
consisted	O	O
of	O	O
five	O	O
treatment	O	O
periods	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
aliskiren	O	O
(	O	O
150	O	O
mg	O	O
)	O	O
,	O	O
aliskiren	O	O
(	O	O
300	O	O
mg	O	O
)	O	O
,	O	O
perindopril	O	O
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
perindopril	O	O
(	O	O
10	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
.	O	O

RESULTS	O	O
Aliskiren	O	O
and	O	O
perindopril	O	O
reduced	O	O
proteinuria	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
dose-dependent	O	O
.	O	O

Furthermore	O	O
,	O	O
24-h	O	O
proteinuria	O	O
was	O	O
reduced	O	O
by	O	O
23	O	O
%	O	O
(	O	O
mean	O	O
95	O	O
%	O	O
CI	O	O
;	O	O
2?44	O	O
)	O	O
by	O	O
treatment	O	O
with	O	O
aliskiren	O	O
(	O	O
150	O	O
mg	O	O
)	O	O
,	O	O
by	O	O
36	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
17?55	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
with	O	O
aliskiren	O	O
(	O	O
300	O	O
mg	O	O
)	O	O
,	O	O
by	O	O
7.1	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
11?26	O	O
)	O	O
with	O	O
perindopril	O	O
(	O	O
5	O	O
mg	O	O
)	O	O
and	O	O
by	O	O
25	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
11?39	O	O
;	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
with	O	O
perindopril	O	O
(	O	O
10	O	O
mg	O	O
)	O	O
,	O	O
compared	O	O
to	O	O
placebo	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
was	O	O
found	O	O
between	O	O
the	O	O
effects	O	O
of	O	O
aliskiren	O	O
and	O	O
perindopril	O	O
.	O	O

CONCLUSIONS	O	O
Aliskiren	O	O
significantly	O	O
reduced	O	O
proteinuria	O	O
.	O	O

The	O	O
antiproteinuric	O	O
effect	O	O
is	O	O
probably	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
perindopril	O	O
,	O	O
for	O	O
equivalent	O	O
hypotensive	O	O
dosages	O	O
.	O	O

The	O	O
renin	O	O
inhibitor	O	O
provides	O	O
a	O	O
promising	O	O
alternative	O	O
approach	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
chronic	O	Condition
proteinuric	O	Condition
non-diabetic	O	Condition
kidney	O	Condition
disease	O	Condition
.	O	O

How	O	O
to	O	O
establish	O	O
equivalence	O	O
when	O	O
data	O	O
are	O	O
censored	O	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
treatments	O	O
for	O	O
B	Condition	O
non-Hodgkin	Condition	O
lymphoma	Condition	O
.	O	O

Interest	O	O
in	O	O
equivalence	O	O
trials	O	O
has	O	O
been	O	O
increasing	O	O
for	O	O
many	O	O
years	O	O
,	O	O
though	O	O
the	O	O
methodology	O	O
which	O	O
has	O	O
been	O	O
developed	O	O
for	O	O
such	O	O
trials	O	O
is	O	O
mainly	O	O
for	O	O
uncensored	O	O
data	O	O
.	O	O

In	O	O
cancer	O	O
research	O	O
we	O	O
are	O	O
more	O	O
often	O	O
concerned	O	O
with	O	O
survival	O	O
.	O	O

In	O	O
an	O	O
efficacy	O	O
trial	O	O
,	O	O
the	O	O
null	O	O
hypothesis	O	O
specifies	O	O
equality	O	O
of	O	O
the	O	O
two	O	O
survival	O	O
distributions	O	O
,	O	O
but	O	O
in	O	O
an	O	O
equivalence	O	O
trial	O	O
,	O	O
a	O	O
null	O	O
hypothesis	O	O
of	O	O
inequivalence	O	O
H0	O	O
has	O	O
to	O	O
be	O	O
tested	O	O
.	O	O

The	O	O
usual	O	O
logrank	O	O
test	O	O
has	O	O
to	O	O
be	O	O
modified	O	O
to	O	O
test	O	O
whether	O	O
the	O	O
true	O	O
value	O	O
r	O	O
of	O	O
the	O	O
ratio	O	O
of	O	O
hazard	O	O
rates	O	O
in	O	O
two	O	O
treatment	O	O
groups	O	O
is	O	O
at	O	O
least	O	O
equal	O	O
to	O	O
a	O	O
limit	O	O
value	O	O
r0	O	O
.	O	O

If	O	O
prognostic	O	O
factors	O	O
have	O	O
to	O	O
be	O	O
taken	O	O
into	O	O
account	O	O
,	O	O
the	O	O
Cox	O	O
model	O	O
provides	O	O
tests	O	O
of	O	O
Ho	O	O
,	O	O
and	O	O
a	O	O
useful	O	O
confidence	O	O
interval	O	O
for	O	O
the	O	O
adjusted	O	O
relative	O	O
derived	O	O
from	O	O
the	O	O
regression	O	O
parameter	O	O
for	O	O
the	O	O
treatment	O	O
indicator	O	O
.	O	O

An	O	O
equivalence	O	O
trial	O	O
of	O	O
maintenance	O	O
therapy	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
children	Age	O
with	O	O
B	Condition	O
non-Hodgkin	Condition	O
lymphoma	Condition	O
,	O	O
and	O	O
serves	O	O
as	O	O
an	O	O
illustration	O	O
.	O	O

Optimization	O	O
of	O	O
acid	O	O
suppression	O	O
for	O	O
patients	O	O
with	O	O
peptic	Condition	O
ulcer	Condition	O
bleeding	Condition	O
:	O	O
an	O	O
intragastric	O	O
pH-metry	O	O
study	O	O
with	O	O
omeprazole	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
study	O	O
whether	O	O
an	O	O
intravenous	O	O
infusion	O	O
dose	O	O
of	O	O
omeprazole	O	O
(	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
)	O	O
during	O	O
24	O	O
h	O	O
can	O	O
be	O	O
subsequently	O	O
reduced	O	O
with	O	O
maintained	O	O
effect	O	O
.	O	O

Second	O	O
,	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
oral	O	O
omeprazole	O	O
20	O	O
mg	O	O
given	O	O
once	O	O
or	O	O
twice	O	O
daily	O	O
up	O	O
to	O	O
day	O	O
10	O	O
,	O	O
after	O	O
cessation	O	O
of	O	O
a	O	O
3-day	O	O
intravenous	O	O
infusion	O	O
(	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
)	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
,	O	O
randomized	O	O
,	O	O
partly	O	O
blinded	O	O
study	O	O
.	O	O

METHODS	O	O
Twelve	SampleSize	O
Helicobacter	Condition	O
pylori	Condition	O
(	Condition	O
+	Condition	O
)	Condition	O
patients	Condition	O
and	O	O
12	SampleSize	O
H.	Condition	O
pylori	Condition	O
(	Condition	O
-	Condition	O
)	Condition	O
subjects	O	O
were	O	O
included	O	O
.	O	O

In	O	O
part	O	O
I	O	O
the	O	O
patients	O	O
received	O	O
omeprazole	O	O
,	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
,	O	O
during	O	O
24	O	O
h	O	O
followed	O	O
by	O	O
8	O	O
,	O	O
4	O	O
or	O	O
2	O	O
mg/h	O	O
.	O	O

In	O	O
part	O	O
II	O	O
the	O	O
subjects	O	O
received	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
during	O	O
3	O	O
days	O	O
followed	O	O
by	O	O
20	O	O
mg	O	O
omeprazole	O	O
orally	O	O
,	O	O
once	O	O
or	O	O
twice	O	O
daily	O	O
until	O	O
day	O	O
10	O	O
.	O	O

Intragastric	O	O
pH	O	O
was	O	O
measured	O	O
.	O	O

RESULTS	O	O
All	O	O
H.	O	O
pylori	O	O
(	O	O
+	O	O
)	O	O
patients	O	O
showed	O	O
a	O	O
rapid	O	O
increase	O	O
of	O	O
intragastric	O	O
pH	O	O
with	O	O
a	O	O
mean	O	O
intragastric	O	O
pH	O	O
of	O	O
6.7	O	O
during	O	O
the	O	O
second	O	O
half	O	O
of	O	O
the	O	O
first	O	O
day	O	O
.	O	O

After	O	O
the	O	O
subsequent	O	O
dose	O	O
reduction	O	O
,	O	O
the	O	O
mean	O	O
pH	O	O
decreased	O	O
to	O	O
6.1-6.2	O	O
.	O	O

Patients	O	O
continuing	O	O
on	O	O
8	O	O
mg/h	O	O
showed	O	O
the	O	O
best	O	O
results	O	O
.	O	O

Likewise	O	O
,	O	O
all	O	O
H.	O	O
pylori	O	O
(	O	O
-	O	O
)	O	O
subjects	O	O
showed	O	O
a	O	O
rapid	O	O
and	O	O
sustained	O	O
reduction	O	O
of	O	O
intragastric	O	O
acidity	O	O
during	O	O
the	O	O
infusion	O	O
.	O	O

Subsequent	O	O
dose	O	O
reduction	O	O
to	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
led	O	O
to	O	O
a	O	O
stable	O	O
fraction	O	O
of	O	O
time	O	O
with	O	O
pH	O	O
>	O	O
3	O	O
of	O	O
72	O	O
%	O	O
.	O	O

CONCLUSIONS	O	O
Omeprazole	O	O
given	O	O
as	O	O
a	O	O
continuous	O	O
infusion	O	O
of	O	O
80	O	O
mg	O	O
+	O	O
8	O	O
mg/h	O	O
for	O	O
72	O	O
h	O	O
followed	O	O
by	O	O
omeprazole	O	O
20	O	O
mg	O	O
once	O	O
daily	O	O
raised	O	O
the	O	O
intragastric	O	O
pH	O	O
to	O	O
and	O	O
above	O	O
levels	O	O
alleged	O	O
to	O	O
allow	O	O
haemostasis	O	O
in	O	O
patients	O	O
with	O	O
peptic	Condition	O
ulcer	Condition	O
bleeding	Condition	O
and	O	O
subsequent	O	O
healing	O	O
of	O	O
the	O	O
ulcer	O	O
.	O	O

Paricalcitol	O	O
capsule	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
secondary	Condition	O
hyperparathyroidism	Condition	O
in	O	O
stages	Condition	O
3	Condition	O
and	Condition	O
4	Condition	O
CKD	Condition	O
.	O	O

BACKGROUND	O	O
The	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
paricalcitol	O	O
injection	O	O
have	O	O
been	O	O
well	O	O
established	O	O
for	O	O
the	O	O
prevention	O	O
and	O	O
treatment	O	O
of	O	O
secondary	O	O
hyperparathyroidism	O	O
(	O	O
SHPT	Condition	O
)	O	O
in	O	O
patients	O	O
with	O	O
chronic	Condition	Condition
kidney	Condition	Condition
disease	Condition	Condition
(	O	Condition
CKD	Condition	Condition
)	O	Condition
stage	Condition	Condition
5	Condition	Condition
.	O	O

The	O	O
capsule	O	O
form	O	O
of	O	O
paricalcitol	O	O
was	O	O
developed	O	O
to	O	O
provide	O	O
a	O	O
convenient	O	O
dosage	O	O
form	O	O
for	O	O
patients	O	O
with	O	O
stages	O	Condition
3	O	Condition
and	O	Condition
4	O	Condition
CKD	O	Condition
.	O	O

METHODS	O	O
Three	O	O
randomized	O	O
,	O	O
placebo-controlled	O	O
,	O	O
phase-3	O	O
trials	O	O
were	O	O
conducted	O	O
in	O	O
patients	O	O
with	O	O
stages	O	O
3	O	O
and	O	O
4	O	O
CKD	O	O
with	O	O
SHPT	O	O
.	O	O

Enrollment	O	O
criteria	O	O
included	O	O
an	O	O
estimated	O	O
glomerular	O	O
filtration	O	O
rate	O	O
between	O	O
15	O	O
and	O	O
60	O	O
mL/min/1.73	O	O
m2	O	O
(	O	O
0.25	O	O
and	O	O
1.00	O	O
mL/s/1.73	O	O
m2	O	O
)	O	O
,	O	O
an	O	O
average	O	O
of	O	O
2	O	O
consecutive	O	O
intact	O	O
parathyroid	O	O
hormone	O	O
(	O	O
iPTH	O	O
)	O	O
levels	O	O
greater	O	O
than	O	O
150	O	O
pg/mL	O	O
(	O	O
ng/L	O	O
)	O	O
,	O	O
2	O	O
consecutive	O	O
serum	O	O
calcium	O	O
levels	O	O
between	O	O
8.0	O	O
and	O	O
10.0	O	O
mg/dL	O	O
(	O	O
2.00	O	O
and	O	O
2.50	O	O
mmol/L	O	O
)	O	O
,	O	O
and	O	O
2	O	O
consecutive	O	O
serum	O	O
phosphorus	O	O
levels	O	O
of	O	O
5.2	O	O
mg/dL	O	O
or	O	O
less	O	O
(	O	O
<	O	O
or	O	O
=	O	O
1.68	O	O
mmol/L	O	O
)	O	O
.	O	O

Two	O	O
studies	O	O
used	O	O
a	O	O
thrice-weekly	O	O
dosing	O	O
regimen	O	O
and	O	O
1	O	O
study	O	O
used	O	O
a	O	O
once-daily	O	O
dosing	O	O
regimen	O	O
for	O	O
24	O	O
weeks	O	O
.	O	O

Dosing	O	O
was	O	O
based	O	O
on	O	O
serum	O	O
iPTH	O	O
,	O	O
calcium	O	O
,	O	O
and	O	O
phosphorus	O	O
levels	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
end	O	O
point	O	O
is	O	O
2	O	O
consecutive	O	O
decreases	O	O
in	O	O
iPTH	O	O
levels	O	O
greater	O	O
than	O	O
30	O	O
%	O	O
from	O	O
baseline	O	O
.	O	O

RESULTS	O	O
Two	SampleSize	SampleSize
hundred	SampleSize	SampleSize
twenty	SampleSize	SampleSize
patients	O	O
participated	O	O
(	O	O
n	O	O
=	O	O
107	SampleSize	O
,	O	O
paricalcitol	O	O
;	O	O
n	O	O
=	O	O
113	SampleSize	O
,	O	O
placebo	O	O
)	O	O
.	O	O

At	O	O
least	O	O
2	O	O
consecutive	O	O
decreases	O	O
in	O	O
iPTH	O	O
levels	O	O
of	O	O
30	O	O
%	O	O
or	O	O
greater	O	O
from	O	O
baseline	O	O
occurred	O	O
in	O	O
91	O	O
%	O	O
of	O	O
paricalcitol	O	O
versus	O	O
13	O	O
%	O	O
of	O	O
placebo	O	O
patients	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Incidences	O	O
of	O	O
hypercalcemia	O	O
,	O	O
hyperphosphatemia	O	O
,	O	O
and	O	O
elevated	O	O
calcium-phosphorus	O	O
product	O	O
levels	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
groups	O	O
.	O	O

Similarly	O	O
,	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
urinary	O	O
calcium	O	O
and	O	O
phosphorus	O	O
excretion	O	O
or	O	O
deterioration	O	O
in	O	O
kidney	O	O
function	O	O
were	O	O
detected	O	O
in	O	O
patients	O	O
administered	O	O
paricalcitol	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

CONCLUSION	O	O
Paricalcitol	O	O
capsule	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
effectively	O	O
decreased	O	O
iPTH	O	O
levels	O	O
with	O	O
minimal	O	O
or	O	O
no	O	O
impact	O	O
on	O	O
calcium	O	O
levels	O	O
,	O	O
phosphorus	O	O
balance	O	O
,	O	O
and	O	O
kidney	O	O
function	O	O
in	O	O
patients	O	O
with	O	O
stages	O	Condition
3	O	Condition
and	O	Condition
4	O	Condition
CKD	O	Condition
.	O	O

[	O	O
Observation	O	O
of	O	O
curative	O	O
effect	O	O
on	O	O
fixed-point	O	O
spin	O	O
reduction	O	O
of	O	O
spinal	O	O
manipulation	O	O
therapy	O	O
for	O	O
cervical	Condition	O
vertigo	Condition	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
explore	O	O
the	O	O
role	O	O
of	O	O
fixed-point	O	O
spin	O	O
reduction	O	O
of	O	O
spinal	O	O
manipulation	O	O
therapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cervical	Condition	O
vertigo	Condition	O
and	O	O
its	O	O
effect	O	O
on	O	O
cervical	O	O
artery	O	O
spasm	O	O
index	O	O
(	O	O
RI	O	O
)	O	O
and	O	O
atlantoaxial	O	O
displacement	O	O
index	O	O
(	O	O
ADI	O	O
)	O	O
.	O	O

METHODS	O	O
From	O	O
January	O	O
2002	O	O
to	O	O
May	O	O
2008	O	O
,	O	O
168	SampleSize	SampleSize
patients	O	O
with	O	O
cervical	O	O
vertigo	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
treatment	O	O
group	O	O
(	O	O
84	SampleSize	O
cases	O	O
)	O	O
and	O	O
the	O	O
control	O	O
group	O	O
(	O	O
84	SampleSize	O
cases	O	O
)	O	O
,	O	O
22	SampleSize	O
males	Sex	O
and	O	O
62	SampleSize	SampleSize
females	Sex	O
in	O	O
treatment	O	O
group	O	O
;	O	O
24	SampleSize	O
males	Sex	O
and	O	O
60	SampleSize	SampleSize
females	Sex	Sex
in	O	O
control	O	O
group	O	O
.	O	O

The	O	O
patients	O	O
of	O	O
treatment	O	O
group	O	O
and	O	O
control	O	O
group	O	O
were	O	O
respectively	O	O
treated	O	O
with	O	O
fixed-point	O	O
spin	O	O
reduction	O	O
of	O	O
spinal	O	O
manipulation	O	O
therapy	O	O
and	O	O
dialectical	O	O
prescription	O	O
.	O	O

The	O	O
score	O	O
of	O	O
symptoms	O	O
and	O	O
signs	O	O
,	O	O
RI	O	O
,	O	O
ADI	O	O
were	O	O
observed	O	O
and	O	O
compared	O	O
between	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
The	O	O
score	O	O
of	O	O
symptoms	O	O
and	O	O
signs	O	O
markedly	O	O
decreased	O	O
after	O	O
treatment	O	O
,	O	O
in	O	O
treatment	O	O
group	O	O
:	O	O
vertigo	O	O
had	O	O
(	O	O
2.75	O	O
+/-	O	O
1.01	O	O
)	O	O
scores	O	O
,	O	O
neck-shoulder	O	O
pain	O	O
(	O	O
1.58	O	O
+/-	O	O
0.36	O	O
)	O	O
,	O	O
headache	O	O
(	O	O
0.39	O	O
+/-	O	O
0.09	O	O
)	O	O
,	O	O
nausea-vomiting	O	O
(	O	O
1.58	O	O
+/-	O	O
1.30	O	O
)	O	O
,	O	O
ear	O	O
noises	O	O
(	O	O
0.48	O	O
+/-	O	O
0.32	O	O
)	O	O
,	O	O
positive	O	O
neck	O	O
rotation	O	O
test	O	O
(	O	O
0.59	O	O
+/-	O	O
0.21	O	O
)	O	O
;	O	O
and	O	O
in	O	O
control	O	O
group	O	O
:	O	O
vertigo	O	O
had	O	O
(	O	O
5.68	O	O
+/-	O	O
2.02	O	O
)	O	O
scores	O	O
,	O	O
neck-shoulder	O	O
pain	O	O
(	O	O
3.12	O	O
+/-	O	O
1.82	O	O
)	O	O
,	O	O
headache	O	O
(	O	O
1.86	O	O
+/-	O	O
0.65	O	O
)	O	O
,	O	O
nausea-vomiting	O	O
(	O	O
3.25	O	O
+/-	O	O
0.69	O	O
)	O	O
,	O	O
ear	O	O
noises	O	O
(	O	O
1.64	O	O
+/-	O	O
0.61	O	O
)	O	O
,	O	O
positive	O	O
neck	O	O
rotation	O	O
test	O	O
(	O	O
1.79	O	O
+/-	O	O
0.67	O	O
)	O	O
.	O	O

Cervical	O	O
artery	O	O
spasm	O	O
index	O	O
and	O	O
atlantoaxial	O	O
displacement	O	O
index	O	O
had	O	O
been	O	O
significantly	O	O
improved	O	O
,	O	O
cervical	O	O
artery	O	O
spasm	O	O
index	O	O
was	O	O
respectively	O	O
0.54	O	O
+/-	O	O
0.07	O	O
and	O	O
0.52	O	O
+/-	O	O
0.13	O	O
,	O	O
atlantoaxial	O	O
displacement	O	O
index	O	O
was	O	O
respectively	O	O
2.92	O	O
+/-	O	O
0.82	O	O
and	O	O
4.50	O	O
+/-	O	O
1.32	O	O
between	O	O
treatment	O	O
group	O	O
and	O	O
control	O	O
group	O	O
.	O	O

CONCLUSION	O	O
Fixed-point	O	O
spin	O	O
reduction	O	O
of	O	O
spinal	O	O
manipulation	O	O
therapy	O	O
for	O	O
cervical	O	O
vertigo	O	O
can	O	O
accurately	O	O
correct	O	O
single	O	O
or	O	O
multiple	O	O
vertebral	Condition	O
body	Condition	O
displacement	Condition	O
,	O	O
restore	O	O
normal	O	O
spinal	O	O
position	O	O
,	O	O
reduce	O	O
the	O	O
oppression	O	O
and	O	O
stimulus	O	O
of	O	O
the	O	O
vertebral	O	O
artery	O	O
,	O	O
release	O	O
ischemia	O	O
of	O	O
vestibular	O	O
labyrinth	O	O
,	O	O
eliminate	O	O
symptoms	O	O
of	O	O
vertigo	O	O
.	O	O

Nitrous	O	O
oxide	O	O
diffusion	O	O
into	O	O
tracheal	O	O
tube	O	O
cuffs	O	O
--	O	O
efficacy	O	O
of	O	O
a	O	O
new	O	O
prototype	O	O
cuff	O	O
pressure	O	O
release	O	O
valve	O	O
.	O	O

BACKGROUND	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
performance	O	O
of	O	O
a	O	O
new	O	O
cuff	O	O
pressure	O	O
release	O	O
valve	O	O
(	O	O
CPRV	O	O
)	O	O
,	O	O
in	O	O
which	O	O
the	O	O
release	O	O
pressure	O	O
can	O	O
be	O	O
adjusted	O	O
from	O	O
10	O	O
to	O	O
25	O	O
cmH2O	O	O
,	O	O
particularly	O	O
intended	O	O
to	O	O
control	O	O
pressure	O	O
in	O	O
paediatric	Age	O
cuffed	Condition	O
tracheal	Condition	O
tubes	Condition	O
and	O	O
to	O	O
avoid	O	O
cuff	O	O
hyperinflation	O	O
caused	O	O
by	O	O
N2O	O	O
diffusion	O	O
.	O	O

METHODS	O	O
In	O	O
vitro	O	O
:	O	O
the	O	O
PRV	O	O
was	O	O
set	O	O
to	O	O
10	O	O
,	O	O
15	O	O
,	O	O
20	O	O
or	O	O
25	O	O
cmH2O	O	O
release	O	O
pressure	O	O
and	O	O
connected	O	O
to	O	O
a	O	O
cuffed	O	O
tube	O	O
placed	O	O
into	O	O
a	O	O
box	O	O
flushed	O	O
with	O	O
66	O	O
%	O	O
N2O	O	O
in	O	O
O2	O	O
.	O	O

The	O	O
cuff	O	O
pressure	O	O
was	O	O
monitored	O	O
with	O	O
and	O	O
without	O	O
CPRV	O	O
for	O	O
60	O	O
min	O	O
.	O	O

Experiments	O	O
were	O	O
performed	O	O
four	O	O
times	O	O
using	O	O
two	O	O
different	O	O
CPRVs	O	O
.	O	O

In	O	O
vivo	O	O
:	O	O
with	O	O
Institutional	O	O
Review	O	O
Board	O	O
approval	O	O
,	O	O
CPRV	O	O
was	O	O
studied	O	O
in	O	O
50	SampleSize	SampleSize
children	Age	O
undergoing	O	O
general	Condition	Condition
anaesthesia	Condition	Condition
with	Condition	Condition
tracheal	Condition	Condition
intubation	Condition	Condition
and	O	O
standardized	Condition	O
anaesthesia	Condition	O
technique	Condition	O
(	O	O
including	O	O
66	O	O
%	O	O
N2O	O	O
in	O	O
O2	O	O
)	O	O
and	O	O
ventilator	Condition	O
settings	Condition	O
.	O	O

Patients	O	O
were	O	O
randomized	O	O
into	O	O
two	O	O
groups	O	O
(	O	O
with	O	O
and	O	O
without	O	O
CPRV	O	O
)	O	O
.	O	O

The	O	O
cuff	O	O
pressure	O	O
baseline	O	O
was	O	O
20	O	O
cmH2O	O	O
and	O	O
CPRV	O	O
was	O	O
set	O	O
to	O	O
25	O	O
cmH2O	O	O
.	O	O

If	O	O
the	O	O
cuff	O	O
pressure	O	O
exceeded	O	O
25	O	O
cmH2O	O	O
,	O	O
it	O	O
was	O	O
manually	O	O
released	O	O
to	O	O
20	O	O
cmH2O	O	O
.	O	O

The	O	O
numbers	O	O
of	O	O
deflations	O	O
in	O	O
both	O	O
groups	O	O
were	O	O
noted	O	O
and	O	O
compared	O	O
by	O	O
Mann-Whitney	O	O
U-test	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

RESULTS	O	O
In	O	O
vitro	O	O
:	O	O
the	O	O
cuff	O	O
pressure	O	O
exceeded	O	O
50	O	O
cmH2O	O	O
after	O	O
60	O	O
min	O	O
without	O	O
CPRV	O	O
,	O	O
but	O	O
did	O	O
not	O	O
exceed	O	O
the	O	O
settings	O	O
with	O	O
CPRV	O	O
.	O	O

In	O	O
vivo	O	O
:	O	O
there	O	O
was	O	O
no	O	O
need	O	O
to	O	O
manually	O	O
deflate	O	O
the	O	O
cuff	O	O
in	O	O
the	O	O
CPRV	O	O
group	O	O
but	O	O
,	O	O
in	O	O
every	O	O
patient	O	O
in	O	O
the	O	O
control	O	O
group	O	O
,	O	O
three	O	O
(	O	O
two	O	O
to	O	O
seven	O	O
)	O	O
deflating	O	O
manoeuvres	O	O
were	O	O
required	O	O
within	O	O
the	O	O
first	O	O
hour	O	O
of	O	O
anaesthesia	O	O
(	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
CPRV	O	O
allows	O	O
reliable	O	O
cuff	O	O
pressure	O	O
release	O	O
at	O	O
various	O	O
pressure	O	O
levels	O	O
and	O	O
reliably	O	O
prevents	O	O
cuff	O	O
pressure	O	O
increases	O	O
caused	O	O
by	O	O
N2O	O	O
.	O	O

Induction	O	O
chemotherapy	O	O
in	O	O
head	Condition	O
and	Condition	O
neck	Condition	O
cancer	Condition	O
:	O	O
results	O	O
of	O	O
a	O	O
phase	O	O
III	O	O
trial	O	O
.	O	O

Between	O	O
December	O	O
1982	O	O
and	O	O
October	O	O
1986	O	O
,	O	O
131	SampleSize	O
patients	O	O
with	O	O
stage	Condition	O
II-III-IV	Condition	O
squamous	Condition	O
cell	Condition	O
carcinoma	Condition	O
of	O	O
the	O	O
oropharynx	Condition	O
or	O	O
oral	Condition	O
cavity	Condition	O
were	O	O
randomized	O	O
to	O	O
induction	O	O
chemotherapy	O	O
,	O	O
consisting	O	O
of	O	O
bleomycin	O	O
(	O	O
10	O	O
mg/m2/day	O	O
in	O	O
continuous	O	O
infusion	O	O
from	O	O
day	O	O
1	O	O
to	O	O
day	O	O
5	O	O
)	O	O
,	O	O
methotrexate	O	O
(	O	O
120	O	O
mg/m2	O	O
on	O	O
day	O	O
2	O	O
)	O	O
followed	O	O
by	O	O
folinic	O	O
acid	O	O
,	O	O
5-fluorouracil	O	O
(	O	O
5	O	O
FU	O	O
)	O	O
(	O	O
600	O	O
mg/m2	O	O
on	O	O
day	O	O
2	O	O
)	O	O
,	O	O
and	O	O
cisplatin	O	O
(	O	O
120	O	O
mg/m2	O	O
on	O	O
day	O	O
4	O	O
)	O	O
every	O	O
4	O	O
weeks	O	O
for	O	O
a	O	O
total	O	O
of	O	O
three	O	O
cycles	O	O
followed	O	O
by	O	O
definitive	O	O
locoregional	O	O
treatment	O	O
versus	O	O
locoregional	O	O
treatment	O	O
alone	O	O
.	O	O

The	O	O
modalities	O	O
of	O	O
definitive	O	O
treatment	O	O
(	O	O
radiotherapy	O	O
+/-	O	O
surgery	O	O
)	O	O
were	O	O
chosen	O	O
prior	O	O
to	O	O
randomization	O	O
.	O	O

A	O	O
total	O	O
of	O	O
116	SampleSize	SampleSize
patients	O	O
were	O	O
evaluable	O	O
.	O	O

Of	O	O
55	O	O
patients	O	O
in	O	O
the	O	O
chemotherapy	O	O
arm	O	O
,	O	O
four	O	O
(	O	O
7	O	O
%	O	O
)	O	O
had	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
and	O	O
23	O	O
(	O	O
42	O	O
%	O	O
)	O	O
a	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
following	O	O
the	O	O
induction	O	O
regimen	O	O
.	O	O

At	O	O
the	O	O
completion	O	O
of	O	O
locoregional	O	O
treatment	O	O
,	O	O
76	O	O
%	O	O
(	O	O
42	O	O
of	O	O
55	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
experimental	O	O
group	O	O
were	O	O
in	O	O
CR	O	O
compared	O	O
to	O	O
89	O	O
%	O	O
(	O	O
54	O	O
of	O	O
61	O	O
)	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
survival	O	O
,	O	O
cause-specific	O	O
survival	O	O
,	O	O
and	O	O
pattern	O	O
of	O	O
relapse	O	O
between	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
median	O	O
survival	O	O
was	O	O
22	O	O
months	O	O
in	O	O
the	O	O
chemotherapy	O	O
group	O	O
and	O	O
29	O	O
months	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Responders	O	O
to	O	O
chemotherapy	O	O
did	O	O
not	O	O
fare	O	O
better	O	O
than	O	O
nonresponders	O	O
.	O	O

Chemotherapy-related	O	O
toxicities	O	O
were	O	O
few	O	O
and	O	O
most	O	O
of	O	O
them	O	O
related	O	O
to	O	O
cisplatin	O	O
which	O	O
was	O	O
reduced	O	O
to	O	O
100	O	O
mg/m2	O	O
for	O	O
35	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
treatment-related	O	O
deaths	O	O
and	O	O
,	O	O
in	O	O
the	O	O
experimental	O	O
arm	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
no	O	O
increased	O	O
morbidity	O	O
from	O	O
locoregional	O	O
treatment	O	O
.	O	O

This	O	O
induction	O	O
regimen	O	O
does	O	O
not	O	O
offer	O	O
any	O	O
advantages	O	O
over	O	O
standard	O	O
treatment	O	O
.	O	O

Intranasal	O	O
nicotine	O	O
for	O	O
postoperative	Condition	O
pain	Condition	O
treatment	O	O
.	O	O

BACKGROUND	O	O
Despite	O	O
pharmacological	O	O
treatment	O	O
,	O	O
70-80	O	O
%	O	O
of	O	O
patients	O	O
report	O	O
moderate	O	O
to	O	O
severe	O	O
pain	O	O
after	O	O
surgery	O	O
.	O	O

Because	O	O
nicotine	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
have	O	O
analgesic	O	O
properties	O	O
in	O	O
animal	O	O
and	O	O
human	O	O
volunteer	O	O
studies	O	O
,	O	O
the	O	O
authors	O	O
assessed	O	O
the	O	O
analgesic	O	O
efficacy	O	O
of	O	O
a	O	O
single	O	O
3	O	O
mg	O	O
dose	O	O
of	O	O
nicotine	O	O
nasal	O	O
spray	O	O
administered	O	O
before	O	O
emergence	O	O
from	O	O
general	O	O
anesthesia	O	O
.	O	O

METHODS	O	O
The	O	O
authors	O	O
conducted	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
blind	O	O
,	O	O
placebo	O	O
controlled	O	O
trial	O	O
of	O	O
20	SampleSize	SampleSize
healthy	Condition	Condition
women	Sex	Sex
(	O	O
mean	O	O
age	O	O
45	Age	O
(	O	O
SD	O	O
8	O	O
)	O	O
yr	O	O
)	O	O
who	O	O
were	O	O
to	O	O
undergo	O	O
uterine	Condition	O
surgery	Condition	O
through	O	O
a	O	O
low	Condition	O
transverse	Condition	O
incision	Condition	O
.	O	O

After	O	O
the	O	O
conclusion	O	O
of	O	O
surgery	O	O
but	O	O
before	O	O
emergence	O	O
from	O	O
general	O	O
anesthesia	O	O
,	O	O
the	O	O
anesthesiologist	O	O
administered	O	O
either	O	O
nicotine	O	O
nasal	O	O
spray	O	O
or	O	O
a	O	O
placebo	O	O
.	O	O

Numerical	O	O
analog	O	O
pain	O	O
score	O	O
and	O	O
morphine	O	O
utilization	O	O
and	O	O
hemodynamic	O	O
values	O	O
were	O	O
measured	O	O
for	O	O
24	O	O
h.	O	O
RESULTS	O	O
The	O	O
patients	O	O
treated	O	O
with	O	O
nicotine	O	O
reported	O	O
lower	O	O
pain	O	O
scores	O	O
during	O	O
the	O	O
first	O	O
hour	O	O
after	O	O
surgery	O	O
(	O	O
peak	O	O
numerical	O	O
analog	O	O
score	O	O
,	O	O
7.6	O	O
(	O	O
SD	O	O
1.4	O	O
)	O	O
versus	O	O
5.3	O	O
(	O	O
SD	O	O
1.6	O	O
)	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
used	O	O
half	O	O
the	O	O
amount	O	O
of	O	O
morphine	O	O
as	O	O
the	O	O
control	O	O
group	O	O
(	O	O
12	O	O
(	O	O
SD	O	O
6	O	O
)	O	O
versus	O	O
6	O	O
(	O	O
SD	O	O
5	O	O
)	O	O
mg	O	O
;	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
nicotine	O	O
still	O	O
reported	O	O
less	O	O
pain	O	O
than	O	O
those	O	O
in	O	O
the	O	O
control	O	O
group	O	O
24	O	O
h	O	O
after	O	O
surgery	O	O
(	O	O
1.5	O	O
(	O	O
SD	O	O
0.5	O	O
)	O	O
versus	O	O
4.9	O	O
(	O	O
SD	O	O
1.4	O	O
)	O	O
;	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Systolic	O	O
blood	O	O
pressure	O	O
was	O	O
lower	O	O
in	O	O
the	O	O
group	O	O
that	O	O
received	O	O
nicotine	O	O
(	O	O
105	O	O
(	O	O
SD	O	O
3	O	O
)	O	O
versus	O	O
122	O	O
(	O	O
SD	O	O
3	O	O
)	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
diastolic	O	O
blood	O	O
pressure	O	O
or	O	O
heart	O	O
rate	O	O
.	O	O

CONCLUSIONS	O	O
Treatment	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
nicotine	O	O
immediately	O	O
before	O	O
emergence	O	O
from	O	O
anesthesia	O	O
was	O	O
associated	O	O
with	O	O
significantly	O	O
lower	O	O
reported	O	O
pain	O	O
scores	O	O
during	O	O
the	O	O
first	O	O
day	O	O
after	O	O
surgery	O	O
.	O	O

The	O	O
decreased	O	O
pain	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
reduction	O	O
in	O	O
morphine	O	O
utilization	O	O
and	O	O
the	O	O
analgesic	O	O
effect	O	O
of	O	O
nicotine	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
hypertension	O	O
or	O	O
tachycardia	O	O
.	O	O

0.1	O	O
%	O	O
bupivacaine	O	O
does	O	O
not	O	O
reduce	O	O
the	O	O
requirement	O	O
for	O	O
epidural	O	O
fentanyl	O	O
infusion	O	O
after	O	O
major	Condition	O
abdominal	Condition	O
surgery	Condition	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Although	O	O
local	O	O
anesthesia	O	O
has	O	O
been	O	O
demonstrated	O	O
to	O	O
potentiate	O	O
spinal	O	O
morphine	O	O
analgesia	O	O
in	O	O
animal	O	O
studies	O	O
,	O	O
results	O	O
comparing	O	O
epidural	O	O
local	O	O
anesthesia/opioid	O	O
mixtures	O	O
with	O	O
opioid	O	O
alone	O	O
are	O	O
contradictory	O	O
in	O	O
clinical	O	O
studies	O	O
.	O	O

The	O	O
hypothesis	O	O
was	O	O
that	O	O
,	O	O
although	O	O
the	O	O
concentration	O	O
of	O	O
bupivacaine	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
low	O	O
to	O	O
minimize	O	O
its	O	O
adverse	O	O
effects	O	O
,	O	O
if	O	O
the	O	O
infusion	O	O
rate	O	O
of	O	O
a	O	O
fentanyl/bupivacaine	O	O
solution	O	O
was	O	O
closely	O	O
adjusted	O	O
according	O	O
to	O	O
need	O	O
,	O	O
the	O	O
presence	O	O
bupivacaine	O	O
would	O	O
reduce	O	O
the	O	O
requirement	O	O
for	O	O
epidural	O	O
fentanyl	O	O
.	O	O

METHODS	O	O
Forty	SampleSize	SampleSize
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
fentanyl	O	O
(	O	O
10	O	O
micrograms/mL	O	O
)	O	O
or	O	O
a	O	O
fentanyl/bupivacaine	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
mixture	O	O
epidurally	O	O
corresponding	O	O
to	O	O
the	O	O
dermatome	O	O
of	O	O
the	O	O
surgical	O	O
incision	O	O
in	O	O
a	O	O
double-blind	O	O
fashion	O	O
for	O	O
the	O	O
first	O	O
18	O	O
hours	O	O
after	O	O
major	Condition	O
abdominal	Condition	O
surgery	Condition	O
.	O	O

The	O	O
infusion	O	O
was	O	O
titrated	O	O
for	O	O
each	O	O
patient	O	O
to	O	O
the	O	O
rate	O	O
required	O	O
for	O	O
pain	O	O
relief	O	O
during	O	O
forced	O	O
inspiration	O	O
(	O	O
pain	O	O
score	O	O
<	O	O
or	O	O
=	O	O
2	O	O
,	O	O
maximum	O	O
10	O	O
)	O	O
.	O	O

Pain	O	O
scores	O	O
,	O	O
the	O	O
fentanyl	O	O
doses	O	O
required	O	O
,	O	O
plasma	O	O
concentrations	O	O
of	O	O
fentanyl	O	O
at	O	O
18	O	O
hours	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
effects	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Patients	O	O
reported	O	O
similar	O	O
median	O	O
pain	O	O
scores	O	O
and	O	O
were	O	O
equally	O	O
satisfied	O	O
with	O	O
pain	O	O
relief	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
mean	O	O
required	O	O
post-operative	O	O
fentanyl	O	O
infusion	O	O
rate	O	O
(	O	O
57.7	O	O
+/-	O	O
19.5	O	O
micrograms/h	O	O
)	O	O
and	O	O
the	O	O
plasma	O	O
concentrations	O	O
(	O	O
0.84	O	O
+/-	O	O
0.36	O	O
ng/mL	O	O
)	O	O
in	O	O
the	O	O
fentanyl	O	O
group	O	O
were	O	O
comparable	O	O
to	O	O
the	O	O
infusion	O	O
rate	O	O
(	O	O
54.4	O	O
+/-	O	O
19.2	O	O
micrograms/h	O	O
)	O	O
and	O	O
the	O	O
plasma	O	O
concentrations	O	O
(	O	O
0.86	O	O
+/-	O	O
0.36	O	O
ng/mL	O	O
)	O	O
in	O	O
the	O	O
fentanyl/bupivacaine	O	O
group	O	O
.	O	O

Respiratory	O	O
and	O	O
cardiovascular	O	O
functions	O	O
were	O	O
preserved	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
nausea	O	O
,	O	O
pruritus	O	O
,	O	O
and	O	O
periods	O	O
of	O	O
drowsiness	O	O
or	O	O
sleep	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
low	O	O
concentrations	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
,	O	O
bupivacaine	O	O
did	O	O
not	O	O
reduce	O	O
the	O	O
titrated	O	O
dose	O	O
of	O	O
epidural	O	O
fentanyl	O	O
required	O	O
for	O	O
adequate	O	O
pain	O	O
relief	O	O
during	O	O
forced	O	O
inspiration	O	O
after	O	O
major	O	O
abdominal	O	O
surgery	O	O
.	O	O

The	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
comparable	O	O
whether	O	O
or	O	O
not	O	O
low-dose	O	O
bupivacaine	O	O
infusion	O	O
was	O	O
used	O	O
.	O	O

Perioperative	O	O
myocardial	O	O
infarctions	O	O
are	O	O
common	O	O
and	O	O
often	O	O
unrecognized	O	O
in	O	O
patients	O	Condition
undergoing	O	Condition
hip	Condition	Condition
fracture	Condition	Condition
surgery	Condition	O
.	O	O

BACKGROUND	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
prospective	O	O
cohort	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
incidence	O	O
and	O	O
characteristics	O	O
of	O	O
acute	O	O
myocardial	O	O
infarction	O	O
in	O	O
patients	O	O
undergoing	O	O
surgery	Condition	O
for	O	O
acute	Condition	Condition
hip	Condition	Condition
fracture	Condition	Condition
.	O	O

METHODS	O	O
A	O	O
consecutive	O	O
cohort	O	O
of	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
200	SampleSize	O
,	O	O
68	SampleSize	O
men	Sex	O
)	O	O
referred	O	O
to	O	O
acute	Condition	O
surgical	Condition	O
correction	O	O
of	O	O
hip	Condition	O
fracture	Condition	O
was	O	O
studied	O	O
.	O	O

Troponin	O	O
T	O	O
(	O	O
TnT	O	O
)	O	O
measurements	O	O
and	O	O
electrocardiographic	O	O
(	O	O
ECG	O	O
)	O	O
recordings	O	O
were	O	O
performed	O	O
at	O	O
admission	O	O
,	O	O
before	O	O
operation	O	O
,	O	O
and	O	O
on	O	O
the	O	O
first	O	O
and	O	O
2nd	O	O
postoperative	O	O
days	O	O
,	O	O
which	O	O
were	O	O
used	O	O
for	O	O
diagnosis	O	O
.	O	O

RESULTS	O	O
The	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
ranged	O	O
from	O	O
32	Age	O
to	Age	O
98	Age	O
years	O	O
(	O	O
mean	O	O
,	O	O
80.8	Age	O
years	Age	O
)	O	O
,	O	O
and	O	O
65	SampleSize	SampleSize
patients	O	O
had	O	O
a	O	O
history	O	O
of	O	O
coronary	Condition	O
artery	Condition	O
disease	Condition	O
.	O	O

A	O	O
significant	O	O
rise	O	O
in	O	O
TnT	O	O
as	O	O
a	O	O
sign	O	O
of	O	O
myocardial	O	O
infarction	O	O
was	O	O
observed	O	O
in	O	O
71	O	O
patients	O	O
(	O	O
35.5	O	O
%	O	O
)	O	O
,	O	O
and	O	O
25	O	O
of	O	O
them	O	O
had	O	O
a	O	O
TnT	O	O
elevation	O	O
exceeding	O	O
five	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

TnT	O	O
elevation	O	O
was	O	O
observed	O	O
in	O	O
36	O	O
patients	O	O
(	O	O
51	O	O
%	O	O
)	O	O
already	O	O
before	O	O
surgery	O	O
.	O	O

Seven	O	O
patients	O	O
(	O	O
10	O	O
%	O	O
)	O	O
had	O	O
ST	O	Condition
elevation	O	Condition
myocardial	O	Condition
infarction	O	Condition
,	O	O
23	O	O
patients	O	O
(	O	O
32	O	O
%	O	O
)	O	O
had	O	O
new	O	O
ST	O	O
depressions	O	O
,	O	O
and	O	O
21	O	O
patients	O	O
(	O	O
30	O	O
%	O	O
)	O	O
had	O	O
no	O	O
new	O	O
ST	O	O
segment	O	O
changes	O	O
in	O	O
the	O	O
serial	O	O
electrocardiographic	O	O
recordings	O	O
.	O	O

In	O	O
40	O	O
patients	O	O
(	O	O
56	O	O
%	O	O
)	O	O
,	O	O
the	O	O
perioperative	O	O
myocardial	O	O
infarction	O	O
was	O	O
the	O	O
first	O	O
manifestation	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

Multivariate	O	O
logistic	O	O
regression	O	O
revealed	O	O
that	O	O
old	O	O
age	O	O
(	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
,	O	O
1.06	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
1.02-1.10	O	O
;	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
,	O	O
earlier	O	O
revascularization	O	O
(	O	O
OR	O	O
,	O	O
3.29	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.12-9.73	O	O
;	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
,	O	O
and	O	O
heart	O	O
failure	O	O
(	O	O
OR	O	O
,	O	O
2.42	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.04-5.61	O	O
;	O	O
p	O	O
=	O	O
0.04	O	O
)	O	O
were	O	O
independent	O	O
predictors	O	O
of	O	O
TnT	O	O
elevation	O	O
.	O	O

Majority	O	O
of	O	O
myocardial	O	O
infarctions	O	O
were	O	O
asymptomatic	O	O
or	O	O
unrecognized	O	O
.	O	O

Evidence-based	O	O
medications	O	O
of	O	O
myocardial	O	O
infarction	O	O
were	O	O
seldom	O	O
started	O	O
and	O	O
cardiologist	O	O
was	O	O
consulted	O	O
in	O	O
12	O	O
patients	O	O
(	O	O
16.9	O	O
%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Patients	O	O
with	O	O
hip	O	O
fracture	O	O
often	O	O
develop	O	O
asymptomatic	O	O
and	O	O
clinically	O	Condition
unrecognized	O	Condition
perioperative	O	Condition
myocardial	O	Condition
infarctions	O	Condition
.	O	O

Earlier	O	O
diagnosis	O	O
and	O	O
appropriate	O	O
treatment	O	O
of	O	O
cardiac	O	O
infarction	O	O
may	O	O
improve	O	O
survival	O	O
of	O	O
hip	O	O
fracture	O	O
patients	O	O
.	O	O

LEVEL	O	O
OF	O	O
EVIDENCE	O	O
Epidemiologic	O	O
study	O	O
,	O	O
level	O	O
III	O	O
.	O	O

The	O	O
prophylactic	O	O
effect	O	O
of	O	O
valproate	O	O
on	O	O
glyceryltrinitrate	O	O
induced	O	O
migraine	Condition	O
.	O	O

In	O	O
this	O	O
study	O	O
the	O	O
human	O	O
glyceryltrinitrate	O	O
(	O	O
GTN	O	O
)	O	O
model	O	O
of	O	O
migraine	O	O
was	O	O
for	O	O
the	O	O
first	O	O
time	O	O
used	O	O
to	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
prophylactic	O	O
drug	O	O
.	O	O

We	O	O
chose	O	O
to	O	O
test	O	O
valproate	O	O
due	O	O
to	O	O
its	O	O
well	O	O
documented	O	O
effect	O	O
as	O	O
a	O	O
migraine	O	O
prophylactic	O	O
drug	O	O
.	O	O

Efficacy	O	O
of	O	O
this	O	O
compound	O	O
would	O	O
support	O	O
the	O	O
usefulness	O	O
of	O	O
the	O	O
model	O	O
in	O	O
prophylactic	O	O
antimigraine	O	O
drug	O	O
development	O	O
.	O	O

Twelve	SampleSize	O
patients	O	O
with	O	O
migraine	Condition	O
without	Condition	O
aura	Condition	O
were	O	O
included	O	O
in	O	O
a	O	O
randomized	O	O
double	O	O
blind	O	O
crossover	O	O
study	O	O
.	O	O

Valproate	O	O
1000	O	O
mg	O	O
or	O	O
placebo	O	O
was	O	O
given	O	O
daily	O	O
,	O	O
each	O	O
for	O	O
a	O	O
minimum	O	O
of	O	O
13	O	O
days	O	O
.	O	O

On	O	O
the	O	O
last	O	O
treatment	O	O
day	O	O
of	O	O
each	O	O
arm	O	O
a	O	O
20	O	O
min	O	O
intravenous	O	O
infusion	O	O
of	O	O
GTN	O	O
(	O	O
0.25	O	O
microg/kg/min	O	O
)	O	O
was	O	O
given	O	O
.	O	O

Headache	O	O
was	O	O
registered	O	O
for	O	O
12	O	O
h	O	O
after	O	O
the	O	O
infusion	O	O
and	O	O
headache	O	O
intensity	O	O
was	O	O
scored	O	O
on	O	O
a	O	O
scale	O	O
from	O	O
0	O	O
to	O	O
10	O	O
.	O	O

Fulfillment	O	O
of	O	O
IHS	O	O
criteria	O	O
was	O	O
recorded	O	O
for	O	O
24	O	O
h.	O	O
The	O	O
middle	O	O
cerebral	O	O
arteries	O	O
were	O	O
evaluated	O	O
by	O	O
transcranial	O	O
Doppler	O	O
and	O	O
the	O	O
diameter	O	O
of	O	O
the	O	O
superficial	O	O
temporal	O	O
and	O	O
radial	O	O
arteries	O	O
were	O	O
measured	O	O
with	O	O
high	O	O
frequency	O	O
ultrasound	O	O
.	O	O

GTN	O	O
evoked	O	O
migraine	O	O
fulfilling	O	O
IHS	O	O
criteria	O	O
1.1	O	O
in	O	O
6	O	O
patients	O	O
after	O	O
placebo	O	O
and	O	O
in	O	O
2	O	O
patients	O	O
after	O	O
valproate	O	O
(	O	O
P	O	O
=	O	O
0.125	O	O
)	O	O
.	O	O

Including	O	O
additionally	O	O
3	O	O
patients	O	O
on	O	O
placebo	O	O
and	O	O
1	O	O
patient	O	O
on	O	O
valproate	O	O
who	O	O
felt	O	O
they	O	O
had	O	O
suffered	O	O
a	O	O
migraine	O	O
attack	O	O
,	O	O
but	O	O
who	O	O
had	O	O
as	O	O
associated	O	O
symptoms	O	O
only	O	O
photophobia	O	O
or	O	O
phonophobia	O	O
,	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
induced	O	O
migraine	O	O
after	O	O
valproate	O	O
was	O	O
seen	O	O
(	O	O
P	O	O
=	O	O
0.031	O	O
)	O	O
.	O	O

Median	O	O
peak	O	O
headache	O	O
intensity	O	O
was	O	O
1	O	O
(	O	O
range	O	O
0-9	O	O
)	O	O
after	O	O
valproate	O	O
compared	O	O
to	O	O
4.5	O	O
(	O	O
range	O	O
0-8	O	O
)	O	O
after	O	O
placebo	O	O
(	O	O
P	O	O
=	O	O
0.120	O	O
)	O	O
.	O	O

Pretreatment	O	O
with	O	O
valproate	O	O
as	O	O
compared	O	O
to	O	O
placebo	O	O
reduced	O	O
the	O	O
velocity	O	O
in	O	O
both	O	O
middle	O	O
cerebral	O	O
arteries	O	O
after	O	O
GTN	O	O
(	O	O
left	O	O
P	O	O
=	O	O
0.021	O	O
,	O	O
right	O	O
P	O	O
=	O	O
0.031	O	O
)	O	O
.	O	O

No	O	O
effect	O	O
of	O	O
valproate	O	O
was	O	O
seen	O	O
in	O	O
the	O	O
diameter	O	O
of	O	O
the	O	O
superficial	O	O
temporal	O	O
artery	O	O
(	O	O
P	O	O
=	O	O
0.781	O	O
)	O	O
or	O	O
the	O	O
radial	O	O
artery	O	O
(	O	O
P	O	O
=	O	O
0.367	O	O
)	O	O
before	O	O
or	O	O
after	O	O
GTN	O	O
.	O	O

The	O	O
study	O	O
indicates	O	O
that	O	O
a	O	O
prophylactic	O	O
effect	O	O
of	O	O
valproate	O	O
may	O	O
be	O	O
demonstrated	O	O
using	O	O
the	O	O
GTN	O	O
human	O	O
migraine	O	O
model	O	O
.	O	O

Although	O	O
,	O	O
all	O	O
headache	O	O
parameters	O	O
were	O	O
reduced	O	O
after	O	O
valproate	O	O
compared	O	O
to	O	O
placebo	O	O
,	O	O
only	O	O
one	O	O
parameter	O	O
was	O	O
statistically	O	O
significantly	O	O
reduced	O	O
probably	O	O
because	O	O
of	O	O
the	O	O
small	O	O
number	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
effect	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
valproate	O	O
in	O	O
clinical	O	O
trials	O	O
.	O	O

The	O	O
GTN	O	O
model	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
valid	O	O
tool	O	O
for	O	O
testing	O	O
new	O	O
prophylactic	O	O
antimigraine	O	O
drugs	O	O
.	O	O

1999	O	O
WHO/ISH	O	O
Guidelines	O	O
applied	O	O
to	O	O
a	O	O
1999	O	O
MONICA	O	O
sample	O	O
from	O	O
northern	O	O
Sweden	O	O
.	O	O

BACKGROUND	O	O
Treating	O	O
hypertension	O	O
with	O	O
drugs	O	O
is	O	O
so	O	O
far	O	O
the	O	O
most	O	O
cost-effective	O	O
way	O	O
to	O	O
reduce	O	O
this	O	O
important	O	O
risk	O	O
factor	O	O
for	O	O
cardiovascular	O	O
disease	O	O
(	O	O
CVD	O	O
)	O	O
.	O	O

It	O	O
is	O	O
,	O	O
however	O	O
,	O	O
important	O	O
to	O	O
determine	O	O
absolute	O	O
risk	O	O
,	O	O
and	O	O
thereby	O	O
estimate	O	O
indication	O	O
for	O	O
drug	O	O
treatment	O	O
,	O	O
in	O	O
order	O	O
to	O	O
maintain	O	O
a	O	O
cost-effective	O	O
drug	O	O
treatment	O	O
.	O	O

WHO/ISH	O	O
Hypertension	O	O
Guidelines	O	O
from	O	O
1999	O	O
propose	O	O
a	O	O
risk	O	O
stratification	O	O
for	O	O
estimating	O	O
absolute	O	O
risk	O	O
for	O	O
CVD	O	O
based	O	O
on	O	O
blood	O	O
pressure	O	O
and	O	O
additional	O	O
risk	O	O
factors	O	O
,	O	O
target	O	O
organ	O	O
damage	O	O
(	O	O
TOD	O	O
)	O	O
and	O	O
CVD	O	O
.	O	O

OBJECTIVES	O	O
We	O	O
studied	O	O
the	O	O
consequences	O	O
of	O	O
applying	O	O
the	O	O
recent	O	O
WHO/ISH	O	O
risk	O	O
stratification	O	O
scheme	O	O
to	O	O
a	O	O
MONICA	O	O
sample	O	O
of	O	O
6000	SampleSize	SampleSize
subjects	O	O
from	O	O
a	O	O
geographically	O	O
defined	O	O
population	O	O
in	O	O
northern	O	O
Sweden	O	O
,	O	O
regarding	O	O
indications	O	O
for	O	O
treatment	O	O
,	O	O
target	O	O
blood	O	O
pressure	O	O
and	O	O
risk	O	O
distribution	O	O
.	O	O

METHODS	O	O
We	O	O
have	O	O
risk-classified	O	O
each	O	O
of	O	O
these	O	O
patients	O	O
using	O	O
a	O	O
computer	O	O
program	O	O
,	O	O
according	O	O
to	O	O
the	O	O
WHO/ISH	O	O
scheme	O	O
.	O	O

Data	O	O
on	O	O
TOD	O	O
were	O	O
not	O	O
available	O	O
.	O	O

RESULTS	O	O
In	O	O
all	O	O
,	O	O
917	O	O
(	O	O
15	O	O
%	O	O
)	O	O
had	O	O
drug-treated	Condition	O
hypertension	Condition	O
.	O	O

Three-quarters	O	O
(	O	O
n	O	O
=	O	O
737	O	O
)	O	O
were	O	O
inadequately	O	O
treated	O	O
,	O	O
with	O	O
blood	O	O
pressure	O	O
levels	O	O
at	O	O
or	O	O
above	O	O
140	O	O
or	O	O
90	O	O
mmHg	O	O
.	O	O

1773	O	O
(	O	O
30	O	O
%	O	O
of	O	O
5997	O	O
)	O	O
untreated	Condition	O
subjects	O	O
had	O	O
a	O	O
blood	O	O
pressure	O	O
of	O	O
140/90	O	O
or	O	O
above	O	O
;	O	O
16	O	O
%	O	O
in	O	O
the	O	O
low-	O	O
,	O	O
62	O	O
%	O	O
in	O	O
the	O	O
medium-	O	O
,	O	O
8	O	O
%	O	O
in	O	O
the	O	O
high-	O	O
,	O	O
and	O	O
14	O	O
%	O	O
in	O	O
the	O	O
very-high-risk	O	O
group	O	O
.	O	O

The	O	O
corresponding	O	O
risk-group	O	O
pattern	O	O
for	O	O
the	O	O
inadequately	O	O
treated	O	O
hypertensives	O	O
(	O	O
n	O	O
=	O	O
737	O	O
)	O	O
was	O	O
5.5	O	O
,	O	O
48.3	O	O
,	O	O
11.1	O	O
and	O	O
35.2	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

If	O	O
we	O	O
shifted	O	O
the	O	O
target	O	O
blood	O	O
pressure	O	O
from	O	O
below	O	O
140/90	O	O
to	O	O
below	O	O
130/85	O	O
for	O	O
drug-treated	O	O
subjects	O	O
under	O	O
60	O	O
(	O	O
n	O	O
=	O	O
278	O	O
)	O	O
the	O	O
number	O	O
of	O	O
inadequately	O	O
treated	O	O
subjects	O	O
increased	O	O
by	O	O
34	O	O
(	O	O
12.2	O	O
%	O	O
of	O	O
278	O	O
)	O	O
;	O	O
14	O	O
in	O	O
the	O	O
low-risk	O	O
group	O	O
,	O	O
15	O	O
in	O	O
the	O	O
medium-risk	O	O
group	O	O
,	O	O
and	O	O
only	O	O
five	O	O
in	O	O
the	O	O
high-	O	O
or	O	O
very-high-risk	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Only	O	O
one-fifth	O	O
of	O	O
the	O	O
drug-treated	O	O
hypertensives	O	O
were	O	O
well	O	O
controlled	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
newly	O	O
detected	O	O
blood	O	O
pressure	O	O
elevation	O	O
was	O	O
high	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
younger	O	O
subjects	O	O
with	O	O
high	O	O
blood	O	O
pressure	O	O
had	O	O
low	O	O
risk	O	O
,	O	O
but	O	O
in	O	O
those	O	O
aged	O	O
45-54	Age	O
this	O	O
had	O	O
already	O	O
risen	O	O
to	O	O
a	O	O
medium	O	O
risk	O	O
.	O	O

Changing	O	O
the	O	O
target	O	O
blood	O	O
pressure	O	O
to	O	O
below	O	O
130/85	O	O
,	O	O
for	O	O
subjects	O	O
aged	Age	O
below	Age	O
60	Age	O
,	O	O
as	O	O
recommended	O	O
by	O	O
WHO/ISH	O	O
,	O	O
affects	O	O
predominantly	O	O
low-	O	O
and	O	O
medium-risk	O	O
groups	O	O
.	O	O

The	O	O
costs	O	O
and	O	O
effects	O	O
of	O	O
a	O	O
nutritional	O	O
education	O	O
program	O	O
following	O	O
work-site	O	O
cholesterol	O	O
screening	O	O
.	O	O

OBJECTIVES	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
costs	O	O
and	O	O
impact	O	O
of	O	O
a	O	O
nutrition	O	O
education	O	O
program	O	O
following	O	O
a	O	O
cholesterol	O	O
screening	O	O
.	O	O

METHODS	O	O
Forty	SampleSize	O
work-sites	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
educational	O	O
interventions	O	O
:	O	O
a	O	O
usual	O	O
intervention	O	O
of	O	O
5	O	O
minutes	O	O
of	O	O
counseling	O	O
,	O	O
or	O	O
a	O	O
special	O	O
intervention	O	O
of	O	O
2	O	O
hours	O	O
of	O	O
behaviorally	O	O
based	O	O
education	O	O
on	O	O
dietary	O	O
changes	O	O
to	O	O
lower	O	O
serum	O	O
cholesterol	O	O
.	O	O

Costs	O	O
were	O	O
monitored	O	O
,	O	O
and	O	O
cholesterol	O	O
levels	O	O
were	O	O
retested	O	O
6	O	O
and	O	O
12	O	O
months	O	O
later	O	O
.	O	O

RESULTS	O	O
The	O	O
total	O	O
per-person	O	O
cost	O	O
for	O	O
screening	O	O
and	O	O
the	O	O
educational	O	O
intervention	O	O
was	O	O
about	O	O
$	O	O
50	O	O
.	O	O

Cholesterol	O	O
levels	O	O
differed	O	O
little	O	O
between	O	O
the	O	O
two	O	O
intervention	O	O
groups	O	O
6	O	O
months	O	O
after	O	O
screening	O	O
,	O	O
but	O	O
after	O	O
12	O	O
months	O	O
those	O	O
in	O	O
the	O	O
special	O	O
intervention	O	O
worksites	O	O
showed	O	O
a	O	O
6.5	O	O
%	O	O
drop	O	O
in	O	O
cholesterol	O	O
,	O	O
whereas	O	O
those	O	O
at	O	O
the	O	O
usual	O	O
intervention	O	O
worksites	O	O
showed	O	O
a	O	O
drop	O	O
of	O	O
only	O	O
3.0	O	O
%	O	O
.	O	O

Hence	O	O
a	O	O
3.5	O	O
%	O	O
cholesterol	O	O
reduction	O	O
was	O	O
attributable	O	O
to	O	O
the	O	O
special	O	O
intervention	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
behaviorally	O	O
based	O	O
nutrition	O	O
education	O	O
program	O	O
following	O	O
cholesterol	O	O
screening	O	O
can	O	O
have	O	O
a	O	O
meaningful	O	O
impact	O	O
on	O	O
long-term	O	O
cholesterol	O	O
levels	O	O
at	O	O
a	O	O
low	O	O
cost	O	O
.	O	O

Nutrition	O	O
education	O	O
in	O	O
work-sites	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
useful	O	O
way	O	O
to	O	O
lower	O	O
the	O	O
risk	O	O
of	O	O
heart	O	O
disease	O	O
in	O	O
communities	O	O
.	O	O

Effect	O	O
of	O	O
upper	O	O
arm	O	O
brachial	O	O
basilic	O	O
and	O	O
prosthetic	O	O
forearm	O	O
arteriovenous	O	O
fistula	O	O
on	O	O
left	O	O
ventricular	O	O
hypertrophy	O	O
.	O	O

BACKGROUND	O	O
Creation	O	O
of	O	O
an	O	O
arteriovenous	O	O
fistula	O	O
(	O	O
AVF	O	O
)	O	O
may	O	O
increase	O	O
left	O	O
ventricular	O	O
hypertrophy	O	O
in	O	O
the	O	O
hemodialysis	Condition	O
population	O	O
.	O	O

Aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
brachial-basilic	O	O
(	O	O
BB	O	O
)	O	O
AVF	O	O
and	O	O
the	O	O
prosthetic	O	O
brachial-antecubital	O	O
forearm	O	O
loop	O	O
access	O	O
(	O	O
PTFE	O	O
)	O	O
on	O	O
cardiac	O	O
performance	O	O
.	O	O

METHODS	O	O
Patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
BB-AVF	O	O
or	O	O
prosthetic	O	O
brachial-antecubital	O	O
forearm	O	O
loop	O	O
access	O	O
.	O	O

Before	O	O
and	O	O
three	O	O
months	O	O
after	O	O
AVF	O	O
creation	O	O
patients	O	O
underwent	O	O
an	O	O
echocardiographic	O	O
examination	O	O
.	O	O

Mann-Whitney	O	O
U-test	O	O
was	O	O
used	O	O
to	O	O
compare	O	O
relative	O	O
increase	O	O
between	O	O
the	O	O
measured	O	O
cardiac	O	O
parameters	O	O
for	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

RESULTS	O	O
Twenty-seven	SampleSize	SampleSize
patients	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
relative	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
parameters	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Only	O	O
left	O	O
ventricular	O	O
end-diastolic	O	O
diameter	O	O
tended	O	O
to	O	O
be	O	O
of	O	O
significance	O	O
.	O	O

Mean	O	O
blood	O	O
flow	O	O
through	O	O
the	O	O
brachial	O	O
artery	O	O
was	O	O
1680+/-156	O	O
and	O	O
1450+/-221	O	O
mL/min	O	O
three	O	O
months	O	O
after	O	O
surgery	O	O
for	O	O
the	O	O
PTFE	O	O
and	O	O
the	O	O
BB-AVF	O	O
group	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSION	O	O
After	O	O
three	O	O
months	O	O
of	O	O
follow-up	O	O
,	O	O
changes	O	O
in	O	O
cardiac	O	O
structure	O	O
were	O	O
comparable	O	O
between	O	O
patients	O	O
with	O	O
BB	Condition	O
and	O	O
PTFE	Condition	O
AVFs	Condition	O
.	O	O

Also	O	O
access	O	O
flow	O	O
was	O	O
comparable	O	O
at	O	O
this	O	O
time	O	O
.	O	O

In	O	O
general	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
creation	O	O
of	O	O
a	O	O
fistula	O	O
on	O	O
LV	O	O
structure	O	O
were	O	O
limited	O	O
.	O	O

Longer	O	O
follow	O	O
up	O	O
time	O	O
may	O	O
be	O	O
needed	O	O
to	O	O
explore	O	O
the	O	O
long	O	O
term	O	O
effects	O	O
of	O	O
different	O	O
vascular	O	O
accesses	O	O
on	O	O
cardiac	O	O
function	O	O
.	O	O

Anti-angiogenic	O	O
effects	O	O
of	O	O
epigallocatechin-3-gallate	O	O
in	O	O
human	O	O
skin	O	O
.	O	O

Epigallocatechin-3-gallate	O	O
(	O	O
EGCG	O	O
)	O	O
is	O	O
the	O	O
main	O	O
polyphenol	O	O
component	O	O
of	O	O
green	O	O
tea	O	O
.	O	O

This	O	O
compound	O	O
exhibits	O	O
antioxidant	O	O
,	O	O
immunomodulatory	O	O
,	O	O
photoprotective	O	O
,	O	O
anti-angiogenic	O	O
,	O	O
and	O	O
anti-inflammatory	O	O
properties	O	O
.	O	O

We	O	O
conducted	O	O
a	O	O
small	O	O
randomized	O	O
,	O	O
double	O	O
blind	O	O
,	O	O
split	O	O
face	O	O
trial	O	O
using	O	O
a	O	O
cream	O	O
containing	O	O
2.5	O	O
%	O	O
w/w	O	O
of	O	O
EGCG	O	O
.	O	O

Four	SampleSize	O
healthy	Condition	O
volunteers	O	O
with	O	O
significant	O	O
erythema	Condition	O
and	O	O
telangiectasia	Condition	O
on	Condition	O
the	Condition	O
face	Condition	O
applied	O	O
EGCG	O	O
cream	O	O
to	O	O
one	O	O
side	O	O
of	O	O
the	O	O
face	O	O
,	O	O
and	O	O
vehicle	O	O
control	O	O
cream	O	O
to	O	O
the	O	O
other	O	O
,	O	O
twice	O	O
daily	O	O
for	O	O
six	O	O
weeks	O	O
.	O	O

After	O	O
six	O	O
weeks	O	O
,	O	O
biopsies	O	O
were	O	O
taken	O	O
from	O	O
EGCG	O	O
and	O	O
vehicle	O	O
treated	O	O
sites	O	O
.	O	O

Immunohistochemistry	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
VEGF	O	O
and	O	O
HIF-1	O	O
?.	O	O
HIF-1	O	O
?	O	O
expression	O	O
was	O	O
decreased	O	O
in	O	O
EGCG	O	O
treated	O	O
sites	O	O
,	O	O
such	O	O
that	O	O
28.4	O	O
%	O	O
of	O	O
the	O	O
epidermis	O	O
showed	O	O
positive	O	O
staining	O	O
in	O	O
vehicle	O	O
treated	O	O
vs.	O	O
13.8	O	O
%	O	O
in	O	O
EGCG	O	O
treated	O	O
sites	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

A	O	O
similar	O	O
decrease	O	O
in	O	O
VEGF	O	O
expression	O	O
was	O	O
found	O	O
(	O	O
6.7	O	O
%	O	O
in	O	O
EGCG	O	O
vs.	O	O
11.0	O	O
%	O	O
in	O	O
in	O	O
vehicle-treated	O	O
skin	O	O
(	O	O
p	O	O
<	O	O
0.005	O	O
)	O	O
.	O	O

EGCG	O	O
topical	O	O
treatments	O	O
influence	O	O
HIF-1	O	O
?	O	O
induction	O	O
and	O	O
VEGF	O	O
expression	O	O
and	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
potential	O	O
agent	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
telangiectasias	O	O
.	O	O

Penetration	O	O
and	O	O
accumulation	O	O
of	O	O
moxifloxacin	O	O
in	O	O
uterine	O	O
tissue	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
whether	O	O
moxifloxacin	O	O
penetrates	O	O
the	O	O
uterine	O	O
tissue	O	O
and	O	O
accumulates	O	O
at	O	O
levels	O	O
sufficient	O	O
to	O	O
eradicate	O	O
the	O	O
major	O	O
pathogens	O	O
causing	O	O
pelvic	Condition	O
inflammatory	Condition	O
disease	Condition	O
(	O	O
PID	Condition	O
)	O	O
.	O	O

METHOD	O	O
In	O	O
a	O	O
prospective	O	O
,	O	O
multicenter	O	O
,	O	O
open-label	O	O
,	O	O
parallel-group	O	O
study	O	O
we	O	O
determined	O	O
the	O	O
concentration	O	O
of	O	O
moxifloxacin	O	O
in	O	O
plasma	O	O
and	O	O
uterine	O	O
tissue	O	O
after	O	O
a	O	O
single	O	O
,	O	O
400-mg	O	O
intravenous	O	O
dose	O	O
of	O	O
moxifloxacin	O	O
.	O	O

Study	O	O
participants	O	O
were	O	O
randomized	O	O
for	O	O
time	O	O
of	O	O
tissue	O	O
sampling	O	O
,	O	O
which	O	O
was	O	O
performed	O	O
1	O	O
,	O	O
2	O	O
,	O	O
4	O	O
,	O	O
7	O	O
,	O	O
or	O	O
24	O	O
hours	O	O
following	O	O
the	O	O
moxifloxacin	O	O
infusion	O	O
.	O	O

RESULTS	O	O
Of	O	O
43	SampleSize	SampleSize
participants	O	O
,	O	O
40	SampleSize	O
were	O	O
randomized	O	O
to	O	O
tissue	O	O
sampling	O	O
.	O	O

Moxifloxacin	O	O
accumulated	O	O
in	O	O
uterine	O	O
tissue	O	O
and	O	O
concentrations	O	O
were	O	O
highest	O	O
1	O	O
hour	O	O
after	O	O
infusion	O	O
in	O	O
both	O	O
plasma	O	O
and	O	O
tissue	O	O
.	O	O

Tissue	O	O
to	O	O
plasma	O	O
ratios	O	O
remained	O	O
between	O	O
1.7	O	O
and	O	O
2.1	O	O
for	O	O
24	O	O
hours	O	O
.	O	O

Moxifloxacin	O	O
was	O	O
found	O	O
to	O	O
be	O	O
safe	O	O
and	O	O
well	O	O
tolerated	O	O
.	O	O

CONCLUSION	O	O
Based	O	O
on	O	O
known	O	O
minimum	O	O
inhibitory	O	O
concentration	O	O
data	O	O
,	O	O
the	O	O
uterine	O	O
tissue	O	O
concentrations	O	O
of	O	O
moxifloxacin	O	O
achieved	O	O
over	O	O
24	O	O
hours	O	O
would	O	O
be	O	O
sufficient	O	O
to	O	O
eradicate	O	O
the	O	O
range	O	O
of	O	O
bacterial	O	O
pathogens	O	O
responsible	O	O
for	O	O
PID	O	O
.	O	O

Laser	O	O
conization	O	O
versus	O	O
cold	O	O
knife	O	O
conization	O	O
.	O	O

This	O	O
prospective	O	O
,	O	O
randomized	O	O
study	O	O
compares	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
measured	O	O
blood	O	O
loss	O	O
at	O	O
conization	O	O
and	O	O
within	O	O
24	O	O
hours	O	O
after	O	O
using	O	O
either	O	O
the	O	O
cold	O	O
knife	O	O
technique	O	O
or	O	O
the	O	O
carbon	O	O
dioxide	O	O
laser	O	O
scalpel	O	O
.	O	O

One	SampleSize	O
hundred	SampleSize	O
and	SampleSize	O
ten	SampleSize	O
consecutive	O	O
patients	O	O
were	O	O
evaluated	O	O
.	O	O

The	O	O
median	O	O
blood	O	O
loss	O	O
in	O	O
the	O	O
laser	O	O
group	O	O
of	O	O
55	O	O
patients	O	O
was	O	O
4.6	O	O
milliliters	O	O
at	O	O
,	O	O
and	O	O
within	O	O
,	O	O
24	O	O
hours	O	O
after	O	O
operation	O	O
compared	O	O
with	O	O
30.1	O	O
milliliters	O	O
in	O	O
the	O	O
cold	O	O
knife	O	O
group	O	O
of	O	O
55	O	O
patients	O	O
.	O	O

More	O	O
important	O	O
,	O	O
however	O	O
,	O	O
is	O	O
that	O	O
the	O	O
corresponding	O	O
figures	O	O
for	O	O
the	O	O
range	O	O
of	O	O
bleeding	O	O
were	O	O
0.4	O	O
to	O	O
155.4	O	O
milliliters	O	O
and	O	O
5.6	O	O
to	O	O
1,570.9	O	O
milliliters	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
incidence	O	O
rate	O	O
for	O	O
bleeding	O	O
complications	O	O
requiring	O	O
surgical	O	O
intervention	O	O
was	O	O
1.8	O	O
per	O	O
cet	O	O
for	O	O
the	O	O
laser	O	O
group	O	O
and	O	O
14.6	O	O
per	O	O
cent	O	O
for	O	O
the	O	O
cold	O	O
knife	O	O
group	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.015	O	O
--	O	O
Fischer	O	O
's	O	O
exact	O	O
test	O	O
.	O	O

Conization	O	O
for	O	O
treatment	O	O
of	O	O
premalignant	Condition	O
changes	Condition	O
of	Condition	O
the	Condition	O
cervix	Condition	O
uteri	Condition	O
will	O	O
probably	O	O
remain	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
for	O	O
some	O	O
time	O	O
to	O	O
come	O	O
.	O	O

It	O	O
is	O	O
our	O	O
opinion	O	O
that	O	O
,	O	O
in	O	O
the	O	O
future	O	O
,	O	O
laser	O	O
conization	O	O
will	O	O
replace	O	O
cold	O	O
knife	O	O
conization	O	O
.	O	O

Intravenous	O	O
or	O	O
intramuscular	O	O
teicoplanin	O	O
once	O	O
daily	O	O
for	O	O
skin	Condition	O
and	Condition	O
soft-tissue	Condition	O
infections	Condition	O
.	O	O

Teicoplanin	O	O
is	O	O
a	O	O
new	O	O
glycopeptide	O	O
antibiotic	O	O
with	O	O
potent	O	O
activity	O	O
against	O	O
gram-positive	O	O
bacteria	O	O
and	O	O
pharmacokinetics	O	O
that	O	O
allow	O	O
once	O	O
daily	O	O
administration	O	O
.	O	O

To	O	O
study	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
teicoplanin	O	O
for	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
,	O	O
75	SampleSize	O
patients	O	O
received	O	O
teicoplanin	O	O
intravenously	O	O
(	O	O
38	SampleSize	O
)	O	O
or	O	O
intramuscularly	O	O
(	O	O
37	SampleSize	O
,	O	O
of	O	O
which	O	O
16	SampleSize	O
were	O	O
outpatients	O	O
)	O	O
.	O	O

Of	O	O
62	SampleSize	SampleSize
clinically	O	O
evaluable	O	O
patients	O	O
,	O	O
97	O	O
percent	O	O
of	O	O
teicoplanin	O	O
iv	O	O
and	O	O
93	O	O
percent	O	O
of	O	O
teicoplanin	O	O
im	O	O
patients	O	O
were	O	O
cured	O	O
or	O	O
improved	O	O
.	O	O

All	O	O
teicoplanin	O	O
iv	O	O
patients	O	O
and	O	O
64	O	O
percent	O	O
of	O	O
teicoplanin	O	O
im	O	O
patients	O	O
were	O	O
cured	O	O
microbiologically	O	O
at	O	O
24-48	O	O
hours	O	O
posttherapy	O	O
.	O	O

Persistence	O	O
of	O	O
organisms	O	O
frequently	O	O
was	O	O
associated	O	O
with	O	O
skin	O	O
ulcers	O	O
or	O	O
abscess	O	O
cavities	O	O
and	O	O
usually	O	O
had	O	O
no	O	O
bearing	O	O
on	O	O
clinical	O	O
outcome	O	O
.	O	O

Possible	O	O
adverse	O	O
clinical	O	O
and	O	O
laboratory	O	O
reactions	O	O
caused	O	O
by	O	O
teicoplanin	O	O
occurred	O	O
in	O	O
4	O	O
of	O	O
38	O	O
teicoplanin	O	O
iv	O	O
patients	O	O
(	O	O
11	O	O
percent	O	O
)	O	O
and	O	O
in	O	O
8	O	O
of	O	O
37	O	O
teicoplanin	O	O
im	O	O
patients	O	O
(	O	O
22	O	O
percent	O	O
)	O	O
.	O	O

Reactions	O	O
were	O	O
mild	O	O
and	O	O
resolved	O	O
with	O	O
discontinuation	O	O
of	O	O
teicoplanin	O	O
in	O	O
most	O	O
cases	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
teicoplanin	O	O
appeared	O	O
to	O	O
be	O	O
safe	O	O
,	O	O
efficacious	O	O
,	O	O
and	O	O
convenient	O	O
for	O	O
both	O	O
hospital	O	O
staff	O	O
and	O	O
patients	O	O
,	O	O
and	O	O
potentially	O	O
cost-effective	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
skin	O	O
and	O	O
soft-tissue	O	O
infections	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
teicoplanin	O	O
appears	O	O
to	O	O
be	O	O
appropriate	O	O
for	O	O
outpatient	O	O
parenteral	O	O
therapy	O	O
.	O	O

A	O	O
comparative	O	O
study	O	O
of	O	O
methyldopa	O	O
and	O	O
labetalol	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
hypertension	Condition	O
.	O	O

1	O	O
Twenty	SampleSize	O
patients	O	O
with	O	O
essential	Condition	O
hypertension	Condition	O
completed	O	O
a	O	O
double-blind	O	O
,	O	O
dose-tritrated	O	O
,	O	O
cross-over	O	O
comparison	O	O
of	O	O
methyldopa	O	O
and	O	O
labetalol	O	O
.	O	O

2	O	O
Average	O	O
lying	O	O
BPs	O	O
(	O	O
systolic/diastolic	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
28/15	O	O
mmHg	O	O
with	O	O
methyldopa	O	O
and	O	O
by	O	O
23/15	O	O
mmHg	O	O
with	O	O
labetalol	O	O
.	O	O

3	O	O
Average	O	O
standing	O	O
BPs	O	O
(	O	O
systolic/diastolic	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
29/14	O	O
mmHg	O	O
with	O	O
methyldopa	O	O
and	O	O
by	O	O
29/15	O	O
mmHg	O	O
with	O	O
labetalol	O	O
.	O	O

4	O	O
Both	O	O
lying	O	O
and	O	O
standing	O	O
heart	O	O
rates	O	O
were	O	O
reduced	O	O
with	O	O
labetalol	O	O
.	O	O

5	O	O
It	O	O
is	O	O
concluded	O	O
that	O	O
the	O	O
antihypertensive	O	O
properties	O	O
of	O	O
labetalol	O	O
and	O	O
methyldopa	O	O
are	O	O
similar	O	O
but	O	O
that	O	O
larger	O	O
patient	O	O
populations	O	O
are	O	O
needed	O	O
to	O	O
study	O	O
the	O	O
relative	O	O
incidence	O	O
of	O	O
subjective	O	O
adverse	O	O
effects	O	O
.	O	O

Phytase	O	O
and	O	O
1alpha-hydroxycholecalciferol	O	O
supplementation	O	O
of	O	O
broiler	Condition	O
chickens	Condition	O
during	O	O
the	O	O
starting	O	O
and	O	O
growing/finishing	O	O
phases	O	O
.	O	O

Supplemental	O	O
1alpha-hydroxycholecalciferol	O	O
(	O	O
1alpha-OHD3	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
qualitatively	O	O
similar	O	O
and	O	O
quantitatively	O	O
additive	O	O
effects	O	O
to	O	O
exogenous	O	O
phytase	O	O
.	O	O

Two	O	O
experiments	O	O
were	O	O
conducted	O	O
from	O	O
0	O	O
to	O	O
35	O	O
d	O	O
in	O	O
floor	O	O
pens	O	O
to	O	O
determine	O	O
the	O	O
additive	O	O
effect	O	O
of	O	O
phytase	O	O
and	O	O
1alpha-OHD3	O	O
when	O	O
supplemented	O	O
to	O	O
Ca-	O	O
and	O	O
P-deficient	O	O
diets	O	O
.	O	O

In	O	O
both	O	O
experiments	O	O
,	O	O
at	O	O
least	O	O
4	O	O
replicates	O	O
per	O	O
treatment	O	O
(	O	O
50	SampleSize	O
chicks	O	O
per	O	O
replicate	O	O
)	O	O
were	O	O
used	O	O
.	O	O

Corn-soybean-meal-and	O	O
soybean-oil-based	O	O
diets	O	O
were	O	O
fed	O	O
and	O	O
birds	O	O
were	O	O
raised	O	O
in	O	O
a	O	O
house	O	O
impervious	O	O
to	O	O
ultraviolet	O	O
light	O	O
.	O	O

During	O	O
the	O	O
starter	O	O
phase	O	O
(	O	O
ST	O	O
)	O	O
,	O	O
from	O	O
0	O	O
to	O	O
18	O	O
d	O	O
,	O	O
chicks	O	O
were	O	O
fed	O	O
a	O	O
23	O	O
%	O	O
CP	O	O
diet	O	O
containing	O	O
0.60	O	O
%	O	O
Ca	O	O
and	O	O
0.47	O	O
%	O	O
total	O	O
P	O	O
(	O	O
tP	O	O
)	O	O
.	O	O

During	O	O
the	O	O
grower/finisher	O	O
phase	O	O
(	O	O
GF	O	O
)	O	O
,	O	O
from	O	O
19	O	O
to	O	O
35	O	O
d	O	O
,	O	O
birds	O	O
were	O	O
fed	O	O
a	O	O
19	O	O
%	O	O
CP	O	O
diet	O	O
containing	O	O
0.30	O	O
%	O	O
Ca	O	O
and	O	O
0.37	O	O
%	O	O
tP	O	O
.	O	O

A	O	O
combination	O	O
of	O	O
1,000	O	O
phytase	O	O
units/kg	O	O
of	O	O
Natuphos	O	O
phytase	O	O
and	O	O
5	O	O
microg/kg	O	O
of	O	O
1alpha-OHD3	O	O
(	O	O
P+1A	O	O
)	O	O
was	O	O
supplemented	O	O
to	O	O
some	O	O
of	O	O
the	O	O
feed	O	O
during	O	O
the	O	O
ST	O	O
and	O	O
GF	O	O
.	O	O

Diets	O	O
containing	O	O
adequate	O	O
Ca	O	O
and	O	O
P	O	O
were	O	O
also	O	O
fed	O	O
during	O	O
the	O	O
ST	O	O
(	O	O
0.90	O	O
%	O	O
Ca	O	O
,	O	O
0.68	O	O
%	O	O
tP	O	O
)	O	O
and	O	O
GF	O	O
(	O	O
0.80	O	O
%	O	O
Ca	O	O
,	O	O
0.67	O	O
%	O	O
tP	O	O
)	O	O
.	O	O

Performance	O	O
characteristics	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
rickets	O	O
and	O	O
tibial	O	O
dyschondroplasia	O	O
were	O	O
measured	O	O
at	O	O
18	O	O
and	O	O
35	O	O
d.	O	O
In	O	O
experiment	O	O
1	O	O
,	O	O
unsupplemented	O	O
chicks	O	O
performed	O	O
well	O	O
but	O	O
had	O	O
considerable	O	O
leg	O	O
problems	O	O
.	O	O

Chicks	O	O
fed	O	O
P+1A	O	O
during	O	O
the	O	O
ST	O	O
or	O	O
GF	O	O
did	O	O
not	O	O
perform	O	O
as	O	O
well	O	O
as	O	O
birds	O	O
fed	O	O
P+1A	O	O
throughout	O	O
.	O	O

Birds	O	O
fed	O	O
P+1A	O	O
throughout	O	O
performed	O	O
as	O	O
well	O	O
birds	O	O
fed	O	O
the	O	O
adequate	O	O
diets	O	O
without	O	O
any	O	O
indication	O	O
of	O	O
leg	O	O
problems	O	O
.	O	O

In	O	O
experiment	O	O
2	O	O
,	O	O
unsupplemented	O	O
birds	O	O
performed	O	O
similarly	O	O
to	O	O
unsupplemented	O	O
birds	O	O
in	O	O
experiment	O	O
1	O	O
.	O	O

However	O	O
,	O	O
chicks	O	O
fed	O	O
the	O	O
supplements	O	O
or	O	O
the	O	O
control	O	O
diets	O	O
did	O	O
not	O	O
perform	O	O
as	O	O
well	O	O
or	O	O
accumulate	O	O
as	O	O
much	O	O
bone	O	O
ash	O	O
as	O	O
birds	O	O
in	O	O
experiment	O	O
1	O	O
,	O	O
although	O	O
the	O	O
diets	O	O
were	O	O
formulated	O	O
identically	O	O
in	O	O
both	O	O
experiments	O	O
.	O	O

Diets	O	O
with	O	O
as	O	O
little	O	O
as	O	O
0.30	O	O
%	O	O
Ca	O	O
and	O	O
0.37	O	O
%	O	O
tP	O	O
appear	O	O
to	O	O
be	O	O
adequate	O	O
for	O	O
broilers	O	O
older	O	O
than	O	O
18	O	O
d	O	O
if	O	O
supplemented	O	O
with	O	O
the	O	O
correct	O	O
amounts	O	O
of	O	O
phytase	O	O
and	O	O
1alpha-OHD3	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
unknown	O	O
variables	O	O
that	O	O
may	O	O
limit	O	O
the	O	O
potential	O	O
of	O	O
broilers	O	O
in	O	O
terms	O	O
of	O	O
bone	O	O
mineralization	O	O
and	O	O
bone	O	O
pathology	O	O
,	O	O
even	O	O
when	O	O
adequate	O	O
diets	O	O
are	O	O
fed	O	O
.	O	O

Clinical	O	O
trial	O	O
:	O	O
exposure	O	O
to	O	O
ribavirin	O	O
predicts	O	O
EVR	O	O
and	O	O
SVR	O	O
in	O	O
patients	O	O
with	O	O
HCV	Condition	O
genotype	Condition	O
1	Condition	O
infection	O	O
treated	O	O
with	O	O
peginterferon	O	O
alpha-2a	O	O
plus	O	O
ribavirin	O	O
.	O	O

BACKGROUND	O	O
The	O	O
impact	O	O
of	O	O
reduced	O	O
drug	O	O
exposure	O	O
on	O	O
outcomes	O	O
in	O	O
patients	O	O
with	O	O
chronic	Condition	O
hepatitis	Condition	O
C	Condition	O
has	O	O
not	O	O
been	O	O
determined	O	O
in	O	O
routine	O	O
clinical	O	O
practice	O	O
.	O	O

AIM	O	O
To	O	O
examine	O	O
the	O	O
impact	O	O
of	O	O
exposure	O	O
to	O	O
peginterferon	O	O
alpha-2a	O	O
and	O	O
ribavirin	O	O
on	O	O
early	O	O
virological	O	O
response	O	O
(	O	O
EVR	O	O
)	O	O
and	O	O
sustained	O	O
virological	O	O
response	O	O
(	O	O
SVR	O	O
)	O	O
in	O	O
treatment-naive	O	O
patients	O	O
with	O	O
HCV	O	O
genotype	O	O
1	O	O
infection	O	O
enrolled	O	O
in	O	O
a	O	O
large	O	O
expanded	O	O
access	O	O
programme	O	O
.	O	O

METHODS	O	O
Eight	SampleSize	SampleSize
hundred	SampleSize	SampleSize
and	SampleSize	SampleSize
ninety-one	SampleSize	SampleSize
patients	O	O
treated	O	O
for	O	O
48	O	O
weeks	O	O
with	O	O
an	O	O
initial	O	O
ribavirin	O	O
dose	O	O
of	O	O
800	O	O
or	O	O
1000/1200	O	O
mg/day	O	O
were	O	O
evaluated	O	O
.	O	O

Ribavirin	O	O
1000	O	O
mg/day	O	O
(	O	O
<	O	O
75	O	O
kg	O	O
)	O	O
or	O	O
1200	O	O
mg/day	O	O
(	O	O
>	O	O
or=75	O	O
kg	O	O
)	O	O
and	O	O
peginterferon	O	O
alpha-2a	O	O
180	O	O
microg/week	O	O
were	O	O
considered	O	O
optimal	O	O
.	O	O

The	O	O
impact	O	O
of	O	O
reduced	O	O
drug	O	O
exposure	O	O
(	O	O
expressed	O	O
as	O	O
a	O	O
percentage	O	O
of	O	O
optimal	O	O
)	O	O
on	O	O
EVR	O	O
and	O	O
SVR	O	O
was	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
Mean	O	O
ribavirin	O	O
exposure	O	O
in	O	O
week	O	O
0-12	O	O
was	O	O
70	O	O
%	O	O
and	O	O
96	O	O
%	O	O
in	O	O
patients	O	O
assigned	O	O
to	O	O
ribavirin	O	O
800	O	O
and	O	O
1000/1200	O	O
mg/day	O	O
,	O	O
respectively	O	O
.	O	O

EVR	O	O
and	O	O
SVR	O	O
rates	O	O
were	O	O
lower	O	O
in	O	O
patients	O	O
assigned	O	O
to	O	O
ribavirin	O	O
800	O	O
than	O	O
1000/1200	O	O
mg/day	O	O
(	O	O
EVR	O	O
,	O	O
75	O	O
%	O	O
vs.	O	O
84	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
;	O	O
SVR	O	O
,	O	O
45	O	O
%	O	O
vs.	O	O
54	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
P	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
there	O	O
was	O	O
a	O	O
strong	O	O
correlation	O	O
between	O	O
achievement	O	O
of	O	O
EVR	O	O
and	O	O
SVR	O	O
and	O	O
ribavirin	O	O
dose	O	O
over	O	O
the	O	O
first	O	O
12	O	O
weeks	O	O
expressed	O	O
either	O	O
as	O	O
absolute	O	O
dose	O	O
or	O	O
proportion	O	O
of	O	O
optimal	O	O
dose	O	O
received	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
for	O	O
both	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Ribavirin	O	O
exposure	O	O
to	O	O
week	O	O
12	O	O
is	O	O
significantly	O	O
associated	O	O
with	O	O
EVR	O	O
and	O	O
SVR	O	O
in	O	O
genotype	O	O
1	O	O
patients	O	O
.	O	O

Maintenance	O	O
of	O	O
an	O	O
optimal	O	O
ribavirin	O	O
dose	O	O
is	O	O
the	O	O
most	O	O
important	O	O
modifiable	O	O
factor	O	O
during	O	O
combination	O	O
therapy	O	O
for	O	O
chronic	O	O
hepatitis	O	O
C	O	O
.	O	O

Timing	O	O
for	O	O
delivering	O	O
individualized	O	O
patient	O	O
education	O	O
intervention	O	O
to	O	O
Coronary	Condition	O
Artery	Condition	O
Bypass	Condition	O
Graft	Condition	O
patients	O	O
:	O	O
An	O	O
RCT	O	O
.	O	O

BACKGROUND	O	O
The	O	O
primary	O	O
focus	O	O
of	O	O
this	O	O
study	O	O
is	O	O
on	O	O
the	O	O
timing	O	O
of	O	O
the	O	O
delivery	O	O
of	O	O
education	O	O
to	O	O
patients	O	O
who	O	O
had	O	O
CABG	Condition	O
surgery	Condition	O
.	O	O

AIM	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
an	O	O
individualized	O	O
telephone	O	O
patient	O	O
education	O	O
intervention	O	O
,	O	O
delivered	O	O
at	O	O
two	O	O
different	O	O
points	O	O
in	O	O
time	O	O
(	O	O
1-2	O	O
days	O	O
pre-discharge	O	O
versus	O	O
1-2	O	O
days	O	O
post-discharge	O	O
)	O	O
in	O	O
enhancing	O	O
the	O	O
CABG	Condition	O
patient	O	O
's	O	O
knowledge	O	O
of	O	O
self-care	O	O
behaviours	O	O
,	O	O
performance	O	O
of	O	O
self-care	O	O
behaviours	O	O
,	O	O
and	O	O
symptom	O	O
frequency	O	O
.	O	O

METHOD	O	O
A	O	O
randomized	O	O
clinical	O	O
trial	O	O
that	O	O
included	O	O
a	O	O
convenience	O	O
sample	O	O
of	O	O
first	O	O
time	O	O
CABG	Condition	O
patients	O	O
.	O	O

Individuals	O	O
who	O	O
received	O	O
education	O	O
pre-discharge	O	O
were	O	O
compared	O	O
to	O	O
individuals	O	O
who	O	O
received	O	O
education	O	O
post-discharge	O	O
on	O	O
the	O	O
outcomes	O	O
.	O	O

RESULTS	O	O
Results	O	O
indicated	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
time	O	O
points	O	O
.	O	O

As	O	O
well	O	O
,	O	O
anxiety	O	O
levels	O	O
were	O	O
found	O	O
to	O	O
be	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
pre-discharge	O	O
group	O	O
than	O	O
the	O	O
post-discharge	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
individualized	O	O
nature	O	O
of	O	O
the	O	O
educational	O	O
intervention	O	O
may	O	O
have	O	O
accounted	O	O
for	O	O
non-significant	O	O
findings	O	O
reported	O	O
in	O	O
outcomes	O	O
between	O	O
the	O	O
two	O	O
time	O	O
points	O	O
.	O	O

PRACTICE	O	O
IMPLICATIONS	O	O
Nurses	O	O
may	O	O
consider	O	O
assessing	O	O
anxiety	O	O
levels	O	O
prior	O	O
to	O	O
delivery	O	O
of	O	O
educational	O	O
interventions	O	O
,	O	O
implement	O	O
interventions	O	O
aimed	O	O
at	O	O
reducing	O	O
anxiety	O	O
levels	O	O
,	O	O
and	O	O
provide	O	O
individualized	O	O
teaching	O	O
.	O	O

The	O	O
effectiveness	O	O
of	O	O
physical	O	O
activity	O	O
monitoring	O	O
and	O	O
distance	O	O
counselling	O	O
in	O	O
an	O	O
occupational	O	O
health	O	O
setting	O	O
--	O	O
a	O	O
research	O	O
protocol	O	O
for	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
(	O	O
CoAct	O	O
)	O	O
.	O	O

BACKGROUND	O	O
The	O	O
CoAct	O	O
(	O	O
Cocreating	O	O
Activity	O	O
)	O	O
study	O	O
is	O	O
investigating	O	O
a	O	O
novel	O	O
lifestyle	O	O
intervention	O	O
,	O	O
aimed	O	O
at	O	O
the	O	O
working	Condition	O
population	Condition	O
,	O	O
with	O	O
daily	O	O
activity	O	O
monitoring	O	O
and	O	O
distance	O	O
counselling	O	O
via	O	O
telephone	O	O
and	O	O
secure	O	O
web	O	O
messages	O	O
.	O	O

The	O	O
main	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
evaluate	O	O
the	O	O
effectiveness	O	O
of	O	O
lifestyle	O	O
counselling	O	O
on	O	O
the	O	O
level	O	O
of	O	O
physical	O	O
activity	O	O
in	O	O
an	O	O
occupational	O	O
health	O	O
setting	O	O
.	O	O

The	O	O
purposes	O	O
include	O	O
also	O	O
analysing	O	O
the	O	O
potential	O	O
effects	O	O
of	O	O
changes	O	O
in	O	O
physical	O	O
activity	O	O
on	O	O
productivity	O	O
at	O	O
work	O	O
and	O	O
sickness	O	O
absence	O	O
,	O	O
and	O	O
healthcare	O	O
costs	O	O
.	O	O

This	O	O
article	O	O
describes	O	O
the	O	O
design	O	O
of	O	O
the	O	O
study	O	O
and	O	O
the	O	O
participant	O	O
flow	O	O
until	O	O
and	O	O
including	O	O
randomization	O	O
.	O	O

METHODS/DESIGN	O	O
CoAct	O	O
is	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
with	O	O
two	O	O
arms	O	O
:	O	O
a	O	O
control	O	O
group	O	O
and	O	O
intervention	O	O
group	O	O
with	O	O
daily	O	O
activity	O	O
monitoring	O	O
and	O	O
distance	O	O
counselling	O	O
.	O	O

The	O	O
intervention	O	O
focuses	O	O
on	O	O
lifestyle	O	O
modification	O	O
and	O	O
takes	O	O
12	O	O
months	O	O
.	O	O

The	O	O
study	O	O
population	O	O
consists	O	O
of	O	O
volunteers	O	O
from	O	O
1100	SampleSize	O
eligible	O	O
employees	O	O
of	O	O
a	O	O
Finnish	O	O
insurance	O	O
company	O	O
.	O	O

The	O	O
primary	O	O
outcomes	O	O
of	O	O
this	O	O
study	O	O
are	O	O
change	O	O
in	O	O
physical	O	O
activity	O	O
measured	O	O
in	O	O
MET	O	O
minutes	O	O
per	O	O
week	O	O
,	O	O
work	O	O
productivity	O	O
and	O	O
sickness	O	O
absence	O	O
,	O	O
and	O	O
healthcare	O	O
utilisation	O	O
.	O	O

Secondary	O	O
outcomes	O	O
include	O	O
various	O	O
physiological	O	O
measures	O	O
.	O	O

Cost-effectiveness	O	O
analysis	O	O
will	O	O
also	O	O
be	O	O
performed	O	O
.	O	O

The	O	O
outcomes	O	O
will	O	O
be	O	O
measured	O	O
by	O	O
questionnaires	O	O
at	O	O
baseline	O	O
,	O	O
after	O	O
6	O	O
,	O	O
12	O	O
,	O	O
and	O	O
24	O	O
months	O	O
,	O	O
and	O	O
sickness	O	O
absence	O	O
will	O	O
be	O	O
obtained	O	O
from	O	O
the	O	O
employer	O	O
's	O	O
registers	O	O
.	O	O

DISCUSSION	O	O
No	O	O
trials	O	O
are	O	O
yet	O	O
available	O	O
that	O	O
have	O	O
evaluated	O	O
the	O	O
effectiveness	O	O
of	O	O
daily	O	O
physical	O	O
activity	O	O
monitoring	O	O
and	O	O
distance	O	O
counselling	O	O
in	O	O
an	O	O
occupational	O	O
health	O	O
setting	O	O
over	O	O
a	O	O
12	O	O
month	O	O
period	O	O
and	O	O
no	O	O
data	O	O
on	O	O
cost-effectiveness	O	O
of	O	O
such	O	O
intervention	O	O
are	O	O
available	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrials.gov	O	O
identifier	O	O
:	O	O
NCT00994565	O	O
.	O	O

Effects	O	O
of	O	O
a	O	O
leisure	O	O
programme	O	O
on	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
stress	O	O
of	O	O
individuals	O	O
with	O	O
ASD	Condition	O
.	O	O

BACKGROUND	O	O
Even	O	O
though	O	O
there	O	O
is	O	O
research	O	O
demonstrating	O	O
a	O	O
positive	O	O
relationship	O	O
between	O	O
leisure	O	O
participation	O	O
and	O	O
the	O	O
two	O	O
constructs	O	O
of	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
stress	O	O
reduction	O	O
,	O	O
current	O	O
conceptualisation	O	O
of	O	O
leisure	O	O
as	O	O
a	O	O
contributor	O	O
to	O	O
quality	O	O
of	O	O
life	O	O
is	O	O
limited	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
in	O	O
spite	O	O
of	O	O
improvements	O	O
in	O	O
accurate	O	O
diagnosis	O	O
of	O	O
autism	Condition	O
spectrum	Condition	O
disorder	Condition	O
(	O	O
ASD	O	O
)	O	O
at	O	O
increasingly	O	O
earlier	O	O
ages	O	O
and	O	O
proliferation	O	O
of	O	O
interventions	O	O
,	O	O
research	O	O
associated	O	O
with	O	O
leisure	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
for	O	O
people	O	O
with	O	O
ASD	O	O
is	O	O
lacking	O	O
.	O	O

METHODS	O	O
Therefore	O	O
,	O	O
a	O	O
study	O	O
using	O	O
a	O	O
repeated	O	O
measures	O	O
design	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
effects	O	O
of	O	O
a	O	O
1-year	O	O
group	O	O
leisure	O	O
programme	O	O
intended	O	O
to	O	O
facilitate	O	O
interaction	O	O
with	O	O
media	O	O
,	O	O
engagement	O	O
in	O	O
exercise	O	O
,	O	O
playing	O	O
games	O	O
and	O	O
doing	O	O
crafts	O	O
,	O	O
attending	O	O
events	O	O
,	O	O
and	O	O
participating	O	O
in	O	O
other	O	O
recreation	O	O
activities	O	O
on	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
stress	O	O
of	O	O
37	SampleSize	SampleSize
participants	O	O
(	O	O
22	SampleSize	O
male	Sex	O
,	O	O
15	SampleSize	O
female	Sex	O
)	O	O
,	O	O
ages	O	O
17-39	Age	O
(	O	O
M	O	O
=	O	O
31.49	Age	O
)	O	O
years	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
programme	O	O
)	O	O
diagnosed	O	O
with	O	O
an	O	O
ASD	O	Condition
and	O	O
a	O	O
group	O	O
of	O	O
34	SampleSize	O
adults	O	O
with	O	O
ASD	O	Condition
as	O	O
control	O	O
group	O	O
(	O	O
waiting	O	O
list	O	O
)	O	O
(	O	O
19	SampleSize	O
male	Sex	O
,	O	O
15	SampleSize	O
female	Sex	O
)	O	O
,	O	O
ages	O	O
24-38	Age	O
(	O	O
M	O	O
=	O	O
30	Age	O
at	O	O
programme	O	O
initiation	O	O
)	O	O
years	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
overall	O	O
scores	O	O
of	O	O
stress	O	O
levels	O	O
for	O	O
participants	O	O
over	O	O
the	O	O
course	O	O
of	O	O
the	O	O
study	O	O
and	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
four	O	O
factors	O	O
of	O	O
quality	O	O
of	O	O
life	O	O
that	O	O
were	O	O
measured	O	O
(	O	O
satisfaction	O	O
,	O	O
independence	O	O
,	O	O
competence	O	O
and	O	O
social	O	O
interaction	O	O
)	O	O
as	O	O
well	O	O
as	O	O
the	O	O
total	O	O
score	O	O
for	O	O
quality	O	O
of	O	O
life	O	O
from	O	O
baseline	O	O
to	O	O
the	O	O
end	O	O
of	O	O
the	O	O
intervention	O	O
12	O	O
months	O	O
later	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
control	O	O
group	O	O
demonstrated	O	O
no	O	O
significant	O	O
improvements	O	O
related	O	O
to	O	O
stress	O	O
or	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

Implications	O	O
of	O	O
these	O	O
findings	O	O
to	O	O
leisure	O	O
services	O	O
and	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
individuals	O	O
with	O	O
ASD	O	Condition
are	O	O
discussed	O	O
.	O	O

CONCLUSION	O	O
Findings	O	O
support	O	O
the	O	O
contention	O	O
that	O	O
participation	O	O
in	O	O
recreation	O	O
activities	O	O
positively	O	O
influenced	O	O
the	O	O
stress	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
adults	Age	O
with	O	O
ASD	O	O
.	O	O

Sex	O	O
risk	O	O
behavior	O	O
among	O	O
adolescent	Age	O
and	O	O
young	Age	O
adult	Age	O
children	Age	O
of	O	O
opiate	Condition	O
addicts	Condition	O
:	O	O
outcomes	O	O
from	O	O
the	O	O
focus	O	O
on	O	O
families	O	O
prevention	O	O
trial	O	O
and	O	O
an	O	O
examination	O	O
of	O	O
childhood	O	O
and	O	O
concurrent	O	O
predictors	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
.	O	O

This	O	O
study	O	O
reports	O	O
on	O	O
rates	O	O
and	O	O
predictors	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
among	O	O
a	O	O
sample	O	O
of	O	O
adolescent	Age	O
and	O	O
young	Age	O
adult	Age	O
children	Age	O
of	O	O
parents	O	O
enrolled	O	O
in	O	O
methadone	O	O
treatment	O	O
for	O	O
opiate	Condition	O
addiction	Condition	O
.	O	O

Data	O	O
are	O	O
from	O	O
151	SampleSize	O
participants	O	O
(	O	O
80	SampleSize	O
males	Sex	O
,	O	O
71	SampleSize	SampleSize
females	Sex	O
)	O	O
in	O	O
the	O	O
Focus	O	O
on	O	O
Families	O	O
(	O	O
FOF	O	O
)	O	O
project	O	O
,	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
a	O	O
family	O	O
intervention	O	O
and	O	O
a	O	O
study	O	O
of	O	O
the	O	O
development	O	O
of	O	O
at-risk	O	O
children	O	O
.	O	O

The	O	O
study	O	O
participants	O	O
are	O	O
children	O	O
of	O	O
parents	O	O
enrolled	O	O
in	O	O
methadone	O	O
treatment	O	O
between	O	O
1990	O	O
and	O	O
1993	O	O
.	O	O

Participants	O	O
were	O	O
interviewed	O	O
in	O	O
2005	O	O
when	O	O
they	O	O
ranged	O	O
in	O	O
age	O	O
from	O	O
15	Age	O
to	Age	O
29	Age	O
years	O	O
.	O	O

In	O	O
the	O	O
year	O	O
prior	O	O
to	O	O
the	O	O
follow-up	O	O
,	O	O
79	O	O
%	O	O
of	O	O
the	O	O
males	O	O
and	O	O
83	O	O
%	O	O
of	O	O
females	O	O
were	O	O
sexually	O	O
active	O	O
,	O	O
26	O	O
%	O	O
of	O	O
males	O	O
and	O	O
10	O	O
%	O	O
of	O	O
females	O	O
had	O	O
more	O	O
than	O	O
one	O	O
partner	O	O
in	O	O
the	O	O
prior	O	O
year	O	O
,	O	O
and	O	O
34	O	O
%	O	O
of	O	O
males	O	O
and	O	O
24	O	O
%	O	O
of	O	O
females	O	O
reported	O	O
having	O	O
sex	O	O
outside	O	O
of	O	O
a	O	O
committed	O	O
relationship	O	O
.	O	O

Twenty-four	O	O
percent	O	O
of	O	O
males	O	O
and	O	O
17	O	O
%	O	O
of	O	O
females	O	O
met	O	O
criteria	O	O
for	O	O
high-risk	O	O
sexual	O	O
behavior	O	O
,	O	O
reporting	O	O
casual	O	O
or	O	O
multiple	O	O
partners	O	O
in	O	O
the	O	O
prior	O	O
year	O	O
and	O	O
inconsistent	O	O
condom	O	O
use	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
intervention	O	O
and	O	O
control	O	O
conditions	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
in	O	O
terms	O	O
of	O	O
any	O	O
measure	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
examined	O	O
.	O	O

None	O	O
of	O	O
the	O	O
measures	O	O
of	O	O
parent	O	O
behavior	O	O
and	O	O
family	O	O
processes	O	O
derived	O	O
from	O	O
data	O	O
at	O	O
baseline	O	O
of	O	O
the	O	O
FOF	O	O
study	O	O
predicted	O	O
whether	O	O
participants	O	O
engaged	O	O
in	O	O
high-risk	O	O
sex	O	O
.	O	O

Among	O	O
measures	O	O
derived	O	O
from	O	O
data	O	O
collected	O	O
at	O	O
long-term	O	O
follow-up	O	O
,	O	O
however	O	O
,	O	O
having	O	O
ever	O	O
met	O	O
criteria	O	O
for	O	O
substance	O	O
abuse	O	O
or	O	O
dependence	O	O
predicted	O	O
greater	O	O
likelihood	O	O
of	O	O
high-risk	O	O
sexual	O	O
behavior	O	O
,	O	O
and	O	O
being	O	O
married	O	O
or	O	O
being	O	O
in	O	O
a	O	O
romantic	O	O
relationship	O	O
was	O	O
associated	O	O
with	O	O
lower	O	O
likelihood	O	O
of	O	O
high-risk	O	O
sexual	O	O
behavior	O	O
.	O	O

The	O	O
findings	O	O
point	O	O
to	O	O
the	O	O
important	O	O
role	O	O
of	O	O
committed	O	O
relationships	O	O
in	O	O
regulating	O	O
sex	O	O
risk	O	O
behavior	O	O
among	O	O
this	O	O
population	O	O
,	O	O
as	O	O
well	O	O
as	O	O
heightened	O	O
levels	O	O
of	O	O
sex	O	O
risk	O	O
behavior	O	O
associated	O	O
with	O	O
substance	O	O
abuse	O	O
or	O	O
dependence	O	O
.	O	O

Direct	O	O
trocar	O	O
insertion	O	O
vs.	O	O
Verres	O	O
needle	O	O
use	O	O
for	O	O
laparoscopic	Condition	O
sterilization	Condition	O
.	O	O

A	O	O
randomized	O	O
,	O	O
prospective	O	O
trial	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
direct	O	O
trocar	O	O
insertion	O	O
with	O	O
prior	O	O
peritoneal	O	O
insufflation	O	O
with	O	O
a	O	O
Verres	O	O
needle	O	O
for	O	O
laparoscopic	Condition	O
tubal	Condition	O
sterilization	Condition	O
.	O	O

Direct	O	O
trocar	O	O
insertion	O	O
resulted	O	O
in	O	O
fewer	O	O
instrument	O	O
insertions	O	O
(	O	O
21.8	O	O
%	O	O
vs.	O	O
7.8	O	O
%	O	O
)	O	O
and	O	O
use	O	O
of	O	O
smaller	O	O
volumes	O	O
of	O	O
CO2	O	O
(	O	O
2.67	O	O
vs.	O	O
2.32	O	O
L	O	O
)	O	O
.	O	O

Direct	O	O
trocar	O	O
use	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
operating	O	O
time	O	O
from	O	O
9	O	O
minutes	O	O
,	O	O
40	O	O
seconds	O	O
in	O	O
the	O	O
needle	O	O
group	O	O
to	O	O
7	O	O
minutes	O	O
,	O	O
30	O	O
seconds	O	O
in	O	O
the	O	O
trocar	O	O
group	O	O
.	O	O

Minor	O	O
omental	Condition	O
injuries	Condition	O
occurred	O	O
in	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
each	O	O
group	O	O
,	O	O
while	O	O
serious	O	O
complications	O	O
occurred	O	O
once	O	O
in	O	O
each	O	O
group	O	O
.	O	O

Docosahexaenoic	O	O
acid-rich	O	O
fish	O	O
oil	O	O
modulates	O	O
the	O	O
cerebral	O	O
hemodynamic	O	O
response	O	O
to	O	O
cognitive	O	O
tasks	O	O
in	O	O
healthy	Condition	O
young	Age	O
adults	Age	O
.	O	O

A	O	O
number	O	O
of	O	O
recent	O	O
studies	O	O
have	O	O
assessed	O	O
the	O	O
impact	O	O
of	O	O
dietary	O	O
omega-3	O	O
polyunsaturated	O	O
fatty	O	O
acids	O	O
(	O	O
n-3	O	O
PUFAs	O	O
)	O	O
on	O	O
behavioral	O	O
outcomes	O	O
;	O	O
however	O	O
,	O	O
very	O	O
little	O	O
attention	O	O
has	O	O
been	O	O
given	O	O
to	O	O
their	O	O
impact	O	O
upon	O	O
brain	O	O
function	O	O
in	O	O
physiological	O	O
terms	O	O
.	O	O

Sixty-five	SampleSize	O
healthy	Condition	O
adults	Age	Age
aged	O	O
18-29yrs	Age	O
took	O	O
part	O	O
in	O	O
this	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
assessing	O	O
the	O	O
effects	O	O
of	O	O
12	O	O
weeks	O	O
daily	O	O
dietary	O	O
supplementation	O	O
with	O	O
docosahexaenoic	O	O
acid-rich	O	O
fish	O	O
oil	O	O
(	O	O
1g	O	O
,	O	O
2g	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
olive	O	O
oil	O	O
)	O	O
.	O	O

Relative	O	O
changes	O	O
in	O	O
the	O	O
concentration	O	O
of	O	O
oxyhemoglobin	O	O
and	O	O
deoxyhemoglobin	O	O
were	O	O
assessed	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
using	O	O
near-infrared	O	O
spectroscopy	O	O
during	O	O
performance	O	O
of	O	O
nine	O	O
computerized	O	O
cognitive	O	O
tasks	O	O
.	O	O

Supplementation	O	O
with	O	O
both	O	O
doses	O	O
of	O	O
fish	O	O
oil	O	O
,	O	O
in	O	O
comparison	O	O
with	O	O
placebo	O	O
,	O	O
resulted	O	O
in	O	O
significantly	O	O
increased	O	O
concentrations	O	O
of	O	O
oxyhemoglobin	O	O
and	O	O
total	O	O
levels	O	O
of	O	O
hemoglobin	O	O
,	O	O
indicative	O	O
of	O	O
increased	O	O
cerebral	O	O
blood	O	O
flow	O	O
,	O	O
during	O	O
the	O	O
cognitive	O	O
tasks	O	O
.	O	O

Changes	O	O
in	O	O
hemodynamic	O	O
response	O	O
to	O	O
tasks	O	O
were	O	O
not	O	O
accompanied	O	O
by	O	O
consistent	O	O
changes	O	O
in	O	O
cognitive	O	O
performance	O	O
.	O	O

Comparative	O	O
drug	O	O
effects	O	O
and	O	O
abuse	O	O
liability	O	O
of	O	O
lorazepam	O	O
,	O	O
buspirone	O	O
,	O	O
and	O	O
secobarbital	O	O
in	O	O
nondependent	Condition	O
subjects	O	O
.	O	O

The	O	O
pharmacologic	O	O
effects	O	O
of	O	O
lorazepam	O	O
(	O	O
2	O	O
mg	O	O
)	O	O
,	O	O
buspirone	O	O
(	O	O
20	O	O
mg	O	O
,	O	O
10	O	O
mg	O	O
)	O	O
,	O	O
secobarbital	O	O
(	O	O
100	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
were	O	O
compared	O	O
in	O	O
15	SampleSize	O
male	Sex	O
,	O	O
experienced	O	O
,	O	O
intermittent	O	O
nontherapeutic	O	O
drug	Condition	O
users	Condition	O
.	O	O

All	O	O
drugs	O	O
produced	O	O
a	O	O
drug	O	O
effect	O	O
,	O	O
however	O	O
,	O	O
buspirone	O	O
20	O	O
mg	O	O
was	O	O
significantly	O	O
less	O	O
liked	O	O
than	O	O
were	O	O
lorazepam	O	O
,	O	O
secobarbital	O	O
,	O	O
or	O	O
buspirone	O	O
10	O	O
mg	O	O
(	O	O
p	O	O
less	O	O
than	O	O
.05	O	O
)	O	O
but	O	O
not	O	O
placebo	O	O
.	O	O

Lorazepam	O	O
was	O	O
liked	O	O
better	O	O
than	O	O
were	O	O
other	O	O
drugs	O	O
only	O	O
at	O	O
1	O	O
hour	O	O
and	O	O
only	O	O
compared	O	O
with	O	O
buspirone	O	O
20	O	O
and	O	O
placebo	O	O
.	O	O

Compared	O	O
with	O	O
other	O	O
drugs	O	O
,	O	O
lorazepam	O	O
drug	O	O
effects	O	O
were	O	O
greater	O	O
and	O	O
resulted	O	O
in	O	O
more	O	O
prolonged	O	O
impairment	O	O
of	O	O
a	O	O
motor	O	O
tracking	O	O
task	O	O
,	O	O
standing	O	O
steadiness	O	O
,	O	O
and	O	O
memory	O	O
.	O	O

Buspirone	O	O
20	O	O
mg	O	O
significantly	O	O
impaired	O	O
memory	O	O
at	O	O
1	O	O
hour	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

Subjects	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
identify	O	O
buspirone	O	O
as	O	O
unfamiliar	O	O
.	O	O

Because	O	O
buspirone	O	O
20	O	O
mg	O	O
was	O	O
less	O	O
liked	O	O
than	O	O
were	O	O
other	O	O
drugs	O	O
,	O	O
dose	O	O
escalation	O	O
as	O	O
part	O	O
of	O	O
drug	O	O
abuse	O	O
is	O	O
not	O	O
likely	O	O
to	O	O
occur	O	O
.	O	O

Lorazepam	O	O
also	O	O
was	O	O
not	O	O
particularly	O	O
liked	O	O
and	O	O
was	O	O
not	O	O
different	O	O
from	O	O
placebo	O	O
on	O	O
most	O	O
subjective	O	O
abuse-relevant	O	O
measures	O	O
.	O	O

Comparison	O	O
of	O	O
thiopentone/guaifenesin	O	O
,	O	O
ketamine/guaifenesin	O	O
and	O	O
ketamine/midazolam	O	O
for	O	O
the	O	O
induction	O	O
of	O	O
horses	O	O
to	O	O
be	O	O
anaesthetised	Condition	O
with	O	O
isoflurane	O	O
.	O	O

Forty-eight	SampleSize	O
horses	O	O
subjected	O	O
to	O	O
elective	Condition	O
surgery	Condition	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
three	SampleSize	O
groups	O	O
of	O	O
16	SampleSize	O
horses	O	O
.	O	O

After	O	O
premedication	O	O
with	O	O
0.1	O	O
mg/kg	O	O
acepromazine	O	O
intramuscularly	O	O
and	O	O
0.6	O	O
mg/kg	O	O
xylazine	O	O
intravenously	O	O
,	O	O
anaesthesia	O	O
was	O	O
induced	O	O
either	O	O
with	O	O
2	O	O
g	O	O
thiopentone	O	O
in	O	O
500	O	O
ml	O	O
of	O	O
a	O	O
10	O	O
per	O	O
cent	O	O
guaifenesin	O	O
solution	O	O
,	O	O
given	O	O
intravenously	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
ml/kg	O	O
(	O	O
group	O	O
TG	O	O
)	O	O
,	O	O
or	O	O
with	O	O
100	O	O
mg/kg	O	O
guaifenesin	O	O
and	O	O
2.2	O	O
mg/kg	O	O
ketamine	O	O
given	O	O
intravenously	O	O
(	O	O
group	O	O
KG	O	O
)	O	O
,	O	O
or	O	O
with	O	O
0.06	O	O
mg/kg	O	O
midazolam	O	O
,	O	O
and	O	O
2.2	O	O
mg/kg	O	O
ketamine	O	O
given	O	O
intravenously	O	O
(	O	O
group	O	O
KM	O	O
)	O	O
.	O	O

Anaesthesia	O	O
was	O	O
maintained	O	O
with	O	O
isoflurane	O	O
.	O	O

The	O	O
mean	O	O
(	O	O
sd	O	O
)	O	O
end	O	O
tidal	O	O
isoflurane	O	O
concentration	O	O
(	O	O
per	O	O
cent	O	O
)	O	O
needed	O	O
to	O	O
maintain	O	O
a	O	O
light	O	O
surgical	O	O
anaesthesia	O	O
(	O	O
stage	O	O
III	O	O
,	O	O
plane	O	O
2	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
KM	O	O
(	O	O
0.91	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
than	O	O
in	O	O
groups	O	O
TG	O	O
(	O	O
1.11	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
and	O	O
KG	O	O
(	O	O
1.14	O	O
[	O	O
0.03	O	O
]	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
(	O	O
sd	O	O
)	O	O
arterial	O	O
pressure	O	O
(	O	O
mmHg	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
KG	O	O
(	O	O
67.4	O	O
[	O	O
2.07	O	O
]	O	O
)	O	O
than	O	O
in	O	O
groups	O	O
TC	O	O
(	O	O
75.6	O	O
[	O	O
2.23	O	O
]	O	O
)	O	O
and	O	O
KM	O	O
(	O	O
81.0	O	O
[	O	O
2.16	O	O
]	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
logarithm	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
,	O	O
recovery	O	O
time	O	O
or	O	O
quality	O	O
of	O	O
recovery	O	O
between	O	O
the	O	O
three	O	O
induction	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
pronounced	O	O
ataxia	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
horses	O	O
of	O	O
group	O	O
KM	O	O
,	O	O
especially	O	O
after	O	O
periods	O	O
of	O	O
anaesthesia	O	O
lasting	O	O
less	O	O
than	O	O
75	O	O
minutes	O	O
.	O	O

Human	O	O
recombinant	O	O
GM-CSF	O	O
in	O	O
allogeneic	O	O
bone	O	O
marrow	O	O
transplantation	O	O
for	O	O
leukaemia	O	O
:	O	O
double-blind	O	O
placebo	O	O
controlled	O	O
trial	O	O
.	O	O

A	O	O
double-blind	O	O
randomised	O	O
trial	O	O
compared	O	O
20	SampleSize	SampleSize
patients	O	O
with	O	O
leukaemia	Condition	O
receiving	O	O
human	O	O
recombinant	O	O
granulocyte	O	O
macrophage	O	O
colony	O	O
stimulating	O	O
factor	O	O
(	O	O
GM	O	O
CSF	O	O
)	O	O
,	O	O
with	O	O
20	SampleSize	O
patients	O	O
receiving	O	O
placebo	O	O
for	O	O
14	O	O
days	O	O
after	O	O
allogeneic	O	O
matched	O	O
sibling	O	O
bone	O	O
marrow	O	O
transplantation	O	O
.	O	O

The	O	O
median	O	O
neutrophil	O	O
count	O	O
at	O	O
14	O	O
days	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
GM	O	O
CSF	O	O
group	O	O
(	O	O
1.90	O	O
vs.	O	O
0.46	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/l	O	O
)	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
hospital	O	O
stay	O	O
,	O	O
the	O	O
number	O	O
of	O	O
antibiotic	O	O
days	O	O
,	O	O
and	O	O
the	O	O
number	O	O
of	O	O
fever	O	O
days	O	O
was	O	O
the	O	O
same	O	O
for	O	O
both	O	O
patient	O	O
groups	O	O
.	O	O

The	O	O
lymphocyte	O	O
count	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
GM-CSF	O	O
group	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
between	O	O
days	O	O
10	O	O
and	O	O
15	O	O
after	O	O
transplantation	O	O
.	O	O

The	O	O
GM-CSF	O	O
group	O	O
had	O	O
lower	O	O
haemoglobin	O	O
concentrations	O	O
and	O	O
platelets	O	O
counts	O	O
,	O	O
and	O	O
higher	O	O
plasma	O	O
urea	O	O
creatinine	O	O
and	O	O
bilirubin	O	O
,	O	O
than	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
that	O	O
GM	O	O
CSF	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
greater	O	O
incidence	O	O
of	O	O
leukaemic	O	O
relapse	O	O
.	O	O

Gefitinib	O	O
plus	O	O
best	O	O
supportive	O	O
care	O	O
in	O	O
previously	O	O
treated	O	O
patients	O	O
with	O	O
refractory	Condition	O
advanced	Condition	O
non-small-cell	Condition	O
lung	Condition	O
cancer	Condition	O
:	O	O
results	O	O
from	O	O
a	O	O
randomised	O	O
,	O	O
placebo-controlled	O	O
,	O	O
multicentre	O	O
study	O	O
(	O	O
Iressa	O	O
Survival	O	O
Evaluation	O	O
in	O	O
Lung	O	O
Cancer	O	O
)	O	O
.	O	O

BACKGROUND	O	O
This	O	O
placebo-controlled	O	O
phase	O	O
III	O	O
study	O	O
investigated	O	O
the	O	O
effect	O	O
on	O	O
survival	O	O
of	O	O
gefitinib	O	O
as	O	O
second-line	O	O
or	O	O
third-line	O	O
treatment	O	O
for	O	O
patients	O	O
with	O	O
locally	Condition	O
advanced	Condition	O
or	Condition	O
metastatic	Condition	O
non-small-cell	Condition	O
lung	Condition	O
cancer	Condition	O
.	O	O

METHODS	O	O
1692	SampleSize	SampleSize
patients	O	O
who	O	O
were	O	O
refractory	Condition	O
to	Condition	O
or	Condition	O
intolerant	Condition	O
of	O	O
their	O	O
latest	Condition	O
chemotherapy	Condition	O
regimen	O	O
were	O	O
randomly	O	O
assigned	O	O
in	O	O
a	O	O
ratio	O	O
of	O	O
two	O	O
to	O	O
one	O	O
either	O	O
gefitinib	O	O
(	O	O
250	O	O
mg/day	O	O
)	O	O
or	O	O
placebo	O	O
,	O	O
plus	O	O
best	O	O
supportive	O	O
care	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O	O
was	O	O
survival	O	O
in	O	O
the	O	O
overall	O	O
population	O	O
of	O	O
patients	O	O
and	O	O
those	O	O
with	O	O
adenocarcinoma	O	O
.	O	O

The	O	O
primary	O	O
analysis	O	O
of	O	O
the	O	O
population	O	O
for	O	O
survival	O	O
was	O	O
by	O	O
intention	O	O
to	O	O
treat	O	O
.	O	O

This	O	O
study	O	O
has	O	O
been	O	O
submitted	O	O
for	O	O
registration	O	O
with	O	O
ClinicalTrials.gov	O	O
,	O	O
number	O	O
1839IL/709	O	O
.	O	O

FINDINGS	O	O
1129	SampleSize	SampleSize
patients	O	O
were	O	O
assigned	O	O
gefitinib	O	O
and	O	O
563	SampleSize	O
placebo	O	O
.	O	O

At	O	O
median	O	O
follow-up	O	O
of	O	O
7.2	O	O
months	O	O
,	O	O
median	O	O
survival	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
groups	O	O
in	O	O
the	O	O
overall	O	O
population	O	O
(	O	O
5.6	O	O
months	O	O
for	O	O
gefitinib	O	O
and	O	O
5.1	O	O
months	O	O
for	O	O
placebo	O	O
;	O	O
hazard	O	O
ratio	O	O
0.89	O	O
[	O	O
95	O	O
%	O	O
CI	O	O
0.77-1.02	O	O
]	O	O
,	O	O
p=0.087	O	O
)	O	O
or	O	O
among	O	O
the	O	O
812	SampleSize	O
patients	O	O
with	O	O
adenocarcinoma	Condition	O
(	O	O
6.3	O	O
months	O	O
vs	O	O
5.4	O	O
months	O	O
;	O	O
0.84	O	O
[	O	O
0.68-1.03	O	O
]	O	O
,	O	O
p=0.089	O	O
)	O	O
.	O	O

Preplanned	O	O
subgroup	O	O
analyses	O	O
showed	O	O
significantly	O	O
longer	O	O
survival	O	O
in	O	O
the	O	O
gefitinib	O	O
group	O	O
than	O	O
the	O	O
placebo	O	O
group	O	O
for	O	O
never-smokers	O	O
(	O	O
n=375	O	O
;	O	O
0.67	O	O
[	O	O
0.49-0.92	O	O
]	O	O
,	O	O
p=0.012	O	O
;	O	O
median	O	O
survival	O	O
8.9	O	O
vs	O	O
6.1	O	O
months	O	O
)	O	O
and	O	O
patients	O	O
of	O	O
Asian	O	O
origin	O	O
(	O	O
n=342	O	O
;	O	O
0.66	O	O
[	O	O
0.48-0.91	O	O
]	O	O
,	O	O
p=0.01	O	O
;	O	O
median	O	O
survival	O	O
9.5	O	O
vs	O	O
5.5	O	O
months	O	O
)	O	O
.	O	O

Gefitinib	O	O
was	O	O
well	O	O
tolerated	O	O
,	O	O
as	O	O
in	O	O
previous	O	O
studies	O	O
.	O	O

INTERPRETATION	O	O
Treatment	O	O
with	O	O
gefitinib	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
significant	O	O
improvement	O	O
in	O	O
survival	O	O
in	O	O
either	O	O
coprimary	O	O
population	O	O
.	O	O

There	O	O
was	O	O
pronounced	O	O
heterogeneity	O	O
in	O	O
survival	O	O
outcomes	O	O
between	O	O
groups	O	O
of	O	O
patients	O	O
,	O	O
with	O	O
some	O	O
evidence	O	O
of	O	O
benefit	O	O
among	O	O
never-smokers	O	O
and	O	O
patients	O	O
of	O	O
Asian	O	O
origin	O	O
.	O	O

Role	O	O
of	O	O
posterior	O	O
tibial	O	O
nerve	O	O
stimulation	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
refractory	O	O
monosymptomatic	O	O
nocturnal	O	O
enuresis	O	O
:	O	O
a	O	O
pilot	O	O
study	O	O
.	O	O

PURPOSE	O	O
We	O	O
evaluated	O	O
the	O	O
early	O	O
clinical	O	O
and	O	O
urodynamic	O	O
results	O	O
of	O	O
posterior	O	O
tibial	O	O
nerve	O	O
stimulation	O	O
in	O	O
patients	O	O
with	O	O
refractory	Condition	O
monosymptomatic	Condition	O
nocturnal	Condition	O
enuresis	Condition	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
We	O	O
randomly	O	O
assigned	O	O
28	SampleSize	SampleSize
patients	O	O
with	O	O
refractory	O	O
monosymptomatic	O	O
nocturnal	O	O
enuresis	O	O
to	O	O
2	O	O
equal	O	O
groups	O	O
.	O	O

Group	O	O
1	O	O
received	O	O
a	O	O
weekly	O	O
session	O	O
of	O	O
posterior	O	O
tibial	O	O
nerve	O	O
stimulation	O	O
for	O	O
12	O	O
weeks	O	O
and	O	O
group	O	O
2	O	O
was	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

Evaluation	O	O
was	O	O
performed	O	O
in	O	O
each	O	O
group	O	O
at	O	O
baseline	O	O
and	O	O
after	O	O
posterior	O	O
tibial	O	O
nerve	O	O
stimulation	O	O
to	O	O
compare	O	O
clinical	O	O
and	O	O
urodynamic	O	O
findings	O	O
.	O	O

Another	O	O
clinical	O	O
assessment	O	O
was	O	O
done	O	O
3	O	O
months	O	O
after	O	O
the	O	O
first	O	O
followup	O	O
.	O	O

RESULTS	O	O
The	O	O
2	O	O
groups	O	O
were	O	O
comparable	O	O
in	O	O
baseline	O	O
clinical	O	O
and	O	O
urodynamic	O	O
data	O	O
.	O	O

Overall	O	O
,	O	O
13	O	O
patients	O	O
(	O	O
46.4	O	O
%	O	O
)	O	O
had	O	O
detrusor	O	O
overactivity	O	O
and	O	O
14	O	O
(	O	O
50	O	O
%	O	O
)	O	O
had	O	O
decreased	O	O
bladder	O	O
capacity	O	O
.	O	O

After	O	O
treatment	O	O
11	O	O
group	O	O
1	O	O
patients	O	O
(	O	O
78.6	O	O
%	O	O
)	O	O
had	O	O
a	O	O
partial	O	O
or	O	O
full	O	O
response	O	O
to	O	O
posterior	O	O
tibial	O	O
nerve	O	O
stimulation	O	O
but	O	O
only	O	O
2	O	O
(	O	O
14.3	O	O
%	O	O
)	O	O
in	O	O
group	O	O
2	O	O
had	O	O
a	O	O
partial	O	O
response	O	O
(	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
average	O	O
number	O	O
of	O	O
wet	O	O
nights	O	O
in	O	O
group	O	O
1	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
at	O	O
baseline	O	O
(	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
.	O	O

All	O	O
urodynamic	O	O
parameters	O	O
significantly	O	O
improved	O	O
in	O	O
group	O	O
1	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
number	O	O
of	O	O
wet	O	O
nights	O	O
and	O	O
urodynamic	O	O
parameters	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
in	O	O
group	O	O
2	O	O
.	O	O

At	O	O
3-month	O	O
followup	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
a	O	O
partial	O	O
or	O	O
full	O	O
response	O	O
in	O	O
group	O	O
1	O	O
had	O	O
decreased	O	O
from	O	O
11	O	O
(	O	O
78.6	O	O
%	O	O
)	O	O
to	O	O
6	O	O
(	O	O
42.9	O	O
%	O	O
)	O	O
.	O	O

No	O	O
change	O	O
was	O	O
evident	O	O
in	O	O
group	O	O
2	O	O
.	O	O

CONCLUSIONS	O	O
Posterior	O	O
tibial	O	O
nerve	O	O
stimulation	O	O
can	O	O
be	O	O
a	O	O
viable	O	O
treatment	O	O
option	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
refractory	O	O
monosymptomatic	O	O
nocturnal	O	O
enuresis	O	O
.	O	O

However	O	O
,	O	O
deterioration	O	O
in	O	O
some	O	O
responders	O	O
with	O	O
time	O	O
suggests	O	O
the	O	O
need	O	O
for	O	O
maintenance	O	O
protocols	O	O
.	O	O

[	O	O
Clinical	O	O
observation	O	O
on	O	O
different	O	O
acupuncture	O	O
and	O	O
moxibustion	O	O
therapies	O	O
for	O	O
treatment	O	O
of	O	O
postsurgical	Condition	O
gastroparesis	Condition	O
syndrome	Condition	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
optimize	O	O
therapy	O	O
of	O	O
acupuncture	O	O
and	O	O
moxibustion	O	O
for	O	O
postsurgical	O	O
gastroparesis	O	O
syndrome	O	O
(	O	O
PGS	Condition	O
)	O	O
.	O	O

METHODS	O	O
Forty-one	SampleSize	O
cases	O	O
of	O	O
PGS	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
3	O	O
groups	O	O
in	O	O
order	O	O
of	O	O
visiting	O	O
.	O	O

Group	O	O
A	O	O
(	O	O
n	O	O
=	O	O
17	SampleSize	O
)	O	O
were	O	O
treated	O	O
by	O	O
warming	O	O
needle	O	O
moxibustion	O	O
,	O	O
group	O	O
B	O	O
(	O	O
n	O	O
=	O	O
12	SampleSize	O
)	O	O
by	O	O
acupuncture	O	O
plus	O	O
auricular	O	O
point	O	O
sticking	O	O
,	O	O
and	O	O
group	O	O
C	O	O
(	O	O
n	O	O
=	O	O
12	SampleSize	O
)	O	O
by	O	O
routine	O	O
acupuncture	O	O
.	O	O

Changes	O	O
of	O	O
gastric	O	O
drainage	O	O
volume	O	O
,	O	O
therapeutic	O	O
times	O	O
and	O	O
cured	O	O
rate	O	O
were	O	O
investigated	O	O
in	O	O
the	O	O
3	O	O
groups	O	O
.	O	O

RESULTS	O	O
All	O	O
the	O	O
3	O	O
therapeutic	O	O
methods	O	O
could	O	O
significantly	O	O
decrease	O	O
gastric	O	O
drainage	O	O
volume	O	O
.	O	O

The	O	O
cured	O	O
rate	O	O
was	O	O
100.0	O	O
%	O	O
and	O	O
the	O	O
therapeutic	O	O
times	O	O
was	O	O
(	O	O
7.24	O	O
+/-	O	O
3.87	O	O
)	O	O
in	O	O
the	O	O
group	O	O
A	O	O
,	O	O
66.7	O	O
%	O	O
,	O	O
(	O	O
9.83	O	O
+/-	O	O
4.60	O	O
)	O	O
times	O	O
in	O	O
the	O	O
group	O	O
B	O	O
and	O	O
75.0	O	O
%	O	O
,	O	O
(	O	O
15.25	O	O
+/-	O	O
3.81	O	O
)	O	O
times	O	O
in	O	O
the	O	O
group	O	O
C	O	O
,	O	O
with	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
cured	O	O
rate	O	O
and	O	O
the	O	O
therapeutic	O	O
times	O	O
among	O	O
the	O	O
3	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
warming	O	O
needle	O	O
moxibustion	O	O
is	O	O
the	O	O
best	O	O
method	O	O
for	O	O
PGS	O	O
,	O	O
with	O	O
less	O	O
therapeutic	O	O
times	O	O
,	O	O
high	O	O
cured	O	O
rate	O	O
and	O	O
rapid	O	O
effect	O	O
.	O	O

The	O	O
development	O	O
of	O	O
a	O	O
web-	O	O
and	O	O
a	O	O
print-based	O	O
decision	O	O
aid	O	O
for	O	O
prostate	Condition	O
cancer	Condition	O
screening	O	O
.	O	O

BACKGROUND	O	O
Whether	O	O
early	O	O
detection	O	O
and	O	O
treatment	O	O
of	O	O
prostate	O	O
cancer	O	O
(	O	O
PCa	O	O
)	O	O
will	O	O
reduce	O	O
disease-related	O	O
mortality	O	O
remains	O	O
uncertain	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
tools	O	O
are	O	O
needed	O	O
to	O	O
facilitate	O	O
informed	O	O
decision	O	O
making	O	O
.	O	O

While	O	O
there	O	O
have	O	O
been	O	O
several	O	O
decision	O	O
aids	O	O
(	O	O
DAs	O	O
)	O	O
developed	O	O
and	O	O
tested	O	O
,	O	O
very	O	O
few	O	O
have	O	O
included	O	O
an	O	O
exercise	O	O
to	O	O
help	O	O
men	O	O
clarify	O	O
their	O	O
values	O	O
and	O	O
preferences	O	O
about	O	O
PCa	O	O
screening	O	O
.	O	O

Further	O	O
,	O	O
only	O	O
one	O	O
DA	O	O
has	O	O
utilized	O	O
an	O	O
interactive	O	O
web-based	O	O
format	O	O
,	O	O
which	O	O
allows	O	O
for	O	O
an	O	O
expansion	O	O
and	O	O
customization	O	O
of	O	O
the	O	O
material	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
development	O	O
of	O	O
two	O	O
DAs	O	O
,	O	O
a	O	O
booklet	O	O
and	O	O
an	O	O
interactive	O	O
website	O	O
,	O	O
each	O	O
with	O	O
a	O	O
values	O	O
clarification	O	O
component	O	O
and	O	O
designed	O	O
for	O	O
use	O	O
in	O	O
diverse	O	O
settings	O	O
.	O	O

METHODS	O	O
We	O	O
conducted	O	O
two	O	O
feasibility	O	O
studies	O	O
to	O	O
assess	O	O
men	Sex	O
's	Sex	O
(	O	O
45-70	Age	O
years	O	O
)	O	O
Internet	O	O
access	O	O
and	O	O
their	O	O
willingness	O	O
to	O	O
use	O	O
a	O	O
web-	O	O
vs.	O	O
a	O	O
print-based	O	O
tool	O	O
.	O	O

The	O	O
booklet	O	O
was	O	O
adapted	O	O
from	O	O
two	O	O
previous	O	O
versions	O	O
evaluated	O	O
in	O	O
randomized	O	O
controlled	O	O
trials	O	O
(	O	O
RCTs	O	O
)	O	O
and	O	O
the	O	O
website	O	O
was	O	O
created	O	O
to	O	O
closely	O	O
match	O	O
the	O	O
content	O	O
of	O	O
the	O	O
revised	O	O
booklet	O	O
.	O	O

Usability	O	O
testing	O	O
was	O	O
conducted	O	O
to	O	O
obtain	O	O
feedback	O	O
regarding	O	O
draft	O	O
versions	O	O
of	O	O
the	O	O
materials	O	O
.	O	O

The	O	O
tools	O	O
were	O	O
also	O	O
reviewed	O	O
by	O	O
a	O	O
plain	O	O
language	O	O
expert	O	O
and	O	O
the	O	O
interdisciplinary	O	O
research	O	O
team	O	O
.	O	O

Feedback	O	O
on	O	O
the	O	O
content	O	O
and	O	O
presentation	O	O
led	O	O
to	O	O
iterative	O	O
modifications	O	O
of	O	O
the	O	O
tools	O	O
.	O	O

RESULTS	O	O
The	O	O
feasibility	O	O
studies	O	O
confirmed	O	O
that	O	O
the	O	O
Internet	O	O
was	O	O
a	O	O
viable	O	O
medium	O	O
,	O	O
as	O	O
the	O	O
majority	O	O
of	O	O
men	O	O
used	O	O
a	O	O
computer	O	O
,	O	O
had	O	O
access	O	O
to	O	O
the	O	O
Internet	O	O
,	O	O
and	O	O
Internet	O	O
use	O	O
increased	O	O
over	O	O
time	O	O
.	O	O

Feedback	O	O
from	O	O
the	O	O
usability	O	O
testing	O	O
on	O	O
the	O	O
length	O	O
,	O	O
presentation	O	O
,	O	O
and	O	O
content	O	O
of	O	O
the	O	O
materials	O	O
was	O	O
incorporated	O	O
into	O	O
the	O	O
final	O	O
versions	O	O
of	O	O
the	O	O
booklet	O	O
and	O	O
website	O	O
.	O	O

Both	O	O
the	O	O
feasibility	O	O
studies	O	O
and	O	O
the	O	O
usability	O	O
testing	O	O
highlighted	O	O
the	O	O
need	O	O
to	O	O
address	O	O
men	O	O
's	O	O
informed	O	O
decision	O	O
making	O	O
regarding	O	O
screening	O	O
.	O	O

CONCLUSIONS	O	O
Informed	O	O
decision	O	O
making	O	O
for	O	O
PCa	O	O
screening	O	O
is	O	O
crucial	O	O
at	O	O
present	O	O
and	O	O
may	O	O
be	O	O
important	O	O
for	O	O
some	O	O
time	O	O
,	O	O
particularly	O	O
if	O	O
a	O	O
definitive	O	O
recommendation	O	O
either	O	O
for	O	O
or	O	O
against	O	O
screening	O	O
does	O	O
not	O	O
emerge	O	O
from	O	O
ongoing	O	O
prostate	O	O
cancer	O	O
screening	O	O
trials	O	O
.	O	O

We	O	O
have	O	O
detailed	O	O
our	O	O
efforts	O	O
at	O	O
developing	O	O
print-	O	O
and	O	O
web-based	O	O
DAs	O	O
to	O	O
assist	O	O
men	O	O
in	O	O
determining	O	O
how	O	O
to	O	O
best	O	O
meet	O	O
their	O	O
PCa	O	O
screening	O	O
preferences	O	O
.	O	O

Following	O	O
completion	O	O
of	O	O
our	O	O
ongoing	O	O
RCT	O	O
designed	O	O
to	O	O
test	O	O
these	O	O
materials	O	O
,	O	O
our	O	O
goal	O	O
will	O	O
be	O	O
to	O	O
develop	O	O
a	O	O
dissemination	O	O
project	O	O
for	O	O
the	O	O
more	O	O
effective	O	O
tool	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
NCT00623090	O	O
.	O	O

Pilot	O	O
study	O	O
of	O	O
imiquimod	O	O
5	O	O
%	O	O
cream	O	O
as	O	O
adjunctive	O	O
therapy	O	O
to	O	O
curettage	O	O
and	O	O
electrodesiccation	O	O
for	O	O
nodular	Condition	O
basal	Condition	O
cell	Condition	O
carcinoma	Condition	O
.	O	O

BACKGROUND	O	O
Curettage	O	O
and	O	O
electrodesiccation	O	O
(	O	O
C	O	O
&	O	O
D	O	O
)	O	O
is	O	O
a	O	O
widely	O	O
used	O	O
method	O	O
to	O	O
treat	O	O
nodular	Condition	O
basal	Condition	O
cell	Condition	O
carcinoma	Condition	O
(	O	O
BCC	Condition	O
)	O	O
.	O	O

However	O	O
,	O	O
residual	O	O
tumor	O	O
is	O	O
present	O	O
immediately	O	O
after	O	O
the	O	O
procedure	O	O
in	O	O
approximately	O	O
20	O	O
to	O	O
40	O	O
%	O	O
of	O	O
cases	O	O
.	O	O

Imiquimod	O	O
,	O	O
a	O	O
topical	O	O
immune	O	O
response	O	O
modifier	O	O
that	O	O
targets	O	O
Toll-like	O	O
receptor	O	O
7	O	O
,	O	O
is	O	O
currently	O	O
approved	O	O
for	O	O
superficial	O	O
BCC	O	O
.	O	O

OBJECTIVE	O	O
In	O	O
a	O	O
double-blind	O	O
,	O	O
vehicle-controlled	O	O
study	O	O
,	O	O
the	O	O
administration	O	O
of	O	O
imiquimod	O	O
after	O	O
C	O	O
&	O	O
D	O	O
was	O	O
investigated	O	O
to	O	O
determine	O	O
if	O	O
the	O	O
combination	O	O
regimen	O	O
would	O	O
reduce	O	O
the	O	O
frequency	O	O
of	O	O
residual	O	O
tumor	O	O
compared	O	O
with	O	O
C	O	O
&	O	O
D	O	O
alone	O	O
in	O	O
patients	O	O
with	O	O
nodular	Condition	O
BCC	Condition	O
.	O	O

METHODS	O	O
Twenty	SampleSize	SampleSize
patients	O	O
received	O	O
three	O	O
cycles	O	O
of	O	O
C	O	O
&	O	O
D	O	O
followed	O	O
by	O	O
imiquimod	O	O
5	O	O
%	O	O
or	O	O
vehicle	O	O
cream	O	O
once	O	O
daily	O	O
for	O	O
1	O	O
month	O	O
as	O	O
adjunctive	O	O
therapy	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
the	O	O
frequency	O	O
of	O	O
residual	O	O
tumor	O	O
.	O	O

The	O	O
secondary	O	O
end	O	O
points	O	O
included	O	O
the	O	O
time	O	O
to	O	O
heal	O	O
and	O	O
cosmetic	O	O
appearance	O	O
.	O	O

RESULTS	O	O
Twenty	SampleSize	SampleSize
patients	O	O
were	O	O
randomized	O	O
to	O	O
the	O	O
imiquimod	O	O
(	O	O
n	O	O
=	O	O
10	SampleSize	O
)	O	O
or	O	O
vehicle	O	O
(	O	O
n	O	O
=	O	O
10	SampleSize	O
)	O	O
treatment	O	O
group	O	O
.	O	O

At	O	O
8	O	O
weeks	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
residual	O	O
tumor	O	O
was	O	O
substantially	O	O
decreased	O	O
with	O	O
imiquimod	O	O
therapy	O	O
(	O	O
10	O	O
%	O	O
)	O	O
compared	O	O
with	O	O
vehicle	O	O
(	O	O
40	O	O
%	O	O
)	O	O
.	O	O

Wounds	O	O
in	O	O
the	O	O
vehicle	O	O
group	O	O
healed	O	O
more	O	O
quickly	O	O
than	O	O
those	O	O
in	O	O
the	O	O
imiquimod	O	O
group	O	O
,	O	O
although	O	O
by	O	O
8	O	O
weeks	O	O
,	O	O
all	O	O
excision	O	O
sites	O	O
were	O	O
healed	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
scars	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
atrophic	O	O
and	O	O
hypopigmented	O	O
,	O	O
whereas	O	O
most	O	O
scars	O	O
in	O	O
the	O	O
imiquimod	O	O
group	O	O
were	O	O
flat	O	O
and	O	O
slightly	O	O
pink	O	O
.	O	O

CONCLUSION	O	O
Imiquimod	O	O
5	O	O
%	O	O
cream	O	O
once	O	O
daily	O	O
for	O	O
1	O	O
month	O	O
as	O	O
adjunctive	O	O
therapy	O	O
after	O	O
C	O	O
&	O	O
D	O	O
substantially	O	O
reduced	O	O
the	O	O
frequency	O	O
of	O	O
residual	O	O
tumor	O	O
and	O	O
improved	O	O
the	O	O
cosmetic	O	O
appearance	O	O
compared	O	O
with	O	O
C	O	O
&	O	O
D	O	O
alone	O	O
.	O	O

These	O	O
preliminary	O	O
results	O	O
suggest	O	O
that	O	O
further	O	O
studies	O	O
to	O	O
investigate	O	O
imiquimod	O	O
adjunctive	O	O
therapy	O	O
are	O	O
warranted	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
on	O	O
subjective	O	O
and	O	O
autonomic	O	O
responses	O	O
to	O	O
needle	O	O
insertion	O	O
.	O	O

BACKGROUND	O	O
Premedication	O	O
with	O	O
sedatives	O	O
can	O	O
decrease	O	O
the	O	O
discomfort	O	O
associated	O	O
with	O	O
invasive	O	O
anesthetic	O	O
procedures	O	O
.	O	O

Some	O	O
researchers	O	O
have	O	O
shown	O	O
that	O	O
acupressure	O	O
on	O	O
the	O	O
acupuncture	O	O
extra	O	O
1	O	O
point	O	O
is	O	O
effective	O	O
for	O	O
sedation	O	O
.	O	O

We	O	O
investigated	O	O
whether	O	O
acupressure	O	O
on	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
could	O	O
alleviate	O	O
the	O	O
pain	O	O
of	O	O
needle	O	O
insertion	O	O
.	O	O

METHODS	O	O
We	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
or	O	O
a	O	O
sham	O	O
point	O	O
on	O	O
needle	O	O
insertion	O	O
using	O	O
verbal	O	O
rating	O	O
scale	O	O
(	O	O
VRS	O	O
)	O	O
pain	O	O
scores	O	O
and	O	O
heart	O	O
rate	O	O
variability	O	O
(	O	O
HRV	O	O
)	O	O
.	O	O

Twenty-two	SampleSize	SampleSize
healthy	Condition	Condition
female	Sex	Sex
volunteers	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
two	O	O
groups	O	O
:	O	O
the	O	O
extra	O	O
1	O	O
group	O	O
received	O	O
acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
,	O	O
and	O	O
the	O	O
sham	O	O
group	O	O
received	O	O
acupressure	O	O
at	O	O
a	O	O
sham	O	O
point	O	O
.	O	O

After	O	O
starting	O	O
the	O	O
electrocardiogram	O	O
record	O	O
,	O	O
a	O	O
27-gauge	O	O
needle	O	O
was	O	O
inserted	O	O
into	O	O
the	O	O
skin	O	O
of	O	O
a	O	O
forearm	O	O
.	O	O

Thereafter	O	O
,	O	O
another	O	O
needle	O	O
was	O	O
inserted	O	O
into	O	O
the	O	O
skin	O	O
of	O	O
the	O	O
other	O	O
forearm	O	O
during	O	O
acupressure	O	O
.	O	O

RESULTS	O	O
Acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
significantly	O	O
reduced	O	O
the	O	O
VRS	O	O
,	O	O
but	O	O
acupressure	O	O
at	O	O
the	O	O
sham	O	O
increased	O	O
the	O	O
VRS	O	O
.	O	O

Acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
significantly	O	O
reduced	O	O
the	O	O
low	O	O
frequency/high	O	O
frequency	O	O
ratio	O	O
of	O	O
HRV	O	O
responding	O	O
to	O	O
needle	O	O
insertion	O	O
.	O	O

CONCLUSIONS	O	O
Acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
significantly	O	O
reduced	O	O
needle	O	O
insertion	O	O
pain	O	O
compared	O	O
with	O	O
acupressure	O	O
at	O	O
the	O	O
sham	O	O
point	O	O
.	O	O

Also	O	O
,	O	O
acupressure	O	O
at	O	O
the	O	O
extra	O	O
1	O	O
point	O	O
significantly	O	O
reduced	O	O
the	O	O
low	O	O
frequency/high	O	O
frequency	O	O
ratio	O	O
of	O	O
HRV	O	O
responding	O	O
to	O	O
needle	O	O
insertion	O	O
,	O	O
which	O	O
implies	O	O
a	O	O
reduction	O	O
in	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
.	O	O

[	O	O
Effect	O	O
of	O	O
Yufeining	O	O
on	O	O
induced	O	O
sputum	O	O
interleukin-8	O	O
in	O	O
patients	O	O
with	O	O
chronic	Condition	O
obstructive	Condition	O
pulmonary	Condition	O
disease	Condition	O
at	O	O
the	O	O
stable	O	O
phase	O	O
]	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
Yufeining	O	O
,	O	O
a	O	O
traditional	O	O
Chinese	O	O
medicine	O	O
,	O	O
on	O	O
induced	O	O
sputum	O	O
interleukin-8	O	O
(	O	O
IL-8	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
obstructive	O	O
pulmonary	O	O
disease	O	O
(	O	O
COPD	Condition	O
)	O	O
at	O	O
the	O	O
stable	Condition	O
phase	Condition	O
.	O	O

METHODS	O	O
Thirty-six	SampleSize	O
patients	O	O
with	O	O
COPD	Condition	Condition
were	O	O
divided	O	O
into	O	O
trial	O	O
group	O	O
(	O	O
18	O	O
cases	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
18	O	SampleSize
cases	O	O
)	O	O
randomly	O	O
.	O	O

The	O	O
trial	O	O
group	O	O
was	O	O
treated	O	O
with	O	O
Yufeining	O	O
pills	O	O
taken	O	O
orally	O	O
for	O	O
half	O	O
a	O	O
year	O	O
;	O	O
the	O	O
control	O	O
group	O	O
was	O	O
not	O	O
given	O	O
any	O	O
medicine	O	O
.	O	O

Routine	O	O
lung	O	O
function	O	O
was	O	O
recorded	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
.	O	O

Total	O	O
cell	O	O
count	O	O
(	O	O
TCC	O	O
)	O	O
,	O	O
differential	O	O
cell	O	O
counts	O	O
(	O	O
DCCs	O	O
)	O	O
and	O	O
IL-8	O	O
in	O	O
induced	O	O
sputum	O	O
were	O	O
determined	O	O
at	O	O
the	O	O
baseline	O	O
and	O	O
6	O	O
months	O	O
later	O	O
.	O	O

RESULTS	O	O
The	O	O
indices	O	O
of	O	O
lung	O	O
function	O	O
improved	O	O
significantly	O	O
after	O	O
6	O	O
months	O	O
'	O	O
treatment	O	O
in	O	O
trial	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
;	O	O
TCC	O	O
and	O	O
absolute	O	O
neutrophil	O	O
count	O	O
decreased	O	O
significantly	O	O
compared	O	O
with	O	O
baseline	O	O
in	O	O
the	O	O
trial	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
;	O	O
Sputum	O	O
IL-8	O	O
concentration	O	O
dropped	O	O
significantly	O	O
after	O	O
6	O	O
months	O	O
'	O	O
treatment	O	O
,	O	O
from	O	O
a	O	O
mean	O	O
of	O	O
5.216	O	O
+/-	O	O
2.914	O	O
microg/L	O	O
to	O	O
4.222	O	O
+/-	O	O
2.140	O	O
microg/L	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

There	O	O
were	O	O
insignificant	O	O
changes	O	O
in	O	O
the	O	O
parameters	O	O
in	O	O
the	O	O
control	O	O
group	O	O
between	O	O
baseline	O	O
and	O	O
6	O	O
months	O	O
later	O	O
.	O	O

CONCLUSION	O	O
Yufeining	O	O
could	O	O
improve	O	O
lung	O	O
function	O	O
,	O	O
decrease	O	O
sputum	O	O
TCC	O	O
,	O	O
absolute	O	O
neutrophil	O	O
count	O	O
and	O	O
IL-8	O	O
concentration	O	O
,	O	O
and	O	O
relieve	O	O
airway	O	O
inflammation	O	O
in	O	O
patients	O	O
with	O	O
COPD	O	O
in	O	O
the	O	O
stable	O	O
phase	O	O
.	O	O

Pedantic	O	O
speaking	O	O
style	O	O
differentiates	O	O
Asperger	O	O
syndrome	O	O
from	O	O
high-functioning	O	Condition
autism	O	Condition
.	O	O

Asperger	O	O
syndrome	O	O
(	O	O
AS	O	O
)	O	O
is	O	O
a	O	O
pervasive	O	O
developmental	O	O
disorder	O	O
recently	O	O
introduced	O	O
as	O	O
a	O	O
new	O	O
diagnostic	O	O
category	O	O
in	O	O
the	O	O
ICD-10	O	O
and	O	O
the	O	O
DSM-IV	O	O
.	O	O

Along	O	O
with	O	O
motor	O	O
clumsiness	O	O
,	O	O
pedantic	O	O
speech	O	O
has	O	O
been	O	O
proposed	O	O
as	O	O
a	O	O
clinical	O	O
feature	O	O
of	O	O
AS	O	O
.	O	O

However	O	O
,	O	O
few	O	O
attempts	O	O
have	O	O
been	O	O
made	O	O
to	O	O
define	O	O
and	O	O
measure	O	O
this	O	O
symptom	O	O
.	O	O

We	O	O
studied	O	O
17	SampleSize	O
patients	O	O
with	O	O
AS	Condition	O
(	O	O
ICD-10	O	O
;	O	O
14	SampleSize	O
male	Sex	O
,	O	O
3	SampleSize	O
female	Sex	O
;	O	O
mean	O	O
age	O	O
16.4	Age	Age
years	O	Age
,	O	O
mean	O	O
full-scale	O	O
IQ	O	O
97	O	O
)	O	O
and	O	O
compared	O	O
them	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
13	SampleSize	O
patients	O	O
with	O	O
normal-intelligence	Condition	Condition
autism	Condition	Condition
or	O	O
high-functioning	Condition	O
autism	Condition	O
(	O	O
HFA	Condition	O
)	O	O
(	O	O
ICD-10/DSM-III-R	O	O
;	O	O
12	SampleSize	O
male	Sex	O
,	O	O
1	SampleSize	O
female	Sex	O
;	O	O
mean	O	O
age	O	O
15.5	Age	Age
years	O	Age
,	O	O
mean	O	O
full-scale	O	O
IQ	O	O
81.2	O	O
)	O	O
.	O	O

An	O	O
operational	O	O
definition	O	O
of	O	O
pedantic	O	O
speech	O	O
was	O	O
formulated	O	O
and	O	O
a	O	O
rating	O	O
scale	O	O
devised	O	O
.	O	O

13	O	O
(	O	O
76	O	O
%	O	O
)	O	O
of	O	O
the	O	O
AS	Condition	O
patients	O	O
were	O	O
rated	O	O
as	O	O
pedantic	O	O
compared	O	O
to	O	O
4	O	O
(	O	O
31	O	O
%	O	O
)	O	O
of	O	O
the	O	O
HFA	Condition	O
group	O	O
(	O	O
chi	O	O
2	O	O
=	O	O
6.3	O	O
;	O	O
p	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

Results	O	O
suggest	O	O
that	O	O
pedantic	O	O
speech	O	O
is	O	O
common	O	O
in	O	O
AS	O	O
and	O	O
may	O	O
help	O	O
differentiate	O	O
AS	O	O
from	O	O
high-functioning	O	O
autism	O	O
.	O	O

Simvastatin	O	O
reduces	O	O
sympathetic	O	O
outflow	O	O
and	O	O
augments	O	O
endothelium-independent	O	O
dilation	O	O
in	O	O
non-hyperlipidaemic	Condition	O
primary	Condition	O
hypertension	Condition	O
.	O	O

OBJECTIVES	O	O
Previous	O	O
reports	O	O
,	O	O
involving	O	O
hypercholesterolaemic	O	O
hypertensive	O	O
subjects	O	O
,	O	O
that	O	O
statins	O	O
reduce	O	O
muscle	O	O
sympathetic	O	O
nerve	O	O
activity	O	O
(	O	O
MSNA	O	O
)	O	O
did	O	O
not	O	O
investigate	O	O
potential	O	O
neural	O	O
sites	O	O
of	O	O
such	O	O
sympathoinhibition	O	O
or	O	O
determine	O	O
its	O	O
consequences	O	O
for	O	O
endothelial	O	O
function	O	O
or	O	O
insulin	O	O
resistance	O	O
.	O	O

This	O	O
study	O	O
of	O	O
hypertensive	Condition	Condition
subjects	Condition	O
with	Condition	O
lower	Condition	O
plasma	Condition	O
cholesterol	Condition	O
tested	O	O
the	O	O
hypotheses	O	O
that	O	O
lipophilic	O	O
simvastatin	O	O
would	O	O
attenuate	O	O
resting	O	O
sympathoexcitation	O	O
and	O	O
augment	O	O
baroreflex	O	O
modulation	O	O
of	O	O
MSNA	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
flow-mediated	O	O
vasodilation	O	O
and	O	O
insulin	O	O
sensitivity	O	O
.	O	O

DESIGN	O	O
Prospective	O	O
,	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
crossover	O	O
study	O	O
.	O	O

SETTING	O	O
Academic	O	O
hospital-based	O	O
study	O	O
.	O	O

PATIENTS	O	O
Fourteen	O	O
non-hyperlipidaemic	O	O
primary	O	O
hypertensive	O	Condition
subjects	O	O
(	O	O
10	O	O
men	O	O
;	O	O
overall	O	O
mean?SD	O	O
age	O	O
58?12	O	O
years	O	O
)	O	O
.	O	O

INTERVENTIONS	O	O
Four	O	O
weeks	O	O
of	O	O
simvastatin	O	O
(	O	O
80	O	O
mg/day	O	O
)	O	O
or	O	O
placebo	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Resting	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
,	O	O
HR	O	O
,	O	O
MSNA	O	O
,	O	O
spontaneous	O	O
arterial	O	O
baroreflex	O	O
MSNA	O	O
and	O	O
HR	O	O
modulation	O	O
,	O	O
endothelium-dependent	O	O
and	O	O
endothelium-independent	O	O
vasodilation	O	O
,	O	O
and	O	O
the	O	O
homoeostatic	O	O
model	O	O
assessment	O	O
of	O	O
insulin	O	O
resistance	O	O
(	O	O
HOMA-IR	O	O
)	O	O
.	O	O

RESULTS	O	O
Simvastatin	O	O
lowered	O	O
MSNA	O	O
burst	O	O
frequency	O	O
(	O	O
from	O	O
32?12	O	O
to	O	O
25?9	O	O
bursts/min	O	O
)	O	O
and	O	O
MSNA	O	O
burst	O	O
incidence	O	O
(	O	O
from	O	O
55?23	O	O
%	O	O
to	O	O
43?17	O	O
%	O	O
;	O	O
all	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
without	O	O
affecting	O	O
BP	O	O
,	O	O
HR	O	O
,	O	O
baroreflex	O	O
modulation	O	O
of	O	O
either	O	O
MSNA	O	O
or	O	O
HR	O	O
,	O	O
or	O	O
HR	O	O
variability	O	O
(	O	O
all	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

Plasma	O	O
glucose	O	O
,	O	O
insulin	O	O
,	O	O
HOMA-IR	O	O
and	O	O
endothelium-dependent	O	O
vasodilation	O	O
(	O	O
all	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
were	O	O
unchanged	O	O
,	O	O
whereas	O	O
endothelium-independent	O	O
vasodilation	O	O
increased	O	O
(	O	O
7.1?3.8	O	O
%	O	O
to	O	O
9.7?3.9	O	O
%	O	O
,	O	O
n=13	O	O
;	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

The	O	O
fall	O	O
in	O	O
MSNA	O	O
was	O	O
unrelated	O	O
to	O	O
the	O	O
decrease	O	O
in	O	O
low-density	O	O
lipoprotein	O	O
cholesterol	O	O
(	O	O
r=0.41	O	O
,	O	O
p=0.14	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
These	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
concept	O	O
that	O	O
,	O	O
in	O	O
non-hyperlipidaemic	O	O
subjects	O	O
with	O	O
primary	O	O
hypertension	O	O
,	O	O
simvastatin	O	O
causes	O	O
a	O	O
cholesterol-independent	O	O
reduction	O	O
in	O	O
an	O	O
elevated	O	O
central	O	O
set-point	O	O
for	O	O
MSNA	O	O
,	O	O
without	O	O
affecting	O	O
arterial	O	O
baroreflex	O	O
modulation	O	O
of	O	O
either	O	O
MSNA	O	O
or	O	O
HR	O	O
.	O	O

There	O	O
may	O	O
be	O	O
less	O	O
neurogenic	O	O
constraint	O	O
on	O	O
endothelium-independent	O	O
vasodilation	O	O
as	O	O
a	O	O
consequence	O	O
.	O	O

Contingency	O	O
management	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
antipsychotic-induced	O	O
weight	O	O
gain	O	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
pilot	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
Weight	O	O
gain	O	O
is	O	O
common	O	O
for	O	O
individuals	O	O
with	O	O
serious	Condition	O
mental	Condition	O
illness	Condition	O
(	O	O
SMI	Condition	O
)	O	O
receiving	O	O
antipsychotic	O	O
drug	O	O
therapy	O	O
.	O	O

Contingency	O	O
management	O	O
(	O	O
CM	O	O
)	O	O
is	O	O
a	O	O
behavioral	O	O
intervention	O	O
that	O	O
rewards	O	O
positive	O	O
performance	O	O
and	O	O
has	O	O
demonstrated	O	O
effectiveness	O	O
in	O	O
reducing	O	O
drug	O	O
use	O	O
in	O	O
SMI	O	O
populations	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
the	O	O
feasibility	O	O
of	O	O
using	O	O
CM	O	O
to	O	O
promote	O	O
weight	O	O
loss	O	O
in	O	O
individuals	O	O
with	O	O
SMI	O	O
over	O	O
8	O	O
weeks	O	O
.	O	O

METHOD	O	O
30	O	SampleSize
individuals	O	O
(	O	O
BMI	O	O
?	O	O
28	O	O
kg/m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
one	O	O
of	O	O
three	O	O
conditions	O	O
:	O	O
i	O	O
)	O	O
The	O	O
combination	O	O
of	O	O
a	O	O
standardized	O	O
lifestyle	O	O
modification	O	O
(	O	O
LM	O	O
)	O	O
program	O	O
for	O	O
individuals	O	O
with	O	O
SMI	O	O
and	O	O
payment	O	O
for	O	O
group	O	O
attendance	O	O
(	O	O
CM	O	O
(	O	O
attendance	O	O
)	O	O
)	O	O
,	O	O
ii	O	O
)	O	O
The	O	O
combination	O	O
of	O	O
LM	O	O
and	O	O
payment	O	O
for	O	O
weight	O	O
loss	O	O
(	O	O
CM	O	O
(	O	O
weight	O	O
)	O	O
)	O	O
,	O	O
and	O	O
iii	O	O
)	O	O
waitlist	O	O
control	O	O
(	O	O
CON	O	O
)	O	O
.	O	O

After	O	O
the	O	O
waitlist	O	O
period	O	O
,	O	O
those	O	O
participants	O	O
joined	O	O
a	O	O
LM	O	O
group	O	O
and	O	O
received	O	O
payment	O	O
for	O	O
behavioral	O	O
change	O	O
(	O	O
CM	O	O
(	O	O
behavior	O	O
)	O	O
)	O	O
.	O	O

RESULTS	O	O
Subjects	O	O
in	O	O
the	O	O
CM	O	O
(	O	O
attendance	O	O
)	O	O
and	O	O
in	O	O
the	O	O
CM	O	O
(	O	O
weight	O	O
)	O	O
group	O	O
lost	O	O
a	O	O
mean	O	O
of	O	O
1.16	O	O
kg	O	O
and	O	O
1.23	O	O
kg	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
subjects	O	O
in	O	O
the	O	O
CON	O	O
gained	O	O
a	O	O
mean	O	O
of	O	O
0.68	O	O
kg	O	O
.	O	O

Subjects	O	O
receiving	O	O
CM	O	O
(	O	O
behavior	O	O
)	O	O
,	O	O
lost	O	O
a	O	O
mean	O	O
of	O	O
2.54	O	O
kg	O	O
,	O	O
which	O	O
was	O	O
a	O	O
significant	O	O
weight	O	O
loss	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
period	O	O
.	O	O

CONCLUSION	O	O
LM	O	O
supplemented	O	O
with	O	O
CM	O	O
may	O	O
facilitate	O	O
weight	O	O
loss	O	O
in	O	O
patients	O	O
taking	O	O
antipsychotic	O	O
medications	O	O
;	O	O
financial	O	O
reimbursement	O	O
for	O	O
behavioral	O	O
change	O	O
may	O	O
be	O	O
particularly	O	O
effective	O	O
in	O	O
this	O	O
population	O	O
.	O	O

Effect	O	O
of	O	O
entacapone	O	O
,	O	O
a	O	O
peripherally	O	O
acting	O	O
catechol-O-methyltransferase	O	O
inhibitor	O	O
,	O	O
on	O	O
the	O	O
motor	O	O
response	O	O
to	O	O
acute	O	O
treatment	O	O
with	O	O
levodopa	O	O
in	O	O
patients	O	O
with	O	O
Parkinson	Condition	Condition
's	Condition	Condition
disease	Condition	Condition
.	O	O

Catechol-O-methyltransferase	O	O
(	O	O
COMT	O	O
)	O	O
inhibitors	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Parkinson	O	Condition
's	O	Condition
disease	O	Condition
by	O	O
improving	O	O
the	O	O
bioavailability	O	O
of	O	O
levodopa	O	O
and	O	O
by	O	O
prolonging	O	O
its	O	O
effects	O	O
.	O	O

Entacapone	O	O
(	O	O
OR-611	O	O
)	O	O
,	O	O
a	O	O
novel	O	O
COMT	O	O
inhibitor	O	O
,	O	O
which	O	O
does	O	O
not	O	O
cross	O	O
the	O	O
blood	O	O
brain	O	O
barrier	O	O
,	O	O
was	O	O
assessed	O	O
in	O	O
12	SampleSize	O
patients	O	O
with	O	O
Parkinson	Condition	Condition
's	Condition	Condition
disease	Condition	Condition
and	O	O
motor	Condition	O
fluctuations	Condition	O
in	O	O
a	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
cross-over	O	O
,	O	O
single	O	O
dose	O	O
study	O	O
.	O	O

The	O	O
magnitude	O	O
and	O	O
duration	O	O
of	O	O
the	O	O
therapeutic	O	O
response	O	O
to	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
levodopa/50	O	O
mg	O	O
carbidopa	O	O
was	O	O
evaluated	O	O
after	O	O
concomitant	O	O
placebo	O	O
,	O	O
or	O	O
200	O	O
or	O	O
800	O	O
mg	O	O
entacapone	O	O
.	O	O

A	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
motor	O	O
response	O	O
to	O	O
levodopa	O	O
was	O	O
seen	O	O
when	O	O
200	O	O
mg	O	O
entacapone	O	O
was	O	O
given	O	O
with	O	O
levodopa/carbidopa	O	O
.	O	O

Plasma	O	O
levodopa	O	O
concentrations	O	O
were	O	O
increased	O	O
with	O	O
both	O	O
doses	O	O
of	O	O
the	O	O
COMT	O	O
inhibitor	O	O
.	O	O

The	O	O
latency	O	O
to	O	O
onset	O	O
of	O	O
motor	O	O
response	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
active	O	O
drug	O	O
and	O	O
placebo	O	O
.	O	O

Entacapone	O	O
may	O	O
prove	O	O
useful	O	O
in	O	O
prolonging	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
benefit	O	O
obtained	O	O
from	O	O
individual	O	O
doses	O	O
of	O	O
levodopa	O	O
.	O	O

Efficacy	O	O
and	O	O
safety	O	O
of	O	O
transient	O	O
ulnar	O	O
artery	O	O
compression	O	O
to	O	O
recanalize	O	O
acute	O	O
radial	O	O
artery	O	O
occlusion	O	O
after	O	O
transradial	O	Condition
catheterization	O	Condition
.	O	O

Radial	O	O
artery	O	O
occlusion	O	O
(	O	O
RAO	O	O
)	O	O
can	O	O
result	O	O
from	O	O
transradial	O	O
catheterization	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
incidence	O	O
of	O	O
RAO	O	O
with	O	O
2	O	O
heparin	O	O
dosage	O	O
regimens	O	O
after	O	O
transradial	O	Condition
coronary	O	Condition
angiography	O	Condition
,	O	O
and	O	O
we	O	O
evaluated	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
transient	O	O
homolateral	O	O
ulnar	O	O
artery	O	O
compression	O	O
to	O	O
achieve	O	O
acute	O	O
radial	O	O
artery	O	O
recanalization	O	O
.	O	O

Patients	O	O
referred	O	O
for	O	O
coronary	Condition	O
angiography	Condition	O
were	O	O
randomized	O	O
to	O	O
very-low-dose	O	O
heparin	O	O
(	O	O
2,000	O	O
IU	O	O
)	O	O
or	O	O
low-dose	O	O
heparin	O	O
(	O	O
5,000	O	O
IU	O	O
)	O	O
.	O	O

On	O	O
sheath	O	O
removal	O	O
,	O	O
hemostasis	O	O
was	O	O
obtained	O	O
using	O	O
the	O	O
TR	O	O
band	O	O
with	O	O
a	O	O
plethysmography-guided	O	O
patent	O	O
hemostasis	O	O
technique	O	O
.	O	O

In	O	O
the	O	O
case	O	O
of	O	O
RAO	O	O
as	O	O
assessed	O	O
by	O	O
duplex	O	O
ultrasonography	O	O
3	O	O
to	O	O
4	O	O
hours	O	O
after	O	O
hemostasis	O	O
,	O	O
immediate	O	O
1-hour	O	O
ulnar	O	O
artery	O	O
compression	O	O
was	O	O
applied	O	O
.	O	O

Hematomas	O	O
>	O	O
15	O	O
cm	O	O
(	O	O
2	O	O
)	O	O
were	O	O
also	O	O
assessed	O	O
.	O	O

We	O	O
randomized	O	O
465	SampleSize	SampleSize
patients	O	O
,	O	O
222	O	SampleSize
in	O	O
the	O	O
2,000-IU	O	O
group	O	O
and	O	O
243	O	SampleSize
in	O	O
the	O	O
5,000-IU	O	O
group	O	O
.	O	O

The	O	O
baseline	O	O
and	O	O
procedural	O	O
characteristics	O	O
were	O	O
comparable	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
initial	O	O
RAO	O	O
was	O	O
5.9	O	O
%	O	O
in	O	O
the	O	O
2,000-IU	O	O
group	O	O
and	O	O
2.9	O	O
%	O	O
in	O	O
the	O	O
5,000-IU	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.17	O	O
)	O	O
,	O	O
with	O	O
a	O	O
compression	O	O
time	O	O
of	O	O
2.10	O	O
?	O	O
0.78	O	O
hours	O	O
and	O	O
2.25	O	O
?	O	O
0.82	O	O
hours	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0.051	O	O
)	O	O
.	O	O

After	O	O
ulnar	O	O
artery	O	O
compression	O	O
,	O	O
the	O	O
final	O	O
incidence	O	O
of	O	O
RAO	O	O
was	O	O
4.1	O	O
%	O	O
in	O	O
the	O	O
2,000-IU	O	O
group	O	O
and	O	O
0.8	O	O
%	O	O
in	O	O
the	O	O
5,000-IU	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
local	O	O
hematoma	O	O
was	O	O
2.3	O	O
%	O	O
and	O	O
3.7	O	O
%	O	O
in	O	O
the	O	O
2,000-	O	O
and	O	O
5,000-IU	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0.42	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
acute	O	O
RAO	O	O
after	O	O
transradial	O	O
catheterization	O	O
can	O	O
be	O	O
recanalized	O	O
by	O	O
early	O	O
1-hour	O	O
homolateral	O	O
ulnar	O	O
artery	O	O
compression	O	O
.	O	O

This	O	O
simple	O	O
nonpharmacologic	O	O
method	O	O
was	O	O
effective	O	O
and	O	O
safe	O	O
in	O	O
patients	O	O
with	O	O
very-low-	O	O
and	O	O
low-dose	O	O
heparin	O	O
.	O	O

Nevertheless	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
final	O	O
RAO	O	O
remained	O	O
significantly	O	O
lower	O	O
after	O	O
a	O	O
higher	O	O
anticoagulation	O	O
level	O	O
.	O	O

Problem-based	O	O
learning	O	O
:	O	O
is	O	O
anatomy	O	O
a	O	O
casualty	O	O
?	O	O
INTRODUCTION	O	O
The	O	O
teaching	O	O
of	O	O
medical	O	O
anatomy	O	O
is	O	O
changing	O	O
.	O	O

Medical	O	O
schools	O	O
worldwide	O	O
are	O	O
moving	O	O
away	O	O
from	O	O
dissection	O	O
and	O	O
lectures	O	O
to	O	O
a	O	O
more	O	O
integrated	O	O
course	O	O
,	O	O
where	O	O
basic	O	O
science	O	O
and	O	O
clinical	O	O
skills	O	O
are	O	O
taught	O	O
simultaneously	O	O
.	O	O

Medical	O	O
students	O	O
on	O	O
these	O	O
integrated	O	O
courses	O	O
have	O	O
reported	O	O
a	O	O
lack	O	O
of	O	O
confidence	O	O
in	O	O
their	O	O
basic	O	O
science	O	O
knowledge	O	O
,	O	O
especially	O	O
concerning	O	O
anatomy	O	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
perform	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
(	O	O
RCT	O	O
)	O	O
to	O	O
compare	O	O
anatomical	O	O
knowledge	O	O
of	O	O
two	O	O
groups	O	O
of	O	O
second-year	O	O
medical	O	O
students	O	O
,	O	O
the	O	O
first	O	O
group	O	O
taught	O	O
on	O	O
a	O	O
traditional	O	O
course	O	O
,	O	O
the	O	O
second	O	O
on	O	O
an	O	O
integrated	O	O
course	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Testing	O	O
was	O	O
done	O	O
using	O	O
a	O	O
Questionnaire	O	O
in	O	O
a	O	O
True/False	O	O
format	O	O
.	O	O

There	O	O
were	O	O
80	SampleSize	O
students	O	O
in	O	O
each	O	O
group	O	O
.	O	O

There	O	O
was	O	O
no	O	O
penalty	O	O
for	O	O
an	O	O
incorrect	O	O
answer	O	O
.	O	O

The	O	O
test	O	O
was	O	O
performed	O	O
under	O	O
examination	O	O
conditions	O	O
.	O	O

Papers	O	O
were	O	O
marked	O	O
under	O	O
blind	O	O
conditions	O	O
.	O	O

Results	O	O
were	O	O
analysed	O	O
using	O	O
a	O	O
Student	O	O
's	O	O
t	O	O
test	O	O
analysis	O	O
.	O	O

RESULTS	O	O
Those	O	O
students	O	O
taught	O	O
on	O	O
a	O	O
traditional	O	O
course	O	O
exhibited	O	O
a	O	O
significantly	O	O
higher	O	O
level	O	O
of	O	O
basic	O	O
anatomical	O	O
knowledge	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
than	O	O
those	O	O
taught	O	O
on	O	O
an	O	O
integrated	O	O
course	O	O
.	O	O

The	O	O
students	O	O
taught	O	O
on	O	O
an	O	O
integrated	O	O
course	O	O
showed	O	O
a	O	O
much	O	O
greater	O	O
range	O	O
of	O	O
results	O	O
.	O	O

CONCLUSIONS	O	O
Students	O	O
taught	O	O
on	O	O
a	O	O
traditional	O	O
course	O	O
have	O	O
a	O	O
higher	O	O
level	O	O
of	O	O
anatomical	O	O
knowledge	O	O
than	O	O
those	O	O
taught	O	O
on	O	O
an	O	O
integrated	O	O
course	O	O
.	O	O

Our	O	O
results	O	O
differ	O	O
from	O	O
previous	O	O
studies	O	O
done	O	O
in	O	O
Europe	O	O
which	O	O
show	O	O
no	O	O
difference	O	O
between	O	O
the	O	O
courses	O	O
.	O	O

Immunological	O	O
changes	O	O
after	O	O
minimally	O	O
invasive	O	O
or	O	O
conventional	O	O
esophageal	O	O
resection	O	O
for	O	O
cancer	Condition	O
:	O	O
a	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
This	O	O
study	O	O
was	O	O
performed	O	O
as	O	O
a	O	O
substudy	O	O
analysis	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
comparing	O	O
conventional	O	O
open	O	O
esophagectomy	O	O
[	O	O
open	O	O
surgical	O	O
technique	O	O
(	O	O
OE	O	O
)	O	O
]	O	O
by	O	O
thoracotomy	O	O
and	O	O
laparotomy	O	O
with	O	O
minimally	O	O
invasive	O	O
esophagectomy	O	O
[	O	O
minimally	O	O
invasive	O	O
procedure	O	O
(	O	O
MIE	O	O
)	O	O
]	O	O
by	O	O
thoracoscopy	O	O
and	O	O
laparoscopy	O	O
.	O	O

This	O	O
additional	O	O
analysis	O	O
focuses	O	O
on	O	O
the	O	O
immunological	O	O
changes	O	O
and	O	O
surgical	O	O
stress	O	O
response	O	O
in	O	O
these	O	O
two	O	O
randomized	O	O
groups	O	O
of	O	O
a	O	O
single	O	O
center	O	O
.	O	O

METHODS	O	O
Patients	O	O
with	O	O
a	O	O
resectable	Condition	Condition
esophageal	Condition	Condition
cancer	Condition	Condition
were	O	O
randomized	O	O
to	O	O
OE	O	O
(	O	O
n	O	O
=	O	O
13	SampleSize	O
)	O	O
or	O	O
MIE	O	O
(	O	O
n	O	O
=	O	O
14	SampleSize	O
)	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
neoadjuvant	O	O
chemoradiotherapy	O	O
.	O	O

The	O	O
immunological	O	O
response	O	O
was	O	O
measured	O	O
by	O	O
means	O	O
of	O	O
leukocyte	O	O
counts	O	O
,	O	O
HLA-DR	O	O
expression	O	O
on	O	O
monocytes	O	O
,	O	O
the	O	O
acute-phase	O	O
response	O	O
by	O	O
means	O	O
of	O	O
C-reactive	O	O
protein	O	O
(	O	O
CRP	O	O
)	O	O
,	O	O
interleukin-6	O	O
(	O	O
IL-6	O	O
)	O	O
,	O	O
and	O	O
interleukin-8	O	O
(	O	O
IL-8	O	O
)	O	O
,	O	O
and	O	O
the	O	O
stress	O	O
response	O	O
was	O	O
measured	O	O
by	O	O
cortisol	O	O
,	O	O
growth	O	O
hormone	O	O
,	O	O
and	O	O
prolactin	O	O
.	O	O

All	O	O
parameters	O	O
were	O	O
determined	O	O
at	O	O
baseline	O	O
(	O	O
preoperatively	O	O
)	O	O
and	O	O
24	O	O
,	O	O
72	O	O
,	O	O
96	O	O
,	O	O
and	O	O
168	O	O
h	O	O
postoperatively	O	O
.	O	O

RESULTS	O	O
Significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
seen	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
MIE	O	O
group	O	O
with	O	O
regard	O	O
to	O	O
leukocyte	O	O
counts	O	O
,	O	O
IL-8	O	O
,	O	O
and	O	O
prolactin	O	O
at	O	O
168	O	O
h	O	O
(	O	O
1	O	O
week	O	O
)	O	O
postoperatively	O	O
.	O	O

For	O	O
HLA-DR	O	O
expression	O	O
,	O	O
IL-6	O	O
,	O	O
and	O	O
CRP	O	O
levels	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
clear	O	O
rise	O	O
in	O	O
levels	O	O
upon	O	O
operation	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
In	O	O
this	O	O
substudy	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
comparing	O	O
minimally	O	O
invasive	O	O
and	O	O
conventional	O	O
open	O	O
esophagectomies	O	O
for	O	O
cancer	O	O
,	O	O
significantly	O	O
better	O	O
preserved	O	O
leukocyte	O	O
counts	O	O
and	O	O
IL-8	O	O
levels	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
open	O	O
group	O	O
.	O	O

Both	O	O
findings	O	O
can	O	O
be	O	O
related	O	O
to	O	O
fewer	O	O
respiratory	O	O
infections	O	O
found	O	O
postoperatively	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
.	O	O

Moreover	O	O
,	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
prolactin	O	O
levels	O	O
at	O	O
168	O	O
h	O	O
after	O	O
surgery	O	O
imply	O	O
that	O	O
the	O	O
stress	O	O
response	O	O
is	O	O
better	O	O
preserved	O	O
in	O	O
the	O	O
MIE	O	O
group	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
less	O	O
surgical	O	O
trauma	O	O
could	O	O
lead	O	O
to	O	O
better	O	O
preserved	O	O
acute-phase	O	O
and	O	O
stress	O	O
responses	O	O
and	O	O
fewer	O	O
clinical	O	O
manifestations	O	O
of	O	O
respiratory	O	O
infections	O	O
.	O	O

Effect	O	O
of	O	O
acute	O	O
exercise	O	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	Age	Age
with	O	O
attention	Condition	O
deficit	Condition	O
hyperactivity	Condition	O
disorder	Condition	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
acute	O	O
aerobic	O	O
exercise	O	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	Age	Age
with	O	O
attention	Condition	O
deficit	Condition	O
hyperactivity	Condition	O
disorder	Condition	O
(	O	O
ADHD	Condition	O
)	O	O
.	O	O

Forty	SampleSize	O
children	Age	O
with	O	O
ADHD	Condition	Condition
were	O	O
randomly	O	O
assigned	O	O
into	O	O
exercise	O	O
or	O	O
control	O	O
groups	O	O
.	O	O

Participants	O	O
in	O	O
the	O	O
exercise	O	O
group	O	O
performed	O	O
a	O	O
moderate	O	O
intensity	O	O
aerobic	O	O
exercise	O	O
for	O	O
30	O	O
min	O	O
,	O	O
whereas	O	O
the	O	O
control	O	O
group	O	O
watched	O	O
a	O	O
running/exercise-related	O	O
video	O	O
.	O	O

Neuropsychological	O	O
tasks	O	O
,	O	O
the	O	O
Stroop	O	O
Test	O	O
and	O	O
the	O	O
Wisconsin	O	O
Card	O	O
Sorting	O	O
Test	O	O
(	O	O
WCST	O	O
)	O	O
,	O	O
were	O	O
assessed	O	O
before	O	O
and	O	O
after	O	O
each	O	O
treatment	O	O
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
acute	O	O
exercise	O	O
facilitated	O	O
performance	O	O
in	O	O
the	O	O
Stroop	O	O
Test	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
Stroop	O	O
Color-Word	O	O
condition	O	O
.	O	O

Additionally	O	O
,	O	O
children	O	O
in	O	O
the	O	O
exercise	O	O
group	O	O
demonstrated	O	O
improvement	O	O
in	O	O
specific	O	O
WCST	O	O
performances	O	O
in	O	O
Non-perseverative	O	O
Errors	O	O
and	O	O
Categories	O	O
Completed	O	O
,	O	O
whereas	O	O
no	O	O
influences	O	O
were	O	O
found	O	O
in	O	O
those	O	O
performances	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Tentative	O	O
explanations	O	O
for	O	O
the	O	O
exercise	O	O
effect	O	O
postulate	O	O
that	O	O
exercise	O	O
allocates	O	O
attention	O	O
resources	O	O
,	O	O
influences	O	O
the	O	O
dorsolateral	O	O
prefrontal	O	O
cortex	O	O
,	O	O
and	O	O
is	O	O
implicated	O	O
in	O	O
exercise-induced	O	O
dopamine	O	O
release	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
promising	O	O
and	O	O
additional	O	O
investigations	O	O
to	O	O
explore	O	O
the	O	O
efficacy	O	O
of	O	O
exercise	O	O
on	O	O
executive	O	O
function	O	O
in	O	O
children	O	O
with	O	O
ADHD	O	O
are	O	O
encouraged	O	O
.	O	O

Relationship	O	O
between	O	O
baseline	O	O
blood	O	O
pressure	O	O
parameters	O	O
(	O	O
including	O	O
mean	O	O
pressure	O	O
,	O	O
pulse	O	O
pressure	O	O
,	O	O
and	O	O
variability	O	O
)	O	O
and	O	O
early	O	O
outcome	O	O
after	O	O
stroke	Condition	O
:	O	O
data	O	O
from	O	O
the	O	O
Tinzaparin	O	O
in	O	O
Acute	Condition	O
Ischaemic	Condition	O
Stroke	Condition	O
Trial	O	O
(	O	O
TAIST	O	O
)	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
PURPOSE	O	O
High	Condition	O
blood	Condition	O
pressure	Condition	O
(	O	O
BP	O	O
)	O	O
in	O	O
acute	Condition	O
stroke	Condition	O
is	O	O
associated	O	O
independently	O	O
with	O	O
a	O	O
poor	O	O
outcome	O	O
.	O	O

Recent	O	O
evidence	O	O
suggests	O	O
that	O	O
other	O	O
hemodynamic	O	O
parameters	O	O
may	O	O
also	O	O
be	O	O
associated	O	O
with	O	O
outcomes	O	O
following	O	O
stroke	O	O
.	O	O

METHODS	O	O
The	O	O
relationship	O	O
between	O	O
baseline	O	O
BP	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
other	O	O
hemodynamic	O	O
parameters	O	O
,	O	O
and	O	O
early	O	O
outcomes	O	O
were	O	O
assessed	O	O
using	O	O
data	O	O
from	O	O
TAIST	O	O
trial	O	O
.	O	O

RESULTS	O	O
Death	O	O
or	O	O
neurological	O	O
deterioration	O	O
at	O	O
day	O	O
10	O	O
was	O	O
associated	O	O
,	O	O
both	O	O
in	O	O
unadjusted	O	O
and	O	O
adjusted	O	O
analyses	O	O
,	O	O
with	O	O
systolic	O	O
BP	O	O
(	O	O
adjusted	O	O
OR	O	O
,	O	O
1.02	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.03	O	O
)	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
OR	O	O
,	O	O
1.02	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.04	O	O
)	O	O
,	O	O
pulse	O	O
pressure	O	O
(	O	O
OR	O	O
,	O	O
1.02	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.03	O	O
)	O	O
,	O	O
and	O	O
BP	O	O
variability	O	O
(	O	O
OR	O	O
,	O	O
1.03	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.05	O	O
)	O	O
.	O	O

Similar	O	O
relationships	O	O
were	O	O
noted	O	O
for	O	O
deterioration	O	O
alone	O	O
,	O	O
and	O	O
recurrent	O	O
stroke	O	O
.	O	O

CONCLUSIONS	O	O
Early	O	O
death	O	O
or	O	O
neurologic	O	O
deterioration	O	O
,	O	O
deterioration	O	O
,	O	O
and	O	O
recurrent	O	O
stroke	O	O
are	O	O
associated	O	O
independently	O	O
with	O	O
high	O	O
systolic	O	O
BP	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
pulse	O	O
pressure	O	O
,	O	O
and	O	O
BP	O	O
variability	O	O
.	O	O

These	O	O
measures	O	O
offer	O	O
potential	O	O
therapeutic	O	O
targets	O	O
for	O	O
improving	O	O
early	O	O
outcome	O	O
after	O	O
acute	Condition	O
ischemic	Condition	O
stroke	Condition	O
.	O	O

Late	O	O
patient-reported	O	O
toxicity	O	O
after	O	O
preoperative	O	O
radiotherapy	O	O
or	O	O
chemoradiotherapy	O	O
in	O	O
nonresectable	Condition	O
rectal	Condition	O
cancer	Condition	O
:	O	O
results	O	O
from	O	O
a	O	O
randomized	O	O
Phase	O	O
III	O	O
study	O	O
.	O	O

PURPOSE	O	O
Preoperative	O	O
chemoradiotherapy	O	O
(	O	O
CRT	O	O
)	O	O
is	O	O
superior	O	O
to	O	O
radiotherapy	O	O
(	O	O
RT	O	O
)	O	O
in	O	O
locally	Condition	O
advanced	Condition	O
rectal	Condition	O
cancer	Condition	O
,	O	O
but	O	O
the	O	O
survival	O	O
gain	O	O
is	O	O
limited	O	O
.	O	O

Late	O	O
toxicity	O	O
is	O	O
,	O	O
therefore	O	O
,	O	O
important	O	O
.	O	O

The	O	O
aim	O	O
was	O	O
to	O	O
compare	O	O
late	O	O
bowel	O	O
,	O	O
urinary	O	O
,	O	O
and	O	O
sexual	O	O
functions	O	O
after	O	O
CRT	O	O
or	O	O
RT	O	O
.	O	O

METHODS	O	O
AND	O	O
MATERIALS	O	O
Patients	O	O
(	O	O
N	O	O
=	O	O
207	O	O
)	O	O
with	O	O
nonresectable	O	O
rectal	O	O
cancer	O	O
were	O	O
randomized	O	O
to	O	O
preoperative	O	O
CRT	O	O
or	O	O
RT	O	O
(	O	O
2	O	O
Gy	O	O
?	O	O
25	O	O
?	O	O
5-fluorouracil/leucovorin	O	O
)	O	O
.	O	O

Extended	O	O
surgery	O	O
was	O	O
often	O	O
required	O	O
.	O	O

Self-reported	O	O
late	O	O
toxicity	O	O
was	O	O
scored	O	O
according	O	O
to	O	O
the	O	O
LENT	O	O
SOMA	O	O
criteria	O	O
in	O	O
a	O	O
structured	O	O
telephone	O	O
interview	O	O
and	O	O
with	O	O
questionnaires	O	O
European	O	O
Organisation	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	O	O
(	O	O
EORTC	O	O
)	O	O
Quality	O	O
of	O	O
Life	O	O
Questionnaire	O	O
(	O	O
QLQ-C30	O	O
)	O	O
,	O	O
International	O	O
Index	O	O
of	O	O
Erectile	O	O
Function	O	O
(	O	O
IIEF	O	O
)	O	O
,	O	O
and	O	O
sexual	O	O
function-vaginal	O	O
changes	O	O
questionnaire	O	O
(	O	O
SVQ	O	O
)	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
105	O	SampleSize
patients	O	O
alive	O	O
in	O	O
Norway	O	O
and	O	O
Sweden	O	O
after	O	O
4	O	O
to	O	O
12	O	O
years	O	O
of	O	O
follow-up	O	O
,	O	O
78	O	O
(	O	O
74	O	O
%	O	O
)	O	O
responded	O	O
.	O	O

More	O	O
patients	O	O
in	O	O
the	O	O
CRT	O	O
group	O	O
had	O	O
received	O	O
a	O	O
stoma	O	O
(	O	O
73	O	O
%	O	O
vs.	O	O
52	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.09	O	O
)	O	O
.	O	O

Most	O	O
patients	O	O
without	O	O
a	O	O
stoma	O	O
(	O	O
7	O	O
of	O	O
12	O	O
in	O	O
CRT	O	O
group	O	O
and	O	O
9	O	O
of	O	O
16	O	O
in	O	O
RT	O	O
group	O	O
)	O	O
had	O	O
incontinence	O	O
for	O	O
liquid	O	O
stools	O	O
or	O	O
gas	O	O
.	O	O

No	O	O
stoma	O	O
and	O	O
good	O	O
anal	O	O
function	O	O
were	O	O
seen	O	O
in	O	O
5	O	O
patients	O	O
(	O	O
11	O	O
%	O	O
)	O	O
in	O	O
the	O	O
CRT	O	O
group	O	O
and	O	O
in	O	O
11	O	O
(	O	O
30	O	O
%	O	O
)	O	O
in	O	O
the	O	O
RT	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.046	O	O
)	O	O
.	O	O

Of	O	O
44	O	O
patients	O	O
in	O	O
the	O	O
CRT	O	O
group	O	O
,	O	O
12	O	O
(	O	O
28	O	O
%	O	O
)	O	O
had	O	O
had	O	O
bowel	O	O
obstruction	O	O
compared	O	O
with	O	O
5	O	O
of	O	O
33	O	O
(	O	O
15	O	O
%	O	O
)	O	O
in	O	O
the	O	O
RT	O	O
group	O	O
(	O	O
p	O	O
=	O	O
0.27	O	O
)	O	O
.	O	O

One-quarter	O	O
of	O	O
the	O	O
patients	O	O
reported	O	O
urinary	O	O
incontinence	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
men	O	O
had	O	O
severe	O	Condition
erectile	O	Condition
dysfunction	O	Condition
.	O	O

Few	O	O
women	O	O
reported	O	O
sexual	O	O
activity	O	O
during	O	O
the	O	O
previous	O	O
month	O	O
.	O	O

However	O	O
,	O	O
the	O	O
majority	O	O
did	O	O
not	O	O
have	O	O
concerns	O	O
about	O	O
their	O	O
sex	O	O
life	O	O
.	O	O

CONCLUSIONS	O	O
Fecal	O	O
incontinence	O	O
and	O	O
erectile	O	O
dysfunction	O	O
are	O	O
frequent	O	O
after	O	O
combined	O	O
treatment	O	O
for	O	O
locally	O	Condition
advanced	O	Condition
rectal	O	Condition
cancer	O	Condition
.	O	O

There	O	O
was	O	O
a	O	O
clear	O	O
tendency	O	O
for	O	O
the	O	O
problems	O	O
to	O	O
be	O	O
more	O	O
common	O	O
after	O	O
CRT	O	O
than	O	O
after	O	O
RT	O	O
.	O	O

Oral	O	O
health	O	O
impacts	O	O
on	O	O
daily	O	O
living	O	O
related	O	O
to	O	O
four	O	O
different	O	O
treatment	O	O
protocols	O	O
for	O	O
chronic	Condition	Condition
periodontitis	Condition	Condition
.	O	O

BACKGROUND	O	O
The	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
evaluate	O	O
the	O	O
oral	O	O
health	O	O
impacts	O	O
perceived	O	O
by	O	O
patients	O	O
submitted	O	O
to	O	O
different	O	O
treatments	O	O
of	O	O
chronic	Condition	Condition
periodontitis	Condition	Condition
and	O	O
their	O	O
association	O	O
with	O	O
clinical	O	O
parameters	O	O
.	O	O

METHODS	O	O
Sixty	SampleSize	SampleSize
patients	O	O
were	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
the	O	O
following	O	O
therapeutic	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
treated	O	O
with	O	O
full-mouth	O	O
scaling	O	O
and	O	O
root	O	O
planing	O	O
(	O	O
SRP	O	O
)	O	O
;	O	O
test	O	O
1	O	O
,	O	O
treated	O	O
with	O	O
SRP	O	O
and	O	O
400	O	O
mg	O	O
systemically	O	O
administered	O	O
metronidazole	O	O
(	O	O
MET	O	O
)	O	O
three	O	O
times	O	O
per	O	O
day	O	O
for	O	O
10	O	O
days	O	O
;	O	O
test	O	O
2	O	O
,	O	O
treated	O	O
with	O	O
SRP	O	O
and	O	O
professional	O	O
supragingival	O	O
plaque	O	O
removal	O	O
(	O	O
PP	O	O
)	O	O
every	O	O
week	O	O
for	O	O
3	O	O
months	O	O
;	O	O
and	O	O
test	O	O
3	O	O
,	O	O
treated	O	O
with	O	O
SRP	O	O
and	O	O
MET	O	O
plus	O	O
PP	O	O
.	O	O

Clinical	O	O
periodontal	O	O
measurements	O	O
and	O	O
data	O	O
regarding	O	O
patients	O	O
'	O	O
oral	O	O
health	O	O
impacts	O	O
(	O	O
perceived	O	O
impacts	O	O
on	O	O
bleeding	O	O
gums	O	O
,	O	O
gingival	O	O
recession	O	O
,	O	O
sensitivity	O	O
to	O	O
cold	O	O
,	O	O
packing	O	O
foods	O	O
,	O	O
aesthetics	O	O
,	O	O
bad	O	O
breath	O	O
,	O	O
and	O	O
tooth	O	O
mobility	O	O
)	O	O
were	O	O
collected	O	O
at	O	O
baseline	O	O
and	O	O
3	O	O
months	O	O
after	O	O
therapy	O	O
.	O	O

RESULTS	O	O
All	O	O
groups	O	O
presented	O	O
significant	O	O
improvement	O	O
in	O	O
oral	O	O
health	O	O
perceived	O	O
impacts	O	O
.	O	O

There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
improvement	O	O
of	O	O
oral	O	O
health	O	O
impacts	O	O
among	O	O
groups	O	O
subjected	O	O
to	O	O
different	O	O
treatments	O	O
.	O	O

The	O	O
clinical	O	O
data	O	O
of	O	O
percentage	O	O
of	O	O
deep	O	O
probing	O	O
depth	O	O
,	O	O
deep	O	O
clinical	O	O
attachment	O	O
level	O	O
,	O	O
and	O	O
bleeding	O	O
on	O	O
probing	O	O
were	O	O
found	O	O
to	O	O
be	O	O
correlated	O	O
significantly	O	O
with	O	O
oral	O	O
health	O	O
impacts	O	O
.	O	O

CONCLUSIONS	O	O
Periodontal	O	O
treatment	O	O
leads	O	O
to	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
self-perceived	O	O
impacts	O	O
regardless	O	O
of	O	O
the	O	O
non-surgical	O	O
treatment	O	O
protocol	O	O
employed	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
clinical	O	O
data	O	O
were	O	O
associated	O	O
with	O	O
oral	O	O
health	O	O
impacts	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
dietary	O	O
fibre	O	O
source	O	O
and	O	O
gender	O	O
on	O	O
the	O	O
postprandial	O	O
glucose	O	O
and	O	O
lipid	O	O
response	O	O
in	O	O
healthy	Condition	Condition
subjects	O	O
.	O	O

BACKGROUND	O	O
Consumption	O	O
of	O	O
soluble	O	O
dietary	O	O
fibre	O	O
is	O	O
correlated	O	O
with	O	O
decreased	O	O
postprandial	O	O
glucose	O	O
and	O	O
insulin	O	O
responses	O	O
and	O	O
hence	O	O
has	O	O
beneficial	O	O
effects	O	O
on	O	O
the	O	O
metabolic	O	O
syndrome	O	O
.	O	O

AIM	O	O
OF	O	O
THE	O	O
STUDY	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
on	O	O
postprandial	O	O
glucose	O	O
,	O	O
insulin	O	O
and	O	O
triglyceride	O	O
concentrations	O	O
of	O	O
meals	O	O
enriched	O	O
with	O	O
soluble	O	O
dietary	O	O
fibres	O	O
from	O	O
oats	O	O
,	O	O
rye	O	O
bran	O	O
,	O	O
sugar	O	O
beet	O	O
fibre	O	O
or	O	O
a	O	O
mixture	O	O
of	O	O
these	O	O
three	O	O
fibres	O	O
.	O	O

METHODS	O	O
Thirteen	SampleSize	SampleSize
healthy	O	Condition
human	O	Condition
volunteers	O	Condition
(	O	Condition
6	Sex	Condition
men	Sex	Condition
and	Sex	O
7	Sex	O
women	Sex	O
,	O	O
aged	O	O
20-28	Age	Age
years	O	Age
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
subjects	O	O
came	O	O
to	O	O
the	O	O
study	O	O
centre	O	O
once	O	O
a	O	O
week	O	O
after	O	O
an	O	O
overnight	O	O
fast	O	O
to	O	O
ingest	O	O
test	O	O
meals	O	O
and	O	O
a	O	O
control	O	O
meal	O	O
in	O	O
random	O	O
order	O	O
.	O	O

The	O	O
meals	O	O
contained	O	O
either	O	O
oat	O	O
powder	O	O
(	O	O
62	O	O
g	O	O
,	O	O
of	O	O
which	O	O
2.7	O	O
soluble	O	O
fibre	O	O
)	O	O
,	O	O
rye	O	O
bran	O	O
(	O	O
31	O	O
g	O	O
,	O	O
of	O	O
which	O	O
1.7	O	O
g	O	O
soluble	O	O
fibre	O	O
)	O	O
,	O	O
sugar	O	O
beet	O	O
fibre	O	O
(	O	O
19	O	O
g	O	O
,	O	O
of	O	O
which	O	O
5	O	O
g	O	O
soluble	O	O
fibre	O	O
)	O	O
,	O	O
a	O	O
mixture	O	O
of	O	O
these	O	O
three	O	O
fibres	O	O
(	O	O
74	O	O
g	O	O
,	O	O
of	O	O
which	O	O
1.7	O	O
g	O	O
soluble	O	O
fibre	O	O
from	O	O
each	O	O
source	O	O
,	O	O
giving	O	O
5	O	O
g	O	O
soluble	O	O
fibre	O	O
)	O	O
or	O	O
no	O	O
added	O	O
fibre	O	O
(	O	O
control	O	O
)	O	O
and	O	O
were	O	O
all	O	O
adjusted	O	O
to	O	O
contain	O	O
the	O	O
same	O	O
total	O	O
amount	O	O
of	O	O
available	O	O
carbohydrates	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
drawn	O	O
before	O	O
and	O	O
every	O	O
30	O	O
min	O	O
up	O	O
to	O	O
180	O	O
min	O	O
after	O	O
the	O	O
meals	O	O
.	O	O

RESULTS	O	O
Meals	O	O
with	O	O
rye	O	O
bran	O	O
gave	O	O
a	O	O
lower	O	O
postprandial	O	O
glucose	O	O
peak	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
meal	O	O
,	O	O
and	O	O
this	O	O
effect	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
women	O	O
compared	O	O
to	O	O
men	O	O
.	O	O

Oat	O	O
powder	O	O
,	O	O
containing	O	O
a	O	O
low	O	O
amount	O	O
of	O	O
total	O	O
fibre	O	O
and	O	O
a	O	O
high	O	O
amount	O	O
of	O	O
carbohydrates	O	O
in	O	O
liquid	O	O
matrix	O	O
,	O	O
gave	O	O
a	O	O
higher	O	O
incremental	O	O
glucose	O	O
peak	O	O
concentration	O	O
compared	O	O
to	O	O
rye	O	O
bran	O	O
and	O	O
sugar	O	O
beet	O	O
fibre	O	O
and	O	O
higher	O	O
insulin	O	O
incremental	O	O
area	O	O
under	O	O
curve	O	O
compared	O	O
to	O	O
control	O	O
.	O	O

The	O	O
oat	O	O
powder	O	O
also	O	O
influenced	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
mixed	O	O
meal	O	O
,	O	O
diminishing	O	O
the	O	O
glucose-lowering	O	O
effects	O	O
.	O	O

Postprandial	O	O
triglyceride	O	O
levels	O	O
tended	O	O
to	O	O
be	O	O
higher	O	O
after	O	O
all	O	O
fibre-rich	O	O
meals	O	O
,	O	O
but	O	O
only	O	O
significant	O	O
for	O	O
oat	O	O
powder	O	O
and	O	O
the	O	O
mixed	O	O
meal	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
meal	O	O
.	O	O

CONCLUSIONS	O	O
Postprandial	O	O
glucose	O	O
,	O	O
insulin	O	O
and	O	O
triglyceride	O	O
concentrations	O	O
are	O	O
influenced	O	O
by	O	O
dietary	O	O
fibre-rich	O	O
meals	O	O
,	O	O
depending	O	O
on	O	O
fibre	O	O
source	O	O
,	O	O
dose	O	O
of	O	O
soluble	O	O
and	O	O
total	O	O
fibre	O	O
and	O	O
possibly	O	O
gender	O	O
.	O	O

Smoking	O	O
cessation	O	O
with	O	O
smokeless	O	O
tobacco	O	O
and	O	O
group	O	O
therapy	O	O
:	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
.	O	O

Smokeless	O	O
tobacco	O	O
might	O	O
be	O	O
effective	O	O
as	O	O
an	O	O
adjunct	O	O
for	O	O
smoking	O	O
cessation	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
efficacy	O	O
of	O	O
smokeless	O	O
tobacco	O	O
and	O	O
group	O	O
support	O	O
for	O	O
smoking	O	O
cessation	O	O
in	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
study	O	O
that	O	O
compared	O	O
smokeless	O	O
tobacco	O	O
plus	O	O
group	O	O
support	O	O
versus	O	O
group	O	O
support	O	O
only	O	O
.	O	O

The	O	O
study	O	O
enrolled	O	O
263	SampleSize	O
healthy	Condition	O
smokers	Condition	O
(	O	O
M	O	O
(	O	O
age	O	O
)	O	O
=	O	O
49	Age	O
years	Age	O
)	O	O
who	O	O
smoked	Condition	O
a	O	O
mean	O	O
of	O	O
24	Condition	O
cigarettes/day	Condition	O
,	O	O
with	O	O
a	O	O
mean	O	O
of	O	O
31	Condition	O
pack-years	Condition	O
.	O	O

Smokeless	O	O
tobacco	O	O
was	O	O
provided	O	O
for	O	O
7	O	O
weeks	O	O
(	O	O
or	O	O
up	O	O
to	O	O
12	O	O
)	O	O
,	O	O
combined	O	O
with	O	O
eight	O	O
group	O	O
support	O	O
visits	O	O
provided	O	O
by	O	O
nurses	O	O
.	O	O

The	O	O
control	O	O
group	O	O
received	O	O
group	O	O
support	O	O
only	O	O
.	O	O

Smoking	O	O
cessation	O	O
rates	O	O
were	O	O
statistically	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
smokeless	O	O
tobacco	O	O
group	O	O
than	O	O
in	O	O
the	O	O
control	O	O
group	O	O
during	O	O
the	O	O
first	O	O
7	O	O
weeks	O	O
.	O	O

Point-prevalence	O	O
abstinence	O	O
rates	O	O
at	O	O
7	O	O
weeks	O	O
were	O	O
36.4	O	O
%	O	O
versus	O	O
20.8	O	O
%	O	O
(	O	O
OR	O	O
=	O	O
2.52	O	O
,	O	O
p	O	O
=	O	O
.001	O	O
)	O	O
,	O	O
respectively	O	O
;	O	O
and	O	O
continuous	O	O
abstinence	O	O
rates	O	O
from	O	O
weeks	O	O
4	O	O
to	O	O
7	O	O
were	O	O
31.5	O	O
%	O	O
versus	O	O
19.2	O	O
%	O	O
(	O	O
OR	O	O
=	O	O
1.94	O	O
,	O	O
p	O	O
=	O	O
.023	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
primary	O	O
outcomes	O	O
(	O	O
i.e.	O	O
,	O	O
6-month	O	O
point	O	O
prevalence	O	O
)	O	O
were	O	O
23.1	O	O
%	O	O
versus	O	O
20.8	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
OR	O	O
=	O	O
1.31	O	O
,	O	O
ns	O	O
)	O	O
.	O	O

Smokeless	O	O
tobacco	O	O
was	O	O
relatively	O	O
well	O	O
tolerated	O	O
,	O	O
although	O	O
15	O	O
subjects	O	O
(	O	O
11.2	O	O
%	O	O
)	O	O
stopped	O	O
use	O	O
due	O	O
to	O	O
adverse	O	O
events	O	O
.	O	O

A	O	O
total	O	O
of	O	O
25	O	O
subjects	O	O
(	O	O
17.5	O	O
%	O	O
)	O	O
were	O	O
still	O	O
using	O	O
smokeless	O	O
tobacco	O	O
after	O	O
6	O	O
months	O	O
.	O	O

This	O	O
trial	O	O
demonstrated	O	O
short-term	O	O
efficacy	O	O
of	O	O
smokeless	O	O
tobacco	O	O
in	O	O
combination	O	O
with	O	O
group	O	O
support	O	O
for	O	O
smoking	O	O
cessation	O	O
but	O	O
no	O	O
long-term	O	O
efficacy	O	O
.	O	O

Brief	O	O
report	O	O
:	O	O
imitation	O	O
effects	O	O
on	O	O
children	Age	O
with	O	O
autism	Condition	O
.	O	O

Twenty	SampleSize	O
children	Age	O
with	O	O
autism	Condition	O
(	O	O
mean	O	O
age	O	O
,	O	O
5	Age	O
years	Age	O
)	O	O
were	O	O
recruited	O	O
for	O	O
the	O	O
study	O	O
from	O	O
a	O	O
school	O	O
for	O	O
children	Age	Age
with	O	O
autism	Condition	Condition
.	O	O

The	O	O
children	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
an	O	O
imitation	O	O
(	O	O
n	O	O
=	O	O
10	SampleSize	O
)	O	O
or	O	O
contingently	O	O
responsive	O	O
(	O	O
n	O	O
=	O	O
10	SampleSize	O
)	O	O
interaction	O	O
group	O	O
based	O	O
on	O	O
a	O	O
stratification	O	O
table	O	O
for	O	O
gender	O	O
and	O	O
developmental	O	O
and	O	O
chronological	O	O
age	O	O
.	O	O

The	O	O
sessions	O	O
consisted	O	O
of	O	O
four	O	O
phases	O	O
,	O	O
with	O	O
each	O	O
phase	O	O
lasting	O	O
3	O	O
minutes	O	O
.	O	O

In	O	O
the	O	O
first	O	O
phase	O	O
,	O	O
the	O	O
child	O	O
walked	O	O
into	O	O
a	O	O
room	O	O
that	O	O
was	O	O
furnished	O	O
with	O	O
a	O	O
sofa	O	O
,	O	O
a	O	O
table	O	O
,	O	O
chairs	O	O
,	O	O
and	O	O
two	O	O
sets	O	O
of	O	O
identical	O	O
toys	O	O
.	O	O

An	O	O
adult	O	O
was	O	O
in	O	O
the	O	O
room	O	O
sitting	O	O
very	O	O
still	O	O
like	O	O
a	O	O
statue	O	O
(	O	O
first	O	O
still-face	O	O
condition	O	O
)	O	O
.	O	O

In	O	O
the	O	O
second	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
either	O	O
imitated	O	O
the	O	O
child	O	O
or	O	O
was	O	O
contingently	O	O
responsive	O	O
to	O	O
the	O	O
child	O	O
.	O	O

In	O	O
the	O	O
third	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
sat	O	O
still	O	O
again	O	O
(	O	O
second	O	O
still-face	O	O
condition	O	O
)	O	O
,	O	O
and	O	O
in	O	O
the	O	O
fourth	O	O
phase	O	O
,	O	O
the	O	O
adult	O	O
engaged	O	O
in	O	O
a	O	O
spontaneous	O	O
interaction	O	O
.	O	O

During	O	O
the	O	O
third	O	O
phase	O	O
(	O	O
the	O	O
second	O	O
still-face	O	O
condition	O	O
)	O	O
,	O	O
the	O	O
children	O	O
in	O	O
the	O	O
imitation	O	O
group	O	O
spent	O	O
less	O	O
time	O	O
in	O	O
gross	O	O
motor	O	O
activity	O	O
and	O	O
more	O	O
time	O	O
touching	O	O
the	O	O
adult	O	O
,	O	O
as	O	O
if	O	O
attempting	O	O
to	O	O
initiate	O	O
an	O	O
interaction	O	O
.	O	O

The	O	O
contingency	O	O
condition	O	O
appeared	O	O
to	O	O
be	O	O
a	O	O
more	O	O
effective	O	O
way	O	O
to	O	O
facilitate	O	O
a	O	O
distal	O	O
social	O	O
behavior	O	O
(	O	O
attention	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
imitative	O	O
condition	O	O
was	O	O
a	O	O
more	O	O
effective	O	O
way	O	O
to	O	O
facilitate	O	O
a	O	O
proximal	O	O
social	O	O
behavior	O	O
(	O	O
touching	O	O
)	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
intermittent	O	O
vaginal	O	O
administration	O	O
of	O	O
misoprostol	O	O
with	O	O
continuous	O	O
dinoprostone	O	O
for	O	O
cervical	O	O
ripening	O	O
and	O	O
labor	O	O
induction	O	O
.	O	O

OBJECTIVE	O	O
Our	O	O
purpose	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effect	O	O
of	O	O
vaginal	O	O
administration	O	O
of	O	O
misoprostol	O	O
(	O	O
Cytotec	O	O
)	O	O
with	O	O
that	O	O
of	O	O
dinoprostone	O	O
(	O	O
Cervidil	O	O
)	O	O
on	O	O
cervical	O	O
ripening	O	O
and	O	O
labor	O	O
induction	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
Two	SampleSize	O
hundred	SampleSize	O
patients	O	O
with	O	O
indications	O	O
for	O	O
induction	Condition	O
of	Condition	O
labor	Condition	O
and	O	O
unfavorable	Condition	O
cervical	Condition	O
examinations	Condition	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
vaginally	O	O
administered	O	O
misoprostol	O	O
(	O	O
prostaglandin	O	O
E1	O	O
)	O	O
or	O	O
the	O	O
dinoprostone	O	O
(	O	O
prostaglandin	O	O
E2	O	O
)	O	O
vaginal	O	O
insert	O	O
.	O	O

Twenty-five	O	O
microgram	O	O
tablets	O	O
of	O	O
misoprostol	O	O
were	O	O
placed	O	O
in	O	O
the	O	O
posterior	O	O
vaginal	O	O
fornix	O	O
every	O	O
4	O	O
hours	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
six	O	O
doses	O	O
.	O	O

Additional	O	O
misoprostol	O	O
was	O	O
not	O	O
given	O	O
after	O	O
either	O	O
spontaneous	O	O
rupture	O	O
of	O	O
membranes	O	O
,	O	O
adequate	O	O
cervical	O	O
ripening	O	O
(	O	O
Bishop	O	O
score	O	O
of	O	O
>	O	O
or	O	O
=	O	O
8	O	O
or	O	O
cervical	O	O
dilatation	O	O
of	O	O
>	O	O
or	O	O
=	O	O
3	O	O
cm	O	O
)	O	O
,	O	O
or	O	O
beginning	O	O
of	O	O
active	O	Condition
labor	O	Condition
.	O	O

The	O	O
vaginal	O	O
insert	O	O
,	O	O
Cervidil	O	O
,	O	O
containing	O	O
10	O	O
mg	O	O
of	O	O
dinoprostone	O	O
in	O	O
a	O	O
timed-release	O	O
preparation	O	O
was	O	O
placed	O	O
in	O	O
the	O	O
posterior	O	O
vaginal	O	O
formix	O	O
for	O	O
a	O	O
maximum	O	O
period	O	O
of	O	O
24	O	O
hours	O	O
.	O	O

The	O	O
vaginal	O	O
insert	O	O
was	O	O
removed	O	O
for	O	O
spontaneous	O	O
rupture	O	O
of	O	O
membranes	O	O
,	O	O
entry	O	O
into	O	O
active	O	O
labor	O	O
,	O	O
adequate	O	O
cervical	O	O
ripening	O	O
,	O	O
or	O	O
abnormality	O	O
of	O	O
uterine	O	O
contractile	O	O
pattern	O	O
or	O	O
fetal	O	O
cardiac	O	O
activity	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
200	SampleSize	O
patients	O	O
enrolled	O	O
,	O	O
99	SampleSize	O
were	O	O
randomized	O	O
to	O	O
misoprostol	O	O
and	O	O
101	SampleSize	O
to	O	O
dinoprostone	O	O
.	O	O

The	O	O
average	O	O
interval	O	O
from	O	O
start	O	O
of	O	O
induction	O	O
to	O	O
vaginal	O	O
delivery	O	O
was	O	O
1	O	O
hour	O	O
shorter	O	O
in	O	O
the	O	O
misoprostol	O	O
group	O	O
(	O	O
1296.7	O	O
+/-	O	O
722.1	O	O
minutes	O	O
)	O	O
than	O	O
in	O	O
the	O	O
dinoprostone	O	O
group	O	O
(	O	O
1360.0	O	O
+/-	O	O
792.0	O	O
minutes	O	O
)	O	O
,	O	O
but	O	O
this	O	O
difference	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
=	O	O
0.97	O	O
)	O	O
.	O	O

Oxytocin	O	O
augmentation	O	O
of	O	O
labor	O	O
was	O	O
used	O	O
in	O	O
50	O	O
(	O	O
50.5	O	O
%	O	O
)	O	O
misoprostol-treated	O	O
patients	O	O
and	O	O
43	O	O
(	O	O
43.5	O	O
%	O	O
)	O	O
dinoprostone-treated	O	O
patients	O	O
(	O	O
relative	O	O
risk	O	O
1.14	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.86	O	O
to	O	O
1.51	O	O
,	O	O
p	O	O
=	O	O
0.35	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
routes	O	O
of	O	O
delivery	O	O
with	O	O
misoprostol	O	O
or	O	O
dinoprostone	O	O
.	O	O

Overall	O	O
,	O	O
38	SampleSize	O
patients	O	O
(	O	O
19.3	O	O
%	O	O
)	O	O
had	O	O
cesarean	O	O
deliveries	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significantly	O	O
lower	O	O
prevalence	O	O
of	O	O
tachysystole	O	O
(	O	O
six	O	O
or	O	O
more	O	O
uterine	O	O
contractions	O	O
in	O	O
a	O	O
10-minute	O	O
window	O	O
for	O	O
two	O	O
consecutive	O	O
10-minute	O	O
periods	O	O
)	O	O
in	O	O
the	O	O
misoprostol	O	O
group	O	O
(	O	O
7.1	O	O
%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
dinoprostone	O	O
group	O	O
(	O	O
18.4	O	O
%	O	O
)	O	O
(	O	O
relative	O	O
risk	O	O
0.52	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.31	O	O
to	O	O
0.89	O	O
,	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
frequency	O	O
of	O	O
uterine	O	O
hyperstimulation	O	O
or	O	O
hypertonus	O	Condition
.	O	Condition

Abnormal	O	O
fetal	O	O
heart	O	O
rate	O	O
tracings	O	O
were	O	O
found	O	O
in	O	O
23	O	O
(	O	O
23.2	O	O
%	O	O
)	O	O
of	O	O
misoprostol-treated	O	O
patients	O	O
and	O	O
35	O	O
(	O	O
35.7	O	O
%	O	O
)	O	O
of	O	O
dinoprostone-treated	O	O
patients	O	O
(	O	O
relative	O	O
risk	O	O
0.73	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
0.52	O	O
to	O	O
1.01	O	O
,	O	O
p	O	O
=	O	O
0.0546	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
meconium	O	O
passage	O	O
,	O	O
1-	O	O
or	O	O
5-minute	O	O
Apgar	O	O
scores	O	O
<	O	O
7	O	O
,	O	O
neonatal	O	O
resuscitations	O	O
,	O	O
or	O	O
admissions	O	O
to	O	O
the	O	O
neonatal	O	O
intensive	O	O
care	O	O
unit	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Vaginally	O	O
administered	O	O
misoprostol	O	O
is	O	O
as	O	O
effective	O	O
as	O	O
dinoprostone	O	O
for	O	O
cervical	O	O
ripening	O	O
and	O	O
the	O	O
induction	O	O
of	O	O
labor	O	O
.	O	O

Mean	O	O
time	O	O
intervals	O	O
to	O	O
delivery	O	O
,	O	O
need	O	O
for	O	O
oxytocin	O	O
augmentation	O	O
,	O	O
and	O	O
routes	O	O
of	O	O
delivery	O	O
were	O	O
similar	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Incidence	O	O
of	O	O
uterine	O	O
tachysystole	O	O
with	O	O
misoprostol	O	O
every	O	O
4	O	O
hours	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
with	O	O
dinoprostone	O	O
.	O	O

Albendazole	O	O
trial	O	O
at	O	O
15	O	O
or	O	O
30	O	O
mg/kg/day	O	O
for	O	O
subarachnoid	Condition	O
and	O	O
intraventricular	Condition	O
cysticercosis	Condition	O
.	O	O

Thirty-six	SampleSize	O
patients	O	O
with	O	O
subarachnoid	Condition	O
and	O	O
intraventricular	Condition	O
cysticercosis	Condition	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
albendazole	O	O
at	O	O
15	O	O
or	O	O
30	O	O
mg/kg/day	O	O
plus	O	O
dexamethasone	O	O
for	O	O
8	O	O
days	O	O
.	O	O

Results	O	O
favored	O	O
a	O	O
higher	O	O
dose	O	O
,	O	O
with	O	O
larger	O	O
cyst	O	O
reduction	O	O
on	O	O
MRI	O	O
at	O	O
90	O	O
and	O	O
180	O	O
days	O	O
and	O	O
higher	O	O
albendazole	O	O
sulfoxide	O	O
levels	O	O
in	O	O
plasma	O	O
.	O	O

An	O	O
albendazole	O	O
course	O	O
at	O	O
30	O	O
mg/kg/day	O	O
combined	O	O
with	O	O
corticosteroids	O	O
is	O	O
safe	O	O
and	O	O
more	O	O
effective	O	O
than	O	O
the	O	O
usual	O	O
dose	O	O
.	O	O

A	O	O
single	O	O
treatment	O	O
was	O	O
insufficient	O	O
in	O	O
intraventricular	O	O
and	O	O
giant	O	O
cysts	O	O
.	O	O

Once-daily	O	O
MMX	O	O
(	O	O
?	O	O
)	O	O
mesalamine	O	O
for	O	O
endoscopic	O	O
maintenance	O	O
of	O	O
remission	O	O
of	O	O
ulcerative	O	O
colitis	O	O
.	O	O

OBJECTIVES	O	O
Treatment	O	O
with	O	O
mesalamine	O	O
to	O	O
maintain	O	O
endoscopic	O	O
remission	O	O
(	O	O
mucosal	O	O
healing	O	O
)	O	O
of	O	O
ulcerative	O	O
colitis	O	O
(	O	O
UC	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
relapse	O	O
and	O	O
is	O	O
the	O	O
recommended	O	O
first-line	O	O
maintenance	O	O
therapy	O	O
.	O	O

To	O	O
improve	O	O
treatment	O	O
adherence	O	O
,	O	O
a	O	O
mesalamine	O	O
formulation	O	O
that	O	O
can	O	O
be	O	O
administered	O	O
once-daily	O	O
,	O	O
MMX	O	O
(	O	O
?	O	O
)	O	O
mesalamine	O	O
(	O	O
Lialda	O	O
;	O	O
Shire	O	O
Pharmaceuticals	O	O
LLC	O	O
,	O	O
Wayne	O	O
,	O	O
PA	O	O
)	O	O
,	O	O
was	O	O
developed	O	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
once-daily	O	O
MMX	O	O
mesalamine	O	O
compared	O	O
with	O	O
twice-daily	O	O
delayed-release	O	O
mesalamine	O	O
(	O	O
Asacol	O	O
;	O	O
Warner	O	O
Chilcott	O	O
,	O	O
Dublin	O	O
,	O	O
Ireland	O	O
)	O	O
for	O	O
maintaining	O	O
endoscopic	O	O
remission	O	O
in	O	O
patients	O	O
with	O	O
UC	O	O
.	O	O

METHODS	O	O
A	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
6-month	O	O
,	O	O
active-control	O	O
trial	O	O
was	O	O
conducted	O	O
to	O	O
assess	O	O
the	O	O
non-inferiority	O	O
of	O	O
once-daily	O	O
MMX	O	O
mesalamine	O	O
2.4	O	O
g/day	O	O
compared	O	O
with	O	O
twice-daily	O	O
delayed-release	O	O
mesalamine	O	O
at	O	O
a	O	O
total	O	O
daily	O	O
dose	O	O
of	O	O
1.6	O	O
g/day	O	O
in	O	O
patients	O	O
with	O	O
UC	O	O
in	O	O
endoscopic	O	O
remission	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
maintenance	O	O
of	O	O
endoscopic	O	O
remission	O	O
at	O	O
month	O	O
6	O	O
in	O	O
the	O	O
per-protocol	O	O
(	O	O
PP	O	O
)	O	O
population	O	O
.	O	O

RESULTS	O	O
Overall	O	O
,	O	O
826	O	SampleSize
patients	O	O
were	O	O
randomized	O	O
and	O	O
dosed	O	O
.	O	O

The	O	O
primary	O	O
objective	O	O
(	O	O
non-inferiority	O	O
)	O	O
was	O	O
met	O	O
.	O	O

At	O	O
month	O	O
6	O	O
,	O	O
83.7	O	O
and	O	O
77.8	O	O
%	O	O
of	O	O
patients	O	O
receiving	O	O
MMX	O	O
mesalamine	O	O
in	O	O
the	O	O
PP	O	O
and	O	O
intent-to-treat	O	O
(	O	O
ITT	O	O
)	O	O
populations	O	O
,	O	O
respectively	O	O
,	O	O
had	O	O
maintained	O	O
endoscopic	O	O
remission	O	O
compared	O	O
with	O	O
81.5	O	O
%	O	O
(	O	O
PP	O	O
)	O	O
and	O	O
76.9	O	O
%	O	O
(	O	O
ITT	O	O
)	O	O
of	O	O
patients	O	O
receiving	O	O
delayed-release	O	O
mesalamine	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
for	O	O
difference	O	O
:	O	O
-3.9	O	O
%	O	O
,	O	O
8.1	O	O
%	O	O
(	O	O
PP	O	O
)	O	O
;	O	O
-5.0	O	O
%	O	O
,	O	O
6.9	O	O
%	O	O
(	O	O
ITT	O	O
)	O	O
)	O	O
.	O	O

Time	O	O
to	O	O
relapse	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
groups	O	O
(	O	O
log-rank	O	O
test	O	O
,	O	O
P=0.5116	O	O
(	O	O
PP	O	O
)	O	O
;	O	O
P=0.5455	O	O
(	O	O
ITT	O	O
)	O	O
)	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
adverse	O	O
events	O	O
was	O	O
37.1	O	O
and	O	O
36.0	O	O
%	O	O
in	O	O
patients	O	O
receiving	O	O
MMX	O	O
mesalamine	O	O
and	O	O
delayed-release	O	O
mesalamine	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSIONS	O	O
Once-daily	O	O
dosing	O	O
of	O	O
MMX	O	O
mesalamine	O	O
2.4	O	O
g/day	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
well	O	O
tolerated	O	O
and	O	O
non-inferior	O	O
to	O	O
twice-daily	O	O
dosing	O	O
with	O	O
delayed-release	O	O
mesalamine	O	O
1.6	O	O
g/day	O	O
for	O	O
maintenance	O	O
of	O	O
endoscopic	O	O
remission	O	O
in	O	O
patients	O	O
with	O	O
UC	O	O
.	O	O

Effect	O	O
of	O	O
testosterone	O	O
and	O	O
a	O	O
nutritional	O	O
supplement	O	O
,	O	O
alone	O	O
and	O	O
in	O	O
combination	O	O
,	O	O
on	O	O
hospital	O	O
admissions	O	O
in	O	O
undernourished	Condition	O
older	Age	O
men	Sex	O
and	Sex	O
women	Sex	O
.	O	O

BACKGROUND	O	O
In	O	O
older	Age	O
people	Age	O
,	O	O
undernutrition	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
hospitalization	O	O
rates	O	O
and	O	O
mortality	O	O
.	O	O

Because	O	O
weight	O	O
loss	O	O
in	O	O
older	O	O
people	O	O
often	O	O
reflects	O	O
a	O	O
disproportionate	O	O
reduction	O	O
of	O	O
skeletal	O	O
muscle	O	O
,	O	O
anabolic	O	O
treatments	O	O
may	O	O
be	O	O
beneficial	O	O
.	O	O

OBJECTIVE	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
hypothesis	O	O
that	O	O
testosterone	O	O
treatment	O	O
and	O	O
a	O	O
nutritional	O	O
supplement	O	O
have	O	O
additive	O	O
benefits	O	O
.	O	O

DESIGN	O	O
Oral	O	O
testosterone	O	O
undecanoate	O	O
(	O	O
40	O	O
mg	O	O
daily	O	O
for	O	O
women	O	O
,	O	O
80	O	O
mg	O	O
twice	O	O
daily	O	O
for	O	O
men	O	O
)	O	O
and	O	O
an	O	O
oral	O	O
nutritional	O	O
supplement	O	O
(	O	O
475	O	O
kcal/d	O	O
)	O	O
were	O	O
administered	O	O
,	O	O
alone	O	O
or	O	O
combined	O	O
,	O	O
for	O	O
1	O	O
y	O	O
to	O	O
49	SampleSize	O
community-dwelling	O	O
,	O	O
undernourished	Condition	O
people	O	O
[	O	O
Mini	Condition	O
Nutritional	Condition	O
Assessment	Condition	O
score	Condition	O
<	Condition	O
24	Condition	O
and	O	O
low	Condition	O
body	Condition	O
weight	Condition	O
(	O	O
body	Condition	O
mass	Condition	O
index	Condition	O
,	Condition	O
in	Condition	O
kg/m	Condition	O
(	Condition	O
2	Condition	O
)	Condition	O
:	Condition	O
<	Condition	O
22	Condition	O
)	O	O
or	O	O
recent	Condition	O
weight	Condition	O
loss	Condition	O
(	O	O
>	O	O
7.5	O	O
%	O	O
over	O	O
3	O	O
mo	O	O
)	O	O
]	O	O
aged	Age	O
>	Age	O
65	Age	O
y	O	O
(	O	O
mean	O	O
age	O	O
:	O	O
77	Age	O
y	O	O
;	O	O
26	SampleSize	O
women	Sex	O
and	O	O
23	SampleSize	O
men	Sex	O
)	O	O
.	O	O

Hospital	O	O
admissions	O	O
and	O	O
other	O	O
variables	O	O
were	O	O
assessed	O	O
.	O	O

RESULTS	O	O
In	O	O
subjects	O	O
receiving	O	O
combined	O	O
testosterone	O	O
and	O	O
nutritional	O	O
supplements	O	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
hospital	O	O
admissions	O	O
,	O	O
whereas	O	O
there	O	O
were	O	O
9	O	O
admissions	O	O
(	O	O
2	O	O
elective	O	O
)	O	O
in	O	O
13	O	O
subjects	O	O
in	O	O
the	O	O
no-treatment	O	O
group	O	O
,	O	O
4	O	O
in	O	O
the	O	O
testosterone-treated	O	O
group	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
,	O	O
and	O	O
5	O	O
in	O	O
the	O	O
supplement-treated	O	O
group	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
;	O	O
P	O	O
=	O	O
0.06	O	O
with	O	O
no-treatment	O	O
compared	O	O
with	O	O
combined	O	O
treatment	O	O
.	O	O

When	O	O
compared	O	O
with	O	O
the	O	O
no-treatment	O	O
group	O	O
,	O	O
the	O	O
combined-treatment	O	O
group	O	O
had	O	O
significantly	O	O
fewer	O	O
subjects	O	O
admitted	O	O
to	O	O
hospital	O	O
(	O	O
0	O	O
compared	O	O
with	O	O
5	O	O
,	O	O
P	O	O
=	O	O
0.03	O	O
)	O	O
,	O	O
fewer	O	O
days	O	O
in	O	O
hospital	O	O
(	O	O
0	O	O
compared	O	O
with	O	O
74	O	O
,	O	O
P	O	O
=	O	O
0.041	O	O
)	O	O
,	O	O
and	O	O
a	O	O
longer	O	O
time	O	O
to	O	O
hospital	O	O
admission	O	O
(	O	O
P	O	O
=	O	O
0.017	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
undernourished	Condition	O
older	Age	O
people	O	O
,	O	O
combined	O	O
treatment	O	O
with	O	O
testosterone	O	O
and	O	O
nutritional	O	O
supplementation	O	O
reduced	O	O
the	O	O
number	O	O
of	O	O
people	O	O
hospitalized	O	O
and	O	O
the	O	O
duration	O	O
of	O	O
hospital	O	O
admissions	O	O
,	O	O
which	O	O
are	O	O
important	O	O
endpoints	O	O
in	O	O
this	O	O
group	O	O
.	O	O

Larger	O	O
,	O	O
confirmatory	O	O
studies	O	O
are	O	O
now	O	O
needed	O	O
.	O	O

This	O	O
trial	O	O
was	O	O
registered	O	O
before	O	O
commencement	O	O
at	O	O
clinical	O	O
trials.gov	O	O
as	O	O
NCT00117000	O	O
.	O	O

Effects	O	O
of	O	O
self-directed	O	O
stress	O	O
management	O	O
training	O	O
and	O	O
home-based	O	O
exercise	O	O
on	O	O
stress	O	O
management	O	O
skills	O	O
in	O	O
cancer	Condition	O
patients	O	O
receiving	O	Condition
chemotherapy	Condition	Condition
.	O	O

Although	O	O
exercise	O	O
may	O	O
be	O	O
used	O	O
by	O	O
some	O	O
to	O	O
decrease	O	O
distress	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
how	O	O
it	O	O
may	O	O
contribute	O	O
to	O	O
stress	O	O
management	O	O
(	O	O
SM	O	O
)	O	O
among	O	O
patients	O	O
receiving	O	O
chemotherapy	O	O
.	O	O

We	O	O
evaluated	O	O
whether	O	O
exercise	O	O
separately	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
SM	O	O
training	O	O
is	O	O
effective	O	O
at	O	O
increasing	O	O
perceived	O	O
ability	O	O
to	O	O
manage	O	O
stress	O	O
.	O	O

Patients	O	O
receiving	O	O
chemotherapy	O	O
(	O	O
N	O	O
=	O	O
391	SampleSize	O
)	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
usual	O	O
care	O	O
only	O	O
(	O	O
UCO	O	O
)	O	O
,	O	O
SM	O	O
,	O	O
exercise	O	O
(	O	O
EX	O	O
)	O	O
,	O	O
or	O	O
stress	O	O
management	O	O
and	O	O
exercise	O	O
(	O	O
SMEX	O	O
)	O	O
.	O	O

They	O	O
completed	O	O
the	O	O
Measure	O	O
of	O	O
Current	O	O
Status	O	O
prior	O	O
to	O	O
receiving	O	O
chemotherapy	O	O
and	O	O
12	O	O
weeks	O	O
after	O	O
the	O	O
first	O	O
infusion	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
participants	O	O
randomized	O	O
to	O	O
an	O	O
intervention	O	O
condition	O	O
would	O	O
report	O	O
improvements	O	O
in	O	O
relaxation	O	O
,	O	O
awareness	O	O
of	O	O
tension	O	O
,	O	O
getting	O	O
needs	O	O
met	O	O
and	O	O
coping	O	O
confidence	O	O
compared	O	O
with	O	O
those	O	O
receiving	O	O
UCO	O	O
.	O	O

Results	O	O
indicated	O	O
significant	O	O
group-by-time	O	O
interactions	O	O
for	O	O
the	O	O
following	O	O
:	O	O
relaxation	O	O
(	O	O
UCO	O	O
versus	O	O
SM	O	O
,	O	O
p	O	O
=	O	O
0.008	O	O
)	O	O
,	O	O
awareness	O	O
of	O	O
tension	O	O
(	O	O
UCO	O	O
versus	O	O
SMEX	O	O
,	O	O
p	O	O
=	O	O
0.029	O	O
and	O	O
UCO	O	O
versus	O	O
EX	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
getting	O	O
needs	O	O
met	O	O
(	O	O
UCO	O	O
versus	O	O
SMEX	O	O
,	O	O
p	O	O
=	O	O
0.020	O	O
)	O	O
and	O	O
Measure	O	O
of	O	O
Current	O	O
Status	O	O
total	O	O
score	O	O
(	O	O
UCO	O	O
versus	O	O
SMEX	O	O
,	O	O
p	O	O
=	O	O
0.007	O	O
and	O	O
UCO	O	O
versus	O	O
EX	O	O
,	O	O
p	O	O
=	O	O
0.016	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
group-by-time	O	O
interactions	O	O
for	O	O
coping	O	O
confidence	O	O
(	O	O
p-values	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

This	O	O
study	O	O
provides	O	O
support	O	O
for	O	O
including	O	O
an	O	O
exercise	O	O
component	O	O
in	O	O
SM	O	O
interventions	O	O
for	O	O
cancer	O	O
patients	O	O
receiving	O	O
chemotherapy	O	O
(	O	O
clinicaltrials.gov	O	O
identifier	O	O
:	O	O
NCT00740038	O	O
)	O	O
.	O	O

Coagulation	O	O
factor	O	O
concentrate	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
the	O	O
haemorrhagic	Condition	O
diathesis	Condition	O
of	O	O
fulminant	Condition	O
hepatic	Condition	O
failure	Condition	O
.	O	O

To	O	O
assess	O	O
the	O	O
value	O	O
of	O	O
clotting	O	O
factor	O	O
concentrate	O	O
infusions	O	O
in	O	O
fulminant	Condition	O
hepatic	Condition	O
failure	Condition	O
,	O	O
a	O	O
controlled	O	O
trial	O	O
was	O	O
performed	O	O
in	O	O
which	O	O
nine	SampleSize	O
patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
treatment	O	O
with	O	O
either	O	O
concentrate	O	O
alone	O	O
or	O	O
concentrate	O	O
plus	O	O
heparin	O	O
.	O	O

The	O	O
five	O	O
patients	O	O
receiving	O	O
concentrate	O	O
alone	O	O
all	O	O
died	O	O
,	O	O
with	O	O
major	O	O
bleeding	O	O
as	O	O
the	O	O
direct	O	O
cause	O	O
of	O	O
death	O	O
in	O	O
three	O	O
,	O	O
whereas	O	O
in	O	O
the	O	O
four	O	O
receiving	O	O
heparin	O	O
as	O	O
well	O	O
there	O	O
was	O	O
only	O	O
one	O	O
instance	O	O
of	O	O
bleeding	O	O
and	O	O
one	O	O
patient	O	O
survived	O	O
.	O	O

Clinical	O	O
evidence	O	O
of	O	O
intravascular	O	O
coagulation	O	O
appeared	O	O
in	O	O
two	O	O
patients	O	O
treated	O	O
with	O	O
concentrate	O	O
alone	O	O
and	O	O
the	O	O
laboratory	O	O
evidence	O	O
of	O	O
this	O	O
progressed	O	O
during	O	O
the	O	O
period	O	O
of	O	O
infusions	O	O
in	O	O
all	O	O
patients	O	O
in	O	O
both	O	O
treatment	O	O
groups	O	O
,	O	O
although	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
in	O	O
those	O	O
receiving	O	O
heparin	O	O
.	O	O

Additional	O	O
evidence	O	O
for	O	O
intravascular	O	O
coagulation	O	O
came	O	O
from	O	O
the	O	O
changes	O	O
observed	O	O
in	O	O
factor	O	O
VIII	O	O
levels	O	O
which	O	O
,	O	O
although	O	O
initially	O	O
high	O	O
in	O	O
all	O	O
patients	O	O
,	O	O
fell	O	O
subsequently	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
given	O	O
concentrate	O	O
alone	O	O
.	O	O

There	O	O
was	O	O
some	O	O
improvement	O	O
in	O	O
the	O	O
prothrombin	O	O
ratio	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
patients	O	O
but	O	O
not	O	O
complete	O	O
correction	O	O
,	O	O
and	O	O
serial	O	O
assays	O	O
of	O	O
clotting	O	O
factors	O	O
showed	O	O
that	O	O
although	O	O
factor	O	O
II	O	O
rose	O	O
to	O	O
high	O	O
levels	O	O
during	O	O
treatment	O	O
,	O	O
factors	O	O
IX	O	O
and	O	O
X	O	O
showed	O	O
little	O	O
response	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
use	O	O
of	O	O
concentrate	O	O
of	O	O
factor	O	O
IX	O	O
in	O	O
this	O	O
trial	O	O
,	O	O
as	O	O
well	O	O
as	O	O
potentiating	O	O
intravascular	O	O
coagulation	O	O
,	O	O
was	O	O
inadequate	O	O
as	O	O
replacement	O	O
for	O	O
the	O	O
clotting	O	O
factor	O	O
deficiencies	O	O
.	O	O

No	O	O
effect	O	O
of	O	O
acetylsalicylic	O	O
acid	O	O
on	O	O
B-thromboglobulin	O	O
and	O	O
platelet	O	O
factor	O	O
4	O	O
plasma	O	O
levels	O	O
in	O	O
patients	O	O
with	O	O
transient	Condition	O
ischaemic	Condition	O
attacks	Condition	O
.	O	O

We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
acetylsalicylic	O	O
acid	O	O
(	O	O
ASA	O	O
)	O	O
versus	O	O
placebo	O	O
on	O	O
B-thromboglobulin	O	O
(	O	O
B-TG	O	O
)	O	O
and	O	O
platelet	O	O
factor	O	O
4	O	O
(	O	O
PF4	O	O
)	O	O
plasma	O	O
levels	O	O
and	O	O
ADP-induced	O	O
platelet	O	O
aggregation	O	O
in	O	O
25	SampleSize	SampleSize
male	Sex	Sex
patients	O	O
with	O	O
transient	Condition	O
ischaemic	Condition	O
attacks	Condition	O
(	O	O
TIA	Condition	O
)	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
allocated	O	O
randomly	O	O
to	O	O
two	O	O
groups	O	O
:	O	O
14	O	O
patients	O	O
received	O	O
oral	O	O
treatment	O	O
with	O	O
ASA	O	O
500	O	O
mg	O	O
b.i.d	O	O
.	O	O

for	O	O
14	O	O
days	O	O
,	O	O
11	O	O
patients	O	O
placebo	O	O
b.i.d	O	O
.	O	O

for	O	O
the	O	O
same	O	O
period	O	O
.	O	O

B-TG	O	O
and	O	O
PF4	O	O
plasma	O	O
levels	O	O
and	O	O
ADP-induced	O	O
platelet	O	O
aggregation	O	O
were	O	O
determined	O	O
in	O	O
basal	O	O
conditions	O	O
,	O	O
and	O	O
two	O	O
hours	O	O
,	O	O
and	O	O
seven	O	O
and	O	O
fourteen	O	O
days	O	O
after	O	O
starting	O	O
with	O	O
ASA	O	O
or	O	O
placebo	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
same	O	O
parameters	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
20	SampleSize	O
healthy	Condition	O
males	Sex	O
of	O	O
matched	O	O
age	O	O
.	O	O

Basal	O	O
levels	O	O
of	O	O
plasma	O	O
B-TG	O	O
and	O	O
PF4	O	O
and	O	O
the	O	O
maximal	O	O
amplitude	O	O
of	O	O
ADP-induced	O	O
platelet	O	O
aggregation	O	O
were	O	O
abnormally	O	O
high	O	O
in	O	O
TIA	O	O
patients	O	O
.	O	O

ASA	O	O
caused	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
B-TG	O	O
plasma	O	O
levels	O	O
in	O	O
TIA	O	O
patients	O	O
2	O	O
hours	O	O
after	O	O
the	O	O
first	O	O
administration	O	O
,	O	O
but	O	O
no	O	O
effect	O	O
was	O	O
observed	O	O
at	O	O
the	O	O
7th	O	O
and	O	O
14th	O	O
day	O	O
of	O	O
treatment	O	O
.	O	O

PF4	O	O
plasma	O	O
levels	O	O
were	O	O
unaffected	O	O
by	O	O
ASA	O	O
treatment	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
ASA	O	O
,	O	O
at	O	O
the	O	O
dose	O	O
conventionally	O	O
used	O	O
in	O	O
clinical	O	O
trials	O	O
,	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
release	O	O
of	O	O
two	O	O
alpha-granule	O	O
proteins	O	O
.	O	O

Midazolam	O	O
vs	O	O
ondansetron	O	O
for	O	O
preventing	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
prophylactic	O	O
anti-emetic	O	O
efficacy	O	O
of	O	O
midazolam	O	O
and	O	O
ondansetron	O	O
in	O	O
90	SampleSize	SampleSize
patients	O	O
scheduled	O	O
for	O	O
minor	Condition	O
gynaecological	Condition	O
(	O	O
hysteroscopy	Condition	O
)	O	O
or	O	O
urological	Condition	O
(	O	O
ureteroscopy	Condition	O
)	O	O
procedures	O	O
planned	O	O
to	O	O
last	O	O
1-2	O	O
h	O	O
under	O	O
sevoflurane	O	O
anaesthesia	O	O
with	O	O
spontaneous	O	Condition
ventilation	O	Condition
of	O	Condition
the	O	Condition
lungs	O	Condition
via	O	O
a	O	O
laryngeal	O	O
mask	O	O
airway	O	O
.	O	O

Midazolam	O	O
2	O	O
mg	O	O
or	O	O
ondansetron	O	O
4	O	O
mg	O	O
were	O	O
administered	O	O
intravenously	O	O
30	O	O
min	O	O
before	O	O
the	O	O
end	O	O
of	O	O
surgery	O	O
.	O	O

The	O	O
proportions	O	O
of	O	O
patients	O	O
who	O	O
experienced	O	O
postoperative	Condition	O
nausea	Condition	O
and	O	O
vomiting	Condition	O
in	O	O
the	O	O
first	O	O
24	O	O
h	O	O
(	O	O
30	O	O
%	O	O
and	O	O
27	O	O
%	O	O
for	O	O
the	O	O
midazolam	O	O
and	O	O
ondansetron	O	O
groups	O	O
,	O	O
respectively	O	O
)	O	O
were	O	O
similar	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
was	O	O
significantly	O	O
smaller	O	O
in	O	O
both	O	O
groups	O	O
than	O	O
predicted	O	O
according	O	O
to	O	O
the	O	O
patients	O	O
'	O	O
underlying	O	O
risks	O	O
(	O	O
midazolam	O	O
group	O	O
:	O	O
p	O	O
=	O	O
0.018	O	O
;	O	O
ondansetron	O	O
group	O	O
:	O	O
p	O	O
=	O	O
0.017	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
average	O	O
sedation	O	O
scores	O	O
or	O	O
pain	O	O
scores	O	O
.	O	O

Treatment	O	O
using	O	O
ondansetron	O	O
for	O	O
anti-emetic	O	O
prophylaxis	O	O
did	O	O
not	O	O
provide	O	O
a	O	O
superior	O	O
benefit	O	O
compared	O	O
to	O	O
midazolam	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

Measurement	O	O
of	O	O
transfer	O	O
factor	O	O
during	O	O
constant	O	O
exhalation	O	O
.	O	O

BACKGROUND	O	O
Transfer	O	O
factor	O	O
of	O	O
the	O	O
lung	O	O
for	O	O
carbon	O	O
monoxide	O	O
(	O	O
TLCO	O	O
)	O	O
was	O	O
measured	O	O
by	O	O
a	O	O
new	O	O
method	O	O
based	O	O
on	O	O
analysis	O	O
of	O	O
the	O	O
ratio	O	O
of	O	O
the	O	O
concentrations	O	O
of	O	O
carbon	O	O
monoxide	O	O
to	O	O
an	O	O
inert	O	O
gas	O	O
(	O	O
methane	O	O
)	O	O
relative	O	O
to	O	O
lung	O	O
volume	O	O
during	O	O
a	O	O
constant	O	O
exhalation	O	O
.	O	O

Since	O	O
this	O	O
new	O	O
technique	O	O
is	O	O
based	O	O
solely	O	O
upon	O	O
exhalation	O	O
,	O	O
anomalies	O	O
associated	O	O
with	O	O
inspiration	O	O
and	O	O
breath	O	O
holding	O	O
do	O	O
not	O	O
affect	O	O
results	O	O
.	O	O

Additionally	O	O
,	O	O
because	O	O
prolonged	O	O
breath	O	O
holding	O	O
is	O	O
not	O	O
required	O	O
,	O	O
measurements	O	O
can	O	O
readily	O	O
be	O	O
made	O	O
in	O	O
dyspnoeic	Condition	O
patients	O	O
.	O	O

METHODS	O	O
Exhalation	O	O
TLCO	O	O
(	O	O
TLCO	O	O
,	O	O
ex	O	O
)	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
standard	O	O
(	O	O
Jones	O	O
and	O	O
Meade	O	O
)	O	O
10	O	O
second	O	O
breath	O	O
holding	O	O
TLCO	O	O
(	O	O
TLCO	O	O
,	O	O
bh	O	O
)	O	O
in	O	O
100	SampleSize	O
consecutive	O	O
patients	O	O
.	O	O

Patients	O	O
did	O	O
not	O	O
practise	O	O
the	O	O
exhalation	O	O
manoeuvre	O	O
prior	O	O
to	O	O
testing	O	O
.	O	O

RESULTS	O	O
The	O	O
comparative	O	O
results	O	O
were	O	O
very	O	O
close	O	O
;	O	O
mean	O	O
difference	O	O
(	O	O
bias	O	O
)	O	O
+/-	O	O
standard	O	O
deviation	O	O
(	O	O
precision	O	O
)	O	O
was	O	O
0.05	O	O
(	O	O
0.84	O	O
)	O	O
mmol/min/kPa	O	O
.	O	O

The	O	O
relation	O	O
was	O	O
equally	O	O
strong	O	O
in	O	O
patients	O	O
with	O	O
severe	Condition	O
pulmonary	Condition	O
disease	Condition	O
;	O	O
for	O	O
patients	O	O
with	O	O
FEV1	O	O
<	O	O
1.51	O	O
the	O	O
mean	O	O
difference	O	O
was	O	O
0.21	O	O
(	O	O
0.80	O	O
)	O	O
mmol/min/kPa	O	O
.	O	O

CONCLUSIONS	O	O
Since	O	O
the	O	O
results	O	O
were	O	O
essentially	O	O
identical	O	O
between	O	O
the	O	O
techniques	O	O
,	O	O
it	O	O
seems	O	O
that	O	O
comparable	O	O
pathophysiological	O	O
factors	O	O
affect	O	O
TLCO	O	O
during	O	O
breath	O	O
holding	O	O
and	O	O
constant	O	O
exhalation	O	O
.	O	O

Constant	O	O
exhalation	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
useful	O	O
alternative	O	O
to	O	O
the	O	O
breath	O	O
holding	O	O
technique	O	O
for	O	O
clinical	O	O
measurement	O	O
of	O	O
TLCO	O	O
.	O	O

Physostigmine	O	O
reverses	O	O
propofol-induced	O	O
unconsciousness	O	O
and	O	O
attenuation	O	O
of	O	O
the	O	O
auditory	O	O
steady	O	O
state	O	O
response	O	O
and	O	O
bispectral	O	O
index	O	O
in	O	O
human	O	O
volunteers	O	O
.	O	O

BACKGROUND	O	O
It	O	O
is	O	O
postulated	O	O
that	O	O
alteration	O	O
of	O	O
central	O	O
cholinergic	O	O
transmission	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
anesthetics	O	O
produce	O	O
unconsciousness	O	O
.	O	O

The	O	O
authors	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
altering	O	O
central	O	O
cholinergic	O	O
transmission	O	O
,	O	O
by	O	O
physostigmine	O	O
and	O	O
scopolamine	O	O
,	O	O
on	O	O
unconsciousness	O	O
produced	O	O
by	O	O
propofol	O	O
.	O	O

METHODS	O	O
Propofol	O	O
was	O	O
administered	O	O
to	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
physical	Condition	O
status	Condition	O
1	Condition	O
(	O	O
n	O	O
=	O	O
17	SampleSize	O
)	O	O
volunteers	O	O
with	O	O
use	O	O
of	O	O
a	O	O
computer-controlled	O	O
infusion	O	O
pump	O	O
at	O	O
increasing	O	O
concentrations	O	O
until	O	O
unconsciousness	O	O
resulted	O	O
(	O	O
inability	O	O
to	O	O
respond	O	O
to	O	O
verbal	O	O
commands	O	O
,	O	O
abolition	O	O
of	O	O
spontaneous	O	O
movement	O	O
)	O	O
.	O	O

Central	O	O
nervous	O	O
system	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
use	O	O
of	O	O
the	O	O
Auditory	O	O
Steady	O	O
State	O	O
Response	O	O
(	O	O
ASSR	O	O
)	O	O
and	O	O
Bispectral	O	O
Index	O	O
(	O	O
BIS	O	O
)	O	O
analysis	O	O
of	O	O
electrooculogram	O	O
.	O	O

During	O	O
continuous	O	O
administration	O	O
of	O	O
propofol	O	O
,	O	O
reversal	O	O
of	O	O
unconsciousness	O	O
produced	O	O
by	O	O
physostigmine	O	O
(	O	O
28	O	O
microgram/kg	O	O
)	O	O
and	O	O
block	O	O
of	O	O
this	O	O
reversal	O	O
by	O	O
scopolamine	O	O
(	O	O
8.6	O	O
microgram/kg	O	O
)	O	O
were	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
Propofol	O	O
produced	O	O
unconsciousness	O	O
at	O	O
a	O	O
plasma	O	O
concentration	O	O
of	O	O
3.2	O	O
+/-	O	O
0.8	O	O
(	O	O
+/-	O	O
SD	O	O
)	O	O
microgram/ml	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
.	O	O

Unconsciousness	O	O
was	O	O
associated	O	O
with	O	O
reductions	O	O
in	O	O
ASSR	O	O
(	O	O
0.10	O	O
+/-	O	O
0.08	O	O
microV	O	O
[	O	O
awake	O	O
baseline	O	O
0.32	O	O
+/-	O	O
0.18	O	O
microV	O	O
]	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
BIS	O	O
(	O	O
55.7	O	O
+/-	O	O
8.8	O	O
[	O	O
awake	O	O
baseline	O	O
92.4	O	O
+/-	O	O
3.9	O	O
]	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Physostigmine	O	O
restored	O	O
consciousness	O	O
in	O	O
9	O	O
of	O	O
11	O	O
subjects	O	O
,	O	O
with	O	O
concomitant	O	O
increases	O	O
in	O	O
ASSR	O	O
(	O	O
0.38	O	O
+/-	O	O
0.17	O	O
microV	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
BIS	O	O
(	O	O
75.3	O	O
+/-	O	O
8.3	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

In	O	O
all	O	O
subjects	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
scopolamine	O	O
blocked	O	O
the	O	O
physostigmine-induced	O	O
reversal	O	O
of	O	O
unconsciousness	O	O
and	O	O
the	O	O
increase	O	O
of	O	O
the	O	O
ASSR	O	O
and	O	O
BIS	O	O
(	O	O
ASSR	O	O
and	O	O
BIS	O	O
during	O	O
propofol-induced	O	O
unconsciousness	O	O
:	O	O
0.09	O	O
+/-	O	O
0.09	O	O
microV	O	O
and	O	O
58.2	O	O
+/-	O	O
7.5	O	O
,	O	O
respectively	O	O
;	O	O
ASSR	O	O
and	O	O
BIS	O	O
after	O	O
physostigmine	O	O
administration	O	O
:	O	O
0.08	O	O
+/-	O	O
0.06	O	O
microV	O	O
and	O	O
56.8	O	O
+/-	O	O
6.7	O	O
,	O	O
respectively	O	O
,	O	O
NS	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
unconsciousness	O	O
produced	O	O
by	O	O
propofol	O	O
is	O	O
mediated	O	O
at	O	O
least	O	O
in	O	O
part	O	O
via	O	O
interruption	O	O
of	O	O
central	O	O
cholinergic	O	O
muscarinic	O	O
transmission	O	O
.	O	O

Double-blind	O	O
,	O	O
placebo-controlled	O	O
trial	O	O
of	O	O
risperidone	O	O
plus	O	O
amantadine	O	O
in	O	O
children	Age	O
with	O	O
autism	Condition	Condition
:	O	O
a	O	O
10-week	O	O
randomized	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
adding	O	O
amantadine	O	O
to	O	O
risperidone	O	O
for	O	O
treatment	O	O
of	O	O
autism	O	O
.	O	O

METHODS	O	O
Forty	SampleSize	O
outpatients	O	O
aged	O	O
4	Age	O
to12	Age	O
years	O	O
,	O	O
who	O	O
were	O	O
diagnosed	O	O
with	O	O
autism	Condition	O
spectrum	Condition	O
disorders	Condition	O
based	O	O
on	O	O
the	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	O	O
Disorders	O	O
,	O	O
Fourth	O	O
Edition	O	O
,	O	O
Text	O	O
Revision	O	O
criteria	O	O
,	O	O
were	O	O
assigned	O	O
to	O	O
this	O	O
double-blind	O	O
clinical	O	O
trial	O	O
.	O	O

The	O	O
subjects	O	O
were	O	O
divided	O	O
randomly	O	O
into	O	O
2	O	O
groups	O	O
.	O	O

One	O	O
group	O	O
received	O	O
risperidone	O	O
plus	O	O
amantadine	O	O
,	O	O
and	O	O
the	O	O
other	O	O
group	O	O
received	O	O
risperidone	O	O
plus	O	O
placebo	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
risperidone	O	O
was	O	O
titrated	O	O
between	O	O
1	O	O
and	O	O
2.0	O	O
mg/d	O	O
,	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
amantadine	O	O
was	O	O
100	O	O
or	O	O
150	O	O
mg/d	O	O
for	O	O
patients	O	O
less	O	O
than	O	O
30	O	O
kg	O	O
or	O	O
more	O	O
than	O	O
30	O	O
kg	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
assessed	O	O
using	O	O
the	O	O
Aberrant	O	O
Behavioral	O	O
Checklist-Community	O	O
(	O	O
ABC-C	O	O
)	O	O
and	O	O
adverse	O	O
effects	O	O
checklist	O	O
as	O	O
well	O	O
as	O	O
clinical	O	O
global	O	O
impression-improvement	O	O
(	O	O
CGI-I	O	O
)	O	O
at2	O	O
checkpoints	O	O
of	O	O
5-week	O	O
intervals	O	O
after	O	O
the	O	O
baseline	O	O
.	O	O

Informed	O	O
consentwas	O	O
obtained	O	O
from	O	O
the	O	O
parents	O	O
of	O	O
each	O	O
participant	O	O
.	O	O

RESULTS	O	O
Among	O	O
ABC-C	O	O
subscales	O	O
,	O	O
Hyperactivity	O	O
and	O	O
Irritability	O	O
showed	O	O
significantly	O	O
greater	O	O
reduction	O	O
in	O	O
the	O	O
amantadine	O	O
group	O	O
than	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
adverse	O	O
effects	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

The	O	O
CGI-I	O	O
scores	O	O
show	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
amantadine	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
present	O	O
study	O	O
suggests	O	O
that	O	O
amantadine	O	O
may	O	O
be	O	O
a	O	O
potential	O	O
adjunctive	O	O
treatment	O	O
strategy	O	O
for	O	O
autism	O	O
and	O	O
it	O	O
was	O	O
generally	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
dipeptidyl	O	O
peptidase-4	O	O
inhibitor	O	O
PHX1149	O	O
improves	O	O
blood	O	O
glucose	O	O
control	O	O
in	O	O
patients	O	O
with	O	O
type	Condition	Condition
2	Condition	Condition
diabetes	Condition	Condition
mellitus	Condition	Condition
.	O	O

AIM	O	O
To	O	O
determine	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
PHX1149	O	O
,	O	O
a	O	O
novel	O	O
dipeptidyl	O	O
peptidase-4	O	O
(	O	O
DPP4	O	O
)	O	O
inhibitor	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
type	Condition	Condition
2	Condition	Condition
diabetes	Condition	Condition
.	O	O

METHODS	O	O
This	O	O
is	O	O
a	O	O
multicentre	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
4-week	O	O
study	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
with	O	O
suboptimal	O	O
metabolic	O	O
control	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
baseline	O	O
haemoglobin	O	O
A	O	O
(	O	O
1c	O	O
)	O	O
(	O	O
HbA	O	O
(	O	O
1c	O	O
)	O	O
)	O	O
of	O	O
7.3	O	O
to	O	O
11.0	O	O
%	O	O
were	O	O
randomized	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
to	O	O
receive	O	O
once-daily	O	O
oral	O	O
therapy	O	O
with	O	O
either	O	O
PHX1149	O	O
(	O	O
100	O	O
,	O	O
200	O	O
or	O	O
400	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
;	O	O
patients	O	O
were	O	O
on	O	O
a	O	O
constant	O	O
background	O	O
therapy	O	O
of	O	O
either	O	O
metformin	O	O
alone	O	O
or	O	O
metformin	O	O
plus	O	O
a	O	O
glitazone	O	O
.	O	O

RESULTS	O	O
Treatment	O	O
with	O	O
100	O	O
,	O	O
200	O	O
or	O	O
400	O	O
mg	O	O
of	O	O
PHX1149	O	O
significantly	O	O
decreased	O	O
postprandial	O	O
glucose	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
AUC	O	O
(	O	O
0-2	O	O
h	O	O
)	O	O
by	O	O
approximately	O	O
20	O	O
%	O	O
(	O	O
+0.11	O	O
+/-	O	O
0.50	O	O
,	O	O
-2.08	O	O
+/-	O	O
0.51	O	O
,	O	O
-1.73	O	O
+/-	O	O
0.49	O	O
and	O	O
-1.88	O	O
+/-	O	O
0.48	O	O
mmol/l	O	O
x	O	O
h	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
placebo	O	O
and	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0.002	O	O
,	O	O
0.008	O	O
and	O	O
0.004	O	O
vs.	O	O
placebo	O	O
)	O	O
.	O	O

Postprandial	O	O
AUC	O	O
(	O	O
0-2	O	O
h	O	O
)	O	O
of	O	O
intact	O	O
glucagon-like	O	O
peptide-1	O	O
,	O	O
the	O	O
principal	O	O
mediator	O	O
of	O	O
the	O	O
biological	O	O
effects	O	O
of	O	O
DPP4	O	O
inhibitors	O	O
,	O	O
was	O	O
increased	O	O
by	O	O
3.90	O	O
+/-	O	O
2.83	O	O
,	O	O
11.63	O	O
+/-	O	O
2.86	O	O
,	O	O
16.42	O	O
+/-	O	O
2.72	O	O
and	O	O
15.75	O	O
+/-	O	O
2.71	O	O
pmol/l	O	O
x	O	O
h	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
placebo	O	O
and	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0.053	O	O
,	O	O
0.001	O	O
and	O	O
0.002	O	O
vs.	O	O
placebo	O	O
)	O	O
.	O	O

Mean	O	O
HbA	O	O
(	O	O
1c	O	O
)	O	O
was	O	O
lower	O	O
in	O	O
all	O	O
dose	O	O
groups	O	O
;	O	O
the	O	O
placebo-corrected	O	O
change	O	O
in	O	O
the	O	O
groups	O	O
receiving	O	O
400	O	O
mg	O	O
PHX1149	O	O
was	O	O
-0.28	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

DPP4	O	O
inhibition	O	O
on	O	O
day	O	O
28	O	O
was	O	O
53	O	O
,	O	O
73	O	O
and	O	O
78	O	O
%	O	O
at	O	O
24	O	O
h	O	O
postdose	O	O
in	O	O
the	O	O
groups	O	O
receiving	O	O
100	O	O
,	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
PHX1149	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
adverse	O	O
events	O	O
between	O	O
PHX1149-treated	O	O
and	O	O
placebo	O	O
subjects	O	O
.	O	O

CONCLUSIONS	O	O
Addition	O	O
of	O	O
the	O	O
DPP4	O	O
inhibitor	O	O
PHX1149	O	O
to	O	O
a	O	O
stable	O	O
regimen	O	O
of	O	O
metformin	O	O
or	O	O
metformin	O	O
plus	O	O
a	O	O
glitazone	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
improved	O	O
blood	O	O
glucose	O	O
control	O	O
.	O	O

The	O	O
problem	O	O
of	O	O
measurement	O	O
error	O	O
in	O	O
multisite	O	O
clinical	O	O
trials	O	O
.	O	O

The	O	O
implementation	O	O
of	O	O
a	O	O
multisite	O	O
,	O	O
randomized	O	O
,	O	O
clinical	O	O
psychopharmacologic	O	O
trial	O	O
involves	O	O
a	O	O
substantial	O	O
investment	O	O
of	O	O
time	O	O
and	O	O
effort	O	O
on	O	O
the	O	O
part	O	O
of	O	O
all	O	O
participants	O	O
.	O	O

Because	O	O
of	O	O
their	O	O
complexity	O	O
,	O	O
such	O	O
clinical	O	O
trials	O	O
present	O	O
unique	O	O
methodological	O	O
and	O	O
design	O	O
challenges	O	O
.	O	O

Indeed	O	O
,	O	O
it	O	O
is	O	O
not	O	O
uncommon	O	O
for	O	O
such	O	O
studies	O	O
to	O	O
conclude	O	O
with	O	O
uninterpretable	O	O
results	O	O
,	O	O
due	O	O
in	O	O
part	O	O
to	O	O
such	O	O
methodological	O	O
pitfalls	O	O
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
clarification	O	O
of	O	O
such	O	O
methodologic	O	O
dilemmas	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
important	O	O
challenges	O	O
facing	O	O
the	O	O
future	O	O
of	O	O
industry-sponsored	O	O
psychopharmacologic	O	O
drug	O	O
development	O	O
.	O	O

Among	O	O
the	O	O
many	O	O
factors	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
problematic	O	O
clinical	O	O
trial	O	O
results	O	O
,	O	O
error	O	O
in	O	O
measuring	O	O
the	O	O
phenomena	O	O
being	O	O
studied	O	O
is	O	O
of	O	O
particular	O	O
concern	O	O
.	O	O

In	O	O
this	O	O
article	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
outcome	O	O
of	O	O
an	O	O
intensive	O	O
series	O	O
of	O	O
interrater	O	O
reliability	O	O
training	O	O
sessions	O	O
for	O	O
the	O	O
17-item	O	O
Hamilton	O	O
Depression	O	O
Rating	O	O
Scale	O	O
conducted	O	O
at	O	O
the	O	O
start	O	O
of	O	O
a	O	O
Phase	O	O
II	O	O
multisite	O	O
clinical	O	O
drug	O	O
trial	O	O
.	O	O

The	O	O
data	O	O
underscore	O	O
the	O	O
magnitude	O	O
of	O	O
error	O	O
present	O	O
in	O	O
such	O	O
a	O	O
test	O	O
setting	O	O
and	O	O
provide	O	O
preliminary	O	O
evidence	O	O
for	O	O
the	O	O
potential	O	O
effect	O	O
of	O	O
this	O	O
problem	O	O
on	O	O
the	O	O
detection	O	O
of	O	O
clinical	O	O
change	O	O
.	O	O

The	O	O
acute	O	O
effects	O	O
of	O	O
fluid	O	O
intake	O	O
on	O	O
urine	O	O
specific	O	O
gravity	O	O
and	O	O
fluid	O	O
retention	O	O
in	O	O
a	O	O
mildly	Condition	O
dehydrated	Condition	O
state	Condition	O
.	O	O

Many	O	O
athletes	O	O
arrive	O	O
at	O	O
training	O	O
sessions	O	O
and	O	O
competitions	O	O
in	O	O
a	O	O
mildly	O	O
hypohydrated	O	O
(	O	O
HYPO	Condition	O
)	O	O
state	O	O
and	O	O
are	O	O
instructed	O	O
to	O	O
drink	O	O
fluids	O	O
before	O	O
exercise	O	O
to	O	O
reach	O	O
a	O	O
euhydrated	O	O
(	O	O
HYD	O	O
)	O	O
state	O	O
.	O	O

Ten	O	O
recreational	O	O
athletes	O	O
(	O	O
6	O	O
women	O	O
,	O	O
4	O	O
men	O	O
;	O	O
71.9	O	O
?	O	O
4.6	O	O
kg	O	O
,	O	O
25.2	O	O
?	O	O
0.9	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
the	O	O
studies	O	O
to	O	O
examine	O	O
(	O	O
a	O	O
)	O	O
the	O	O
day-to-day	O	O
variability	O	O
of	O	O
morning	O	O
urine	O	O
specific	O	O
gravity	O	O
(	O	O
USG	O	O
)	O	O
,	O	O
(	O	O
b	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
consuming	O	O
600	O	O
ml	O	O
of	O	O
water	O	O
on	O	O
the	O	O
hydration	O	O
status	O	O
of	O	O
HYD	O	O
and	O	O
HYPO	O	O
(	O	O
USG	O	O
>	O	O
1.020	O	O
)	O	O
subjects	O	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
the	O	O
effects	O	O
of	O	O
consuming	O	O
water	O	O
(	O	O
W	O	O
)	O	O
,	O	O
salt-water	O	O
(	O	O
SW	O	O
,	O	O
40	O	O
mM	O	O
Na	O	O
)	O	O
,	O	O
a	O	O
carbohydrate-electrolyte	O	O
solution	O	O
with	O	O
3	O	O
%	O	O
or	O	O
light	O	O
carbohydrate	O	O
(	O	O
CES-L	O	O
,	O	O
20	O	O
mM	O	O
Na	O	O
)	O	O
or	O	O
a	O	O
CES	O	O
with	O	O
6	O	O
%	O	O
carbohydrate	O	O
(	O	O
CES	O	O
,	O	O
20	O	O
mM	O	O
Na	O	O
)	O	O
on	O	O
the	O	O
hydration	O	O
status	O	O
of	O	O
HYPO	O	O
subjects	O	O
.	O	O

The	O	O
hydration	O	O
status	O	O
was	O	O
assessed	O	O
with	O	O
USG	O	O
and	O	O
body	O	O
mass	O	O
measures	O	O
and	O	O
urine	O	O
volume	O	O
collections	O	O
.	O	O

The	O	O
day-to-day	O	O
variability	O	O
in	O	O
morning	O	O
USG	O	O
(	O	O
coefficient	O	O
of	O	O
variation	O	O
=	O	O
0.2	O	O
?	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
low	O	O
and	O	O
the	O	O
responses	O	O
to	O	O
600	O	O
ml	O	O
of	O	O
W	O	O
ingestion	O	O
were	O	O
repeatable	O	O
.	O	O

Pretrial	O	O
USG	O	O
was	O	O
1.022	O	O
?	O	O
0.001	O	O
in	O	O
the	O	O
HYPO	O	O
trial	O	O
and	O	O
decreased	O	O
<	O	O
1.020	O	O
by	O	O
45	O	O
minutes	O	O
(	O	O
1.013	O	O
?	O	O
0.003	O	O
)	O	O
.	O	O

In	O	O
the	O	O
CES	O	O
study	O	O
,	O	O
HYPO	O	O
subjects	O	O
reached	O	O
HYD	O	O
status	O	O
at	O	O
45	O	O
minutes	O	O
in	O	O
all	O	O
conditions	O	O
(	O	O
W	O	O
1.013	O	O
?	O	O
0.003	O	O
,	O	O
SW	O	O
1.013	O	O
?	O	O
0.003	O	O
,	O	O
CES-L	O	O
1.011	O	O
?	O	O
0.003	O	O
,	O	O
CES	O	O
1.017	O	O
?	O	O
0.004	O	O
)	O	O
because	O	O
salt	O	O
or	O	O
CES	O	O
ingestion	O	O
did	O	O
not	O	O
affect	O	O
fluid	O	O
retention	O	O
(	O	O
W	O	O
68	O	O
%	O	O
,	O	O
SW	O	O
72	O	O
%	O	O
,	O	O
CES-L	O	O
68	O	O
%	O	O
,	O	O
CES	O	O
76	O	O
%	O	O
)	O	O
.	O	O

This	O	O
study	O	O
demonstrated	O	O
that	O	O
mildly	O	O
HYPO	O	O
subjects	O	O
could	O	O
reach	O	O
euhydration	O	O
within	O	O
45	O	O
minutes	O	O
of	O	O
the	O	O
ingestion	O	O
of	O	O
600	O	O
ml	O	O
of	O	O
W	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
salt	O	O
and	O	O
CES	O	O
solutions	O	O
.	O	O

Following	O	O
this	O	O
practice	O	O
will	O	O
minimize	O	O
the	O	O
incidence	O	O
of	O	O
starting	O	O
a	O	O
practice	O	O
or	O	O
competition	O	O
hypohydrated	O	O
.	O	O

A	O	O
randomized	O	O
controlled	O	O
trial	O	O
to	O	O
improve	O	O
colon	O	O
cancer	O	O
screening	O	O
in	O	O
rural	Condition	O
family	Condition	O
medicine	O	O
:	O	O
an	O	O
Iowa	O	O
Research	O	O
Network	O	O
(	O	O
IRENE	O	O
)	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Many	O	O
adults	O	O
have	O	O
not	O	O
been	O	O
screened	O	O
for	O	O
colon	O	O
cancer	O	O
,	O	O
a	O	O
potentially	O	O
preventable	O	O
cause	O	O
of	O	O
death	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
conducted	O	O
between	O	O
December	O	O
2008	O	O
and	O	O
April	O	O
2011	O	O
to	O	O
improve	O	O
CRC	O	O
screening	O	O
in	O	O
16	O	O
rural	O	O
family	O	O
physician	O	O
offices	O	O
.	O	O

Subjects	Condition	O
due	O	O
for	O	O
CRC	Condition	O
screening	Condition	O
were	O	O
randomized	O	O
within	O	O
each	O	O
practice	O	O
to	O	O
1	O	O
of	O	O
4	O	O
groups	O	O
:	O	O
(	O	O
1	O	O
)	O	O
usual	O	O
care	O	O
;	O	O
(	O	O
2	O	O
)	O	O
physician	O	O
chart	O	O
reminder	O	O
;	O	O
(	O	O
3	O	O
)	O	O
physician	O	O
chart	O	O
reminder	O	O
,	O	O
mailed	O	O
education	O	O
,	O	O
CRC	O	O
reminder	O	O
magnet	O	O
,	O	O
and	O	O
fecal	O	O
immunochemical	O	O
test	O	O
(	O	O
FIT	O	O
)	O	O
(	O	O
mailed	O	O
education/FIT	O	O
)	O	O
;	O	O
or	O	O
(	O	O
4	O	O
)	O	O
all	O	O
the	O	O
preceding	O	O
plus	O	O
a	O	O
structured	O	O
telephone	O	O
call	O	O
to	O	O
the	O	O
patient	O	O
from	O	O
project	O	O
staff	O	O
to	O	O
provide	O	O
education	O	O
,	O	O
assess	O	O
interest	O	O
in	O	O
screening	O	O
,	O	O
explain	O	O
the	O	O
screening	O	O
tests	O	O
,	O	O
and	O	O
address	O	O
barriers	O	O
(	O	O
mailed	O	O
education/FIT	O	O
plus	O	O
phone	O	O
call	O	O
)	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
completion	O	O
of	O	O
any	O	O
CRC	O	O
screening	O	O
.	O	O

RESULTS	O	O
This	O	O
study	O	O
enrolled	O	O
743	SampleSize	O
patients	O	O
.	O	O

CRC	O	O
screening	O	O
was	O	O
completed	O	O
by	O	O
17.8	O	O
%	O	O
in	O	O
the	O	O
usual	O	O
care	O	O
group	O	O
,	O	O
20.5	O	O
%	O	O
in	O	O
the	O	O
chart	O	O
reminder	O	O
group	O	O
,	O	O
56.5	O	O
%	O	O
in	O	O
the	O	O
mailed	O	O
education/FIT	O	O
group	O	O
,	O	O
and	O	O
57.2	O	O
%	O	O
in	O	O
the	O	O
mailed	O	O
education/FIT	O	O
plus	O	O
phone	O	O
call	O	O
group	O	O
.	O	O

We	O	O
found	O	O
no	O	O
effect	O	O
from	O	O
the	O	O
chart	O	O
reminder	O	O
compared	O	O
with	O	O
usual	O	O
care	O	O
(	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
,	O	O
1.2	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.7-2.0	O	O
)	O	O
;	O	O
and	O	O
a	O	O
beneficial	O	O
effect	O	O
from	O	O
the	O	O
mailed	O	O
education/FIT	O	O
(	O	O
OR	O	O
,	O	O
6.0	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
3.7-9.6	O	O
)	O	O
and	O	O
the	O	O
mailed	O	O
education/FIT	O	O
plus	O	O
phone	O	O
call	O	O
(	O	O
OR	O	O
,	O	O
6.2	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
3.8-9.9	O	O
)	O	O
.	O	O

Both	O	O
FIT	O	O
and	O	O
colonoscopy	O	O
rates	O	O
increased	O	O
significantly	O	O
in	O	O
both	O	O
mailed	O	O
education	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
CRC	O	O
screening	O	O
rates	O	O
increased	O	O
significantly	O	O
among	O	O
patients	O	O
who	O	O
were	O	O
overdue	O	O
for	O	O
screening	O	O
after	O	O
they	O	O
received	O	O
mailed	O	O
educational	O	O
materials	O	O
and	O	O
a	O	O
FIT	O	O
.	O	O

The	O	O
addition	O	O
of	O	O
a	O	O
phone	O	O
call	O	O
did	O	O
not	O	O
further	O	O
increase	O	O
screening	O	O
rates	O	O
.	O	O

Randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
trial	O	O
of	O	O
oral	O	O
sirolimus	O	O
for	O	O
restenosis	O	O
prevention	O	O
in	O	O
patients	O	O
with	O	O
in-stent	Condition	O
restenosis	Condition	O
:	O	O
the	O	O
Oral	O	O
Sirolimus	O	O
to	O	O
Inhibit	O	O
Recurrent	O	O
In-stent	O	O
Stenosis	O	O
(	O	O
OSIRIS	O	O
)	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Despite	O	O
recent	O	O
advances	O	O
in	O	O
interventional	O	O
cardiology	O	O
,	O	O
including	O	O
the	O	O
introduction	O	O
of	O	O
drug-eluting	O	O
stents	O	O
for	O	O
de	O	O
novo	O	O
coronary	O	O
lesions	O	O
,	O	O
the	O	O
treatment	O	O
of	O	O
in-stent	O	O
restenosis	O	O
(	O	O
ISR	O	O
)	O	O
remains	O	O
a	O	O
challenging	O	O
clinical	O	O
issue	O	O
.	O	O

Given	O	O
the	O	O
efficacy	O	O
of	O	O
systemic	O	O
sirolimus	O	O
administration	O	O
to	O	O
prevent	O	O
neointimal	O	O
hyperplasia	O	O
in	O	O
animal	O	O
models	O	O
and	O	O
to	O	O
halt	O	O
and	O	O
even	O	O
reverse	O	O
the	O	O
progression	O	O
of	O	O
allograft	O	O
vasculopathy	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
a	O	O
10-day	O	O
oral	O	O
sirolimus	O	O
treatment	O	O
with	O	O
2	O	O
different	O	O
loading	O	O
regimens	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
recurrent	O	O
restenosis	O	O
in	O	O
patients	O	O
with	O	O
ISR	Condition	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
Three	SampleSize	O
hundred	SampleSize	O
symptomatic	Condition	O
patients	O	O
with	O	O
ISR	Condition	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
1	O	O
of	O	O
3	O	O
treatment	O	O
arms	O	O
:	O	O
placebo	O	O
or	O	O
usual-dose	O	O
or	O	O
high-dose	O	O
sirolimus	O	O
.	O	O

Patients	O	O
received	O	O
a	O	O
cumulative	O	O
loading	O	O
dose	O	O
of	O	O
0	O	O
,	O	O
8	O	O
,	O	O
or	O	O
24	O	O
mg	O	O
of	O	O
sirolimus	O	O
2	O	O
days	O	O
before	O	O
and	O	O
the	O	O
day	O	O
of	O	O
repeat	O	O
intervention	O	O
followed	O	O
by	O	O
maintenance	O	O
therapy	O	O
of	O	O
2	O	O
mg/d	O	O
for	O	O
7	O	O
days	O	O
.	O	O

Angiographic	O	O
restenosis	O	O
at	O	O
6-month	O	O
angiography	O	O
was	O	O
the	O	O
primary	O	O
end	O	O
point	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Restenosis	O	O
was	O	O
significantly	O	O
reduced	O	O
from	O	O
42.2	O	O
%	O	O
to	O	O
38.6	O	O
%	O	O
and	O	O
to	O	O
22.1	O	O
%	O	O
in	O	O
the	O	O
placebo	O	O
,	O	O
usual-dose	O	O
,	O	O
and	O	O
high-dose	O	O
sirolimus	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
P=0.005	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
the	O	O
need	O	O
for	O	O
target	O	O
vessel	O	O
revascularization	O	O
was	O	O
reduced	O	O
from	O	O
25.5	O	O
%	O	O
to	O	O
24.2	O	O
%	O	O
and	O	O
to	O	O
15.2	O	O
%	O	O
in	O	O
the	O	O
placebo	O	O
,	O	O
usual-dose	O	O
,	O	O
and	O	O
high-dose	O	O
groups	O	O
,	O	O
respectively	O	O
(	O	O
P=0.08	O	O
)	O	O
.	O	O

The	O	O
sirolimus	O	O
blood	O	O
concentration	O	O
on	O	O
the	O	O
day	O	O
of	O	O
the	O	O
procedure	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
late	O	O
lumen	O	O
loss	O	O
at	O	O
follow-up	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
patients	O	O
with	O	O
ISR	O	O
,	O	O
an	O	O
oral	O	O
adjunctive	O	O
sirolimus	O	O
treatment	O	O
with	O	O
an	O	O
intensified	O	O
loading	O	O
regimen	O	O
before	O	O
coronary	O	O
intervention	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
angiographic	O	O
parameters	O	O
of	O	O
restenosis	O	O
.	O	O

Three-year	O	O
clinical	O	O
outcome	O	O
after	O	O
primary	O	O
stenting	O	O
of	O	O
totally	O	O
occluded	O	O
native	O	O
coronary	O	O
arteries	O	O
:	O	O
a	O	O
randomized	O	O
comparison	O	O
of	O	O
bare-metal	O	O
stent	O	O
implantation	O	O
with	O	O
sirolimus-eluting	O	O
stent	O	O
implantation	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
total	Condition	O
coronary	Condition	O
occlusions	Condition	O
(	O	O
Primary	O	O
Stenting	O	O
of	O	O
Totally	O	O
Occluded	O	O
Native	O	O
Coronary	O	O
Arteries	O	O
[	O	O
PRISON	O	O
]	O	O
II	O	O
study	O	O
)	O	O
.	O	O

BACKGROUND	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
3-year	O	O
clinical	O	O
outcome	O	O
in	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
Primary	O	O
Stenting	O	O
of	O	O
Totally	O	O
Occluded	O	O
Native	O	O
Coronary	O	O
Arteries	O	O
II	O	O
study	O	O
.	O	O

METHODS	O	O
Patients	O	O
with	O	O
totally	Condition	O
occluded	Condition	O
coronary	Condition	O
arteries	Condition	O
randomized	O	O
to	O	O
either	O	O
sirolimus-eluting	O	O
Cypher	O	O
stents	O	O
(	O	O
SESs	O	O
)	O	O
(	O	O
Cordis	O	O
,	O	O
a	O	O
Johnson	O	O
&	O	O
Joshson	O	O
Company	O	O
,	O	O
Miami	O	O
Lakes	O	O
,	O	O
FL	O	O
)	O	O
(	O	O
100	SampleSize	O
patients	O	O
)	O	O
or	O	O
bare-metal	O	O
BxVelocity	O	O
stents	O	O
(	O	O
BMSs	O	O
)	O	O
(	O	O
Cordis	O	O
)	O	O
(	O	O
100	SampleSize	O
patients	O	O
)	O	O
were	O	O
followed	O	O
clinically	O	O
for	O	O
3	O	O
years	O	O
.	O	O

RESULTS	O	O
Between	O	O
1	O	O
and	O	O
3	O	O
years	O	O
,	O	O
there	O	O
were	O	O
infrequent	O	O
additional	O	O
clinical	O	O
events	O	O
that	O	O
were	O	O
equally	O	O
distributed	O	O
between	O	O
the	O	O
SES	O	O
and	O	O
the	O	O
BMS	O	O
group	O	O
.	O	O

After	O	O
3	O	O
years	O	O
,	O	O
target	O	O
lesion	O	O
revascularization	O	O
was	O	O
7	O	O
%	O	O
in	O	O
the	O	O
SES	O	O
group	O	O
versus	O	O
27	O	O
%	O	O
in	O	O
the	O	O
BMS	O	O
group	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
;	O	O
and	O	O
target	O	O
vessel	O	O
revascularization	O	O
was	O	O
seen	O	O
in	O	O
11	O	O
%	O	O
in	O	O
the	O	O
SES	O	O
group	O	O
versus	O	O
30	O	O
%	O	O
in	O	O
the	O	O
BMS	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.002	O	O
)	O	O
.	O	O

Major	O	O
adverse	O	O
cardiac	O	O
events	O	O
were	O	O
noted	O	O
in	O	O
10	O	O
%	O	O
of	O	O
the	O	O
SES	O	O
group	O	O
versus	O	O
34	O	O
%	O	O
in	O	O
the	O	O
BMS	O	O
group	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
death	O	O
,	O	O
myocardial	O	O
infarction	O	O
,	O	O
and	O	O
stent	O	O
thrombosis	O	O
according	O	O
to	O	O
the	O	O
Academic	O	O
Research	O	O
Consortium	O	O
criteria	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Clinical	O	O
outcome	O	O
up	O	O
to	O	O
3	O	O
years	O	O
after	O	O
implantation	O	O
of	O	O
SESs	O	O
for	O	O
total	O	O
coronary	O	O
occlusions	O	O
continues	O	O
to	O	O
demonstrate	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
adverse	O	O
clinical	O	O
events	O	O
compared	O	O
with	O	O
BMSs	O	O
without	O	O
the	O	O
evidence	O	O
for	O	O
either	O	O
disproportionate	O	O
late	O	O
restenosis	O	O
or	O	O
late	O	O
stent	O	O
thrombosis	O	O
.	O	O

An	O	O
evaluation	O	O
of	O	O
chemical	O	O
arthrodesis	O	O
of	O	O
the	O	O
proximal	Condition	O
interphalangeal	Condition	O
joint	Condition	O
in	O	O
the	O	O
horse	O	O
by	O	O
using	O	O
monoiodoacetate	O	O
.	O	O

The	O	O
use	O	O
of	O	O
monoiodoacetate	O	O
(	O	O
MIA	O	O
)	O	O
for	O	O
arthrodesis	O	O
of	O	O
the	O	O
proximal	O	O
interphalangeal	O	O
joint	O	O
(	O	O
PIJ	O	O
)	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
degree	O	O
of	O	O
fusion	O	O
were	O	O
investigated	O	O
.	O	O

Eight	SampleSize	O
horses	O	O
received	O	O
3	O	O
injections	O	O
(	O	O
Weeks	O	O
0	O	O
,	O	O
3	O	O
,	O	O
6	O	O
)	O	O
of	O	O
MIA	O	O
(	O	O
2	O	O
mL	O	O
;	O	O
60	O	O
mg/mL	O	O
)	O	O
into	O	O
the	O	O
right	O	O
or	O	O
left	O	O
front	O	O
PIJ	O	O
.	O	O

Peri-operatively	O	O
,	O	O
the	O	O
horses	O	O
received	O	O
phenylbutazone	O	O
,	O	O
butorphanol	O	O
,	O	O
and	O	O
abaxial	O	O
sesamoidean	O	O
nerve	O	O
blocks	O	O
to	O	O
relieve	O	O
pain	O	O
.	O	O

During	O	O
the	O	O
study	O	O
,	O	O
the	O	O
horses	O	O
were	O	O
monitored	O	O
for	O	O
general	O	O
health	O	O
,	O	O
lameness	O	O
,	O	O
and	O	O
swelling	O	O
around	O	O
the	O	O
injection	O	O
area	O	O
.	O	O

Radiographs	O	O
were	O	O
taken	O	O
biweekly	O	O
to	O	O
evaluate	O	O
bony	O	O
fusion	O	O
.	O	O

Horses	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
non-exercised	O	O
and	O	O
exercised	O	O
groups	O	O
.	O	O

Exercise	O	O
consisted	O	O
of	O	O
20	O	O
minutes	O	O
of	O	O
trotting	O	O
on	O	O
a	O	O
treadmill	O	O
(	O	O
4	O	O
m/s	O	O
)	O	O
,	O	O
3	O	O
days	O	O
per	O	O
week	O	O
for	O	O
13	O	O
weeks	O	O
.	O	O

The	O	O
horses	O	O
were	O	O
euthanized	O	O
at	O	O
24	O	O
weeks	O	O
.	O	O

Slab	O	O
sections	O	O
of	O	O
the	O	O
PIJ	O	O
were	O	O
evaluated	O	O
grossly	O	O
and	O	O
radiographically	O	O
for	O	O
bony	O	O
fusion	O	O
.	O	O

Histologic	O	O
examinations	O	O
were	O	O
performed	O	O
to	O	O
evaluate	O	O
articular	O	O
cartilage	O	O
.	O	O

Three	O	O
horses	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
after	O	O
developing	O	O
soft	O	O
tissue	O	O
necrosis	O	O
around	O	O
the	O	O
injection	O	O
site	O	O
,	O	O
septic	O	Condition
arthritis	O	Condition
,	O	O
and	O	O
necrotic	O	O
tendinitis	O	O
.	O	O

The	O	O
remaining	O	O
horses	O	O
remained	O	O
healthy	O	O
,	O	O
developed	O	O
a	O	O
grade	O	O
1	O	O
to	O	O
4	O	O
lameness	O	O
with	O	O
minimal	O	O
to	O	O
severe	O	O
swelling	O	O
in	O	O
the	O	O
PIJ	O	O
region	O	O
.	O	O

All	O	O
5	O	O
horses	O	O
showed	O	O
radiographic	O	O
evidence	O	O
of	O	O
bony	O	O
fusion	O	O
,	O	O
however	O	O
,	O	O
no	O	O
fusion	O	O
was	O	O
present	O	O
when	O	O
injected	O	O
joints	O	O
were	O	O
examined	O	O
on	O	O
postmortem	O	O
examination	O	O
.	O	O

Histologic	O	O
examination	O	O
revealed	O	O
thinning	O	O
of	O	O
the	O	O
cartilage	O	O
,	O	O
diffuse	O	O
necrosis	O	O
of	O	O
chondrocytes	O	O
,	O	O
with	O	O
the	O	O
calcified	O	O
zone	O	O
intact	O	O
.	O	O

Subjectively	O	O
,	O	O
exercise	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
degree	O	O
of	O	O
cartilage	O	O
destruction	O	O
.	O	O

Based	O	O
on	O	O
this	O	O
study	O	O
,	O	O
chemical	O	O
arthrodesis	O	O
can	O	O
not	O	O
be	O	O
advocated	O	O
in	O	O
clinical	O	O
cases	O	O
because	O	O
of	O	O
the	O	O
high	O	O
complication	O	O
rate	O	O
and	O	O
lack	O	O
of	O	O
bony	O	O
fusion	O	O
.	O	O

Psychological	O	O
well-being	O	O
correlates	O	O
with	O	O
free	O	O
thyroxine	O	O
but	O	O
not	O	O
free	O	O
3,5,3'-triiodothyronine	O	O
levels	O	O
in	O	O
patients	O	O
on	O	O
thyroid	Condition	O
hormone	Condition	O
replacement	Condition	O
.	O	O

CONTEXT	O	O
AND	O	O
OBJECTIVE	O	O
An	O	O
association	O	O
between	O	O
mood	O	O
disorders	O	O
and	O	O
overt	O	O
thyroid	O	O
dysfunction	O	O
is	O	O
well	O	O
established	O	O
,	O	O
but	O	O
there	O	O
are	O	O
few	O	O
data	O	O
on	O	O
the	O	O
potential	O	O
for	O	O
thyroid	O	O
hormone	O	O
levels	O	O
closer	O	O
to	O	O
the	O	O
reference	O	O
range	O	O
to	O	O
correlate	O	O
with	O	O
psychological	O	O
well-being	O	O
.	O	O

DESIGN	O	O
,	O	O
SETTING	O	O
,	O	O
AND	O	O
PATIENTS	O	O
We	O	O
analyzed	O	O
the	O	O
relationship	O	O
between	O	O
psychological	O	O
well-being	O	O
and	O	O
free	O	O
T	O	O
(	O	O
4	O	O
)	O	O
(	O	O
fT4	O	O
)	O	O
,	O	O
free	O	O
T	O	O
(	O	O
3	O	O
)	O	O
(	O	O
fT3	O	O
)	O	O
,	O	O
TSH	O	O
,	O	O
and	O	O
total	O	O
rT	O	O
(	O	O
3	O	O
)	O	O
in	O	O
697	SampleSize	O
patients	O	O
on	O	O
thyroid	O	O
hormone	O	O
replacement	O	O
therapy	O	O
at	O	O
entry	O	O
to	O	O
a	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
of	O	O
combined	O	O
T	O	O
(	O	O
4	O	O
)	O	O
and	O	O
T	O	O
(	O	O
3	O	O
)	O	O
replacement	O	O
therapy	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
on	O	O
100	O	O
mug	O	O
or	O	O
more	O	O
T	O	O
(	O	O
4	O	O
)	O	O
.	O	O

INTERVENTIONS	O	O
AND	O	O
MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Psychological	O	O
well-being	O	O
was	O	O
assessed	O	O
with	O	O
General	O	O
Health	O	O
Questionnaire-12	O	O
(	O	O
GHQ-12	O	O
)	O	O
,	O	O
Thyroid	O	O
Symptom	O	O
Questionnaire	O	O
,	O	O
and	O	O
Hospital	O	O
Anxiety	O	O
and	O	O
Depression	O	O
Scale	O	O
.	O	O

RESULTS	O	O
fT	O	O
(	O	O
4	O	O
)	O	O
and	O	O
TSH	O	O
showed	O	O
a	O	O
strong	O	O
correlation	O	O
with	O	O
GHQ-12	O	O
scores	O	O
(	O	O
fT4	O	O
-	O	O
b	O	O
:	O	O
-0.16	O	O
,	O	O
P	O	O
=	O	O
0.005	O	O
;	O	O
TSH	O	O
-	O	O
b	O	O
:	O	O
0.663	O	O
,	O	O
P	O	O
=	O	O
0.04	O	O
)	O	O
.	O	O

No	O	O
correlations	O	O
were	O	O
seen	O	O
between	O	O
the	O	O
GHQ	O	O
scores	O	O
and	O	O
fT3	O	O
(	O	O
b	O	O
:	O	O
0.318	O	O
,	O	O
P	O	O
=	O	O
0.275	O	O
)	O	O
,	O	O
rT	O	O
(	O	O
3	O	O
)	O	O
(	O	O
b	O	O
:	O	O
0.095	O	O
,	O	O
P	O	O
=	O	O
0.95	O	O
)	O	O
,	O	O
rT	O	O
(	O	O
3	O	O
)	O	O
to	O	O
fT4	O	O
ratio	O	O
(	O	O
b	O	O
:	O	O
71.83	O	O
,	O	O
P	O	O
=	O	O
0.09	O	O
)	O	O
or	O	O
fT3	O	O
to	O	O
rT	O	O
(	O	O
3	O	O
)	O	O
ratio	O	O
(	O	O
b	O	O
:	O	O
0.05	O	O
,	O	O
P	O	O
=	O	O
0.32	O	O
)	O	O
.	O	O

The	O	O
correlations	O	O
remained	O	O
when	O	O
the	O	O
data	O	O
set	O	O
was	O	O
limited	O	O
to	O	O
patients	O	O
with	O	O
TSH	O	O
in	O	O
the	O	O
range	O	O
0.3-4.0	O	O
mIU/liter	O	O
.	O	O

Similar	O	O
correlations	O	O
were	O	O
seen	O	O
with	O	O
the	O	O
Thyroid	O	O
Symptom	O	O
Questionnaire	O	O
,	O	O
although	O	O
not	O	O
with	O	O
the	O	O
Hospital	O	O
Anxiety	O	O
and	O	O
Depression	O	O
Scale	O	O
scores	O	O
.	O	O

CONCLUSIONS	O	O
Differences	O	O
in	O	O
fT4	O	O
and	O	O
TSH	O	O
concentration	O	O
,	O	O
even	O	O
within	O	O
the	O	O
reference	O	O
range	O	O
,	O	O
may	O	O
be	O	O
a	O	O
determinant	O	O
of	O	O
psychological	O	O
well-being	O	O
in	O	O
treated	O	O
hypothyroid	Condition	O
patients	O	O
although	O	O
not	O	O
necessarily	O	O
with	O	O
symptoms	O	O
typical	O	O
of	O	O
anxiety	O	O
or	O	O
depression	O	O
.	O	O

Genotyping	O	O
of	O	O
CYP21	O	O
,	O	O
linked	O	O
chromosome	O	O
6p	O	O
markers	O	O
,	O	O
and	O	O
a	O	O
sex-specific	O	O
gene	O	O
in	O	O
neonatal	Age	O
screening	O	O
for	O	O
congenital	Condition	O
adrenal	Condition	O
hyperplasia	Condition	O
.	O	O

We	O	O
investigated	O	O
the	O	O
feasibility	O	O
and	O	O
diagnostic	O	O
utility	O	O
of	O	O
genotyping	O	O
9	O	O
CYP21	O	O
mutations	O	O
,	O	O
linked	O	O
chromosome	O	O
6p	O	O
markers	O	O
,	O	O
and	O	O
a	O	O
dimorphic	O	O
X-Y	O	O
marker	O	O
from	O	O
neonatal	Age	O
screening	O	O
samples	O	O
.	O	O

Blood-impregnated	O	O
filter	O	O
papers	O	O
(	O	O
Guthrie	O	O
cards	O	O
)	O	O
from	O	O
603	SampleSize	O
randomly	O	O
chosen	O	O
New	O	O
Zealand	O	O
neonates	Age	O
were	O	O
genotyped	O	O
blind	O	O
to	O	O
17-hydroxyprogesterone	O	O
(	O	O
17-OHP	O	O
)	O	O
levels	O	O
.	O	O

Another	O	O
50	SampleSize	O
samples	O	O
from	O	O
Swiss	O	O
and	O	O
North	O	O
American	O	O
infants	O	O
with	O	O
correlative	O	O
hormonal	O	O
data	O	O
were	O	O
also	O	O
genotyped	O	O
.	O	O

DNA	O	O
was	O	O
extracted	O	O
,	O	O
and	O	O
gene-specific	O	O
PCR	O	O
was	O	O
performed	O	O
.	O	O

CYP21	O	O
PCR	O	O
products	O	O
were	O	O
subjected	O	O
to	O	O
ligase	O	O
detection	O	O
reaction	O	O
,	O	O
simultaneously	O	O
analyzing	O	O
9	O	O
CYP21	O	O
mutations	O	O
;	O	O
PCR	O	O
products	O	O
of	O	O
other	O	O
genes	O	O
were	O	O
subjected	O	O
to	O	O
direct	O	O
gel	O	O
analysis	O	O
.	O	O

CYP21	O	O
genotyping	O	O
indicated	O	O
a	O	O
heterozygote	O	O
rate	O	O
of	O	O
2.8	O	O
%	O	O
for	O	O
classic	O	O
mutations	O	O
(	O	O
excluding	O	O
CYP21	O	O
deletions	O	O
)	O	O
,	O	O
and	O	O
2.0	O	O
%	O	O
for	O	O
nonclassic	O	O
mutations	O	O
in	O	O
New	O	O
Zealanders	O	O
.	O	O

Ten	O	O
full-term	O	O
affected	O	O
neonates	O	O
showed	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
17-OHP	O	O
levels	O	O
(	O	O
15-1400	O	O
nmol/L	O	O
)	O	O
.	O	O

Sick	O	O
or	O	O
preterm	O	O
infants	O	O
or	O	O
infants	O	O
screened	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
life	O	O
with	O	O
high	O	O
17-OHP	O	O
proved	O	O
genetically	O	O
unaffected	O	O
.	O	O

Genetic	O	O
linkage	O	O
disequilibrium	O	O
was	O	O
found	O	O
between	O	O
two	O	O
CYP21	O	O
mutations	O	O
and	O	O
chromosome	O	O
6p	O	O
markers	O	O
.	O	O

Guthrie	O	O
cards	O	O
can	O	O
be	O	O
used	O	O
to	O	O
accurately	O	O
genotype	O	O
CYP21	O	O
and	O	O
other	O	O
relevant	O	O
markers	O	O
,	O	O
potentially	O	O
enhancing	O	O
the	O	O
specificity	O	O
and	O	O
sensitivity	O	O
of	O	O
congenital	O	O
adrenal	O	O
hyperplasia	O	O
screening	O	O
.	O	O

CYP21	O	O
heterozygote	O	O
frequency	O	O
for	O	O
classic	O	O
mutations	O	O
is	O	O
higher	O	O
than	O	O
expected	O	O
based	O	O
on	O	O
genotype	O	O
compared	O	O
with	O	O
that	O	O
predicted	O	O
by	O	O
hormonal	O	O
newborn	Age	O
screening	O	O
.	O	O

Pegfilgrastim	O	O
for	O	O
peripheral	O	O
CD34+	O	O
mobilization	O	O
in	O	O
patients	O	O
with	O	O
solid	Condition	O
tumours	Condition	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
pegfilgrastim+/-chemotherapy	O	O
for	O	O
mobilizing	O	O
stem	O	O
cells	O	O
in	O	O
patients	O	O
with	O	O
solid	Condition	O
tumours	Condition	O
was	O	O
assessed	O	O
.	O	O

In	O	O
cycle	O	O
0	O	O
,	O	O
a	O	O
14-day	O	O
prechemotherapy	O	O
cycle	O	O
,	O	O
patients	O	O
(	O	O
N=61	SampleSize	SampleSize
)	O	O
were	O	O
randomized	O	O
open-label	O	O
to	O	O
single	O	O
doses	O	O
of	O	O
pegfilgrastim	O	O
(	O	O
6	O	O
,	O	O
12	O	O
or	O	O
18	O	O
mg	O	O
)	O	O
on	O	O
day	O	O
1	O	O
,	O	O
or	O	O
daily	O	O
filgrastim	O	O
(	O	O
10	O	O
microg/kg	O	O
)	O	O
for	O	O
<	O	O
or	O	O
=7	O	O
days	O	O
.	O	O

Mean	O	O
peak	O	O
peripheral	O	O
CD34+	O	O
cell	O	O
counts	O	O
increased	O	O
with	O	O
pegfilgrastim	O	O
dose	O	O
,	O	O
but	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
filgrastim	O	O
only	O	O
at	O	O
the	O	O
18	O	O
mg	O	O
dose	O	O
(	O	O
10.17	O	O
vs	O	O
4.96	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
;	O	O
P=0.014	O	O
)	O	O
.	O	O

In	O	O
the	O	O
clinically	O	O
relevant	O	O
period	O	O
of	O	O
days	O	O
3-7	O	O
,	O	O
both	O	O
12	O	O
and	O	O
18	O	O
mg	O	O
pegfilgrastim	O	O
doses	O	O
produced	O	O
significantly	O	O
higher	O	O
peak	O	O
CD34+	O	O
counts	O	O
(	O	O
8.18	O	O
and	O	O
9.96	O	O
vs	O	O
4.51	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
for	O	O
filgrastim	O	O
;	O	O
P=0.034	O	O
and	O	O
0.006	O	O
)	O	O
.	O	O

In	O	O
cycle	O	O
1	O	O
,	O	O
patients	O	O
received	O	O
carboplatin/paclitaxel	O	O
on	O	O
day	O	O
1	O	O
,	O	O
followed	O	O
from	O	O
day	O	O
2	O	O
by	O	O
pegfilgrastim	O	O
6-18	O	O
mg	O	O
or	O	O
daily	O	O
filgrastim	O	O
(	O	O
5	O	O
microg/kg/day	O	O
for	O	O
<	O	O
or	O	O
=14	O	O
days	O	O
)	O	O
as	O	O
per	O	O
randomization	O	O
in	O	O
cycle	O	O
0	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
mean	O	O
peak	O	O
CD34+	O	O
count	O	O
between	O	O
pegfilgrastim	O	O
and	O	O
filgrastim	O	O
,	O	O
but	O	O
there	O	O
was	O	O
an	O	O
advantage	O	O
for	O	O
pegfilgrastim	O	O
18	O	O
mg	O	O
in	O	O
the	O	O
relevant	O	O
period	O	O
of	O	O
days	O	O
7-12	O	O
(	O	O
3.14	O	O
vs	O	O
1.19	O	O
x	O	O
10	O	O
(	O	O
4	O	O
)	O	O
/ml	O	O
;	O	O
P=0.043	O	O
)	O	O
.	O	O

A	O	O
single	O	O
pegfilgrastim	O	O
dose	O	O
(	O	O
>	O	O
or	O	O
=6	O	O
mg	O	O
)	O	O
could	O	O
be	O	O
substituted	O	O
for	O	O
daily	O	O
filgrastim	O	O
in	O	O
cytokine-only	O	O
peripheral	O	O
CD34+	O	O
cell	O	O
mobilization	O	O
.	O	O

Influence	O	O
of	O	O
occlusal	O	O
access	O	O
on	O	O
demineralized	O	O
dentin	O	O
removal	O	O
in	O	O
the	O	O
atraumatic	O	O
restorative	O	O
treatment	O	O
(	O	O
ART	O	O
)	O	O
approach	O	O
.	O	O

PURPOSE	O	O
To	O	O
verify	O	O
the	O	O
influence	O	O
of	O	O
cavity	O	O
access	O	O
diameter	O	O
on	O	O
demineralized	O	O
dentin	O	O
removal	O	O
in	O	O
the	O	O
ART	O	O
approach	O	O
.	O	O

METHODS	O	O
40	SampleSize	SampleSize
non-carious	Condition	O
human	Condition	O
premolars	Condition	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
four	O	O
groups	O	O
.	O	O

The	O	O
occlusal	O	O
surface	O	O
was	O	O
ground	O	O
flat	O	O
and	O	O
the	O	O
teeth	O	O
were	O	O
sectioned	O	O
mesio-distally	O	O
.	O	O

The	O	O
hemi-sections	O	O
were	O	O
reassembled	O	O
and	O	O
occlusal	O	O
access	O	O
preparations	O	O
were	O	O
carried	O	O
out	O	O
using	O	O
ball-shaped	O	O
diamonds	O	O
.	O	O

The	O	O
resulting	O	O
size	O	O
of	O	O
the	O	O
occlusal	O	O
opening	O	O
was	O	O
1.0	O	O
mm	O	O
,	O	O
1.4	O	O
mm	O	O
,	O	O
1.6	O	O
mm	O	O
and	O	O
1.8	O	O
mm	O	O
for	O	O
Groups	O	O
A	O	O
,	O	O
B	O	O
,	O	O
C	O	O
,	O	O
and	O	O
D	O	O
,	O	O
respectively	O	O
.	O	O

Standardized	O	O
artificial	O	O
carious	O	O
lesions	O	O
were	O	O
created	O	O
and	O	O
demineralized	O	O
dentin	O	O
was	O	O
excavated	O	O
.	O	O

After	O	O
excavation	O	O
,	O	O
the	O	O
cavities	O	O
were	O	O
analyzed	O	O
using	O	O
:	O	O
(	O	O
a	O	O
)	O	O
the	O	O
tactile	O	O
method	O	O
,	O	O
(	O	O
b	O	O
)	O	O
caries-detection	O	O
dye	O	O
to	O	O
stain	O	O
demineralized	O	O
dentin	O	O
,	O	O
as	O	O
proposed	O	O
by	O	O
Smales	O	O
&	O	O
Fang	O	O
,	O	O
and	O	O
(	O	O
c	O	O
)	O	O
Demineralized	O	O
Tissue	O	O
Removal	O	O
index	O	O
,	O	O
as	O	O
proposed	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Statistical	O	O
analysis	O	O
was	O	O
performed	O	O
using	O	O
Fisher	O	O
,	O	O
Spearman	O	O
correlation	O	O
coefficient	O	O
,	O	O
kappa	O	O
,	O	O
Kruskal-Wallis	O	O
and	O	O
Miller	O	O
tests	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

RESULTS	O	O
The	O	O
three	O	O
methods	O	O
of	O	O
evaluation	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
Groups	O	O
A	O	O
vs.	O	O
B	O	O
,	O	O
and	O	O
C	O	O
vs.	O	O
D	O	O
,	O	O
while	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
Groups	O	O
A	O	O
vs.	O	O
C	O	O
,	O	O
A	O	O
vs.	O	O
D	O	O
,	O	O
B	O	O
vs.	O	O
C	O	O
and	O	O
B	O	O
vs.	O	O
D.	O	O
Based	O	O
on	O	O
the	O	O
results	O	O
of	O	O
this	O	O
study	O	O
,	O	O
the	O	O
size	O	O
of	O	O
occlusal	O	O
access	O	O
significantly	O	O
affected	O	O
the	O	O
efficacy	O	O
of	O	O
demineralized	O	O
tissue	O	O
removal	O	O
.	O	O

A	O	O
pilot	O	O
study	O	O
of	O	O
extended	O	O
duration	O	O
peginterferon	O	O
alfa-2a	O	O
for	O	O
patients	O	O
with	O	O
hepatitis	Condition	O
B	Condition	O
e	Condition	O
antigen-negative	Condition	O
chronic	Condition	O
hepatitis	Condition	O
B	Condition	O
.	O	O

OBJECTIVES	O	O
Forty-eight	O	O
weeks	O	O
of	O	O
peginterferon	O	O
alfa-2a	O	O
is	O	O
the	O	O
approved	O	O
regimen	O	O
for	O	O
chronic	Condition	O
hepatitis	Condition	O
B	Condition	O
(	O	O
CHB	Condition	O
)	O	O
.	O	O

Standard	O	O
interferon	O	O
is	O	O
more	O	O
effective	O	O
for	O	O
hepatitis	O	O
B	O	O
e	O	O
antigen	O	O
(	O	O
HBeAg	O	O
)	O	O
-negative	O	O
CHB	O	O
when	O	O
given	O	O
for	O	O
longer	O	O
than	O	O
1	O	O
yr	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
peginterferon	O	O
alfa-2a	O	O
for	O	O
60	O	O
wk	O	O
,	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
lamivudine	O	O
.	O	O

METHODS	O	O
Thirteen	SampleSize	SampleSize
patients	O	O
with	O	O
HBeAg-negative	O	O
CHB	O	O
received	O	O
peginterferon	O	O
alfa-2a	O	O
(	O	O
180	O	O
microg/week	O	O
)	O	O
for	O	O
60	O	O
wk	O	O
or	O	O
peginterferon	O	O
alfa-2a	O	O
(	O	O
180	O	O
microg/week	O	O
)	O	O
for	O	O
12	O	O
wk	O	O
followed	O	O
by	O	O
48	O	O
wk	O	O
of	O	O
peginterferon	O	O
alfa-2a	O	O
plus	O	O
lamivudine	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
,	O	O
sustained	O	O
virologic	O	O
response	O	O
(	O	O
SVR	O	O
)	O	O
,	O	O
was	O	O
defined	O	O
as	O	O
a	O	O
reduction	O	O
in	O	O
hepatitis	O	O
B	O	O
virus	O	O
deoxyribonucleic	O	O
acid	O	O
(	O	O
HBV	O	O
DNA	O	O
)	O	O
of	O	O
>	O	O
or=2	O	O
log10	O	O
copies/mL	O	O
and	O	O
HBV	O	O
DNA	O	O
<	O	O
20,000	O	O
copies/mL	O	O
at	O	O
24	O	O
wk	O	O
of	O	O
follow-up	O	O
(	O	O
week	O	O
84	O	O
)	O	O
.	O	O

Hepatitis	O	O
B	O	O
surface	O	O
antigen	O	O
(	O	O
HBsAg	O	O
)	O	O
concentrations	O	O
were	O	O
analyzed	O	O
and	O	O
compared	O	O
to	O	O
changes	O	O
in	O	O
HBV	O	O
DNA	O	O
.	O	O

RESULTS	O	O
SVR	O	O
was	O	O
achieved	O	O
by	O	O
9/13	O	O
patients	O	O
(	O	O
69	O	O
%	O	O
)	O	O
.	O	O

At	O	O
week	O	O
84	O	O
,	O	O
HBV	O	O
DNA	O	O
was	O	O
undetectable	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
in	O	O
5/13	O	O
(	O	O
38	O	O
%	O	O
)	O	O
patients	O	O
,	O	O
and	O	O
3	O	O
additional	O	O
patients	O	O
had	O	O
a	O	O
sustained	O	O
2-3	O	O
log	O	O
reduction	O	O
in	O	O
HBV	O	O
DNA	O	O
.	O	O

Five	O	O
patients	O	O
demonstrated	O	O
a	O	O
>	O	O
90	O	O
%	O	O
decrease	O	O
in	O	O
HBsAg	O	O
concentration	O	O
at	O	O
week	O	O
60	O	O
,	O	O
including	O	O
3	O	O
with	O	O
undetectable	O	O
HBV	O	O
DNA	O	O
at	O	O
week	O	O
84	O	O
and	O	O
a	O	O
fourth	O	O
who	O	O
met	O	O
criteria	O	O
for	O	O
SVR	O	O
.	O	O

CONCLUSIONS	O	O
Sixty	O	O
weeks	O	O
of	O	O
peginterferon	O	O
alfa-2a	O	O
with	O	O
or	O	O
without	O	O
lamivudine	O	O
resulted	O	O
in	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
SVR	O	O
compared	O	O
to	O	O
historical	O	O
controls	O	O
with	O	O
HBeAg-negative	Condition	O
CHB	Condition	O
treated	O	O
with	O	O
48	O	O
wk	O	O
of	O	O
pegylated	O	O
interferon	O	O
.	O	O

Larger	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
assess	O	O
if	O	O
longer	O	O
duration	O	O
therapy	O	O
is	O	O
more	O	O
effective	O	O
than	O	O
the	O	O
standard	O	O
regimen	O	O
and	O	O
results	O	O
in	O	O
a	O	O
greater	O	O
decline	O	O
in	O	O
HBsAg	O	O
concentration	O	O
.	O	O

Efficacy	O	O
and	O	O
safety	O	O
of	O	O
routine	O	O
blood	O	O
pressure	O	O
lowering	O	O
in	O	O
older	O	O
patients	O	O
with	O	O
diabetes	Condition	O
:	O	O
results	O	O
from	O	O
the	O	O
ADVANCE	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
blood	O	O
pressure	O	O
lowering	O	O
in	O	O
elderly	Age	O
patients	O	O
have	O	O
not	O	O
been	O	O
sufficiently	O	O
investigated	O	O
in	O	O
patients	O	O
with	O	O
diabetes	Condition	Condition
.	O	O

Using	O	O
data	O	O
from	O	O
the	O	O
Action	O	O
in	O	O
Diabetes	O	O
and	O	O
Vascular	O	O
disease	O	O
:	O	O
preterAx	O	O
and	O	O
diamicroN-MR	O	O
Controlled	O	O
Evaluation	O	O
study	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
routine	O	O
blood	O	O
pressure	O	O
lowering	O	O
to	O	O
prevent	O	O
major	O	O
clinical	O	O
outcomes	O	O
in	O	O
elderly	O	O
patients	O	O
with	O	O
type	Condition	Condition
2	Condition	Condition
diabetes	Condition	Condition
.	O	O

METHODS	O	O
Eleven	SampleSize	O
thousand	SampleSize	O
one	SampleSize	SampleSize
hundred	SampleSize	SampleSize
and	SampleSize	SampleSize
forty	SampleSize	SampleSize
patients	O	O
aged	O	O
at	O	O
least	O	O
55	Age	O
years	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
(	O	O
mean	O	O
66+/-6	Age	O
years	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
perindopril-indapamide	O	O
or	O	O
placebo	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O	O
was	O	O
a	O	O
composite	O	O
of	O	O
major	O	O
macrovascular	O	O
and	O	O
microvascular	O	O
disease	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
active	O	O
treatment	O	O
on	O	O
outcomes	O	O
were	O	O
estimated	O	O
in	O	O
subgroups	O	O
according	O	O
to	O	O
age	O	O
:	O	O
below	Age	O
65	Age	O
,	O	O
65-74	Age	O
and	O	O
at	Age	O
least	Age	O
75	Age	O
years	Age	O
.	O	O

RESULTS	O	O
During	O	O
a	O	O
mean	O	O
4.3-year	O	O
follow-up	O	O
,	O	O
1799	O	O
(	O	O
16.1	O	O
%	O	O
)	O	O
patients	O	O
experienced	O	O
a	O	O
major	O	O
event	O	O
.	O	O

Active	O	O
treatment	O	O
produced	O	O
similar	O	O
relative	O	O
risk	O	O
reductions	O	O
for	O	O
the	O	O
primary	O	O
outcome	O	O
,	O	O
major	O	O
macrovascular	O	O
disease	O	O
,	O	O
death	O	O
and	O	O
renal	O	O
events	O	O
across	O	O
age	O	O
groups	O	O
(	O	O
all	O	O
P	O	O
heterogeneity	O	O
>	O	O
0.3	O	O
)	O	O
.	O	O

Over	O	O
5	O	O
years	O	O
,	O	O
active	O	O
treatment	O	O
was	O	O
estimated	O	O
to	O	O
prevent	O	O
one	O	O
primary	O	O
outcome	O	O
in	O	O
every	O	O
21	O	O
,	O	O
71	O	O
and	O	O
118	O	SampleSize
patients	O	O
of	O	O
at	O	O
least	O	O
75	O	O
,	O	O
65-74	O	O
and	O	O
below	O	O
65	O	O
years	O	O
,	O	O
respectively	O	O
.	O	O

Similar	O	O
patterns	O	O
of	O	O
benefits	O	O
were	O	O
observed	O	O
for	O	O
secondary	O	O
outcomes	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
tolerability	O	O
between	O	O
randomized	O	O
allocations	O	O
across	O	O
age	O	O
groups	O	O
(	O	O
all	O	O
P	O	O
heterogeneity	O	O
>	O	O
0.6	O	O
)	O	O
CONCLUSION	O	O
Routine	O	O
administration	O	O
of	O	O
perindopril-indapamide	O	O
lowers	O	O
blood	O	O
pressure	O	O
safely	O	O
and	O	O
reduces	O	O
the	O	O
risk	O	O
of	O	O
major	O	O
clinical	O	O
outcomes	O	O
in	O	O
patients	O	O
of	O	O
at	O	O
least	O	O
75	O	O
years	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

The	O	O
greater	O	O
absolute	O	O
benefits	O	O
in	O	O
older	O	O
patients	O	O
in	O	O
this	O	O
age	O	O
group	O	O
were	O	O
not	O	O
offset	O	O
by	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
side	O	O
effects	O	O
.	O	O

Gamma-hydroxybutyric	O	O
acid	O	O
versus	O	O
clomethiazole	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
alcohol	Condition	O
withdrawal	Condition	O
syndrome	Condition	O
in	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
:	O	O
an	O	O
open	O	O
,	O	O
single-center	O	O
randomized	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Clomethiazole	O	O
(	O	O
CLO	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
in	O	O
treating	O	O
alcohol	Condition	O
withdrawal	Condition	O
syndrome	Condition	O
(	O	O
AWS	Condition	O
)	O	O
.	O	O

Gamma-Hydroxybutyric	O	O
acid	O	O
(	O	O
GHB	O	O
)	O	O
has	O	O
also	O	O
been	O	O
introduced	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
alcoholic	O	O
patients	O	O
and	O	O
is	O	O
effective	O	O
in	O	O
surgical	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
ICU	O	O
)	O	O
patients	O	O
in	O	O
preventing	O	O
and	O	O
treating	O	O
AWS	O	O
.	O	O

There	O	O
are	O	O
no	O	O
comparative	O	O
studies	O	O
between	O	O
CLO	O	O
and	O	O
GHB	O	O
in	O	O
a	O	O
medical	O	O
ICU	O	O
setting	O	O
.	O	O

METHODS	O	O
Twenty-six	SampleSize	O
alcoholic	O	O
patients	O	O
with	O	O
severe	O	O
AWS	O	O
and	O	O
concomitant	O	O
medical	O	O
diseases	O	O
were	O	O
randomally	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
.	O	O

CLO	O	O
was	O	O
given	O	O
orally	O	O
to	O	O
12	O	O
patients	O	O
in	O	O
a	O	O
dosage	O	O
of	O	O
250	O	O
mg	O	O
every	O	O
4	O	O
hours	O	O
as	O	O
a	O	O
liquid	O	O
;	O	O
GHB	O	O
(	O	O
initially	O	O
30	O	O
mg/kg	O	O
body	O	O
weight	O	O
(	O	O
BW	O	O
)	O	O
followed	O	O
by	O	O
15	O	O
mg/kg	O	O
BW	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
to	O	O
14	O	O
patients	O	O
.	O	O

Four	O	O
major	O	O
AWS	O	O
symptoms	O	O
(	O	O
tremor	O	O
,	O	O
sweating	O	O
,	O	O
nausea	O	O
,	O	O
restlessness	O	O
)	O	O
were	O	O
scored	O	O
,	O	O
and	O	O
the	O	O
administration	O	O
of	O	O
additional	O	O
medication	O	O
was	O	O
registered	O	O
.	O	O

RESULTS	O	O
GHB	O	O
was	O	O
more	O	O
effective	O	O
in	O	O
treating	O	O
AWS	O	O
symptoms	O	O
.	O	O

In	O	O
the	O	O
GHB	O	O
group	O	O
,	O	O
AWS	O	O
score	O	O
dropped	O	O
from	O	O
6.6	O	O
+/-	O	O
2.6	O	O
to	O	O
1.8	O	O
+/-	O	O
2.1	O	O
(	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
,	O	O
while	O	O
in	O	O
the	O	O
CLO	O	O
group	O	O
,	O	O
the	O	O
score	O	O
dropped	O	O
from	O	O
6	O	O
+/-	O	O
2.5	O	O
to	O	O
4.1	O	O
+/-	O	O
2.4	O	O
(	O	O
n.	O	O
s.	O	O
)	O	O
.	O	O

Differences	O	O
between	O	O
groups	O	O
were	O	O
significant	O	O
(	O	O
p	O	O
=.021	O	O
,	O	O
two-way	O	O
ANOVA	O	O
)	O	O
.	O	O

The	O	O
treatment	O	O
did	O	O
not	O	O
alter	O	O
outcome	O	O
or	O	O
the	O	O
duration	O	O
of	O	O
ICU	O	O
stay	O	O
.	O	O

No	O	O
serious	O	O
side	O	O
effects	O	O
were	O	O
detected	O	O
.	O	O

CONCLUSION	O	O
GHB	O	O
effectively	O	O
controls	O	O
AWS	O	O
symptoms	O	O
in	O	O
medical	O	O
ICU	O	O
patients	O	O
.	O	O

The	O	O
rapid	O	O
initial	O	O
treatment	O	O
response	O	O
of	O	O
GHB	O	O
in	O	O
contrast	O	O
to	O	O
CLO	O	O
has	O	O
no	O	O
influence	O	O
on	O	O
duration	O	O
of	O	O
patient	O	O
withdrawal	O	O
.	O	O

Moist	O	O
Exposed	O	O
Burn	O	O
Ointment	O	O
(	O	O
MEBO	O	O
)	O	O
in	O	O
partial	Condition	O
thickness	Condition	O
burns	Condition	O
-	O	O
a	O	O
randomized	O	O
,	O	O
comparative	O	O
open	O	O
mono-center	O	O
study	O	O
on	O	O
the	O	O
efficacy	O	O
of	O	O
dermaheal	O	O
(	O	O
MEBO	O	O
)	O	O
ointment	O	O
on	O	O
thermal	Condition	O
2nd	Condition	O
degree	Condition	O
burns	Condition	O
compared	O	O
to	O	O
conventional	O	O
therapy	O	O
.	O	O

OBJECTIVE	O	O
Wound	O	O
healing	O	O
in	O	O
burn	O	O
wounds	O	O
presents	O	O
a	O	O
challenge	O	O
in	O	O
healthcare	O	O
,	O	O
and	O	O
there	O	O
is	O	O
still	O	O
a	O	O
lack	O	O
of	O	O
alternatives	O	O
in	O	O
topical	O	O
burn	O	O
wound	O	O
treatments	O	O
.	O	O

-	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
a	O	O
new	O	O
therapeutic	O	O
ointment	O	O
(	O	O
MEBO	O	O
)	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
partial	Condition	O
thickness	Condition	O
burns	Condition	O
.	O	O

METHODS	O	O
40	SampleSize	O
patients	O	O
received	O	O
either	O	O
topical	O	O
treatment	O	O
with	O	O
Moist	O	O
Exposed	O	O
Burn	O	O
Ointment	O	O
(	O	O
MEBO	O	O
)	O	O
or	O	O
standard	O	O
Flammazine	O	O
treatment	O	O
.	O	O

All	O	O
patients	O	O
suffered	O	O
from	O	O
partial-thickness	O	O
burn	O	O
injuries	O	O
(	O	O
<	O	O
20	O	O
%	O	O
TBSA	O	O
)	O	O
.	O	O

Wounds	O	O
were	O	O
evaluated	O	O
for	O	O
60	O	O
up	O	O
to	O	O
days	O	O
regarding	O	O
wound	O	O
healing	O	O
,	O	O
water	O	O
loss	O	O
,	O	O
inflammation	O	O
,	O	O
and	O	O
pain	O	O
alleviation	O	O
.	O	O

RESULTS	O	O
For	O	O
transepidermal	O	O
water	O	O
loss	O	O
,	O	O
there	O	O
was	O	O
a	O	O
difference	O	O
of	O	O
2.3	O	O
gr/m2/h	O	O
between	O	O
MEBO	O	O
,	O	O
and	O	O
Flammazine	O	O
,	O	O
favoring	O	O
MEBO	O	O
.	O	O

However	O	O
,	O	O
this	O	O
difference	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
(	O	O
p=0.78	O	O
)	O	O
.	O	O

For	O	O
all	O	O
secondary	O	O
efficacy	O	O
parameter	O	O
results	O	O
were	O	O
similar	O	O
.	O	O

-	O	O
CONCLUSIONS	O	O
This	O	O
study	O	O
showed	O	O
that	O	O
MEBO	O	O
ointment	O	O
for	O	O
topical	O	O
treatment	O	O
of	O	O
burn	O	O
injuries	O	O
presents	O	O
an	O	O
attractive	O	O
alternative	O	O
for	O	O
the	O	O
topical	O	O
treatment	O	O
of	O	O
limited	Condition	O
partial	Condition	O
thickness	Condition	O
thermal	Condition	O
burns	Condition	O
.	O	O

Dose	O	O
response	O	O
effect	O	O
of	O	O
cyclical	O	O
medroxyprogesterone	O	O
on	O	O
blood	O	O
pressure	O	O
in	O	O
postmenopausal	Condition	Condition
women	Sex	Sex
.	O	O

OBJECTIVE	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
compare	O	O
with	O	O
placebo	O	O
the	O	O
dose-response	O	O
effect	O	O
of	O	O
cyclical	O	O
doses	O	O
of	O	O
the	O	O
C21	O	O
progestogen	O	O
,	O	O
medroxyprogesterone	O	O
acetate	O	O
(	O	O
MPA	O	O
)	O	O
on	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
when	O	O
administered	O	O
to	O	O
normotensive	Condition	O
postmenopausal	Condition	O
women	Sex	O
receiving	O	O
a	O	O
fixed	O	O
mid-range	O	O
daily	O	O
dose	O	O
of	O	O
conjugated	O	O
equine	O	O
oestrogen	O	O
(	O	O
CEE	O	O
)	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
Twenty	SampleSize	O
normotensive	Condition	O
postmenopausal	Condition	O
women	Sex	O
(	O	O
median	O	O
age	O	O
53	Age	Age
years	O	Age
)	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
which	O	O
used	O	O
a	O	O
double-blind	O	O
crossover	O	O
design	O	O
.	O	O

There	O	O
were	O	O
four	O	O
randomised	O	O
treatment	O	O
phases	O	O
,	O	O
each	O	O
of	O	O
4	O	O
weeks	O	O
duration	O	O
.	O	O

The	O	O
four	O	O
blinded	O	O
treatments	O	O
were	O	O
MPA	O	O
2.5	O	O
mg	O	O
,	O	O
MPA	O	O
5	O	O
mg	O	O
,	O	O
MPA	O	O
10	O	O
mg	O	O
and	O	O
matching	O	O
placebo	O	O
,	O	O
taken	O	O
for	O	O
the	O	O
last	O	O
14	O	O
days	O	O
of	O	O
each	O	O
28	O	O
day	O	O
treatment	O	O
cycle	O	O
.	O	O

CEE	O	O
0.625	O	O
mg	O	O
was	O	O
also	O	O
administered	O	O
once	O	O
daily	O	O
as	O	O
open	O	O
labelled	O	O
tablets	O	O
to	O	O
all	O	O
subjects	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Clinic	O	O
BP	O	O
was	O	O
measured	O	O
weekly	O	O
with	O	O
the	O	O
mean	O	O
values	O	O
of	O	O
weeks	O	O
3	O	O
and	O	O
4	O	O
of	O	O
each	O	O
phase	O	O
used	O	O
for	O	O
analysis	O	O
.	O	O

Ambulatory	O	O
BP	O	O
was	O	O
performed	O	O
in	O	O
the	O	O
final	O	O
week	O	O
of	O	O
each	O	O
phase	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
the	O	O
placebo	O	O
phase	O	O
,	O	O
end	O	O
of	O	O
phase	O	O
clinic	O	O
BP	O	O
was	O	O
unchanged	O	O
by	O	O
any	O	O
of	O	O
the	O	O
progestogen	O	O
treatments	O	O
.	O	O

There	O	O
was	O	O
a	O	O
dose-dependent	O	O
decrease	O	O
in	O	O
ambulatory	O	O
daytime	O	O
diastolic	O	O
and	O	O
mean	O	O
arterial	O	O
BP	O	O
with	O	O
the	O	O
progestogen	O	O
treatments	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
In	O	O
a	O	O
regimen	O	O
of	O	O
postmenopausal	O	O
hormone	O	O
replacement	O	O
therapy	O	O
with	O	O
a	O	O
fixed	O	O
mid-range	O	O
daily	O	O
dose	O	O
of	O	O
CEE	O	O
combined	O	O
with	O	O
a	O	O
cyclical	O	O
regimen	O	O
of	O	O
a	O	O
C21	O	O
progestogen	O	O
spanning	O	O
the	O	O
current	O	O
clinical	O	O
dose	O	O
range	O	O
,	O	O
the	O	O
progestogen	O	O
has	O	O
either	O	O
no	O	O
effect	O	O
or	O	O
a	O	O
small	O	O
dose-dependent	O	O
reduction	O	O
in	O	O
clinic	O	O
and	O	O
ambulatory	O	O
BPs	O	O
over	O	O
one	O	O
treatment	O	O
cycle	O	O
.	O	O

B-domain	O	O
deleted	O	O
recombinant	O	O
factor	O	O
VIII	O	O
preparations	O	O
are	O	O
bioequivalent	O	O
to	O	O
a	O	O
monoclonal	O	O
antibody	O	O
purified	O	O
plasma-derived	O	O
factor	O	O
VIII	O	O
concentrate	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
three-way	O	O
crossover	O	O
study	O	O
.	O	O

BACKGROUND	O	O
Deletion	O	O
of	O	O
the	O	O
B-domain	O	O
of	O	O
recombinant	O	O
blood	O	O
coagulation	O	O
factor	O	O
VIII	O	O
(	O	O
BDDrFVIII	O	O
)	O	O
increases	O	O
the	O	O
manufacturing	O	O
yield	O	O
of	O	O
the	O	O
product	O	O
but	O	O
does	O	O
not	O	O
impair	O	O
in	O	O
vitro	O	O
or	O	O
in	O	O
vivo	O	O
functionality	O	O
.	O	O

BDDrFVIII	O	O
(	O	O
ReFacto	O	O
)	O	O
has	O	O
been	O	O
developed	O	O
with	O	O
the	O	O
additional	O	O
benefit	O	O
of	O	O
being	O	O
formulated	O	O
without	O	O
human	O	O
albumin	O	O
.	O	O

OBJECTIVE	O	O
The	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
three-way	O	O
crossover-design	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
pharmacokinetic	O	O
(	O	O
PK	O	O
)	O	O
parameters	O	O
of	O	O
two	O	O
BDDrFVIII	O	O
formulations	O	O
(	O	O
one	O	O
reconstituted	O	O
with	O	O
5	O	O
mL	O	O
of	O	O
sterile	O	O
water	O	O
,	O	O
the	O	O
other	O	O
reconstituted	O	O
with	O	O
4	O	O
mL	O	O
sodium	O	O
chloride	O	O
0.9	O	O
%	O	O
USP	O	O
)	O	O
with	O	O
those	O	O
of	O	O
a	O	O
plasma-derived	O	O
,	O	O
full-length	O	O
FVIII	O	O
preparation	O	O
(	O	O
Hemofil	O	O
M	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
haemophilia	Condition	O
A	Condition	O
to	O	O
determine	O	O
bioequivalence	O	O
.	O	O

METHODS	O	O
A	O	O
series	O	O
of	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
over	O	O
a	O	O
period	O	O
of	O	O
48	O	O
h	O	O
after	O	O
i.v	O	O
.	O	O

administration	O	O
of	O	O
each	O	O
of	O	O
the	O	O
FVIII	O	O
preparations	O	O
.	O	O

Plasma	O	O
FVIII	O	O
activity	O	O
was	O	O
determined	O	O
using	O	O
a	O	O
validated	O	O
chromogenic	O	O
substrate	O	O
assay	O	O
.	O	O

Plasma	O	O
FVIII	O	O
activity	O	O
vs.	O	O
time	O	O
curves	O	O
was	O	O
characterized	O	O
for	O	O
a	O	O
standard	O	O
set	O	O
of	O	O
PK	O	O
parameter	O	O
estimates	O	O
.	O	O

Two	O	O
parameter	O	O
estimates	O	O
,	O	O
the	O	O
maximum	O	O
plasma	O	O
concentration	O	O
(	O	O
Cmax	O	O
)	O	O
and	O	O
the	O	O
area	O	O
under	O	O
plasma	O	O
concentration	O	O
vs.	O	O
time	O	O
curves	O	O
(	O	O
AUCs	O	O
)	O	O
,	O	O
were	O	O
used	O	O
to	O	O
evaluate	O	O
bioequivalence	O	O
.	O	O

The	O	O
two	O	O
preparations	O	O
were	O	O
considered	O	O
bioequivalent	O	O
if	O	O
the	O	O
90	O	O
%	O	O
confidence	O	O
intervals	O	O
for	O	O
the	O	O
ratio	O	O
of	O	O
geometric	O	O
means	O	O
for	O	O
Cmax	O	O
and	O	O
AUCs	O	O
fell	O	O
within	O	O
the	O	O
bioequivalence	O	O
window	O	O
of	O	O
80	O	O
%	O	O
to	O	O
125	O	O
%	O	O
.	O	O

RESULTS/CONCLUSION	O	O
Results	O	O
show	O	O
that	O	O
each	O	O
BDDrFVIII	O	O
formulation	O	O
is	O	O
bioequivalent	O	O
to	O	O
Hemofil	O	O
M	O	O
and	O	O
the	O	O
two	O	O
formulations	O	O
of	O	O
BDDrFVIII	O	O
are	O	O
bioequivalent	O	O
to	O	O
each	O	O
other	O	O
.	O	O

Rehabilitation	O	O
of	O	O
therapy-related	O	O
cognitive	O	O
deficits	O	O
in	O	O
patients	O	O
after	O	O
hematopoietic	Condition	O
stem	Condition	O
cell	Condition	O
transplantation	Condition	O
.	O	O

Neuropsychological	O	O
deficits	O	O
are	O	O
potential	O	O
side	O	O
effects	O	O
of	O	O
hematopoietic	O	O
stem	O	O
cell	O	O
therapy	O	O
(	O	O
HSCT	O	O
)	O	O
.	O	O

Systematic	O	O
data	O	O
on	O	O
the	O	O
long-term	O	O
course	O	O
of	O	O
and	O	O
therapeutic	O	O
options	O	O
for	O	O
these	O	O
consequences	O	O
are	O	O
limited	O	O
.	O	O

One	SampleSize	SampleSize
hundred	SampleSize	SampleSize
fifty-seven	SampleSize	SampleSize
patients	O	O
were	O	O
screened	O	O
for	O	O
cognitive	Condition	O
deficits	Condition	O
following	O	O
HSCT	O	O
for	O	O
malignant	Condition	O
diseases	Condition	O
at	O	O
an	O	O
in-patient	O	O
oncologic	O	O
rehabilitation	O	O
clinic	O	O
.	O	O

Patients	O	O
showing	O	O
evidence	O	O
of	O	O
impairment	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
two	O	O
training	O	O
groups	O	O
:	O	O
individualized	O	O
PC-supported	O	O
training	O	O
or	O	O
neuropsychological	O	O
group	O	O
therapy	O	O
.	O	O

The	O	SampleSize
control	O	SampleSize
group	O	SampleSize
consisted	O	SampleSize
of	O	SampleSize
patients	O	SampleSize
who	O	O
received	O	O
no	O	O
specific	O	O
training	O	O
.	O	O

During	O	O
in-patient	O	O
rehabilitation	O	O
,	O	O
the	O	O
results	O	O
of	O	O
a	O	O
comprehensive	O	O
neuropsychological	O	O
test	O	O
battery	O	O
improved	O	O
significantly	O	O
in	O	O
all	O	O
three	O	O
groups	O	O
,	O	O
and	O	O
no	O	O
specific	O	O
intervention	O	O
effects	O	O
were	O	O
identified	O	O
.	O	O

Neuropsychological	O	O
deficits	O	O
were	O	O
still	O	O
evident	O	O
in	O	O
a	O	O
subgroup	O	O
of	O	O
patients	O	O
6	O	O
months	O	O
later	O	O
.	O	O

Correlation	O	O
between	O	O
neuropsychological	O	O
testing	O	O
and	O	O
patients	O	O
'	O	O
self-evaluation	O	O
of	O	O
cognitive	O	O
functioning	O	O
in	O	O
daily	O	O
life	O	O
was	O	O
generally	O	O
low	O	O
.	O	O

Sustained	O	O
attention	O	O
and	O	O
verbal-semantic	O	O
memory	O	O
played	O	O
the	O	O
main	O	O
role	O	O
for	O	O
self-appraisal	O	O
and	O	O
in	O	O
the	O	O
designation	O	O
as	O	O
'neuropsychologically	O	O
impaired	O	O
'	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
a	O	O
substantial	O	O
number	O	O
of	O	O
patients	O	O
revealed	O	O
evidence	O	O
of	O	O
cognitive	O	O
deficits	O	O
a	O	O
long	O	O
time	O	O
after	O	O
HSCT	O	O
.	O	O

There	O	O
is	O	O
a	O	O
need	O	O
for	O	O
more	O	O
studies	O	O
and	O	O
for	O	O
the	O	O
development	O	O
of	O	O
differentiated	O	O
rehabilitative	O	O
measures	O	O
for	O	O
such	O	O
therapeutic	O	O
consequences	O	O
.	O	O

Effects	O	O
of	O	O
long-term	O	O
vitamin	O	O
E	O	O
supplementation	O	O
on	O	O
cardiovascular	Condition	O
events	Condition	O
and	O	O
cancer	Condition	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

CONTEXT	O	O
Experimental	O	O
and	O	O
epidemiological	O	O
data	O	O
suggest	O	O
that	O	O
vitamin	O	O
E	O	O
supplementation	O	O
may	O	O
prevent	O	O
cancer	Condition	O
and	O	O
cardiovascular	Condition	O
events	Condition	O
.	O	O

Clinical	O	O
trials	O	O
have	O	O
generally	O	O
failed	O	O
to	O	O
confirm	O	O
benefits	O	O
,	O	O
possibly	O	O
due	O	O
to	O	O
their	O	O
relatively	O	O
short	O	O
duration	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
whether	O	O
long-term	O	O
supplementation	O	O
with	O	O
vitamin	O	O
E	O	O
decreases	O	O
the	O	O
risk	O	O
of	O	O
cancer	O	O
,	O	O
cancer	O	O
death	O	O
,	O	O
and	O	O
major	O	O
cardiovascular	O	O
events	O	O
.	O	O

DESIGN	O	O
,	O	O
SETTING	O	O
,	O	O
AND	O	O
PATIENTS	O	O
A	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
international	O	O
trial	O	O
(	O	O
the	O	O
initial	O	O
Heart	O	O
Outcomes	O	O
Prevention	O	O
Evaluation	O	O
[	O	O
HOPE	O	O
]	O	O
trial	O	O
conducted	O	O
between	O	O
December	O	O
21	O	O
,	O	O
1993	O	O
,	O	O
and	O	O
April	O	O
15	O	O
,	O	O
1999	O	O
)	O	O
of	O	O
patients	O	O
at	O	O
least	O	O
55	Age	O
years	O	O
old	O	O
with	O	O
vascular	Condition	O
disease	Condition	O
or	O	O
diabetes	Condition	O
mellitus	Condition	O
was	O	O
extended	O	O
(	O	O
HOPE-The	O	O
Ongoing	O	O
Outcomes	O	O
[	O	O
HOPE-TOO	O	O
]	O	O
)	O	O
between	O	O
April	O	O
16	O	O
,	O	O
1999	O	O
,	O	O
and	O	O
May	O	O
26	O	O
,	O	O
2003	O	O
.	O	O

Of	O	O
the	O	O
initial	O	O
267	O	O
HOPE	O	O
centers	O	O
that	O	O
had	O	O
enrolled	O	O
9541	SampleSize	O
patients	O	O
,	O	O
174	O	O
centers	O	O
participated	O	O
in	O	O
the	O	O
HOPE-TOO	O	O
trial	O	O
.	O	O

Of	O	O
7030	SampleSize	O
patients	O	O
enrolled	O	O
at	O	O
these	O	O
centers	O	O
,	O	O
916	O	O
were	O	O
deceased	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
extension	O	O
,	O	O
1382	O	O
refused	O	O
participation	O	O
,	O	O
3994	O	O
continued	O	O
to	O	O
take	O	O
the	O	O
study	O	O
intervention	O	O
,	O	O
and	O	O
738	O	O
agreed	O	O
to	O	O
passive	O	O
follow-up	O	O
.	O	O

Median	O	O
duration	O	O
of	O	O
follow-up	O	O
was	O	O
7.0	O	O
years	O	O
.	O	O

INTERVENTION	O	O
Daily	O	O
dose	O	O
of	O	O
natural	O	O
source	O	O
vitamin	O	O
E	O	O
(	O	O
400	O	O
IU	O	O
)	O	O
or	O	O
matching	O	O
placebo	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Primary	O	O
outcomes	O	O
included	O	O
cancer	O	O
incidence	O	O
,	O	O
cancer	O	O
deaths	O	O
,	O	O
and	O	O
major	O	O
cardiovascular	O	O
events	O	O
(	O	O
myocardial	O	O
infarction	O	O
,	O	O
stroke	O	O
,	O	O
and	O	O
cardiovascular	O	O
death	O	O
)	O	O
.	O	O

Secondary	O	O
outcomes	O	O
included	O	O
heart	O	O
failure	O	O
,	O	O
unstable	O	O
angina	O	O
,	O	O
and	O	O
revascularizations	O	O
.	O	O

RESULTS	O	O
Among	O	O
all	O	O
HOPE	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
primary	O	O
analysis	O	O
:	O	O
for	O	O
cancer	O	O
incidence	O	O
,	O	O
there	O	O
were	O	O
552	O	O
patients	O	O
(	O	O
11.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
vitamin	O	O
E	O	O
group	O	O
vs	O	O
586	O	O
(	O	O
12.3	O	O
%	O	O
)	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
relative	O	O
risk	O	O
[	O	O
RR	O	O
]	O	O
,	O	O
0.94	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.84-1.06	O	O
;	O	O
P	O	O
=	O	O
.30	O	O
)	O	O
;	O	O
for	O	O
cancer	O	O
deaths	O	O
,	O	O
156	O	O
(	O	O
3.3	O	O
%	O	O
)	O	O
vs	O	O
178	O	O
(	O	O
3.7	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
RR	O	O
,	O	O
0.88	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.71-1.09	O	O
;	O	O
P	O	O
=	O	O
.24	O	O
)	O	O
;	O	O
and	O	O
for	O	O
major	O	O
cardiovascular	O	O
events	O	O
,	O	O
1022	O	O
(	O	O
21.5	O	O
%	O	O
)	O	O
vs	O	O
985	O	O
(	O	O
20.6	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
RR	O	O
,	O	O
1.04	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.96-1.14	O	O
;	O	O
P	O	O
=	O	O
.34	O	O
)	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
vitamin	O	O
E	O	O
group	O	O
had	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
heart	O	O
failure	O	O
(	O	O
RR	O	O
,	O	O
1.13	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.01-1.26	O	O
;	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
and	O	O
hospitalization	O	O
for	O	O
heart	O	O
failure	O	O
(	O	O
RR	O	O
,	O	O
1.21	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.00-1.47	O	O
;	O	O
P	O	O
=	O	O
.045	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
among	O	O
patients	O	O
enrolled	O	O
at	O	O
the	O	O
centers	O	O
participating	O	O
in	O	O
the	O	O
HOPE-TOO	O	O
trial	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
cancer	O	O
incidence	O	O
,	O	O
cancer	O	O
deaths	O	O
,	O	O
and	O	O
major	O	O
cardiovascular	O	O
events	O	O
,	O	O
but	O	O
higher	O	O
rates	O	O
of	O	O
heart	O	O
failure	O	O
and	O	O
hospitalizations	O	O
for	O	O
heart	O	O
failure	O	O
.	O	O

CONCLUSION	O	O
In	O	O
patients	O	O
with	O	O
vascular	O	O
disease	O	O
or	O	O
diabetes	O	O
mellitus	O	O
,	O	O
long-term	O	O
vitamin	O	O
E	O	O
supplementation	O	O
does	O	O
not	O	O
prevent	O	O
cancer	O	O
or	O	O
major	O	O
cardiovascular	O	O
events	O	O
and	O	O
may	O	O
increase	O	O
the	O	O
risk	O	O
for	O	O
heart	O	O
failure	O	O
.	O	O

Does	O	O
the	O	O
result	O	O
of	O	O
completion	O	O
axillary	O	O
lymph	O	O
node	O	O
dissection	O	O
influence	O	O
the	O	O
recommendation	O	O
for	O	O
adjuvant	O	O
treatment	O	O
in	O	O
sentinel	Condition	Condition
lymph	Condition	Condition
node-positive	Condition	Condition
patients	O	Condition
?	O	O
OBJECTIVE	O	O
The	O	O
Hungarian	O	O
National	O	O
Institute	O	O
of	O	O
Oncology	O	O
has	O	O
just	O	O
closed	O	O
a	O	O
single-center	O	O
randomized	O	O
clinical	O	O
study	O	O
.	O	O

The	O	O
Optimal	O	O
Treatment	O	O
of	O	O
the	O	O
Axilla-Surgery	O	O
or	O	O
Radiotherapy	O	O
(	O	O
OTOASOR	O	O
)	O	O
trial	O	O
compares	O	O
completion	O	O
axillary	O	O
lymph	O	O
node	O	O
dissection	O	O
(	O	O
cALND	O	O
)	O	O
with	O	O
regional	O	O
nodal	O	O
irradiation	O	O
(	O	O
RNI	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
sentinel	Condition	O
lymph	Condition	O
node-positive	Condition	O
(	Condition	O
SLN+	Condition	O
)	Condition	O
primary	Condition	O
invasive	Condition	O
breast	Condition	O
cancer	Condition	O
.	O	O

In	O	O
the	O	O
investigational	O	O
treatment	O	O
arm	O	O
,	O	O
patients	O	O
received	O	O
50	O	O
Gy	O	O
RNI	O	O
instead	O	O
of	O	O
cALND	O	O
.	O	O

In	O	O
these	O	O
patients	O	O
we	O	O
had	O	O
information	O	O
only	O	O
about	O	O
the	O	O
sentinel	O	O
lymph	O	O
node	O	O
(	O	O
SLN	O	O
)	O	O
status	O	O
,	O	O
but	O	O
the	O	O
further	O	O
axillary	O	O
nodal	O	O
involvement	O	O
remained	O	O
unknown	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
result	O	O
of	O	O
cALND	O	O
influenced	O	O
the	O	O
recommendation	O	O
for	O	O
adjuvant	O	O
treatment	O	O
in	O	O
patients	O	O
with	O	O
SLN+	Condition	Condition
breast	Condition	Condition
cancer	Condition	Condition
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Patients	O	O
with	O	O
SLN+	Condition	O
primary	Condition	O
breast	Condition	O
cancer	Condition	O
were	O	O
randomized	O	O
for	O	O
cALND	O	O
(	O	O
arm	O	O
A	O	O
,	O	O
standard	O	O
treatment	O	O
)	O	O
or	O	O
RNI	O	O
(	O	O
arm	O	O
B	O	O
,	O	O
investigational	O	O
treatment	O	O
)	O	O
.	O	O

Adjuvant	O	O
systemic	O	O
treatments	O	O
were	O	O
given	O	O
according	O	O
to	O	O
the	O	O
standard	O	O
institutional	O	O
protocol	O	O
,	O	O
and	O	O
patients	O	O
were	O	O
followed	O	O
according	O	O
to	O	O
the	O	O
actual	O	O
institutional	O	O
guidelines	O	O
.	O	O

RESULTS	O	O
Between	O	O
August	O	O
2002	O	O
and	O	O
June	O	O
2009	O	O
,	O	O
474	SampleSize	O
SLN+	Condition	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
cALND	O	O
(	O	O
arm	O	O
A	O	O
,	O	O
standard	O	O
treatment	O	O
=	O	O
244	O	O
patients	O	O
)	O	O
or	O	O
RNI	O	O
(	O	O
arm	O	O
B	O	O
,	O	O
investigational	O	O
treatment	O	O
=	O	O
230	O	O
patients	O	O
)	O	O
.	O	O

The	O	O
2	O	O
arms	O	O
were	O	O
well	O	O
balanced	O	O
according	O	O
to	O	O
the	O	O
majority	O	O
of	O	O
main	O	O
prognostic	O	O
factors	O	O
.	O	O

However	O	O
,	O	O
more	O	O
patients	O	O
were	O	O
premenopausal	Condition	O
(	O	O
34	O	O
%	O	O
vs.	O	O
27	O	O
%	O	O
;	O	O
P	O	O
=	O	O
.095	O	O
)	O	O
and	O	O
had	O	O
pT2-3	O	O
tumors	O	O
(	O	O
57	O	O
%	O	O
vs.	O	O
40	O	O
%	O	O
;	O	O
P	O	O
=	O	O
.003	O	O
)	O	O
in	O	O
the	O	O
completion	O	O
axillary	O	O
lymph	O	O
node	O	O
dissection	O	O
(	O	O
ALND	O	O
)	O	O
arm	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
there	O	O
were	O	O
more	O	O
patients	O	O
with	O	O
known	O	O
human	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
type	O	O
2	O	O
positive	O	O
tumor	O	O
(	O	O
12	O	O
%	O	O
vs.	O	O
17	O	O
%	O	O
,	O	O
P	O	O
=	O	O
.066	O	O
)	O	O
in	O	O
the	O	O
RNI	O	O
arm	O	O
.	O	O

In	O	O
the	O	O
ALND	O	O
and	O	O
RNI	O	O
arms	O	O
,	O	O
78	O	O
%	O	O
(	O	O
190/244	O	O
)	O	O
and	O	O
69	O	O
%	O	O
(	O	O
159/230	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
received	O	O
chemotherapy	O	O
(	O	O
P	O	O
=	O	O
.020	O	O
)	O	O
.	O	O

Endocrine	O	O
therapy	O	O
was	O	O
administered	O	O
in	O	O
87	O	O
%	O	O
(	O	O
213/244	O	O
)	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
the	O	O
ALND	O	O
arm	O	O
and	O	O
89	O	O
%	O	O
(	O	O
204/230	O	O
)	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
the	O	O
RNI	O	O
arm	O	O
(	O	O
P	O	O
=	O	O
.372	O	O
)	O	O
.	O	O

Six	O	O
patients	O	O
(	O	O
2.5	O	O
%	O	O
)	O	O
on	O	O
arm	O	O
A	O	O
and	O	O
13	O	O
patients	O	O
(	O	O
5.7	O	O
%	O	O
)	O	O
on	O	O
arm	O	O
B	O	O
received	O	O
adjuvant	O	O
trastuzumab	O	O
treatment	O	O
(	O	O
P	O	O
=	O	O
not	O	O
significant	O	O
)	O	O
.	O	O

Subgroup	O	O
analyses	O	O
explored	O	O
that	O	O
more	O	O
frequent	O	O
administration	O	O
of	O	O
adjuvant	O	O
chemotherapy	O	O
in	O	O
arm	O	O
A	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
higher	O	O
percentage	O	O
of	O	O
premenopausal	O	O
patients	O	O
and	O	O
patients	O	O
with	O	O
larger	O	O
(	Condition	O
pT2-3	Condition	O
)	Condition	O
tumors	Condition	O
.	O	O

CONCLUSIONS	O	O
The	O	O
result	O	O
of	O	O
cALND	O	O
after	O	O
positive	O	O
SLN	O	O
biopsy	O	O
seems	O	O
to	O	O
have	O	O
no	O	O
major	O	O
impact	O	O
on	O	O
the	O	O
administration	O	O
of	O	O
adjuvant	O	O
systemic	O	O
therapy	O	O
.	O	O

Hip	O	O
protectors	O	O
improve	O	O
falls	O	O
self-efficacy	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
use	O	O
of	O	O
external	O	O
hip	O	O
protectors	O	O
on	O	O
subjects	O	O
'	O	O
fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
self-efficacy	O	O
(	O	O
belief	O	O
in	O	O
their	O	O
own	O	O
ability	O	O
to	O	O
avoid	O	O
falling	O	O
)	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Aged-care	Age	O
health	O	O
services	O	O
in	O	O
Sydney	O	O
,	O	O
Australia	O	O
.	O	O

PARTICIPANTS	O	O
131	SampleSize	O
women	Sex	O
aged	O	O
75	Age	Age
years	Age	Age
or	Age	Age
older	Age	Age
,	O	O
who	O	O
had	O	O
two	O	O
or	O	O
more	O	O
falls	Condition	O
or	O	O
one	O	O
fall	Condition	O
requiring	Condition	O
hospital	Condition	O
admission	Condition	O
in	O	O
the	O	O
previous	O	O
year	O	O
and	O	O
who	O	O
live	O	O
at	O	O
home	O	O
.	O	O

Sixty-one	SampleSize	SampleSize
subjects	O	O
were	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
and	O	O
70	SampleSize	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

INTERVENTION	O	O
Use	O	O
of	O	O
external	O	O
hip	O	O
protectors	O	O
and	O	O
encouragement	O	O
to	O	O
use	O	O
the	O	O
protectors	O	O
by	O	O
an	O	O
adherence	O	O
nurse	O	O
.	O	O

MEASUREMENTS	O	O
At	O	O
the	O	O
time	O	O
of	O	O
enrolment	O	O
into	O	O
a	O	O
wider	O	O
study	O	O
examining	O	O
the	O	O
effect	O	O
of	O	O
hip	O	O
protectors	O	O
on	O	O
hip	O	O
fractures	O	O
,	O	O
participants	O	O
recruited	O	O
at	O	O
home	O	O
completed	O	O
an	O	O
assessment	O	O
of	O	O
fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
efficacy	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
and	O	O
the	O	O
Modified	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
.	O	O

At	O	O
4-month	O	O
follow-up	O	O
,	O	O
these	O	O
scales	O	O
were	O	O
readministered	O	O
by	O	O
an	O	O
observer	O	O
who	O	O
was	O	O
not	O	O
aware	O	O
of	O	O
the	O	O
allocation	O	O
of	O	O
the	O	O
participant	O	O
to	O	O
intervention	O	O
or	O	O
control	O	O
groups	O	O
.	O	O

RESULTS	O	O
Fear	O	O
of	O	O
falling	O	O
and	O	O
falls	O	O
self-efficacy	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	O	O
Efficacy	O	O
and	O	O
Modified	O	O
Falls	O	O
Efficacy	O	O
Scales	O	O
,	O	O
were	O	O
similar	O	O
at	O	O
baseline	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Fear	O	O
of	O	O
falling	O	O
was	O	O
present	O	O
at	O	O
follow-up	O	O
in	O	O
43	O	O
%	O	O
of	O	O
subjects	O	O
using	O	O
hip	O	O
protectors	O	O
and	O	O
57	O	O
%	O	O
of	O	O
the	O	O
control	O	O
group	O	O
(	O	O
chi2	O	O
=	O	O
2.58	O	O
,	O	O
P	O	O
=	O	O
0.11	O	O
)	O	O
.	O	O

Hip	O	O
protector	O	O
users	O	O
had	O	O
greater	O	O
improvement	O	O
in	O	O
falls	O	O
self-efficacy	O	O
at	O	O
follow-up	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
(	O	O
t	O	O
=	O	O
2.44	O	O
,	O	O
P	O	O
=	O	O
0.016	O	O
)	O	O
and	O	O
the	O	O
Modified	O	O
Falls	O	O
Efficacy	O	O
Scale	O	O
(	O	O
t	O	O
=	O	O
2.08	O	O
,	O	O
P	O	O
=	O	O
0.039	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Hip	O	O
protectors	O	O
improve	O	O
falls	O	O
self-efficacy	O	O
.	O	O

As	O	O
users	O	O
of	O	O
hip	O	O
protectors	O	O
feel	O	O
more	O	O
confident	O	O
that	O	O
they	O	O
can	O	O
complete	O	O
tasks	O	O
safely	O	O
,	O	O
they	O	O
may	O	O
become	O	O
more	O	O
physically	O	O
active	O	O
and	O	O
require	O	O
less	O	O
assistance	O	O
with	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
.	O	O

Hyperbaric	O	O
oxygen	O	O
attenuation	O	O
of	O	O
lipopolysaccharide-induced	Condition	O
acute	Condition	O
lung	Condition	O
injury	Condition	O
involves	O	O
heme	O	O
oxygenase-1	O	O
.	O	O

BACKGROUND	O	O
Hyperbaric	O	O
oxygen	O	O
(	O	O
HBO	O	O
)	O	O
attenuates	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
-induced	O	O
acute	Condition	O
lung	Condition	O
injury	Condition	O
.	O	O

This	O	O
beneficial	O	O
effect	O	O
of	O	O
HBO	O	O
involves	O	O
inhibition	O	O
of	O	O
inducible	O	O
nitric	O	O
oxide	O	O
synthase	O	O
(	O	O
iNOS	O	O
)	O	O
expression	O	O
and	O	O
subsequent	O	O
nitric	O	O
oxide	O	O
(	O	O
NO	O	O
)	O	O
biosynthesis	O	O
.	O	O

We	O	O
sought	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
(	O	O
HO-1	O	O
)	O	O
on	O	O
this	O	O
HBO	O	O
inhibition	O	O
of	O	O
iNOS	O	O
induction	O	O
and	O	O
acute	O	O
lung	O	O
injury	O	O
in	O	O
septic	O	Condition
rat	O	Condition
lungs	O	Condition
.	O	O

METHODS	O	O
Before	O	O
the	O	O
experiment	O	O
,	O	O
72	SampleSize	O
rats	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
HBO	O	O
or	O	O
air	O	O
treatment	O	O
.	O	O

With	O	O
or	O	O
without	O	O
HBO	O	O
pre-treatment	O	O
,	O	O
the	O	O
rats	O	O
were	O	O
further	O	O
divided	O	O
into	O	O
the	O	O
following	O	O
subgroups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
:	O	O
(	O	O
i	O	O
)	O	O
LPS	O	O
injection	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
normal	O	O
saline	O	O
(	O	O
N/S	O	O
)	O	O
injection	O	O
,	O	O
(	O	O
iii	O	O
)	O	O
hemin	O	O
(	O	O
a	O	O
HO-1	O	O
inducer	O	O
)	O	O
plus	O	O
LPS	O	O
,	O	O
(	O	O
iv	O	O
)	O	O
hemin	O	O
alone	O	O
,	O	O
(	O	O
v	O	O
)	O	O
tin	O	O
protoporphyrin	O	O
(	O	O
SnPP	O	O
;	O	O
a	O	O
HO-1	O	O
inhibitor	O	O
)	O	O
plus	O	O
LPS	O	O
,	O	O
and	O	O
(	O	O
vi	O	O
)	O	O
SnPP	O	O
alone	O	O
.	O	O

All	O	O
rats	O	O
were	O	O
maintained	O	O
for	O	O
6	O	O
h	O	O
and	O	O
then	O	O
sacrificed	O	O
with	O	O
a	O	O
high-dose	O	O
pentobarbital	O	O
injection	O	O
.	O	O

Lung	O	O
injuries	O	O
and	O	O
relevant	O	O
enzymes	O	O
expression	O	O
were	O	O
thus	O	O
assayed	O	O
.	O	O

RESULTS	O	O
Histological	O	O
analysis	O	O
,	O	O
PMNs/alveoli	O	O
ratio	O	O
,	O	O
and	O	O
wet/dry	O	O
weight	O	O
ratio	O	O
measurements	O	O
demonstrated	O	O
that	O	O
LPS	O	O
caused	O	O
significant	O	O
lung	O	O
injury	O	O
and	O	O
HBO	O	O
and/or	O	O
hemin	O	O
significantly	O	O
attenuated	O	O
this	O	O
LPS-induced	O	O
lung	O	O
injury	O	O
.	O	O

Increased	O	O
pulmonary	O	O
iNOS	O	O
expression	O	O
and	O	O
NO	O	O
production	O	O
were	O	O
associated	O	O
with	O	O
lung	O	O
injury	O	O
.	O	O

Induction	O	O
of	O	O
HO-1	O	O
,	O	O
by	O	O
HBO	O	O
and/or	O	O
hemin	O	O
,	O	O
significantly	O	O
attenuated	O	O
this	O	O
LPS-induced	O	O
iNOS	O	O
expression	O	O
and	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

SnPP	O	O
,	O	O
on	O	O
the	O	O
contrary	O	O
,	O	O
offset	O	O
the	O	O
effects	O	O
of	O	O
HBO	O	O
and	O	O
worsened	O	O
the	O	O
LPS-induced	O	O
lung	O	O
injury	O	O
.	O	O

CONCLUSIONS	O	O
HBO	O	O
may	O	O
act	O	O
through	O	O
inhibiting	O	O
pulmonary	O	O
iNOS	O	O
expression	O	O
to	O	O
attenuate	O	O
LPS-induced	O	O
acute	O	O
lung	O	O
injury	O	O
in	O	O
septic	Condition	Condition
rats	Condition	Condition
.	O	O

Furthermore	O	O
,	O	O
this	O	O
HBO	O	O
attenuation	O	O
of	O	O
iNOS	O	O
expression	O	O
involves	O	O
HO-1	O	O
induction	O	O
.	O	O

Are	O	O
tyrosine	O	O
kinase	O	O
inhibitors	O	O
still	O	O
active	O	O
in	O	O
patients	O	O
with	O	O
metastatic	Condition	Condition
renal	Condition	Condition
cell	Condition	Condition
carcinoma	Condition	Condition
previously	O	O
treated	O	O
with	O	O
a	O	O
tyrosine	O	O
kinase	O	O
inhibitor	O	O
and	O	O
everolimus	O	O
?	O	O
Experience	O	O
of	O	O
36	SampleSize	O
patients	O	O
treated	O	O
in	O	O
France	O	O
in	O	O
the	O	O
RECORD-1	O	O
Trial	O	O
.	O	O

BACKGROUND	O	O
Because	O	O
the	O	O
response	O	O
to	O	O
treatment	O	O
is	O	O
limited	O	O
,	O	O
patients	O	O
with	O	O
metastatic	O	Condition
renal	O	Condition
cell	O	Condition
carcinoma	O	Condition
(	O	O
mRCC	Condition	O
)	O	O
typically	O	O
receive	O	O
multiple	O	O
treatments	O	O
.	O	O

Guidelines	O	O
recommend	O	O
everolimus	O	O
for	O	O
patients	O	O
previously	O	O
treated	O	O
with	O	O
tyrosine	O	O
kinase	O	O
inhibitors	O	O
(	O	O
TKI	O	O
)	O	O
sunitinib	O	O
or	O	O
sorafenib	O	O
.	O	O

This	O	O
study	O	O
evaluated	O	O
the	O	O
efficacy	O	O
of	O	O
TKI	O	O
re-treatment	O	O
in	O	O
patients	O	O
with	O	O
disease	O	O
progression	O	O
after	O	O
a	O	O
TKI-everolimus	O	O
sequence	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
Data	O	O
were	O	O
reviewed	O	O
for	O	O
patients	O	O
enrolled	O	O
in	O	O
RECORD-1	O	O
(	O	O
Renal	Condition	O
Cell	Condition	O
Cancer	Condition	O
Treatment	O	O
With	O	O
Oral	O	O
RAD001	O	O
Given	O	O
Daily	O	O
)	O	O
at	O	O
French	O	O
sites	O	O
.	O	O

Response	O	O
,	O	O
progression-free	O	O
survival	O	O
(	O	O
PFS	O	O
)	O	O
,	O	O
and	O	O
overall	O	O
survival	O	O
were	O	O
evaluated	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
a	O	O
TKI-everolimus-TKI	O	O
sequence	O	O
.	O	O

RESULTS	O	O
Thirty-six	O	O
patients	O	O
received	O	O
a	O	O
TKI	O	O
after	O	O
everolimus	O	O
:	O	O
sunitinib	O	O
in	O	O
17	O	O
patients	O	O
,	O	O
sorafenib	O	O
in	O	O
15	O	O
,	O	O
and	O	O
dovitinib	O	O
(	O	O
TKI258	O	O
)	O	O
in	O	O
4	O	O
.	O	O

The	O	O
response	O	O
rate	O	O
with	O	O
TKI	O	O
re-treatment	O	O
was	O	O
8	O	O
%	O	O
,	O	O
and	O	O
the	O	O
disease-control	O	O
rate	O	O
(	O	O
response	O	O
plus	O	O
stable	O	O
disease	O	O
)	O	O
was	O	O
75	O	O
%	O	O
.	O	O

The	O	O
median	O	O
PFS	O	O
with	O	O
each	O	O
component	O	O
of	O	O
the	O	O
TKI-everolimus-TKI	O	O
sequence	O	O
was	O	O
10.7	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.8-28.5	O	O
months	O	O
)	O	O
,	O	O
8.9	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.7-34.6	O	O
months	O	O
)	O	O
,	O	O
and	O	O
8.2	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5.2-11.9	O	O
months	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
median	O	O
overall	O	O
survival	O	O
from	O	O
the	O	O
start	O	O
of	O	O
everolimus	O	O
was	O	O
29.1	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
21.1	O	O
to	O	O
not	O	O
reached	O	O
months	O	O
)	O	O
,	O	O
which	O	O
suggests	O	O
a	O	O
benefit	O	O
in	O	O
using	O	O
TKI	O	O
in	O	O
this	O	O
setting	O	O
.	O	O

CONCLUSIONS	O	O
Administration	O	O
of	O	O
a	O	O
TKI-everolimus-TKI	O	O
sequence	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
clinical	O	O
benefit	O	O
and	O	O
should	O	O
be	O	O
prospectively	O	O
investigated	O	O
.	O	O

Dissociation	O	O
between	O	O
cortical	O	O
activation	O	O
and	O	O
cognitive	O	O
performance	O	O
under	O	O
pharmacological	O	Condition
blood	O	Condition
pressure	O	Condition
elevation	O	Condition
in	O	Condition
chronic	O	Condition
hypotension	O	Condition
.	O	O

The	O	O
present	O	O
study	O	O
explored	O	O
the	O	O
impact	O	O
of	O	O
pharmacological	O	O
blood	O	O
pressure	O	O
elevation	O	O
on	O	O
cortical	O	O
activation	O	O
and	O	O
reaction	O	O
time	O	O
in	O	O
chronic	Condition	Condition
hypotension	Condition	Condition
.	O	O

Effects	O	O
of	O	O
the	O	O
sympathomimetic	O	O
etilefrine	O	O
were	O	O
investigated	O	O
in	O	O
50	SampleSize	O
hypotensive	Condition	O
persons	O	O
based	O	O
on	O	O
a	O	O
randomized	O	O
,	O	O
placebo-controlled	O	O
double	O	O
blind	O	O
design	O	O
.	O	O

As	O	O
an	O	O
indicator	O	O
of	O	O
cortical	O	O
excitability	O	O
,	O	O
the	O	O
contingent	O	O
negative	O	O
variation	O	O
(	O	O
CNV	O	O
)	O	O
,	O	O
induced	O	O
by	O	O
a	O	O
constant	O	O
foreperiod	O	O
reaction	O	O
time	O	O
task	O	O
,	O	O
was	O	O
assessed	O	O
at	O	O
frontal	O	O
(	O	O
F3	O	O
,	O	O
Fz	O	O
,	O	O
F4	O	O
)	O	O
and	O	O
central	O	O
(	O	O
C3	O	O
,	O	O
Cz	O	O
,	O	O
C4	O	O
)	O	O
scalp	O	O
sites	O	O
.	O	O

Etilefrine	O	O
provoked	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
frontal	O	O
and	O	O
central	O	O
CNV	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
shorter	O	O
reaction	O	O
times	O	O
were	O	O
observed	O	O
following	O	O
drug	O	O
administration	O	O
.	O	O

The	O	O
degree	O	O
of	O	O
pharmacologically	O	O
induced	O	O
blood	O	O
pressure	O	O
elevation	O	O
was	O	O
correlated	O	O
to	O	O
CNV	O	O
attrition	O	O
as	O	O
well	O	O
as	O	O
to	O	O
performance	O	O
enhancement	O	O
.	O	O

Inhibitory	O	O
effects	O	O
of	O	O
baroreceptor	O	O
activation	O	O
on	O	O
cortical	O	O
excitability	O	O
and	O	O
enhanced	O	O
cerebral	O	O
blood	O	O
flow	O	O
are	O	O
considered	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
mediating	O	O
the	O	O
effects	O	O
of	O	O
blood	O	O
pressure	O	O
elevation	O	O
on	O	O
cerebral	O	O
functioning	O	O
.	O	O

Implications	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	O	O
hypotension	O	O
are	O	O
discussed	O	O
.	O	O

A	O	O
pilot	O	O
study	O	O
of	O	O
a	O	O
low-tilt	O	O
biphasic	O	O
waveform	O	O
for	O	O
transvenous	O	O
cardioversion	O	O
of	O	O
atrial	Condition	O
fibrillation	Condition	O
:	O	O
improved	O	O
efficacy	O	O
compared	O	O
with	O	O
conventional	O	O
capacitor-based	O	O
waveforms	O	O
in	O	O
patients	O	O
.	O	O

BACKGROUND	O	O
The	O	O
optimal	O	O
waveform	O	O
tilt	O	O
for	O	O
defibrillation	O	O
is	O	O
not	O	O
known	O	O
.	O	O

Most	O	O
modern	O	O
defibrillators	O	O
used	O	O
for	O	O
the	O	O
cardioversion	O	O
of	O	O
atrial	O	O
fibrillation	O	O
(	O	O
AF	O	O
)	O	O
employ	O	O
high-tilt	O	O
,	O	O
capacitor-based	O	O
biphasic	O	O
waveforms	O	O
.	O	O

METHODS	O	O
We	O	O
have	O	O
developed	O	O
a	O	O
low-tilt	O	O
biphasic	O	O
waveform	O	O
for	O	O
defibrillation	O	O
.	O	O

This	O	O
low-tilt	O	O
waveform	O	O
was	O	O
compared	O	O
with	O	O
a	O	O
conventional	O	O
waveform	O	O
of	O	O
equivalent	O	O
duration	O	O
and	O	O
voltage	O	O
in	O	O
patients	O	O
with	O	O
AF	O	O
.	O	O

Patients	O	O
with	O	O
persistent	Condition	O
AF	Condition	O
or	O	O
AF	Condition	O
induced	Condition	O
during	O	O
a	O	O
routine	O	O
electrophysiology	Condition	O
study	Condition	O
(	O	O
EPS	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
the	O	O
low-tilt	O	O
waveform	O	O
or	O	O
a	O	O
conventional	O	O
waveform	O	O
.	O	O

Defibrillation	O	O
electrodes	O	O
were	O	O
positioned	O	O
in	O	O
the	O	O
right	O	O
atrial	O	O
appendage	O	O
and	O	O
distal	O	O
coronary	O	O
sinus	O	O
.	O	O

Phase	O	O
1	O	O
peak	O	O
voltage	O	O
was	O	O
increased	O	O
in	O	O
a	O	O
stepwise	O	O
progression	O	O
from	O	O
50	O	O
V	O	O
to	O	O
300V	O	O
.	O	O

Shock	O	O
success	O	O
was	O	O
defined	O	O
as	O	O
return	O	O
of	O	O
sinus	O	O
rhythm	O	O
for	O	O
>	O	O
/=30	O	O
seconds	O	O
.	O	O

RESULTS	O	O
The	O	O
low-tilt	O	O
waveform	O	O
produced	O	O
successful	O	O
termination	O	O
of	O	O
persistent	O	O
AF	O	O
at	O	O
a	O	O
mean	O	O
voltage	O	O
of	O	O
223	O	O
V	O	O
(	O	O
8.2	O	O
J	O	O
)	O	O
versus	O	O
270	O	O
V	O	O
(	O	O
6.7	O	O
J	O	O
)	O	O
with	O	O
the	O	O
conventional	O	O
waveform	O	O
(	O	O
P	O	O
=	O	O
0.002	O	O
for	O	O
voltage	O	O
,	O	O
P	O	O
=	O	O
ns	O	O
for	O	O
energy	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
induced	O	O
AF	O	O
the	O	O
mean	O	O
voltage	O	O
for	O	O
the	O	O
low-tilt	O	O
waveform	O	O
was	O	O
91V	O	O
(	O	O
1.6	O	O
J	O	O
)	O	O
and	O	O
for	O	O
the	O	O
conventional	O	O
waveform	O	O
was	O	O
158	O	O
V	O	O
(	O	O
2.0	O	O
J	O	O
)	O	O
(	O	O
P	O	O
=	O	O
0.005	O	O
for	O	O
voltage	O	O
,	O	O
P	O	O
=	O	O
ns	O	O
for	O	O
energy	O	O
)	O	O
.	O	O

The	O	O
waveform	O	O
was	O	O
much	O	O
more	O	O
successful	O	O
at	O	O
very	O	O
low	O	O
voltages	O	O
(	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
100	O	O
V	O	O
)	O	O
compared	O	O
with	O	O
the	O	O
conventional	O	O
waveform	O	O
(	O	O
Novel	O	O
:	O	O
82	O	O
%	O	O
vs	O	O
Conventional	O	O
22	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.008	O	O
)	O	O
.	O	O

CONCLUSION	O	O
The	O	O
low-tilt	O	O
biphasic	O	O
waveform	O	O
was	O	O
more	O	O
successful	O	O
for	O	O
the	O	O
internal	O	O
cardioversion	O	O
of	O	O
both	O	O
persistent	O	O
and	O	O
induced	O	O
AF	O	O
in	O	O
patients	O	O
(	O	O
in	O	O
terms	O	O
of	O	O
leading	O	O
edge	O	O
voltage	O	O
)	O	O
.	O	O

Margarines	O	O
fortified	O	O
with	O	O
?-linolenic	O	O
acid	O	O
,	O	O
eicosapentaenoic	O	O
acid	O	O
,	O	O
or	O	O
docosahexaenoic	O	O
acid	O	O
alter	O	O
the	O	O
fatty	O	O
acid	O	O
composition	O	O
of	O	O
erythrocytes	O	O
but	O	O
do	O	O
not	O	O
affect	O	O
the	O	O
antioxidant	O	O
status	O	O
of	O	O
healthy	O	O
adults	O	Age
.	O	O

We	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
increased	O	O
intake	O	O
of	O	O
?-linolenic	O	O
acid	O	O
(	O	O
ALA	O	O
)	O	O
,	O	O
EPA	O	O
,	O	O
or	O	O
DHA	O	O
incorporated	O	O
into	O	O
a	O	O
food	O	O
matrix	O	O
on	O	O
the	O	O
fatty	O	O
acid	O	O
composition	O	O
of	O	O
erythrocytes	O	O
and	O	O
on	O	O
biomarkers	O	O
of	O	O
oxidant/antioxidant	O	O
status	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
a	O	O
controlled	O	O
dietary	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
74	O	SampleSize
healthy	O	O
men	O	O
and	O	O
women	O	O
.	O	O

The	O	O
participants	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
1	O	O
of	O	O
3	O	O
interventions	O	O
in	O	O
which	O	O
margarines	O	O
fortified	O	O
with	O	O
either	O	O
10	O	O
weight	O	O
percent	O	O
ALA	O	O
,	O	O
EPA	O	O
,	O	O
or	O	O
DHA	O	O
ethyl	O	O
esters	O	O
replaced	O	O
their	O	O
normal	O	O
spread	O	O
for	O	O
6	O	O
wk	O	O
.	O	O

The	O	O
total	O	O
intakes	O	O
of	O	O
ALA	O	O
,	O	O
EPA	O	O
,	O	O
and	O	O
DHA	O	O
were	O	O
4.4	O	O
,	O	O
2.2	O	O
,	O	O
and	O	O
2.3	O	O
g/d	O	O
,	O	O
respectively	O	O
.	O	O

Consuming	O	O
EPA	O	O
increased	O	O
the	O	O
erythrocyte	O	O
proportion	O	O
of	O	O
EPA	O	O
(	O	O
394	O	O
%	O	O
)	O	O
and	O	O
the	O	O
omega-3	O	O
index	O	O
(	O	O
sum	O	O
of	O	O
EPA	O	O
and	O	O
DHA	O	O
,	O	O
38	O	O
%	O	O
)	O	O
.	O	O

Consumption	O	O
of	O	O
DHA	O	O
increased	O	O
erythrocyte	O	O
DHA	O	O
(	O	O
91	O	O
%	O	O
)	O	O
,	O	O
the	O	O
omega-3	O	O
index	O	O
(	O	O
98	O	O
%	O	O
)	O	O
,	O	O
and	O	O
EPA	O	O
(	O	O
137	O	O
%	O	O
)	O	O
.	O	O

The	O	O
omega-3	O	O
index	O	O
increased	O	O
to	O	O
a	O	O
significantly	O	O
greater	O	O
extent	O	O
in	O	O
the	O	O
DHA	O	O
group	O	O
than	O	O
in	O	O
the	O	O
EPA	O	O
group	O	O
.	O	O

ALA	O	O
did	O	O
not	O	O
increase	O	O
erythrocyte	O	O
EPA	O	O
or	O	O
the	O	O
omega-3	O	O
index	O	O
.	O	O

We	O	O
found	O	O
no	O	O
change	O	O
in	O	O
plasma	O	O
uric	O	O
acid	O	O
or	O	O
antioxidant	O	O
capacity	O	O
in	O	O
any	O	O
of	O	O
the	O	O
groups	O	O
.	O	O

Plasma	O	O
malondialdehyde	O	O
(	O	O
MDA	O	O
)	O	O
increased	O	O
with	O	O
the	O	O
EPA	O	O
and	O	O
DHA	O	O
interventions	O	O
.	O	O

All	O	O
3	O	O
interventions	O	O
decreased	O	O
erythrocyte	O	O
linoleic	O	O
acid	O	O
hydroperoxides	O	O
but	O	O
did	O	O
not	O	O
affect	O	O
their	O	O
MDA	O	O
concentrations	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
intake	O	O
of	O	O
both	O	O
isolated	O	O
EPA	O	O
and	O	O
DHA	O	O
incorporated	O	O
into	O	O
margarine	O	O
resulted	O	O
in	O	O
an	O	O
enhanced	O	O
incorporation	O	O
of	O	O
EPA	O	O
and	O	O
DHA	O	O
into	O	O
erythrocytes	O	O
.	O	O

Our	O	O
findings	O	O
indicate	O	O
that	O	O
DHA	O	O
is	O	O
quantitatively	O	O
superior	O	O
to	O	O
EPA	O	O
in	O	O
view	O	O
of	O	O
the	O	O
EPA+DHA	O	O
tissue	O	O
incorporation	O	O
and	O	O
also	O	O
that	O	O
4	O	O
g/d	O	O
ALA	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
increase	O	O
the	O	O
omega-3	O	O
index	O	O
over	O	O
a	O	O
6-wk	O	O
period	O	O
.	O	O

Memantine	O	O
add-on	O	O
to	O	O
risperidone	O	O
for	O	O
treatment	O	O
of	O	O
negative	O	O
symptoms	O	O
in	O	O
patients	O	O
with	O	O
stable	Condition	Condition
schizophrenia	Condition	Condition
:	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
memantine	O	O
add-on	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
negative	O	O
symptoms	O	O
of	O	O
patients	O	O
with	O	O
stable	O	O
schizophrenia	O	O
.	O	O

In	O	O
a	O	O
double-blind	O	O
placebo-controlled	O	O
clinical	O	O
trial	O	O
,	O	O
40	SampleSize	O
patients	O	O
with	O	O
schizophrenia	Condition	Condition
(	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	O	O
Disorders	O	O
,	O	O
Fourth	O	O
Edition	O	O
)	O	O
who	O	O
were	O	O
stabilized	O	O
on	O	O
risperidone	O	O
for	O	O
a	O	O
minimum	O	O
of	O	O
8	O	O
weeks	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
memantine	O	O
(	O	O
20	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
in	O	O
addition	O	O
to	O	O
risperidone	O	O
,	O	O
6	O	O
mg/d	O	O
,	O	O
for	O	O
eight	O	O
weeks	O	O
.	O	O

Assessment	O	O
was	O	O
done	O	O
using	O	O
the	O	O
Positive	O	O
and	O	O
Negative	O	O
Syndrome	O	O
Scale	O	O
at	O	O
baseline	O	O
,	O	O
week	O	O
4	O	O
,	O	O
and	O	O
week	O	O
8	O	O
.	O	O

The	O	O
Hamilton	O	O
Depression	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Extrapyramidal	O	O
Symptom	O	O
Rating	O	O
Scale	O	O
at	O	O
baseline	O	O
and	O	O
week	O	O
8	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
depression	O	O
and	O	O
extrapyramidal	O	O
symptoms	O	O
,	O	O
respectively	O	O
.	O	O

All	O	O
40	O	O
patients	O	O
had	O	O
at	O	O
least	O	O
one	O	O
postbaseline	O	O
measurement	O	O
,	O	O
and	O	O
38	SampleSize	O
patients	O	O
completed	O	O
the	O	O
trial	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
memantine	O	O
group	O	O
showed	O	O
a	O	O
significantly	O	O
greater	O	O
improvement	O	O
on	O	O
negative	O	O
subscale	O	O
than	O	O
the	O	O
placebo	O	O
group	O	O
at	O	O
end	O	O
point	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
same	O	O
effect	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
total	O	O
score	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
the	O	O
general	O	O
psychopathology	O	O
subscale	O	O
score	O	O
(	O	O
P	O	O
=	O	O
0.002	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
reduction	O	O
of	O	O
positive	O	O
symptoms	O	O
score	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
(	O	O
P	O	O
=	O	O
0.757	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
the	O	O
Hamilton	O	O
Depression	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Extrapyramidal	O	O
Symptom	O	O
Rating	O	O
Scale	O	O
scores	O	O
and	O	O
frequency	O	O
of	O	O
adverse	O	O
effects	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

Our	O	O
study	O	O
showed	O	O
that	O	O
memantine	O	O
is	O	O
a	O	O
tolerable	O	O
and	O	O
efficacious	O	O
add-on	O	O
treatment	O	O
for	O	O
primary	O	O
negative	O	O
symptoms	O	O
of	O	O
schizophrenia	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
rTMS	O	O
over	O	O
the	O	O
left	O	O
dorsolateral	O	O
prefrontal	O	O
cortex	O	O
on	O	O
Stroop	O	O
task	O	O
performance	O	O
.	O	O

Several	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
repetitive	O	O
transcranial	O	O
magnetic	O	O
stimulation	O	O
(	O	O
rTMS	O	O
)	O	O
can	O	O
improve	O	O
cognitive	O	O
processing	O	O
.	O	O

Neuroimaging	O	O
studies	O	O
have	O	O
shown	O	O
the	O	O
engagement	O	O
of	O	O
the	O	O
left	O	O
dorsolateral	O	O
prefrontal	O	O
cortex	O	O
(	O	O
DLPFC	O	O
)	O	O
in	O	O
executive	O	O
functioning	O	O
,	O	O
and	O	O
more	O	O
specifically	O	O
during	O	O
selective	O	O
attention	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
influence	O	O
of	O	O
high-frequency	O	O
rTMS	O	O
over	O	O
the	O	O
left	O	O
DLPFC	O	O
on	O	O
Stroop	O	O
task	O	O
performance	O	O
in	O	O
healthy	Condition	O
female	Sex	O
volunteers	O	O
was	O	O
investigated	O	O
.	O	O

As	O	O
expected	O	O
,	O	O
reaction	O	O
time	O	O
on	O	O
both	O	O
the	O	O
incongruent	O	O
and	O	O
congruent	O	O
trials	O	O
decreased	O	O
significantly	O	O
after	O	O
stimulation	O	O
,	O	O
and	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
Stroop	O	O
interference	O	O
effect	O	O
.	O	O

Mood	O	O
remained	O	O
unchanged	O	O
after	O	O
rTMS	O	O
.	O	O

Such	O	O
a	O	O
pattern	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
role	O	O
of	O	O
the	O	O
left	O	O
DLPFC	O	O
in	O	O
implementing	O	O
top-down	O	O
attentional	O	O
control	O	O
.	O	O

Similar	O	O
effects	O	O
of	O	O
rofecoxib	O	O
and	O	O
indomethacin	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
heterotopic	O	Condition
ossification	O	Condition
after	O	Condition
hip	Condition	Condition
arthroplasty	Condition	Condition
.	O	O

BACKGROUND	O	O
Although	O	O
indomethacin	O	O
is	O	O
effective	O	O
in	O	O
preventing	O	O
heterotopic	O	O
ossification	O	O
(	O	O
HO	O	O
)	O	O
after	O	O
primary	Condition	O
total	Condition	O
hip	Condition	O
arthroplasty	Condition	O
,	O	O
side	O	O
effects	O	O
are	O	O
frequently	O	O
observed	O	O
.	O	O

In	O	O
the	O	O
last	O	O
decade	O	O
a	O	O
new	O	O
class	O	O
of	O	O
drugs	O	O
--	O	O
the	O	O
COX-2	O	O
selective	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drugs	O	O
--	O	O
has	O	O
been	O	O
developed	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
these	O	O
COX-2	O	O
selective	O	O
NSAIDs	O	O
on	O	O
heterotopic	O	O
ossification	O	O
(	O	O
HO	O	O
)	O	O
after	O	O
primary	O	O
total	O	O
hip	O	O
arthroplasty	O	O
(	O	O
THA	O	O
)	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
using	O	O
either	O	O
indomethacin	O	O
or	O	O
rofecoxib	O	O
for	O	O
7	O	O
days	O	O
.	O	O

METHODS	O	O
186	SampleSize	SampleSize
patients	O	O
received	O	O
either	O	O
indomethacin	O	O
3	O	O
times	O	O
daily	O	O
,	O	O
or	O	O
rofecoxib	O	O
twice	O	O
,	O	O
and	O	O
1	O	O
placebo	O	O
,	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

HO	O	O
was	O	O
graded	O	O
according	O	O
to	O	O
the	O	O
1-year	O	O
postoperative	O	O
radiographs	O	O
according	O	O
to	O	O
the	O	O
Brooker	O	O
classification	O	O
.	O	O

RESULTS	O	O
12	O	O
of	O	O
the	O	O
186	O	SampleSize
patients	O	O
included	O	O
discontinued	O	O
their	O	O
medication	O	O
before	O	O
the	O	O
end	O	O
of	O	O
the	O	O
trial	O	O
due	O	O
to	O	O
side	O	O
effects	O	O
.	O	O

The	O	O
remaining	O	O
174	SampleSize	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

In	O	O
the	O	O
indomethacin	O	O
group	O	O
(	O	O
n	O	O
=	O	O
89	SampleSize	O
)	O	O
,	O	O
77	O	O
patients	O	O
(	O	O
87	O	O
%	O	O
)	O	O
showed	O	O
no	O	O
HO	O	O
,	O	O
9	O	O
showed	O	O
HO	O	O
of	O	O
grade	O	O
1	O	O
and	O	O
3	O	O
showed	O	O
HO	O	O
of	O	O
grade	O	O
2	O	O
according	O	O
to	O	O
the	O	O
Brooker	O	O
classification	O	O
.	O	O

In	O	O
the	O	O
rofecoxib	O	O
group	O	O
(	O	O
n	O	O
=	O	O
85	SampleSize	O
)	O	O
73	O	O
patients	O	O
(	O	O
86	O	O
%	O	O
)	O	O
showed	O	O
no	O	O
ossification	O	O
,	O	O
9	O	O
showed	O	O
grade	O	O
1	O	O
,	O	O
and	O	O
3	O	O
showed	O	O
grade	O	O
2	O	O
.	O	O

INTERPRETATION	O	O
The	O	O
prophylactic	O	O
effect	O	O
of	O	O
rofecoxib	O	O
for	O	O
7	O	O
days	O	O
in	O	O
preventing	O	O
heterotopic	O	O
ossification	O	O
after	O	O
primary	O	O
total	O	O
hip	O	O
arthroplasty	O	O
is	O	O
comparable	O	O
to	O	O
the	O	O
effect	O	O
of	O	O
indomethacin	O	O
given	O	O
for	O	O
7	O	O
days	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
development	O	O
of	O	O
HO	O	O
follows	O	O
a	O	O
COX-2	O	O
pathway	O	O
.	O	O

Cognitive-behavioural	O	O
stress	O	O
management	O	O
with	O	O
HIV-positive	Condition	O
homosexual	O	O
men	Sex	O
:	O	O
mechanisms	O	O
of	O	O
sustained	O	O
reductions	O	O
in	O	O
depressive	O	O
symptoms	O	O
.	O	O

BACKGROUND	O	O
We	O	O
examined	O	O
the	O	O
sustained	O	O
efficacy	O	O
of	O	O
a	O	O
group-based	O	O
cognitive-behavioural	O	O
stress	O	O
management	O	O
(	O	O
CBSM	O	O
)	O	O
intervention	O	O
in	O	O
comparison	O	O
to	O	O
a	O	O
modified	O	O
wait-list	O	O
control	O	O
condition	O	O
on	O	O
measures	O	O
of	O	O
mood	O	O
,	O	O
coping	O	O
and	O	O
social	O	O
support	O	O
in	O	O
mildly	O	O
symptomatic	O	O
HIV-positive	Condition	O
homosexual	Condition	O
and	O	O
bisexual	Condition	O
men	Sex	O
.	O	O

Participants	O	O
were	O	O
recruited	O	O
largely	O	O
during	O	O
the	O	O
era	O	O
prior	O	O
to	O	O
highly	O	O
active	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
HAART	O	O
;	O	O
1992-1997	O	O
)	O	O
.	O	O

METHODS	O	O
Men	O	O
were	O	O
randomized	O	O
to	O	O
either	O	O
a	O	O
10-week	O	O
,	O	O
group-based	O	O
CBSM	O	O
intervention	O	O
(	O	O
n	O	O
=	O	O
83	O	O
)	O	O
or	O	O
a	O	O
psychoeducational	O	O
seminar	O	O
group	O	O
(	O	O
n	O	O
=	O	O
46	SampleSize	O
)	O	O
.	O	O

All	O	O
participants	O	O
completed	O	O
a	O	O
battery	O	O
of	O	O
psychosocial	O	O
questionnaires	O	O
administered	O	O
by	O	O
a	O	O
research	O	O
assistant	O	O
at	O	O
baseline	O	O
,	O	O
immediately	O	O
following	O	O
the	O	O
10-week	O	O
CBSM	O	O
intervention	O	O
period	O	O
,	O	O
and	O	O
at	O	O
a	O	O
6-month	O	O
follow-up	O	O
.	O	O

RESULTS	O	O
Men	O	O
in	O	O
the	O	O
CBSM	O	O
group	O	O
maintained	O	O
previously	O	O
observed	O	O
effects	O	O
on	O	O
depressive	O	O
symptoms	O	O
and	O	O
perceived	O	O
social	O	O
support	O	O
.	O	O

These	O	O
sustained	O	O
effects	O	O
of	O	O
CBSM	O	O
on	O	O
depressive	O	O
symptoms	O	O
were	O	O
mediated	O	O
by	O	O
10-week	O	O
increases	O	O
in	O	O
cognitive	O	O
coping	O	O
(	O	O
i.e	O	O
.	O	O

positive	O	O
reframing	O	O
)	O	O
.	O	O

DISCUSSION	O	O
CBSM	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
potentially	O	O
efficacious	O	O
treatment	O	O
that	O	O
reduces	O	O
and	O	O
maintains	O	O
lower	O	O
levels	O	O
of	O	O
depressive	O	O
symptoms	O	O
and	O	O
enhances	O	O
social	O	O
support	O	O
in	O	O
HIV-positive	O	O
homosexual	O	O
and	O	O
bisexual	O	O
men	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
changes	O	O
in	O	O
positive	O	O
reframing	O	O
during	O	O
the	O	O
10-week	O	O
intervention	O	O
period	O	O
remain	O	O
a	O	O
crucial	O	O
factor	O	O
contributing	O	O
to	O	O
sustained	O	O
reductions	O	O
in	O	O
depressive	O	O
symptoms	O	O
.	O	O

International	O	O
Czech	O	O
and	O	O
Slovak	O	O
cooperation	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
differentiated	Condition	O
thyroid	Condition	O
cancer	Condition	O
.	O	O

BACKGROUND	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
paper	O	O
is	O	O
to	O	O
present	O	O
our	O	O
experience	O	O
concerning	O	O
cooperation	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Slovak	O	O
patients	O	O
with	O	O
differentiated	O	O
thyroid	O	O
cancer	O	O
in	O	O
Slovak	O	O
and	O	O
Czech	O	O
hospitals	O	O
.	O	O

The	O	O
objectives	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
demonstrate	O	O
the	O	O
means	O	O
of	O	O
this	O	O
cooperation	O	O
and	O	O
the	O	O
results	O	O
of	O	O
therapy	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
From	O	O
September	O	O
1991	O	O
to	O	O
October	O	O
2005	O	O
in	O	O
the	O	O
Department	O	O
of	O	O
Nuclear	O	O
Medicine	O	O
in	O	O
Ostrava	O	O
357	SampleSize	SampleSize
patients	O	O
from	O	O
the	O	O
Slovak	O	O
Republic	O	O
with	O	O
differentiated	Condition	O
thyroid	Condition	O
cancers	Condition	O
(	O	O
follicular	Condition	O
and	Condition	O
papillary	Condition	O
)	O	O
underwent	O	O
complex	O	O
therapy	O	O
.	O	O

They	O	O
were	O	O
diagnosed	O	O
and	O	O
operated	O	O
due	O	O
to	O	O
the	O	O
cancer	O	O
(	O	O
near-total	Condition	O
thyroidectomy	Condition	O
and	O	O
removal	Condition	O
of	Condition	O
lymph	Condition	O
node	Condition	O
metastases	Condition	O
)	O	O
in	O	O
Slovak	O	O
hospitals	O	O
.	O	O

Then	O	O
they	O	O
were	O	O
sent	O	O
to	O	O
the	O	O
Department	O	O
of	O	O
Nuclear	O	O
Medicine	O	O
in	O	O
Ostrava	O	O
in	O	O
the	O	O
Czech	O	O
Republic	O	O
.	O	O

In	O	O
this	O	O
department	O	O
a	O	O
radioiodine	O	O
ablation	O	O
of	O	O
thyroid	O	O
remnants	O	O
,	O	O
by	O	O
means	O	O
of	O	O
the	O	O
treatment	O	O
amount	O	O
of	O	O
radioiodine	O	O
of	O	O
a	O	O
standard	O	O
activity	O	O
of	O	O
3.7	O	O
GBq	O	O
,	O	O
was	O	O
performed	O	O
,	O	O
and	O	O
then	O	O
a	O	O
suppression	O	O
and	O	O
substitution	O	O
therapy	O	O
of	O	O
thyroid	O	O
hormones	O	O
was	O	O
started	O	O
.	O	O

After	O	O
3-6	O	O
months	O	O
some	O	O
patients	O	O
were	O	O
examined	O	O
by	O	O
means	O	O
of	O	O
diagnostic	O	O
whole	O	O
body	O	O
scintigraphy	O	O
after	O	O
application	O	O
of	O	O
300	O	O
MBq	O	O
131I	O	O
.	O	O

Some	O	O
patients	O	O
were	O	O
treated	O	O
by	O	O
means	O	O
of	O	O
a	O	O
standard	O	O
activity	O	O
of	O	O
7.4	O	O
GBq	O	O
131I	O	O
and	O	O
after	O	O
5	O	O
days	O	O
whole	O	O
body	O	O
scintigraphy	O	O
(	O	O
WBS	O	O
)	O	O
was	O	O
performed	O	O
.	O	O

In	O	O
both	O	O
of	O	O
these	O	O
groups	O	O
of	O	O
patients	O	O
the	O	O
diagnostic	O	O
or	O	O
therapeutic	O	O
radioiodine	O	O
application	O	O
was	O	O
done	O	O
after	O	O
withdrawal	O	O
of	O	O
thyroid	O	O
hormone	O	O
treatment	O	O
.	O	O

If	O	O
thyroglobulin	O	O
levels	O	O
were	O	O
low	O	O
and	O	O
WBSs	O	O
were	O	O
negative	O	O
,	O	O
patients	O	O
were	O	O
followed	O	O
up	O	O
in	O	O
the	O	O
Department	O	O
of	O	O
Nuclear	O	O
Medicine	O	O
in	O	O
Martin	O	O
.	O	O

Patients	O	O
with	O	O
radioiodine	O	O
accumulated	O	O
metastases	O	O
were	O	O
again	O	O
treated	O	O
with	O	O
radioiodine	O	O
in	O	O
Ostrava	O	O
.	O	O

If	O	O
indicated	O	O
,	O	O
external	O	O
radiation	O	O
therapy	O	O
targeted	O	O
on	O	O
the	O	O
neck	O	O
and	O	O
upper	O	O
mediastinum	O	O
was	O	O
performed	O	O
in	O	O
the	O	O
Slovak	O	O
Republic	O	O
,	O	O
in	O	O
the	O	O
University	O	O
Hospital	O	O
in	O	O
Martin	O	O
.	O	O

Newly	O	O
formed	O	O
lymph	O	O
node	O	O
metastases	O	O
were	O	O
surgically	O	O
treated	O	O
in	O	O
Slovakia	O	O
,	O	O
too	O	O
.	O	O

Generally	O	O
we	O	O
have	O	O
very	O	O
good	O	O
treatment	O	O
results	O	O
.	O	O

Also	O	O
,	O	O
economically	O	O
our	O	O
partnership	O	O
is	O	O
cost	O	O
effective	O	O
.	O	O

Our	O	O
collaboration	O	O
also	O	O
successfully	O	O
continues	O	O
after	O	O
entrance	O	O
of	O	O
the	O	O
Slovak	O	O
Republic	O	O
and	O	O
the	O	O
Czech	O	O
Republic	O	O
to	O	O
the	O	O
European	O	O
Union	O	O
in	O	O
2004	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
results	O	O
of	O	O
this	O	O
multi-centre	O	O
study	O	O
show	O	O
that	O	O
international	O	O
Czech	O	O
and	O	O
Slovak	O	O
cooperation	O	O
in	O	O
the	O	O
complex	O	O
therapy	O	O
of	O	O
patients	O	O
with	O	O
differentiated	O	O
thyroid	O	O
cancers	O	O
is	O	O
successful	O	O
,	O	O
with	O	O
high	O	O
efficacy	O	O
.	O	O

The	O	O
treatment	O	O
results	O	O
were	O	O
very	O	O
similar	O	O
to	O	O
therapeutic	O	O
results	O	O
in	O	O
our	O	O
patients	O	O
from	O	O
the	O	O
Czech	O	O
Republic	O	O
.	O	O

Immunologic	O	O
response	O	O
after	O	O
laparoscopic	O	O
colon	Condition	O
cancer	Condition	O
operation	O	O
within	O	O
an	O	O
enhanced	O	O
recovery	O	O
program	O	O
.	O	O

OBJECTIVE	O	O
It	O	O
has	O	O
been	O	O
demonstrated	O	O
that	O	O
colon	O	O
operation	O	O
combined	O	O
with	O	O
fast-track	O	O
(	O	O
FT	O	O
)	O	O
surgery	O	O
and	O	O
laparoscopic	O	O
technique	O	O
can	O	O
shorten	O	O
the	O	O
length	O	O
of	O	O
hospital	O	O
stay	O	O
,	O	O
accelerate	O	O
recovery	O	O
of	O	O
intestinal	O	O
function	O	O
,	O	O
and	O	O
reduce	O	O
the	O	O
occurrence	O	O
of	O	O
post-operative	O	O
complications	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
no	O	O
reports	O	O
regarding	O	O
the	O	O
combined	O	O
effects	O	O
of	O	O
FT	O	O
colon	O	O
operation	O	O
and	O	O
laparoscopic	O	O
technique	O	O
on	O	O
humoral	O	O
inflammatory	O	O
cellular	O	O
immunity	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
controlled	O	O
study	O	O
.	O	O

One	SampleSize	SampleSize
hundred	SampleSize	SampleSize
sixty-three	SampleSize	SampleSize
colon	Condition	Condition
cancer	Condition	Condition
patients	O	O
underwent	O	O
the	O	O
traditional	O	O
protocol	O	O
and	O	O
open	O	O
operation	O	O
(	O	O
traditional	O	O
open	O	O
group	O	O
,	O	O
n=42	SampleSize	O
)	O	O
,	O	O
the	O	O
traditional	O	O
protocol	O	O
and	O	O
laparoscopic	O	O
operation	O	O
(	O	O
traditional	O	O
laparoscopic	O	O
group	O	O
,	O	O
n=40	SampleSize	O
)	O	O
,	O	O
the	O	O
FT	O	O
protocol	O	O
and	O	O
open	O	O
operation	O	O
(	O	O
FT	O	O
open	O	O
group	O	O
,	O	O
n=41	SampleSize	O
)	O	O
,	O	O
or	O	O
the	O	O
FT	O	O
protocol	O	O
and	O	O
laparoscopic	O	O
operation	O	O
(	O	O
FT	O	O
laparoscopic	O	O
group	O	O
,	O	O
n=40	SampleSize	O
)	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
taken	O	O
prior	O	O
to	O	O
operation	O	O
as	O	O
well	O	O
as	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
after	O	O
operation	O	O
.	O	O

The	O	O
number	O	O
of	O	O
lymphocyte	O	O
subpopulations	O	O
was	O	O
determined	O	O
by	O	O
flow	O	O
cytometry	O	O
,	O	O
and	O	O
serum	O	O
interleukin-6	O	O
and	O	O
C-reactive	O	O
protein	O	O
levels	O	O
were	O	O
measured	O	O
.	O	O

Post-operative	O	O
hospital	O	O
stay	O	O
,	O	O
post-operative	O	O
morbidity	O	O
,	O	O
readmission	O	O
rate	O	O
,	O	O
and	O	O
in-hospital	O	O
mortality	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Compared	O	O
with	O	O
open	O	O
operation	O	O
,	O	O
laparoscopic	O	O
colon	O	O
operation	O	O
effectively	O	O
inhibited	O	O
the	O	O
release	O	O
of	O	O
post-operative	O	O
inflammatory	O	O
factors	O	O
and	O	O
yielded	O	O
good	O	O
protection	O	O
via	O	O
post-operative	O	O
cell	O	O
immunity	O	O
.	O	O

FT	O	O
surgery	O	O
had	O	O
a	O	O
better	O	O
protective	O	O
role	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
post-operative	O	O
immune	O	O
system	O	O
compared	O	O
with	O	O
traditional	O	O
peri-operative	O	O
care	O	O
.	O	O

Inflammatory	O	O
reactions	O	O
,	O	O
based	O	O
on	O	O
interleukin-6	O	O
and	O	O
C-reactive	O	O
protein	O	O
levels	O	O
,	O	O
were	O	O
less	O	O
intense	O	O
following	O	O
FT	O	O
laparoscopic	O	O
operation	O	O
compared	O	O
to	O	O
FT	O	O
open	O	O
operation	O	O
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
specific	O	O
immunity	O	O
(	O	O
CD3+	O	O
and	O	O
CD4+	O	O
counts	O	O
,	O	O
and	O	O
the	O	O
CD4+/CD8+	O	O
ratio	O	O
)	O	O
during	O	O
these	O	O
two	O	O
types	O	O
of	O	O
surgical	O	O
procedures	O	O
.	O	O

Post-operative	O	O
hospital	O	O
stay	O	O
in	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
FT	O	O
laparoscopic	O	O
group	O	O
was	O	O
significantly	O	O
shorter	O	O
than	O	O
in	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Post-operative	O	O
complications	O	O
in	O	O
patients	O	O
who	O	O
underwent	O	O
FT	O	O
laparoscopic	O	O
treatment	O	O
were	O	O
less	O	O
than	O	O
in	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
four	O	O
treatment	O	O
groups	O	O
regarding	O	O
readmission	O	O
rate	O	O
and	O	O
in-hospital	O	O
mortality	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
laparoscopic	O	O
technique	O	O
and	O	O
FT	O	O
surgery	O	O
rehabilitation	O	O
program	O	O
effectively	O	O
inhibited	O	O
release	O	O
of	O	O
post-operative	O	O
inflammatory	O	O
factors	O	O
with	O	O
a	O	O
reduction	O	O
in	O	O
peri-operative	O	O
trauma	O	O
and	O	O
stress	O	O
,	O	O
which	O	O
together	O	O
played	O	O
a	O	O
protective	O	O
role	O	O
on	O	O
the	O	O
post-operative	O	O
immune	O	O
system	O	O
.	O	O

Combining	O	O
two	O	O
treatment	O	O
measures	O	O
during	O	O
colon	O	O
operation	O	O
produced	O	O
better	O	O
protective	O	O
effects	O	O
via	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

The	O	O
beneficial	O	O
clinical	O	O
effects	O	O
support	O	O
that	O	O
the	O	O
better-preserved	O	O
post-operative	O	O
immune	O	O
system	O	O
may	O	O
also	O	O
contribute	O	O
to	O	O
the	O	O
improvement	O	O
of	O	O
post-operative	O	O
results	O	O
in	O	O
FT	O	O
laparoscopic	O	O
patients	O	O
.	O	O

Comparison	O	O
of	O	O
rectal	O	O
midazolam	O	O
and	O	O
diazepam	O	O
for	O	O
premedication	O	O
in	O	O
pediatric	Age	O
dental	Condition	O
patients	Condition	O
.	O	O

Rectally	O	O
administered	O	O
midazolam	O	O
(	O	O
0.35	O	O
mg/kg	O	O
)	O	O
and	O	O
diazepam	O	O
(	O	O
0.70	O	O
mg/kg	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
each	O	O
other	O	O
and	O	O
with	O	O
placebo	O	O
for	O	O
preanesthetic	O	O
medication	O	O
in	O	O
children	Age	Condition
undergoing	O	Condition
dental	Condition	Condition
extractions	Condition	Condition
.	O	O

All	O	O
rectal	O	O
medications	O	O
were	O	O
very	O	O
well	O	O
accepted	O	O
,	O	O
but	O	O
mask	O	O
acceptance	O	O
,	O	O
improvement	O	O
in	O	O
anxiety	O	O
,	O	O
and	O	O
sedation	O	O
were	O	O
best	O	O
in	O	O
the	O	O
midazolam	O	O
group	O	O
.	O	O

Improvement	O	O
in	O	O
anxiety	O	O
and	O	O
sedation	O	O
were	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
two	O	O
drug	O	O
groups	O	O
than	O	O
in	O	O
those	O	O
patients	O	O
who	O	O
had	O	O
received	O	O
placebo	O	O
.	O	O

Thirty	O	O
minutes	O	O
after	O	O
rectal	O	O
administration	O	O
of	O	O
midazolam	O	O
,	O	O
patients	O	O
showed	O	O
a	O	O
decrease	O	O
in	O	O
both	O	O
systolic	O	O
and	O	O
diastolic	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
.	O	O

Although	O	O
these	O	O
decreases	O	O
differed	O	O
significantly	O	O
from	O	O
the	O	O
premedication	O	O
values	O	O
,	O	O
they	O	O
were	O	O
probably	O	O
of	O	O
little	O	O
clinical	O	O
importance	O	O
.	O	O

Only	O	O
minor	O	O
adverse	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Overall	O	O
rectally	O	O
administered	O	O
midazolam	O	O
appeared	O	O
to	O	O
be	O	O
somewhat	O	O
more	O	O
efficacious	O	O
than	O	O
diazepam	O	O
.	O	O

Action	O	O
observation	O	O
treatment	O	O
improves	O	O
recovery	O	O
of	O	O
postsurgical	Condition	O
orthopedic	Condition	O
patients	Condition	O
:	O	O
evidence	O	O
for	O	O
a	O	O
top-down	O	O
effect	O	O
?	O	O
OBJECTIVE	O	O
To	O	O
assess	O	O
whether	O	O
action	O	O
observation	O	O
treatment	O	O
(	O	O
AOT	O	O
)	O	O
may	O	O
also	O	O
improve	O	O
motor	O	O
recovery	O	O
in	O	O
postsurgical	Condition	O
orthopedic	Condition	O
patients	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
conventional	O	O
physiotherapy	O	O
.	O	O

DESIGN	O	O
Randomized	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
Department	O	O
of	O	O
rehabilitation	O	O
.	O	O

PARTICIPANTS	O	O
Patients	O	O
(	O	O
N=60	SampleSize	SampleSize
)	O	O
admitted	O	O
to	O	O
our	O	O
department	O	O
postorthopedic	O	O
surgery	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
either	O	O
a	O	O
case	O	O
(	O	O
n=30	O	O
)	O	O
or	O	O
control	O	O
(	O	O
n=30	O	O
)	O	O
group	O	O
.	O	O

Exclusion	O	O
criteria	O	O
were	O	O
age	O	O
18	Age	O
years	Age	O
or	Age	O
younger	Age	O
and	Age	O
90	Age	O
years	Age	O
or	Age	O
older	Age	O
,	O	O
Mini-Mental	O	O
State	O	O
Examination	O	O
score	O	O
of	O	O
21	O	O
of	O	O
30	O	O
or	O	O
lower	O	O
,	O	O
no	O	O
ambulating	O	O
order	O	O
,	O	O
advanced	O	O
vision	O	O
impairment	O	O
,	O	O
malignancy	O	O
,	O	O
pneumonia	O	O
,	O	O
or	O	O
heart	O	O
failure	O	O
.	O	O

INTERVENTIONS	O	O
All	O	O
participants	O	O
underwent	O	O
conventional	O	O
physiotherapy	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
case	O	O
group	O	O
were	O	O
asked	O	O
to	O	O
observe	O	O
video	O	O
clips	O	O
showing	O	O
daily	O	O
actions	O	O
and	O	O
to	O	O
imitate	O	O
them	O	O
afterward	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
asked	O	O
to	O	O
observe	O	O
video	O	O
clips	O	O
with	O	O
no	O	O
motor	O	O
content	O	O
and	O	O
to	O	O
execute	O	O
the	O	O
same	O	O
actions	O	O
as	O	O
patients	O	O
in	O	O
the	O	O
case	O	O
group	O	O
afterward	O	O
.	O	O

Participants	O	O
were	O	O
scored	O	O
on	O	O
functional	O	O
scales	O	O
at	O	O
baseline	O	O
and	O	O
after	O	O
treatment	O	O
by	O	O
a	O	O
physician	O	O
blinded	O	O
to	O	O
group	O	O
assignment	O	O
.	O	O

MAIN	O	O
OUTCOMES	O	O
MEASURES	O	O
Changes	O	O
in	O	O
FIM	O	O
and	O	O
Tinetti	O	O
scale	O	O
scores	O	O
,	O	O
and	O	O
dependence	O	O
on	O	O
walking	O	O
aids	O	O
.	O	O

RESULTS	O	O
At	O	O
baseline	O	O
,	O	O
groups	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
clinical	O	O
and	O	O
functional	O	O
scale	O	O
scores	O	O
.	O	O

After	O	O
treatment	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
case	O	O
group	O	O
scored	O	O
better	O	O
than	O	O
patients	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
FIM	O	O
total	O	O
score	O	O
,	O	O
P=.02	O	O
;	O	O
FIM	O	O
motor	O	O
subscore	O	O
,	O	O
P=.001	O	O
;	O	O
Tinetti	O	O
scale	O	O
score	O	O
,	O	O
P=.04	O	O
)	O	O
;	O	O
patients	O	O
in	O	O
the	O	O
case	O	O
group	O	O
were	O	O
assigned	O	O
more	O	O
frequently	O	O
to	O	O
1	O	O
crutch	O	O
(	O	O
P=.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
In	O	O
addition	O	O
to	O	O
conventional	O	O
physiotherapy	O	O
,	O	O
AOT	O	O
is	O	O
effective	O	O
in	O	O
the	O	O
rehabilitation	O	O
of	O	O
postsurgical	O	O
orthopedic	O	O
patients	O	O
.	O	O

The	O	O
present	O	O
results	O	O
strongly	O	O
support	O	O
top-down	O	O
effects	O	O
of	O	O
this	O	O
treatment	O	O
in	O	O
motor	O	O
recovery	O	O
,	O	O
even	O	O
in	O	O
nonneurologic	O	O
patients	O	O
.	O	O

Norfloxacin	O	O
modulates	O	O
the	O	O
inflammatory	O	O
response	O	O
and	O	O
directly	O	O
affects	O	O
neutrophils	O	O
in	O	O
patients	O	O
with	O	O
decompensated	Condition	O
cirrhosis	Condition	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
Patients	O	O
with	O	O
cirrhosis	Condition	O
undergoing	O	O
selective	O	O
intestinal	O	O
decontamination	O	O
with	O	O
norfloxacin	O	O
show	O	O
a	O	O
reduction	O	O
in	O	O
serum	O	O
cytokine	O	O
levels	O	O
,	O	O
probably	O	O
because	O	O
of	O	O
a	O	O
combined	O	O
effect	O	O
of	O	O
norfloxacin	O	O
on	O	O
bowel	O	O
flora	O	O
and	O	O
neutrophils	O	O
.	O	O

METHODS	O	O
Thirty-one	SampleSize	SampleSize
patients	O	O
with	O	O
cirrhosis	O	O
receiving	O	O
norfloxacin	O	O
(	O	O
400	O	O
mg/day	O	O
)	O	O
were	O	O
included	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
collected	O	O
at	O	O
0.5-4	O	O
hours	O	O
(	O	O
peak	O	O
samples	O	O
group	O	O
,	O	O
n	O	O
=	O	O
47	O	O
)	O	O
and	O	O
at	O	O
22-24	O	O
hours	O	O
(	O	O
trough	O	O
samples	O	O
group	O	O
,	O	O
n	O	O
=	O	O
84	O	O
)	O	O
after	O	O
dose	O	O
.	O	O

Fifty-nine	O	O
ascitic	O	O
fluid	O	O
samples	O	O
were	O	O
obtained	O	O
.	O	O

Single	O	O
doses	O	O
of	O	O
norfloxacin	O	O
and	O	O
trimethoprim/sulfamethoxazole	O	O
were	O	O
administered	O	O
to	O	O
13	O	O
and	O	O
5	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
(	O	O
temporal	O	O
profile	O	O
group	O	O
)	O	O
and	O	O
samples	O	O
were	O	O
collected	O	O
at	O	O
0	O	O
,	O	O
0.5	O	O
,	O	O
1	O	O
,	O	O
1.5	O	O
,	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
24	O	O
hours	O	O
.	O	O

Norfloxacin	O	O
,	O	O
trimethoprim/sulfamethoxazole	O	O
,	O	O
cytokines	O	O
,	O	O
nitric	O	O
oxide	O	O
,	O	O
expression	O	O
levels	O	O
of	O	O
nuclear	O	O
factor	O	O
(	O	O
NF	O	O
)	O	O
-kappaB	O	O
and	O	O
inhibitor	O	O
of	O	O
NF-kappaB	O	O
(	O	O
IkB-alpha	O	O
)	O	O
,	O	O
neutrophil	O	O
oxidative	O	O
burst	O	O
,	O	O
and	O	O
rate	O	O
of	O	O
apoptotic	O	O
events	O	O
were	O	O
determined	O	O
.	O	O

RESULTS	O	O
All	O	O
samples	O	O
were	O	O
bacterial	O	O
DNA	O	O
negative	O	O
and	O	O
had	O	O
no	O	O
significant	O	O
levels	O	O
of	O	O
lipopolysaccharide	O	O
.	O	O

Serum	O	O
and	O	O
ascitic	O	O
levels	O	O
of	O	O
tumor	O	O
necrosis	O	O
factor-alpha	O	O
,	O	O
interferon-gamma	O	O
,	O	O
interleukin-12	O	O
,	O	O
and	O	O
nitric	O	O
oxide	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
peak	O	O
than	O	O
in	O	O
trough	O	O
samples	O	O
.	O	O

A	O	O
correlation	O	O
was	O	O
present	O	O
between	O	O
serum	O	O
norfloxacins	O	O
concentrations	O	O
and	O	O
tumor	O	O
necrosis	O	O
factor-alpha	O	O
(	O	O
r	O	O
=	O	O
-0.68	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
interferon-gamma	O	O
(	O	O
r	O	O
=	O	O
-0.66	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
interleukin-12	O	O
(	O	O
r	O	O
=	O	O
-0.66	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
and	O	O
nitric	O	O
oxide	O	O
(	O	O
r	O	O
=	O	O
-0.68	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Serum	O	O
norfloxacin	O	O
's	O	O
highest	O	O
concentrations	O	O
(	O	O
1	O	O
+/-	O	O
0.5	O	O
microg/mL	O	O
)	O	O
were	O	O
achieved	O	O
at	O	O
1-2	O	O
hours	O	O
and	O	O
concurred	O	O
in	O	O
time	O	O
with	O	O
the	O	O
lower	O	O
levels	O	O
of	O	O
cytokines	O	O
and	O	O
nitric	O	O
oxide	O	O
.	O	O

Intracellular	O	O
norfloxacin	O	O
's	O	O
highest	O	O
levels	O	O
(	O	O
2	O	O
+/-	O	O
1	O	O
microg/mL/10	O	O
(	O	O
7	O	O
)	O	O
cells	O	O
)	O	O
were	O	O
observed	O	O
at	O	O
2	O	O
hours	O	O
and	O	O
concurred	O	O
with	O	O
a	O	O
lower	O	O
NF-kappaB	O	O
expression	O	O
,	O	O
a	O	O
reduced	O	O
anion	O	O
superoxide	O	O
generation	O	O
,	O	O
and	O	O
apoptotic	O	O
rate	O	O
in	O	O
response	O	O
to	O	O
phorbol	O	O
myristate	O	O
acetate	O	O
.	O	O

Trimethoprim/sulfamethoxazole	O	O
did	O	O
not	O	O
significantly	O	O
modulate	O	O
cytokine	O	O
expression	O	O
.	O	O

CONCLUSIONS	O	O
Norfloxacin	O	O
but	O	O
not	O	O
trimethoprim/sulfamethoxazole	O	O
modulates	O	O
inflammatory	O	O
response	O	O
and	O	O
directly	O	O
affects	O	O
neutrophils	O	O
in	O	O
patients	O	O
with	O	O
cirrhosis	Condition	O
.	O	O

The	O	O
effect	O	O
of	O	O
person-centred	O	O
dementia	O	O
care	O	O
to	O	O
prevent	O	O
agitation	O	O
and	O	O
other	O	O
neuropsychiatric	O	O
symptoms	O	O
and	O	O
enhance	O	O
quality	O	O
of	O	O
life	O	O
in	O	O
nursing	Condition	O
home	Condition	O
patients	Condition	O
:	O	O
a	O	O
10-month	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

AIMS	O	O
We	O	O
examined	O	O
whether	O	O
Dementia	O	O
Care	O	O
Mapping	O	O
(	O	O
DCM	O	O
)	O	O
or	O	O
the	O	O
VIPS	O	O
practice	O	O
model	O	O
(	O	O
VPM	O	O
)	O	O
is	O	O
more	O	O
effective	O	O
than	O	O
education	O	O
of	O	O
the	O	O
nursing	O	O
home	O	O
staff	O	O
about	O	O
dementia	O	O
(	O	O
control	O	O
group	O	O
)	O	O
in	O	O
reducing	O	O
agitation	O	O
and	O	O
other	O	O
neuropsychiatric	O	O
symptoms	O	O
as	O	O
well	O	O
as	O	O
in	O	O
enhancing	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
among	O	O
nursing	O	O
home	O	O
patients	O	O
.	O	O

METHODS	O	O
A	O	O
10-month	O	O
three-armed	O	O
cluster-randomized	O	O
controlled	O	O
trial	O	O
compared	O	O
DCM	O	O
and	O	O
VPM	O	O
with	O	O
control	O	O
.	O	O

Of	O	O
624	SampleSize	SampleSize
nursing	O	O
home	O	O
patients	O	O
with	O	O
dementia	Condition	O
,	O	O
446	SampleSize	O
completed	O	O
follow-up	O	O
assessments	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
the	O	O
change	O	O
on	O	O
the	O	O
Brief	O	O
Agitation	O	O
Rating	O	O
Scale	O	O
(	O	O
BARS	O	O
)	O	O
.	O	O

Secondary	O	O
outcomes	O	O
were	O	O
changes	O	O
on	O	O
the	O	O
10-item	O	O
version	O	O
of	O	O
the	O	O
Neuropsychiatric	O	O
Inventory	O	O
Questionnaire	O	O
(	O	O
NPI-Q	O	O
)	O	O
,	O	O
the	O	O
Cornell	O	O
Scale	O	O
for	O	O
Depression	O	O
in	O	O
Dementia	O	O
(	O	O
CSDD	O	O
)	O	O
and	O	O
the	O	O
Quality	O	O
of	O	O
Life	O	O
in	O	O
Late-Stage	O	O
Dementia	O	O
(	O	O
QUALID	O	O
)	O	O
scale	O	O
.	O	O

RESULTS	O	O
Changes	O	O
in	O	O
the	O	O
BARS	O	O
score	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
DCM	O	O
and	O	O
the	O	O
control	O	O
group	O	O
or	O	O
between	O	O
the	O	O
VPM	O	O
and	O	O
the	O	O
control	O	O
group	O	O
after	O	O
10	O	O
months	O	O
.	O	O

Positive	O	O
differences	O	O
were	O	O
found	O	O
for	O	O
changes	O	O
in	O	O
the	O	O
secondary	O	O
outcomes	O	O
:	O	O
the	O	O
NPI-Q	O	O
sum	O	O
score	O	O
as	O	O
well	O	O
as	O	O
the	O	O
subscales	O	O
NPI-Q	O	O
agitation	O	O
and	O	O
NPI-Q	O	O
psychosis	O	O
were	O	O
in	O	O
favour	O	O
of	O	O
both	O	O
interventions	O	O
versus	O	O
control	O	O
,	O	O
the	O	O
QUALID	O	O
score	O	O
was	O	O
in	O	O
favour	O	O
of	O	O
DCM	O	O
versus	O	O
control	O	O
and	O	O
the	O	O
CSDD	O	O
score	O	O
was	O	O
in	O	O
favour	O	O
of	O	O
VPM	O	O
versus	O	O
control	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
failed	O	O
to	O	O
find	O	O
a	O	O
significant	O	O
effect	O	O
of	O	O
both	O	O
interventions	O	O
on	O	O
the	O	O
primary	O	O
outcome	O	O
.	O	O

Positive	O	O
effects	O	O
on	O	O
the	O	O
secondary	O	O
outcomes	O	O
indicate	O	O
that	O	O
the	O	O
methods	O	O
merit	O	O
further	O	O
investigation	O	O
.	O	O

A	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
clinical	O	O
trial	O	O
comparing	O	O
standard	O	O
wound	O	O
care	O	O
with	O	O
adjunctive	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
(	O	O
HBOT	O	O
)	O	O
to	O	O
standard	O	O
wound	O	O
care	O	O
only	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	Condition	O
,	O	O
non-healing	Condition	Condition
ulcers	Condition	Condition
of	O	O
the	O	O
lower	Condition	O
limb	Condition	O
in	O	O
patients	O	O
with	O	O
diabetes	Condition	Condition
mellitus	Condition	Condition
:	O	O
a	O	O
study	O	O
protocol	O	O
.	O	O

BACKGROUND	O	O
It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
the	O	O
use	O	O
of	O	O
adjunctive	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
improves	O	O
the	O	O
healing	O	O
of	O	O
diabetic	O	Condition
foot	O	Condition
ulcers	O	Condition
,	O	O
and	O	O
decreases	O	O
the	O	O
risk	O	O
of	O	O
lower	O	O
extremity	O	O
amputations	O	O
.	O	O

A	O	O
limited	O	O
number	O	O
of	O	O
studies	O	O
have	O	O
used	O	O
a	O	O
double	O	O
blind	O	O
approach	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
diabetic	Condition	Condition
ulcers	Condition	Condition
.	O	O

The	O	O
primary	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
of	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
plus	O	O
standard	O	O
wound	O	O
care	O	O
compared	O	O
with	O	O
standard	O	O
wound	O	O
care	O	O
alone	O	O
in	O	O
preventing	O	O
the	O	O
need	O	O
for	O	O
major	O	O
amputation	O	O
in	O	O
patients	O	O
with	O	O
diabetes	O	Condition
mellitus	O	Condition
and	O	Condition
chronic	Condition	Condition
ulcers	Condition	Condition
of	O	O
the	O	O
lower	Condition	O
limb	Condition	O
.	O	O

METHODS/DESIGN	O	O
One	SampleSize	O
hundred	SampleSize	O
and	SampleSize	O
eighteen	SampleSize	O
(	O	O
59	SampleSize	O
patients	O	O
per	O	O
arm	O	O
)	O	O
patients	O	O
with	O	O
non-healing	Condition	Condition
diabetic	Condition	Condition
ulcers	Condition	Condition
of	O	O
the	O	O
lower	Condition	O
limb	Condition	O
,	O	O
referred	O	O
to	O	O
the	O	O
Judy	O	O
Dan	O	O
Research	O	O
and	O	O
Treatment	O	O
Centre	O	O
are	O	O
being	O	O
recruited	O	O
if	O	O
they	O	O
are	O	O
at	O	O
least	O	O
18	Age	O
years	O	O
of	O	O
age	O	O
,	O	O
have	O	O
either	O	O
Type	Condition	O
1	Condition	O
or	Condition	O
2	Condition	O
diabetes	Condition	O
with	O	O
a	O	O
Wagner	O	O
grading	O	O
of	O	O
foot	O	O
lesions	O	O
2	O	O
,	O	O
3	O	O
or	O	O
4	O	O
on	O	O
lower	O	O
limb	O	O
not	O	O
healing	O	O
for	O	O
at	O	O
least	O	O
4	O	O
weeks	O	O
.	O	O

Patients	O	O
receive	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
every	O	O
day	O	O
for	O	O
6	O	O
weeks	O	O
during	O	O
the	O	O
treatment	O	O
phase	O	O
and	O	O
are	O	O
provided	O	O
ongoing	O	O
wound	O	O
care	O	O
and	O	O
weekly	O	O
assessments	O	O
.	O	O

Patients	O	O
are	O	O
required	O	O
to	O	O
return	O	O
to	O	O
the	O	O
study	O	O
centre	O	O
every	O	O
week	O	O
for	O	O
an	O	O
additional	O	O
6	O	O
weeks	O	O
of	O	O
follow-up	O	O
for	O	O
wound	O	O
evaluation	O	O
and	O	O
management	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
is	O	O
freedom	O	O
from	O	O
having	O	O
,	O	O
or	O	O
meeting	O	O
the	O	O
criteria	O	O
for	O	O
,	O	O
a	O	O
major	O	O
amputation	O	O
(	O	O
below	O	O
knee	O	O
amputation	O	O
,	O	O
or	O	O
metatarsal	O	O
level	O	O
)	O	O
up	O	O
to	O	O
12	O	O
weeks	O	O
after	O	O
randomization	O	O
.	O	O

The	O	O
decision	O	O
to	O	O
amputate	O	O
is	O	O
made	O	O
by	O	O
a	O	O
vascular	O	O
surgeon	O	O
.	O	O

Other	O	O
outcomes	O	O
include	O	O
wound	O	O
healing	O	O
,	O	O
effectiveness	O	O
,	O	O
safety	O	O
,	O	O
healthcare	O	O
resource	O	O
utilization	O	O
,	O	O
quality	O	O
of	O	O
life	O	O
,	O	O
and	O	O
cost-effectiveness	O	O
.	O	O

The	O	O
study	O	O
will	O	O
run	O	O
for	O	O
a	O	O
total	O	O
of	O	O
about	O	O
3	O	O
years	O	O
.	O	O

DISCUSSION	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
will	O	O
provide	O	O
detailed	O	O
information	O	O
on	O	O
the	O	O
efficacy	O	O
of	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
non-healing	O	Condition
ulcers	O	Condition
of	O	O
the	O	O
lower	O	O
limb	O	O
.	O	O

This	O	O
will	O	O
be	O	O
the	O	O
first	O	O
double-blind	O	O
randomized	O	O
controlled	O	O
trial	O	O
for	O	O
this	O	O
health	O	O
technology	O	O
which	O	O
evaluates	O	O
the	O	O
efficacy	O	O
of	O	O
hyperbaric	O	O
oxygen	O	O
therapy	O	O
in	O	O
prevention	O	O
of	O	O
amputations	O	O
in	O	O
diabetic	O	O
patients	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
ClinicalTrials.gov	O	O
Identifier	O	O
:	O	O
NCT00621608	O	O
.	O	O

[	O	O
Dose-reduced	O	O
antihypertensive	O	O
agents	O	O
--	O	O
use	O	O
in	O	O
complex	O	O
nonmedicamentous	O	O
therapy	O	O
of	O	O
hypertension	O	O
]	O	O
.	O	O

In	O	O
order	O	O
to	O	O
estimate	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
non-medicamentous	O	O
therapy	O	O
(	O	O
CNT	O	O
)	O	O
on	O	O
the	O	O
consumption	O	O
of	O	O
medicaments	O	O
and	O	O
coronary	O	O
risk	O	O
in	O	O
high	O	O
blood	O	O
pressure	O	O
73	SampleSize	O
hypertensives	Condition	O
of	O	O
a	O	O
medicamentously	O	O
stabilized	O	O
CNT-group	O	O
were	O	O
examined	O	O
in	O	O
comparison	O	O
to	O	O
a	O	O
group	O	O
of	O	O
the	O	O
same	O	O
size	O	O
of	O	O
patients	O	O
with	O	O
hypertension	Condition	Condition
who	O	O
were	O	O
managed	O	O
exclusively	O	O
medicamentously	O	O
for	O	O
behaviour	O	O
of	O	O
blood	O	O
pressure	O	O
,	O	O
need	O	O
of	O	O
antihypertensive	O	O
drugs	O	O
and	O	O
changes	O	O
of	O	O
hypertension-associated	O	O
risk	O	O
factors	O	O
.	O	O

After	O	O
an	O	O
exactly	O	O
controlled	O	O
6-month	O	O
treatment	O	O
hypertensives	Condition	O
with	O	O
additionally	O	O
recommended	O	O
far-reaching	O	O
CNT	O	O
showed	O	O
an	O	O
economization	O	O
of	O	O
medicaments	O	O
by	O	O
scarcely	O	O
the	O	O
half	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
reference	O	O
group	O	O
.	O	O

By	O	O
means	O	O
of	O	O
suitable	O	O
control	O	O
methods	O	O
a	O	O
causal	O	O
non-medicamentously	O	O
conditioned	O	O
decrease	O	O
of	O	O
blood	O	O
pressure	O	O
could	O	O
be	O	O
excluded	O	O
.	O	O

A	O	O
different	O	O
need	O	O
of	O	O
antihypertensive	O	O
drugs	O	O
was	O	O
simulated	O	O
by	O	O
the	O	O
exacter	O	O
intake	O	O
of	O	O
medicaments	O	O
in	O	O
the	O	O
index-patients	O	O
.	O	O

Notwithstanding	O	O
the	O	O
metabolic	O	O
effects	O	O
of	O	O
the	O	O
additional	O	O
therapy	O	O
have	O	O
induced	O	O
a	O	O
positive	O	O
change	O	O
of	O	O
atherogenic	O	O
lipids	O	O
.	O	O

The	O	O
examinations	O	O
indicate	O	O
in	O	O
general	O	O
the	O	O
difficulty	O	O
of	O	O
the	O	O
judgement	O	O
of	O	O
efficacy	O	O
of	O	O
non-medicamentous	O	O
therapeutic	O	O
measures	O	O
in	O	O
connection	O	O
with	O	O
a	O	O
rational	O	O
dose-reduced	O	O
long-term	O	O
therapy	O	O
with	O	O
antihypertensive	O	O
drugs	O	O
.	O	O

A	O	O
description	O	O
of	O	O
the	O	O
clinical	O	O
characteristics	O	O
at	O	O
baseline	O	O
of	O	O
patients	O	O
recruited	O	O
into	O	O
the	O	O
Carvedilol	O	O
or	O	O
Metoprolol	O	O
European	O	O
Trial	O	O
(	O	O
COMET	O	O
)	O	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
The	O	O
COMET	O	O
trial	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
double-blind	O	O
,	O	O
randomised	O	O
trial	O	O
comparing	O	O
carvedilol	O	O
,	O	O
a	O	O
comprehensive	O	O
adrenergic	O	O
receptor	O	O
antagonist	O	O
,	O	O
with	O	O
metoprolol	O	O
,	O	O
a	O	O
beta-1-selective	O	O
agent	O	O
in	O	O
patients	O	O
with	O	O
heart	Condition	O
failure	Condition	O
and	O	O
left	Condition	O
ventricular	Condition	O
systolic	Condition	O
dysfunction	Condition	O
.	O	O

The	O	O
trial	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
mortality	O	O
with	O	O
carvedilol	O	O
that	O	O
was	O	O
consistent	O	O
across	O	O
subgroups	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
report	O	O
is	O	O
to	O	O
describe	O	O
in	O	O
greater	O	O
detail	O	O
the	O	O
heterogeneity	O	O
of	O	O
this	O	O
population	O	O
at	O	O
baseline	O	O
with	O	O
particular	O	O
reference	O	O
to	O	O
the	O	O
impact	O	O
of	O	O
symptomatic	O	O
severity	O	O
,	O	O
age	O	O
and	O	O
gender	O	O
on	O	O
patient	O	O
characteristics	O	O
.	O	O

METHODS	O	O
A	O	O
descriptive	O	O
report	O	O
using	O	O
data	O	O
entered	O	O
in	O	O
the	O	O
COMET	O	O
study	O	O
data-base	O	O
.	O	O

RESULTS	O	O
The	O	O
characteristics	O	O
of	O	O
the	O	O
population	O	O
studied	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
in	O	O
previous	O	O
trials	O	O
of	O	O
beta-blockers	O	O
.	O	O

Almost	O	O
all	O	O
patients	O	O
were	O	O
receiving	O	O
diuretics	O	O
and	O	O
ACE	O	O
inhibitors	O	O
with	O	O
few	O	O
patients	O	O
taking	O	O
angiotensin	O	O
receptor	O	O
blockers	O	O
.	O	O

As	O	O
expected	O	O
,	O	O
older	O	O
patients	O	O
had	O	O
more	O	O
co-morbidity	O	O
.	O	O

Older	O	O
patients	O	O
and	O	O
women	O	O
reported	O	O
worse	O	O
symptoms	O	O
and	O	O
poorer	O	O
well-being	O	O
despite	O	O
similar	O	O
ventricular	O	O
dimensions	O	O
and	O	O
systolic	O	O
dysfunction	O	O
.	O	O

NT-proBNP	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
with	O	O
more	O	O
severe	O	O
symptoms	O	O
and	O	O
older	O	O
patients	O	O
but	O	O
not	O	O
in	O	O
women	O	O
,	O	O
although	O	O
differences	O	O
in	O	O
NT-proBNP	O	O
may	O	O
have	O	O
been	O	O
confounded	O	O
by	O	O
differences	O	O
in	O	O
renal	O	O
function	O	O
.	O	O

CONCLUSION	O	O
Age	O	O
and	O	O
gender	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
severity	O	O
of	O	O
cardiac	O	O
dysfunction	O	O
,	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
important	O	O
effect	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
heart	O	O
failure	O	O
symptoms	O	O
and	O	O
patient	O	O
'well-being	O	O
'	O	O
.	O	O

This	O	O
could	O	O
have	O	O
important	O	O
implications	O	O
for	O	O
the	O	O
relationship	O	O
between	O	O
symptoms	O	O
and	O	O
prognosis	O	O
and	O	O
therefore	O	O
the	O	O
way	O	O
in	O	O
which	O	O
patients	O	O
are	O	O
selected	O	O
for	O	O
clinical	O	O
trials	O	O
and	O	O
the	O	O
goals	O	O
of	O	O
treatment	O	O
.	O	O

This	O	O
will	O	O
be	O	O
the	O	O
subject	O	O
of	O	O
further	O	O
analyses	O	O
.	O	O

Relation	O	O
of	O	O
total	O	O
homocysteine	O	O
and	O	O
lipid	O	O
levels	O	O
in	O	O
children	Age	O
to	O	O
premature	O	O
cardiovascular	O	O
death	O	O
in	O	O
male	Sex	O
relatives	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
relative	O	O
importance	O	O
of	O	O
lipid	O	O
,	O	O
apo	O	O
B	O	O
,	O	O
lipoprotein	O	O
(	O	O
a	O	O
)	O	O
[	O	O
Lp	O	O
(	O	O
a	O	O
)	O	O
]	O	O
,	O	O
and	O	O
total	O	O
homocysteine	O	O
(	O	O
tHcy	O	O
)	O	O
levels	O	O
in	O	O
children	Age	O
in	O	O
relation	O	O
to	O	O
premature	O	O
cardiovascular	O	O
disease	O	O
in	O	O
family	O	O
members	O	O
.	O	O

Parents	O	O
of	O	O
381	SampleSize	SampleSize
girls	Sex	Sex
and	O	O
375	SampleSize	O
boys	Sex	O
age	O	O
8-12	Age	Age
y	O	O
completed	O	O
family	O	O
history	O	O
questionnaires	O	O
.	O	O

Nonfasting	O	O
serum	O	O
lipid	O	O
and	O	O
lipoproteins	O	O
and	O	O
plasma	O	O
tHcy	O	O
and	O	O
cysteine	O	O
levels	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
children	O	O
.	O	O

Serum	O	O
folate	O	O
and	O	O
vitamin	O	O
B12	O	O
levels	O	O
were	O	O
determined	O	O
in	O	O
a	O	O
random	O	O
subsample	O	O
of	O	O
23	O	O
%	O	O
of	O	O
the	O	O
children	O	O
,	O	O
who	O	O
participated	O	O
in	O	O
a	O	O
food	O	O
frequency	O	O
interview	O	O
.	O	O

Children	O	O
whose	O	O
parents	O	O
reported	O	O
hypercholesterolemia	O	O
had	O	O
higher	O	O
total	O	O
and	O	O
non-HDL	O	O
cholesterol	O	O
and	O	O
apo	O	O
B	O	O
levels	O	O
than	O	O
the	O	O
rest	O	O
,	O	O
but	O	O
these	O	O
levels	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
cardiovascular	O	O
disease	O	O
.	O	O

tHcy	O	O
levels	O	O
were	O	O
similar	O	O
in	O	O
girls	O	O
and	O	O
boys	O	O
.	O	O

tHcy	O	O
was	O	O
higher	O	O
in	O	O
children	Age	O
whose	O	O
father	O	O
,	O	O
grandfather	O	O
,	O	O
or	O	O
uncle	O	O
died	O	O
at	O	O
age	O	O
<	O	O
or	O	O
=	O	O
55	O	O
y	O	O
of	O	O
myocardial	O	O
infarction	O	O
or	O	O
sudden	O	O
cardiac	O	O
arrest	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
than	O	O
in	O	O
control	O	O
children	O	O
[	O	O
5.92	O	O
mumol/L	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
of	O	O
5.47-6.36	O	O
)	O	O
versus	O	O
5.25	O	O
mumol/L	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5.16-5.34	O	O
)	O	O
]	O	O
,	O	O
also	O	O
after	O	O
adjustment	O	O
for	O	O
socioeconomic	O	O
group	O	O
.	O	O

Intake	O	O
and	O	O
serum	O	O
levels	O	O
of	O	O
vitamin	O	O
B12	O	O
and	O	O
folate	O	O
were	O	O
within	O	O
recommended	O	O
or	O	O
reference	O	O
ranges	O	O
.	O	O

In	O	O
a	O	O
stepwise	O	O
multiple	O	O
regression	O	O
analysis	O	O
,	O	O
serum	O	O
folate	O	O
(	O	O
negative	O	O
correlation	O	O
)	O	O
,	O	O
plasma	O	O
creatinine	O	O
,	O	O
and	O	O
sugar	O	O
intake	O	O
as	O	O
percent	O	O
of	O	O
dietary	O	O
energy	O	O
(	O	O
positive	O	O
correlations	O	O
)	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
tHcy	O	O
(	O	O
multiple	O	O
r	O	O
=	O	O
0.44	O	O
,	O	O
adjusted	O	O
r2	O	O
=	O	O
18	O	O
%	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
5-30	O	O
%	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
a	O	O
modest	O	O
elevation	O	O
in	O	O
tHcy	O	O
in	O	O
children	O	O
was	O	O
related	O	O
to	O	O
premature	O	O
cardiovascular	O	O
death	O	O
in	O	O
their	O	O
male	O	O
relatives	O	O
and	O	O
may	O	O
partly	O	O
account	O	O
for	O	O
the	O	O
contribution	O	O
of	O	O
family	O	O
history	O	O
to	O	O
risk	O	O
of	O	O
cardiovascular	O	O
disease	O	O
.	O	O

tHcy	O	O
may	O	O
be	O	O
modifiable	O	O
through	O	O
the	O	O
diet	O	O
,	O	O
even	O	O
in	O	O
children	O	O
with	O	O
apparently	O	O
adequate	O	O
vitamin	O	O
nutriture	O	O
.	O	O

Chemotherapy	O	O
of	O	O
large	Condition	O
bowel	Condition	O
carcinoma	Condition	O
--	O	O
fluorouracil	O	O
(	O	O
FU	O	O
)	O	O
+	O	O
hydroxyurea	O	O
(	O	O
HU	O	O
)	O	O
vs.	O	O
methyl-CCNU	O	O
,	O	O
oncovin	O	O
,	O	O
fluorouracil	O	O
,	O	O
and	O	O
streptozotocin	O	O
(	O	O
MOF-Strep	O	O
)	O	O
.	O	O

An	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
study	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
randomized	O	O
study	O	O
of	O	O
initial	O	O
chemotherapy	O	O
for	O	O
advanced	Condition	O
measurable	Condition	O
metastatic	Condition	O
large	Condition	O
bowel	Condition	O
carcinoma	Condition	O
,	O	O
the	O	O
response	O	O
rate	O	O
was	O	O
6/32	O	O
(	O	O
19	O	O
%	O	O
)	O	O
for	O	O
FU	O	O
+	O	O
HU	O	O
and	O	O
5/32	O	O
(	O	O
16	O	O
%	O	O
)	O	O
for	O	O
MOF-Strep	O	O
;	O	O
the	O	O
estimated	O	O
median	O	O
survival	O	O
is	O	O
43	O	O
weeks	O	O
for	O	O
both	O	O
treatments	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
MOF-Strep	O	O
experienced	O	O
substantially	O	O
greater	O	O
vomiting	O	O
and	O	O
hematologic	O	O
toxicity	O	O
than	O	O
patients	O	O
who	O	O
received	O	O
FU	O	O
+	O	O
HU	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Computer-navigated	O	O
versus	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
a	O	O
prospective	O	O
randomized	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
The	O	O
literature	O	O
lacks	O	O
studies	O	O
that	O	O
confirm	O	O
whether	O	O
the	O	O
improved	O	O
radiographic	O	O
alignment	O	O
that	O	O
can	O	O
be	O	O
achieved	O	O
with	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
improves	O	O
patients?	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
or	O	O
the	O	O
durability	O	O
of	O	O
total	O	O
knee	O	O
prostheses	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
improves	O	O
the	O	O
clinical	O	O
function	O	O
,	O	O
alignment	O	O
,	O	O
and	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
.	O	O

METHODS	O	O
We	O	O
prospectively	O	O
compared	O	O
the	O	O
results	O	O
of	O	O
520	O	O
patients	O	O
with	O	O
osteoarthritis	O	O
who	O	O
underwent	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
for	O	O
one	O	O
knee	O	O
and	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
for	O	O
the	O	O
other	O	O
.	O	O

The	O	O
assignment	O	O
of	O	O
the	O	O
knee	O	O
to	O	O
navigation	O	O
or	O	O
not	O	O
was	O	O
done	O	O
randomly	O	O
.	O	O

There	O	O
were	O	O
452	O	SampleSize
women	O	Sex
(	O	O
904	O	O
knees	O	O
)	O	O
and	O	O
sixty-eight	O	O
men	O	O
(	O	O
136	O	O
knees	O	O
)	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
sixty-eight	O	O
years	O	O
(	O	O
range	O	O
,	O	O
forty-nine	O	O
to	O	O
eighty-eight	O	O
years	O	O
)	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
index	O	O
arthroplasty	O	O
.	O	O

The	O	O
mean	O	O
follow-up	O	O
period	O	O
was	O	O
10.8	O	O
years	O	O
(	O	O
range	O	O
,	O	O
ten	O	O
to	O	O
twelve	O	O
years	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
assessed	O	O
clinically	O	O
and	O	O
radiographically	O	O
with	O	O
the	O	O
rating	O	O
system	O	O
of	O	O
the	O	O
Knee	O	O
Society	O	O
and	O	O
with	O	O
the	O	O
Western	O	O
Ontario	O	O
and	O	O
McMaster	O	O
Universities	O	O
Osteoarthritis	O	O
Index	O	O
(	O	O
WOMAC	O	O
)	O	O
score	O	O
at	O	O
three	O	O
months	O	O
,	O	O
one	O	O
year	O	O
,	O	O
and	O	O
annually	O	O
thereafter	O	O
.	O	O

RESULTS	O	O
Total	O	O
knee	O	O
scores	O	O
,	O	O
knee	O	O
function	O	O
scores	O	O
,	O	O
pain	O	O
scores	O	O
,	O	O
WOMAC	O	O
scores	O	O
,	O	O
knee	O	O
motion	O	O
,	O	O
and	O	O
activity	O	O
scores	O	O
did	O	O
not	O	O
show	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
preoperatively	O	O
or	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
final	O	O
follow-up	O	O
.	O	O

Alignment	O	O
and	O	O
the	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
Kaplan-Meier	O	O
survivorship	O	O
with	O	O
revision	O	O
as	O	O
the	O	O
end	O	O
point	O	O
at	O	O
10.8	O	O
years	O	O
was	O	O
98.8	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
0.96	O	O
to	O	O
1.00	O	O
)	O	O
in	O	O
the	O	O
computernavigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
group	O	O
and	O	O
99.2	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.96	O	O
to	O	O
1.00	O	O
)	O	O
in	O	O
the	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
Our	O	O
data	O	O
demonstrated	O	O
no	O	O
difference	O	O
in	O	O
clinical	O	O
function	O	O
or	O	O
alignment	O	O
and	O	O
survivorship	O	O
of	O	O
the	O	O
components	O	O
between	O	O
the	O	O
knees	O	O
that	O	O
underwent	O	O
computer-navigated	O	O
total	O	O
knee	O	O
arthroplasty	O	O
and	O	O
those	O	O
that	O	O
underwent	O	O
conventional	O	O
total	O	O
knee	O	O
arthroplasty	O	O
.	O	O

Pilot	O	O
study	O	O
of	O	O
Panax	O	O
quinquefolius	O	O
(	O	O
American	O	O
ginseng	O	O
)	O	O
to	O	O
improve	O	O
cancer-related	Condition	O
fatigue	Condition	O
:	O	O
a	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
dose-finding	O	O
evaluation	O	O
:	O	O
NCCTG	O	O
trial	O	O
N03CA	O	O
.	O	O

PURPOSE	O	O
This	O	O
pilot	O	O
trial	O	O
sought	O	O
to	O	O
investigate	O	O
whether	O	O
any	O	O
of	O	O
three	O	O
doses	O	O
of	O	O
American	O	O
ginseng	O	O
(	O	O
Panax	O	O
quinquefolius	O	O
)	O	O
might	O	O
help	O	O
cancer-related	Condition	O
fatigue	Condition	O
.	O	O

A	O	O
secondary	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
toxicity	O	O
.	O	O

METHODS	O	O
Eligible	O	O
adults	Age	O
with	O	O
cancer	Condition	O
were	O	O
randomized	O	O
in	O	O
a	O	O
double-blind	O	O
manner	O	O
,	O	O
to	O	O
receive	O	O
American	O	O
ginseng	O	O
in	O	O
doses	O	O
of	O	O
750	O	O
,	O	O
1,000	O	O
,	O	O
or	O	O
2,000	O	O
mg/day	O	O
or	O	O
placebo	O	O
given	O	O
in	O	O
twice	O	O
daily	O	O
dosing	O	O
over	O	O
8	O	O
weeks	O	O
.	O	O

Outcome	O	O
measures	O	O
included	O	O
the	O	O
Brief	O	O
Fatigue	O	O
Inventory	O	O
,	O	O
vitality	O	O
subscale	O	O
of	O	O
the	O	O
Medical	O	O
Outcome	O	O
Scale	O	O
Short	O	O
Form-36	O	O
(	O	O
SF-36	O	O
)	O	O
,	O	O
and	O	O
the	O	O
Global	O	O
Impression	O	O
of	O	O
Benefit	O	O
Scale	O	O
at	O	O
4	O	O
and	O	O
8	O	O
weeks	O	O
.	O	O

RESULTS	O	O
Two	SampleSize	SampleSize
hundred	SampleSize	SampleSize
ninety	SampleSize	SampleSize
patients	O	O
were	O	O
accrued	O	O
to	O	O
this	O	O
trial	O	O
.	O	O

Nonsignificant	O	O
trends	O	O
for	O	O
all	O	O
outcomes	O	O
were	O	O
seen	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
doses	O	O
of	O	O
American	O	O
ginseng	O	O
.	O	O

Area	O	O
under	O	O
the	O	O
curve	O	O
analysis	O	O
of	O	O
activity	O	O
interference	O	O
from	O	O
the	O	O
Brief	O	O
Fatigue	O	O
Inventory	O	O
was	O	O
460-467	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
and	O	O
750	O	O
mg/day	O	O
group	O	O
versus	O	O
480-551	O	O
in	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
arms	O	O
,	O	O
respectively	O	O
.	O	O

Change	O	O
from	O	O
baseline	O	O
in	O	O
the	O	O
vitality	O	O
subscale	O	O
of	O	O
the	O	O
SF-36	O	O
was	O	O
7.3-7.8	O	O
in	O	O
the	O	O
placebo	O	O
and	O	O
the	O	O
750-mg/day	O	O
arm	O	O
,	O	O
versus	O	O
10.5-14.6	O	O
in	O	O
the	O	O
1,000-	O	O
and	O	O
2,000-mg/day	O	O
arms	O	O
.	O	O

Over	O	O
twice	O	O
as	O	O
many	O	O
patients	O	O
on	O	O
ginseng	O	O
perceived	O	O
a	O	O
benefit	O	O
and	O	O
were	O	O
satisfied	O	O
with	O	O
treatment	O	O
over	O	O
those	O	O
on	O	O
placebo	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
any	O	O
measured	O	O
toxicities	O	O
between	O	O
any	O	O
of	O	O
the	O	O
arms	O	O
.	O	O

CONCLUSION	O	O
There	O	O
appears	O	O
to	O	O
be	O	O
some	O	O
activity	O	O
and	O	O
tolerable	O	O
toxicity	O	O
at	O	O
1,000-2,000	O	O
mg/day	O	O
doses	O	O
of	O	O
American	O	O
ginseng	O	O
with	O	O
regard	O	O
to	O	O
cancer-related	O	O
fatigue	O	O
.	O	O

Thus	O	O
,	O	O
further	O	O
study	O	O
of	O	O
American	O	O
ginseng	O	O
is	O	O
warranted	O	O
.	O	O

Effect	O	O
of	O	O
four	O	O
intermediate	O	O
layer	O	O
treatments	O	O
on	O	O
microleakage	Condition	O
of	O	O
Class	Condition	O
II	Condition	O
composite	Condition	O
restorations	Condition	O
.	O	O

This	O	O
in	O	O
vitro	O	O
study	O	O
examines	O	O
the	O	O
marginal	O	O
sealing	O	O
ability	O	O
of	O	O
four	O	O
different	O	O
intermediate	O	O
materials	O	O
applied	O	O
before	O	O
placement	O	O
of	O	O
a	O	O
condensable	O	O
composite	O	O
.	O	O

Class	Condition	O
II	Condition	O
preparations	Condition	O
were	O	O
made	O	O
with	O	O
gingival	O	O
margins	O	O
placed	O	O
1.0	O	O
mm	O	O
apical	O	O
to	O	O
the	O	O
cementoenamel	O	O
junction	O	O
of	O	O
60	SampleSize	O
extracted	Condition	O
teeth	Condition	O
,	O	O
randomly	O	O
assigned	O	O
to	O	O
five	O	O
groups	O	O
of	O	O
12	SampleSize	O
.	O	O

Following	O	O
restoration	O	O
,	O	O
teeth	O	O
were	O	O
thermocycled	O	O
,	O	O
soaked	O	O
in	O	O
0.5	O	O
%	O	O
basic	O	O
fuchsin	O	O
,	O	O
and	O	O
sectioned	O	O
longitudinally	O	O
.	O	O

The	O	O
resin-modified	O	O
glass	O	O
ionomer	O	O
cement	O	O
demonstrated	O	O
significantly	O	O
less	O	O
microleakage	O	O
than	O	O
the	O	O
use	O	O
of	O	O
a	O	O
dentin	O	O
bonding	O	O
agent	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
flowable	O	O
composite	O	O
,	O	O
flowable	O	O
compomer	O	O
,	O	O
or	O	O
autoploymerizing	O	O
composite	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
,	O	O
Dunn	O	O
's	O	O
test	O	O
)	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
the	O	O
use	O	O
of	O	O
the	O	O
glass	O	O
ionomer	O	O
open	O	O
sandwich	O	O
technique	O	O
in	O	O
deep	Condition	O
Class	Condition	O
II	Condition	O
direct	Condition	O
composite	Condition	O
restorations	Condition	O
.	O	O

Efficacy	O	O
of	O	O
patient	O	O
education	O	O
and	O	O
supervised	O	O
exercise	O	O
vs	O	O
patient	O	O
education	O	O
alone	O	O
in	O	O
patients	O	Condition
with	O	Condition
hip	Condition	Condition
osteoarthritis	Condition	Condition
:	O	Condition
a	O	O
single	O	O
blind	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
compare	O	O
the	O	O
efficacy	O	O
of	O	O
patient	O	O
education	O	O
and	O	O
supervised	O	O
exercise	O	O
with	O	O
that	O	O
of	O	O
patient	O	O
education	O	O
alone	O	O
for	O	O
the	O	O
management	O	O
of	O	O
pain	O	O
in	O	O
patients	O	O
with	O	O
hip	O	O
osteoarthritis	O	O
(	O	O
OA	Condition	O
)	O	O
.	O	O

DESIGN	O	O
Single	O	O
blind	O	O
randomized	O	O
clinical	O	O
trial	O	O
.	O	O

SETTING	O	O
Recruitment	O	O
of	O	O
patients	O	O
from	O	O
hospitals	O	O
,	O	O
primary	O	O
health	O	O
care	O	O
and	O	O
advertisement	O	O
,	O	O
Oslo	O	O
,	O	O
Norway	O	O
.	O	O

PARTICIPANTS	O	O
109	SampleSize	O
patients	O	O
with	O	O
radiographic	O	O
and	O	O
symptomatic	O	O
hip	O	O
OA	O	O
with	O	O
mild	O	O
to	O	O
moderate	O	O
symptoms	O	O
.	O	O

INTERVENTIONS	O	O
Patient	O	O
education	O	O
(	O	O
PE	O	O
)	O	O
.	O	O

Patient	O	O
education	O	O
and	O	O
supervised	O	O
exercise	O	O
(	O	O
PE+SE	O	O
)	O	O
.	O	O

PRIMARY	O	O
OUTCOME	O	O
MEASURE	O	O
The	O	O
pain	O	O
subscale	O	O
of	O	O
the	O	O
Western	O	O
Ontario	O	O
and	O	O
McMaster	O	O
Universities	O	O
Osteoarthritis	O	O
Index	O	O
(	O	O
WOMAC	O	O
pain	O	O
)	O	O
.	O	O

RESULTS	O	O
No	O	O
significant	O	O
between	O	O
group	O	O
differences	O	O
were	O	O
found	O	O
for	O	O
WOMAC	O	O
pain	O	O
over	O	O
the	O	O
16-month	O	O
follow-up	O	O
.	O	O

Significant	O	O
improvements	O	O
were	O	O
found	O	O
for	O	O
the	O	O
secondary	O	O
outcome	O	O
WOMAC	O	O
physical	O	O
function	O	O
(	O	O
P=0.011	O	O
)	O	O
in	O	O
the	O	O
group	O	O
receiving	O	O
PE+SE	O	O
compared	O	O
to	O	O
the	O	O
group	O	O
receiving	O	O
PE	O	O
only	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
for	O	O
WOMAC	O	O
stiffness	O	O
,	O	O
the	O	O
SF-36	O	O
subscales	O	O
or	O	O
the	O	O
activity	O	O
scale	O	O
.	O	O

The	O	O
effect	O	O
sizes	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
)	O	O
for	O	O
WOMAC	O	O
pain	O	O
were	O	O
-0.26	O	O
(	O	O
0.11	O	O
,	O	O
-0.64	O	O
)	O	O
,	O	O
-0.35	O	O
(	O	O
0.07	O	O
,	O	O
-0.77	O	O
)	O	O
,	O	O
and	O	O
-0.30	O	O
(	O	O
0.15	O	O
,	O	O
-0.75	O	O
)	O	O
,	O	O
and	O	O
for	O	O
WOMAC	O	O
physical	O	O
function	O	O
-0.29	O	O
(	O	O
0.09	O	O
,	O	O
-0.67	O	O
)	O	O
,	O	O
-0.48	O	O
(	O	O
-0.06	O	O
,	O	O
-0.91	O	O
)	O	O
,	O	O
and	O	O
-0.47	O	O
(	O	O
-0.02	O	O
,	O	O
-0.93	O	O
)	O	O
at	O	O
4	O	O
,	O	O
10	O	O
and	O	O
16	O	O
months	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
group	O	O
receiving	O	O
both	O	O
PE	O	O
and	O	O
SE	O	O
.	O	O

All	O	O
patients	O	O
attended	O	O
the	O	O
three-session	O	O
PE	O	O
program	O	O
,	O	O
and	O	O
75	O	O
%	O	O
performed	O	O
?16	O	O
sessions	O	O
of	O	O
the	O	O
12-week	O	O
SE	O	O
program	O	O
.	O	O

CONCLUSION	O	O
The	O	O
study	O	O
could	O	O
not	O	O
demonstrate	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
pain	O	O
reduction	O	O
over	O	O
time	O	O
between	O	O
PE+SE	O	O
vs	O	O
PE	O	O
alone	O	O
.	O	O

Adding	O	O
SE	O	O
to	O	O
PE	O	O
may	O	O
improve	O	O
physical	O	O
function	O	O
,	O	O
but	O	O
the	O	O
magnitude	O	O
of	O	O
possible	O	O
benefit	O	O
is	O	O
unknown	O	O
as	O	O
the	O	O
95	O	O
%	O	O
confidence	O	O
intervals	O	O
around	O	O
the	O	O
mean	O	O
difference	O	O
were	O	O
wide	O	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
Clinical	O	O
Trials	O	O
NCT00319423	O	O
.	O	O

Use	O	O
and	O	O
limitations	O	O
of	O	O
Holter	O	O
electrocardiography	O	O
in	O	O
assessing	O	O
drug	O	O
therapy	O	O
of	O	O
myocardial	Condition	O
ischemia	Condition	O
during	O	O
the	O	O
peri-PTCA	Condition	O
period	O	O
.	O	O

Incidence	O	O
and	O	O
pattern	O	O
of	O	O
myocardial	O	O
ischemia	O	O
during	O	O
the	O	O
peri-PTCA	Condition	O
(	O	O
percutaneous	Condition	O
transluminal	Condition	O
coronary	Condition	O
angioplasty	Condition	O
)	O	O
period	O	O
and	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
continuous	O	O
intravenous	O	O
isosorbide	O	O
dinitrate	O	O
in	O	O
its	O	O
prevention	O	O
were	O	O
examined	O	O
prospectively	O	O
in	O	O
30	SampleSize	O
patients	O	O
.	O	O

Holter	O	O
electrocardiographic	O	O
monitoring	O	O
was	O	O
performed	O	O
for	O	O
21	O	O
+/-	O	O
3	O	O
h	O	O
before	O	O
PTCA	O	O
and	O	O
continued	O	O
during	O	O
and	O	O
for	O	O
41	O	O
+/-	O	O
8	O	O
h	O	O
after	O	O
the	O	O
procedure	O	O
.	O	O

Before	O	O
PTCA	O	O
,	O	O
19	O	O
ischemic	O	O
episodes	O	O
were	O	O
present	O	O
in	O	O
10	O	O
(	O	O
33	O	O
%	O	O
)	O	O
of	O	O
30	SampleSize	O
patients	O	O
.	O	O

PTCA	O	O
produced	O	O
an	O	O
abrupt	O	O
decrease	O	O
in	O	O
number	O	O
(	O	O
p	O	O
=	O	O
0.015	O	O
)	O	O
and	O	O
duration	O	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
of	O	O
spontaneous	O	O
ischemic	O	O
episodes	O	O
.	O	O

The	O	O
rarity	O	O
of	O	O
recurrent	O	O
myocardial	O	O
ischemic	O	O
events	O	O
by	O	O
Holter	O	O
monitoring	O	O
after	O	O
PTCA	O	O
negated	O	O
any	O	O
attempt	O	O
at	O	O
assessing	O	O
the	O	O
efficacy	O	O
of	O	O
intravenous	O	O
isosorbide	O	O
dinitrate	O	O
in	O	O
their	O	O
prevention	O	O
.	O	O

Holter	O	O
monitoring	O	O
could	O	O
not	O	O
be	O	O
used	O	O
as	O	O
an	O	O
early	O	O
predictor	O	O
of	O	O
late	O	O
coronary	O	O
restenosis	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
vaginal	O	O
tolerance	O	O
to	O	O
Acidform	O	O
,	O	O
an	O	O
acid-buffering	O	O
,	O	O
bioadhesive	O	O
gel	O	O
.	O	O

Vaginal	O	O
tolerance	O	O
tests	O	O
were	O	O
performed	O	O
with	O	O
a	O	O
new	O	O
potential	O	O
microbicidal	O	O
and	O	O
spermicidal	O	O
product	O	O
,	O	O
an	O	O
acid-buffering	O	O
vaginal	O	O
gel	O	O
(	O	O
Acidform	O	O
)	O	O
without	O	O
or	O	O
with	O	O
nonoxynol-9	O	O
(	O	O
N-9	O	O
)	O	O
.	O	O

The	O	O
potential	O	O
advantages	O	O
over	O	O
other	O	O
vaginal	O	O
products	O	O
include	O	O
keeping	O	O
a	O	O
low	O	O
pH	O	O
,	O	O
decrease	O	O
of	O	O
the	O	O
irritating	O	O
effect	O	O
of	O	O
N-9	O	O
on	O	O
the	O	O
cervix	O	O
or	O	O
vaginal	O	O
mucosa	O	O
associated	O	O
with	O	O
greater	O	O
retention	O	O
of	O	O
the	O	O
product	O	O
after	O	O
application	O	O
,	O	O
and	O	O
decreasing	O	O
messiness	O	O
as	O	O
compared	O	O
to	O	O
other	O	O
vaginal	O	O
products	O	O
.	O	O

Three	O	O
groups	O	O
of	O	O
six	SampleSize	O
women	Sex	O
were	O	O
admitted	O	O
and	O	O
randomly	O	O
assigned	O	O
to	O	O
use	O	O
Acidform	O	O
with	O	O
0	O	O
%	O	O
,	O	O
2.5	O	O
%	O	O
,	O	O
and	O	O
5	O	O
%	O	O
N-9	O	O
.	O	O

Colposcopic	O	O
evaluation	O	O
for	O	O
vulvar	O	O
,	O	O
vaginal	O	O
,	O	O
and	O	O
cervical	O	O
signs	O	O
of	O	O
irritation	O	O
was	O	O
performed	O	O
and	O	O
photographs	O	O
were	O	O
taken	O	O
,	O	O
following	O	O
a	O	O
specific	O	O
World	O	O
Health	O	O
Organization	O	O
protocol	O	O
,	O	O
at	O	O
time	O	O
0	O	O
,	O	O
and	O	O
after	O	O
24	O	O
h	O	O
and	O	O
6	O	O
days	O	O
of	O	O
application	O	O
of	O	O
the	O	O
gel	O	O
.	O	O

No	O	O
irritation	O	O
or	O	O
symptom	O	O
was	O	O
reported	O	O
by	O	O
users	O	O
of	O	O
Acidform	O	O
without	O	O
N-9	O	O
.	O	O

A	O	O
generalized	O	O
and	O	O
intense	O	O
erythema	O	O
in	O	O
cervix	O	O
was	O	O
observed	O	O
in	O	O
10	O	O
of	O	O
12	O	O
Acidform/N-9	O	O
users	O	O
and	O	O
abrasion	O	O
occurred	O	O
in	O	O
nine	O	O
of	O	O
them	O	O
.	O	O

Vulvar	O	O
irritation	O	O
was	O	O
seen	O	O
in	O	O
seven	O	O
of	O	O
these	O	O
10	SampleSize	O
volunteers	O	O
.	O	O

N-9	O	O
concentration	O	O
in	O	O
the	O	O
gel	O	O
(	O	O
2.5	O	O
%	O	O
or	O	O
5.0	O	O
%	O	O
)	O	O
was	O	O
not	O	O
related	O	O
to	O	O
the	O	O
findings	O	O
.	O	O

No	O	O
ulcer	O	O
,	O	O
exulceration	O	O
,	O	O
or	O	O
de-epithelialization	O	O
was	O	O
observed	O	O
.	O	O

Acidform	O	O
without	O	O
N-9	O	O
was	O	O
well	O	O
tolerated	O	O
by	O	O
volunteers	O	O
,	O	O
but	O	O
it	O	O
was	O	O
unable	O	O
to	O	O
protect	O	O
the	O	O
cervix	O	O
,	O	O
vagina	O	O
,	O	O
and	O	O
vulva	O	O
from	O	O
the	O	O
N-9	O	O
effects	O	O
.	O	O

Utility	O	O
of	O	O
the	O	O
bladder	O	O
flap	O	O
at	O	O
cesarean	Condition	O
delivery	Condition	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
omission	O	O
of	O	O
the	O	O
bladder	O	O
flap	O	O
in	O	O
primary	Condition	O
and	O	O
repeat	Condition	O
cesarean	Condition	O
deliveries	Condition	O
shortens	O	O
operating	O	O
time	O	O
without	O	O
increasing	O	O
intraoperative	O	O
and	O	O
postoperative	O	O
complications	O	O
.	O	O

METHODS	O	O
We	O	O
randomized	O	O
258	SampleSize	SampleSize
women	Sex	Sex
undergoing	O	O
primary	O	O
and	O	O
repeat	O	O
cesarean	O	O
deliveries	O	O
at	O	O
32	O	O
weeks	O	O
of	O	O
gestation	O	O
or	O	O
more	O	O
to	O	O
creation	O	O
(	O	O
n=131	SampleSize	O
)	O	O
or	O	O
omission	O	O
(	O	O
n=127	SampleSize	O
)	O	O
of	O	O
the	O	O
bladder	O	O
flap	O	O
.	O	O

Emergency	O	O
cesarean	O	O
deliveries	O	O
,	O	O
planned	O	O
vertical	O	O
uterine	O	O
incisions	O	O
,	O	O
and	O	O
previous	O	O
abdominal	O	O
surgeries	O	O
besides	O	O
cesarean	O	O
deliveries	O	O
were	O	O
excluded	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
measure	O	O
was	O	O
total	O	O
operating	O	O
time	O	O
.	O	O

Secondary	O	O
outcomes	O	O
were	O	O
bladder	O	O
injury	O	O
,	O	O
incision-to-delivery	O	O
time	O	O
,	O	O
incision-to-fascial	O	O
closure	O	O
time	O	O
,	O	O
estimated	O	O
blood	O	O
loss	O	O
,	O	O
postoperative	O	O
microhematuria	O	O
,	O	O
postoperative	O	O
pain	O	O
,	O	O
hospital	O	O
days	O	O
,	O	O
endometritis	O	O
,	O	O
and	O	O
urinary	O	O
tract	O	O
infection	O	O
.	O	O

Analysis	O	O
followed	O	O
the	O	O
intention-to-treat	O	O
principle	O	O
.	O	O

RESULTS	O	O
The	O	O
median	O	O
skin	O	O
incision	O	O
to	O	O
delivery	O	O
interval	O	O
was	O	O
shorter	O	O
with	O	O
omission	O	O
of	O	O
the	O	O
bladder	O	O
flap	O	O
(	O	O
9	O	O
[	O	O
range	O	O
1-43	O	O
]	O	O
compared	O	O
with	O	O
10	O	O
[	O	O
range	O	O
2-70	O	O
]	O	O
minutes	O	O
;	O	O
P=.04	O	O
)	O	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
total	O	O
operating	O	O
time	O	O
(	O	O
51	O	O
[	O	O
range	O	O
18-124	O	O
]	O	O
minutes	O	O
compared	O	O
with	O	O
51	O	O
[	O	O
range	O	O
16-178	O	O
]	O	O
;	O	O
P=.10	O	O
)	O	O
.	O	O

No	O	O
bladder	O	O
injuries	O	O
occurred	O	O
in	O	O
either	O	O
group	O	O
and	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
estimated	O	O
blood	O	O
loss	O	O
,	O	O
change	O	O
in	O	O
hemoglobin	O	O
level	O	O
,	O	O
postoperative	O	O
microhematuria	O	O
,	O	O
postoperative	O	O
pain	O	O
,	O	O
hospital	O	O
days	O	O
,	O	O
endometritis	O	O
,	O	O
or	O	O
urinary	O	O
tract	O	O
infection	O	O
.	O	O

CONCLUSION	O	O
Omission	O	O
of	O	O
the	O	O
bladder	O	O
flap	O	O
at	O	O
primary	O	O
and	O	O
repeat	O	O
cesarean	O	O
deliveries	O	O
does	O	O
not	O	O
increase	O	O
intraoperative	O	O
or	O	O
postoperative	O	O
complications	O	O
.	O	O

Incision-to-delivery	O	O
time	O	O
is	O	O
shortened	O	O
but	O	O
total	O	O
operating	O	O
time	O	O
appears	O	O
unchanged	O	O
.	O	O

CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
ClinicalTrials.gov	O	O
,	O	O
www.ClinicalTrials.gov	O	O
,	O	O
NCT00918996	O	O
.	O	O

LEVEL	O	O
OF	O	O
EVIDENCE	O	O
I	O	O
.	O	O

Effectiveness	O	O
of	O	O
Dader	O	O
Method	O	O
for	O	O
pharmaceutical	O	O
care	O	O
on	O	O
control	O	O
of	O	O
blood	O	O
pressure	O	O
and	O	O
total	O	O
cholesterol	O	O
in	O	O
outpatients	O	O
with	O	O
cardiovascular	Condition	Condition
disease	Condition	Condition
or	O	O
cardiovascular	Condition	O
risk	Condition	O
:	O	O
EMDADER-CV	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

BACKGROUND	O	O
Although	O	O
some	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
pharmacist	O	O
intervention	O	O
can	O	O
improve	O	O
drug	O	O
therapy	O	O
among	O	O
patients	O	O
with	O	O
cardiovascular	Condition	O
disease	Condition	O
(	O	O
CVD	Condition	O
)	O	O
,	O	O
more	O	O
evidence	O	O
derived	O	O
from	O	O
randomized	O	O
controlled	O	O
trials	O	O
(	O	O
RCTs	O	O
)	O	O
is	O	O
needed	O	O
,	O	O
including	O	O
assessment	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
community	O	O
pharmacist	O	O
interventions	O	O
in	O	O
patients	O	O
with	O	O
CVD	Condition	O
.	O	O

OBJECTIVE	O	O
To	O	O
assess	O	O
the	O	O
effectiveness	O	O
of	O	O
the	O	O
Dader	O	O
Method	O	O
for	O	O
pharmaceutical	O	O
care	O	O
on	O	O
achieving	O	O
therapeutic	O	O
goals	O	O
for	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
,	O	O
total	O	O
cholesterol	O	O
(	O	O
TC	O	O
)	O	O
,	O	O
and	O	O
both	O	O
BP	O	O
and	O	O
TC	O	O
(	O	O
BP/TC	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
CVD	O	O
and/or	O	O
high	Condition	O
or	Condition	O
intermediate	Condition	O
cardiovascular	Condition	O
(	Condition	O
CV	Condition	O
)	Condition	O
risk	Condition	O
attending	O	O
community	O	O
pharmacies	O	O
in	O	O
Spain	O	O
.	O	O

METHODS	O	O
Patients	O	O
aged	O	O
25	Age	Age
to	Age	Age
74	Age	Age
years	O	O
attending	O	O
community	O	O
pharmacies	O	O
with	O	O
a	O	O
prescription	O	O
for	O	O
at	O	O
least	O	O
1	O	O
drug	O	O
indicated	O	O
for	O	O
CVD	O	O
or	O	O
CV	Condition	O
risk	O	O
factors	O	O
were	O	O
randomized	O	O
to	O	O
2	O	O
groups	O	O
:	O	O
an	O	O
intervention	O	O
group	O	O
that	O	O
received	O	O
pharmaceutical	O	O
care	O	O
,	O	O
which	O	O
was	O	O
provided	O	O
by	O	O
specially	O	O
trained	O	O
pharmacists	O	O
working	O	O
in	O	O
collaboration	O	O
with	O	O
physicians	O	O
,	O	O
and	O	O
a	O	O
control	O	O
group	O	O
that	O	O
received	O	O
usual	O	O
care	O	O
(	O	O
routine	O	O
dispensing	O	O
counseling	O	O
)	O	O
and	O	O
verbal	O	O
and	O	O
written	O	O
counseling	O	O
regarding	O	O
CVD	O	O
prevention	O	O
.	O	O

Patients	O	O
were	O	O
recruited	O	O
from	O	O
December	O	O
2005	O	O
to	O	O
September	O	O
2006	O	O
,	O	O
and	O	O
both	O	O
groups	O	O
were	O	O
followed	O	O
for	O	O
8	O	O
months	O	O
.	O	O

Study	O	O
outcomes	O	O
were	O	O
assessed	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
16	O	O
and	O	O
32	O	O
weeks	O	O
after	O	O
randomization	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
measures	O	O
were	O	O
the	O	O
proportions	O	O
of	O	O
patients	O	O
achieving	O	O
BP	O	O
,	O	O
TC	O	O
,	O	O
and	O	O
BP/TC	O	O
therapeutic	O	O
goals	O	O
(	O	O
BP	O	O
lower	O	O
than	O	O
140/90	O	O
mm	O	O
Hg	O	O
for	O	O
patients	O	O
with	O	O
uncomplicated	O	O
hypertension	O	Condition
and	O	O
lower	O	O
than	O	O
130/80	O	O
mm	O	O
Hg	O	O
for	O	O
patients	O	O
with	O	O
diabetes	O	O
,	O	O
chronic	O	Condition
kidney	O	Condition
disease	O	Condition
,	O	O
or	O	O
history	O	O
of	O	O
myocardial	O	O
infarction	O	O
or	O	O
stroke	O	O
;	O	O
TC	O	O
lower	O	O
than	O	O
200	O	O
mg	O	O
per	O	O
dL	O	O
for	O	O
patients	O	O
without	O	O
CVD	O	O
and	O	O
lower	O	O
than	O	O
175	O	O
mg	O	O
per	O	O
dL	O	O
for	O	O
patients	O	O
with	O	O
CVD	O	O
)	O	O
.	O	O

Secondary	O	O
outcomes	O	O
were	O	O
mean	O	O
BP	O	O
and	O	O
TC	O	O
values	O	O
.	O	O

BP	O	O
was	O	O
assessed	O	O
manually	O	O
by	O	O
the	O	O
pharmacist	O	O
after	O	O
a	O	O
10-minute	O	O
rest	O	O
in	O	O
the	O	O
supine	O	O
position	O	O
.	O	O

This	O	O
measurement	O	O
was	O	O
performed	O	O
twice	O	O
for	O	O
every	O	O
participant	O	O
,	O	O
and	O	O
the	O	O
average	O	O
of	O	O
the	O	O
2	O	O
measurements	O	O
was	O	O
calculated	O	O
.	O	O

TC	O	O
was	O	O
measured	O	O
by	O	O
the	O	O
pharmacist	O	O
during	O	O
the	O	O
study	O	O
visit	O	O
using	O	O
the	O	O
enzymatic	O	O
dry	O	O
method	O	O
.	O	O

Statistical	O	O
analyses	O	O
were	O	O
performed	O	O
using	O	O
2-tailed	O	O
McNemar	O	O
tests	O	O
,	O	O
Pearson	O	O
chi-square	O	O
tests	O	O
,	O	O
and	O	O
Student	O	O
's	O	O
t-tests	O	O
;	O	O
P	O	O
<	O	O
0.05	O	O
was	O	O
considered	O	O
statistically	O	O
significant	O	O
.	O	O

RESULTS	O	O
714	SampleSize	O
patients	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
(	O	O
356	O	O
intervention	O	O
,	O	O
358	O	O
control	O	O
)	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
[	O	O
SD	O	O
]	O	O
age	O	O
was	O	O
62.8	Age	O
[	O	O
8.1	O	O
]	O	O
years	O	O
.	O	O

The	O	O
2	O	O
groups	O	O
were	O	O
similar	O	O
at	O	O
baseline	O	O
in	O	O
clinical	O	O
and	O	O
demographic	O	O
characteristics	O	O
,	O	O
including	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
at	O	O
therapeutic	O	O
goals	O	O
for	O	O
BP	O	O
,	O	O
TC	O	O
,	O	O
and	O	O
BP/TC	O	O
.	O	O

After	O	O
8	O	O
months	O	O
of	O	O
follow-up	O	O
,	O	O
there	O	O
were	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
favor	O	O
of	O	O
pharmaceutical	O	O
care	O	O
in	O	O
the	O	O
proportions	O	O
of	O	O
patients	O	O
who	O	O
achieved	O	O
therapeutic	O	O
goals	O	O
for	O	O
BP	O	O
(	O	O
52.5	O	O
%	O	O
vs.	O	O
43.0	O	O
%	O	O
,	O	O
P=0.017	O	O
)	O	O
,	O	O
TC	O	O
(	O	O
56.5	O	O
%	O	O
vs.	O	O
44.1	O	O
%	O	O
,	O	O
P=0.001	O	O
)	O	O
,	O	O
and	O	O
BP/TC	O	O
(	O	O
37.1	O	O
%	O	O
vs.	O	O
21.8	O	O
%	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

CONCLUSION	O	O
Compared	O	O
with	O	O
usual	O	O
care	O	O
plus	O	O
written	O	O
education	O	O
,	O	O
pharmaceutical	O	O
care	O	O
focused	O	O
on	O	O
patient	O	O
evaluation	O	O
and	O	O
follow-up	O	O
in	O	O
collaboration	O	O
with	O	O
physicians	O	O
improved	O	O
the	O	O
achievement	O	O
of	O	O
BP	O	O
,	O	O
TC	O	O
,	O	O
and	O	O
BP/TC	O	O
treatment	O	O
goals	O	O
in	O	O
patients	O	O
with	O	O
CVD	O	O
and/or	O	O
high	O	O
or	O	O
intermediate	O	O
CV	O	O
risk	O	O
attending	O	O
community	O	O
pharmacies	O	O
in	O	O
Spain	O	O
.	O	O

Social	O	O
support	O	O
and	O	O
abstinence	O	O
from	O	O
opiates	O	O
and	O	O
cocaine	O	O
during	O	O
opioid	Condition	O
maintenance	Condition	O
treatment	Condition	O
.	O	O

Social	O	O
support	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
helping	O	O
drug	Condition	O
users	Condition	O
achieve	O	O
abstinence	O	O
;	O	O
however	O	O
these	O	O
benefits	O	O
may	O	O
depend	O	O
on	O	O
the	O	O
type	O	O
of	O	O
support	O	O
experienced	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
observational	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
extent	O	O
to	O	O
which	O	O
general	O	O
and	O	O
abstinence-specific	O	O
support	O	O
,	O	O
both	O	O
structural	O	O
and	O	O
functional	O	O
,	O	O
predicted	O	O
opiate	O	O
and	O	O
cocaine	O	O
abstinence	O	O
in	O	O
128	SampleSize	O
opioid	Condition	O
maintenance	Condition	O
patients	Condition	O
receiving	O	O
either	O	O
methadone	O	O
or	O	O
LAAM	O	O
.	O	O

A	O	O
new	O	O
multidimensional	O	O
self-report	O	O
instrument	O	O
assessing	O	O
abstinence-specific	O	O
functional	O	O
support	O	O
was	O	O
developed	O	O
for	O	O
the	O	O
study	O	O
.	O	O

Previously	O	O
validated	O	O
measures	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
remaining	O	O
types	O	O
of	O	O
support	O	O
.	O	O

With	O	O
baseline	O	O
abstinence	O	O
and	O	O
other	O	O
statistically	O	O
important	O	O
covariates	O	O
adjusted	O	O
,	O	O
hierarchical	O	O
logistic	O	O
regression	O	O
analyses	O	O
demonstrated	O	O
that	O	O
the	O	O
associations	O	O
between	O	O
social	O	O
support	O	O
at	O	O
study	O	O
baseline	O	O
and	O	O
biochemically	O	O
confirmed	O	O
abstinence	O	O
3	O	O
months	O	O
later	O	O
varied	O	O
by	O	O
type	O	O
of	O	O
support	O	O
and	O	O
by	O	O
drug	O	O
.	O	O

Greater	O	O
abstinence-specific	O	O
structural	O	O
support	O	O
(	O	O
operationalized	O	O
as	O	O
fewer	O	O
drug	O	O
users	O	O
in	O	O
the	O	O
social	O	O
network	O	O
)	O	O
and	O	O
decreases	O	O
in	O	O
three	O	O
types	O	O
of	O	O
negative	O	O
abstinence-specific	O	O
functional	O	O
support	O	O
(	O	O
Complaints	O	O
about	O	O
Drug	O	O
Use	O	O
,	O	O
Drug	O	O
Exposure	O	O
,	O	O
and	O	O
Demoralization	O	O
)	O	O
predicted	O	O
cocaine	O	O
,	O	O
but	O	O
not	O	O
opiate	O	O
abstinence	O	O
.	O	O

There	O	O
were	O	O
no	O	O
effects	O	O
for	O	O
general	O	O
support	O	O
,	O	O
whether	O	O
structural	O	O
or	O	O
functional	O	O
,	O	O
on	O	O
abstinence	O	O
from	O	O
either	O	O
drug	O	O
.	O	O

Interventions	O	O
that	O	O
focus	O	O
on	O	O
modifying	O	O
patients	O	O
'	O	O
abstinence-specific	O	O
support	O	O
may	O	O
be	O	O
helpful	O	O
in	O	O
reducing	O	O
the	O	O
high	O	O
rates	O	O
of	O	O
cocaine	Condition	O
use	Condition	O
disorders	Condition	O
in	O	O
this	O	O
population	O	O
.	O	O

Transurethral	Condition	O
prostate	Condition	O
resection	Condition	O
and	O	O
bleeding	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
placebo	O	O
controlled	O	O
trial	O	O
of	O	O
role	O	O
of	O	O
finasteride	O	O
for	O	O
decreasing	O	O
operative	O	O
blood	O	O
loss	O	O
.	O	O

PURPOSE	O	O
Bleeding	O	O
associated	O	O
with	O	O
transurethral	O	O
prostate	O	O
resection	O	O
can	O	O
often	O	O
be	O	O
significant	O	O
and	O	O
lead	O	O
to	O	O
increased	O	O
morbidity	O	O
and	O	O
occasionally	O	O
mortality	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
finasteride	O	O
decreases	O	O
bleeding	O	O
in	O	O
patients	O	O
with	O	O
hematuria	Condition	O
of	O	O
prostatic	O	O
origin	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
bleeding	O	O
in	O	O
patients	O	O
undergoing	O	O
transurethral	Condition	O
prostate	Condition	O
resection	Condition	O
could	O	O
be	O	O
decreased	O	O
by	O	O
giving	O	O
finasteride	O	O
for	O	O
2	O	O
weeks	O	O
before	O	O
surgery	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
A	O	O
total	O	O
70	SampleSize	O
patients	O	O
scheduled	O	O
to	O	O
undergo	O	O
elective	Condition	O
transurethral	Condition	O
prostate	Condition	O
resection	Condition	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
5	O	O
mg.	O	O
finasteride	O	O
daily	O	O
or	O	O
placebo	O	O
for	O	O
2	O	O
weeks	O	O
before	O	O
surgery	O	O
.	O	O

Serum	O	O
hemoglobin	O	O
was	O	O
measured	O	O
before	O	O
and	O	O
after	O	O
surgery	O	O
,	O	O
and	O	O
the	O	O
following	O	O
day	O	O
.	O	O

The	O	O
volume	O	O
of	O	O
irrigation	O	O
fluid	O	O
used	O	O
and	O	O
its	O	O
hemoglobin	O	O
concentration	O	O
as	O	O
well	O	O
as	O	O
resected	O	O
prostate	O	O
weight	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
Of	O	O
the	O	O
68	SampleSize	O
patients	O	O
who	O	O
underwent	O	O
transurethral	Condition	O
prostate	Condition	O
resection	Condition	O
2	O	O
were	O	O
withdrawn	O	O
before	O	O
surgery	O	O
,	O	O
and	O	O
so	O	O
32	O	SampleSize
received	O	O
finasteride	O	O
and	O	O
36	O	O
received	O	O
placebo	O	O
.	O	O

There	O	O
was	O	O
significantly	O	O
less	O	O
mean	O	O
blood	O	O
loss	O	O
in	O	O
irrigation	O	O
fluid	O	O
in	O	O
the	O	O
finasteride	O	O
group	O	O
than	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
43.6	O	O
versus	O	O
69.3	O	O
gm	O	O
.	O	O

hemoglobin	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
difference	O	O
was	O	O
more	O	O
significant	O	O
when	O	O
blood	O	O
loss	O	O
per	O	O
gm	O	O
.	O	O

resected	O	O
prostate	O	O
was	O	O
calculated	O	O
(	O	O
2.65	O	O
versus	O	O
4.65	O	O
gm	O	O
.	O	O

hemoglobin	O	O
per	O	O
gm	O	O
.	O	O

prostate	O	O
,	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
finasteride	O	O
given	O	O
for	O	O
2	O	O
weeks	O	O
preoperatively	O	O
decreases	O	O
bleeding	O	O
in	O	O
patients	O	O
undergoing	O	O
transurethral	Condition	Condition
prostate	Condition	Condition
resection	Condition	Condition
.	O	O

Further	O	O
study	O	O
is	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
timing	O	O
and	O	O
dose	O	O
duration	O	O
to	O	O
minimize	O	O
blood	O	O
loss	O	O
and	O	O
identify	O	O
how	O	O
relevant	O	O
such	O	O
a	O	O
decrease	O	O
in	O	O
bleeding	O	O
is	O	O
in	O	O
clinical	O	O
practice	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
magnesium	O	O
added	O	O
to	O	O
levobupivacaine	O	O
for	O	O
femoral	O	O
nerve	O	O
block	O	O
on	O	O
postoperative	O	O
analgesia	O	O
in	O	O
patients	O	O
undergoing	O	O
ACL	Condition	O
reconstruction	Condition	O
.	O	O

PURPOSE	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
prospective	O	O
randomised	O	O
double-blind	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
magnesium	O	O
added	O	O
to	O	O
local	O	O
anaesthetics	O	O
on	O	O
postoperative	O	O
VAS	O	O
scores	O	O
,	O	O
total	O	O
opioid	O	O
consumption	O	O
,	O	O
time	O	O
to	O	O
first	O	O
mobilisation	O	O
,	O	O
patient	O	O
satisfaction	O	O
and	O	O
rescue	O	O
analgesic	O	O
requirements	O	O
in	O	O
arthroscopic	O	O
ACL	O	O
reconstruction	O	O
surgery	O	O
.	O	O

METHODS	O	O
A	O	O
total	O	O
of	O	O
107	SampleSize	O
American	O	O
Society	O	O
of	O	O
Anaesthesiologists	O	O
physical	O	O
status	O	O
grade	O	O
I	O	O
and	O	O
II	O	O
patients	O	O
between	O	O
18	Age	Age
and	Age	Age
65	Age	Age
years	O	Age
of	O	Age
age	O	Age
who	O	O
were	O	O
scheduled	O	O
to	O	O
undergo	O	O
elective	Condition	O
anterior	Condition	O
crucial	Condition	O
ligament	Condition	O
(	Condition	O
ACL	Condition	O
)	Condition	O
reconstruction	Condition	O
with	O	O
hamstring	O	O
autografts	O	O
were	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
Groups	O	O
L	O	O
(	O	O
n	O	O
=	O	O
51	O	O
)	O	O
and	O	O
LM	O	O
(	O	O
n	O	O
=	O	O
56	O	O
)	O	O
using	O	O
the	O	O
closed-envelope	O	O
method	O	O
.	O	O

Group	O	O
LM	O	O
was	O	O
administered	O	O
19	O	O
ml	O	O
of	O	O
0.25	O	O
%	O	O
levobupivacaine	O	O
and	O	O
1	O	O
ml	O	O
of	O	O
15	O	O
%	O	O
magnesium	O	O
sulphate	O	O
,	O	O
while	O	O
Group	O	O
L	O	O
was	O	O
administered	O	O
20	O	O
ml	O	O
of	O	O
0.25	O	O
%	O	O
levobupivacaine	O	O
for	O	O
femoral	O	O
blockade	O	O
.	O	O

General	O	O
anaesthesia	O	O
was	O	O
administered	O	O
using	O	O
laryngeal	O	O
airway	O	O
masks	O	O
following	O	O
neural	O	O
blockade	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
evaluated	O	O
for	O	O
heart	O	O
rate	O	O
and	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
oxygen	O	O
saturation	O	O
,	O	O
visual	O	O
analogue	O	O
score	O	O
(	O	O
VAS	O	O
)	O	O
,	O	O
verbal	O	O
rating	O	O
scale	O	O
(	O	O
VRS	O	O
)	O	O
,	O	O
rescue	O	O
analgesic	O	O
requirements	O	O
,	O	O
total	O	O
opioid	O	O
consumption	O	O
,	O	O
side	O	O
effects	O	O
and	O	O
time	O	O
to	O	O
first	O	O
mobilisation	O	O
at	O	O
the	O	O
1st	O	O
,	O	O
2nd	O	O
,	O	O
4th	O	O
,	O	O
6th	O	O
,	O	O
12th	O	O
and	O	O
24th	O	O
hours	O	O
postoperatively	O	O
.	O	O

RESULTS	O	O
There	O	O
was	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
in	O	O
terms	O	O
of	O	O
demographic	O	O
data	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
or	O	O
oxygen	O	O
saturation	O	O
between	O	O
groups	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
VAS	O	O
and	O	O
VRS	O	O
scores	O	O
were	O	O
lower	O	O
at	O	O
4	O	O
,	O	O
6	O	O
,	O	O
12	O	O
and	O	O
24	O	O
h	O	O
in	O	O
Group	O	O
LM	O	O
(	O	O
p	O	O
=	O	O
0.001	O	O
,	O	O
p	O	O
=	O	O
0.016	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
rescue	O	O
analgesic	O	O
requirement	O	O
and	O	O
the	O	O
total	O	O
opioid	O	O
consumption	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
LM	O	O
(	O	O
p	O	O
=	O	O
0.015	O	O
,	O	O
p	O	O
=	O	O
0.019	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
time	O	O
to	O	O
first	O	O
mobilisation	O	O
and	O	O
the	O	O
Likert	O	O
score	O	O
(	O	O
completely	O	O
comfortable	O	O
;	O	O
quite	O	O
comfortable	O	O
;	O	O
slight	O	O
discomfort	O	O
;	O	O
painful	O	O
;	O	O
very	O	O
painful	O	O
)	O	O
were	O	O
higher	O	O
,	O	O
and	O	O
the	O	O
block	O	O
onset	O	O
time	O	O
was	O	O
lower	O	O
in	O	O
Group	O	O
LM	O	O
(	O	O
p	O	O
=	O	O
0.014	O	O
and	O	O
p	O	O
=	O	O
0.012	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
terms	O	O
of	O	O
side	O	O
effects	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
addition	O	O
of	O	O
magnesium	O	O
to	O	O
levobupivacaine	O	O
prolongs	O	O
the	O	O
sensory	O	O
and	O	O
motor	O	O
block	O	O
duration	O	O
without	O	O
increasing	O	O
side	O	O
effects	O	O
,	O	O
enhances	O	O
the	O	O
quality	O	O
of	O	O
postoperative	O	O
analgesia	O	O
and	O	O
increases	O	O
patient	O	O
satisfaction	O	O
;	O	O
however	O	O
,	O	O
the	O	O
addition	O	O
of	O	O
magnesium	O	O
delays	O	O
the	O	O
time	O	O
to	O	O
first	O	O
mobilisation	O	O
and	O	O
decreases	O	O
rescue	O	O
analgesic	O	O
requirements	O	O
.	O	O

Efficacy	O	O
and	O	O
long-term	O	O
tolerability	O	O
of	O	O
sublingual	O	O
fentanyl	O	O
orally	O	O
disintegrating	O	O
tablet	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
breakthrough	O	O
cancer	O	O
pain	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Breakthrough	O	O
cancer	O	O
pain	O	O
(	O	O
BTcP	O	O
)	O	O
represents	O	O
an	O	O
important	O	O
clinical	O	O
challenge	O	O
in	O	O
the	O	O
care	O	O
of	O	O
patients	O	O
with	O	O
cancer	Condition	O
.	O	O

This	O	O
trial	O	O
evaluated	O	O
the	O	O
efficacy	O	O
and	O	O
long-term	O	O
tolerability	O	O
of	O	O
a	O	O
sublingual	O	O
formulation	O	O
of	O	O
the	O	O
fast-acting	O	O
opioid	O	O
fentanyl	O	O
,	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
BTcP	O	O
in	O	O
opioid-tolerant	O	O
patients	O	O
with	O	O
cancer	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
placebo-controlled	O	O
,	O	O
multi-center	O	O
,	O	O
phase	O	O
III	O	O
trial	O	O
,	O	O
conducted	O	O
in	O	O
opioid-tolerant	O	O
male	Sex	O
and	Sex	O
female	Sex	O
patients	O	O
(	O	O
aged	O	O
>	Age	O
or	Age	O
=17	Age	O
years	O	O
)	O	O
with	O	O
BTcP	O	O
.	O	O

The	O	O
study	O	O
was	O	O
conducted	O	O
at	O	O
36	O	O
centers	O	O
across	O	O
the	O	O
USA	O	O
.	O	O

The	O	O
study	O	O
comprised	O	O
a	O	O
2-week	O	O
open-label	O	O
titration	O	O
phase	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
double-blind	O	O
efficacy	O	O
phase	O	O
,	O	O
during	O	O
which	O	O
patients	O	O
received	O	O
sublingual	O	O
fentanyl	O	O
citrate	O	O
orally	O	O
disintegrating	O	O
tablet	O	O
(	O	O
sublingual	O	O
fentanyl	O	O
ODT	O	O
)	O	O
or	O	O
placebo	O	O
,	O	O
in	O	O
a	O	O
random	O	O
order	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
endpoint	O	O
was	O	O
the	O	O
sum	O	O
of	O	O
pain	O	O
intensity	O	O
difference	O	O
(	O	O
SPID	O	O
)	O	O
over	O	O
30	O	O
min	O	O
post-administration	O	O
.	O	O

Secondary	O	O
efficacy	O	O
endpoints	O	O
included	O	O
pain	O	O
intensity	O	O
difference	O	O
(	O	O
PID	O	O
)	O	O
and	O	O
pain	O	O
relief	O	O
(	O	O
PR	O	O
)	O	O
throughout	O	O
the	O	O
60-min	O	O
post-dose	O	O
assessment	O	O
period	O	O
.	O	O

Following	O	O
efficacy	O	O
evaluation	O	O
,	O	O
patients	O	O
entered	O	O
a	O	O
long-term	O	O
safety	O	O
phase	O	O
of	O	O
up	O	O
to	O	O
12	O	O
months	O	O
.	O	O

Adverse	O	O
events	O	O
were	O	O
recorded	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

[	O	O
CLINICAL	O	O
TRIAL	O	O
REGISTRATION	O	O
NCT00262678	O	O
]	O	O
RESULTS	O	O
A	O	O
total	O	O
of	O	O
131	SampleSize	O
patients	O	O
entered	O	O
the	O	O
titration	O	O
phase	O	O
,	O	O
of	O	O
whom	O	O
61	SampleSize	SampleSize
were	O	O
included	O	O
in	O	O
the	O	O
primary	O	O
efficacy	O	O
analysis	O	O
.	O	O

Sublingual	O	O
fentanyl	O	O
ODT	O	O
provided	O	O
significant	O	O
improvements	O	O
in	O	O
SPID	O	O
relative	O	O
to	O	O
placebo	O	O
at	O	O
30	O	O
min	O	O
(	O	O
49.5	O	O
vs.	O	O
36.6	O	O
,	O	O
p	O	O
=	O	O
0.0004	O	O
)	O	O
and	O	O
60	O	O
min	O	O
post-administration	O	O
(	O	O
143.0	O	O
vs.	O	O
104.5	O	O
,	O	O
p	O	O
=	O	O
0.0002	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
sublingual	O	O
fentanyl	O	O
ODT	O	O
provided	O	O
significant	O	O
improvements	O	O
in	O	O
PID	O	O
and	O	O
PR	O	O
compared	O	O
to	O	O
placebo	O	O
,	O	O
from	O	O
10	O	O
min	O	O
post-dose	O	O
(	O	O
p	O	O
=	O	O
0.0055	O	O
and	O	O
p	O	O
=	O	O
0.049	O	O
for	O	O
PID	O	O
and	O	O
PR	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Patient	O	O
recruitment	O	O
was	O	O
stopped	O	O
early	O	O
,	O	O
due	O	O
to	O	O
positive	O	O
interim	O	O
analysis	O	O
results	O	O
(	O	O
significant	O	O
at	O	O
prespecified	O	O
level	O	O
,	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0.0414	O	O
)	O	O
.	O	O

Overall	O	O
,	O	O
sublingual	O	O
fentanyl	O	O
ODT	O	O
was	O	O
well-tolerated	O	O
both	O	O
systemically	O	O
and	O	O
sublingually	O	O
,	O	O
with	O	O
41	O	O
patients	O	O
experiencing	O	O
>	O	O
or	O	O
=1	O	O
study	O	O
drug-related	O	O
adverse	O	O
event	O	O
(	O	O
AE	O	O
)	O	O
.	O	O

The	O	O
most	O	O
common	O	O
AEs	O	O
included	O	O
nausea	O	O
(	O	O
12.2	O	O
%	O	O
)	O	O
,	O	O
vomiting	O	O
(	O	O
5.3	O	O
%	O	O
)	O	O
and	O	O
somnolence	O	O
(	O	O
4.6	O	O
%	O	O
)	O	O
.	O	O

One	O	O
serious	O	O
AE	O	O
(	O	O
mild	O	O
affect	O	O
lability	O	O
)	O	O
was	O	O
considered	O	O
possibly	O	O
related	O	O
to	O	O
study	O	O
medication	O	O
.	O	O

The	O	O
observed	O	O
pattern	O	O
of	O	O
AEs	O	O
was	O	O
consistent	O	O
with	O	O
that	O	O
previously	O	O
observed	O	O
with	O	O
fentanyl	O	O
.	O	O

CONCLUSIONS	O	O
Sublingual	O	O
fentanyl	O	O
ODT	O	O
was	O	O
efficacious	O	O
and	O	O
well-tolerated	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
BTcP	O	O
in	O	O
opioid-tolerant	O	O
patients	O	O
with	O	O
cancer	O	O
.	O	O

Sublingual	O	O
fentanyl	O	O
ODT	O	O
provided	O	O
significant	O	O
improvements	O	O
in	O	O
pain	O	O
intensity	O	O
compared	O	O
to	O	O
placebo	O	O
,	O	O
from	O	O
10	O	O
min	O	O
post-administration	O	O
and	O	O
throughout	O	O
the	O	O
60-min	O	O
post-dose	O	O
assessment	O	O
period	O	O
.	O	O

Sublingual	O	O
fentanyl	O	O
ODT	O	O
was	O	O
well	O	O
tolerated	O	O
over	O	O
12	O	O
months	O	O
of	O	O
treatment	O	O
.	O	O

Lack	O	O
of	O	O
effect	O	O
of	O	O
food	O	O
on	O	O
the	O	O
steady	O	O
state	O	O
pharmacokinetics	O	O
of	O	O
BMS-181101	O	O
,	O	O
an	O	O
antidepressant	O	O
,	O	O
in	O	O
healthy	Condition	Condition
subjects	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
food	O	O
on	O	O
the	O	O
pharmacokinetics	O	O
of	O	O
BMS-181101	O	O
,	O	O
a	O	O
new	O	O
anti-depressant	O	O
under	O	O
development	O	O
,	O	O
was	O	O
investigated	O	O
in	O	O
12	SampleSize	SampleSize
healthy	Condition	Condition
male	Sex	Sex
volunteers	O	O
at	O	O
steady	O	O
state	O	O
.	O	O

Each	O	O
subject	O	O
received	O	O
a	O	O
15	O	O
mg	O	O
oral	O	O
dose	O	O
of	O	O
BMS-181101	O	O
twice	O	O
a	O	O
day	O	O
(	O	O
q	O	O
12	O	O
h	O	O
)	O	O
for	O	O
11	O	O
days	O	O
and	O	O
a	O	O
morning	O	O
dose	O	O
of	O	O
BMS-181101	O	O
on	O	O
day	O	O
12	O	O
.	O	O

Six	SampleSize	O
subjects	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
BMS-181101	O	O
under	O	O
fasted	O	O
conditions	O	O
from	O	O
days	O	O
1	O	O
to	O	O
6	O	O
and	O	O
then	O	O
crossed	O	O
over	O	O
to	O	O
fed	O	O
conditions	O	O
from	O	O
days	O	O
7	O	O
to	O	O
12	O	O
.	O	O

The	O	O
other	O	O
six	SampleSize	SampleSize
subjects	O	O
received	O	O
the	O	O
reverse	O	O
conditions	O	O
,	O	O
fed	O	O
for	O	O
days	O	O
1-6	O	O
and	O	O
fasted	O	O
for	O	O
days	O	O
7-12	O	O
.	O	O

Serial	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
up	O	O
to	O	O
12	O	O
h	O	O
on	O	O
days	O	O
6	O	O
and	O	O
12	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
morning	O	O
dose	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
trough	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
on	O	O
days	O	O
4	O	O
,	O	O
5	O	O
,	O	O
10	O	O
,	O	O
and	O	O
11	O	O
prior	O	O
to	O	O
the	O	O
morning	O	O
dose	O	O
.	O	O

Plasma	O	O
samples	O	O
were	O	O
analyzed	O	O
for	O	O
intact	O	O
BMS-181101	O	O
using	O	O
a	O	O
validated	O	O
high-performance	O	O
liquid	O	O
chromatography	O	O
method	O	O
with	O	O
an	O	O
electrochemical	O	O
detector	O	O
.	O	O

BMS-181101	O	O
was	O	O
well	O	O
tolerated	O	O
both	O	O
with	O	O
and	O	O
without	O	O
ingestion	O	O
of	O	O
food	O	O
.	O	O

The	O	O
statistical	O	O
evaluation	O	O
of	O	O
the	O	O
Cmin	O	O
values	O	O
indicated	O	O
that	O	O
steady	O	O
state	O	O
of	O	O
BMS-181101	O	O
was	O	O
achieved	O	O
by	O	O
the	O	O
fourth	O	O
day	O	O
of	O	O
dosing	O	O
regardless	O	O
of	O	O
whether	O	O
the	O	O
subject	O	O
was	O	O
fasted	O	O
or	O	O
fed	O	O
.	O	O

When	O	O
BMS-181101	O	O
was	O	O
administered	O	O
with	O	O
food	O	O
,	O	O
Cmax	O	O
was	O	O
reduced	O	O
by	O	O
about	O	O
25	O	O
%	O	O
and	O	O
tmax	O	O
was	O	O
prolonged	O	O
by	O	O
1	O	O
h.	O	O
However	O	O
,	O	O
AUCtau	O	O
,	O	O
t1/2	O	O
,	O	O
and	O	O
time	O	O
to	O	O
attain	O	O
steady	O	O
state	O	O
of	O	O
BMS-181101	O	O
were	O	O
not	O	O
altered	O	O
by	O	O
ingestion	O	O
of	O	O
food	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
BMS-181101	O	O
can	O	O
be	O	O
given	O	O
with	O	O
food	O	O
without	O	O
adversely	O	O
impacting	O	O
the	O	O
safety	O	O
or	O	O
pharmacokinetic	O	O
profiles	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Efficacy	O	O
of	O	O
nebulized	O	O
flunisolide	O	O
combined	O	O
with	O	O
salbutamol	O	O
and	O	O
ipratropium	O	O
bromide	O	O
in	O	O
stable	O	O
patients	O	O
with	O	O
moderate-to-severe	O	Condition
chronic	Condition	Condition
obstructive	Condition	Condition
pulmonary	Condition	Condition
disease	Condition	Condition
.	O	O

BACKGROUND	O	O
The	O	O
efficacy	O	O
of	O	O
nebulized	O	O
corticosteroids	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
exacerbation	O	O
of	O	O
chronic	O	O
obstructive	O	O
pulmonary	O	O
disease	O	O
(	O	O
COPD	Condition	O
)	O	O
has	O	O
been	O	O
poorly	O	O
studied	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
nebulized	O	O
flunisolide	O	O
(	O	O
1	O	O
mg	O	O
)	O	O
+	O	O
salbutamol/ipratropium	O	O
bromide	O	O
(	O	O
1,875/375	O	O
microg	O	O
)	O	O
b.i.d	O	O
.	O	O

in	O	O
comparison	O	O
with	O	O
placebo	O	O
+	O	O
salbutamol/ipratropium	O	O
bromide	O	O
.	O	O

METHODS	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
parallel-group	O	O
,	O	O
double-blind	O	O
study	O	O
on	O	O
114	SampleSize	SampleSize
patients	O	O
with	O	O
COPD	Condition	O
of	O	O
moderate-to-severe	O	O
degree	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
the	O	O
frequency	O	O
of	O	O
severe	O	O
exacerbations	O	O
over	O	O
a	O	O
6-month	O	O
period	O	O
.	O	O

Before	O	O
and	O	O
after	O	O
treatment	O	O
,	O	O
respiratory	O	O
symptoms	O	O
,	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
s	O	O
(	O	O
FEV	O	O
(	O	O
1	O	O
)	O	O
)	O	O
,	O	O
shuttle	O	O
walking	O	O
test	O	O
distance	O	O
and	O	O
St.	O	O
George	O	O
's	O	O
Respiratory	O	O
Questionnaire	O	O
scores	O	O
were	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
The	O	O
total	O	O
number	O	O
of	O	O
exacerbations	O	O
was	O	O
slightly	O	O
lower	O	O
in	O	O
the	O	O
flunisolide	O	O
group	O	O
compared	O	O
to	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
19	O	O
vs.	O	O
34	O	O
,	O	O
p	O	O
=	O	O
0.054	O	O
)	O	O
;	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
experiencing	O	O
at	O	O
least	O	O
one	O	O
exacerbation	O	O
during	O	O
the	O	O
study	O	O
was	O	O
also	O	O
decreased	O	O
(	O	O
16	O	O
vs.	O	O
26	O	O
,	O	O
p	O	O
=	O	O
0.059	O	O
)	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
type	O	O
3	O	O
Anthonisens	O	O
's	O	O
exacerbations	O	O
were	O	O
significantly	O	O
reduced	O	O
by	O	O
flunisolide	O	O
(	O	O
p	O	O
=	O	O
0.044	O	O
)	O	O
.	O	O

In	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
scores	O	O
were	O	O
higher	O	O
than	O	O
in	O	O
the	O	O
flunisolide	O	O
group	O	O
but	O	O
nonsignificant	O	O
for	O	O
dyspnea	O	O
,	O	O
cough	O	O
,	O	O
sputum	O	O
amount	O	O
and	O	O
purulence	O	O
.	O	O

FEV	O	O
(	O	O
1	O	O
)	O	O
was	O	O
significantly	O	O
increased	O	O
compared	O	O
to	O	O
baseline	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
and	O	O
the	O	O
area	O	O
under	O	O
the	O	O
FEV	O	O
(	O	O
1	O	O
)	O	O
-time	O	O
curve	O	O
during	O	O
the	O	O
6-month	O	O
period	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
flunisolide	O	O
group	O	O
(	O	O
5.2	O	O
+/-	O	O
10.6	O	O
vs.	O	O
2.1	O	O
+/-	O	O
5.0	O	O
,	O	O
flunisolide	O	O
vs.	O	O
placebo	O	O
,	O	O
respectively	O	O
;	O	O
p	O	O
=	O	O
0.047	O	O
)	O	O
.	O	O

For	O	O
shuttle	O	O
walking	O	O
test	O	O
distance	O	O
and	O	O
scores	O	O
of	O	O
the	O	O
St.	O	O
George	O	O
's	O	O
Respiratory	O	O
Questionnaire	O	O
,	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
baseline	O	O
evaluation	O	O
and	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	O	O
was	O	O
observed	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
Nebulized	O	O
flunisolide	O	O
is	O	O
a	O	O
good	O	O
alternative	O	O
to	O	O
other	O	O
inhaled	O	O
corticosteroids	O	O
when	O	O
added	O	O
to	O	O
nebulized	O	O
salbutamol/ipratropium	O	O
bromide	O	O
in	O	O
the	O	O
long-term	O	O
treatment	O	O
of	O	O
moderate-to-severe	Condition	O
COPD	Condition	O
patients	O	O
.	O	O

